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 Abstract  1 
1 Abstract 
1.1 Zusammenfassung 
Hülsenfrüchte (Leguminosen) sind eine wichtige Nahrungsquelle für hochwertige Proteine und 
pflanzliche Öle. Jedoch sind sie auch als Auslöser schwerer allergischer Reaktionen bekannt. 
Allergische Reaktionen vom Soforttyp werden durch allergene Proteine (Allergene) ausgelöst, 
vermittelt durch deren Interaktion mit dem Immunsystem über allergenspezifische Antikörper 
vom Typ Immunglobulin E (IgE). Um eine allergische Sensibilisierung zu diagnostizieren, 
können diese spezifischen IgE-Antikörper gegen Gesamtproteinextrakt des allergenen 
Lebensmittels, wie z.B. Erdnuss, in vitro bestimmt werden. Eine Sensibilisierung gegen 
Gesamtproteinextrakt ist jedoch nicht zwangsläufig ein Beleg für eine klinisch relevante 
Allergie. Um die diagnostische Spezifität zu erhöhen, wurde in den letzten Jahren vermehrt das 
spezifische IgE gegen einzelne Allergenkomponenten bestimmt. In diesem Zusammenhang wird 
z.B. das 2S Albumin aus Erdnuss, Ara h 2, als diagnostischer Marker für eine klinisch relevante 
Erdnussallergie beschrieben. Demnach könnten spezifische IgE-Bindungsmuster auf Protein- 
und Peptidebene als Ansatzpunkt für die Entwicklung neuer diagnostischer, aber auch 
therapeutischer Werkzeuge dienen. Jedoch ist die Relevanz allergener Speicherproteine, wie 
den 2S Albuminen und den 7S Globulinen, aus Erdnuss, Erbse und Soja teils unbekannt oder 
wird kontrovers diskutiert. Gleiches gilt für deren IgE-Bindungsstellen. 
Daher war das Ziel dieser Arbeit, die IgE-Bindung von Leguminosenallergikern und Patienten, 
welche eine Leguminosensensibilisierung aufweisen, aber klinisch tolerant sind, zu vergleichen. 
Hierfür wurde die IgE-Bindung der allergischen und toleranten Patienten an homologe 2S- und 
7S-Leguminosenallergene aus Erdnuss, Erbse und Soja auf Protein- und Peptidebene bestimmt. 
In diese Arbeit wurden Seren von allergischen und sensibilisierten, aber toleranten, Kindern mit 
einem Leguminosenextrakt spezifischem IgE ≥ 0.35 kUA/L eingeschlossen. Für die 
Untersuchungen wurden jeweils Gesamtproteinextrakte und rekombinante 7S Globuline und 
2S Albumine aus Erdnuss, Erbse und Soja hergestellt. Anschließend wurde in Immunoblot-
Analysen die IgE-Bindung an die Extrakte und die rekombinanten Leguminosenallergene 
bestimmt und das spezifische IgE densitometrisch quantifiziert. Zur Untersuchung der IgE-
Bindung auf Peptidebene wurden überlappende Peptide (15 Aminosäuren lang, 4 Aminosäuren 
Überlappung) aller untersuchten Leguminosenallergene synthetisiert und mittels CelluSpotTM-
Multipeptidmikroarrays gegen die Patientenseren getestet. Zusätzlich wurde auf Peptidebene 
der Einfluss der posttranslationalen Prolinhydroxylierung von Ara h 2 aus Erdnuss auf dessen 
IgE-Bindungsfähigkeit und auf die diagnostische Genauigkeit untersucht. Für Erdnuss- und 
Erbsenallergie konnten, gemäß der in dieser Studie festgelegten Selektionskriterien, spezifische 
diagnostische Kandidatenpeptide identifiziert werden. Anschließend wurde mittels ROC-
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Kurvenanalyse (Receiver Operating Characteristic) der diagnostische Vorhersagewert der 
einzelnen rekombinanten Allergene und der spezifischen Kandidatenpeptide bestimmt und 
miteinander verglichen. Dadurch sollte bestimmt werden, ob Peptide als zusätzliche oder 
alternative Reagenzien in der in-vitro-Allergiediagnostik eingesetzt werden können. Aufgrund 
der sehr begrenzten Anzahl an verfügbaren und eingeschlossenen Sojaallergikern wurde Soja 
jedoch von einer detaillierten Peptid- und ROC-Kurvenanalyse ausgeschlossen. 
Basierend auf den Immunoblot-Analysen und den jeweiligen Nachweisgrenzen zeigten 48%, 
79% und 50% der Erdnuss-, Erbsen- und Sojaallergiker jeweils eine Serum IgE-Bindung an die 
7S Globuline rAra h 1, rPis s 1 und rGly m 5.03. Im Gegensatz dazu zeigten von den gegen 
Erdnuss, Erbse und Soja sensibilisierten, aber klinisch toleranten Kindern jeweils nur 8%, 20% 
und 20% eine IgE-Bindung an die entsprechenden 7S Globuline. 
Der auffälligste Unterschied zwischen den drei Leguminosen zeigte sich jedoch in Bezug auf die 
Relevanz der 2S Albumine. In der Immunoblot-Analyse zeigten jeweils 65% und 78% der 
erdnussallergischen Kinder eine IgE-Bindung an rAra h 2.01 bzw. rAra h 2.02. Im Gegensatz 
dazu zeigten die gegen Erdnuss sensibilisierten, aber klinisch toleranten Kinder keinerlei 
Bindung an die beiden Ara h 2 Isoformen. Diese Entdeckung unterstreicht die Relevanz und 
den diagnostische Wert der beiden Isoformen, insbesondere von Ara h 2.02, in der Vorhersage 
einer klinisch relevanten Erdnussallergie. Solch eine klinische Relevanz der 2S Albumine konnte 
in Erbse und Soja, basierend auf den Immunoblot-Analysen, nicht nachgewiesen werden. Hier 
zeigte sich eine vernachlässigbare oder fehlende IgE-Bindung der erbsen- und sojaallergischen 
Kinder an die jeweils untersuchten 2S Albumine. Eine ROC-Kurvenanalyse der mittels 
Immunoblot untersuchten rekombinanten Proteine ergab, dass rAra h 2.02 (AUC (Area under 
curve) 0.86) und rPis s 1 (AUC 0.86) den höchsten diagnostischen Vorhersagewert für eine 
klinisch relevante Erdnuss- bzw. Erbsenallergie besaßen, auch im Vergleich zum jeweiligen 
Leguminosenextrakt.  
Im Hinblick auf potenzielle diagnostische Peptide konnten bei Ara h 2 zwei Peptidpaare 
(AUC 0.87-0.90) mit einem diagnostischen Vorhersagewert identifiziert werden, welcher mit 
dem des Volllängenproteins rAra h 2.02 (AUC 0.86) vergleichbar war. Jedes der beiden 
Peptidpaare enthielt mindestens ein Peptid mit hydroxylierten Prolinresten. Darüber hinaus 
konnte für Peptide von Ara h 2 beobachtet werden, dass die Hydroxylierung von Prolinresten 
die Sensitivität bei gleichbleibender Spezifität erhöht, was diese posttranslationale Modifikation 
zu einem interessanten Ziel für zukünftige diagnostische Ansätze macht. Für eine mögliche in-
vitro-Diagnostik der Erbsenallergie konnten elf diagnostische Peptide von Pis s 1 identifiziert 
werden, welche mit einer AUC von 0.99, verglichen mit Erbsenextrakt (AUC 0.81) und rPis s 1 
(AUC 0.86), den höchsten diagnostischen Vorhersagewert in dieser Studienpopulation hatten. 
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Zusammengefasst waren in dieser pädiatrischen Studienpopulation signifikante Unterschiede 
hinsichtlich der allergenen Potenz der 2S und 7S Speicherproteine in den drei untersuchten 
Hülsenfrüchten erkennbar. In Erdnuss konnten Ara h 1 und Ara h 2 als relevante Allergene 
identifiziert werden. Jedoch zeigte sich, basierend auf den Immunoblot-Analysen, dass das 2S 
Albumin Ara h 2 und insbesondere die Isoform Ara h 2.02 das relevanteste Allergen mit dem 
höchsten diagnostischen Vorhersagewert in dieser Studienpopulation war. Im Gegensatz dazu 
konnten in dieser Studie die 2S Albumine aus Erbse und Soja als relevante Allergene 
ausgeschlossen werden. Wohingegen das 7S Globulin Pis s 1 als Haupt- und 
immunodominantes Allergen in Erbse identifiziert werden konnte. Ein ähnlicher Trend schien 
sich bei Gly m 5.03 aus Soja abzuzeichnen. Aber aufgrund der sehr begrenzten Anzahl an 
eingeschlossenen sojaallergischen Kindern, ließen sich keine weiteren Schlussfolgerungen 
ziehen. 
Darüber hinaus ergab die Untersuchung der IgE-Bindung auf Peptidebene, dass Peptide mit 
einem diagnostischen Vorhersagewert identifiziert werden konnten, welcher vergleichbar oder 
sogar besser als der der jeweiligen rekombinanten Volllängenproteine war. Diese Peptide 
können möglicherweise als zusätzliche oder alternative Reagenzien in der in-vitro-
Allergiediagnostik dienen. Dies erfordert jedoch zunächst eine weitere Überprüfung in einer 
prospektiven Studie.  
Außerdem wurden auf der Grundlage dieser Arbeit neue Erkenntnisse über relevante Allergene 
und deren IgE-Bindungsstellen gewonnen, welche die Entwicklung neuartiger therapeutischer 
Reagenzien mit verbesserten Eigenschaften unterstützen können. In diesem Zusammenhang 
wurde die IgE-Bindung an lineare Peptide in Annäherung an lineare IgE-Epitope untersucht. 
Anhand eines 27-mer Peptids, welches hydroxylierte Prolinreste enthielt, konnte eindeutig 
gezeigt werden, dass lineare IgE-bindende Epitope von natürlichem Ara h 2 eine relevante 
Mastzelldegranulation induzieren können. Dieses Resultat unterstreicht die potenzielle 
Relevanz linearer IgE-Bindungsstellen bezüglich der Gesamtallergenität und sollte daher bei 
der Entwicklung neuer immuntherapeutischer Ansätze zur Behandlung von Erdnussallergien 
berücksichtigt werden, da andernfalls Patienten einem höheren Risiko unerwünschter 
Nebenwirkungen ausgesetzt sein könnten. Darüber hinaus können die in dieser Studie 
identifizierten immunodominanten IgE-Bindungsstellen von Pis s 1 als Grundlage für die 
Entwicklung von hypoallergenen Substitutionsvarianten für die allergenspezifische 
Immuntherapie von Erbsenallergien dienen. Die Relevanz dieser Ergebnisse sollte in Bezug auf 
Wirksamkeit und Sicherheit in präklinischen Studien zur Therapie von Erdnuss- bzw. 
Erbsenallergie weiter untersucht werden. 
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1.2 Abstract 
Legumes are an important source of high-value proteins and edible oils in the human diet. 
However, they are also a known and frequent source of severe allergic reactions to foods. 
Immediate-type allergic reactions are elicited by allergenic proteins (allergens), mediated by 
their interaction with the immune system via allergen-specific antibodies of the isotype 
immunoglobulin E (IgE). These specific IgE antibodies to total protein of the allergenic food, 
e.g. peanut, can be measured in vitro to diagnose an allergic sensitization. While specific IgE to 
total protein extracts indicates a sensitization, it is not necessarily a proof for clinical reactivity. 
In contrast, the measurement of specific IgE to selected allergen components, such as the peanut 
2S albumin Ara h 2, has been proposed to improve the in vitro diagnostic specificity for a clinical 
reactivity. In this context, specific recognition patterns of IgE binding at the protein level, and 
further at the peptide level, may allow the development of advanced diagnostic approaches, 
and innovative therapeutic reagents. However, knowledge about the relevance of allergenic 
storage proteins, such as 2S albumins and 7S globulins, of the legumes peanut, pea and soybean 
and their IgE-binding peptides is in part controversial or limited. 
Therefore, this study aimed to determine the serum IgE binding of legume-allergic versus 
sensitized but clinically tolerant children to homologous 2S and 7S legume allergens from 
peanut, pea and soybean at the protein and peptide level. 
In this study, sera from legume-allergic as well as sensitized but clinically tolerant children with 
legume extract-specific IgE ≥ 0.35 kUA/L were included. Total protein extracts and recombinant 
7S globulins and 2S albumins of peanut, pea, and soybean, respectively, were prepared. 
Afterwards, serum IgE binding to legume extracts and recombinant legume allergens was 
individually determined by means of densitometric immunoblot analysis. Overlapping peptides 
(15 AA; offset 4 AA) representing the full-length allergens were synthesized and analyzed for 
their ability to bind serum IgE on CelluSpotTM multipeptide microarrays. The influence of post-
translational hydroxylation of proline residues in peanut Ara h 2 on the capacity to bind serum 
IgE and thus on the diagnostic value was additionally investigated on the peptide level. 
Potential candidate diagnostic peptides specific for peanut and pea allergy were identified, 
according to predefined selection criteria that were established in this study. Finally, the 
diagnostic value of the investigated recombinant legume allergens and of the potential 
candidate diagnostic peptides was determined as area under curve (AUC) by receiver operating 
characteristic (ROC) curve analysis. By doing so, it should be determined whether peptides may 
serve as additional or alternative reagents in the in vitro diagnosis of legume allergy. However, 
due to the very limited number of available and included soybean-allergic patients, soybean 
was excluded from a detailed analysis of candidate diagnostic peptides and ROC curve analysis. 
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According to immunoblot analysis and the specific limit of detection, serum IgE of 48%, 79% 
and 50% of peanut-, pea- and soybean-allergic children bound to the 7S globulins rAra h 1, 
rPis s 1 and rGly m 5.03, respectively. Of the peanut-, pea- and soybean-sensitized but tolerant 
children 8%, 20% and 20% showed a serum IgE binding to the respective 7S globulins. 
The most striking difference between the three legumes could be observed regarding the 
relevance of the 2S albumins. In immunoblot analysis, 65% and 78% of peanut-allergic children 
showed a serum IgE binding to rAra h 2.01 and rAra h 2.02, respectively. In contrast, serum 
IgE of peanut-sensitized but tolerant patients did not bind to any of both Ara h 2 isoforms. 
Hence, the relevance and the diagnostic value of both 2S albumin isoforms, especially of 
rAra h 2.02, in peanut allergy were further highlighted. Based on immunoblot analyses, such 
clinical relevance of 2S albumins could not be found in pea and soybean. Here, negligible or no 
serum IgE binding to 2S albumins was detectable in pea- as well as soybean-allergic children. 
Based on the ROC curve analysis of the investigated recombinant proteins analyzed in 
immunoblot, rAra h 2.02 (AUC 0.86) and rPis s 1 (AUC 0.86) had the highest diagnostic value 
in peanut and pea allergy, respectively, also compared to the respective total legume protein 
extract. 
With regard to potential diagnostic peptides, two Ara h 2-derived peptide pairs (AUC 0.87-0.90) 
with a diagnostic value comparable to that of full-length rAra h 2.02 (AUC 0.86) could be 
identified for peanut allergy. Each of the two peptide pairs contains at least one peptide with 
hydroxylated proline residues. In addition, it could be observed that hydroxylation of proline 
residues in Ara h 2-derived peptides increased the sensitivity while maintaining the specificity 
which makes this post-translational modification an interesting target for future diagnostic 
approaches. Moreover, for pea allergy eleven candidate diagnostic peptides of Pis s 1 could be 
identified. Compared to pea extract and rPis s 1, the candidate peptides had, with an AUC of 
0.99, the highest diagnostic value in this pea study population. 
In this pediatric study population, general differences in allergenic potency of the 2S and 7S 
storage proteins of the three investigated legumes were apparent. In peanut, Ara h 1 and Ara h 2 
could be identified as relevant allergens. However, based on immunoblot analysis, the 2S 
albumin Ara h 2, in particular the isoform Ara h 2.02, was the most relevant allergen with the 
highest diagnostic value in this peanut study population. In contrast, in pea and soybean 2S 
albumins were excluded as relevant allergens in this study. In pea, the 7S globulin Pis s 1 was 
identified as a major and immunodominant allergen. A similar trend seemed to be observed for 
Gly m 5.03 and soybean, but due to the limited number of soybean-allergic patients included 
in this study, no further conclusions can be drawn.  
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In addition, the investigation of IgE binding at the linear peptide level revealed that peptides 
with a diagnostic value that is comparable or even better than that of the respective full-length 
recombinant proteins could be identified. These peptides may potentially serve as additional or 
alternative reagents in the in vitro diagnosis of legume allergy; however, this requires 
verification in a prospective study. 
Moreover, based on this study, additional knowledge about relevant allergens and their IgE-
binding sites was obtained. This knowledge can support the development of novel therapeutic 
reagents with improved characteristics. In this context, IgE binding to short peptides of allergens 
was investigated to localize IgE-binding sites in approximation to linear (continuous) IgE 
epitopes. It could be shown that linear IgE-binding epitopes of natural Ara h 2, as represented 
by a 27-mer peptide, still induced relevant mast cell degranulation. This finding underpins the 
potential relevance of linear IgE-binding sites with regard to total allergenic potency, and 
should thus be considered in the development of novel reagents for the immunotherapeutic 
treatment of peanut allergy as otherwise patients might be at high risk of unintended side 
effects. In addition, identified immunodominant IgE-binding sites of Pis s 1 may allow the 
development of hypoallergenic substitution variants for allergen-specific immunotherapy of pea 
allergy. The relevance of these findings with regard to efficacy and safety can be further 
addressed in preclinical models of peanut and pea allergy, respectively.  
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2 Introduction 
2.1 Pathomechanism of type I allergic reaction 
With an increasing prevalence, approximately 20-30% of the population suffer worldwide from 
allergic diseases making them a public health concern (Pawankar et al. 2011). 
In 1906, the pediatrician Clemens von Pirquet firstly described the term ‘allergy’ as a change in 
reactivity of the immune system comprising similarly hyper- and hyposensitivity reactions 
(Huber 2006). Today the term ‘allergy’ describes an immunological hypersensitivity reaction 
against harmless, non-infectious environmental proteins, called allergens (Galli et al. 2008; 
Johansson et al. 2004). Known allergen sources are, for example, pollen, animal dander, house 
dust mite, food, latex and insect venoms (Galli et al. 2008). 
According to the Gell-Coombs classification hypersensitivity reactions are divided into four 
types: the IgE-mediated immediate reaction (type I), the antibody-mediated cytotoxic reaction 
(type II), the immune-complex-mediated reaction (type III) and the cell-mediated reaction 
(type IV) (Descotes and Choquet-Kastylevsky 2001). 
IgE-mediated type I allergic reactions (Figure 1), including food allergy, are divided into a 
sensitization phase followed by the immediate phase, in which the patient shows the typical 
allergic symptoms (Larché et al. 2006). The sensitization phase is initiated by the internalization 
and the processing of allergens by antigen-presenting cells such as dendritic cells which 
afterwards present resulting allergen-derived peptides on major histocompatibility complex 
(MHC) class II molecules on their surface to naïve T cells (Galli et al. 2008; Holgate and Polosa 
2008). The recognition of the peptide MHC class II complex by the T-cell receptor (TCR) on 
naïve T cells and the interaction of co-stimulatory molecules located on antigen-presenting cells 
and naïve T cells leads to an activation and differentiation of the respective naïve T cell 
(Humeniuk et al. 2017). Depending on the surrounding cytokines, T cells can differentiate into 
T helper 1 (Th1), Th2, Th17 and induced regulatory T (iTreg) cells (Zhu and Paul 2008). In 
the case of type I allergic reactions T cells differentiate into Th2 cells (Humeniuk et al. 2017). 
Naïve B cells interact with the native allergen through their B cell receptor and load it on their 
surface via MHC class II molecule (Poulsen and Hummelshoj 2007). Activated B cells ligate 
with Th2 cells via CD40-CD40L and CD80/86-CD28 interactions (Galli et al. 2008; Poulsen and 
Hummelshoj 2007). These interactions in combination with the presence of cytokines such as 
IL-4 induce the differentiation of the activated B cell into an allergen-specific IgE-producing 
plasma B cell. Allergen-specific IgE antibodies bind to mast cells and basophil granulocytes by 
their high-affinity IgE receptor (FcεRI) (Poulsen and Hummelshoj 2007). The production of 
allergen-specific IgE antibodies and their binding to mast cells and basophils constitute the 
sensitization phase. It is noteworthy that the presence of allergen-specific IgE antibodies does 
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not necessarily mean that a patient is allergic, it only indicates that a sensitization took place 
(Poulsen and Hummelshoj 2007).  
The immediate phase of the allergic reaction is characterized by the cross-linking of FcεRI-
bound IgE on mast cells and basophils after repeated allergen exposure (Larché et al. 2006; 
Poulsen and Hummelshoj 2007). This requires the presence of at least two binding sites 
(epitopes) for allergen-specific IgE on the surface of allergens. In general, linear and 
conformational epitopes can be distinguished. Linear epitopes are displayed by a continuous 
stretch of the amino acid sequence of the allergen. In contrast, conformational epitopes consist 
of amino acids that are discontinuous in the primary structure but folding of the allergen brings 
the amino acids into spatial proximity (Pomés 2010). The cross-linking of FcεRI-bound IgE then 
induces the degranulation and the release of vasoactive amines (mainly histamine), lipid 
mediators (prostaglandins and cysteinyl leukotrienes), chemokines and other cytokines (Larché 
et al. 2006; Poulsen and Hummelshoj 2007). Finally, the release of these mediators causes 
immediate allergic symptoms such as allergic rhinitis, asthma, urticaria, gastrointestinal 
reactions (vomiting and diarrhea) and anaphylaxis (Galli et al. 2008).  
 
 
Figure 1: Pathomechanism of IgE-mediated type I allergic reaction (adapted from (Poulsen and Hummelshoj 
2007)). 
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The reasons why some people develop allergies compared to others remaining tolerant are still 
unclear. Several host (e.g. heredity) and environmental factors (e.g. exposure to allergens) are 
suggested being responsible for the development of an allergy. Furthermore, reduced infections 
in childhood may increase the risk of developing an allergic disease (Swert 1999).  
Several properties are described that can explain the allergenicity of a protein but so far no 
general paradigm is developed for the prediction of a protein’s allergenicity. Structural, 
physicochemical and biochemical properties or aspects like functional domains, hydrophobicity, 
stability, formation of oligomers or aggregates, solubility and post-translational modifications 
(e.g. hydroxylation) are described as contributing to the allergenicity of a protein (Bernard et 
al. 2015; Scheurer et al. 2015). Furthermore, with increasing evidence allergens are attributed 
to possess intrinsic adjuvant properties (e.g. lipid- and carbohydrate binding properties, and 
protease activity) stimulating the innate immunity (Scheurer et al. 2015). 
 
2.2 IgE-mediated food allergy 
Precise data on the prevalence of food allergy are lacking but published data suggest that, 
depended on the investigated food, up to 10% can be affected, with food allergies being more 
common in children compared to adults (Sicherer and Sampson 2018). However, the accurate 
determination of food allergy prevalence is hindered by influencing factors such as geographic 
variation, study populations and methodologies (Sicherer and Sampson 2014). For example, 
the prevalence of self-reported food allergy is compared to the prevalence defined by objective 
methods like oral food challenges of lower evidence (Rona et al. 2007). 
Depending on the clinical appearance, the route of allergic sensitization and the underlying 
immunologic mechanisms, IgE-mediated food allergies can be divided into class 1 (classic) and 
class 2 (pollen-associated) food allergies (Breiteneder and Ebner 2000; Valenta et al. 2015). In 
class 1, also known as classic food allergy, the sensitization occurs via the gastrointestinal tract 
and eliciting allergens are described as being resistant to gastric digestion. The most important 
class 1 food allergens are cow’s milk, hen’s egg and legumes. Class 1 food allergy affects more 
frequently young children, whereas class 2 food allergy is more frequently found in adults. 
Class 2 or pollen-associated food allergy is caused by IgE cross-reactivity between sensitizing 
inhalant allergens (e.g. birch pollen Bet v 1) and homologous nonsensitizing but allergic 
reaction eliciting food allergens (e.g. apple Mal d 1, celery Api g 1) (Breiteneder and Ebner 
2000). Compared to class 1 food allergens, stability of class 2 food allergens is considered to be 
more affected by heat and proteolytic digestion. Therefore, class 2 food allergens may likely not 
cause a sensitization via the gastrointestinal tract but instead via the respiratory tract (Egger et 
al. 2006; Valenta et al. 2015). However, this is also controversially discussed.  
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Food allergy can lead to severe allergic reactions and especially legumes are described as the 
most common foods triggering anaphylaxis. A more detailed analysis showed age-dependent 
trigger profiles with hen’s egg, cow’s milk and peanut being the most frequently elicitors in 
children, and wheat, celery, soy and shellfish in adults (Worm et al. 2014). 
According to structural and biological properties, animal and plant food allergens can be 
classified into families and superfamilies. The majority of animal food allergens belong to one 
of three major families, the caseins, tropomyosins and EF-hand proteins (Mills 2011).  
Plant food allergens can be classified into four common protein families and superfamilies: the 
cupin superfamily (7S and 11S globulin seed storage proteins), the prolamin superfamily (2S 
albumin seed storage proteins, nonspecific lipid-transfer proteins, cereal α-amylase and 
protease inhibitors, and cereal prolamins), the proteins of the plant defense system 
(pathogenesis-related proteins, Kunitz-type protease inhibitors and proteases) and the profilins 
(Breiteneder and Radauer 2004). 
Seed storage proteins are known food allergens and a sensitization to legume seed storage 
proteins, such as peanut Ara h 1, Ara h 2 and Ara h 3 or soybean Gly m 5 and Gly m 6, is 
considered as an indication for an increased risk of severe allergic reactions (Asarnoj et al. 2010; 
Holzhauser et al. 2009; Vereda et al. 2011).   
 
2.2.1 Legume seed storage proteins 
Legumes belong to the Fabaceae family and include many allergenic foods, for example, peanut, 
soybean, lentil, lupine, chickpea and pea. Due to their high protein and lipid content, legumes 
have a high nutritional value and are thus preferably included in the human diet (Verma et al. 
2013). 
More than 80% of total legume seed protein is constituted by the seed storage proteins (Kigel 
and Galili 1995). They serve as a source of amino acids and nitrogen during germination and 
seedling growth. Despite different structures, seed storage proteins share common properties. 
Their expression is tissue-specific and dependent on the stage of development. In the mature 
seed, seed storage proteins form discrete compartments called protein bodies. Seed storage 
proteins are commonly secretory proteins containing an N-terminal signal peptide which is co-
translationally cleaved as the protein is translocated from the cytosol into the lumen of the 
endoplasmic reticulum. In the lumen of the endoplasmic reticulum, post-translational 
modifications like folding, disulfide bond formation, subunit assembly and glycosylation take 
place. Depending on their solubility and their sedimentation coefficients, legume seed storage 
proteins can be classified into three groups: 2S albumins, 7S and 11S globulins (Shewry et al. 
1995). 
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2S albumins are small water-soluble proteins and although 2S albumins, like the other storage 
proteins, exhibit a high level of polymorphism they share common characteristics (Shewry et 
al. 1995). Typical 2S albumins are composed of a large and a small subunit linked by two 
disulfide bonds (Moreno and Clemente 2008). There are, however, some variations regarding 
subunit and disulfide bond formation. For example, peanut Ara h 2 is composed of a single 
chain. Whereas pea albumin 1 (PA1) is so far described as being composed of two separate 
subunits not linked by disulfide bonds (Higgins et al. 1986; Lehmann et al. 2006). 2S albumins 
have in common to contain five α-helices, a C-terminal loop and a solvent-exposed and flexible 
hypervariable region. The hypervariable region of 2S albumins is described as an important 
region containing immunodominant IgE epitopes (Moreno and Clemente 2008). Moreover, the 
whole protein is stabilized by four disulfide bonds that are formed between eight conserved 
cysteine residues (Moreno and Clemente 2008). The disulfide bonds result in the formation of 
a stable core structure that is highly resistant to proteolytic digestion and heating, another 
common characteristic of 2S albumins (Lehmann et al. 2006). Despite the above-mentioned 
common properties of 2S albumins, they share only a low sequence homology of 14 to 40% 
(Moreno and Clemente 2008).  
The globulin storage proteins are salt-soluble proteins that can be divided on the basis of their 
sedimentation coefficients into 7S vicilin-type globulins and 11S legumin-type globulins 
(Shewry et al. 1995). Both storage proteins are bicupins characterized by two β-barrel core 
domains and belong to the cupin superfamily (Breiteneder and Radauer 2004).    
7S globulins are trimeric proteins with molecular weights of 150 to 190 kDa. The subunits have 
molecular weights between 40 and 80 kDa and their composition varies considerably among 
different legume species due to different degrees of post-translational modifications such as 
proteolytic processing and/or glycosylation (Breiteneder and Radauer 2004; Shewry et al. 
1995). Pis s 1 from pea, for example, undergoes post-translational proteolysis leading to 
subunits of different molecular weights (Gatehouse et al. 1982). Compared to 2S albumins, 7S 
globulins do not contain cysteine residues leading to the absence of disulfide bonds (Shewry et 
al. 1995).  
The stabile structure of the trimeric complex of the 7S globulins is suggested being responsible 
for the relative resistance to heating and digestion. This stability is a property they have in 
common with the 2S albumins (Deshpande and Damodaran 1989; Maleki et al. 2000a).   
11S globulins are hexameric proteins with each subunit being composed of an acidic and a basic 
chain associated by one interchain disulfide bond (Shewry et al. 1995). Mature hexameric 11S 
globulins have molecular weights between 300 and 400 kDa and are generally not glycosylated 
(Fukushima 1991).  
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It should also be pointed out that cross-reactivity between different legume species is a frequent 
immunological phenomenon (Verma et al. 2013). Cross-reactivity is the binding of antibodies 
directed against a specific allergen to other homologous proteins. High sequence identity and 
structural homologies are often the cause of cross-reactivity (Aalberse 2000). This cross-
reaction can be of clinical relevance. For example, in peanut-allergic patients it could be shown 
that a clinically relevant cross-reactivity with lupine occurs frequently (Moneret-Vautrin et al. 
1999). On the contrary, it is reported that a serological cross-reactivity between peanut and 
other legumes, which occurs frequently, is in less than 5% of clinical relevance (Sicherer and 
Wood 2012). Different dietary habits of the respective study population may be one reason 
explaining this controversy.  
 
2.2.2 Diagnosis  
An accurate allergy diagnosis is important to avoid unnecessary dietary restrictions and allergic 
reactions. The first steps in the diagnostic process are often a detailed analysis of the medical 
history and a physical examination. Both approaches should help identifying the offending food 
allergens and to differentiate the reaction from nonallergic disorders (Boyce et al. 2010). 
However, food allergies based on the reports of parents and patients need further verification 
as they tend to be overestimated (Rona et al. 2007). Moreover, hidden allergens or 
contaminated foods can influence the patient’s history and lead to an incorrect allergy diagnosis 
(Ebo and Stevens 2001). An expert panel from the United States agrees that a diagnosis based 
alone on either medical history or physical examination is not sufficient sensitive and specific 
(Boyce et al. 2010). As add-on to a convincing history, sometimes an elimination diet avoiding 
the suspected offending food is recommended. Clearing allergic symptoms during elimination 
diet of a particular food can support the previous allergy diagnosis. However, elimination diets 
can lead to malnutrition and should therefore not be carried out over a longer period of time 
(Boyce et al. 2010).  
Once the history is obtained and an IgE-mediated food allergy is suspected, skin prick tests 
(SPT) are often performed for further evaluation. During SPT food allergen extracts or fresh 
foods are pricked under the skin of the forearm or upper back of the patient with a lancet 
(Muraro et al. 2014). The test is considered positive when the patient shows a wheal at the 
prick site that is at least 3 mm larger than the wheal of the negative control. Accordingly, a 
positive SPT indicates a sensitization meaning that the patient has specific IgE antibodies to the 
tested food. Cross-linking of these IgE antibodies bound to cutaneous mast cells by food 
allergens induces wheal development (Boyce et al. 2010). The SPT is easy to handle, safe and 
a useful method to determine whether a patient is sensitized or not. A negative SPT result 
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excludes with a high predictive accuracy a clinically relevant food allergy (Sampson 2004). A 
positive SPT result, on the other hand, must be interpreted with caution as a sensitization does 
not necessarily mean that a patient is allergic and shows clinical symptoms. Which means that 
the SPT cannot differentiate between clinically relevant sensitization, leading to allergy, and 
irrelevant sensitization, i.e. tolerance. Moreover, cross-reactive proteins within different foods 
can lead to false-positive test results further hindering an accurate allergy diagnosis (Sicherer 
2001). This illustrates that by using an extract-based SPT a differentiation between a co-
sensitization and a cross-reactivity is not possible and is especially a problem when multiple 
positive test results are observed (Ferreira et al. 2014). 
Another frequently used diagnostic method is the in vitro quantitative measurement of specific 
IgE antibodies to food extracts or to single allergen components in patients’ blood samples 
(Renz et al. 2018). Very common in this context is the ImmunoCAPTM system (Thermo Fisher 
Scientific). The ImmunoCAPTM is an automated system using a cellulose matrix as solid phase 
to which the allergens are covalently bound. Allergen-bound serum IgE is afterwards detected 
by a fluorescently labeled anti-human IgE. sIgE levels are quantified by means of a World Health 
Organization (WHO) reference used for standard curve generation (Hamilton 2010). For some 
foods, like peanut, egg, milk and fish, 95% predictive food-specific IgE levels were established 
(Sampson and Ho 1997). However, there are some patients with sIgE levels below the specific 
cut-off/decision point but still showing allergic symptoms (Lopes de Oliveira et al. 2013). 
Furthermore, it could be shown that specific decision points vary depended on, for example, 
the used test system, patients’ ages and the population (Komata et al. 2007; Perry et al. 2004; 
Wang et al. 2008). Like the SPT, the quantitative measurement of food extract-specific IgE poses 
the same problems to physicians: a positive result just indicates a sensitization and not 
necessarily a clinically relevant allergy. In addition, extracts contain different proteins that can 
be responsible for the allergic reaction on one side, but on the other side contain cross-reactive 
proteins binding serum IgE that can result in clinically irrelevant sIgE levels (Renz et al. 2018). 
Furthermore, missing or underrepresented as well as instable allergens within commercial 
extracts can lead to false-negative sensitization results (Muraro et al. 2014). The mentioned 
limitations of an extract-based diagnosis gave rise to a more sensitive and specific diagnostic 
approach, called component-resolved diagnostics (CRD), that measures the specific IgE to single 
allergen components. Allergen components used for CRD are either natural, purified allergens 
or recombinant allergens. Measurement of sIgE can be done via the above-mentioned 
ImmunoCAPTM system or via ImmunoCAPTM ISAC (Immuno-Solid phase Allergen Chip, Thermo 
Fisher Scientific). The ISAC is a multiplex platform where the sIgE in a low quantity of serum 
to more than 100 natural or recombinant allergen components can be measured in a single 
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assay in parallel (Canonica et al. 2013). A major advantage of CRD over extract-based testing 
is that it may enable a differentiation between genuine sensitization and cross-reactivity 
(Canonica et al. 2013; Ferreira et al. 2014). In some study populations, the use of food-specific 
marker allergens allows i) the identification of patients at high risk for developing an allergic 
reaction and ii) the prediction of the severity of the allergic reaction. For example, Beyer et al. 
identified sIgE to Ara h 2 and Cor a 14 as risk markers for peanut and hazelnut allergy, 
respectively (Beyer et al. 2015). A study from Asarnoj et al. analyzing a Swedish birth cohort 
suggested that a sensitization to the storage proteins Ara h 1, Ara h 2 or Ara h 3 is predictive 
for severe peanut allergy, whereas a sensitization to the birch-related protein Ara h 8 and birch 
pollen is predictive for mild peanut symptoms, if any (Asarnoj et al. 2010). This observation 
was further verified by an add-on study showing that a sensitization only to Ara h 8 is a strong 
indication for peanut tolerance (Asarnoj et al. 2012). Another study from Vereda et al. showed 
comparable results regarding the correlation between the sensitization profiles and the severity 
of the reaction, but also illustrates the limitations of this component-resolved approach. 
Depending on the geographical region, different component sensitization profiles could be 
observed. US patients were primarily sensitized to Ara h 1, Ara h 2 and Ara h 3, Spanish patients 
to Ara h 9 (nonspecific lipid-transfer protein) and Swedish patients to Ara h 8 (Vereda et al. 
2011). Another limitation of CRD is that most of the used components are recombinant proteins 
representing just one isoform compared to their natural counterpart. The usage of a single 
recombinant isoform in CRD, however, can lead to a lower test sensitivity as some isoforms are 
less allergenic. Comparable with the other mentioned diagnostic approaches, CRD suffers from 
the same limitation as, except for a few examples, based on the presence or absence of sIgE to 
allergen components, the clinical phenotype cannot clearly be predicted in all cases. 
Nevertheless, CRD is a useful diagnostic approach but further studies are needed to establish 
and confirm correlations between sensitization profiles and clinical phenotypes in different 
study populations. 
For the future, an epitope-resolved diagnosis analyzing the IgE binding on the epitope level 
instead of on the protein level is under investigation. By doing so, it might be possible to identify 
homologous IgE-binding areas on different allergens that might explain cross-reactivity, or to 
identify different IgE-binding areas that might explain a divergent allergic phenotype. Several 
studies suggest an additional diagnostic value of epitope information over extract and 
component-resolved diagnosis. Studies from Beyer et al. and Shreffler et al. on peanut allergy 
showed that the recognition of specific epitopes correlates with the clinical reactivity and that 
the IgE epitope diversity correlates with the severity of an allergic reaction, respectively (Beyer 
et al. 2003; Shreffler et al. 2004). Similar results could be observed for milk allergy where 
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higher IgE epitope diversity and affinity correlated with the clinical phenotype and the severity 
of the reaction (Wang et al. 2010). Another study from Lin et al. combined peptide microarray 
data with bioinformatic analyses to predict peanut allergy with an improved and high accuracy 
(Lin et al. 2012). However, at this time these studies require further validation before applied 
in clinical routine. Therefore, despite the many diagnostic efforts that have been made, the 
double-blind, placebo-controlled food challenge (DBPCFC) remains the gold standard in allergy 
diagnosis (Boyce et al. 2010). Here, increasing doses of the suspected offending food blinded 
in a matrix are administered to the patients and symptoms are recorded (Renz et al. 2018). 
Compared to the single-blind and the open food challenge, the DBPCFC is the least subjective 
and is least influenced by patient and physician bias (Boyce et al. 2010). As neither the patient 
nor the physician knows whether the placebo or the allergenic food is offered to the patient. To 
date, DBPCFC shows the highest specificity in the diagnosis of food allergy. However, it is time 
consuming, expensive and harbors the risk of severe allergic reactions limiting its use in routine 
clinical application (Boyce et al. 2010).  
Thus, alternative diagnostic methods such as the above-mentioned promising epitope analysis 
reducing the need for DBPCFCs should be explored for their potential value in allergy diagnosis. 
 
2.2.3 Treatment 
Currently no causative therapy is available for food allergies in clinical routine and allergen 
avoidance is the only effective method of preventing an allergic reaction (Renz et al. 2018). 
However, allergen avoidance is often complicated by unlabeled food allergens (hidden 
allergens). Shared equipment during the manufacture of foods can lead to allergen cross-
contamination and is therefore often the source of hidden allergens (Röder et al. 2008). Further, 
an extensive and longterm allergen avoidance can lead to nutritional deficiencies and affect 
quality of life (Muraro et al. 2014). For treatment of severe allergic symptoms adrenaline is 
administered, whereas local mild symptoms are treated with antihistamines (Renz et al. 2018). 
Currently, several allergen-specific and non-specific therapy strategies are under investigation. 
To date, due to safety and efficacy issues allergen-specific immunotherapies for food allergies 
are only administered in clinical trials (Muraro et al. 2014; Renz et al. 2018).  
During allergen-specific immunotherapy (SIT) increasing doses of the offending food allergen 
are administered to patients with the goal to induce persistent tolerance (Jutel and Akdis 2011). 
Although SIT has been used for a longer time for the treatment of venom or inhalant allergies, 
its exact underlying mechanism is not yet fully understood. Several mechanisms effecting T- 
and B-cells are described. SIT induces the generation of regulatory T-cells suppressing Th2 cells 
and thereby the release of inflammatory Th2 cytokines (Jutel and Akdis 2011). Regulatory T-
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cells secret IL-10 and TGF-β, two anti-inflammatory cytokines that suppress effector cells like 
mast cells, eosinophils and basophils of the allergic inflammation (Jutel and Akdis 2011; Jutel 
et al. 2013). Furthermore, regulatory T-cells and especially their secreted anti-inflammatory 
cytokine IL-10 suppress an inflammatory reaction on the B-cell level by suppressing IgE and by 
leading to an isotype switch from IgE to IgG4 (Jutel and Akdis 2011; Jutel et al. 2013; Meiler 
et al. 2008). IgG4 antibodies compete with IgE bound to mast cells for allergen binding and 
thereby inhibit mast cell and basophil degranulation which in turn leads to reduced allergic 
reactions (Jutel et al. 2013; Niederberger 2009).   
Severe side effects during subcutaneous immunotherapy (SCIT) shifted the focus to oral 
immunotherapy (OIT). Several studies on peanut, egg or milk OIT report a successful 
desensitization in a subgroup of patients leading to a temporary tolerance immediately after 
the immunotherapy (Anagnostou et al. 2014; Caminiti et al. 2015; Pajno et al. 2010). However, 
only a limited number of desensitized patients develop a persistent tolerance where no regular 
allergen exposure is required to maintain protection (Caminiti et al. 2015). In addition, side 
effects ranging from mild to severe during OIT have led to the development of novel and safer 
therapeutic approaches (Anagnostou et al. 2014; Blumchen et al. 2010). These therapeutic 
approaches comprise, for example, other routes of application or the use of modified food 
allergens. Other routes of application include sublingual immunotherapy (SLIT) or 
epicutaneous immunotherapy (EPIT). A study comparing SLIT and OIT in peanut-allergic 
patients revealed that SLIT is safer but less efficacious (Narisety et al. 2015). Approaches 
combining SLIT with subsequent OIT showed promising results regarding efficacy, but 
nonetheless, oral administration caused in comparison to sublingual administration more 
systemic side effects (Keet et al. 2012). In EPIT, the allergen is administered to the skin via a 
patch. A study on EPIT showed a good safety profile, but similar to SLIT, OIT seems more 
efficacious (Jones et al. 2017). 
Another approach to reduce the risk of side effects during immunotherapy and to increase 
efficacy is the use of modified allergens. In this context, for example, hypoallergens, synthetic 
peptides, plasmid DNA-based methods, conjugation to immunostimulatory sequences and 
chimeric allergen-human fusion proteins were investigated, as was summarized elsewhere 
(Cook and Burks 2018; Nowak-Węgrzyn and Sampson 2011). Allergens are modified by means 
of site-directed mutagenesis or chemical methods (e.g. reduction/alkylation) with the goal to 
generate hypoallergenic proteins that show a reduced IgE-binding capacity but a retained T-cell 
immunogenicity (Bannon et al. 2001; Swoboda et al. 2007; Toda et al. 2011; Zuidmeer-
Jongejan et al. 2012). The use of single hypoallergens to treat food allergy can be hampered by 
allergies that are caused by multiple allergens. Furthermore, the use of unfolded allergens for 
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immunotherapy is not applicable for every food allergen. A study from Bernard et al. on peanut 
Ara h 2 showed that a sensitization to linear and conformational epitopes is dependent on the 
patient, highlighting that unfolded allergens can still be allergenic for some patients (Bernard 
et al. 2015).  
Another approach using heat/phenol killed Escherichia coli expressing hypoallergenic peanut 
allergens Ara h 1, Ara h 2 and Ara h 3 modified by amino acid substitutions failed due to severe 
side effects (Wood et al. 2013).  
Besides hypoallergens, allergen-derived peptides are also under investigation for their 
applicability in immunotherapy. Like hypoallergenic proteins, peptides aim at reducing side 
effects during immunotherapy while inducing immunologic tolerance. Therefore, short 
synthetic peptides containing allergen-derived T-cell epitopes are applied. The idea behind that 
approach is that peptides comprising between 8-16 amino acids are too short for cross-linking 
of FcεRI-bound IgE on effector cells and thus reduce the risk of an allergic reaction (Cook and 
Burks 2018). Simms et al. reported that an Ara h 1-derived peptide containing one T-cell epitope 
can protect against peanut-induced anaphylaxis in a mouse model (Simms et al. 2016). Further 
studies are required to investigate this in humans. Furthermore, the length of the administered 
peptides should be chosen carefully, as 15 AA long peptides can still induce a mediator-release 
in vitro (Bernard et al. 2015).  
A further approach uses plasmid DNA encoding a major allergen to treat anaphylaxis in mice. 
Here, the oral administration of chitosan-plasmid DNA nanoparticles encoding Ara h 2 resulted 
in a modified immune system that protects against anaphylaxis (Roy et al. 1999).  
The administration of allergens coupled to immunostimulatory sequences (e.g. CpG motives) 
represents another promising approach. Nanoparticles composed of protamine and CpG-
oligonucleotides complexed with Ara h 2 were able to shift the immune system of mice toward 
Th1-cell response (Pali-Schöll et al. 2013). A further novel therapeutic strategy uses chimeric 
allergen-human fusion proteins. The idea behind this approach is that allergens fused to human 
IgG Fcγ1 can inhibit mast cell degranulation by an indirect cross-linking of FcεRI and FcγRIIb 
(Liu et al. 2013).  
Beside allergen-specific, also non-specific strategies like anti-IgE therapy, traditional Chinese 
herbs, probiotics and cytokine/anticytokine therapies are in the focus of research (Nowak-
Węgrzyn and Sampson 2011; Sicherer and Sampson 2009). Very promising in this context is 
the use of anti-IgE therapy in combination with OIT. Studies on peanut and cow’s milk OIT 
showed that a treatment with omalizumab (humanized anti-IgE antibodies) allowed the 
administration of higher doses and reduced side effects, respectively (MacGinnitie et al. 2017; 
Wood et al. 2016).    
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2.3 Peanut allergy 
Peanut allergy is one of the best-studied legume allergies so far and is especially associated with 
severe allergic reactions in children (Worm et al. 2014). Even small amounts like 0.2 mg peanut 
protein can elicit allergic reactions in 5% of peanut-allergic subjects (Taylor et al. 2014). 
Compared with other legume allergies, peanut allergy is reported to persist throughout life in 
most patients with only approximately 22% outgrowing it (Peters et al. 2015; Skolnick et al. 
2001). According to a meta-analysis in Europe, the prevalence of food-challenged-defined 
peanut allergy is 0.2% (Nwaru et al. 2014).  
Peanut has a total protein content of 21-29% which is comparable to pea but below the protein 
content of soybean (Dwivedi et al. 1990; Koppelman et al. 2001). However, peanut has with 
an average of 44% a high oil content (Dwivedi et al. 1990).  
To date 16 peanut allergens (Ara h 1 to 17) and numerous isoforms are listed in the WHO/IUIS 
allergen nomenclature database (http://www.allergen.org/). These 16 allergens can be divided 
into the following families and superfamilies: cupins (Ara h 1, Ara h 3), prolamins (Ara h 2, 
Ara h 6, Ara h 7, Ara h 9, Ara h 16, Ara h 17), profilin (Ara h 5), Bet v 1-like (Ara h 8), glycosyl 
transferases GT-C (Ara h 10, Ara h 11, Ara h 14, Ara h 15) and scorpion toxin-like knottins 
(Ara h 12, Ara h 13) (Cabanillas et al. 2018; Mueller et al. 2014). Among these allergens, 
Ara h 1, Ara h 2 and Ara h 3 account together for the vast majority of the total peanut protein 
content and are together with Ara h 6 considered as the major peanut allergens (Hebling et al. 
2012; Mueller et al. 2014). In particular, Ara h 2 is described in several publications as an 
important diagnostic marker for the prediction of peanut allergy (Beyer et al. 2015; Lieberman 
et al. 2013; van Erp et al. 2017).   
Peanut, like most other legumes, is boiled or roasted before consumption. Therefore, the effect 
of thermal processing on its allergenicity has been widely studied with the result that roasting 
can lead to an increase in IgE-binding capacity while boiling decreases IgE-binding capacity of 
peanut extract (Maleki et al. 2000b; Mondoulet et al. 2005). However, the relevance of this 
finding with regard to clinical reactivity is still unclear. 
 
2.3.1 Peanut allergen Ara h 1 
Ara h 1, the first identified peanut allergen, is a well characterized vicilin-type 7S globulin with 
a molecular weight of ~64 kDa (Burks et al. 1991; Burks et al. 1995). It is a very abundant 
protein in peanut accounting for approximately 12-16% of the total peanut protein (Koppelman 
et al. 2001). Burks et al. identified two cDNA clones encoding Ara h 1, clone P41B and clone 
P17 with the sequence of P41B being registered in the WHO/IUIS database. Both sequences 
share high sequence homology and contain one N-linked glycosylation site and an N-terminal 
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signal peptide (Burks et al. 1995). Ara h 1 is described as a stable homotrimeric protein held 
together by hydrophobic interactions (Maleki et al. 2000a; Shin et al. 1998). Even roasting does 
not significantly affect the secondary structure of Ara h 1 and leads to an increased IgE-binding 
capacity and resistance to heating and digestion (Maleki et al. 2000b; Nesbit et al. 2012). 
Whereas boiling causes aggregation of Ara h 1 and resulted in a reduction in IgE binding (Blanc 
et al. 2011). The resolved crystal structure of the Ara h 1 core region shows high similarity with 
other known vicilin allergens like soybean Gly m 5 (Cabanos et al. 2011). In addition to the 
high structural similarity, Ara h 1 shows high sequence similarity with other vicilins like, for 
example, from lentil, pea and soybean, which additionally can cause IgE cross-reactivity (Barre 
et al. 2005; Kroghsbo et al. 2011).  
Ara h 1 is a major allergen recognized by the great majority of peanut-allergic patients in most 
published studies (Burks et al. 1995; Kleber-Janke et al. 1999; Shreffler et al. 2004). A review 
focusing on the diagnostic accuracy of peanut components revealed for sIgE to Ara h 1, 
dependent on the study population and study design, sensitivities between 26-92% (median 
56%) and specificities between 41-95% (median 85%). While the specificity of the 11S globulin 
Ara h 3 is comparable (median 86%), its sensitivity is lower (median 45%) (Klemans et al. 
2015).  
To date, 24 linear IgE epitopes of Ara h 1 have been identified, of which four are considered 
immunodominant as being recognized by more than 80% of peanut-allergic patients (Burks et 
al. 1997; Shreffler et al. 2004). It could be shown that the majority of the identified IgE epitopes 
of Ara h 1 are located at the monomer-monomer contact sites protected from degradation 
(Maleki et al. 2000a). Studies analyzing the allergenic potential of Ara h 1 digestion peptides 
revealed a significant IgE-binding capacity and an induction of mediator release in basophils 
(Eiwegger et al. 2006; Wichers et al. 2004).  
Shreffler et al. observed a heterogeneous IgE binding to Ara h 1-derived peptides among peanut-
allergic patients, but the authors could also show that the number of recognized peptides seems 
to correlate with the severity of the allergic reaction (Shreffler et al. 2004). Another study from 
Lin et al. analyzed peanut-allergic and peanut-tolerant patients for their IgE binding to peptides 
of peanut proteins. Amongst other results, an improvement in the diagnostic accuracy of Ara h 1 
peptides compared to whole peanut extract could be shown (Lin et al. 2012).  
 
2.3.2 Peanut allergen Ara h 2 
Ara h 2, the second major allergen from peanut, is a monomeric 2S albumin seed storage protein 
with a molecular weight of ~18 kDa whose allergenic potential has been reported in several 
studies (Burks et al. 1992; Clarke et al. 1998; Kleber-Janke et al. 1999; Steven Stanley and 
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Bannon 1999). It accounts for 6-9% of the total peanut protein content and functions as trypsin 
inhibitor (Koppelman et al. 2001; Maleki et al. 2003). The allergen is composed of a single 
chain and as a member of the 2S albumins it contains the conserved eight cysteine residue motif 
forming 4 disulfide bonds (Lehmann et al. 2006). Another post-translational modification of 
Ara h 2 is the hydroxylation of specific proline residues (Li et al. 2010).  
In general, Ara h 2 contains two isoforms, Ara h 2.01 (~17 kDa) and Ara h 2.02 (~18 kDa). 
Both share high sequence identity with the major difference being a 12 amino acid insertion in 
the isoform Ara 2.02 (Chatel et al. 2003). In addition, compared to Ara h 2.01, Ara h 2.02 
contains three instead of two hydroxylated proline residues (Li et al. 2010).  
Ara h 2 is a largely α-helical protein that shares high sequence and structure homology with 
Ara h 6 which in turn is responsible for the observed cross-reactivity of both peanut allergens 
(Lehmann et al. 2003; Lehmann et al. 2006). The structure of Ara h 2 and especially its core 
structure protects the protein from proteolytic digestion (Lehmann et al. 2006; Sen et al. 2002). 
It is reported that protease (trypsin and chymotrypsin) digested Ara h 2 still possess allergenic 
potency by inducing mediator release (Lehmann et al. 2006). In addition, Sen et al. reported 
that a 10 kDa protease-resistant fragment of Ara h 2 containing immunodominant IgE-epitopes 
can bind serum IgE from pooled peanut-sensitized patients (Sen et al. 2002).  
Controversial data are available regarding the importance of linear and conformational IgE 
epitopes of Ara h 2 (Albrecht et al. 2009; Apostolovic et al. 2013; Bublin et al. 2013; King et al. 
2005; Starkl et al. 2012). However, Bernard et al. convincingly showed that a sensitization to 
linear and conformational epitopes is dependent on the respective patient. The authors 
observed that in approximately half of the investigated peanut-allergic patients reduced and 
alkylated natural Ara h 2 and a 27-mer Ara h 2-derived peptide are still allergenic triggering 
mast cell degranulation (Bernard et al. 2015). In addition, the study by Starkl and co-workers 
showed a relevant remaining IgE binding and mediator release capacity of reduced and 
alkylated natural Ara h 2 (Starkl et al. 2012).  
Furthermore, by comparing natural and recombinant Ara h 2 as well as Ara h 2-derived peptides 
with and without hydroxyproline residues, Bernard et al. highlighted the relevance of proline 
hydroxylation for proper IgE binding and allergenicity (Bernard et al. 2015). These observations 
highlight the importance of both types of epitopes and of post-translational hydroxylation as 
well as their consideration in the development of diagnostic and therapeutic approaches. 
So far, more than ten IgE-binding epitopes of Ara h 2 have been identified and three of them 
suggested as being immunodominant. Two of the three immunodominant epitopes contain the 
amino acid sequence DPYSPS that is described as an important motif for IgE binding (Han et 
al. 2016; Stanley et al. 1997). This motif is present on a flexible surface loop and occurs two 
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and three times in Ara h 2.01 and Ara h 2.02, respectively (Chatel et al. 2003; Lehmann et al. 
2006). Studies on both recombinant and natural Ara h 2 isoforms showed a higher IgE-binding 
capacity and assumed a higher allergenicity of Ara h 2.02 (Bernard et al. 2015; Chatel et al. 
2003; Hales et al. 2004). Furthermore, Li et al. identified the second proline within this DPYSPS 
motif as being hydroxylated and Bernard et al. showed that this hydroxylation is relevant for 
the IgE-binding capacity and the allergenicity of Ara h 2 (Bernard et al. 2015; Li et al. 2010). 
In another experimental setup using liposomal nanoparticles, called nanoallergens, that display 
different linear IgE-binding epitopes of Ara h 2, similar results could be shown. Nanoallergens 
presenting a 15-mer peptide containing 2 repeated DPYSPS motifs with the second proline 
being hydroxylated showed, compared to the other analyzed epitopes and its counterpart 
without hydroxyproline, an enhanced immunogenicity triggering mast cell degranulation (Deak 
et al. 2017).   
In general, Ara h 2 is attributed as high allergenic protein being a more potent elicitor in 
inducing mediator release in comparison to other peanut allergens (Blanc et al. 2009; Kulis et 
al. 2012; Palmer et al. 2005; Peeters et al. 2007).    
The diagnostic value of sIgE to Ara h 2 in comparison to peanut extract and other peanut 
allergens has been widely investigated with the result that Ara h 2 shows the best accuracy in 
predicting peanut allergy in infants and children (Beyer et al. 2015; Dang et al. 2012; Ebisawa 
et al. 2012; Keet et al. 2013; Klemans et al. 2013b; Lieberman et al. 2013; Nicolaou et al. 2011; 
van Erp et al. 2017). In this context, the review of Klemans and co-workers reported for sIgE to 
Ara h 2 sensitivities ranging from 60% to 100% (median 88%) and specificities from 60% to 
96% (median 85%) (Klemans et al. 2015).  
Of all studies, Nicolaou et al. reported at a cut-off of 0.35 kUA/L of Ara h 2 sIgE the highest 
sensitivity/specificity pair of 100% and 96%, respectively (Nicolaou et al. 2011). Areas under 
the receiver operating characteristic (ROC) curves (AUC) of 0.84-0.99 highlight an almost 
perfect accuracy in diagnosing peanut allergy (Beyer et al. 2015; Dang et al. 2012; Ebisawa et 
al. 2012; Klemans et al. 2013b; Lieberman et al. 2013; Nicolaou et al. 2011; van Erp et al. 
2017). However, all published studies on the diagnostic value of sIgE to Ara h 2 are based on 
ImmunoCAPTM or ImmunoCAPTM ISAC measurements using E. coli-expressed recombinant 
Ara h 2.01 (personal communication Dr. Jonas Lidholm, Thermo Fisher Scientific and 
http://www.phadia.com/en/Products/Allergy-testing-products/ImmunoCAP-Allergen-
Information/Food-of-Plant-Origin/Allergen-Components/rAra-h-1-recombinant-Peanut/). A 
potential increase in the diagnostic accuracy due to the use of Ara h 2.02 compared to Ara h 2.01 
has not yet been shown. 
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Ara h 2.01-derived peptides are also under investigation with regard to their diagnostic 
application (Beyer et al. 2003; Lin et al. 2012; Otsu et al. 2015). Using SPOT-membrane peptide 
arrays displaying the three immunodominant epitopes of Ara h 2.01, formerly identified by 
Stanley et al., and sera from peanut-allergic and peanut-sensitized but clinically tolerant 
patients, Beyer et al. could show that differences in IgE binding exist between both study groups. 
Between ~60-70% of peanut-allergic patients recognize each of the three immunodominant 
epitopes compared to less than 10% of peanut-tolerant patients (Beyer et al. 2003).  In a more 
recent approach, Lin et al. used peptide microarray data and combined them with bioinformatic 
analyses to increase the accuracy of IgE-binding peptides in diagnosing peanut allergy. The 
authors determined serum IgE binding from peanut-allergic and tolerant patients to overlapping 
peptides covering the entire primary structures of Ara h 1, Ara h 2.01 and Ara h 3. Hereby, 
especially the IgE binding to peptides of Ara h 2.01 showed, in comparison to Ara h 1 and 
Ara h 3, the best discrimination between allergic and tolerant patients. By applying machine 
learning methods on microarray data, the authors could identify four peptide biomarkers 
increasing the diagnostic accuracy and reaching a sensitivity and specificity of 90% and 97%, 
respectively. These four peptides are each one peptide of Ara h 1 and Ara h 3 and two of 
Ara h 2.01 with the two Ara h 2.01 peptides being described as the key biomarkers (Lin et al. 
2012).  
Even though the mentioned studies show promising results, the isoform Ara h 2.02 and the 
post-translational hydroxylation of proline within the DPYSPOHS motif have not been considered 
in any such study so far.  
 
2.3.3 Identified gaps in peanut allergen knowledge 
Ara h 1, Ara h 2 and Ara h 3 are considered as the major peanut allergens. Of these proteins, 
Ara h 2 has so far the highest diagnostic value, including high sensitivity and specificity. 
Compared to Ara h 2, Ara h 1 also has a high specificity but a lower sensitivity, whereas Ara h 3 
has an even lower sensitivity (as outlined in chapters 2.3.1 and 2.3.2). Therefore, the 2S 
albumin Ara h 2 and the 7S globulin Ara h 1 were selected for further investigation.  
Despite the fact that several studies are published on the relevance and the diagnostic value of 
Ara h 1, Ara h 2.01 and derived peptides, at the beginning of this PhD project, no diagnostic 
studies have been published that also take into account the second Ara h 2 isoform Ara h 2.02. 
Although there is evidence that Ara h 2.02 may be even more relevant than Ara h 2.01 and may 
possibly improve peanut allergy diagnosis (Bernard et al. 2015; Hales et al. 2004). Therefore, 
recombinant Ara h 1, Ara h 2.01, Ara h 2.02 and derived peptides should be analyzed for their 
relevance and diagnostic value using sera from symptomatic peanut-allergic versus tolerant 
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sensitized subjects without clinical symptoms. In addition, special attention should be given to 
peptides of Ara h 2.01 and Ara h 2.02 containing hydroxylated proline residues as the diagnostic 
and therapeutic relevance of the post-translational site-specific hydroxylation within the Ara h 2 
binding sites has not been investigated at the beginning of this PhD project to the best of 
knowledge. 
 
2.4 Pea allergy 
Pea as well as chickpea and lentil play an increasingly important role as basic ingredients in the 
vegan diet. After boiling, these legumes are processed into different dishes like spreads, salads 
or real main dishes. 
Allergy to pea (Pisum sativum) is with an estimated prevalence of 0.2% less common compared 
to other legume allergies (Kroghsbo et al. 2011). Some basic work on pea allergens and pea 
allergy has been done by Sanchez and co-workers (Sanchez-Monge et al. 2004). However, pea 
allergy has been less investigated than, for example, peanut allergy. Hence, only limited data 
are published on pea allergens. 
Moreover, compared to soybean and peanut, pea has not been assigned as an ingredient for 
mandatory labeling in the EU (Regulation (EU) No 1169/2011). However, pea has been 
recognized as an emerging allergenic food (personal communication Prof. Dr. K. Beyer) and 
severe allergic reactions have been described in children and adults after ingestion of pea 
(Lavine and Ben-Shoshan 2019; Wensing et al. 2003). The unintended ingestion of hidden pea 
protein in food products was reported as the major cause of anaphylactic reactions in a recently 
published Canadian pediatric case series (Lavine and Ben-Shoshan 2019).  
Moreover, relevant clinical cross-reactivity has been described with chickpea, lentil and peanut 
(Martínez San Ireneo et al. 2008; Wensing et al. 2003).  
The protein content of pea seeds is on average 22% and the majority of extractable pea proteins 
are globulins with an average content of 70% of the total protein (Tzitzikas et al. 2006). So far, 
only three pea allergens, namely Pis s 1, Pis s 2 and Pis s 3, have been registered by the 
WHO/IUIS Allergen Nomenclature Sub-Committee (http://www.allergen.org/). Pis s 1 and 
Pis s 2 are globulin storage proteins and have been suggested by Sanchez and co-workers as 
potential major pea allergens. However, this study was essentially based on a serum pool and 
natural protein preparations enriched in vicilins. In addition, individual data on serum IgE 
binding were largely undisclosed (Sanchez-Monge et al. 2004). 
Pis s 1 is a 44 kDa vicilin, whereas Pis s 2 is described as a 63 kDa convicilin (Croy et al. 1980; 
Sanchez-Monge et al. 2004). Both proteins share high sequence identity (~70%) and 
serological cross-reactivity, with the major difference being an N-terminal insertion in the 
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sequence of Pis s 2 (Bown et al. 1988; Croy et al. 1980). Pis s 3 belongs to the prolamin 
superfamily and is a 9.5 kDa non-specific lipid-transfer protein (nsLTP) that was recently 
identified and structurally characterized as a putative food allergen with IgE cross-reactivity to 
the nsLTP and major peach allergen Pru p 3 (Bogdanov et al. 2016).  
Despite IgE cross-reactivity to Pis s 3, Bogdanov and co-workers just included patients with a 
sensitization to Pru p 3 and did not provide evidence for a pea allergy (Bogdanov et al. 2016). 
Compared to other legumes, such as peanut and soybean, no albumin has yet been described 
as an allergen in pea. However, it is reported that the albumin fraction might also include 
allergenic proteins (Malley et al. 1975; Sell et al. 2005). 
 
2.4.1 Pea allergen Pis s 1 
It is reported that Pis s 1 comprises between 1% and 8% of the total protein in pea extract. In 
this context, Kroghsbo et al. calculated a content of 1% to 4%, whereas Tzitzikas et al. reported 
that Pis s 1 accounts for 4% to 8% of the total pea protein content (Kroghsbo et al. 2011; 
Tzitzikas et al. 2006). 
Pis s 1 is described as a glycosylated protein that undergoes extensive post-translational 
proteolysis leading to subunits ranging from 12.5 to 36 kDa (Badenoch-Jones et al. 1981; 
Gatehouse et al. 1981; Gatehouse et al. 1982; Sanchez-Monge et al. 2004). In contrast, Pis s 2 
is not glycosylated and does not undergo such post-translational cleavage (Bown et al. 1988; 
Croy et al. 1980).  
Published data on immunochemical properties of Pis s 1 are rare and are only based on purified 
vicilin fractions. Before Pis s 1 was identified as an allergen, a study by Wensing et al. detected 
clinically relevant cross-reactivity between pea and peanut with Ara h 1 and pea vicilin being 
responsible for this cross-reactivity. By investigating sera from three pea-allergic patients who 
subsequently developed peanut allergy, the authors could identify pea vicilin as the primary 
sensitizer in this study population using immunoblot as well as ELISA inhibition experiments 
with extracts, natural Ara h 1 and pea vicilin (Wensing et al. 2003). In 2004, Sanchez-Monge 
et al. identified Pis s 1 as potential major allergen from pea. In this study, sera from 18 pea-
allergic patients were pooled or individually analyzed for their IgE binding to pea extract or pea 
extract fractions enriched in pea vicilin. The authors reported that 77% and 55% of the analyzed 
patients showed an IgE binding to full-length Pis s 1 and its proteolytic 32 kDa subunit, 
respectively. The other proteolytic subunits of Pis s 1 were also bound by serum IgE but to a 
lower extent (16-26%). Furthermore, the study revealed that Pis s 1 is heat stabile to boiling 
and cross-reacts with Len c 1 from lentil. Within this study the sequences of two isoforms of 
Pis s 1, namely Pis s 1.0101 and Pis s 1.0102, could be identified (Sanchez-Monge et al. 2004).  
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2.4.2 Putative pea allergens PA1 and PA2 
The albumin fraction of pea contains two major components, the low molecular weight pea 
albumin 1 (PA1) and the high molecular weight pea albumin 2 (PA2) (Gruen et al. 1987).  
Although both proteins belong to the albumins, their suspected particular functions are different 
and their respective belonging to the conventional storage proteins is assumed being different.  
PA1 is a sulfur-rich protein that contributes ~50% of the total pea seed sulfur amino acids 
although it accounts for less than 10% of the pea seed total protein (Higgins et al. 1986). This 
in combination with its degradation upon germination suggests that it may function as sulfur 
storage protein (Gatehouse et al. 1985; Gruen et al. 1987; Higgins et al. 1986). The 11 kDa 
PA1 proprotein can be proteolytically cleaved into two mature proteins, PA1a (~6 kDa) and 
PA1b (~4 kDa). The described potential proteolytic cleavage of PA1 comprises the removal of 
a linker propeptide and a C-terminal propeptide composed of 6 and 8 amino acids, respectively. 
Unlike the conventional 2S albumin storage proteins, PA1a and PA1b are described as not being 
linked by interchain disulfide bonds, thus, potentially leading to two separate monomers 
(Higgins et al. 1986). Currently, six variants of PA1 (PA1 A-F) with only minor sequence 
variations are listed in the UniProt database (http://www.uniprot.org/) highlighting the 
multigenic character of this pea 2S albumin. More recent research on PA1b has shown that this 
protein possess insecticidal activity (Da Silva et al. 2010; Jouvensal et al. 2003).         
The content of PA2 in pea seeds is comparable to PA1 but due to a lower content of sulfur 
amino acids, it accounts for only ~11% of the total pea seed sulfur amino acids (Higgins et al. 
1987). In contrast to conventional storage proteins, PA2 is synthesized without signal peptide, 
is localized in the cytosol and is not significantly degraded in germinating seeds which seems 
to exclude a function as conventional storage protein (Croy et al. 1984; Higgins et al. 1987). 
Regarding the function of PA2, Vioque et al. suggested that it may function as a lectin and 
Vigeolas et al. observed a role of PA2 in polyamine metabolism (Vigeolas et al. 2008; Vioque et 
al. 1998). PA2 shows high sequence homology with a 2S albumin from lentil and is a 
homodimer (48-53 kDa) consisting of the two subunits PA2a (~25 kDa) and PA2b (~24 kDa) 
that show high sequence identity (Croy et al. 1984; Gruen et al. 1987; Higgins et al. 1987).  
The relevance of both pea albumins, PA1 and PA2, as potential allergens in pea-allergic patients 
is still unclear and none of both is so far registered as an allergen. Beside two studies by Vioque 
et al., who analyzed chickpea-sensitive individuals for their IgE binding to purified natural PA1 
and PA2 in dot blot analysis, no IgE-binding data are currently available (Vioque et al. 1998; 
Vioque et al. 1999).  
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2.4.3 Identified gaps in pea allergen knowledge 
At the beginning of this PhD project, allergy to pea has been little investigated at the clinical 
and molecular level compared to peanut. Due to the very limited data on the relevance of 
individual allergens, in vitro diagnosis of pea allergy, that complements clinical anamnesis, is 
based solely on pea extract allergen preparations. In contrast, a component-based approach 
may improve the diagnostic accuracy as outlined for peanut. With regard to the relevance of 
individual pea components, the 7S globulin Pis s 1 has been suggested as a potential major 
allergen. In addition, it is speculated that the albumin fraction, including the major components 
PA1 and PA2, may also contain allergenic proteins. However, detailed data on relevant or major 
albumin and vicilin allergens of pea and their IgE-binding sites are currently lacking. 
Therefore, recombinant Pis s 1, PA1 and PA2 should be generated and investigated for their 
relevance and diagnostic value using sera from symptomatic pea-allergic versus pea-sensitized 
but clinically tolerant children. Moreover, derived peptides should be additionally investigated 
for their serum IgE-binding capacity and their diagnostic value. 
 
2.5 Soybean allergy 
The estimated prevalence of food-challenged-defined soybean allergy is 0.3% in Europe (Nwaru 
et al. 2014). It is reported that the majority (~50%) of soybean-allergic children outgrow their 
allergy and develop tolerance at the age of 7 years (Savage et al. 2010). Compared with the 
other two legumes, peanut and pea, soybean has with ~40% the highest protein content making 
it an even more important nutrient supplier (Liu 1997). The consumption of soybean products 
like soy milk, soy sauce, soy oil and tofu has increased in Europe over the last few years. 
Especially tofu is preferably included in the vegetarian diet as meat substitute. In addition, soy 
is used as emulsifier, protein filler and texturizer in the industrial food production. Many foods 
like breads, cakes, sausages and margarine contain soy proteins and thus harbor the risk of 
triggering an allergic reaction due to accidental consumption (Steinman 1996).  
Several IgE-binding soybean proteins have been identified but only eight of them are registered 
as allergens in the WHO/IUIS database: the hullproteins Gly m 1 and Gly m 2, the birch pollen-
related allergens Gly m 3 and Gly m 4, the storage globulins Gly m 5 and Gly m 6, the storage 
albumin Gly m 8 as well as the seed biotinylated protein Gly m 7 (Ballmer-Weber and Vieths 
2008; Cabanillas et al. 2018; Holzhauser et al. 2009; Kattan et al. 2011; Riascos et al. 2016).  
Especially the storage proteins are described as major soybean allergens in children (Ebisawa 
et al. 2013; Ito et al. 2011). However, the diagnostic value of soybean allergens is limited due 
to controversial results of independent studies (Ebisawa et al. 2013; Fukutomi et al. 2012; 
Holzhauser et al. 2009; Ito et al. 2011; Kattan and Sampson 2015; Klemans et al. 2013a; Lin et 
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al. 2006; Vissers et al. 2011). Differences in the study populations (e.g. age) or in the dietary 
habits due to geographic variations might explain the observed inconsistencies. 
In addition, Maruyama and co-workers recently published the so far largest component-resolved 
diagnostic (CRD) study including all soybean allergen components. By investigating the serum 
IgE binding of Japanese children with suspected soybean allergy to soybean extract and 
individual components, the authors observed a patient-dependent, rather individual 
sensitization profile. Moreover, no single soybean component alone had a high diagnostic value 
in this Japanese cohort (Maruyama et al. 2018).   
Currently, for serological soybean allergy diagnosis using ImmunoCAPTM or ImmunoCAPTM ISAC 
recombinant (r) and natural (n) allergen components rGly m 4, nGly m 5 and nGly m 6 are 
available (www.thermoscientific.com/phadia/de), in addition to soybean extract-based 
analysis.  
 
2.5.1 Soybean allergen Gly m 5 
Gly m 5, or β-conglycinin, is a vicilin-type 7S globulin that accounts for approximately 30% of 
the total seed proteins (Maruyama et al. 2001). The whole protein has a molecular weight of 
150-200 kDa and is composed of the three subunits α, α’ and β having molecular weights of 
67 kDa, 71 kDa and 50 kDa, respectively (Maruyama et al. 1998). The three subunits α, α’ and β are referred to as Gly m 5.0101, Gly m 5.0201 and Gly m 5.0301/Gly m 5.0302, respectively 
(Holzhauser et al. 2009). After their synthesis on the rough endoplasmic reticulum and the 
cotranslational processing including removal of signal peptide and N-glycosylation, the subunits 
assemble into trimers which are transported into the vacuole where the subunits are further 
processed to the mature densely packed trimeric from. Different trimeric subunit compositions 
are described including homotrimers. Despite N-terminal extension regions in α and α’, all three 
subunits consist of a homologous core region that shows a sequence homology of ~70-90% 
(Maruyama et al. 1998). Furthermore, Gly m 5 shows sequence homology with other 7S 
globulins from hazelnut, pea and peanut leading to serological cross-reactivity (Kroghsbo et al. 
2011).  
One of the first studies analyzing the IgE-binding capacity of Gly m 5 was published by 
Holzhauser et al. in 2009. The authors analyzed soybean-allergic children and adults and could 
identify a sensitization to Gly m 5 in 43% of the study population, with all children being 
sensitized to Gly m 5 (Holzhauser et al. 2009). Furthermore, this study and a study from Japan 
by Ito et al., who analyzed Japanese soybean-allergic children, revealed a correlation of sIgE to 
Gly m 5 and Gly m 6 with the severity of symptoms of soybean allergy (Holzhauser et al. 2009; 
Ito et al. 2011).  
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All three subunits of Gly m 5 can bind serum IgE from soybean-allergic patients (Holzhauser et 
al. 2009; Maruyama et al. 2018).  
Depending on the investigated study population, different sensitization frequencies to the three 
subunits of Gly m 5 were reported. In previous unpublished investigations in the research group 
of Dr. Thomas Holzhauser (Division of Allergology, Paul-Ehrlich-Institut), sensitization to the 
the β-subunit Gly m 5.03 was more frequent in European soybean-allergic subjects (adults and 
children) than to the α or α’ subunits of Gly m 5, namely Gly m 5.01 and Gly m 5.02. In contrast, 
a recently published CRD study from Japan reported the highest frequency of sensitization to 
the α-subunit Gly m 5.01 (92.5%) and only a 60% sensitization frequency to Gly m 5.03 in 
Japanese soy-allergic children (Maruyama et al. 2018). 
Studies on adult soybean-allergic patients instead reported no predominant sensitization to 
Gly m 5 and Gly m 6 or no correlation of Gly m 5 and Gly m 6 with the severity of symptoms 
(Fukutomi et al. 2012; Klemans et al. 2013a; Vissers et al. 2011). Klemans et al. from the 
Netherlands detected a correlation of sIgE to Gly m 5 and Gly m 6 with rather mild and not 
severe allergic symptoms (Klemans et al. 2013a). Studies from Vissers et al. and Fukutomi et al. 
found a predominant sensitization to Gly m 4 and no or only a limited sensitization to Gly m 5 
and Gly m 6 in adult soybean-allergic patients (Fukutomi et al. 2012; Vissers et al. 2011). The 
findings of these three studies show that the sensitization profiles are different between 
soybean-allergic adults and children. All three studies report a correlation between the sIgE to 
soybean Gly m 4 and birch pollen Bet v 1. This suggests that in adult soybean-allergic patients 
a sensitization via the gastrointestinal tract is rather rare and soybean allergy is probably 
mediated by IgE cross-reactivity between Bet v 1 and its homologue Gly m 4. 
The diagnostic value of sIgE to Gly m 5 was assessed in comparison to other soybean 
components in  soybean-allergic children from Japan, from the US and in soybean-allergic 
adults from the Netherlands, respectively, in three independent studies. All studies could detect 
a sensitization to Gly m 5 in their soybean-allergic study population; however in all three study 
populations the diagnostic value of Gly m 5 was below that of Gly m 8, the soybean 2S albumin, 
leading to the author’s hypothesis that Gly m 8 might be a better marker for soybean allergy 
(Ebisawa et al. 2013; Kattan and Sampson 2015; Klemans et al. 2013a). However, in a larger 
CRD study, sensitization to Gly m 8 in Japanese children was only 60% (Maruyama et al. 2018). 
To date only IgE-binding peptides of Gly m 5.01 have been analyzed and identified, but the 
potential of IgE-binding peptides to improve soybean allergy diagnosis has never been 
investigated (Sun et al. 2013).  
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2.5.2 Soybean allergen Gly m 8 
Two 2S albumins sharing 74% sequence identity could be isolated from soybean seeds: 2S 
albumin 1 (AL1) and 2S albumin 3 (AL3) (Lin et al. 2004). Since 2014, AL3 (UniProt accession 
no. P19594) is registered as an allergen in the IUIS database and is designated as Gly m 8.  
The mature Gly m 8 is described as being composed of two subunits linked by two disulfide 
bonds (Lin et al. 2004). Furthermore, it is characterized as an α-helical protein, which is 
resistant to heating and chemical denaturation (Lin et al. 2004).   
Regarding the relevance of this soybean allergen, controversial data are available. The first 
study on the IgE reactivity of Gly m 8 was published by Lin et al. in 2006. Using sera from 
European soybean-allergic patients with the majority being children, the authors could not 
detect any serum IgE binding to rAL1, rAL3 and nAL3 (Lin et al. 2006). Although Vissers et al. 
reported a higher level of sIgE to Gly m 8 compared to Gly m 5 and Gly m 6, the authors 
identified Gly m 4 as the protein with the highest predictive value in their study population. 
This study population was composed of adult soybean-allergic patients having a very low level 
of soybean-specific IgE but being primarily sensitized to Bet v 1 (Vissers et al. 2011). Other 
studies in contrast report a predominant role of sIgE to natural Gly m 8 (nGly m 8) in predicting 
soybean allergy (Ebisawa et al. 2013; Kattan and Sampson 2015; Klemans et al. 2013a). Using 
sera from Japanese children sensitized to soybean, ~90% of soybean-allergic children showed 
a sensitization to nGly m 8 (nAL3). ROC curve analysis in comparison to Gly m 5 (AUC 0.69) 
and Gly m 6 (AUC 0.64) showed a better diagnostic accuracy of Gly m 8 (AUC 0.75) in this 
Japanese cohort (Ebisawa et al. 2013). This result is in accordance with a study from Klemans 
et al. analyzing soybean-allergic and tolerant adults for their sensitization to Gly m 4, Gly m 5, 
Gly m 6 and Gly m 8. The authors from this Dutch study concluded, based on their ROC curve 
analyses, that Gly m 8 had the best diagnostic value in their study population, although the 
AUC of Gly m 8 (0.79) was comparable to Gly m 6 and soybean extract (both 0.77) (Klemans 
et al. 2013a). In addition, a study from the US on soybean-allergic and sensitized but tolerant 
children diagnosed by oral food challenge suggested Gly m 8 (AUC 0.82) as the best diagnostic 
marker for clinical soybean allergy (Kattan and Sampson 2015).  
However, a recently published CRD study by Maruyama and co-workers, who analyzed 
Japanese soybean-allergic children for their sensitization to recombinant soybean components, 
reported lower AUC values of rGly m 8 (AUC 0.71) and the subunits of rGly m 5 (AUC 0.49-
0.61). No single component alone had a high diagnostic value and therefore the authors  
established a novel approach by generating a fusion protein composed of Gly m 8 and the low 
cross-reactive N-terminal extension region of Gly m 5.02 (α’ subunit of Gly m 5). By doing so, 
 30  Introduction 
the diagnostic accuracy could be increased in this Japanese study population (AUC 0.80) 
(Maruyama et al. 2018).  
However, the diagnostic value of the soybean 2S albumin Gly m 8 (maximum AUC 0.82) is not 
as high as that of its peanut counterpart Ara h 2 (maximum AUC 0.99) (Nicolaou et al. 2011). 
Neither the single component Gly m 8 nor the Gly m 5-Gly m 8 fusion component showed such 
a high diagnostic accuracy as peanut Ara h 2. 
 
2.5.3 Identified gaps in soybean allergen knowledge 
Depending on the respective study population with regard to population age and geographical 
region, controversial data on the relevance of soybean components Gly m 5 and Gly m 8 have 
been published at the beginning of this PhD project. Therefore, recombinant Gly m 5 and 
Gly m 8 should be analyzed for their serum IgE binding and their diagnostic value. The subunit 
Gly m 5.03 was chosen for further investigations of Gly m 5 using serum samples from German 
subjects because it previously showed the highest IgE-binding frequency among all three 
Gly m 5 subunits in European soybean-allergic subjects (unpublished data, Paul-Ehrlich-
Institut). In addition, the potential of IgE binding to peptides of Gly m 5.03 and Gly m 8 to 
improve soybean allergy diagnosis has not yet been investigated.   
 
2.6 Aim of this PhD project 
The determination of specific recognition patterns of IgE-binding at the protein and peptide 
level may result in novel and more accurate diagnostic approaches, as well as in safe and 
efficacious therapeutic reagents, as compared to traditional total protein extract-based 
diagnostic or therapeutic allergen preparations. 2S albumins and 7S globulins have been shown 
as important legume allergens.  However, controversial or incomplete data exist, at least in 
part, about their relevance in pediatric legume-allergic populations. 
Therefore, the aim of this PhD project was to compare legume-allergic and sensitized but 
clinically tolerant children regarding their IgE binding to 2S albumin and 7S globulin legume 
allergens from peanut, pea and soybean at the protein level. By doing so, the relevance and the 
diagnostic value of individual allergen components should be determined for each investigated 
legume. According to the mentioned gaps in legume allergy knowledge (chapter 2.3.3, 2.4.3 
and 2.5.3), the following 7S globulins and 2S albumins were in the focus of this PhD project: 
Ara h 1 and both Ara h 2 isoforms (Ara h 2.01 and Ara h 2.02) from peanut, Pis s 1 and both 
major albumin components (PA1 and PA2) from pea, and Gly m 5.03 and Gly m 8 from soybean.  
Furthermore, IgE-binding peptides specific for the individual allergen should be investigated 
and analyzed for their diagnostic value for the respective legume allergy. The in vitro diagnostic 
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value of allergen-specific peptides should be compared to that of the full-length allergen 
components and to total protein extracts in order to evaluate their use as potential diagnostic 
reagents to differentiate between allergy and sensitization without clinical reactivity.  
In order to determine the relevance and the diagnostic value of individual full-length allergens, 
they were heterologously expressed, purified and physicochemically and immunochemically 
characterized. As expression system, Pichia pastoris was favored as it enables a simple non-
denaturing purification of recombinant proteins from its cell culture supernatant and further it 
enables post-translational modifications such as disulfide bond formation and folding. These 
properties are especially advantageous in the generation and purification of 2S albumins that 
form disulfide bonds. Due to comparability, 7S globulins should be also expressed using 
Pichia pastoris. In the case of problems during expression in Pichia pastoris, Escherichia coli 
should be used as an alternative expression system. 
For peptide analysis, multipeptide microarray slides displaying synthetic overlapping peptides 
that represent the investigated full-length allergen were generated. Using individual patient 
sera testing, IgE-binding peptides in approximation to linear epitopes were identified. 
Conformational epitopes were not investigated because of the complexity of elucidation but 
there is awareness of the potential relevance. Diagnostic values of total protein extracts, purified 
recombinant allergens and selected allergen-specific peptides should be done statistically using 
receiver operating characteristic (ROC) curve analysis.   
Finally, by comparing the outcome of the three legume projects, attention will be drawn to 
concordance or divergence between the different legume allergens in children. Furthermore, 
based on protein and epitope data, additional knowledge for the development of optimized, 
therapeutic approaches should be discussed, e.g. with regard to an improved safety profile. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Equipment 
Table 1: Commonly used equipment. 
Equipment Company 
Biofuge (Heraeus® 28RS) Thermo Fisher Scientific, Waltham, MA, USA 
Cell density meter (Biowave WPA CO 8000) Biochrom Ltd., Cambridge, UK 
Centrifuge (5804 R) Eppendorf AG, Hamburg, Germany 
Centrifuge (5415 R) Eppendorf AG, Hamburg, Germany 
Centrifuge (5414 C) Eppendorf AG, Hamburg, Germany 
Circular dichroism (CD) spectropolarimeter  
(J-810S) 
JASCO Germany GmbH, Groß-Umstadt, 
Germany 
Constant Systems cell disruptor (TS series) Constant Systems Ltd., Daventry, UK 
Diaphragm pump (ME 2 NT) 
Vacuubrand GmbH & Co. KG, Wertheim, 
Germany 
Freezer -80°C New Brunswick Scientific, Edison, NJ, USA 
Freezer -20°C (Premium No Frost) 
Liebherr-International Deutschland GmbH, 
Biberach an der Riß, Germany 
Fridge (FK 5440) 
Liebherr-International Deutschland GmbH, 
Biberach an der Riß, Germany 
Gene Pulser® II electroporation system 
Bio-Rad Laboratories GmbH, München, 
Germany 
Heating and drying oven (Heraeus® UT 6060) Thermo Fisher Scientific, Waltham, MA, USA 
HPLC Smartline System 
KNAUER Wissenschaftliche Geräte GmbH, 
Berlin, Germany 
Imager system Fusion FX 
Vilber Lourmat Deutschland GmbH, 
Eberhardzell, Germany 
Incubator (Heraeus® B6060) Thermo Fisher Scientific, Waltham, MA, USA 
Incubator shaker (New BrunswickTM Innova® 44) Eppendorf AG, Hamburg, Germany 
Intas Gel Jet Imager 
INTAS Science Imaging Instruments GmbH, 
Göttingen, Germany 
Microwave (MICRO-CHEF FM 1915) Moulinex, Alençon, France 
Mini-PROTEAN® 3 Cell 
Bio-Rad Laboratories GmbH, München, 
Germany 
Multifuge® (Heraeus® 3S-R) Thermo Fisher Scientific, Waltham, MA, USA 
MultiPep peptide synthesizer Intavis AG, Köln, Germany 
NanoPhotometer® (NP80) Implen GmbH, München, Germany 
Novex™ XCell SureLock™ Mini-Cell 
Electrophoresis System 
Thermo Fisher Scientific, Waltham, MA, USA 
Orbital shaker (Polymax 2040) 
Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany 
RAGE® (Rapid Agarose Gel Electrophoresis) 
device (RGX-60/RGX-100) 
Cascade Biologics, Inc., Portland, USA 
Savant Speed Vac® Thermo Fisher Scientific, Waltham, MA, USA 
Scanner (HP Scanjet 8300) HP Inc., Palo Alto, CA, USA 
Semi-dry blotter (Pegasus) 
PHASE Gesell. für Phorese, Analytik und 
Separation mbH, Lübeck, Germany 
Slide Spotting Robot Intavis AG, Köln, Germany 
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SpectraMax 340PC microplate reader Molecular Devices, Sunnyvale, USA  
Standard Power Pack (P25/P25T) Biometra, Göttingen, Germany 
Thermal cycler (2720) Applied Biosystems, Foster City, CA, USA 
Thermomixer comfort (1.5 ml  Eppendorf AG, Hamburg, Germnay 
Ultracentrifuge (Sorvall Evolution RC) Thermo Fisher Scientific, Waltham, MA, USA 
Universal grinder (M20) 
IKA®-Werke GmbH & Co. KG, Staufen, 
Germany 
Vortex mixer (REAX 2000) 
Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany  
X-ray film processor (CURIX 60) Agfa HealthCare GmbH, Bonn, Germany  
Zetasizer Nano-ZS Malvern Panalytical GmbH, Kassel, Germany  
 
 
3.1.2 Chemicals and reagents 
If not stated otherwise, chemicals and reagents were used in pro analysis (p.a.) grade. 
Chemicals and reagents used for peptide synthesis were purchased with the addition “for 
peptide synthesis”. All chemicals and reagents were provided from Agfa (Bonn, Germany), 
AppliChem (Darmstadt, Germany), Bio-Rad (München, Germany), Carl Roth (Karlsruhe, 
Germany), KPL (Gaithersburg, MD, USA), Merck (Darmstadt, Germany), Roche Diagnostics 
(Mannheim, Germany), Sigma-Aldrich (Steinheim, Germany), Thermo Fisher Scientific 
(Schwerte, Germany) and VWR (Darmstadt, Germany) respectively. 
 
3.1.3 Buffers and solutions 
Table 2: Composition of buffers and solutions. 
Buffer/Solution Composition 
Alkylation solution (LC-MSE) 
260 mM iodacetamide  
50 mM NH4HCO3 
Anode buffer 1 (pH 10.4) 
0.3 M tris 
20% (v/v) methanol 
Anode buffer 2 (pH 10.4) 
25 mM tris 
20% (v/v) methanol 
Blocking buffer (immunoblot) 
TBS pH 7.4 
2% powdered milk 
Blocking buffer (microarray) 
10% blocking buffer (10x) (B6429; Sigma-Aldrich) 
0.05% Tween20® 
5% sucrose 
Cathode buffer (pH 7.6) 
40 mM 6-aminohexanoic acid 
20% (v/v) methanol 
CapMixture 
4% (v/v) acetic anhydride 
5% 2,6-lutidine 
91% 1-methyl-2-pyrrolidinone  
Cleavage solution 
5% (v/v) dH2O 
2.5% (v/v) triisopropylsilane 
88.5% (v/v) trifluoroacetic acid 
4% trifluoromethanesulfonic acid 
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Coomassie staining solution 
36% glacial acetic acid 
28.5% methanol 
0.2% (w/v) Coomassie Brilliant Blue G250 
Coomassie destaining solution 
10% glacial acetic acid 
30% methanol 
Denaturing buffer 
20 mM sodium phosphate buffer pH 7.6 
500 mM NaCl 
20 mM imidazole 
8 M urea 
per 500 ml buffer one protease inhibitor cocktail tablet 
(cOmplete Tablets, Mini,  EDTA-free, Roche 
Diagnostics) 
Destaining solution (LC-MSE) 
40% ethanol 
50mM NH4HCO3 
Dialysis buffer 1 
20 mM sodium phosphate buffer pH 7.6 
10 mM NaCl 
1 mM EDTA 
Dialysis buffer 2 
20 mM sodium phosphate buffer pH 7.6 
500 mM NaCl 
1 mM EDTA 
Elution buffer 1 
20 mM sodium phosphate buffer pH 7.6 
100 mM NaCl 
1 mM EDTA 
500 mM imidazole 
Elution buffer 2 
20 mM sodium phosphate buffer pH 7.6 
500 mM NaCl 
500 mM imidazole 
per 500 ml buffer one protease inhibitor cocktail tablet 
(cOmplete Tablets, Mini, EDTA-free, Roche Diagnostics) 
Elution buffer (LC-MSE) 
25 mM NH4HCO3 
10% acetonitrile 
Incubation buffer (immunoblot) 
TBS pH 7.4 
0.05% Tween20®  
2% powdered milk 
Native PAGE running buffer (10x) 
0.25 M tris 
1.92 M glycine 
Native PAGE sample buffer (5x) 
0.31 M Tris-HCl pH 6.8 
0.05% bromphenol blue 
50% glyercol 
Native PAGE separation gel (15%) 
4.8 ml dH2O 
10 ml Rotiphorese® NF-Acrylamide/bis-solution 30% 
5 ml Tris-HCl (1.5 M) pH 8.8  
200 μl APS (10%)  
20 μl TEMED 
Native PAGE stacking gel (5%) 
6.9 ml dH2O 
1.7 ml Rotiphorese® NF-Acrylamide/bis-solution 30% 
1.25 ml Tris-HCl (1 M) pH 6.8 
100 μl APS (10%) 
10 μl TEMED 
PBS (pH 7.4) 
137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
Ponceau S solution 
0.1% (w/v) Ponceau S 
5% glacial acetic acid 
Reduction solution (LC-MSE) 
65 mM DTT 
50 mM NH4HCO3 
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Renaturing buffer 
20 mM sodium phosphate buffer pH 7.6 
500 mM NaCl 
20 mM imidazole 
per 500 ml buffer one protease inhibitor cocktail tablet 
(cOmplete Tablets, Mini,  EDTA-free, Roche 
Diagnostics) 
SDS-PAGE running buffer (10x) 
0.25 M tris 
1.92 M glycine 
1% (w/v) SDS 
SDS-PAGE sample buffer (5x) 
10% (w/v) SDS  
0.1% (w/v) bromphenol blue  
0.25 M Tris-HCl pH 6.8  
50% glycerol  
7.7% (w/v) DTT 
SDS-PAGE separation gel (15%) 
4.6 ml dH2O 
10 ml Rotiphorese® NF-Acrylamide/bis-solution 30% 
5 ml Tris-HCl (1.5 M) pH 8.8 
200 µl SDS (10%) 
200 µl APS (10%) 
20 µl TEMED 
SDS-PAGE stacking gel (5%) 
6.8 ml dH2O 
1.7 ml Rotiphorese® NF-Acrylamide/bis-solution 30% 
1.25 ml Tris-HCl (1 M) pH 6.8 
100 µl SDS (10%) 
100 µl APS (10%) 
10 µl TEMED 
Side-chain cleavage solution 
5% (v/v) dH2O 
3% (v/v) triisopropylsilane 
12% (v/v) dichloromethane 
80% (v/v) trifluoroacetic acid 
Sodium phosphate buffer (0.1 M, pH 7.6) 
84.5 ml Na2HPO4 (1 M) 
15.5 ml NaH2PO4 (1 M) 
ad 1000 ml dH2O 
TAE buffer 
40 mM tris  
20 mM acetic acid 
1 mM EDTA 
TBS (pH 7.4) 
50 mM tris  
150 mM NaCl 
50 mM HCl (37%) 
Size exclusion buffer 
20 mM sodium phosphate buffer pH 7.6 
10 mM NaCl 
1 mM EDTA 
Washing buffer (IMAC) 
20 mM sodium phosphate buffer pH 7.6 
100 mM NaCl 
Washing buffer (immunoblot/microarray) 
TBS pH 7.4 
0.05% Tween20®  
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3.1.4 Cell culture media 
Table 3: Media composition. 
Medium Composition 
BMGY medium 
1% yeast extract 
2% peptone 
100 mM potassium phosphate, pH 6.0 
1.34% yeast nitrogen base (without amino acids) 
4 x 10-5% biotin 
1% glycerol 
BMMY medium 
1% yeast extract 
2% peptone 
100 mM potassium phosphate, pH 6.0 
1.34% yeast nitrogen base (without amino acids) 
4 x 10-5% biotin 
0.5% methanol 
LB medium (pH 7.0) 
1% tryptone 
1% yeast extract 
0.5% NaCl 
LB agar 
LB medium 
1.5% agar-agar 
RBL medium 
MEM (Mimimal Essential Medium) 
5% [v/v] fetal calf serum (FCS) 
1% [v/v] L-glutamine 
YPD medium 
1% yeast extract 
2% peptone 
2% dextrose 
YPDS medium 
1% yeast extract 
2% peptone 
2% dextrose 
1 M sorbitol 
YPDS agar 
YPDS medium 
1.5% agar-agar 
 
 
3.1.5 Specific antibodies and secondary conjugates 
Table 4: Antibodies and secondary conjugates. 
Antibody/Secondary conjugate Clone Company 
Mouse anti-human IgE Fc-HRP B3102E8 
SouthernBiotech via Biozol, Eching, 
Germany 
Mouse anti-(His)6-tag 13/45/31 DIANOVA GmbH, Hamburg, Germany 
Mouse anti-Ara h 1 (PN-t) unknown 
Dr. Wolf-Meinhard Becker, 
Forschungszentrum Borstel, Germany 
Goat anti-mouse IgG (γ-chain 
specific)-HRP 
polyclonal Sigma-Aldrich, Steinheim, Germany 
Streptavidin-HRP not applicable 
SouthernBiotech via Biozol, Eching, 
Germany 
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3.1.6 Patient sera 
In the peanut, pea and soybean project 35, 19 and 21 children were included (Table 14, 24 and 
32), respectively. Inclusion was based on a peanut-, pea- and soybean-specific IgE level 
≥ 0.35 kUA/L, respectively. According to oral food challenge or convincing history, patients were 
either allergic to the respective legume or clinically tolerant. Patient serum samples were 
collected at the Charité Universitätmedizin Berlin and local ethics committees authorized 
donations. In this PhD thesis the following serum overlaps between the three legume projects 
were: peanut patient 30 corresponded to soybean patient 13, peanut patient 12 equaled 
soybean patient 9, and pea patient 8 equaled soybean patient 1. Detailed information on patient 
characteristics are given in Table 14, 24 and 32. In immunoblot analyses, serum from a non-
allergic subject (N) served as negative control and was used for calculating the respective limit 
of detection (LOD). For standard curve generation for densitometric quantifications of specific 
IgE levels in immunoblot analyses, serum RS14239 (103.61 kUA/L sIgE to Ara h 1), serum 
RS14231 (54.1 kUA/L sIgE to Ara h 2) or serum PEI163 (27.32 kUA/L sIgE to Gly m 5) were 
used. In addition, in the pea project serum PEI131 (22.1 kUA/L sIgE to peach extract 
(ImmunoCAPTM f95) and 23.7 kUA/L sIgE to natural Pru p 3 (nPru p 3) (ImmunoCAPTM f420)) 
was used in immunoblot analysis for the detection of Pis s 3 in pea extract. In multipeptide 
microarray analysis, different combinations of negative controls were used. Table 5 shows the 
respective negative controls used in the individual microarray experiments. Serum N and 
PEI177 were from the internal serum collection of the Paul-Ehrlich-Institut, and DLab sera were 
bought from DLab Diagnose GmbH (Hamburg, Germany). These non-allergic subjects showed 
no sensitization to the respective investigated legume allergen. Sera A-J were provided by the 
Charité Berlin. Sera A-E were from atopic subjects (fx5 [egg white, milk, fish, wheat, peanut, 
soybean] negative; SX1 [Dermatophagoides pteronyssinus, cat dander, dog dander, timothy 
grass, cultivated rye, Cladosporium herbarum, common silver birch, mugwort] positive) and 
sera F-J from non-atopic subjects (fx5 negative; SX1 negative). PEI163, an in-house positive 
control serum, was additionally used in all immunoblot and microarray analyses. The measured 
sIgE levels (ImmunoCAPTM) of PEI163 were (amongst others): > 100 kUA/L sIgE to peanut 
extract, 38.5 kUA/L sIgE to soybean extract and 16.73 kUA/L sIgE to pea extract. 
 
Table 5: Multipeptide microarray experiments and used controls. 
Proteins written with forward slash were analyzed on the same array. 
Microarray experiment Negative controls 
Ara h 1 Serum N, DLab71S1 
Ara h 2.01/Ara h 2.02 Serum N, DLab71S1, DLab72S1 
Pis s 1 Serum A-J 
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PA1/PA2 Serum N, PEI177 
Gly m 5.03 Serum N 
Gly m 8 Serum N 
 
 
3.1.7 Plasmids 
For the expression of recombinant proteins in Pichia pastoris, the yeast expression vector 
pPICZαA (Invitrogen/Thermo Fisher Scientific) was used. pPICZαA contains the ZeocinTM 
resistance gene allowing the selection of transformants. For the expression of rPis s 1 in 
Escherichia coli, the E. coli expression vector pET-11a (Novagen, Darmstadt, Germany) was 
used. This vector carries the gene for ampicillin resistance. Vector maps and multiple cloning 
sites are shown in the appendix (Figure A1 and Figure A2). 
 
3.1.8 Primer 
Table 6: Oligonucleotides used for colony PCR and DNA sequencing. 
Primer Sequence 
5’AOX (forward) 5'-GACTGGTTCCAATTGACAAGC-3' 
3’AOX (reverse) 5'-GCAAATGGCATTCTGACATCC-3' 
Pis s 1 mid (forward) 5‘-AGATCTGCGTGTTCTGGATCTG-3‘ 
T7 promoter (forward) 5'-TAATACGACTCACTATAGGG-3' 
T7 terminator (reverse) 5’-GCTAGTTATTGCTCAGCGG-3‘ 
 
 
3.1.9 Pichia pastoris and Escherichia coli strains 
Table 7: Pichia pastoris and Escherichia coli cloning and expression strains. 
Strain Company Genotype 
Phenotype (Pichia 
pastoris only) 
X-33 
Invitrogen/Thermo Fisher 
Scientific 
Wild-type Mut+ 
SMD1168H 
Invitrogen/Thermo Fisher 
Scientific 
pep4 Mut+ His+ 
One Shot® BL21 
(DE3) 
Invitrogen/Thermo Fisher 
Scientific 
F– ompT hsdSB (rB-mB-) gal dcm (DE3) 
Stellar™ Clontech Laboratories, Inc., 
Mountain View, CA, USA 
F-, endA1, supE44, thi-1, recA1, relA1, gyrA96, 
phoA, Φ80d lacZΔ M15, Δ(lacZYA-argF) U169, 
Δ(mrr-hsdRMS-mcrBC), ΔmcrA, λ– 
One Shot® 
TOP10 
Invitrogen/Thermo Fisher 
Scientific 
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara-leu)7697 galU galK 
rpsL (StrR) endA1 nupG 
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3.2 Methods 
3.2.1 Cloning of DNA fragments into expression vectors 
3.2.1.1 Restriction 
For cloning of cDNA into pPICZαA or pET-11a, both expression vectors had to be linearized 
first. P. pastoris expression vector pPICZαA was linearized using FastDigest EcoRI restriction 
enzyme (Thermo Fisher Scientific) according to the manufacturer’s instructions. For efficient 
linearization, the incubation time was extended to 1 h. For linearization of E. coli expression 
vector pET-11a, 1.5 µl FastDigest restriction enzyme NdeI (Thermo Fisher Scientific) was used 
per 1 µg plasmid DNA. The incubation time was 7 h at 37°C. 
 
3.2.1.2 Agarose gel electrophoresis 
Linearization of expression vectors and colony PCR reactions (described in 3.2.2.4) were 
analyzed on 1.5% agarose-gels in TAE buffer. DNA samples were loaded with 6x Orange DNA 
Loading Dye (Thermo Fisher Scientific) and separated together with GeneRulerTM 1 kb Plus 
DNA Ladder (ready-to-use; Thermo Fisher Scientific) for 10-20 minutes at 210-275 V. After 
electrophoresis, gels were stained using ethidium bromide for 30 minutes. 
 
3.2.1.3 Purification of linearized vectors 
Linearized vector DNA was subsequently purified using QIAquick® PCR purification KIT 
(QIAgen®). The procedure was according to the manufacturer’s instructions. For elution of 
DNA, 30 µl H2O was used. After purification, the DNA concentration was determined 
photometrically. 
 
3.2.1.4 Cloning of DNA fragments into linearized pPICZαA or pET-11a 
The codon optimized cDNA sequences encoding the investigated proteins without signal peptide 
were purchased from Geneart (Geneart Strings DNA Fragments, Thermo Fisher Scientific) and 
inserted into EcoRI-linearized purified pPICZαA or NdeI-linearized purified pET-11a. The cDNA 
sequences of all proteins listed in Table 8A were cloned into pPICZαA and the sequence of 
rPis s 1 was additionally cloned into pET-11a (Table 8B). Cloning into EcoRI restriction site of 
pPICZαA resulted in two additional amino acid residues (Glu-Phe) at the N-terminus of each 
protein. Whereas cloning into ATG cloning site NdeI in pET-11a resulted in an additional Met 
at the N-terminus of rPis s 1. In addition, in order to prevent N-glycosylation in Pichia pastoris 
potential N-glycosylation sites were predicted using NetNGlyc 1.0 Server 
(http://www.cbs.dtu.dk/services/NetNGlyc/) and substituted by an aspartic acid (D). Potential 
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N-glycosylation sites were found in Ara h 1, Pis s 1, PA2, Gly m 5.03 and Gly m 8. Further 
modifications of the recombinant proteins were linker and His6-tag attached to the C-terminus 
of each protein expressed in P. pastoris (see e.g. Figure A3 in the appendix and Table 8A) and 
thrombin cleavage site, linker, and His6-tag attached to the C-terminus of rPis s 1 expressed in 
E. coli (Figure A7 in the appendix and Table 8B). Modifications and accession numbers of the 
proteins are summarized in Table 8. In addition, Table 8 shows in the first column in 
parentheses the specific IUIS database nomenclature of the investigated allergen or as in the 
case of PA1 and PA2, the specific UniProt protein name. For simplification, abbreviated protein 
names (Table 8, bold) will be used in this thesis. 
Sequences of DNA fragments used for cloning into pPICZαA or pET-11a and derived amino acid 
sequences are listed in the appendix, in Figure A3-A11. 
 
Table 8: Accession numbers and modifications of recombinant proteins. 
A 
Recombinant protein 
(specific IUIS or 
UniProt name) 
UniProt accession number 
Modifications in 
recombinant proteins 
rAra h 1, clone P41B 
(Ara h 1.0101) P43238-1 N496D, linker*, His6-tag 
rAra h 2.01 
(Ara h 2.0101) Q6PSU2-2 variant G40E E130D Linker*, His6-tag 
rAra h 2.02 
(Ara h 2.0201) Q6PSU2-1 Linker*, His6-tag 
rPis s 1 
(Pis s 1.0101) Q702P1-1 N345D, linker*, His6-tag 
rPA1 
(PA1 B) P62927-1 Linker*, His6-tag 
rPA2 
(PA2a) P08688-1 N56D, linker*, His6-tag 
rGly m 5.03 
(Gly m 5.0302) P25974-1 variant V28G N328D, linker*, His6-tag 
rGly m 8 
(Gly m 8.0101) P19594-1 N99D, linker*, His6-tag 
 
B 
Recombinant protein 
(specific IUIS or 
UniProt name) 
UniProt accession number 
Modifications in 
recombinant proteins 
rPis s 1 
(Pis s 1.0101) Q702P1-1 
Thrombin cleavage site, linker#, 
His6-tag 
(A) Recombinant proteins aimed to be expressed in P. pastoris. (B) rPis s 1 expressed in E. coli. Amino acid 
substitutions of variants and substitutions due to prevention of N-glycosylation refer to the UniProt protein sequence 
without signal peptide; *linker: VD; #linker: SSG. 
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Cloning into expression vectors was done using the In-Fusion® HD EcoDryTM Cloning Kit 
(Clontech Laboratories, Inc., Mountain View, CA, USA). For In-Fusion Cloning, the cDNA 
sequences of the recombinant proteins contained at each end additional bases homologous to 
the ends of the linearized vector in which the cDNA should be cloned (see appendix Figure A3-
A11). In-Fusion® Cloning was done according to the manufacturer’s instructions. Briefly, 100 ng 
of purified linearized vector was mixed with 100 ng of the DNA fragment and incubated 
according to the manufacturer’s instructions. For transformation of StellarTM cells, 30 µl 
competent cells and 3 µl of the In-Fusion® reaction mixture was used. Transformation reactions 
were spread on LB agar-plates containing either zeocin (75 µg/ml) or ampicillin (50 µg/ml). 
 
3.2.1.5 Plasmid isolation and quantification of DNA 
Plasmid DNA was isolated from 5 ml E. coli overnight cultures (37°C, 210 rpm) in LB medium 
with 75 µg/ml zeocin or 50 µg/ml ampicillin. Isolation was done using the QIAprep® Spin 
Miniprep Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer’s instructions. 
For elution of DNA, 40 µl H2O was used.  
Afterwards, DNA concentration was determined by measuring the absorbance at wavelength 
260 nm and 280 nm using NanoPhotometer®. 
 
3.2.1.6 Sequencing 
Successful cloning of DNA fragments into pPICZαA or pET-11a was confirmed by Sanger 
sequencing (Eurofins Genomics GmbH, Ebersberg, Germany). For sequencing of pPICZαA 
constructs, primer 3’AOX with or without primer 5’AOX was used. pET-11a-Pis s 1 was 
sequenced and confirmed using primers T7, T7 term and Pis s 1 mid. 
 
3.2.1.7 Transformation of plasmid DNA into E. coli 
For amplification, plasmid DNA was transformed into One Shot® TOP10 chemically competent 
cells according to the manufacturer’s instructions (Thermo Fisher Scientific, Document Part 
Number C4040). For transformation, 10 µl cells were incubated with 0,5 µl plasmid DNA for 
30 min on ice. After a heat shock at 42°C for 30 sec, cells were incubated on ice for 2 min. 
250 µl SOC medium were added and cells were shaked at 37°C for 1 h at 500 rpm. Afterwards, 
the transformation mix was plated on LB agar-plates containing either zeocin (75 µg/ml) or 
ampicillin (50 µg/ml). Of grown colonies plasmid DNA was isolated as described in chapter 
3.2.1.5. 
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3.2.2 Expression of recombinant proteins using Pichia pastoris 
3.2.2.1 Linearization and purification of pPICZαA constructs 
For integration into the Pichia genome, pPICZαA plasmids containing the genes of interest had 
to be linearized. Linearization was done using the restriction enzyme SacI (FastDigest; Thermo 
Fisher Scientific). As the sequence of both Ara h 2 isoforms contained the SacI restriction site, 
the restriction enzyme BstXI (FastDigest; Thermo Fisher Scientific) was used for linearization. 
10 µg of each plasmid was linearized using up to 10 µl restriction enzyme and an incubation 
time of 4 h at 37°C. Successful linearization was confirmed by agarose gel electrophoresis (see 
chapter 3.2.1.2). Restriction enzymes SacI and BstXI were inactivated by heating for 5 min at 
65°C and 80°C, respectively. Prior to transformation of Pichia pastoris, linearized plasmids were 
purified using QIAquick® PCR purification KIT as described in chapter 3.2.1.3. 
 
3.2.2.2 Preparation of electrocompetent P. pastoris X-33 cells 
Competent cells were prepared according to the instructions in the EasySelect™ Pichia 
Expression Kit manual (Cat. no. K1740-01). Pichia pastoris X-33 cells were grown overnight in 
5 ml YPD at 30°C and 200 rpm. 500 µl of this overnight culture was used to inoculate 500 ml 
fresh YPD medium in a 2 L flask. Culture was shaken overnight until an OD600 of 1.3-1.5 was 
reached. Cells were harvested by centrifugation at 1,500 x g for 5 min at 4°C. Afterwards, cell 
pellet was resuspended with 500 ml ice-cold, sterile H2O. Cells were again harvested by 
centrifugation as described above and pellet resuspended with 250 ml ice-cold sterile H2O. After 
a third centrifugation step, pellet was resuspended with 20 ml ice-cold 1 M sorbitol. This step 
was followed by a centrifugation step and a resuspendation step with 1 ml ice-cold 1 M sorbitol 
and by three wash steps composed of centrifugation and resuspendation with 500 µl ice-cold 
1 M sorbitol. Finally, cells were harvested and the cell pellet was resuspended in ice-cold 1 M 
sorbitol to a final volume of ~1.5 ml. Cells were kept on ice before electroporation. 
 
3.2.2.3 Transformation 
80 µl of competent X-33 cells were mixed with 5 µg of the linearized purified pPICZαA 
constructs in an ice-cold electroporation cuvette (0.2 cm gap width) and incubated on ice for 
5 min. Cells were pulsed at 1.5 kV, 25 µF and 200Ω. Immediately afterwards, 1 ml ice cold 1 M 
sorbitol was added and the contents were transferred to a 15 ml sterile tube. After 1-2 h 
incubation at 30°C different volumes were spread on YPDS plates containing 100 µg/ml 
ZeocinTM. Until colonies grew, plates were incubated at 30°C. 
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3.2.2.4 Colony PCR 
To confirm a successful integration of the construct/gene of interest into the Pichia pastoris 
genome, a PCR analysis was performed. Using 5’AOX and 3’AOX as primers, the PCR gives 
additional information about the Mut phenotype. Analyzing Mut+ or MutS integrants resulted 
in two or one PCR product, respectively. One PCR product corresponds to the gene of interest 
and if present, the second to the AOX1 gene. 
For PCR analysis, a single colony was picked and transferred to a 0.5 ml sterile tube. The DNA 
was released by a heating step for 1.5 min at 600 watt in the microwave and was afterwards 
resuspended in 20 µl sterile H2O. The reaction setup is listed in Table 9. 
 
Table 9: Reaction setup colony PCR. 
Component Amount 
10X ThermoPol buffer (New England Biolabs) 1.8 µl 
100 mM dNTPs (25 mM each) 0.26 µl 
5’AOX Primer (100 pmol/µl) 0.54 µl 
3’AOX Primer (100 pmol/μl) 0.54 µl 
Taq Polymerase 5,000 units/ml (New England Biolabs) 0.18 µl 
Pichia pastoris solution 2 µl 
Sterile water to 18 µl 
 
After pipetting the PCR sample, PCR was performed according to the conditions listed in 
Table 10. Afterwards, PCR products were analyzed on a 1.5% agarose gel as described in 
chapter 3.2.1.2. 
 
Table 10: PCR conditions. 
Temperature Time Cycles 
95°C 5 min 1 cycle 
95°C 30 sec  
50°C 45 sec 30 cycles 
68°C 1 min/kb  
68°C 5 min 1 cycle 
 
 
3.2.2.5 Expression 
All recombinant proteins were expressed using Mut+ Pichia recombinant clones, except rPA2, 
which was expressed using a MutS recombinant clone. As the screening of Pichia clones by 
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colony PCR revealed that only clones of the MutS phenotype contained the gene of interest, i.e. 
PA2. 
Protein expression was performed according to the manufacturer’s instructions written in 
EasySelect™ Pichia Expression Kit manual with minor modifications. Briefly, a small-scale 
expression was used to determine optimal conditions for protein expression. Afterwards, 
expression was scaled up using up to 3 L of culture volume.  
For the expression using Mut+ Pichia recombinant clones the following protocol was used. A 
single colony was grown in 5 ml of BMGY medium overnight at 30°C and 210 rpm. The 
following day, this overnight culture was used to inoculate 650 ml of BMGY medium in a 5 L 
baffled flask. Culture was grown at 30°C and 210 rpm until it reached an OD600 of 2-6. Cells 
were harvested by centrifugation at 1,500 x g for 5 min at room temperature. For inducing 
protein expression, the cell pellet was resuspended to an OD600 of 1 in 3L BMMY medium. 
750 ml aliquots were transferred to 5 L baffled flasks and incubated at 30°C at 210 rpm for 4 to 
8 days. Incubation time was dependent on the respective recombinant protein. To maintain 
induction, 100% methanol was added to a final concentration of 0.5% every day. Finally, 
expression was terminated by centrifuging the culture twice at 4,000 x g for 15 min at room 
temperature. Supernatant was filtered (0.2 µm, asymmetrical polyethersulfone, Thermo Fisher 
Scientific) and stored until use at 4°C.  
For the expression of rPA2 using a MutS Pichia recombinant clone the following protocol was 
used. A single colony was grown in 10 ml of BMGY medium at 30°C until an OD600 of 2-6 was 
reached. Afterwards, this culture was used to inoculate 1 L of BMGY medium. The culture was 
grown until again an OD600 of 2-6 was reached. Cells were harvested by centrifugation as 
described above. For induction, the cell pellet was resuspended in 200 ml BMMY medium. 
Culture was incubated at 30°C and 210 rpm for 8 days. Maintenance of induction and 
termination of expression was carried out as described for Mut+ recombinant clones. 
Supernatant was filtered and stored until use at 4°C. 
Of note, a recombinant X-33 clone carrying pPICZαA without insert/gene of interest was 
additionally used in every expression experiment as control for background protein expression. 
 
3.2.2.6 Optimization strategies 
Several optimization strategies were applied within this thesis. In the case of rAra h 2.01 and 
rAra h 2.02 proteolysis was decreased by the daily addition of ~10 ml 7x protease inhibitor 
stock solution (cOmplete Tablets, Mini, EDTA-free, Roche Diagnostics GmbH, Mannheim, 
Germany) to the 3 L culture supernatant. This optimization strategy was also applied for rPis s 1, 
however as the extent of the degradation was higher 1.5 ml 7x protease inhibitor stock solution 
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was added per 100 ml culture supernatant. In addition, proteolysis of rPis s 1 was tried to 
reduce by the daily addition of PMSF and EDTA each to a final concentration of 1 mM and by 
the use of a Pichia pastoris SMD1168H strain lacking protease A activity. The protocol for 
transformation and expression was identical to the protocol described above for Pichia pastoris 
X-33 strain. Expression of rAra h 1 was checked using multiple recombinant Pichia pastoris 
clones. Furthermore, culture supernatant was concentrated using Vivaspin 20 centrifugal 
concentrator (Merck) to check for a potential low expression level. 
 
3.2.3 Expression of recombinant Pis s 1 using E. coli BL21 (DE3) 
3.2.3.1 Transformation 
50 µl chemically competent One Shot® BL21 (DE3) cells were mixed with 1 µl plasmid DNA 
and incubated on ice for 30 min. The following steps equaled the protocol described in chapter 
3.2.1.7. 
 
3.2.3.2 Expression 
A single colony of BL21 (DE3) transformants was grown over night in 100 ml LB medium 
containing 50 µg/ml ampicillin. This overnight culture was used to inoculate 4 L of fresh LB 
medium containing 50 µg/ml ampicillin to an OD600 of 0.1. The culture was grown at 37°C and 
210 rpm and at an OD600 of ~0.6 protein expression was induced by the addition of IPTG to a 
final concentration of 1 mM. Induction was carried out for 3 h at 37°C and 210 rpm. Afterwards 
cells were harvested by centrifugation at 7,000 x g for 10 min at 4°C. Resulting cell pellet was 
washed twice with cold (4°C) sterile H2O and stored at -20°C until use. 
 
3.2.3.3 Protein extraction using BugBusterTM Protein Extraction Reagent 
To examine whether rPis s 1 was expressed in the soluble fraction or in inclusion bodies, cell 
culture samples were analyzed using the BugBusterTM Protein Extraction Reagent (Merck). 
Therefore, 2 ml E.coli culture from chapter 3.2.3.2 was centrifuged (16,000 x g, 10 min and 
4°C) to obtain the cell pellet. Cell pellet was resuspended in 300 µl BugBuster reagent. 
Afterwards, 0.5 µl Benzonase® Nuclease (250 U/µl, Merck) and 43 µl 7x protease inhibitor stock 
solution (cOmplete Tablets, Mini, EDTA-free) were added and the suspension was incubated 
for 20 min at room temperature on an orbital shaker. The following steps were done according 
to the manufacturer’s protocol (User Protocol TB245 Rev. F 1108). Samples were analyzed by 
SDS-PAGE as described in chapter 3.2.8.2. 
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3.2.4 Purification of recombinant proteins 
3.2.4.1 Protein extraction using cell disruptor 
Compared to the recombinant proteins secreted into P. pastoris cell culture supernatant, rPis s 1 
was purified from E. coli inclusion bodies. Therefore, prior to purification, rPis s 1 had to be 
extracted from the cell. Cells were lysed using a cell disruptor and a pressure of 1,900 bar. For 
this, the frozen cell pellet was thawed on ice and resuspended in 15 ml 20 mM sodium 
phosphate (pH 7.6) including one protease inhibitor cocktail tablet (cOmplete Tablets, Mini, 
EDTA-free) and a spatula tip of lysozyme (from chicken egg white, 100,000 U/mg, Sigma-
Aldrich). The suspension was stirred for 20 min at room temperature, a spatula tip of DNAse I 
(3230.7 U/mg, AppliChem) was added and stirring was continued for further 20 min. 
Afterwards, cells were lysed using a cell disruptor with a pressure of 1,900 bar. The resulting 
lysate was centrifuged at 12,000 x g at 4°C for 20 min. Pellet was resuspended in 15 ml 
denaturing buffer and stirred for 3 h at room temperature. The lysate was sterile filtered 
(0.22 µm, polyethersulfone, Carl Roth) and used for further purification. 
 
3.2.4.2 IMAC of recombinant proteins expressed in P. pastoris 
Filtered P. pastoris culture supernatants from chapter 3.2.2.5 were incubated overnight each 
with 5 ml Ni-beads (Ni-NTA Superflow, Qiagen, Hilden, Germany) equilibrated in washing 
buffer. Beads were pelleted by centrifugation (1,000 x g, 1 min, 4°C) and transferred to a Bioline 
HR glass column (Knauer) which was afterwards connected to the HPLC system. 
The purification procedure was composed of a washing step using washing buffer at a flow rate 
of 0.5 ml/min (2-5 column volumes). Afterwards, bound target protein was eluted using elution 
buffer 1 at a flow rate of 0.5 ml/min. Elution fractions were analyzed on SDS-PAGE as described 
in chapter 3.2.8.2. Fractions containing target protein were either pooled and dialyzed against 
dialysis buffer 1 or further purified by size exclusion chromatography. For dialysis and all 
following dialysis, D-TubeTM Dialyzers (MWCO 3.5 kDa, Merck) were used. 
 
3.2.4.3 IMAC of recombinant Pis s 1 expressed in E. coli inclusion bodies 
Lysate from chapter 3.2.4.1 was incubated overnight with 8 ml Ni-beads equilibrated in 
denaturing buffer. After a washing step with denaturing buffer at a flow rate of 0.5 ml/min and 
15 column volumes, bound target protein was refolded by gradually lowering the urea 
concentration from 8 M urea in denaturing buffer down to 0 M urea in renaturing buffer. The 
linear gradient was performed at a flow rate of 0.2 ml/min and ~15 column volumes. 
Afterwards, rPis s 1 was eluted using elution buffer 2. Elution fractions were analyzed by SDS-
PAGE. Fractions containing high amounts of rPis s 1 were pooled and dialyzed against dialysis 
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buffer 2. rPis s 1 was sterile filtered (0.22 µm, polyethersulfone, Carl Roth), aliquots were snap-
frozen and stored at -80°C until use. 
 
3.2.4.4 SEC of recombinant proteins 
For size exclusion chromatography either single IMAC elution fractions containing target 
protein or pooled IMAC elution fractions that were concentrated (Amicon® Ultra Centrifugal 
filters, Merck) were used. Prior to injection into sample loop (1 ml), fractions were sterile 
filtered using Spin-X® Centrifuge Tube Filters (0.22 µm; cellulose acetate, Sigma-Aldrich). 
Size exclusion chromatography was performed using a prepacked BioFox 40/1200 SEC column 
(Knauer) connected to the HPLC system. Recombinant proteins were purified using dialysis 
buffer 1 at a flow rate of 0.2 ml/min (2 column volumes). SEC fractions were analyzed by SDS-
PAGE and fractions containing target protein were pooled and dialyzed against dialysis buffer 
1. After dialysis, rPA1 was once again filtered using Spin-X® Centrifuge Tube Filters. Aliquots 
of recombinant proteins were snap-frozen and stored at -80°C until use. 
 
3.2.5 Total legume protein extraction 
Dried mature pea seeds of Pisum sativum (cultivar Regina) and yellow soybeans of Glycine max 
(Hensel Soja-Kost, W. Schoenenberger GmbH & Co. KG, Magstadt, Germany), respectively, 
were washed with dH2O and dried overnight. Peanut kernels of Arachis hypogaea cultivar Giant 
USA were used for protein extraction. For total protein extraction, seeds and kernels were 
ground to powder under liquid nitrogen. 2 g of soybean and pea flour, respectively, were 
extracted in 20 ml PBS for 4 h at 4°C. For total peanut extraction, 4 g peanut flour was extracted 
in 20 ml PBS for 4 h at 4°C. After total protein extraction, extracts were centrifuged at 13,000 x g 
for 30 min at 4°C. The protein containing supernatants were filtered (pore size 0.22 µm, 
polyethersulfone, Carl Roth) and stored at -80°C until use. 
 
3.2.6 Reduction and alkylation 
Peanut extract, rAra h 1 and rAra h 2.02 were reduced and alkylated as described by Albrecht 
and co-workers in 2009 (Albrecht et al. 2009). Briefly, peanut extract (11 mg), rAra h 1 (0.7 mg) 
and rAra h 2.02 (0.5 mg), respectively, were denatured using 5.3 M urea and 0.13 M Tris-HCl. 
Afterwards, samples were reduced with 28 mM dithiothreitol and alkylated using 55.5 M 
iodacetamide. Obtained reduced and alkylated peanut extract and recombinant peanut proteins 
were dialyzed overnight at 4°C against PBS and dialysis buffer 1, respectively. 
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3.2.7 Peptide synthesis and spotting 
3.2.7.1 Synthesis and preparation of overlapping CelluspotTM peptides 
Overlapping CelluspotTM peptides (length: 15 amino acids; offset: 4 amino acids) covering the 
entire primary sequence of all legume proteins listed in Table 8 were synthesized and processed 
as described earlier (Kühne et al. 2015). Peptides are derived from the mature natural proteins, 
i.e. without signal peptide and without the modifications of the recombinant proteins (N/D 
substitutions, additional amino acids due to cloning, thrombin cleavage site, linker and His6-
tag). Furthermore, peptides of mature Gly m 5.0301 (UniProt accession number P25974-1 
variant F13L V28G F174L) were also synthesized. In addition to the in-house synthesized 
peptides of Ara h 2.0101 and Ara h 2.0201 containing a proline in the DPYSPS motif, the 
respective peptides containing hydroxyproline residues were purchased from Intavis AG. One 
biotinylated control peptide (sequence by Intavis AG: Bio-A-A-N-W-S-H-P-Q-F-E-K-A-A) 
containing an N-terminal biotin (Biotin ≥ 99% (TLC), Sigma-Aldrich) was in-house synthesized 
and also purchased from Intavis AG. 
Peptide synthesis and processing were almost identical to the protocol published by Kühne and 
co-workers (Kühne et al. 2015) with only minor modifications. Briefly, peptides were 
synthesized on modified (Fmoc-protected) cellulose discs (CelluSpot discs, Intavis AG) as solid 
support. The synthesis followed the Fmoc-protection chemistry meaning that all amino acids 
were protected at their amino terminus by Fmoc. In addition, the amino acid side chains were 
permanently protected during the synthesis by Pbf, Trt, OtBu, Boc or tBu. Amino acids used for 
peptide synthesis were purchased from Intavis AG. The synthesis was a cyclic procedure of 
deprotection using piperidine, washing, activation of amino acids using HOBt/DIC, coupling, 
capping of un-reacted free amino groups using CapMixture and washing. After peptide 
synthesis, side chain protection groups were removed using Side-chain cleavage solution. Next, 
cellulose discs with bound peptides were dissolved using cleavage solution. Dissolved peptide-
cellulose conjugates were stored until use at -20°C. 
 
3.2.7.2 Peptide spotting 
Overlapping 15-mer peptides were spotted in quadruplicate onto coated microscope slides using 
a Slide Spotting Robot (Intavis AG) according to the manufacturer’s instructions (Intavis AG) 
and according to Kühne et al. (Kühne et al. 2015). For coating of microscope slides adhesive 
foil (Lasertab® Markers, Brady Deutschland, Egelsbach, Germany) was used. Peptides 
representing Ara h 1, Pis s 1 and Gly m 8 were spotted individually on separate array slides. 
Peptides representing Ara h 2.01 and Ara h 2.02 including peptides with hydroxyproline(s) 
were spotted onto the same array slide, with peptides shared by both isoforms being spotted 
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once for both isoforms. The same procedure was applied for peptides of Gly m 5.0301 and 
Gly m 5.0302. Due to no significant sequence similarity between PA1 and PA2, peptides 
representing both pea proteins were spotted onto the same array. The biotinylated control 
peptide was additionally spotted in different dilutions (1:20 and 1:80 in DMSO) on every array 
and served both as a position marker to simplify the grid alignment during array analysis, and 
as a quality marker to verify consistency of chemiluminescent detection. In addition, blank spots 
composed of peptide buffer (DMSO) without peptide were spotted as technical replicates on 
every array and served for the measurement of background signal. For Ara h 1, Ara h 2, Pis s 1, 
PA1/2, Gly m 5.03 and Gly m 8 arrays, 76, 266, 134, 210, 152 and 306 blank spots were spotted 
in duplicate, respectively. Per spot 0.04 µl peptide, control peptide or blank was spotted. 
Coomassie-staining of a randomly chosen subset of array slides confirmed successful spotting 
of all peptide spots. 
 
3.2.8 Characterization of purified proteins, total protein extracts and a 27-mer Ara h 2.02 
peptide 
3.2.8.1 Measuring protein concentration 
The concentration of recombinant proteins was determined either by measuring the absorbance 
at 280 nm using NanoPhotometer® or by using BCATM Protein Assay Kit (Thermo Fisher 
Scientific). Usage of BCATM Protein Assay Kit occurred according to the manufacturer’s 
instructions. For nanophotometric analysis, proteins’ extinction coefficients and molecular 
weights were computed using ExPASy ProtParam tool (http://web.expasy.org/protparam/). 
For determining the protein concentration of protein extracts, Roti®-Nanoquant (Carl Roth 
GmbH) was used according to the manufacturer’s instructions. 
 
3.2.8.2 SDS-PAGE 
Recombinant proteins and legume extracts were separated under reducing conditions using 
discontinuous SDS-PAGE according to the principle described by Laemmli (Laemmli 1970). For 
this, commercial NuPAGETM 4-12% Bis-Tris SDS-PAGE precast gels (Invitrogen/Thermo Fisher 
Scientific) or self-prepared gels without polyacrylamide gradient (15% separating gel and 5% 
stacking gel) were used. The composition of the separating and stacking gels is shown in 
Table 2. The respective reagents were pipetted and mixed in their listed order (see Table 2). 
Protein and extract samples were denatured in SDS-PAGE sample buffer (final concentration 
1x) at 95°C for 5 min. Samples were loaded onto the gel and electrophoresis was carried out at 
a current of 25 mA in NuPAGE® MOPS SDS running buffer or in 1x SDS-PAGE running buffer. 
For molecular weight determination, low-molecular weight marker (GE Healthcare, Freiburg, 
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Germany) mixed with SDS-PAGE sample buffer or SpectraTM Multicolor Broad Range Protein 
Ladder (Thermo Fisher Scientific) were additionally loaded onto the gel. 
 
3.2.8.3 Native PAGE 
Soybean extract was further analyzed using native non-denaturing PAGE. For this purpose, the 
extract sample and low-molecular weight marker were each mixed with Native PAGE sample 
buffer (final concentration 1x) and loaded directly onto the gel (15% separating gel and 5% 
stacking gel). To prepare separating and stacking gel, the respective reagents listed in Table 2 
were used in their listed order. Electrophoresis was carried out at a current of 25 mA in 1x 
Native PAGE running buffer.  
 
3.2.8.4 Coomassie staining 
After electrophoresis, gels were washed in dH2O for several minutes and subsequently stained 
in Coomassie staining solution for 5 min. For destaining, gels were incubated in Coomassie 
destaining solution until unbound Coomassie was fully removed and the background of the gel 
reached clarity. After destaining, gels were washed in dH2O and scanned for documentation. 
 
3.2.8.5 Immunoblot 
Recombinant proteins (1 µg/cm) and legume extracts (20 µg/cm) were loaded onto NuPAGETM 
4-12% Bis-Tris SDS-PAGE precast gels and separated under reducing conditions as described in 
chapter 3.2.8.2. In addition, soybean extract (20 µg/cm) was separated under native non-
denaturing conditions as described in chapter 3.2.8.3. 
In order to analyze rAra h 1 expression in Pichia pastoris, an aliquot of cell culture supernatant 
was loaded onto a gel without polyacrylamide gradient (15% separating gel and 5% stacking 
gel) and separated as described above. As positive controls in this experiment, 2.5 µg/cm 
rBet v 1 (containing a His-tag) and 15 µg/cm peanut extract were simultaneously analyzed in 
separate lanes of the same gel. 
After electrophoresis, samples were semi-dry blotted onto nitrocellulose membranes (0.2 µm, 
GE Healthcare). Therefore, the membrane was equilibrated in anode buffer 2 for 30 min. For 
protein transfer, 3 and 2 blotting papers (grade GB003, Whatman, Sigma-Aldrich) dipped into 
anode buffer 1 and anode buffer 2, respectively, were laid on top of each other on a semi-dry 
blotter. On top of the blotting papers dipped in anode buffer 2, the equilibrated nitrocellulose 
membrane and the gel dipped into anode buffer 2 were laid. Finally, 3 blotting papers 
moistened with cathode buffer were laid on top. Blotting was carried out for 1 h at 0.8 mA/cm2. 
After blotting, proteins on nitrocellulose membranes were stained with Ponceau S. After 
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scanning for documentation, membranes were cut into 2 mm strips and destained using TBS. 
Strips were blocked with blocking buffer for 2 x 30 min (one exception: stripes of blotted cell 
culture supernatant of Pichia pastoris were blocked using TBS 0.3% Tween for 2 h). After 
blocking, strips were washed with washing buffer for 5 min and incubated over night with 10 µl 
of patients’ sera. As negative control, serum from a non-allergic subject (N) was used. All sera 
were 1:60 diluted in incubation buffer (10 µl serum + 590 µl incubation buffer) and sera from 
peanut and soybean patients were, prior to incubation on blot strips, defatted by centrifugation 
at 12,000 rpm at 4°C for 10 min (repeated twice). For the analysis of P. pastoris cell culture 
supernatant, the primary antibodies mouse anti-(His)6-tag and mouse anti-Ara h 1 (PN-t) were 
diluted 1:750 in TBS 0.05% Tween 0.1% BSA. The next day, strips were washed with washing 
buffer for 5 x 5 min, followed by incubation of secondary antibody mouse anti-human IgE-HRP 
(diluted 1:10,000 in incubation buffer) for 1 h. For the detection of bound mouse antibodies 
(anti-(His)6-tag and anti-Ara h 1), goat anti-mouse IgG-HRP diluted 1:20,000 in TBS (0.05% 
Tween, 0.1% BSA) was incubated on the strips for 1 h. After incubation of secondary antibody, 
strips were washed 5 times with washing buffer for each 5 min. Bound IgE and bound IgG 
antibodies were detected using LumiGLO ReserveTM Chemiluminescent Substrate Kit according 
to manufacturer’s instructions (KPL, Gaithersburg MD, USA). Chemiluminescence was recorded 
using Imager system Fusion FX (firmware version 1.0.12, Vilber Lourmat Deutschland GmbH). 
 
3.2.8.6 IgE immunoblot inhibition analysis 
For IgE immunoblot inhibition, pea extract was separated and blotted as described above. 
Patients’ sera were preincubated for 2 h at room temperature with either 50 μg rPis s 1, rPA1 
or nPru p 3 (in PBS) prior to overnight incubation on blot strips. In addition, patients’ sera were 
preincubated with the respective protein buffer without inhibitor (serum uninhibited). As 
negative control, serum N preincubated with the respective protein buffer without inhibitor was 
used. Subsequent steps of the immunodetection were identical to chapter 3.2.8.5. 
Using Fusion-Capt Advance FX7 16.02 Software (Vilber Lourmat Deutschland GmbH) 
densitometric quantification of the IgE inhibition by rPis s 1 was carried out. Background signal 
intensity expressed as signal intensity of the non-allergic serum N was subtracted from each pea 
patient analyzed on the same membrane (N1: pea patients’ sera 1-11; N2: pea patients’ sera 
12-19) and subsequently percent inhibition was calculated using to the following equation: 
 
100 - Signal intensity of serum inhibited Signal intensity of serum uninhibited  x 100 
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3.2.8.7 Densitometric quantification of sIgE levels 
Specific IgE levels to recombinant proteins were densitometrically quantified using Fusion-Capt 
Advance FX7 16.02 Software (Vilber Lourmat Deutschland GmbH).  
For the quantification of sIgE to rAra h 1, rAra h 2.01, rAra h 2.02 and rGly m 5.03 the 
corresponding ImmunoCAPTM values of selected sera were available for each calibration. 
Calibration in the quantification of rAra h 1 sIgE levels was done against 1 μg/cm rAra h 1 and 
a 3 fold serial dilution (1:9 to 1:729) of serum RS14239 having 103.61 kUA/L sIgE to rAra h 1. 
The quantification of rAra h 2.01 and rAra h 2.02 sIgE levels was performed using a calibration 
done against 1 μg/cm rAra h 2.02 and serum RS14231 (54.1 kUA/L sIgE to Ara h 2). For 
calibration, serum RS14231 was used undiluted, diluted 1:2, 1:5, 1:20 and 1:50 in incubation 
buffer. In the case of the quantification of rAra h 2.01 sIgE, one further dilution (1:150) was 
used for calibration. rGly m 5.03 sIgE was quantified using undiluted PEI163 (27.32 kUA/L 
Gly m 5 sIgE) and 1 μg/cm rGly m 5.03 for calibration. The limit of detection (LOD) and the 
limit of quantification (LOQ) were calculated in these analyses by multiplying the specific IgE 
concentration (kUA/L) of the non-allergic control serum N analyzed on the same immunoblot 
membrane by two and four, respectively. 
As for rPis s 1 such ImmunoCAPTM values were not available due to the lack of commercially 
available Pis s 1 CAPs, a different strategy for the quantification of rPis s 1 specific IgE was 
developed.  
rPis s 1 sIgE was quantified after linear regression of sIgE level (kUA/L) against densitometric 
signal intensity (volume). Calibration of sIgE levels was based on the densitometric volume 
values of sera from pea patients 3, 11, and 14 (Figure 21A), assuming 32.10 kUA/L, 
23.10 kUA/L, and 6.5 kUA/L rPis s 1 sIgE, because rPis s 1 fully inhibited 32.10 kUA/L (96.55% 
inhibition), 23.10 kUA/L (98.17% inhibition), and 6.5 kUA/L (99.93% inhibition) pea total 
protein specific IgE in immunoblot inhibition (Figure 22, Table 26). Accordingly, sIgE to pea 
total protein was merely constituted by rPis s 1 sIgE in these sera and is therefore identical to 
it. Finally, rPis s 1 sIgE of sera from all pea patients was calculated from the individual 
densitometric volume value using the following linear regression equation: y(sIgE)= 7E-
07x(volume) + 3.8242; R2=0.9976). In this analysis, the LOD and the LOQ were defined as 
two times and four times respectively the volume value of the non-allergic control serum N 
resolved for rPis s 1 sIgE. 
Table 11 summarizes the respective allergens with the corresponding patient sera that were 
analyzed on the same membrane as non-allergic control serum N1 or N2. 
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Table 11: Control sera used for calculating limit of detection in immunoblot analyses. 
Allergen Control serum Patients 
rAra h 1 Serum N1 Peanut patients 24-34 
rAra h 1 Serum N2 Peanut patients 1-23 and 35 
rAra h 2.01 Serum N1 Peanut patients 1-5 and 24-35 
rAra h 2.01 Serum N2 Peanut patients 6-23 
rAra h 2.02 Serum N1 Peanut patients 1-5 and 24-35 
rAra h 2.02 Serum N2 Peanut patients 6-23 
rGly m 5.03 Serum N Soybean patients 1-21 
rPis s 1 Serum N1 Pea patients 1-7 
rPis s 1 Serum N2 Pea patients 8-19 
 
 
3.2.8.8 Measurement of Ara h 2.01 sIgE levels using ImmunoCAPTM 
Using Phadia 100 instrument from Thermo Fisher Scientific sIgE levels to rAra h 2.01 
(ImmunoCAPTM component f423) of the peanut study population were additionally quantified. 
Calibration was done in a range from 0.001 to 100 kUA/L with intermediate steps at 0.35 kUA/L, 
0.70 kUA/L, 3.5 kUA/L and 17.5 kUA/L. Handling of Phadia 100 instrument and measurement 
of rAra h 2.01 sIgE levels were done by Elke Haberkorn (Paul-Ehrlich-Institut). 
 
3.2.8.9 Mediator release assay 
The biological activity of legume extracts, recombinant proteins and two 27-mer synthetic 
peptides of Ara h 2.02 was assessed using a mediator release assay that is based on immortal 
rat basophilic leukemia cells that can be passively sensitized with human IgE. Two 27-mer 
peptides (D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P-Y), one having hydroxylated 
proline residues instead of proline residues (underlined positions) were purchased from PT 
Peptide Technologies GmbH (Berlin, Germany). Both 27-mer peptides were ordered with a 
purity of > 90%. Quality and identity of both purchased peptides was confirmed by HPLC and 
MS analysis according to the commercial provider. 
The mediator release assay followed the protocol published by Vogel et al. (Vogel et al. 2005). 
Briefly, rat basophilic leukemia (RBL-2H3) cells expressing the α-chain of the high-affinity IgE 
receptor (FcεRI) were sensitized overnight with different serum pools that were diluted 1:10 in 
RBL medium. In the peanut project, the following serum pools were generated for mediator 
release assay: serum pool 1 (peanut patients 3 and 17), serum pool 2 (patients 6-8, 10, 12, 15, 
18 and 21-23) and serum pool 3 (peanut patients 2, 4, 5, 13 and 19). Sera for serum pools were 
selected according to the results of immunoblot and multi-peptide microarray analyses. 
As serum agglutination was observed during mediator release pretesting, peanut serum pools 
were pretreated with thrombin (Sigma-Aldrich; 250 U). Therefore, each peanut serum pool was 
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incubated with a final concentration of 1 U/ml thrombin (dissolved in 1M CaCl2). After 1 h at 
room temperature, samples were centrifuged (4°C; 16,000 x g, 20 min) and supernatants were 
used for overnight sensitization of RBL-2H3 cells. 
In addition, in the pea project one serum pool composed of pea patients 1, 3, 4, 8 and 11 was 
generated (here: no thrombin addition was necessary). After overnight sensitization, RBL-2H3 
cells were washed and afterwards stimulated for degranulation with different amounts of either 
legume extract, recombinant proteins or 27-mer peptides. As negative control in the pea project, 
cells were additionally stimulated with BSA. In the peanut project, no BSA was used as negative 
control in mediator release assay due to an observed serum IgE binding of peanut-allergic 
patients (pool 2) to BSA in immunoblot analysis (details not shown). Therefore, serum N served 
as negative control in peanut mediator release assay meaning that RBL-2H3 cells were 
additionally sensitized with serum N (1:20) and afterwards stimulated with all tested 
molecules. 
Total mediator release was determined by cell lysis using 1% Triton X-100 (Sigma-Aldrich) and 
spontaneous release by incubating sensitized cells in buffer without allergen. Released β-
hexosaminidase induced by either legume extracts, recombinant proteins or peptides was 
measured photometrically. Specific mediator release was expressed as percent of total mediator 
release after subtracting spontaneous release. 
 
3.2.8.10 Circular dichroism spectroscopy 
CD spectra of recombinant proteins and 27-mer peptides were recorded using a CD 
spectropolarimeter. Proteins and peptides were measured at 20°C in dialysis buffer 1 
(exception: rPis s 1 measured in 20 mM sodium phosphate, 100 mM NaCl and 0.2 mM EDTA 
pH 7.6) in a quartz cuvette with a path length of 0.1 cm. Measurement settings were: 
band width 1 nm, step width 1 nm, scanning speed 50 nm/min, accumulation 10 (exception: 
rPA2: accumulation 5). Recombinant proteins and 27-mer peptides were measured at 2 to 
11 µM and the respective buffer spectrum was subtracted. For calculating the mean molar 
ellipticity per residue, the following published equation was used (Pokoj et al. 2010): 
 
[θMRW]= 
 
100 x θ [measured ellipticity in mdeg]N [number of amino acid residues] x c [protein concentration in mM] x d [path length in cm] 
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3.2.8.11 Dynamic light scattering (DLS) 
Hydrodynamic radii of recombinant proteins were determined by DLS. Proteins were measured 
in UV cuvettes (10 mm; Carl Roth) in a Zetasizer instrument (software v6.12) in the same 
buffers used for CD spectroscopy. The individual protein concentrations ranged from 3 µM to 
42 µM. Measurements were done at 25°C and were done in triplicate for each protein. 
 
3.2.8.12 Mass spectrometry analysis 
Natural proteins from crude legume extracts and recombinant proteins were separated using 
SDS-PAGE, stained with Coomassie and afterwards analyzed with liquid chromatography mass 
spectrometry (LC-MSE). Mass spectrometry (MS) analyses were performed by Anna Engin, Luisa 
Schwaben, Dr. Jelena Spiric and Dr. Andreas Reuter at the Proteomics Core Facility of the Paul-
Ehrlich-Institut and have not been part of my own experimental work. Nevertheless, the 
experimental methods are presented here for understanding and to allow the reader to assess 
the validity of the results and of the conclusions drawn. This follows a concept previously 
applied in the PhD thesis of Dr. Felix Husslik (PhD thesis 2016, Department of Chemistry, 
Technische Universität Darmstadt). In addition, all parameters used specifically for this study 
are given in detail.  This applies especially to devices, databases and amino acid sequences. 
 
“In-gel digestion: 
The protein spots were excised and destained three times for 15 min in destaining solution. 
Reduction and alkylation of cysteine residues was carried for 15 minutes at 200 rpm 
(thermomixer, Eppendorf) with reduction and alkylation solution, respectively. The gel plugs 
were dehydrated with 100% acetonitrile, vacuum dried (Savant Speed Vac®, Thermo Fisher 
Scientific) and were rehydrated in 25 mM NH4HCO3 containing 75 ng/μl of trypsin (trypsin 
from porcine pancreas, Sigma-Aldrich). After initial digestion for 3 h at 37°C, elution buffer was 
added and further digestion was allowed over night at 37°C in a thermal cycler (Bibby Scientific, 
Staffordshire, UK). The digestion was stopped by adding of 5% formic acid to a volume of 10% 
of the total digestion mixture. The samples were stored at -80°C until further MS analyses. 
 
LC-MS analyses: 
Trypsin digested proteins were analyzed using the nanoACQUITY® UPLC online coupled with 
nano ESI interface to a Q-TOF MS (Synapt, Waters, Manchester, UK). The solvent system 
consisted of solvent A (water with 0.1% (v/v) formic acid), and solvent B (acetonitrile with 
0.1% (v/v) formic acid). Peptides were initially trapped on-line at a flow rate of 5 μl/min using 
the trap column (nanoACQUITY Trap C18, 5 μm particle size, 180 μm × 20 mm). The peptide 
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mixture was separated using a reverse-phase analytical column (nanoACQUITY C18, 1.7 μm 
particle size, 100 μm × 100 mm; Waters) at a flow rate of 0.5 μl/min. The solvent composition 
was at 97% A for 1 min, followed by a linear gradient to 60% A for 30 min, and continued with 
95% B for 1 min. The column was subsequently equilibrated at 97% A for 18 min. Glu-1-
Fibrinopeptide at 1pmol/μl, delivered from the auxiliary pump of the nanoACQUITY® UPLC at 
a 0.5 μl/min flow rate to the reference sprayer of the interface was measured every 20 sec to 
serve as a lock mass during the entire sample run. The mass spectrometer was operated in data 
independent MSE mode at a positive polarity and V mode (Silva et al., 2005; Silva et al., 2006). 
Scan rate was set to 0.4 sec. The collision energy was at a constant value of 4 V during low-
energy scans and ramped from 15-30 V during high energy scans. Data were acquired from 
50 to 1,990 m/z. 
 
Data processing and database search: 
Raw data files were processed using ProteinLynx Global Server (PLGS) version 2.4 (Waters). 
The processing parameters were set as follows: Retention time window, chromatographic peak 
width and MS TOF resolution were set to automatic, lock mass for charge state +1 and for 
charge state +2 were defined as 684.3469 Da and 785.8426 Da, respectively. Low energy 
threshold was set to 250.0 counts, elevated energy threshold to 100.0 counts and intensity 
threshold to 1,500 counts. The search parameters for protein identification were a maximum 
of one missed cleavage site, a minimum of three fragment ion matches per peptide, a minimum 
of seven fragment matches per protein and a minimum of one peptide match per protein with 
a set false positive rate of 4%. Carbamidomethylation of cysteine (C) was defined as a fixed 
modification. Variable modifications were restricted to deamination of asparagine (N) and 
glutamine (Q), and oxidation of methionine (M).”1 
 
Compared to the cited procedure, two different instruments, Synapt G1 and Synapt G2si, were 
used in this PhD project (Table 12). In addition, regarding LC-MS analysis, peptide mixtures of 
nPA1 and nPA2 were separated using a different analytical column (ACQUITY UPLC M-Class 
Peptide HSS T3 Column 10K psi, 1.8 µm particle size, 75 µm X 150 mm). Moreover, raw data 
files were processed using ProteinLynx Global Server (PLGS) version 2.4 Synapt G1 data or 
PLGS 3.01 Synapt G2 data (Waters).  
Finally, the identities of the proteins were confirmed using different UniProt-derived databases 
amended with the amino acid sequences of the recombinant proteins as outlined in Table 12. 
 
 
1Husslik, Felix (2016). Analysis of the IgE epitope profile of the soybean allergen Gly m 4. 
PhD thesis, page 45-47, Technische Universität Darmstadt. URN: http://nbn-
resolving.de/urn:nbn:de:tuda-tuprints-57360. 
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Table 12: Instruments, databases and sequences used for MSE analyses. 
Protein Instrument Database 
Added 
sequence# 
Amino acid sequence of 
recombinant protein 
rAra h 1* Synapt G1 
UniProt restricted 
to reviewed entries 
of all species 
- - 
rAra h 2.01 Synapt G1 
UniProt restricted 
to reviewed entries 
of all species 
PEI077 
underlined sequence in 
Figure A4 in the appendix 
rAra h 2.02 Synapt G1 
UniProt restricted 
to reviewed entries 
of all species 
PEI129 
underlined sequence in 
Figure A5 in the appendix 
natural proteins 
from peanut 
extract 
Synapt G1 
UniProt restricted 
to reviewed entries 
of all species 
- - 
rPis s 1 Synapt G1 
UniProt restricted 
to reviewed entries 
of eucaryotic 
organisms 
PEI112 
underlined sequence in 
Figure A7 in the appendix 
rPA1 Synapt G1 
UniProt restricted 
to reviewed entries 
of all species 
PEI081 
underlined sequence in 
Figure A8 in the appendix 
rPA2 Synapt G1 
UniProt restricted 
to reviewed entries 
of all species 
PEI080 
underlined sequence in 
Figure A9 in the appendix 
nPA1 Synapt G2si 
UniProt restricted 
to reviewed entries 
of all species 
- - 
nPA2 Synapt G2si 
UniProt restricted 
to reviewed entries 
of all species 
- - 
rGly m 5.03 Synapt G1 
UniProt restricted 
to reviewed entries 
of all species 
PEI078 
underlined sequence in 
Figure A10 in the appendix 
rGly m 8 Synapt G1 
UniProt restricted 
to reviewed entries 
of all species 
PEI075 
underlined sequence in 
Figure A11 in the appendix 
natural proteins 
from soybean 
extract 
Synapt G1 
UniProt restricted 
to reviewed entries 
of all species 
- - 
* provided by Dr. Jonas Lidholm (Thermo Fisher Scientific); # UniProt database was amended with the amino acid 
sequence of the recombinant protein. 
 
 
3.2.8.13 Modeling of investigated proteins 
For modeling of protein structures, SWISS-MODEL Workspace server available at 
https://swissmodel.expasy.org/ was used. For this purpose, full-length mature natural protein 
sequences were used. The protein structure of Ara h 1 was modelled using Ara h 1 pdb 3SMH 
(sequence identity 99.8%) as template. The structures of Ara h 2.01 and Ara h 2.02 were 
modelled using the structure of Ara h 6 (pdb 1W2Q) as template. Ara h 6 showed 66.1% and 
64.4% sequence identity to Ara h 2.01 and Ara h 2.02, respectively. Using the structure of the 
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β-subunit of Gly m 5 (pdb 1UIJ) showing 59.4% sequence identity, the structure of Pis s 1 was 
modelled. After modeling, 3-D images were generated using PyMOL Molecular Graphics System 
(Version 1.5.0.4 or Version 2.0.6 Schrödinger, LLC, New York, USA). 
 
3.2.9 Peptide analysis 
3.2.9.1 IgE immunodetection 
IgE-binding peptides were detected following the protocol published by Kühne et al. with some 
modifications (Kühne et al. 2015). Briefly, slides were blocked with blocking buffer for 2 h and 
afterwards incubated for 5 min in washing buffer. After drying the slides for at least 1 h at room 
temperature, 45 µl of defatted patient serum or control serum were applied to the array slide 
underneath a glass cover slip with spacer and incubated overnight. For defatting, serum samples 
were centrifuged twice at 12,000 rpm at 4°C for 10 min. The next day, the glass cover slip was 
removed and slides were washed 5 times with washing buffer. Afterwards, the slides were 
simultaneously incubated for 2 h with Streptavidin-HRP (SouthernBiotech, diluted 1:300,000) 
and mouse anti-human IgE-HRP in blocking buffer (diluted according to the investigated 
allergen). Ara h 1 and Ara h 2 slides were incubated with mouse anti-human IgE-HRP diluted 
1:25,000 and 1:50,000, respectively. For the Pis s 1 and PA1/PA2 microarrays mouse anti-
human IgE-HRP was diluted 1:5,000. Gly m 5 and Gly m 8 slides were incubated with mouse 
anti-human IgE-HRP diluted 1:10,000. Next, slides were washed 4 times with washing buffer 
and, after incubating the slides for 1 min with LumiGLO ReserveTM Chemiluminescent 
Substrate, signals were recorded on X-ray films. 
 
3.2.9.2 IgE inhibition immunoassay 
For IgE inhibition experiments, serum pools were preincubated with the respective inhibitors 
for 3.5-4 h at room temperature. Table 13 shows the investigated peptide microarray with the 
generated serum pools and the used inhibitors. Sera were pooled based on comparable IgE-
binding pattern to the investigated peptides according to microarray analysis. As a reference, 
the respective serum pool was incubated with the respective protein buffer without inhibitor 
(dialysis buffer 1 or 2). Overnight incubation on array slides and all subsequent steps of the 
immunodetection were done as described above. 
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Table 13: Serum pools and inhibitors used for IgE inhibition microarray assay. 
Peptide 
microarray 
Serum pools Inhibitor 
Ara h 1 
Pool 1: Peanut patients 10, 12, 18 and 21 
 
Pool 2: Peanut patients 6, 15, 17 and 23 
20.5 µg rAra h 1 
Ara h 2 Peanut patients 6-8, 10, 12, 15, 18 and 21-23 
13.5 µg rAra h 2.02 
or 
9.5 µg native peanut extract 
or 
9.5 µg red/alk peanut extract 
Pis s 1 
Pool 1: Pea patients 1, 4 and 8 
 
Pool 2: Pea patients 3, 10, 11 and 13 
30 µg rPis s 1 
 
 
3.2.9.3 Microarray data analysis 
X-ray films were scanned at 600 dpi and saved as 16-bit grayscale TIF files. Using Adobe® 
Photoshop® (Version 13.0.1 x64), each slide was cropped to the size of a microscope slide (1796 
x 615 pixel). Afterwards, grayscales were inverted using Image J 1.48v (Rasband, NIH, 
Bethesda, MD, USA; https://imagej.nih.gov/ij/) software and inverted images were again saved 
as TIF files. 
Subsequently, TIGR Spotfinder 3.2.1 was used as software tool for analyzing the signal intensity 
of every spot on the array slide (Saeed et al. 2003). Here, in addition to IgE-bound peptides, 
biotinylated control peptides were used as position markers for grid alignment. TIGR Spotfinder 
program setting during spot analysis were: segmentation method circle, diameter 25, 
background correction off. After analyzing all spot signal intensities on the array, data were 
saved as mev-files and subsequently stored for further analysis as xlsx-files. For all following 
calculation steps, the median intensity value in channel A (MedA) was used for each spot. In 
the next step, the signal intensity of every peptide was transformed into a Z-score. Z-score 
transformation was performed as described by Hansen et al. with slight modifications (Hansen 
et al. 2016). Briefly, the median signal intensity (Si) of quadruplicate peptide signals was 
calculated for every peptide. Exceptions were sera of peanut patients 19 and 25 on Ara h 1 
peptides and sera of pea patients 2, 8 and 10 on Pis s 1 peptides where only one segment 
(peanut patients 19 and 25: right segment; pea patients 2, 8 and 10: left segment) with 
duplicate peptide spots could be analyzed for each patient serum. Next, the constant mean (m) 
was calculated from all blank spots on the same array. The constant mean was obtained by a 
step by step calculation of the mean of the blanks excluding blank signal intensities outside 
mean ± 2 standard deviation. Once the constant mean was obtained, the standard deviation 
(s) was calculated of the blank spots representing the constant mean. Exception in the 
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calculation of the constant mean of the blanks was peanut patient 21 on Ara h 2 peptides, where 
not all blanks (2 x 266 vs. 2 x 138 blanks) were used for the calculation due to too high signal 
intensities of Ara h 2 peptides that overexposed too many neighbouring blank spots. Finally, Z-
scores were calculated for every peptide according to the following equation: 
 
Z-score = Si - ms  
 
In the last step, non-specific binding to peptides was removed by subtracting from the Z-score 
of each peptide the maximum Z-score of the same peptide probed with control serum. As 
controls for multipeptide microarray immunoassays, different sera and serum combinations 
were used which are summarized in Table 5. Important note: in every immunodetection, at 
least one control serum was included. 
For defining positive serum IgE binding to an individual peptide, a Z-score of > 2 after control 
subtraction was used as criterion. 
For calculating percent inhibition in IgE inhibition experiments, Z-scores of serum pools 
(uninhibited and inhibited) were calculated as described above except that no maximum Z-
score of the controls was subtracted afterwards. Solely uninhibited peptides with a Z-score > 2 
were used for further calculation of the percent inhibition. This step should ensure that, despite 
of no control subtraction, just uninhibited signals above the respective microarray background 
were used. In addition, inhibited peptides with a Z-score < 0 were set to zero. Finally, percent 
inhibition was calculated for every peptide according to this formula: 
 
100 - Z-score serum pool inhibitedZ-score serum pool uninhibited  x 100 
 
3.2.9.4 Selection of candidate diagnostic peptides 
For each investigated allergen, candidate diagnostic peptides showing specific IgE binding only 
in the respective legume-allergic subjects were selected according to criteria established within 
this PhD thesis. At first, candidate peptides should be exclusively recognized by the allergic 
patients. Peptides recognized by tolerant patients were excluded from the selection. Secondly, 
candidate peptides should have a high signal intensity. Therefore, for every positive IgE-bound 
peptide (Z-score > 2 after control subtraction), the median Z-score was calculated of all allergic 
patients; peptides with Z-score ≤ 2 were excluded from the median calculation. Subsequently, 
peptides with a median Z-score of > 5 were selected for further analysis. Further, only peptides 
showing an IgE binding in relation to the full-length allergen were selected. Therefore, only 
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peptides were further selected which showed at least 30% inhibition of their IgE binding by the 
corresponding full-length protein in at least one inhibition experiment. Next, candidate 
diagnostic peptides should contain distinct amino acid sequences and represent distinct protein 
areas and therefore an offset of ≥ 4 peptides was applied between two peptides. If there were 
several options, the peptide with the higher IgE-binding frequency among the allergic patients 
was selected. If there were still several possibilities left, because multiple peptides may show 
the same IgE-binding frequency, the peptide with the highest median Z-score (calculated from 
positive IgE-bound peptides) was selected.  
From all preselected peptides fulfilling the above-mentioned criteria those peptides that most 
frequently bound IgE (≥ median frequency of preselected peptides) were finally selected as 
candidate diagnostic peptides. 
 
3.2.10 Receiver operating characteristic (ROC) curve analysis 
Using SigmaPlot 13.0 (Systat Software GmbH, Erkrath, Germany) ROC curve analyses were 
performed. The following software settings were used for the analyses: data format indexed, 
data type paired, classification variable clinical phenotype/status (allergic or tolerant), positive 
state allergic, positive direction high. The following test variables were analyzed: sIgE levels to 
legume extracts, to rAra h 2.01 (both determined by ImmunoCAPTM analysis), to recombinant 
legume proteins (quantified by immunoblot analysis), and maximum Z-scores of selected 
candidate diagnostic peptides (determined by multipeptide microarray analysis) of legume-
allergic and tolerant patients. Prior to ROC curve analysis, peanut extract and rAra h 2.01 sIgE 
levels > 100 kUA/L were set to 100 kUA/L as otherwise the software excluded these patients 
from analysis. A preliminary in silico analysis revealed that setting values > 100 kUA/L to 
100 kUA/L or to randomly chosen 500 kUA/L resulted in both cases in the same AUC (area under 
curve) and the same 95% confidence interval. In addition, prior to ROC curve analysis sIgE 
levels to recombinant peanut and soybean proteins that were quantified by immunoblot analysis 
were subtracted by two times the quantified sIgE level of the non-allergic control serum 
analyzed on the same membrane (N1 or N2). In the pea project, rPis s 1 sIgE levels were 
subtracted by two times the densitometric signal intensity of the non-allergic control serum N1 
or N2 resolved for sIgE. Moreover, the maximum Z-score of the identified candidate diagnostic 
peptides was calculated for each individual patient, and used for ROC curve analysis. For 
maximum calculation, the Z-scores after control subtraction were used. 
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4 Results 
4.1 Peanut project 
4.1.1 Study population 
In total, sera from 35 children were included in this peanut project (Table 14). The inclusion 
criterion was a sensitization to peanut extract, expressed by a peanut extract ImmunoCAPTM 
result of ≥ 0.35 kUA/L. 23 of these children (patients 1-23) had symptomatic peanut allergy 
confirmed by double-blind placebo-controlled food challenge (16/23), single-blind controlled 
food challenge (1/23) or open food challenge (5/23). In patient 23 peanut allergy was 
confirmed by food challenge, however the exact type of challenge was unknown. Peanut allergy 
was excluded in the remaining 12 children (patients 24-35) by double-blind placebo-controlled 
food challenge (8/12) or open food challenge (4/12). 
The allergic symptoms during food challenge ranged from grade II to grade V with V being the 
most severe grade. Severe symptoms (grade IV-V) were reported in 9/23 (39%) patients. In 
addition, no mild (grade I) symptoms were observed highlighting the high allergenicity of this 
legume in children. Due to a lack of symptom data, patient 18 was excluded from this 
calculation. 
Total IgE ranged from 16.8 to 1985 kUA/L in peanut-allergic children (median 296 kUA/L) and 
from 10.3 to 1276 kUA/L in peanut-tolerant children (median 514 kUA/L) demonstrating a 
significant overlap in the total IgE level between both study groups. In contrast, peanut extract 
sIgE level was elevated in the peanut-allergic group compared to the tolerant group with 
median peanut sIgE of 24.5 kUA/L and 1.93 kUA/L, respectively. Additional characteristics are 
listed in the table below. 
Serum N, DLab71S1 and DLab72S1 served as negative controls for immunoblot and microarray 
analyses. 
 
Table 14: Clinical characteristics of the peanut study population.      
Patients allergic to peanut (patients 1-23), patients sensitized to peanut without clinical symptoms (patients 24-35) 
and control sera (N, DLab71S1 and DLab72S1). 
Patient 
No.  
Age (y)*/sex Clinical evidence 
Symptoms to 
peanut  
Severity 
grading# 
Total IgE  
(kUA/L)‡ 
Peanut sIgE  
(kUA/L)‡ 
1 3/f DBPCFC V II n.d. 28.80 
2 1/m OFC P, GU, AE II 63.70 12.80 
3 5/f SBCFC  GU, W IV n.d. 23.90 
4 1/f DBPCFC  GU II 16.80 4.22 
5 3/m DBPCFC  GU II n.d. 1.98 
6 6/m OFC V, S, Cg IV 451.00 >100 
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7 3/f DBPCFC W IV n.d. 14.10 
8 4/f DBPCFC RA V n.d. 63.50 
9 5/f DBPCFC CU, RC, IT III 145.00 0.71 
10 14/f DBPCFC AE, V, H IV n.d. >100 
11 2/f DBPCFC CU, C II 39.00 0.82 
12 6/f DBPCFC  GU, V, S, W IV 953.00 >100 
13 1/m DBPCFC GU, AE, R II 48.00 1.63 
14 4/m DBPCFC  GU, R, W IV 35.00 0.82 
15 4/f DBPCFC GU, V II 542.00 348.00 
16 2/f DBPCFC GU, W IV n.d. 0.85 
17 1/f DBPCFC V II 432.00 78.50 
18 6/m OFC n.d. unknown  >567 >100 
19 5/m DBPCFC V, W IV 231.00 24.50 
20 5/f DBPCFC GU, RC III 57.20 3.45 
21 3/m OFC GU, Cg III 1985.00 100.00 
22 5/m OFC GU, AE, RC III 938.00 84.20 
23 3/m FC GU, V II 361.00 70.70 
24 10/f DBPCFC none - n.d. 1.52 
25 2/m DBPCFC none - 958.00 3.69 
26 2/m DBPCFC none - n.d. 1.32 
27 11/f DBPCFC none - 514.00 2.02 
28 6/f DBPCFC none - n.d. 4.40 
29 9/f OFC none - 610.00 2.42 
30 6/m DBPCFC none - n.d. 2.21 
31 2/m DBPCFC none - n.d. 0.51 
32 7/f OFC none - 293.00 0.57 
33 1/m OFC none - 507.00 1.83 
34 2/m OFC none - 1276.00 7.46 
35 3/m DBPCFC none - 10.30 1.70 
N n.d.  n.d.  n.d.   - n.d. 0.02 
DLab71S1 n.d.  n.d.  n.d.   - n.d. 2.75 
DLab72S1 n.d.  n.d.  n.d.   - n.d. 4.33 
N, serum from a non-allergic control; *age at time of blood sampling; f, female; m, male; n.d., not determined; 
DBPCFC, double-blind placebo-controlled food challenge; SBCFC, single-blind controlled food challenge; OFC, open 
food challenge; FC, food challenge (not further specified); AE, angioedema; C, conjunctivitis; Cg, coughing; CU, 
contact urticaria; GU, generalized urticaria; H, hoarseness; IT; itching throat; P, pruritus; RA, respiratory arrest; RC, 
rhinoconjunctivitis; R, rhinitis; S, stridor; V, vomiting; W, wheezing; #severity grading according to the grading 
system developed by Sampson (Sampson 2003); ‡ determined by ImmunoCAPTM. 
 
 
4.1.2 Generation and physicochemical characterization of recombinant peanut allergens 
cDNA sequences (appendix Figure A3-A5) encoding mature Ara h 1, Ara h 2.01 and Ara h 2.02 
were successfully cloned into expression vector pPICZαA and subsequently integrated into 
Pichia pastoris X-33 genome as confirmed by DNA-sequencing and PCR analysis, respectively 
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(data not shown). Both Ara h 2 isoforms could be successfully expressed using Pichia pastoris. 
However, despite using multiple Ara h 1 recombinant clones, it was not possible to express 
Ara h 1 using Pichia pastoris. A potential low expression level could be excluded as verified by 
the absence after concentrating the cell culture supernatant. In addition, the absence of Ara h 1 
in yeast cell culture supernatant was confirmed by immunoblot analysis using anti-His-tag 
antibody and anti-Ara h 1 (PN-t) antibody (data not shown). As a substitute, rAra h 1 used in 
this PhD project was kindly provided by Dr. Jonas Lidholm from Thermo Fisher Scientific. It 
was an E. coli-expressed recombinant protein used for commercial ImmunoCAPTM analysis. 
For both Ara h 2 isoforms an expression strategy was developed using protease inhibitor 
solution as supplement during expression to reduce proteolysis. Both full-length proteins were 
secreted into cell culture supernatant and purified via their His-tag using IMAC and, in the case 
of rAra h 2.01, via additional SEC. The identity of rAra h 1 and both rAra h 2 isoforms was 
confirmed by mass spectrometry analysis. Sequence coverages for rAra h 1, rAra h 2.01 and 
rAra h 2.02 of 46.8%, 41.6% and 39.8% were determined, respectively (Table 15). 
Furthermore, mass spectrometry analysis identified the sequence of rAra h 1 as the sequence of 
clone P41B. 
 
Table 15: Identity confirmation of recombinant peanut proteins by mass spectrometry analysis. 
Protein 
Accession 
number# 
PLGS protein 
score 
Number of identified 
peptides 
Sequence 
coverage 
Mass error* 
rAra h 1 P43238 3292 30 46.8% 8.1 
rAra h 2.01 PEI077 2053 7 41.6% 11.2 
rAra h 2.02 PEI129 6452 9 39.8% 6.1 
#P, UniProt accession number; PEI, internal accession number; *precursor RMS mass error [ppm]. 
 
Purity and stability of recombinant proteins was assessed on Coomassie-stained SDS-PAGE. 
Figure 2A, shows suitable purity of all recombinant peanut protein preparations. Additional 
bands in the lower molecular weight range in both Ara h 2 isoform preparations were identified 
by MS as degradation products of the respective isoform. Secondary structure was analyzed 
using CD spectroscopy (Figure 2B). Far-UV CD-spectrum of rAra h 1 showed a maximum at 
~196 nm and a minimum at ~208 nm similar to the published CD-spectrum of Ara h 1 
extracted from raw peanuts (Nesbit et al. 2012). However, the calculated hydrodynamic radius 
(RH) of 11.2 ± 3 nm indicated a strong aggregation behavior of rAra h 1. The CD spectra of 
both recombinant Ara h 2 isoforms were comparable to published data and showed 
characteristics typical for α-helical proteins: two minima at ~208 and ~222 nm and one 
maximum at ~193 nm (Lehmann et al. 2003). The calculated RH of rAra h 2.01 and rAra h 2.02 
 Results  65 
was 2.4 ± 0.2 nm and 2.6 ± 0.5 nm, respectively, suggesting that both proteins appeared as 
monomers and did not form aggregates in solution. Both isoforms showed comparable 
physicochemical characteristics and were thus suitable for a direct comparison of their IgE-
binding capacity and their diagnostic value that is not impaired by potential differences in their 
IgE binding as caused by physicochemical differences. 
 
 
 
Figure 2: Purity and physicochemical characterization of rAra h 1, rAra h 2.01 and rAra h 2.02. 
(A) Coomassie-stained SDS-PAGE of rAra h 1 (lane 1; 3 µg/cm), rAra h 2.01 (lane 2; 2 µg/cm) and rAra h 2.02 
(lane 3; 2 µg/cm). Protein samples were analyzed under reducing conditions. M, SpectraTM Multicolor Broad Range 
Protein Ladder. (B) Far-UV CD-spectra (190-255nm) of rAra h 1 (solid line), rAra h 2.01 (dotted line) and rAra h 2.02 
(dashed line). Samples were measured at 2 µM, 3 µM and 3 µM, respectively. The inset depicts the hydrodynamic 
radius (RH) ± SD. 
 
4.1.3 Diagnostic value of full-length peanut proteins 
In the diagnosis of peanut allergy, the ImmunoCAPTM is a commonly used method. 
Commercially available ImmunoCAPTM uses rAra h 2.01, which has been reported in several 
studies to have a high, almost perfect diagnostic accuracy in predicting peanut allergy. 
Therefore, in a first step the sIgE level to rAra h 2.01 of all sera included in the peanut project 
was determined by ImmunoCAPTM analysis. Determined sIgE levels to rAra h 2.01 are shown in 
Table 16. Considering the recommended cut-off value of 0.35 kUA/L, 22/23 (96%) peanut-
allergic children and 1/12 (8%) peanut-tolerant children showed a sensitization to rAra h 2.01. 
This result shows, in accordance with other published studies, a perfect discriminative ability 
of sIgE to rAra h 2.01 between peanut-allergic and peanut-sensitized but clinically tolerant 
children. Therefore, the ImmunoCAPTM result should serve as a reference for subsequent 
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analysis regarding the assessment of the diagnostic value of the self-generated recombinant 
peanut allergens.  
Due to low serum availability sIgE levels to self-generated recombinant Ara h 1, Ara h 2.01 and 
Ara h 2.02 were not investigated using ImmunoCAPTM but immunoblot analysis combined with 
densitometric quantification. Figure 3 shows the serum IgE binding of peanut-allergic (patients 
1-23) and sensitized but tolerant (patients 24-35) children to rAra h 1 (Figure 3A), rAra h 2.01 
(Figure 3B) and rAra h 2.02 (Figure 3C). For quantification, serial dilutions of two sera having 
each 103.61 kUA/L Ara h 1 sIgE and 54.1 kUA/L Ara h 2 sIgE were used for calibration. The 
quantified sIgE levels of each patient are listed in Table 16. For identifying positive or negative 
serum IgE binding to recombinant proteins, the limit of detection (LOD) of each immunoblot 
was defined as 2 x sIgE level (kUA/L) of the non-allergic control serum N used on the same 
membrane. Patients’ quantified sIgE levels exceeding the respective LOD were considered 
positive. LOD’s for the specific IgE binding to rAra h 1, rAra h 2.01 and rAra h 2.02 were 
1.916/2.058 kUA/L, 2.404/3.392 kUA/L and 1.610/2.126 kUA/L (membrane 1/membrane 2), 
respectively. A LOD of 1.916 kUA/L (rAra h 1) was determined for patients 24-34 and of 
2.058 kUA/L for the remaining patients. For rAra h 2.01/rAra h 2.02 immunoblot a LOD of 
2.404/1.610 kUA/L was calculated for patients 1-5 and 24-35, and for the remaining patients a 
LOD of 3.392/2.126 kUA/L was determined. Considering the respective LOD, rAra h 2.01 and 
rAra h 2.02 were recognized by 15/23 (65%) and 18/23 (78%) peanut-allergic children, 
respectively. In contrast, serum IgE of peanut-tolerant children did not bind to any of both 
Ara h 2 isoforms in immunoblot analysis. A comparison of ImmunoCAPTM and immunoblot 
showed that rAra 2.01 was highly specific in immunoblot but less sensitive than in 
ImmunoCAPTM analysis, which was also reflected by the different cut-off levels for positive 
signals and the lower amount of serum used for immunoblot analysis. In addition, the 
immunoblot analysis revealed that rAra h 2.02 had a higher sensitivity compared to rAra h 2.01 
(65% vs. 78%) while keeping the specificity (100%). In general it could be shown that in 
peanut-allergic children sensitized to rAra h 2.01 or rAra h 2.02, the full-length protein (filled 
triangle Figure 3B and 3C) showed compared to its degradation fragment (open triangle Figure 
3B and 3C) a stronger IgE-binding capacity in immunoblot analysis. Moreover, serum IgE of 
11/23 (48%) peanut-allergic children and 1/12 (8%) tolerant children bound to rAra h 1 
highlighting that rAra h 1 had in this peanut study population the lowest sensitivity (48%) and 
specificity (92%) of all investigated recombinant allergens in immunoblot analysis.  
Generally, 10/23 (43%) peanut-allergic children (patients 1, 6, 10, 12, 15, 17, 18, 21-23) 
showed a polysensitization to all investigated recombinant proteins. Due to a higher sensitivity 
of the sIgE detection using ImmunoCAPTM analysis, Ara h 2 sensitizations of patients 2, 4, 13, 
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14 and 16 could only be detected using ImmunoCAPTM analysis. Moreover, the identified 
sensitization to rAra h 2.01 in ImmunoCAPTM analysis of patients 5 and 20 could only be 
reproduced with rAra 2.02 in immunoblot analysis. In contrast, patient 11 showed a 
sensitization below cut-off (< 0.35 kUA/L) in ImmunoCAPTM analysis, which was identified as 
positive, albeit weak, in immunoblot analysis. 
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Figure 3: Serum IgE binding of peanut-allergic and sensitized but tolerant children to rAra h 1, rAra h 2.01 
and rAra h 2.02. 
IgE binding of sera from peanut-allergic children (lane 1-23, patients’ sera 1-23 according to Table 14) and tolerant 
children (lane 24-35, patients’ sera 24-35 according to Table 14) to rAra h 1 (A), rAra h 2.01 (B) and rAra h 2.02 
(C). Recombinant proteins were analyzed under reducing conditions. IgE binding to each protein after 30 sec 
exposure is shown. Filled triangles indicate full-length rAra h 2.01 and rAra h 2.02; open triangles indicate 
degradation products of the respective isoform. M, low-molecular weight marker; P, total protein stain with 
Ponceau S; N1 and N2, serum from a non-allergic subject on membrane 1 and 2, respectively. 
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Table 16: Specific IgE levels of peanut-allergic and sensitized but tolerant children. 
Peanut-allergic (patients 1-23) and sensitized but tolerant children (patients 24-35). N1 and N2, non-allergic control serum 
on membrane 1 and 2, respectively; DLab71S1 and DLab72S1, non-allergic controls for microarray analyses. 
Patient no.  Peanut sIgE 
(kUA/L)‡ 
rAra h 2.01 sIgE 
(kUA/L)‡ 
rAra h 2.01 sIgE 
(kUA/L)† 
rAra h 2.02 sIgE 
(kUA/L)† 
rAra h 1 sIgE 
(kUA/L)† 
1 28.80 15.00 20.382 7.274 9.520 
2 12.80 2.64 (1.633) (1.452) 5.733 
3 23.90 7.99 2.547 5.946 (0.928) 
4 4.22 1.02 (1.445) (0.826) (0.902) 
5 1.98 2.16 (1.351) 6.417 (1.066) 
6 >100 >100 29.270 46.879 23.845 
7 14.10 31.30 27.196 24.789 (0.943) 
8 63.50 71.70 9.674 23.561 (0.746) 
9 0.71 2.48 5.216 11.404 (0.879) 
10 >100 >100 34.891 54.051 27.755 
11 0.82 (0.19) (1.056) 2.754 (0.962) 
12 >100 63.80 23.910 29.540 47.675 
13 1.63 1.41 (0.869) (1.686) (0.836) 
14 0.82 0.46 (0.942) (1.224) (0.843) 
15 348.00 82.40 28.593 48.594 13.258 
16 0.85 0.68 (1.107) (1.419) (0.824) 
17 78.50 27.20 20.411 32.152 12.074 
18 >100 38.80 47.074 62.279 66.386 
19 24.50 11.40 8.669 16.209 (0.856) 
20 3.45 5.12 (1.287) 6.841 (0.942) 
21 100.00 >100 47.182 24.818 12.419 
22 84.20 67.90 21.284 33.563 2.476 
23 70.70 >100 64.958 26.808 53.195 
24 1.52 (0.02) (1.886) (1.517) (1.409) 
25 3.69 (0.07) (1.319) (1.166) 8.794 
26 1.32 (0.01) (1.362) (1.112) (0.985) 
27 2.02 (0.02) (1.224) (1.079) (1.018) 
28 4.40 (0.02) (1.195) (0.996) (0.962) 
29 2.42 (0.00) (1.370) (0.946) (0.973) 
30 2.21 (0.02) (1.161) (1.025) (1.043) 
31 0.51 (0.00) (1.259) (0.909) (1.414) 
32 0.57 (0.03) (1.178) (0.915) (1.025) 
33 1.83 (0.02) (1.377) (0.981) (1.358) 
34 7.46 (0.05) (1.361) (1.014) (1.098) 
35 1.70 0.42 (1.465) (1.042) (0.780) 
N1  0.02 0.00 1.202 0.805 0.958 
N2  0.02 0.00 1.696 1.063 1.029 
DLab71S1 2.75 0.01 n.d.  n.d.  n.d.  
DLab72S1 4.33 0.02 n.d. n.d. n.d.  
‡ determined by ImmunoCAPTM; † determined by immunoblot analysis; n.d., not determined; () sIgE levels in parenthesis 
are below method cut-off (LOD).  
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According to Table 16, the sIgE levels to rAra h 2.01 (> cut-off), determined by ImmunoCAPTM 
analysis, ranged in peanut-allergic children from 0.46 to > 100 kUA/L (median 21.1 kUA/L), 
whereas only one tolerant child showed sIgE of 0.42 kUA/L. A similar trend was shown for the 
sIgE levels (> LOD) to rAra h 2.01 and rAra h 2.02, determined by immunoblot analysis, of 
peanut-allergic children with median values of 23.91 kUA/L and 24.80 kUA/L, respectively, and 
no tolerant child showing a sensitization to rAra h 2.01 or rAra h 2.02. In contrast, rAra h 1 
sIgE levels (> LOD) in peanut-allergic children ranged from 2.48 to 66.39 kUA/L (median 
13.26 kUA/L) and one tolerant child even showed sIgE binding of 8.79 kUA/L. 
Next, it should be investigated in detail whether the densitometric quantification using 
immunoblot analysis showed a linear correlation with the conventional ImmunoCAPTM analysis. 
Therefore, the sIgE levels to rAra h 2.01 determined by ImmunoCAPTM analysis (Table 16) were 
analyzed for their correlation with sIgE levels to rAra h 2.01 and rAra h 2.02 determined by 
immunoblot analysis (Figure 4A and 4B, respectively). As shown in Figure 4A, in the range 
between 0.35 kUA/L and ~40 kUA/L sIgE to rAra h 2.01, determined by ImmunoCAPTM, a linear 
correlation (R2=0.7982) to rAra h 2.01 sIgE levels (> LOQ), determined by immunoblot, was 
observed. LOQ was defined as 2 x LOD resulting in LOQ1/2 (membrane 1/2) of 
4.808/6.784 kUA/L sIgE to rAra h 2.01. A comparable correlation (R2=0.7717) was found 
between sIgE to rAra h 2.01 (ImmunoCAPTM) and sIgE to rAra h 2.02 (immunoblot) within 
analogous limits (Figure 4B). LOQ for sIgE to rAra h 2.02 in immunoblot analysis was 
3.22/4.252 kUA/L for membrane 1/2, respectively. The graphs and the trend lines shown in 
Figure 4A and 4B demonstrate that the quantification of sIgE levels by means of immunoblot 
analysis was in the mentioned range comparable to the commonly used ImmunoCAPTM analysis. 
However, ImmunoCAPTM sIgE levels > 40 kUA/L could not be exactly reproduced using 
immunoblot analysis caused by a lower dynamic range of the immunoblot analysis. 
Moreover, in Figure 4C rAra h 2.01 and rAra h 2.02 sIgE levels quantified by means of 
immunoblot analysis were plotted against each other. No linear regression could be calculated 
but the depicted graph shows that for the great majority of peanut-allergic patients with 
rAra h 2.01 and rAra h 2.02 sIgE levels > LOQ, rAra h 2.02 was the more sensitive isoform with 
regard to IgE-binding capacity. 9/13 (69%) peanut-allergic patients with sIgE levels > LOQ 
showed higher sIgE to rAra h 2.02 and only 4/13 (31%) to rAra h 2.01. This finding suggests 
that rAra h 2.02 may improve measurement sensitivity when used as diagnostic reagent. 
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Figure 4: Correlation analysis of sIgE levels quantified by immunoblot analysis and sIgE levels determined by 
ImmunoCAPTM analysis. 
Correlation between rAra h 2.01 sIgE levels determined by ImmunoCAPTM analysis (‡) and sIgE levels to rAra h 2.01 
(A) and rAra h 2.02 (B) quantified by immunoblot analysis (†). (C) Correlation between rAra h 2.01 sIgE levels (†) 
and rAra h 2.02 sIgE levels (†). In (A) and (B) a linear trend line (black line) was drawn through rAra h 2.01 (†) and 
rAra h 2.02 (†) sIgE levels > LOQ, respectively, and rAra h 2.01 (‡) sIgE levels ≥ 0.35 kUA/L and ≤ 40 kUA/L. For 
simplification in (A)-(C), mean LOD (dashed and single dotted line) and mean LOQ (2 x LOD; dashed line) of 
LOD1/2 and LOQ1/2 are depicted, respectively. rAra h 2.01 sIgE levels (‡) > 100 kUA/L were not depicted in (A) 
and (B). The gray dotted diagonal line represents a perfect correlation (100% correlation with a gradient of 1). R2, 
coefficient of determination. 
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Finally, in order to determine and compare the diagnostic value of the investigated peanut 
proteins, an ROC curve analysis was performed (Figure 5). To obtain plausible results, the sIgE 
levels quantified by immunoblot analysis were subtracted by two times the respective sIgE level 
of the non-allergic control N1 or N2 prior to ROC curve analysis. As otherwise, unexpected high 
areas under the ROC curve (AUC) were obtained. Furthermore, this step enabled a better 
adaptation of the ROC curve results with the determined frequency of IgE binding to the 
respective recombinant proteins. As a reference for ROC curve analysis, the rAra h 2.01 sIgE 
levels determined by ImmunoCAPTM analysis (Table 16) were used, because most publications 
use ImmunoCAPTM analysis for determining the sIgE levels, and in this study the ImmunoCAPTM 
analysis using Ara 2.01 performed almost perfectly. 
In general, the higher the AUC, the better the overall diagnostic accuracy of the parameter. sIgE 
to rAra h 2.01 determined by ImmunoCAPTM analysis showed with an AUC of 1.00 a perfect 
discrimination between peanut-allergic and peanut-tolerant children within this study 
population. Using a cut-off of 0.35 kUA/L a sensitivity of 96% and a specificity of 92% could be 
observed. For sIgE to peanut extract, also determined by ImmunoCAPTM analysis, an AUC of 
0.79 was calculated.  
The sIgE to rAra h 2.01 and rAra h 2.02 quantified by means of immunoblot analysis revealed 
an AUC of 0.75 and 0.86, respectively. In contrast, sIgE to rAra h 1 showed with an AUC of 0.51 
the worst performance of all three proteins investigated by immunoblot analysis. Moreover, 
based on immunoblot analysis, sIgE to rAra h 2.01 reached, at a specificity of 100%, a sensitivity 
of 65%. Compared to rAra h 2.01, sIgE to rAra h 2.02 showed at a specificity of 100% a higher 
sensitivity (78%). 
In summary, the results presented in this chapter show that rAra h 2.01 in the ImmunoCAPTM 
analysis enables a perfect discrimination between peanut-allergic and sensitized but tolerant 
children. In immunoblot analyses, rAra h 1 showed the worst performance compared to 
rAra h 2.01 and rAra h 2.02, with rAra h 2.02 exceeding rAra h 2.01 with regard to sensitivity. 
Therefore, it is likely that rAra h 2.02, when used as reagent in ImmunoCAPTM analysis, may 
additionally improve ImmunoCAPTM performance. At least with regard to measurement 
sensitivity, as shown for patient 11 who was negative in ImmunoCAPTM analysis but positive 
(albeit weak) in immunoblot analysis. 
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Figure 5: Receiver operating characteristic (ROC) curve analysis of sIgE to peanut extract and full-length 
recombinant peanut proteins. 
ROC curves of sIgE to peanut extract (black), rAra h 2.01 (orange) determined by ImmunoCAPTM analysis (‡) and to 
rAra h 1 (red), rAra h 2.01 (green) and rAra h 2.02 (blue) quantified by immunoblot analysis (†). For ROC curve 
analysis, the sIgE levels quantified by means of immunoblot analysis were subtracted by two times the respective 
sIgE level of the non-allergic control serum. ImmunoCAPTM sIgE values > 100 kUA/L were set to 100 kUA/L for ROC 
curve analysis. The gray diagonal line (AUC 0.5) represents a test without discriminatory ability. AUC, area under 
the ROC curve; CI, confidence interval. 
 
 
4.1.4 Differences in IgE binding at the peptide level 
In the next analysis step, peanut-allergic and sensitized but tolerant children were analyzed for 
their differences in IgE binding at the linear peptide level. Therefore, overlapping peptides 
covering the entire sequences of Ara h 1, Ara h 2.01 and Ara h 2.02 were synthesized. Peptide 
microarrays were generated and individually probed with patient sera. After immunodetection, 
peptide signal intensities were recorded and transformed into Z-scores. Proline hydroxylation 
of Ara h 2 was additionally investigated using peptides containing a hydroxyproline in the 
DPYSPOHS motif. 
Starting with Ara h 1, Figure 6 illustrates the procedure from spotting to IgE immunodetection. 
In Figure 6A the spotting layout of Ara h 1 peptide microarrays is shown. For simplification just 
one out of two array segments is shown. In total, 148 peptides comprised the full-length 
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sequence of Ara h 1. To minimize the influence of outliers, every peptide was spotted in 
quadruplicate. Controls composed of biotinylated non-allergen related peptides were included 
for simplifying array analysis. After spotting, Coomassie-staining of randomly chosen array 
slides verified proper spotting of all peptides (Figure 6B). As an example, the serum IgE binding 
of a peanut-allergic child (patient 21) is shown in Figure 6C (for more details see Figure A13 
in the appendix). The depicted IgE immunodetection showed good accordance between the two 
array segments regarding the IgE-binding pattern. Moreover, this patient showed a strong IgE 
binding to the peptides of Ara h 1 with some peptide regions showing maximum IgE binding.  
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Figure 6: Spotting layout, Coomassie-staining and immunodetection of CelluspotTM multipeptide microarray 
of Ara h 1. 
(A) Spotting layout of Ara h 1 multipeptide microarray. For simplification, only the left segment of the multipeptide 
microarray is shown. Full-length sequence of Ara h 1 is represented by 148 peptides that were spotted (each 0.04 µl) 
in duplicate on each segment leading to quadruplicate peptide presentation on the whole array. Biotinylated control 
peptides, abbreviated by a “C”, were spotted in duplicate in different dilutions (top left and bottom right on each 
array element) and were used as position markers. Gray empty spots represent blank spots composed of peptide 
printing buffer (DMSO). Blue empty spots represent internal control peptides not relevant for peptide analysis. (B) 
Successful spotting was verified by staining with Coomassie Brilliant Blue G250. (C) IgE immunodetection using 
serum of a peanut-allergic child (patient 21) after 30 sec exposure. 
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In order to compare the signal intensities of different microarrays, the signal intensity of every 
peptide was transformed into a Z-score. The transformation of signal intensities into Z-scores 
enables inter-array comparability by reducing the influence of outliers, by correcting the 
background noise and by considering the variation of the analyzed array. In the next step, non-
specific IgE binding to peptides was removed by subtracting from the Z-score of each peptide 
the maximum Z-score of the same peptide probed with control serum from non-allergic subjects. 
As control sera, serum N and DLab71S1 were used. IgE binding to a peptide was considered 
positive, when its Z-score exceeded 2 after control subtraction. Using 2 sigma yielded a 
probability of more than 95% of positivity for a truly positive signal (Mitchell and Jolley 2013). 
The calculated Ara h 1 peptide Z-scores of controls (including maximum Z-score) and of allergic 
and tolerant patients after control subtraction are listed in Table A1-A6 in the appendix. 
In order to identify differences in IgE binding between peanut-allergic and tolerant patients, for 
every peptide of Ara h 1 the frequency of recognition by the peanut-allergic patients was 
calculated and compared with the frequency of recognition by the tolerant patients (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: IgE-binding frequencies to peptides of Ara h 1 of peanut-allergic and tolerant children. 
Comparison of the IgE-binding frequencies of peanut-allergic (black) and tolerant (red) children to peptides of 
Ara h 1. Serum IgE binding to a peptide was considered positive if Z-score was > 2. 
 
As shown in Figure 7, peptides of Ara h 1 were recognized by peanut-allergic as well as by 
tolerant patients. However, peanut-allergic patients showed higher IgE-binding diversity and 
bound more frequently to peptides of Ara h 1 compared to tolerant patients. The maximum IgE-
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binding frequency in peanut-allergic patients was 43% vs. 17% in peanut-tolerant children. 
Overall, 13/23 (57%) peanut-allergic children and 3/12 (25%) peanut-tolerant children 
showed an IgE binding to at least one peptide of Ara h 1 (Table 17). Serum IgE from peanut-
allergic patients bound between 0 to 147 peptides (median 2), whereas peanut-tolerant patients 
recognized 0-18 peptides (median 0). 
In general, microarray data showed a good correlation with immunoblot data. Except for 
patients 4, 7, 31 and 34, who only showed an IgE binding in microarray analysis, serum IgE 
binding to rAra h 1 in immunoblot analysis was in complete accordance with IgE binding to 
Ara h 1 peptides in microarray analysis. For patients 7 and 31 a very weak IgE binding to rAra h 1 
was visible which, however, was below the LOD and was therefore considered negative. 
 
Table 17: Number of positive serum IgE-bound peptides of Ara h 1, Ara h 2.01 and Ara h 2.02. 
Positive peptide IgE binding was defined if the Z-score exceeds 2 after control subtraction.  
Patient 
No. 
Number of 
IgE-bound 
peptides of 
Ara h 1 
Number of 
IgE-bound 
peptides of 
Ara h 2.01_P 
Number of IgE-
bound peptides of 
Ara h 2.01_Hyp 
Number of 
IgE-bound 
peptides of 
Ara h 2.02_P 
Number of IgE-
bound peptides of 
Ara h 2.02_Hyp 
1 11 4 6 4 8 
2 1 0 0 0 0 
3 0 1 6 1 9 
4 65 0 0 0 0 
5 0 0 0 0 0 
6 113 5 6 7 9 
7 5 4 7 4 10 
8 0 4 6 5 9 
9 0 0 1 0 4 
10 147 25 25 31 31 
11 0 0 0 0 0 
12 139 5 6 6 9 
13 0 0 0 0 0 
14 0 0 0 0 0 
15 46 9 9 11 12 
16 0 0 5 0 7 
17 140 2 7 2 10 
18 141 14 14 20 20 
19 0 0 0 0 0 
20 0 0 4 0 6 
21 135 10 10 15 15 
22 2 5 5 6 8 
23 35 7 7 10 10 
24 0 0 0 0 0 
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25 2 0 0 0 0 
26 0 0 0 0 0 
27 0 0 0 0 0 
28 0 0 0 0 0 
29 0 0 0 0 0 
30 0 0 0 0 0 
31 1 0 0 0 0 
32 0 0 0 0 0 
33 0 0 0 0 0 
34 18 0 0 0 0 
35 0 0 0 0 0 
Ara h 2.01_P, peptides 9-14 of Ara h 2.01 contain a proline residue in the DPYSPS motif; Ara h 2.01_Hyp, peptides 
9-14 of Ara h 2.01 contain a hydroxylated proline residue in the DPYSPOHS motif; Ara h 2.02_P, peptides 9-17 contain 
a proline residue in the DPYSPS motif; Ara h 2.02_Hyp, peptides 9-17 contain a hydroxylated proline residue in the 
DPYSPOHS motif. 
 
Next, peanut-allergic and tolerant children were analyzed for their differences in IgE binding 
to peptides representing full-length mature Ara h 2.01 and Ara h 2.02. Both sequences share 
high sequence identity (91%) as shown in Figure 8. The differences are shown in red and 
comprise two amino acid substitutions and an insertion of 12 amino acids in the isoform 
Ara h 2.02. This insertion contains a further DPYSPS motif leading to the presence of three 
instead of two DPYSPS motifs in Ara h 2.02. Furthermore, it is reported that natural Ara h 2.01 
and Ara h 2.02 undergo site-specific post-translational hydroxylation leading to DPYSPS motifs 
with the second proline being hydroxylated (Figure 8, blue). 
 
Figure 8: Sequence alignment of Ara h 2.01 and Ara h 2.02. 
Mature full-length sequences of Ara h 2.01 and Ara h 2.02 were aligned using BLAST® (NCBI, Bethesda MD, USA). 
Differences in amino acid sequence are shown in red, DPYSPS motifs are underlined and proline residues undergoing 
post-translational hydroxylation in natural Ara h 2 are shown in blue. 
 
Figure 9A shows the spotting layout of one segment of the Ara h 2 multipeptide microarray. 
Ara h 2.01 and Ara h 2.02 were composed of 32 and 35 peptides, respectively. The individual 
Ara h 2.01  1    RQQWELQGDRRCQSQLERANLRPCEQHLMQKIQRDEDSYERDPYSPSQDPYSPS------ 54
Ara h 2.02  1    RQQWELQGDRRCQSQLERANLRPCEQHLMQKIQRDEDSYGRDPYSPSQDPYSPSQDPDRR 60
Ara h 2.01  55   ------PYDRRGAGSSQHQERCCNELNEFENNQRCMCEALQQIMENQSDRLQGRQQEQQF  108
Ara h 2.02  61   DPYSPSPYDRRGAGSSQHQERCCNELNEFENNQRCMCEALQQIMENQSDRLQGRQQEQQF  120
Ara h 2.01  109  KRELRNLPQQCGLRAPQRCDLDVESGGRDRY  139
Ara h 2.02  121  KRELRNLPQQCGLRAPQRCDLEVESGGRDRY  151
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peptide sequences are listed in the appendix (e.g. Table A8 and A25). Peptides shared by both 
isoforms were just spotted once for both isoforms (half dark blue, half light blue spots 
Figure 9A). In order to analyze the influence of proline hydroxylation on IgE binding, peptides 
containing hydroxyproline residues were additionally investigated on each array. Peptides 
containing hydroxylated proline residues are marked with an asterisk (Ara h 2.01: peptides 9-
4; Ara h 2.02: peptides 9-17). Again, Coomassie-staining confirmed the presence of all peptide 
spots on the array slide (Figure 9B). 
As an example, the immunodetection using serum IgE from allergic patient no. 18 is shown in 
Figure 9C. This patient showed a strong IgE binding to peptides that contain the DPYSPS motif 
(Ara h 2.01: peptides 9-13; Ara h 2.02: peptides 9-16) or at least a partial amino acid sequence 
of it (Ara h 2.01: peptide 14; Ara h 2.02: peptide 17). The proline hydroxylation in the 
mentioned peptides led to a further increase in IgE binding in this patient. The increase in the 
IgE-binding capacity due to the hydroxylation could be observed for the great majority of the 
allergic children (see appendix Figure A15). 
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Figure 9: Spotting layout, Coomassie-staining and IgE immunodetection of CelluspotTM multipeptide 
microarray displaying Ara h 2. 
(A) Spotting layout of Ara h 2 multipeptide microarray. For simplification, only the left segment of the multipeptide 
microarray is shown. Dark and light blue spots represent unique peptides either found in Ara h 2.01 or Ara h 2.02, 
respectively. Half dark blue, half light blue spots represent peptides shared by both isoforms. Peptide numbers written 
in dark blue and light blue areas belong to Ara h 2.01 and Ara h 2.02, respectively. Peptides depicted with asterisks 
contain hydroxyproline residues in comparison to their peptide counterparts depicted without asterisks. In general, 
Ara h 2.01 and Ara h 2.02 are covered by 32 and 35 peptides, respectively. Biotinylated control peptides, abbreviated 
by a “C”, were spotted in different dilutions (top left and bottom right on each array element) and were used as 
position markers. Gray empty spots represent blank spots composed of peptide printing buffer (DMSO). (B) 
Successful spotting was verified by staining with Coomassie Brilliant Blue G250. (C) IgE immunodetection using 
serum of peanut patient 18 after 30 sec exposure. 
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For simplification, the full-length sequences of Ara h 2.01 and Ara h 2.02 without site-specific 
proline hydroxylation will be named as Ara h 2.01_P and Ara h 2.02_P, respectively. Here, 
peptides 9-14 of Ara h 2.01 and peptides 9-17 of Ara h 2.02 contain a proline residue in the 
DPYSPS motif. If the mentioned peptides contain a hydroxylated proline residue in the 
DPYSPOHS motif, both full-length sequences will be named as Ara h 2.01_Hyp and 
Ara h 2.02_Hyp. The calculated Z-scores (after control subtraction) of every peptide of 
Ara h 2.01_P, Ara h 2.01_Hyp, Ara h 2.02_P and Ara h 2.02_Hyp are listed in Table A8-A23 and 
A25-A40 in the appendix. Mentioned tables in the appendix show the peptide Z-scores of all 
peanut-allergic and tolerant children as well as of controls and their derived maximum peptide 
Z-scores. 
For every peptide of the four investigated Ara h 2 sequences the frequency of recognition by the 
allergic children and by the tolerant children was calculated. Again, a Z-score > 2 was used for 
defining positive peptide IgE binding. Figure 10 shows the calculated frequency of positive IgE 
binding of allergic and tolerant children to peptides of Ara h 2.01_P and Ara h 2.01_Hyp 
(Figure 10A) and to peptides of Ara h 2.02_P and Ara h 2.02_Hyp (Figure 10B). 
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Figure 10: IgE-binding frequencies to peptides of Ara h 2. 
Peanut-allergic (black) and tolerant patients (red) were analyzed for their IgE binding frequencies to peptides of 
Ara h 2.01_P and Ara h 2.01_Hyp (A) and to peptides of Ara h 2.02_P and Ara h 2.02_Hyp (B). IgE-binding 
frequencies to peptides containing a hydroxyproline are depicted in (A) and (B) as dashed line. Criterion for positive 
IgE binding was a Z-score > 2. 
 
Comparable to the IgE binding to full-length allergens (Figure 3), only peanut-allergic children 
showed IgE binding to the peptides of both isoforms (Figure 10). Serum IgE of peanut-tolerant 
children did not bind to any peptide, even peptides 9-14 of Ara h 2.01_Hyp and peptides 9-17 
of Ara h 2.02_Hyp containing hydroxylated proline residues did not bind to serum IgE of 
tolerant children. In peanut-allergic children, peptides with maximum IgE-binding frequencies 
can be identified. Peptide 2 located at the amino-terminal part of the protein sequences was 
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recognized by 11/23 (48%) allergic children. In addition, serum IgE of 11 (48%) peanut-
allergic children, with 9 patients also recognizing peptide 2, bound to peptide 11 of Ara h 2.01_P 
and peptide 11 of Ara h 2.02_P. Peptide 11 of Ara h 2.01_P and of Ara h 2.02_P contained two 
DPYSPS motifs, respectively (for peptide sequence information see appendix Table A8 and 
A25). Hydroxylation of proline residues in Ara h 2.01_Hyp and Ara h 2.02_Hyp led to an 
increase in the maximum IgE-binding frequency. Due to hydroxyproline, 16/23 (70%) peanut-
allergic children recognized peptide 11 of Ara h 2.01_Hyp and the same 16 children recognized 
peptides 11, 12, 14 and 15 of Ara h 2.02_Hyp. Peptides representing the carboxy-terminal part 
of the protein sequences seemed to be of lower relevance for linear IgE binding. 
According to Table 17, serum IgE of 13/23 (57%) peanut-allergic children bound to any peptide 
of Ara h 2.01_P and Ara h 2.02_P, respectively. The median of IgE-bound peptides in the allergic 
children was in both sequences 2 peptides. Proline hydroxylation led to an increase in the 
median number of IgE-bound peptides in Ara h 2.01_Hyp and Ara h 2.02_Hyp with a median 
number of 6 and 8 peptides, respectively. Overall, 16/23 (70%) of peanut-allergic children 
showed an IgE binding to at least one peptide of Ara h 2.01_Hyp and Ara h 2.02_Hyp. Serum 
IgE of patients 9, 16 and 20 bound only to peptides containing a hydroxylated proline residue 
and not to peptides of Ara h 2.01_P and Ara h 2.02_P. Due to hydroxylation in Ara h 2.01_Hyp 
and Ara h 2.02_Hyp, 10/23 and 12/23 peanut-allergic children recognized more peptides as in 
Ara h 2.01_P and Ara h 2.02_P, respectively. Furthermore, hydroxylation was also relevant for 
IgE binding of patients 3 and 17. Both patients recognized few peptides in Ara h 2.01_P and 
Ara h 2.02_P, however peptides 9-14 of Ara h 2.01 and peptides 9-17 of Ara h 2.02 were only 
recognized if they contained hydroxylated proline residues. Moreover, as shown in Figure 9C, 
hydroxylation led to higher signal intensities of IgE-bound peptides. 11/23 allergic patients 
showed an IgE binding to the sum of peptides 9-14 of Ara h 2.01_P. Hydroxylation led to an 
increase in serum IgE binding with 16 patients showing an IgE binding to the sum of peptides 
9-14 of Ara h 2.01_Hyp. In 14 of these 16 patients hydroxylation led to higher signal intensities 
of IgE-bound peptides. The same tendency could be detected for peptides 9-17 of Ara h 2.02_P 
versus Ara h 2.02_Hyp. Here, the IgE binding to the sum of these peptides increased from 11 
to 16 allergic patients and in all (16/16) allergic patients showing a positive IgE binding the 
hydroxylation led to higher signal intensities of IgE-bound peptides (for more details see 
appendix Table A8-A23 and A25-A40). 
Subsequently, microarray and immunoblot data were compared with regard to their serum IgE 
binding. As recombinant Ara h 2.01 and Ara h 2.02 cannot undergo proline hydroxylation (see 
Figure 13), the microarray data of Ara h 2.01_P and Ara h 2.02_P were used for the comparison. 
It turned out, that serum IgE binding of tolerant children was in both methods in complete 
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agreement with no detectable IgE binding to either the recombinant isoforms 
Ara h 2.01/Ara h 2.02 or the derived peptides. Furthermore, except for allergic patients 9 and 
19, who only showed IgE binding to Ara h 2.01 in the immunoblot analysis, microarray analysis 
of Ara h 2.01_P of peanut-allergic patients was in complete accordance with the immunoblot 
analysis. Moreover, the comparison of serum IgE binding to Ara h 2.02 in immunoblot and 
microarray analysis revealed that five patients (patients 5, 9, 11, 19 and 20) showed an IgE 
binding to full-length rAra h 2.02 but not to peptides of Ara h 2.02_P. 
 
4.1.5 Identification of candidate diagnostic peptides 
In order to identify peptides with diagnostic specificity for peanut allergy, selection criteria for 
candidate diagnostic peptides were established. Candidate diagnostic peptides should be 
exclusively recognized by peanut-allergic children. Furthermore, only positive IgE-bound 
peptides with high signal intensities in IgE binding were selected. A median Z-score of > 5 
should sufficiently ensure to eliminate weak positive IgE-binding peptides. Further, only 
peptides showing an IgE binding in relation to the full-length allergen were selected. Therefore, 
inhibition experiments using serum pools were performed and only peptides were further 
selected which showed an inhibition of their IgE binding by the corresponding full-length 
protein. In general, sera were pooled based on comparable IgE-binding pattern to the 
investigated peptides.  
To verify the specificity of the IgE binding to Ara h 1-derived peptides, two serum pools were 
generated and IgE binding was inhibited by the addition of 20.5 μg rAra h 1. Pool 1 was 
composed of sera from patients 10, 12, 18 and 21, and pool 2 of sera from patients 6, 15, 17, 
23. For the verification of the specificity of IgE binding to Ara h 2 peptides, sera from patients 
6-8, 10, 12, 15, 18, 21-23 were pooled and preincubated with either 13.5 μg rAra h 2.02, 9.5 μg 
native or r/a peanut extract.  
Candidate peptides of Ara h 1 and Ara h 2 (Ara h 2.01_P/Hyp and Ara h 2.02_P/Hyp) were 
selected if they showed an inhibition of ≥ 30% of their IgE binding in at least one inhibition 
experiment. With Ara h 1 as an example, an at least 30% inhibition of peptide IgE binding by 
rAra h 1 in at least one of the two used serum pools was required to address Ara h 1 specificity. 
In the case of Ara h 2, peptides were selected that could be inhibited in their IgE binding by 
either rAra h 2.02, native or r/a peanut extract by at least 30%. Images of the Ara h 1 and 
Ara h 2 IgE inhibition experiments and calculated Z-scores can be found in the appendix, in 
Figure A14/Table A7 and Figure A16/Table A24 & Table A41, respectively. 
Furthermore, candidate peptides should contain distinct amino acid sequences and represent 
distinct protein areas and therefore an offset of ≥ 4 peptides was applied between two peptides. 
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If there were several options, peptides with the highest IgE-binding frequency were selected. 
Among peptides that showed an identical IgE-binding frequency, those with the highest median 
Z-score were selected.  
Finally, from all preselected peptides fulfilling the above-mentioned criteria, the most 
frequently recognized peptides (≥ median frequency of preselected peptides) were selected as 
candidate diagnostic peptides. 
By applying these criteria, three peptides of Ara h 1, peptide 17, 75 and 86, could be identified 
(Figure 11). These three peptides were individually bound by serum IgE from 10 (43%), 
8 (35%) and 8 (35%) peanut-allergic children, respectively. In addition, 11/23 (48%) peanut-
allergic children recognized at least one of these three peptides in contrast to no tolerant child 
(Table 18). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Identified peptides of Ara h 1 fulfilling the selection criteria for candidate diagnostic peptides. 
Comparison of the IgE-binding frequencies of peanut-allergic (black) and tolerant (red) children to peptides of 
Ara h 1. Serum IgE binding to a peptide was considered positive if Z-score was > 2. Identified candidate diagnostic 
peptides within this study population specific for peanut allergy are shown in blue bars. 
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Table 18: IgE binding of peanut-allergic and tolerant children to identified candidate diagnostic peptides of 
Ara h 1. 
Three peptides were selected as candidate diagnostic peptides of Ara h 1. X depicts positive serum IgE binding to 
candidate peptide; - depicts negative serum IgE binding. 
Patient No. Ara h 1 P17 Ara h 1 P75 Ara h 1 P86 
1 X - - 
2 - - - 
3 - - - 
4 - X X 
5 - - - 
6 X X X 
7 - - - 
8 - - - 
9 - - - 
10 X X X 
11 - - - 
12 X X X 
13 - - - 
14 - - - 
15 X - X 
16 - - - 
17 X X X 
18 X X X 
19 - - - 
20 - - - 
21 X X X 
22 X - - 
23 X X - 
24 - - - 
25 - - - 
26 - - - 
27 - - - 
28 - - - 
29 - - - 
30 - - - 
31 - - - 
32 - - - 
33 - - - 
34 - - - 
35 - - - 
 
The respective amino acid sequence and the molecular surface presentation of the three selected 
peptides is shown in Table 19 and Figure 12, respectively. Interestingly, a relatively high content 
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of charged amino acid residues could be observed in peptide 17 and 86. As peptide 17 is located 
in Ara h 1 where the structure is not resolved, it could not be depicted in Figure 12. Peptide 75 
and peptide 86, as shown in Figure 12, represented two adjacent protein areas. 
 
Table 19: Identified candidate diagnostic peptides of Ara h 1. 
Amino acid sequences of identified candidate diagnostic peptides of Ara h 1. 
Candidate peptides of Ara h 1 Amino acid sequence 
Peptide 17 E-R-T-R-G-R-Q-P-G-D-Y-D-D-D-R 
Peptide 75 E-A-A-F-N-A-E-F-N-E-I-R-R-V-L 
Peptide 86 V-K-V-S-K-E-H-V-E-E-L-T-K-H-A 
 
 
Figure 12: Surface presentation of identified candidate diagnostic peptides of Ara h 1. 
Cyan and orange colored amino acids represent identified candidate diagnostic peptide 75 and peptide 86, 
respectively. Peptide 17, located where the structure of Ara h 1 is not resolved, could not be depicted. Using Ara h 1 
pdb 3SMH and PyMOL, 3-D images were generated. 
 
Candidate diagnostic peptides could also be identified of Ara h 2, but at first, the result of the 
microarray IgE inhibition should be described in more detail.  
On the one hand, the inhibition experiment verified the specificity of the peptide IgE binding, 
since full-length Ara h 2 was able to inhibit IgE binding to peptides.  On the other hand, the 
experiment showed that the recombinant Ara h 2, compared to its natural counterpart, did not 
undergo proline hydroxylation, which led to the absence of hydroxyproline in the 
immunodominant DPYSPS motif. 
As shown in Figure 13, recombinant Ara h 2.02 (13.5 μg) could inhibit IgE binding to 
Ara h 2.01_P and Ara h 2.02_P completely. However, IgE binding to peptides containing 
hydroxylated proline residues (Figure 13, highlighted in red) could be only partially inhibited 
by rAra h 2.02. In contrast, only natural Ara h 2 in native and reduced/alkylated peanut extract 
180° 180° 
Front side view Back side view Top view Bottom view 
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could inhibit IgE binding to these peptides. Taking into account that Ara h 2 accounts for 6-9% 
of the total peanut protein content, it makes up ~0.6-0.9 μg in each peanut extract. However, 
this amount was approximately 10-fold lower than the amount of recombinant Ara h 2.02 used 
in the inhibition experiment, which further supports that recombinant Ara h 2 did not undergo 
proline hydroxylation and thus cannot completely inhibit IgE binding to Hyp-containing 
peptides. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Specificity of IgE binding to Ara h 2-derived peptides verified by IgE inhibition experiments. 
Using rAra h 2.02 (13.5 µg), native peanut extract (9.5 µg) and reduced/alkylated peanut extract (9.5 µg) the 
specificity of the peptide IgE binding was verified. As reference, serum pool plus protein buffer was used. Peptides 
containing hydroxylated proline residues are highlighted in red. IgE immunodetections after 30 sec exposure are 
shown. 
 
Taking into account the mentioned selection criteria for candidate diagnostic peptides, in total 
four peptide pairs could be identified of the analyzed Ara h 2.01 and Ara h 2.02 sequences 
(Figure 14A and 14B; blue full bars and blue dashed bars). Blue full bars represent candidate 
Serum pool of peanut-allergic children 
+ protein buffer (uninhibited) 
Serum pool of peanut-allergic children 
+ rAra h 2.02  
Serum pool of peanut-allergic children 
+ native peanut extract 
Serum pool of peanut-allergic children 
+ red./alk. peanut extract 
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peptides of Ara h 2.01_P and Ara h 2.02_P. Blue dashed bars depict candidate peptides of 
Ara h 2.01_Hyp and Ara h 2.02_Hyp. In each Ara h 2 sequence one peptide pair could be 
identified. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Identified peptides of Ara h 2.01 and Ara h 2.02 fulfilling the selection criteria for candidate 
diagnostic peptides. 
Comparison of the IgE-binding frequencies of peanut-allergic (black) and tolerant (red) children to peptides of 
Ara h 2.01_P and Ara h 2.01_Hyp (A) and to peptides of Ara h 2.02_P and Ara h 2.02_Hyp (B). IgE-binding 
frequencies to peptides containing a hydroxyproline are depicted in (A) and (B) as black dashed line. Serum IgE 
binding to a peptide was considered positive if Z-score was > 2. Identified candidate diagnostic peptides of 
Ara h 2.01_P (A) and Ara h 2.02_P (B) are shown as blue full bars. Candidate peptides of Ara h 2.01_Hyp (A) and 
Ara h 2.02_Hyp (B) are shown as blue dashed bars. 
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In both Ara h 2.01 sequences, Ara h 2.01_P and Ara h 2.01_Hyp, peptide 2 and peptide 11 could 
be identified as candidate diagnostic peptides. Peptide 2 was in both cases the same peptide 
being composed of the same amino acids as it was shared by both investigated Ara h 2.01 
sequences. Peptide 11 of Ara h 2.01_Hyp contained, compared to peptide 11 of Ara h 2.01_P, 
hydroxyproline residues instead of proline residues (Table 20). In addition, two peptide pairs 
could be identified of Ara h 2.02_P and Ara h 2.02_Hyp (Figure 14B). Of Ara h 2.02_P, peptide 
2 and 11 could be identified, and of Ara h 2.02_Hyp, peptide 11 and 15. Peptide 2 of 
Ara h 2.02_P was the same peptide as of Ara h 2.01_P and Ara h 2.01_Hyp (Table 20). 
Compared to peptide 11 of Ara h 2.02_P, peptide 11 of Ara h 2.02_Hyp contained hydroxylated 
proline residues. Interestingly, peptide 11 was in all analyzed Ara h 2 sequences the only 
peptide containing two times the entire DPYSPS motif. The only difference between peptide 11 
of Ara h 2.01_P/Hyp and Ara h 2.02_P/Hyp is a glutamine (Q) instead of a proline (P) in 
Ara h 2.02. 
 
Table 20: Identified candidate diagnostic peptides of Ara h 2. 
Amino acid sequences of identified candidate diagnostic peptides of Ara h 2.01_P, Ara h 2.01_Hyp, Ara h 2.02_P and 
Ara h 2.02_Hyp. 
Candidate 
peptides 
Analyzed protein Amino acid sequence 
Peptide 2 
Ara h 2.01_P; Ara h 2.01_Hyp; 
Ara h 2.02_P 
E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 
Peptide 11 Ara h 2.01_P R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P 
Peptide 11 Ara h 2.01_Hyp R-D-P-Y-S-Hyp-S-Q-D-P-Y-S-Hyp-S-P 
Peptide 11 Ara h 2.02_P R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q 
Peptide 11 Ara h 2.02_Hyp R-D-P-Y-S-Hyp-S-Q-D-P-Y-S-Hyp-S-Q 
Peptide 15 Ara h 2.02_Hyp P-D-R-R-D-P-Y-S-Hyp-S-P-Y-D-R-R 
 
Patients’ IgE binding to identified candidate diagnostic peptides is shown in Table 21. According 
to the selection criteria of candidate diagnostic peptides, serum of no tolerant child showed an 
IgE binding to any of the four selected peptide pairs. In contrast, serum IgE of 13/23 (57%) 
peanut-allergic children showed an IgE binding to the peptide pair (peptide 2 plus peptide 11) 
of Ara h 2.01_P. The same 13 peanut-allergic children also recognized the peptide pair of 
Ara h 2.02_P (peptide 2 plus peptide 11). Nine of these 13 children recognized both peptides 
of the selected peptide pair in both analyzed Ara h 2.01_P and Ara h 2.02_P sequences. 
Individually, peptide 2 and 11 were recognized by 48% (11/23) of peanut-allergic children in 
both Ara h 2.01_P and Ara h 2.02_P. In Ara h 2.01_Hyp, serum IgE from a total of 16/23 (70%) 
peanut-allergic children bound to the peptide pair (peptide 2 plus peptide 11). 11 of these 16 
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patients recognized both peptides and additional five patients recognized solely peptide 11 
leading to an increased IgE-binding frequency of 70% (16/23) to peptide 11. 
Moreover, both selected peptides of Ara h 2.02_Hyp (peptide 11 plus peptide 15) were bound 
by serum IgE of 16/23 peanut-allergic patients, in total. Individually, peptide 11 and peptide 
15 of Ara h 2.02_Hyp were recognized by 16/23 patients, respectively. These 16 patients were 
the same patients who also showed an IgE binding to the selected peptide pair of 
Ara h 2.01_Hyp. 
 
Table 21: IgE binding of peanut-allergic and tolerant children to identified candidate diagnostic peptides of 
Ara h 2. 
Four peptide pairs were selected as candidate diagnostic peptides of Ara h 2.01_P, Ara h 2.01_Hyp, Ara h 2.02_P 
and Ara h 2.02_Hyp, in total. X depicts positive serum IgE binding to candidate peptide; - depicts negative serum 
IgE binding. 
Patient 
No. 
Ara h 
2.01_P  
P2 
Ara h 
2.01_P  
P11 
Ara h 
2.01_Hyp  
P2 
Ara h 
2.01_Hyp  
P11 
Ara h 
2.02_P  
P2 
Ara h 
2.02_P  
P11 
Ara h 
2.02_Hyp  
P11 
Ara h 
2.02_Hyp  
P15 
1 X X X X X X X X 
2 - - - - - - - - 
3 X - X X X - X X 
4 - - - - - - - - 
5 - - - - - - - - 
6 X X X X X X X X 
7 X X X X X X X X 
8 X X X X X X X X 
9 - - - X - - X X 
10 X X X X X X X X 
11 - - - - - - - - 
12 X X X X X X X X 
13 - - - - - - - - 
14 - - - - - - - - 
15 - X - X - X X X 
16 - - - X - - X X 
17 X - X X X - X X 
18 X X X X X X X X 
19 - - - - - - - - 
20 - - - X - - X X 
21 X X X X X X X X 
22 - X - X - X X X 
23 X X X X X X X X 
24 - - - - - - - - 
25 - - - - - - - - 
26 - - - - - - - - 
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27 - - - - - - - - 
28 - - - - - - - - 
29 - - - - - - - - 
30 - - - - - - - - 
31 - - - - - - - - 
32 - - - - - - - - 
33 - - - - - - - - 
34 - - - - - - - - 
35 - - - - - - - - 
 
The molecular surface presentation of the four selected candidate diagnostic peptide pairs is 
depicted in Figure 15. Figure 15A shows the surface of Ara h 2.01 and the selected candidate 
diagnostic peptides, peptide 2 (cyan) and 11 (orange). In addition, Figure 15B illustrates 
Ara h 2.02 and the surface presentation of selected candidate peptides, peptide 2 (cyan), 
peptide 11 (orange) and peptide 15 (magenta). In Ara h 2.01 and Ara h 2.02 peptide 2 and 
peptide 11 were located on opposite protein regions. Whereas in contrast, the identified peptide 
pair of Ara h 2.02_Hyp (peptide 11 and 15) seemed to present two adjacent protein regions on 
Ara h 2.02. 
 
A 
 
 
B 
Figure 15: Surface presentation of identified candidate diagnostic peptides of Ara h 2. 
Four candidate diagnostic peptide pairs could be identified of Ara h 2.01_P, Ara h 2.01_Hyp, Ara h 2.02_P and 
Ara h 2.02_Hyp, in total. (A) Molecular surface presentation of peptide 2 and 11 of Ara h 2.01. (B) Surface 
presentation of peptide 2, 11 and 15 of Ara h 2.02. Peptide 2 is shown in cyan, peptide 11 in orange and peptide 15 
in magenta. Images were generated using pdb 1W2Q and PyMOL. 
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4.1.6 Diagnostic value of candidate diagnostic peptides in comparison to full-length peanut 
proteins 
An ROC curve analysis was performed to compare the diagnostic value of identified candidate 
diagnostic peptides with that of full-length recombinant peanut allergens and peanut extract. 
The goal was to investigate whether peptides have a diagnostic value comparable to allergen 
components in the in vitro diagnosis of peanut allergy.  
For ROC curve analysis of candidate diagnostic peptides, maximum Z-scores of all selected 
peptides were calculated for each individual patient. For this purpose, the Z-score values were 
used after subtraction of the maximum Z-score of the respective non-allergic controls. This 
resulted in a total of five maximum Z-scores for each patient; one maximum Z-score of Ara h 1 
candidate peptides, one of Ara h 2.01_P candidate peptides, one of Ara h 2.01_Hyp candidate 
peptides, one of Ara h 2.02_P candidate peptides and one of Ara h 2.02_Hyp candidate peptides 
(Table 22). 
 
Table 22: Maximum Z-scores of candidate diagnostic peptides of Ara h 1 and Ara h 2. 
Three peptides could be identified as candidate diagnostic peptides of Ara h 1 and four peptide pairs of Ara h 2.01_P, 
Ara h 2.01_Hyp, Ara h 2.02_P and Ara h 2.02_Hyp, in total. For each patient, maximum Z-scores were calculated of 
the candidate peptides of each investigated sequence of Ara h 1 and Ara h 2. Z-scores after subtraction of the controls 
were used. 
Patient 
No. 
Max. Z-score 
Ara h 1  
P17, P75, P86 
Max. Z-score 
Ara h 2.01_P  
P2, P11 
Max. Z-score 
Ara h 2.01_Hyp  
P2, P11 
Max. Z-score 
Ara h 2.02_P  
P2, P11 
Max. Z-score 
Ara h 2.02_Hyp  
P11, P15 
1 10.12457809 24.885217 78.4649735 24.885217 82.91889279 
2 -0.736457615 -5.612952225 -5.86766421 -3.856712921 -3.211413553 
3 -1.994482129 59.08290441 105.1890394 59.08290441 108.5642069 
4 6.326208737 -2.174186829 -6.529736594 -3.54256173 -3.370598332 
5 -0.772796256 -5.58058368 -5.58058368 -4.016345823 -3.073446339 
6 84.79687282 58.36760936 58.81588431 57.86878767 62.61335991 
7 0.359229488 95.69470799 106.1378765 95.69470799 109.8149618 
8 -4.268148045 61.10623904 71.14677276 61.10623904 74.63243398 
9 -0.896450532 -5.912506537 4.091164073 -3.816882925 3.656131376 
10 44.84097185 77.86173548 82.48197642 77.86173548 85.92152561 
11 -0.92839475 -5.508709704 -5.850810739 -3.002554353 -2.147028281 
12 68.73450625 68.56886998 72.7396908 42.40837528 76.22798679 
13 -1.350007928 -4.467335497 -1.048484363 -2.495774503 1.642752389 
14 0.151565805 -3.785217339 -4.363661212 -2.371823791 -1.255727394 
15 94.7420294 57.7869737 77.71325237 38.7617689 81.38323543 
16 -0.78213749 -5.37099605 16.41596601 -3.455771856 21.69132961 
17 156.20918 73.68120369 73.68120369 73.68120369 76.27500298 
18 81.98156277 93.44976207 105.6427058 93.44976207 109.3633373 
19 -1.290067053 -5.432354349 -4.325158196 -2.159810059 -1.604273017 
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20 -0.65664687 -6.048067276 55.90512492 -3.611842067 23.75118361 
21 35.48695418 23.16422157 22.81892271 25.5028631 26.50583576 
22 2.213755576 21.04358948 81.65369551 13.36838318 85.17403264 
23 76.82544973 73.82538437 75.40045852 75.01097686 79.14414255 
24 -1.318952241 -4.624911449 -5.769823188 -3.370943809 -2.674381282 
25 -5.134985571 -3.857155314 -3.937960277 -2.127996643 -1.111020263 
26 -1.204178077 -6.493693218 -8.253576534 -5.046534243 -4.371282651 
27 0.84955672 -5.067266426 -5.568557787 -3.618857988 -2.95359942 
28 0.241959278 -5.496051821 -5.82621013 -3.656318789 -2.954374939 
29 0.192742855 -5.125513941 -5.772635938 -3.64008616 -2.679465266 
30 -0.046595008 -5.523266941 -4.352039899 -3.032464668 -2.44833489 
31 1.006891245 -5.635144517 -6.455953423 -3.234564066 -3.117862372 
32 -0.797950948 -5.740311195 -6.524504949 -3.484622868 -2.951030951 
33 -0.360699853 -5.699112939 -6.555281448 -3.529978186 -2.850839539 
34 1.836338996 -5.986133695 -6.703365933 -4.176955205 -2.726327955 
35 -0.994015772 -6.05307505 -6.43796171 -4.083414897 -2.816811322 
 
Figure 16 shows the result of the ROC curve analysis. Again, sIgE to rAra h 2.01, determined 
by ImmunoCAPTM analysis, served as a reference, as it had the highest diagnostic value in this 
study population. As already shown in Figure 5, rAra h 2.02 had, with an AUC of 0.86, so far 
the highest diagnostic value of investigated recombinant proteins in immunoblot analysis. In 
contrast, rAra h 1 had the lowest diagnostic value in immunoblot analysis. The same applied 
for the identified candidate diagnostic peptides of Ara h 1 that had of all identified candidate 
diagnostic peptides the lowest AUC (0.66) and consequently the lowest diagnostic value in this 
study population. The four identified candidate diagnostic peptide pairs of Ara h 2 had AUCs 
between 0.83 and 0.90. Of these four peptide pairs, the two peptide pairs of Ara h 2.01_Hyp 
and Ara h 2.02_Hyp had, with AUC 0.90 and 0.87, respectively, the highest diagnostic value, 
which was comparable to that of rAra h 2.02 in immunoblot analysis.  
In immunoblot analysis, IgE binding to full-length rAra h 2.02 resulted in a sensitivity of 78% 
at a specificity of 100%. Moreover, using a Z-score of > 2 as cut-off both peptide pairs of 
Ara h 2.01_Hyp and Ara h 2.02_Hyp showed a sensitivity of 70% and a specificity of 100% 
comparable to that of rAra h 2.02 in immunoblot analysis. In comparison, ImmunoCAPTM using 
rAra h 2.01 reached at a sensitivity of 96% a specificity of 92% in this study population. 
Consequently, three reagents with a high diagnostic value could be identified, namely 
rAra h 2.02 in immunoblot and both peptide pairs of Ara h 2.01_Hyp and Ara h 2.02_Hyp in 
multipeptide microarray analysis, which should be compared in detail with the reference 
rAra h 2.01 used in ImmunoCAPTM analysis.  
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The comparison revealed that almost all (22/23) peanut-allergic and just one tolerant patient 
showed a sensitization to rAra h 2.01 according to ImmunoCAPTM analysis. In immunoblot and 
microarray analysis, no tolerant patient showed an IgE binding to full-length rAra h 2.02 and 
to the two candidate diagnostic peptide pairs of Ara h 2.01_Hyp and Ara h 2.02_Hyp, 
respectively. Comparing ImmunoCAPTM with immunoblot revealed that rAra h 2.01 in 
ImmunoCAPTM was more sensitive compared to rAra h 2.02 in immunoblot (96% vs. 78%) and 
performed almost perfectly. Nevertheless, a positive sensitization of patient 11 could only be 
detected with rAra h 2.02 in the immunoblot analysis. In addition, comparing the IgE binding 
to rAra h 2.02 (18/23 peanut-allergic children) with the IgE binding to the two candidate 
diagnostic peptide pairs of Ara h 2.01_Hyp and Ara h 2.02_Hyp (16/23 peanut-allergic children, 
respectively) revealed that serum IgE of patients 5, 11, 19 bound only to full-length rAra h 2.02 
used in immunoblot analysis. Whereas serum IgE of patient 16 bound only to peptides 
containing hydroxylated proline residues of Ara h 2.01_Hyp and Ara h 2.02_Hyp.  
Summing up, despite the fact that different methods were compared for their diagnostic value 
in ROC curve analysis in this study, it could be shown that two peptide pairs of Ara h 2.01_Hyp 
and Ara h 2.02_Hyp could be identified that had a diagnostic value comparable to that of full-
length rAra h 2.02 used in immunoblot analysis. Furthermore, it could be shown that proline 
hydroxylation had a positive impact on the diagnostic sensitivity and accuracy. These results 
should be taken into account in further investigations. 
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Figure 16: Receiver operating characteristic (ROC) curve analysis of sIgE to peanut extract, full-length 
recombinant proteins and identified candidate diagnostic peptides. 
ROC curves of sIgE to peanut extract (black), rAra h 2.01 (orange) determined by ImmunoCAPTM analysis (‡) and to 
rAra h 1 (red), rAra h 2.01 (green) and rAra h 2.02 (blue) quantified by immunoblot analysis (†). Performance of 
identified candidate diagnostic peptides of Ara h 1, Ara h 2.01_P, Ara h 2.01_Hyp, Ara h 2.02_P and Ara h 2.02_Hyp 
are depicted in yellow, purple, pink, cyan and brown, respectively. For ROC curve analysis, ImmunoCAPTM sIgE 
values > 100 kUA/L were set to 100 kUA/L and the sIgE levels quantified by means of immunoblot analysis were 
subtracted by two times the respective sIgE level of the non-allergic control serum. For ROC curve analysis of 
candidate diagnostic peptides, calculated maximum Z-scores were used. Z-scores were determined by microarray 
analysis (§). The gray diagonal line (AUC 0.5) represents a test without discriminatory ability. AUC, area under the 
ROC curve; CI, confidence interval. 
 
Finally, as the number of some candidate diagnostic peptides could be further narrowed while 
maintaining the specificity and sensitivity at a cut-off of Z-score > 2, the influence of narrowing 
on the respective AUC was investigated. Peptide 2 and peptide 11 of Ara h 2.01_Hyp reached 
together a sensitivity of 70% and a specificity of 100%. Peptide 11 alone showed the same 
sensitivity and specificity pair and revealed an AUC of 0.89, which was comparable to that of 
both initially identified candidate diagnostic peptides of Ara h 2.01_Hyp (AUC 0.90). The same 
applied for peptide 15 of Ara h 2.02_Hyp, where ROC curve analysis revealed an AUC of 0.86, 
which was also comparable to that of both selected candidate diagnostic peptides (AUC 0.87). 
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In contrast using solely peptide 11 of Ara h 2.02_Hyp a slightly lower AUC (0.84) was obtained 
(data not shown). 
 
4.1.7 Relevance of linear and conformational IgE epitopes  
For the development of safe hypoallergenic immunotherapeutic approaches, it is important to 
know the contribution of linear and conformational IgE epitopes. Therefore, whole peanut 
extract was reduced and alkylated and Ara h 2, the major allergen in this study population, was 
analyzed for its IgE-binding capacity in comparison to native Ara h 2 (Figure 18).  
Mass spectrometry analysis confirmed the identity of Ara h 2 and Ara h 6 in both extracts 
(Figure 17, Table 23). In the native peanut extract (lane 1 Figure 17) three bands were 
analyzed. MS analysis identified unequivocally Ara h 2.0201 and Ara h 2.0101 in bands 1 and 
2, respectively. Moreover, in band 2 peptides belonging to Ara h 2.0201 and Ara h 6 were 
additionally identified. Band 3 of the native peanut extract contained Ara h 2.0201 as well as 
Ara h 6. In the reduced/alkylated peanut extract (lane 2 Figure 17) MS analysis identified in 
band 4, 5 and 6, which correspond to band 1, 2 and 3 of the native peanut extract, Ara h 2.0201, 
Ara h 2.0101 and Ara h 6, respectively.  
However, as in bands 3, 4 and 5 only C-terminal peptides were detected, the presence of the 
variants Ara h 2.0102 and Ara h 2.0202 described by Hales et al. in 2004 cannot be confirmed 
or excluded (Hales et al. 2004). Sequence alignment of the Ara h 2 sequences described by 
Hales et al. and identified isoform-specific peptides are shown in the appendix (Figure A22 and 
Table A52). The shown MS data only allowed the conclusion that either Ara h 2.0201 or 
Ara h 2.0102 is present. The same applied for Ara h 2.0101 or Ara h 2.0202. 
On the other hand, the reported Ara h 2 sequences by Hales and co-workers were not proven 
to exist at the protein level and are not registered by the IUIS allergen nomenclature sub-
committee. Accordingly, we strictly referred throughout the entire study to the IUIS database 
entry Ara h 2.0101 and Ara h 2.0201 even though Ara h 2.0102 and Ara h 2.0202 would in 
many cases match our data as well. 
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Figure 17: SDS-PAGE of native and reduced/alkylated peanut extract for MS analysis. 
Lane 1, native peanut extract; lane 2, reduced/alkylated peanut extract. Samples were analyzed under reducing 
conditions. Bands 1-6 were analyzed by Mass spectrometry. M, SpectraTM Multicolor Broad Range Protein Ladder. 
 
Table 23: Identification of Ara h 2 and Ara h 6 in peanut extract. 
Band Acc.No. GB Acc. No. UP Description S P C E 
1 AAN77576 Q6PSU2* 
Ara h 2.0201 
Conglutin-7 Arachis hypogaea 
6588 12 47.1 6.4 
2 AAK96887 Q6PSU2* 
Ara h 2.0101 
Conglutin-7 Arachis hypogaea 
12146 14 73.2 6.6 
2 AAN77576 Q6PSU2* 
Ara h 2.0201 
Conglutin-7 Arachis hypogaea 
10006 13 50.0 6.9 
2 AAD56337 Q647G9 
Ara h 6.0101 
Conglutin Arachis hypogaea 
2095 9 46.9 3.7 
3 AAN77576 Q6PSU2* 
Ara h 2.0201 
Conglutin-7 Arachis hypogaea 
3879 7 28.5 9.1 
3 AAD56337 Q647G9 
Ara h 6.0101 
Conglutin Arachis hypogaea 
14300 15 58.0 4.7 
4 AAN77576 Q6PSU2* 
Ara h 2.0201 
Conglutin-7 Arachis hypogaea 
3924 10 36.0 4.1 
5 AAK96887 Q6PSU2* 
Ara h 2.0101 
Conglutin-7 Arachis hypogaea 
6404 10 47.0 5.0 
6 AAD56337 Q647G9 
Ara h 6.0101 
Conglutin Arachis hypogaea 
439 4 24.1 4.8 
Acc.No. GB, accession number of GenBank; Acc.No. UP, accession number of Uniprot; *isoforms were collapsed into 
one UniProt entry only; S, PLGS protein score; P, number of identified peptides; C, protein sequence coverage %; E, 
precursor RMS mass error [ppm]. 
 
Nevertheless, based on their reported molecular weights and published data from Chen et al. it 
was assumed that band 1 and 4 contained Ara h 2.02 (~19 kDa), band 2 and 5 Ara h 2.01 
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(~17 kDa) and band 3 and 6 Ara h 6 (~15 kDa) (Chen et al. 2013). Thus, in the following 
immunoblot shown in Figure 18 the upper, the middle and the lower of the three bands in both 
extracts will be referred to as Ara h 2.02, Ara h 2.01 and Ara h 6, respectively. 
According to Figure 18, peanut-allergic children showed a strong IgE binding to native peanut 
extract, which was especially pronounced in the area of the 2S albumins Ara h 2.01 and 
Ara h 2.02. 
Moreover, IgE immunoblot analysis of native (n) and reduced and alkylated (r/a) peanut 
extract showed that serum IgE of 16/23 (70%) peanut-allergic children (patient 1, 3, 6, 7, 8, 
10, 12, 15, 16, 17, 18, 19, 20, 21, 22 and 23) still showed IgE binding to Ara h 2.02 and 
Ara h 2.01 after reduction and alkylation. Of these 16 children, twelve children (patient 3, 6, 7, 
8, 10, 12, 15, 17, 18, 21, 22 and 23) showed significant IgE binding to r/a Ara h 2.01 and 
r/a Ara h 2.02. Patients 3 and 8 did not even show a change in IgE binding after reduction and 
alkylation. Serum IgE of the remaining four allergic patients showed a reduced IgE-binding 
capacity. In 5/23 (22%) peanut-allergic children (patients 2, 4, 5, 9 and 13) and in peanut-
tolerant child 25 reduction and alkylation resulted in a complete loss of IgE binding to both 
Ara h 2 isoforms. For patients 11 and 14 hardly any IgE binding to peanut extract could be 
observed at all, comparable to the majority of peanut-tolerant children. In addition, as Ara h 1 
is not stabilized by disulfide bonds, reduction and alkylation did not affect its secondary 
structure (van der Kleij et al. 2019) and thus had no impact on its IgE-binding capacity 
(Figure 18, band ~70 kDa). 
However, reduction and alkylation of Ara h 6 resulted in all children (allergic and tolerant) in 
a complete or major loss of IgE binding. 
In general, IgE binding to r/a Ara h 2 was in good agreement with the detected IgE binding to 
Ara h 2-derived peptides. Serum IgE of peanut-tolerant children bound neither to any Ara h 2-
derived peptide nor to r/a Ara h 2. Except for peanut-allergic patients 9 and 19, IgE binding to 
r/a Ara h 2 was in complete accordance with the microarray analysis. Patient 9 recognized few 
Ara h 2-derived peptides, however showed hardly any IgE binding to r/a Ara h 2. For patient 
19 the opposite could be observed. This patient showed a weak IgE binding to r/a Ara h 2, but 
no binding to Ara h 2-derived peptides.  
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Figure 18: Serum IgE binding to native and reduced/alkylated peanut extract. 
IgE binding of sera 1-35 (Table 14) to native (n) and reduced and alkylated (r/a) peanut extract. Peanut extracts were analyzed under reducing conditions. The detection after 1 min 
of exposure is shown. Arrows indicate Ara h 2.02 (~19 kDa), Ara h 2.01 (~17 kDa) and Ara h 6 (~15 kDa). M, SpectraTM Multicolor Broad Range Protein Ladder; P, total protein 
stained with Ponceau S; N, non-allergic control serum. 
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4.1.8 Biological IgE reactivity of conformational and linear IgE epitopes 
To determine the biological IgE reactivity of linear IgE-binding epitopes of Ara h 2, a mediator 
release assay was performed. The mediator release assay should give additional knowledge 
about the influence of proline hydroxylation on the allergenicity of linear IgE epitopes of Ara h 2. 
Therefore, rAra h 2.02 not undergoing proline hydroxylation was reduced and alkylated and 
compared for its allergenicity with two linear DPYSPS-containing 27-mer peptides. One of the 
two 27-mer peptides contained hydroxylated proline residues (27-mer peptide POH), the second 
only proline residues (27-mer peptide P). The loss of the secondary structure of r/a rAra h 2.02 
was confirmed by CD spectroscopy (see appendix Figure A24). A minimum at ~200 nm instead 
of the typical α-helical two minima (208 nm and 222 nm) as shown in Figure 2 for properly 
folded rAra h 2.01 and rAra h 2.02, revealed the unfolding of r/a rAra h 2.02. In addition, both 
27-mer peptides presented no secondary structure elements (appendix Figure A24). Moreover, 
as expected, reduction and alkylation of rAra h 1 had no influence on its secondary structure. 
The CD spectrum of r/a rAra h 1 (appendix Figure A24) was almost identical to untreated 
rAra h 1 shown in Figure 2. 
After confirming an unfolded state of r/a rAra h 2.02 and the absence of secondary structure 
elements in 27-mer peptides, three serum pools composed of peanut-allergic patients with 
similar IgE-binding characteristics were generated. Serum pool 1 was composed of peanut 
patients 3 and 17. Both allergic patients showed a serum IgE binding to rAra h 2 and nAra h 2 
as well as to r/a nAra h 2. In addition, in these two patients proline hydroxylation was necessary 
to induce positive serum IgE binding to peptides containing the DPYSPS motif (peptides 9-14 
of Ara h 2.01_Hyp and peptides 9-17 of Ara h 2.02_Hyp). Furthermore, both patients 
recognized peptide 2 and patient 17 additionally recognized peptide 3. Serum pool 2 included 
patients 6-8, 10, 12, 15, 18, 21-23. These patients showed, in agreement with patients of pool 1, 
serum IgE binding to rAra h 2, nAra h 2 and r/a nAra h 2. However, in contrast to serum pool 1, 
patients of pool 2 recognized the DPYSPS motif with and without hydroxyproline residues. 
Furthermore, the great majority of patients of pool 2 recognized peptide 2 (8/10 patients) and 
6/10 patients recognized other Ara h 2-derived peptides. In contrast to both serum pools 1 and 
2, serum pool 3 was composed of patients showing no IgE binding to Ara h 2-derived peptides. 
Patients of serum pool 3 (patient 2, 4, 5, 13 and 19) showed no or weak serum IgE binding to 
rAra h 2 (with the exception of patient 19). Furthermore, these patients recognized nAra h 2, 
whereas reduction and alkylation of peanut extract resulted in a loss or at least a strong 
reduction in the serum IgE binding to r/a nAra h 2 in these patients. 
The mediator release of RBL cells sensitized with serum pools 1-3 is shown in Figure 19. As 
negative control, cells were additionally sensitized with non-allergic control serum N. None of 
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the tested molecules triggered mast cell degranulation from cells sensitized with control serum 
N (data not shown). 
As expected, cells sensitized with serum pool 3 showed only a mediator release when stimulated 
with native/untreated peanut extract and properly folded rAra h 2.02 (Figure 19C). For these 
patients proper folding of Ara h 2 is mandatory to induce mast cell degranulation demonstrating 
that these patients are sensitized to conformational epitopes on Ara h 2. In addition, the lack of 
a mediator release when cells were stimulated with r/a peanut extract or rAra h 1 showed that 
the whole IgE reactivity/allergenicity of peanut extract was caused by conformational IgE-
epitopes of Ara h 2 (and potentially of Ara h 6) in these patients. 
In contrast, when RBL cells were sensitized with serum pool 2 it could be shown that linear IgE 
epitopes of Ara h 2 were able to induce a mast cell degranulation (Figure 19B). The linear 27-
mer peptide containing hydroxylated proline residues (27-mer peptide POH) could induce a 
maximum mediator release of ~70%, which was comparable to the maximum release induced 
by rAra h 2.02. In contrast, the 27-mer peptide without hydroxylated proline residues (27-mer 
peptide P) and r/a rAra h 2.02 did not show any or at least a strongly reduced allergenic activity. 
The 27-mer peptide POH displaying linear IgE-epitopes showed a potency comparable to 
rAra h 2.02 displaying conformational IgE epitopes. However, considering the molar ratio of 
both (~1:5), both mediator release curves are separated by a factor of ~10 showing that, at 
the molar level, rAra h 2.02 was tenfold more IgE reactive than the 27-mer peptide POH. 
rAra h 2.02 showed, compared to rAra h 1, a 100 times higher allergenic activity. Comparable 
to the unaffected IgE-binding capacity of Ara h 1 shown in Figure 18, reduction and alkylation 
also had no impact on the allergenicity of rAra h 1 (Figure 19B and 19C).  
Due to low serum availability, cells sensitized with serum pool 1 could not be investigated with 
all antigens (Figure 19A). Based on the illustrated curves it can be seen that, although 
rAra h 2.02 was ~1000 times more IgE reactive, the 27-mer peptide POH can still trigger a mast 
cell degranulation. Comparable to serum pool 2, the 27-mer peptide P could not induce a 
mediator release. r/a rAra h 2.02 did not show any allergenic activity in serum pool 1, whereas 
in serum pool 2 a very weak mediator release could be detected, caused by additional linear 
IgE epitopes on Ara h 2. 
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Figure 19: Mediator release induced by peanut extract, recombinant peanut allergens and 27-mer peptides. 
Rat basophilic leukemia cells were sensitized with either serum pool 1 (A), serum pool 2 (B) or serum pool 3 (C) 
and the mediator release induced by native peanut extract (black line, diamond), r/a peanut extract (black line, 
circle), rAra h 1 (red line, diamond), r/a rAra h 1 (red line, circle), rAra h 2.02 (blue line, diamond), r/a rAra h 2.02 
(blue line, circle), 27-mer peptide POH (cyan line, diamond) and 27-mer peptide P (pink line, diamond) was 
determined. Serum pool 1 was composed of peanut patients 3 and 17, pool 2 of patients 6-8, 10, 12, 15, 18, 21-23 
and pool 3 of patients 2, 4, 5, 13 and 19. 
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4.2 Pea project 
4.2.1 Study population 
In total, sera from nineteen children were included in this project based on a pea-specific IgE 
level of ≥ 0.35 kUA/L. Patients characteristics are summarized in Table 24. Fourteen children 
were allergic to pea (patients 1-14) and five children (patients 15-19) were sensitized but 
clinically tolerant. Clinically relevant pea allergy was diagnosed according to a convincing 
history (10/14 pea-allergic children) or by oral food challenge (5/14 pea-allergic children). For 
patient 4, clinical evidence of pea allergy was given by history and food challenge. Pea allergy 
was excluded in 3/5 tolerant children according to a convincing history and in 2/5 children by 
oral food challenge. Pea related allergy symptoms ranged from mild (grade I) to severe 
(grade IV). Both pea study groups were composed of young children. The median age of pea-
allergic children was 4 years (range 1-15 years) and of tolerant children 7 years (range 2-
12 years). Pea-specific IgE ranged from 0.94 to 92.30 kUA/L in pea-allergic children (median 
6.02 kUA/L) and from 0.40 to 3.96 kUA/L in pea-tolerant children (median 1.27 kUA/L). 
 
Table 24: Clinical characteristics of the pea study population. 
Patients allergic to pea (patients 1-14) and patients sensitized to pea without clinical symptoms (patients 15-19). 
Patient 
No.  
Age (y)*/sex Clinical evidence 
Symptoms to 
pea 
Severity 
grading# 
Total IgE  
(kUA/L)‡ 
Pea sIgE  
(kUA/L)‡ 
1 3/m History F, PU I 2239.0 92.30 
2 15/m History Em, N II n.d. 5.50 
3 1/f History U, AE II 104.0 32.10 
4 2/m History/OFC F/GU I/II 226.0 54.70 
5 3/m OFC GU II n.d. 1.95 
6 12/f History AE, Em II n.d. 1.52 
7 2/m History AE II n.d. 1.21 
8 4/m DBPCFC PU, P, R III n.d. 45.30 
9 1/f OFC F, C, R III n.d. 0.94 
10 6/m OFC PU, R, IT III n.d. 8.89 
11 6/m History Em, GU, W, D IV 141.0 23.10 
12 7/f History N II 459.0 5.14 
13 4/m History AE II n.d. 2.12 
14 2/m History Em, SA II 2748.0 6.53 
15 2/m History none - 2813.0 1.27 
16 12/m OFC none - n.d. 3.96 
17 7/m DBPCFC none - 152.0 1.02 
18 2/m History none - 64.6 0.40 
19 8/m History none - 7663.0 3.59 
*Age at time of blood sampling; f, female; m, male; n.d., not determined; DBPCFC, double-blind placebo-controlled 
food challenge; OFC, open food challenge; AE, angioedema; C, conjunctivitis; D, dyspnea; Em, emesis; F, flush; GU, 
generalized urticaria; IT, itching throat; N, nausea; P, pruritus; PU, perioral urticaria; R, rhinitis; SA, stomach ache; 
U, urticaria; W, wheezing; #severity grading according to the grading system developed by Sampson (Sampson 
2003); ‡ determined by ImmunoCAPTM.  
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4.2.2 Generation and physicochemical characterization of rPis s 1, rPA1 and rPA2 
Comparable to the peanut project, cDNA sequences encoding rPis s 1, rPA1 and rPA2 (appendix 
Figure A6, A8 & A9) could be successfully cloned into pPICZαA and afterwards integrated into 
P. pastoris genome. Recombinant PA1 and PA2 were successfully expressed using Pichia pastoris 
without any optimization strategies. However, the expression of full-length rPis s 1 in 
Pichia pastoris failed and resulted in two truncated proteolytic products (appendix Figure A12). 
MS analysis identified the ~20 kDa and the ~27 kDa proteolytic products as N- and C-terminal 
fragments of rPis s 1, respectively (data not shown). In addition, a potential cleavage site at 
K168 and R187 (referring to the UniProt protein sequence) could be identified by MS analysis. 
However, despite several optimization strategies such as the addition of protease inhibitors or 
the use of P. pastoris SMD1168H protease-deficient strain, rPis s 1 could not be expressed as 
full-length protein in Pichia pastoris. Consequently, rPis s 1 was finally expressed in 
Escherichia coli. Recombinant PA1 was expressed as proprotein composed of two chains linked 
by a propeptide (6 amino acid residues). Furthermore, rPA1 contained an additional amino-
terminal propeptide (8 amino acid residues). For sequence information of rPA1 see Figure A8 
in the appendix. 
rPA1 and rPA2 were secreted into Pichia pastoris cell culture supernatant and rPis s 1 was 
expressed in E. coli inclusion bodies. The three pea proteins were subsequently purified via their 
His-tag using IMAC. After IMAC, rPA1 and rPA2 were further purified by SEC. Compared to the 
7S globulin rPis s 1 that needed a high salt concentration (500 mM NaCl) to stay soluble, the 
pea albumins PA1 and PA2 could be stored at low salt concentrations (10 mM NaCl). After 
purification, mass spectrometry analysis confirmed the identity of rPis s 1, rPA1 and rPA2. The 
determined sequence coverages for rPis s 1, rPA1 and rPA2 were 83.1%, 18.4% and 83.8%, 
respectively (Table 25). 
 
Table 25: Identity confirmation of recombinant pea proteins by mass spectrometry analysis. 
Protein 
Accession 
number# 
PLGS protein 
score 
Number of identified 
peptides 
Sequence 
coverage 
Mass error* 
rPis s 1 PEI112 26020 51 83.1% 5.9 
rPA1 PEI081 1683 2 18.4% 8.8 
rPA2 PEI080 13291 32 83.8% 4.4 
#PEI, internal accession number; *precursor RMS mass error [ppm]. 
 
The purity of the three recombinant pea proteins was analyzed on Coomassie-stained SDS-PAGE 
(Figure 20A). As shown in Figure 20A lane 1-3, IMAC with or without subsequent SEC resulted 
in highly pure recombinant protein preparations. Secondary structure integrity of recombinant 
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pea proteins was analyzed by CD spectroscopy (Figure 20B). The CD spectrum of rPis s 1 
indicated predominant β-sheet conformation as a minimum at~215 nm and a maximum at 
~198 nm could be detected. In contrast, the CD spectrum of rPA1 had two minima at 
approximately 208 and 222 nm and a maximum at 197 nm. This CD spectrum was comparable 
to the CD spectra of both Ara h 2 isoforms (Figure 2) and was indicative for an α-helical protein. 
While a native-type secondary structure could be detected for rPis s 1 and rPA1, the CD 
spectrum of rPA2 showed a high content of unstructured protein. Moreover, using dynamic 
light scattering hydrodynamic radii of 5.1 ± 0.7 nm, 3 ± 0.7 nm and 14.8 ± 1.6 nm could be 
determined for rPis s 1, rPA1 and rPA2, respectively (inset Figure 20B). The determined 
hydrodynamic radii of rPis s 1 and rPA1 indicated a possibly trimeric protein and a monomeric 
protein in solution, respectively. In contrast, the RH of rPA2 indicated a strong tendency to 
oligomerization.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Purity and physicochemical characterization of rPis s 1, rPA1 and rPA2. 
(A) Coomassie-stained SDS-PAGE of rPis s 1 (lane 1; 2 µg/cm), rPA1 (lane 2; 2 µg/cm) and rPA2 (lane 3; 4 µg/cm). 
Protein samples were analyzed under reducing conditions. M, low-molecular weight marker. (B) Far-UV CD-spectra 
(195-255 nm) of rPis s 1 1 (solid line), rPA1 (dotted line) and rPA2 (dashed line). Samples were measured at 4 µM, 
11 µM and 6 µM, respectively. The inset depicts the hydrodynamic radius (RH) ± SD. 
 
4.2.3 Relevance of Pis s 1, PA1 and PA2 
As currently serological diagnosis of pea allergy is solely based on pea total protein extract due 
to a lack of single pea allergen components, the relevance of Pis s 1, PA1 and PA2 was 
investigated. Therefore, IgE immunoblot and IgE immunoblot inhibition analyses as well as a 
mediator release assay were performed.  
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Initially, pea-allergic and sensitized but tolerant children were analyzed for their serum IgE 
binding to rPis s 1, rPA1 and rPA2 in immunoblot analysis (Figure 21). Due to no significant 
sequence similarity, rPA1 and rPA2 were analyzed simultaneously for their IgE binding in one 
lane (Figure 21B).  
Compared to pea-tolerant children, allergic children showed strong IgE binding to rPis s 1. In 
addition, serum IgE binding to degradation products of rPis s 1 could also be observed (Figure 
21A, open triangle). In contrast, with the exception of patient 1, neither allergic nor tolerant 
patients showed IgE binding to rPA1 and rPA2.      
Consequently, as relevant IgE binding could only be detected to rPis s 1 (Figure 21A), compared 
to rPA1 and rPA2 (Figure 21B), only rPis s 1 sIgE levels were densitometrically quantified. 
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Figure 21: Serum IgE binding of pea-allergic and sensitized but tolerant children to rPis s 1, rPA1 and rPA2. 
IgE binding of sera from pea-allergic children (lane 1-14, patients’ sera 1-14 according to Table 24) and tolerant 
children (lane 15-19, patients’ sera 15-19 according to Table 24) to rPis s 1 (A) and to rPA1 and rPA2 (B) after 30 sec 
and 5 min exposure, respectively. Protein samples were analyzed under reducing conditions. (A) filled triangle, full-
length rPis s 1; open triangle, degradation products of rPis s 1. (B) filled triangle, rPA2; open triangle, rPA1. M, low-
molecular weight marker; P, total protein stained with Ponceau S; N, non-allergic control serum; N1 or N2, non-
allergic control serum on membrane 1 or 2. 
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As the commercially available ImmunoCAPTM does not contain Pis s 1, the standard for 
quantifying rPis s 1 sIgE was missing in this project. Therefore, a different strategy for the 
quantification of the rPis s 1 sIgE level was developed based on the IgE immunoblot inhibition 
shown in Figure 22. In this immunoblot, IgE binding to pea total protein extract was inhibited 
by the addition of rPis s1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: IgE immunoblot inhibition using rPis s 1. 
IgE immunoblot of sera from pea-allergic children (patients 1-14) and pea-tolerant children (patients 15-19) to pea 
extract. Pea extract was analyzed under reducing conditions. The detection after 1 min of exposure is shown. Serum 
samples were preincubated with rPis s 1 (+) or untreated (-). Arrows illustrate full-length Pis s 1 and its proteolytic 
subunits (< 30 kDa). M, low-molecular weight marker; P, total protein stained with Ponceau S; N1 and N2; non-
allergic control serum (N) used on membrane 1 and 2, respectively.  
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Using densitometric quantification relative to uninhibited pea total protein, percent inhibition 
was calculated for each patient (Table 26, column 2). The inhibition analysis will be discussed 
in detail later, first the quantification of rPis s 1 sIgE will be described in more detail.  
As shown in Figure 22 and Table 26 (column 2), rPis s 1 completely inhibited IgE binding to 
pea total protein in patients 3, 11 and 14. Accordingly, IgE binding to pea total protein was 
merely related to Pis s 1, and sIgE to pea extract could be considered identical to sIgE to rPis s 1 
in these patients. Using these three assumed rPis s 1 sIgE values (32.10, 23.10 and 6.5 kUA/L) 
and the corresponding densitometric signal intensities of the immunoblot (Figure 21A), a linear 
regression was performed and the resulting calibration line was used to determine the rPis s 1 
sIgE levels of all sera. Resulting rPis s 1 sIgE levels of pea-allergic and tolerant children and of 
the non-allergic control serum N used on both membranes (N1 and N2) are shown in Table 26 
(column 3). 
 
Table 26: Percent inhibition of IgE binding to pea total protein by rPis s 1, quantified rPis s 1 sIgE levels and 
pea sIgE levels of pea-allergic and tolerant children. 
N1 and N2, non-allergic control serum on membrane 1 and 2, respectively. Patients 1-7 were analyzed for their IgE 
binding to rPis s 1 on membrane 1 and patients 8-19 on membrane 2. 
Patient No.  % IgE inhibition of pea extract by rPis s 1†  rPis s 1 sIgE (kUA/L)† Pea sIgE (kUA/L)‡ 
1 39.07 42.740 92.30 
2 19.08 11.797 5.50 
3 96.55 29.788 32.10 
4 60.59 45.588 54.70 
5 n.d. 8.001 1.95 
6 n.d. 8.426 1.52 
7 n.d. (5.149) 1.21 
8 57.91 23.659 45.30 
9 26.07 (4.985) 0.94 
10 81.62 16.115 8.89 
11 98.17 22.518 23.10 
12 0 (5.567) 5.14 
13 n.d. 6.249 2.12 
14 99.93 6.146 6.53 
15 n.d. (5.155) 1.27 
16 65.61 6.879 3.96 
17 0 (5.556) 1.02 
18 n.d. (5.107) 0.40 
19 n.d. (5.197) 3.59 
N1 n.d. 4.857 n.d. 
N2 n.d. 4.914 n.d. 
‡determined by ImmunoCAPTM; †determined by immunoblot analysis; n.d., not determined; () sIgE levels in 
parenthesis are below method cut-off (LOD). 
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As in the peanut project, serum IgE binding in immunoblot (Figure 21) was considered positive 
when the quantified specific IgE level (kUA/L) exceeded the respective calculated limit of 
detection (LOD).  
Using two times the densitometric signal intensity of the non-allergic control serum N inserted 
into the linear regression equation and resolved for sIgE, the LOD was calculated. This resulted 
in a LOD1 of 5.889 kUA/L for patients 1-7 and in a LOD2 of 6.005 kUA/L for patients 8-19. 
Considering the respective LOD, serum IgE of 11/14 (79%) pea-allergic children and of 1/5 
(20%) pea-tolerant children bound to rPis s 1. In pea-allergic children, rPis s 1 sIgE levels 
(> LOD) were elevated ranging from 6.15 to 45.59 kUA/L (median 16.12 kUA/L). In contrast, 
only tolerant patient 16 displayed sIgE binding to rPis s 1 of 6.88 kUA/L.  
The elevated rPis s 1 sIgE levels in pea-allergic patients correlated well with the elevated pea 
extract sIgE levels. As shown in Figure 23, a linear correlation (R2=0.8171) between sIgE to 
pea extract and sIgE to rPis s 1 (> LOQ) was observed. Depending on the respective immunoblot 
membrane, LOQ’s of 7.954 kUA/L (LOQ1 for patients 1-7) and of 8.185 kUA/L (LOQ2 for 
patients 8-19) were calculated and used as cut-off for inclusion in the correlation analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Correlation analysis between pea extract sIgE levels and rPis s 1 sIgE levels. 
Correlation analysis was performed between pea extract sIgE levels and rPis s 1 sIgE levels > limit of quantification 
(LOQ). †determined by immunoblot analysis; ‡determined by ImmunoCAPTM; dotted line, cut-off of ImmunoCAPTM 
(0.35 kUA/L); dashed and single dotted line, mean of LOD1 and LOD2 (mean LOD= 5.95 kUA/L). Dashed line, mean 
of LOQ1 and LOQ2 (mean LOQ= 8.07 kUA/L). For correlation analysis, the respective membrane specific LOQ values 
were used. R2, coefficient of determination. 
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In the following, the relevance of Pis s 1 and its contribution to the IgE-binding capacity of pea 
total protein will be discussed in more detail using the IgE immunoblot inhibition and the 
calculated inhibition capacity (Figure 22 and Table 26).  
In pea-allergic patients 3, 10, 11 and 14, rPis s 1 was able to inhibit IgE binding to pea total 
protein extract almost completely. A partial inhibition of serum IgE binding could be observed 
in pea-allergic patients 1, 2, 4, 8, 9 and in pea-tolerant patient 16. In contrast, no inhibition 
could be observed in pea-allergic patient 12 and in pea-tolerant patient 17. Serum IgE of pea-
allergic patients 5, 6, 7 and of pea-tolerant patients 15, 18, 19 did not show a detectable binding 
to pea extract in immunoblot analysis which correlated with low levels of pea extract sIgE 
(Figure 22 and Table 26). Consequently, no percent inhibition could be calculated for these 
patients, as well as for patient 13, for whom due to high background signal intensity after the 
addition of rPis s 1 no calculation was possible. In the remaining twelve patients (patients 1, 2, 
3, 4, 8, 9, 10, 11, 12, 14, 16, 17), rPis s 1 inhibited on average 53.72% of the serum IgE binding 
to pea extract. For pea-allergic children the calculated average inhibition was 57.90%.  
rPis s 1 was also able to inhibit IgE binding to pea extract in the lower molecular weight range 
between 10 and 30 kDa in several patients (patients 1, 3, 4, 8, 10, 11 and 14). The reason for 
this is the post-translational proteolytic cleavage of natural Pis s 1 in pea extract leading to 
fragments of 12.5 to 36 kDa (Gatehouse et al. 1982; Sanchez-Monge et al. 2004) that could be 
fully or partially inhibited by rPis s 1.  
In addition, rPis s 1 could also inhibit serum IgE binding to a pea protein located between 70 
and 80 kDa (Figure 22; patients 3, 4, 10 and 11). This protein might be either a dimer of Pis s 1 
or potentially Pis s 2. However, in patients 1 and 16 no inhibition could be observed in this 
molecular weight range leading to a detectable IgE binding even after the addition of rPis s 1.  
Moreover, after the addition of rPis s 1, only two patients (patients 1 and 16) still showed an 
IgE binding to pea proteins located in the lower molecular weight range (< 25 kDa) where MS 
spectrometry analysis confirmed the presence of PA1 isoforms and PA2 (Figure 24 and 
Table 27). Alignment of individual PA1 isoform sequences and detected isoform-specific 
peptides are shown in the appendix, in Figure A23 and Table A53, respectively. In addition, MS 
analysis identified in contrast to published data nPA1 as a proprotein version containing the 
propeptide linking both PA1 chains (appendix Figure A23 and Table A53). 
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Figure 24: SDS-PAGE of pea extract for MS analysis. 
Pea extract (lane 1) was analyzed under reducing conditions. Bands 1-4 were analyzed by mass spectrometry. M, 
SpectraTM Multicolor Broad Range Protein Ladder. 
 
Table 27: Identification of PA1 and PA2 in pea extract. 
Band Acc. No. UP Description S P C E 
1 P08688 
PA2 
Albumin-2 Pisum sativum 
4819 14 73.6 2.2 
2 P08688 
PA2 
Albumin-2 Pisum sativum 
10881 14 60.6 1.7 
3 P08688 
PA2 
Albumin-2 Pisum sativum 
21719 15 74.9 2.4 
3 P62929 
PA1 D 
Albumin-1 D Pisum sativum 
521 2 19.2 1.2 
4 P08688 
PA2 
Albumin-2 Pisum sativum 
18926 12 67.1 1.4 
4 P62929 
PA1 D 
Albumin-1 D Pisum sativum 
5376 3 36.9 2.2 
4 P62930 
PA1 E 
Albumin-1 E Pisum sativum 
3645 2 24.6 1.0 
4 P62928 
PA1 C 
Albumin-1 C Pisum sativum 
3231 1 6.9 4.1 
Acc.No. UP, accession number of Uniprot; S, PLGS protein score; P, number of identified peptides; C, protein 
sequence coverage %; E, precursor RMS mass error [ppm]. 
 
Furthermore, an IgE immunoblot inhibition was performed to identify the pea protein ~14 kDa 
that still showed an IgE binding after the addition of rPis s 1 (appendix Figure A25). Therefore, 
serum from patients 1 and 16 as well as a PEI-internal serum (PEI131) from a patient sensitized 
to peach Pru p 3, a non-specific lipid-transfer protein (nsLTP) showing high sequence homology 
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to nsLTP from pea (Pis s 3), was used. By using rPA1 and natural Pru p 3 as inhibitors, it should 
be investigated whether the pea protein with a molecular weight of ~14 kDa was possibly PA1 
or Pis s 3. However, the pea protein (~14 kDa) could not be inhibited in its IgE binding by 
either rPA1 or natural Pru p 3 in both pea patients (appendix Figure A25). In addition, serum 
PEI131 also showed IgE binding to this ~14 kDa pea protein and to an additional pea protein 
below (appendix Figure A25C). Using natural Pru p 3 as inhibitor, the second pea protein below 
14 kDa could be inhibited indicating that pea nsLTP (Pis s 3) was presumably present in the 
investigated pea total protein extract. 
Thus, the inhibition experiment shows that low molecular weight proteins, including PA1, PA2 
and Pis s 3, that are not related to Pis s 1 fragments, play a minor role in serum IgE binding of 
pea-allergic children.  
However, as the opposite was the case for Pis s 1, which was identified as a relevant major 
allergen with a high IgE-binding capacity in this study population, its biological activity was 
investigated in a mediator release assay using RBL-2H3 cells sensitized with a serum pool 
composed of pea-allergic patients 1, 3, 4, 8 and 11 (Figure 25). Both pea extract and rPis s 1 
induced a comparable maximal release of approximately 64%. The amount of pea extract 
required for half-maximal mediator release (EC50) was with 2.270 ng/well approximately one 
order of magnitude higher compared to rPis s 1 (EC50= 0.113 ng/well). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Mediator release induced by pea extract and rPis s 1. 
Rat basophilic leukemia cells were sensitized with a serum pool of pea-allergic children (patients 1, 3, 4, 8, 11) and 
the mediator released induced by pea extract (black) and rPis s 1 (red) was determined. BSA (gray) was used as 
negative control. Depicted curves were fitted with a four parameter logistic model. 
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4.2.4 Differences in IgE binding at the peptide level 
In the next step, all pea-allergic and tolerant children were analyzed for their differences in IgE 
binding to Pis s 1 at the linear peptide level. 
In addition, patients 1 and 16 both showing an IgE binding to low molecular weight proteins 
in pea extract after inhibition with rPis s 1 (Figure 22), and in addition patient 1 also to rPA1 
(Figure 21B), were analyzed for their IgE binding to peptides representing full-length PA1 and 
PA2. Spotting layout and peptide sequences of PA1 and PA2 are shown in the appendix, in 
Figure A19 and Table A48 & A49. Images of the immunodetection of the two investigated 
patients and the negative controls are depicted in Figure A19 in the appendix. A visual analysis 
of the immunodetection revealed that patient 1 showed a serum IgE binding which was above 
both negative controls to a limited number of peptides of PA1. This finding was in agreement 
with the immunoblot analysis of patient 1 and rPA1. Furthermore, this patient showed 
negligible or no relevant IgE binding to peptides of PA2 (Figure A19 in the appendix). For 
patient 16, no serum IgE binding could be detected to peptides of PA1 and PA2. This finding 
was also in good agreement with no IgE binding to rPA1 and rPA2 in immunoblot analysis. 
As no significant serum IgE binding could be detected to PA1 and PA2 at the protein and linear 
peptide level, no detailed Z-score calculation was performed and both proteins were not further 
investigated and will not be further discussed in this results section. 
By contrast, Pis s 1 bound serum IgE of the majority of pea-allergic patients and therefore, was 
analyzed in detail for its IgE binding at the peptide level. Similar to the peanut project, peptides 
representing full-length mature Pis s 1 were spotted in quadruplicate and subsequently, 
successful spotting was confirmed by Coomassie staining of randomly chosen array slides 
(Figure 26A and 26B). As an example, the IgE immunodetection using serum of patient 11, who 
showed a strong IgE binding to peptides of Pis s 1, is illustrated in Figure 26C. 
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Figure 26: Spotting layout, Coomassie-staining and IgE immunodetection of CelluspotTM multipeptide 
microarray displaying Pis s 1. 
(A) Spotting layout of Pis s 1 multipeptide microarray. For simplification, only the left segment of the multipeptide 
microarray is shown. Full-length sequence of Pis s 1 is represented by 101 peptides that were spotted (each 0.04 µl) 
in duplicate on each segment leading to quadruplicate peptide presentation on the whole array. Biotinylated control 
peptides, abbreviated by a ”C”, were spotted in duplicate in different dilutions (top left, middle right and bottom 
right on each array element) and were used as position markers. Gray empty spots represent blank spots composed 
of peptide printing buffer (DMSO). Blue empty spots represent internal control peptides not relevant for peptide 
analysis. (B) Successful spotting was verified by staining with Coomassie Brilliant Blue G250. (C) IgE 
immunodetection using serum of a pea-allergic child (patient 11) after 2 min exposure. 
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In total, 101 peptides, that represented the full-length mature sequence of Pis s 1, were spotted. 
Again, quadruplicate peptides should minimize the influence of outliers, and positive controls 
should help to simplify the peptide analysis using SpotfinderTM software. As shown in 
Figure 26C, patient 11 showed a strong serum IgE binding to the peptides of Pis s 1 and 
especially to peptides located at the carboxy-terminal part. 
To identify differences between pea-allergic and tolerant children with regard to their serum 
IgE binding to Pis s 1 peptides, all patients were individually analyzed for their IgE-binding 
propensity. After the immunodetection, the signal intensity of each Pis s 1 peptide, expressed 
as Z-score, was calculated. Similar to the peanut project, serum IgE binding to a peptide was 
defined as positive if its Z-score was > 2 after subtraction of the maximum Z-score of the 
controls. As controls in microarray analysis, sera from five atopic (serum A-E) and five non-
atopic (serum F-J) controls were used. 
The images of the IgE immunodetection as well as calculated Z-scores of controls and of pea 
study subjects after control subtraction are listed in the appendix (Figure A17 and Table A42-
A46). 
After Z-score calculation, the number of positive IgE-bound peptides was calculated for every 
patient (Table 28). Serum IgE of all (14/14) pea-allergic children and of 4/5 (80%) pea-tolerant 
children bound to at least one peptide of Pis s 1. However, serum IgE of pea-allergic children 
bound to more peptides (median of IgE-bound peptides: 31) compared to serum IgE of pea-
tolerant children (median of IgE-bound peptides: 1), this reflected higher IgE-binding diversity 
of pea-allergic children. 
A comparison of the IgE binding to rPis s 1 in immunoblot analysis with the IgE binding to 
linear peptides of Pis s 1 in microarray analysis revealed that patients with a rPis s 1 sIgE level 
below the LOD, meaning with no detectable serum IgE binding to rPis s 1 (patients 7, 9, 12, 15, 
17-19), tended to recognize fewer peptides as patients showing a positive serum IgE binding to 
rPis s 1. Patient 7 was one exception, as no IgE binding to rPis s 1 and to pea total protein was 
detectable in immunoblot analysis, whereas in microarray analysis IgE binding to peptides of 
Pis s 1 could be detected. Allergic patients who recognized the highest number (> median) of 
Pis s 1 peptides (patients 1, 4, 6, 7, 8, 10, 11) tended to have higher rPis s 1 sIgE levels. 
Exceptions here were the above-mentioned patient 7 and patient 6 who recognized a high 
number of peptides but had a very low rPis s 1 sIgE level and showed no IgE binding to pea 
total protein in immunoblot analysis.  
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Table 28: Number of positive serum IgE-bound peptides of Pis s 1. 
Positive peptide IgE binding was defined if the Z-score exceeds 2 after control subtraction. 
Patient No. 
Number of IgE-bound peptides  
of Pis s 1 
Patient No. 
Number of IgE-bound peptides  
of Pis s 1 
1 49 11 70 
2 4 12 2 
3 24 13 16 
4 88 14 2 
5 16 15 0 
6 73 16 25 
7 43 17 1 
8 85 18 1 
9 5 19 2 
10 37 
 
Afterwards, the frequency of recognition by pea-allergic and pea-tolerant patients was 
calculated for every peptide of Pis s 1 (Figure 27). As shown in Figure 27, pea-allergic patients 
showed higher IgE-diversity compared to pea-tolerant patients. Moreover, pea-allergic patients 
showed a maximum IgE-binding frequency of 93% (13/14 patients) to peptides 95 and 96 of 
Pis s 1. However, these two peptides were also recognized by 20% (1/5) of pea-tolerant 
patients. Nevertheless, there were different peptide stretches and individual peptides that were 
only recognized by pea-allergic children.  
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Figure 27: IgE-binding frequencies of pea-allergic and tolerant patients to peptides of Pis s 1. 
Comparison of the IgE-binding frequencies of pea-allergic (black) and tolerant (red) children to peptides of Pis s 1. 
Serum IgE binding to a peptide was considered positive if Z-score was > 2.  
 
4.2.5 Identification of candidate diagnostic peptides of Pis s 1 
For the identification of candidate diagnostic peptides of Pis s 1 specific for pea allergy the same 
established selection criteria as in the peanut project were applied. Briefly, specific candidate 
peptides containing distinct amino acid sequences should be exclusively recognized by pea-
allergic children with high signal intensities and high frequencies. For verifying the specificity 
of peptide IgE binding, inhibition experiments using two serum pools and 30 µg rPis s 1 were 
performed. The two serum pools were composed of patients 1, 4, 8 (pool 1) and patients 3, 10, 
11, 13 (pool 2). Sera within one pool showed comparable IgE-binding pattern to the peptides 
of Pis s 1. Images of the IgE inhibition experiments and calculated Z-scores can be found in the 
appendix (Figure A18 and Table A47). Peptides fulfilling the mentioned criteria were further 
narrowed and finally peptides with an IgE-binding frequency of ≥ 42.85% were selected as 
candidate diagnostic peptides. This percentage value resulted from the calculation of the 
median IgE-binding frequency of the preselected peptides. 
In total, eleven peptides distributed over the entire Pis s 1 primary structure could be identified 
fulfilling the above defined selection criteria for candidate diagnostic peptides that should be 
specific for pea allergy (Figure 28, blue bars). 
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Figure 28: Identified peptides of Pis s 1 fulfilling the selection criteria for candidate diagnostic peptides. 
Comparison of the IgE-binding frequencies of pea-allergic (black) and tolerant (red) children to peptides of Pis s 1. 
Serum IgE binding to a peptide was considered positive if Z-score was > 2. Identified candidate diagnostic peptides 
within this study population specific for pea allergy are shown in blue bars. 
 
The identified candidate diagnostic peptides were peptide 3, 14, 20, 28, 44, 53, 64, 74, 78, 93 
and 100. These candidate diagnostic peptides were recognized by 57%, 43%, 43%, 64%, 50%, 
50%, 57%, 50%, 43%, 43% and 57% of pea-allergic children, respectively. Pea-tolerant patients 
did not show, according to the selection criteria, an IgE binding to the eleven candidate 
diagnostic peptides. Individual serum IgE binding of pea-allergic and tolerant children to the 
selected candidate diagnostic peptides is shown in Table 29. Serum IgE of 13/14 (93%) pea-
allergic children bound to at least one peptide of the eleven candidate diagnostic peptides. Only 
serum IgE of patient 14 did not bind to any of the identified candidate diagnostic peptides. The 
number of recognized candidate diagnostic peptides varied in pea-allergic children between 0 
and 11 peptides with a median number of 6 recognized peptides. 
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Table 29: IgE binding of pea-allergic and tolerant children to identified candidate diagnostic peptides of 
Pis s 1. 
Eleven peptides could be identified as candidate diagnostic peptides of Pis s 1. X depicts positive serum IgE binding 
to candidate peptide; - depicts negative serum IgE binding. 
Patient 
No. 
Pis s 1 
P3 
Pis s 1 
P14 
Pis s 1 
P20 
Pis s 1 
P28 
Pis s 1 
P44 
Pis s 1 
P53 
Pis s 1 
P64 
Pis s 1 
P74 
Pis s 1 
P78 
Pis s 1 
P93 
Pis s 1 
P100 
1 X X - X - X X X X - X 
2 - - - - - - - X - - - 
3 - - - X X - X - X - X 
4 X X X X X X X X X X X 
5 - - - X - X - - - - - 
6 X X X X X X X X X X - 
7 X X X X X X X - - X X 
8 X X X X X X X X X X X 
9 - - - - - - - - - - X 
10 X - - X - - X X - X X 
11 X X X X X X X X X X X 
12 - - X - - - - - - - - 
13 X - - - X - - - - - - 
14 - - - - - - - - - - - 
15 - - - - - - - - - - - 
16 - - - - - - - - - - - 
17 - - - - - - - - - - - 
18 - - - - - - - - - - - 
19 - - - - - - - - - - - 
 
The amino acid sequences of the eleven identified candidate diagnostic peptides are listed in 
Table 30. Peptides like peptide 28, 44 and 78 contained a high portion (7 to 8 amino acid 
residues) of charged amino acid residues and peptide 53 was especially enriched in polar amino 
acid residues compared to other candidate diagnostic peptides. 
 
Table 30: Identified candidate diagnostic peptides of Pis s 1. 
Amino acid sequence of identified candidate diagnostic peptides of Pis s 1. 
Candidate peptides of Pis s 1 Amino acid sequence 
Peptide 3 F-I-F-K-S-N-R-F-Q-T-L-Y-E-N-E 
Peptide 14 S-K-P-H-T-L-F-L-P-Q-Y-T-D-A-D 
Peptide 20 A-T-L-T-V-L-K-S-N-D-R-N-S-F-N 
Peptide 28 A-N-R-D-D-N-E-D-L-R-V-L-D-L-A 
Peptide 44 Q-Q-E-Q-E-P-Q-H-R-R-S-L-K-D-R 
Peptide 53 S-K-N-A-K-S-S-S-K-K-S-V-S-S-E 
Peptide 64 Q-L-Q-D-L-D-I-F-V-N-S-V-D-I-K 
Peptide 74 F-E-L-V-G-Q-R-N-E-N-Q-G-K-E-N 
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Peptide 78 K-E-E-E-Q-E-E-E-T-S-K-Q-V-Q-L 
Peptide 93 G-E-E-D-N-V-I-S-Q-V-E-R-P-V-K 
Peptide 100 L-L-K-N-Q-K-Q-S-Y-F-A-N-A-Q-P 
 
Figure 29 depicts the molecular surface presentation of the eleven identified candidate 
diagnostic peptides on Pis s 1. The eleven peptides were distributed over the entire molecular 
surface of Pis s 1. No predominant location of the eleven candidate diagnostic peptides could 
be observed within this pea study group. 
 
 
 
 
Figure 29: Surface presentation of identified candidate diagnostic peptides of Pis s 1. 
Molecular surface presentation of the eleven candidate diagnostic peptides of Pis s 1. P3, violetpurple; P14, green; 
P20, cyan; P28, yellow; P44, blue; P53, red; P64, magenta; P74, orange; P78, brown; P93, black; P100, sand. Images 
were generated using pdb 1UIJ and PyMOL. 
 
4.2.6 Diagnostic value of candidate diagnostic peptides in comparison to full-length rPis s 1 
and pea extract 
Finally, an ROC curve analysis was performed in order to determine and compare the diagnostic 
value of pea total protein extract, full-length rPis s 1 and identified candidate diagnostic 
peptides. Prior to ROC curve analysis rPis s 1 sIgE levels (kUA/L) were subtracted by two times 
the signal intensity of the non-allergic control serum N1 or N2 resolved for sIgE (as described 
in chapter 3.2.8.7). In addition, of the eleven candidate diagnostic peptides, the maximum Z-
score was calculated. The calculated maximum Z-score of the eleven peptides for each 
individual study subject is listed in Table 31. 
 
 
 
180° 180° 
Front side view Back side view Top view Bottom view 
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Table 31: Maximum Z-scores of candidate diagnostic peptides of Pis s 1. 
For each patient, the maximum Z-score was calculated of the eleven candidate peptides of Pis s 1. For this, Z-scores 
after subtraction of the controls were used. 
Patient No. 
Max. Z-score candidate peptides 
Pis s 1 (n=11 peptides) 
Patient No. 
Max. Z-score candidate peptides 
Pis s 1 (n=11 peptides) 
1 8.456176757 11 28.93225251 
2 4.390234033 12 2.513176118 
3 13.75090006 13 2.794986271 
4 33.82082034 14 1.672636293 
5 5.107092898 15 -1.208033918 
6 13.19017001 16 1.992643739 
7 6.94685405 17 0.593583355 
8 32.05170301 18 -0.850040617 
9 2.05895219 19 -0.115452683 
10 5.604967253 
 
The ROC curves and the AUC values of pea extract, rPis s 1 and candidate diagnostic peptides 
are shown in Figure 30. sIgE to pea extract and rPis s 1 had an AUC of 0.81 and 0.86, 
respectively. Candidate diagnostic peptides had an AUC of 0.99 and represented a perfect 
discriminative ability between pea-allergic and tolerant children.  
sIgE to pea extract as well as sIgE to rPis s 1 reached at a specificity of 100% a sensitivity of 
64%. Using positive IgE binding to rPis s 1 as cut-off, a specificity of 80% and a sensitivity of 
79% could be achieved. In contrast, the eleven identified candidate diagnostic peptides reached 
at a specificity of 100% the highest sensitivity of 93%. Consequently, candidate diagnostic 
peptides increased the sensitivity (79% vs. 93%) and the specificity (80% vs. 100%). The 
identified candidate diagnostic peptides enabled, in comparison to the IgE binding to full-length 
rPis s 1, the serum IgE binding of three additional patients (patients 7, 9 and 12). Serum IgE of 
pea-allergic patient 14, on the other hand, bound to full-length rPis s 1, but not to any of the 
eleven candidate diagnostic peptides. 
In a last analysis step, it should be analyzed whether the eleven peptides could be further 
narrowed while keeping the specificity (100%) and the sensitivity (93%). An analysis of the 
minimum number of peptides required to maintain 93% sensitivity (13/14 pea-allergic 
patients) revealed a minimum number of five peptides. Peptide 20 was required for the 
detection of patient 12, peptide 74 for patient 2 and peptide 100 for patient 9. Using these three 
peptides resulted in a sensitivity of just 79%, as patients 5 and 13 did not show an IgE binding 
to any of these three peptides. Patient 5 showed only an IgE binding to peptides 28 and 53 and 
patient 13 to peptides 3 and 44. Of these two peptide pairs, the two peptides with the highest 
frequency of recognition in pea-allergic children were finally selected. This resulted in the 
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selection of peptides 3 and 28. An ROC curve analysis using the maximum Z-score of these five 
peptides (peptides 3, 20, 28, 74 and 100) resulted in an AUC of 0.99 (95% CI: 0.95-1.03) which 
was identical to the AUC of the eleven candidate diagnostic peptides (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Receiver operating characteristic (ROC) curve analysis of sIgE to pea total protein extract, full-
length recombinant Pis s1 and identified candidate diagnostic peptides. 
ROC curves of sIgE to pea extract, rPis s 1 and candidate peptides of Pis s 1 are shown in black, red and green, 
respectively. sIgE to pea extract was determined by ImmunoCAPTM analysis (‡) and sIgE to rPis s 1 was quantified by 
immunoblot analysis (†). For ROC curve analysis of candidate diagnostic peptides, calculated maximum Z-score was 
used. Z-scores were determined by microarray analysis (§). The gray diagonal line (AUC 0.5) represents a test without 
discriminatory ability. AUC, area under the ROC curve; CI, confidence interval. 
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4.3 Soybean project 
4.3.1 Study population 
Included in the soybean project were sera from twenty-one children (median age 3 years), in 
total. Characteristics of soybean patients are listed in Table 32. The inclusion criterion was, 
similar to the both other projects, a soybean sIgE level of ≥ 0.35 kUA/L. In six of these twenty-
one children (patients 1-6) soybean allergy was confirmed by oral food challenge. 2/6 
underwent a double-blind placebo-controlled food challenge (DBPCFC) and 4/6 an open food 
challenge (OFC). In the remaining fifteen children (patients 7-21) soybean allergy was excluded 
and thus, soybean tolerance, despite sensitization, was confirmed by oral food challenge 
(11/15 DBPCFC and 4/15 OFC). All six allergic patients showed during food challenge 
moderate (grade II/III) soybean-related symptoms. Soybean sIgE level ranged in allergic 
children from 1.51 to 93.20 kUA/L. The calculated median soybean sIgE level was 15.85 kUA/L 
in allergic children which was elevated compared to tolerant children having a median soybean 
sIgE level of 2.60 kUA/L (range 0.60 to 42.70 kUA/L). 
 
Table 32: Clinical characteristics of the soybean study population. 
Patients allergic to soybean (patients 1-6) and patients sensitized to soybean without clinical symptoms (patients 7-
21). 
Patient 
No. 
Age (y)*/sex 
Clinical 
evidence 
Symptoms to 
soybean 
Severity 
grading# 
Total IgE 
(kUA/L)‡ 
Soybean sIgE 
(kUA/L)‡ 
1 2/m OFC GU II 219.00 4.16 
2 11/m OFC N, rGC II n.d. 93.20 
3 6/f DBPCFC N, IT III n.d. 1.51 
4 5/m OFC GU, I II 417.00 11.30 
5 2/m OFC GU, I II 695.00 20.40 
6 2/m DBPCFC CU, N, RC III 238.00 24.90 
7 1/m DBPCFC none - 404.00 2.60 
8 1/m DBPCFC none - 259.00 0.72 
9 6/f DBPCFC none - 953.00 42.70 
10 4/m DBPCFC none - 202.00 1.64 
11 2/f OFC none - 275.00 0.60 
12 4/m DBPCFC none - 82.00 1.52 
13 6/m DBPCFC none - n.d. 3.27 
14 2/m DBPCFC none - n.d. 2.61 
15 3/m DBPCFC none - n.d. 0.81 
16 2/m DBPCFC none - n.d. 0.61 
17 4/f DBPCFC none - n.d. 1.38 
18 10/f DBPCFC none - n.d. 7.35 
19 2/m OFC none - 1094.00 3.00 
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20 1/f OFC none - 1962.00 6.10 
21 7/m OFC none - n.d. 2.86 
*Age at time of blood sampling; f, female; m, male; n.d., not determined; DBPCFC, double-blind placebo-controlled 
food challenge; OFC, open food challenge; CU, contact urticaria; GU, generalized urticaria; I, itching; IT, itching 
throat; N, nausea; RC, rhinoconjunctivitis; rGC, reduced general conditions; #severity grading according to the 
grading system developed by Sampson (Sampson 2003); ‡ determined by ImmunoCAPTM. 
 
4.3.2 Generation and physicochemical characterization of rGly m 5.03 and rGly m 8 
Both proteins, the β subunit of Gly m 5 (Gly m 5.03) and Gly m 8, could be successfully 
expressed using Pichia pastoris and were purified from cell culture supernatant using IMAC and 
SEC. rGly m 8 was expressed as proprotein composed of two chains linked by a 17 amino acid 
residue propeptide (for sequence information see Figure A11 in the appendix). 
The identity of both recombinant proteins was confirmed by mass spectrometry analysis 
(Table 33). Sequence coverages for rGly m 5.03 and rGly m 8 of 45.5% and 30.6% were 
determined, respectively. 
 
Table 33: Identity confirmation of recombinant soybean proteins by mass spectrometry analysis. 
Protein 
Accession  
number# 
PLGS protein  
score 
Number of identified  
peptides 
Sequence  
coverage 
Mass error* 
rGly m 5.03 PEI078 4026 20 45.5% 19.9 
rGly m 8 PEI075 821 6 30.6% 6.2 
#PEI, internal accession number; *precursor RMS mass error [ppm]. 
 
According to Coomassie-stained SDS-PAGE shown in Figure 31A, rGly m 5.03 (49.3 kDa) in 
lane 1 and rGly m 8 (17.5 kDa) in lane 2 showed high purity suitable for further IgE binding 
analyses. Weak bands < 49 kDa in lane 1 were degradation products of rGly m 5.03 and 
additional weak bands between 140 and 260 kDa were possibly trimeric or polymeric 
rGly m 5.03. 
CD spectroscopy indicated structural integrity of both recombinant soybean proteins 
(Figure 31B and 31C) and revealed for rGly m 5.03 (Figure 31B) a CD spectrum comparable to 
pea 7S globulin rPis s 1 (Figure 20B). The CD spectrum showed a minimum at ~217 nm and a 
maximum at ~197 nm. In addition, the CD spectrum of rGly m 8 (Figure 31C) was comparable 
to peanut 2S albumins Ara h 2 (Figure 2B) and pea albumin 1 (Figure 20B). Here, the typical 
α-helical characteristics, two minima at ~208 nm and ~222 nm and a maximum at ~193 nm, 
could be detected. Using dynamic light scattering, the hydrodynamic radii (RH) of both soybean 
allergens was measured. For rGly m 5.03 a RH of 7.4 ± 1.2 nm was detected suggesting a 
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trimeric protein in solution comparable to rPis s 1. Whereas, rGly m 8 (RH of 2.6 ± 0.4 nm), 
comparable to the other investigated 2S albumins, seemed to be present as a monomeric protein 
in solution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Purity and physicochemical characterization of rGly m 5.03 and rGly m 8. 
(A) Coomassie-stained SDS-PAGE of rGly m 5.03 (lane 1; 7 µg/cm) and rGly m 8 (lane 2; 1.5 µg/cm). Protein 
samples were analyzed under reducing conditions. M, SpectraTM Multicolor Broad Range Protein Ladder. (B) Far-UV 
CD-spectrum (190-255 nm) of rGly m 5.03 (solid line) at 3 µM. (C) Far-UV CD-spectrum (190-255 nm) of rGly m 8 
(dashed line) at 2 µM. The inset depicts the hydrodynamic radius (RH) ± SD. 
 
4.3.3 Relevance of Gly m 5.03 and Gly m 8 
In order to determine the relevance of both proteins in this study population, they were 
analyzed for their IgE-binding properties using immunoblot analysis (Figure 32). Patients’ sIgE 
levels were densitometrically quantified and, comparable to the two other legume projects, 
serum IgE binding was considered positive when the sIgE level exceeds the LOD (2x sIgE level 
of non-allergic control serum N). As neither an allergic nor a tolerant patient showed obviously 
a serum IgE binding to rGly m 8 (Figure 32B), densitometric quantification of rGly m 8 sIgE 
levels was omitted. 
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Figure 32: Serum IgE binding of soybean-allergic and sensitized but tolerant children to rGly m 5.03 and 
rGly m 8. 
IgE binding of sera from soybean-allergic children (lane 1-6, patients’ sera 1-6 according to Table 32) and tolerant 
children (lane 7-21, patients’ sera 7-21 according to Table 32) to rGly m 5.03 (A) and to rGly m 8 (B) after 1 min 
and 4 min exposure, respectively. Protein samples were analyzed under reducing conditions. M, low-molecular 
weight marker; P, total protein stained with Ponceau S; N, non-allergic control serum. 
 
rGly m 5.03, in contrast, showed serum IgE binding (Figure 32A) and patients’ quantified 
rGly m 5.03 sIgE levels are listed in Table 34. All patients were analyzed for their serum IgE 
binding on one immunoblot membrane and the calculated LOD was 1.104 kUA/L. Considering 
the LOD, serum IgE of 3/6 (50%; patients 1, 2, 6) soybean-allergic children and of 3/15 (20%; 
patients 9, 16, 18) soybean-tolerant children bound to rGly m 5.03. Patient 2 also recognized 
degradation products of rGly m 5.03 and di/trimeric rGly m 5.03. 
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Quantified rGly m 5.03 sIgE levels (> LOD) ranged from 4.15 to 58.02 kUA/L (median 
10.05 kUA/L) in the allergic group and from 1.72 to 37.20 kUA/L (median 1.99 kUA/L) in the 
tolerant group. 
 
Table 34: Quantified rGly m 5.03 sIgE levels of soybean-allergic and sensitized but tolerant children. 
Densitometrically quantified rGly m 5.03 sIgE levels of soybean-allergic (patients 1-6) and sensitized but tolerant 
children (patients 7-21). N, non-allergic control serum. 
Patient No. rGly m 5.03 sIgE (kUA/L)† Patient No. rGly m 5.03 sIgE (kUA/L)† 
1 10.050 12 (0.919) 
2 58.016 13 (0.594) 
3 (0.749) 14 (1.073) 
4 (0.891) 15 (0.891) 
5 (0.790) 16 1.717 
6 4.149 17 (1.011) 
7 (0.800) 18 1.991 
8 (0.816) 19 (0.973) 
9 37.202 20 (1.050) 
10 (1.033) 21 (0.785) 
11 (0.789) N 0.552 
† determined by immunoblot analysis; () sIgE levels in parenthesis are below method cut-off (LOD). 
 
In addition, serum IgE binding to total soybean protein was analyzed and the result of the IgE 
immunoblot is shown in Figure 33. Soybean-allergic patients 2 and 6 as well as soybean-tolerant 
patients 8, 9 and 20 showed a strong IgE binding to soybean total protein. In contrast, no or 
only minor IgE binding could be detected for patients 3-5, 7, 11-16, 19 and 21 which, for the 
majority of the mentioned patients, correlated with low levels of soybean extract sIgE 
(Table 32). However, soybean-allergic patients 4 and 5 had moderate levels of sIgE (11.3 and 
20.4 kUA/L, respectively) to soybean extract, nevertheless only minor serum IgE binding to total 
soybean extract could be identified. This could be caused by the different soybean extracts used 
in this study and in the ImmunoCAPTM and potentially underrepresented or missing allergens. 
The native β subunit of Gly m 5 (Gly m 5.03) has a molecular weight of approximately 48 kDa. 
Soybean-allergic patients 1, 2, 6 and soybean-tolerant patients 8, 9 and, albeit weak, patients 
12 and 18, showed IgE binding to a soybean protein at > 45 kDa, which was presumably 
Gly m 5.03. Except for patients 8 and 12, this IgE binding was in accordance with a positive IgE 
binding to rGly m 5.03 determined in immunoblot analysis (Figure 32A). In addition, patient 
16 showed a weak IgE binding to rGly m 5.03 which could not be detected using soybean extract 
with nGly m 5.03. 
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Figure 33: Serum IgE binding of soybean-allergic and sensitized but tolerant children to soybean total protein 
extract. 
IgE binding of sera from soybean-allergic children (lane 1-6, patients’ sera 1-6 according to Table 32) and tolerant 
children (lane 7-21, patients’ sera 7-21 according to Table 32) to soybean extract. Soybean extract was analyzed 
under reducing conditions. The detection is shown after 1 min of exposure (except for patient 2: 15 sec of exposure). 
M, low-molecular weight marker; P, total protein stained with Ponceau S; N, non-allergic control serum. 
 
In general, no dominant serum IgE binding to soybean proteins located in the lower molecular 
weight range could be detected in either soybean-allergic or tolerant patients. Only soybean-
tolerant patients 10 and 20 showed a significant serum IgE binding to soybean proteins below 
25 kDa, where MS analysis confirmed the presence of nGly m 8 in multiple bands (Figure 34 
lane 1 and Table 35 bands 1-4). 
rGly m 8 was investigated under reducing conditions and as one peptide chain that includes a 
propeptide. Both characteristics may impact the IgE-binding properties of rGly m 8 compared 
to natural Gly m 8 in soybean extract which is composed of two chains linked by disulfide bonds. 
Accordingly, a native PAGE of the soybean extract was performed in order to present natural 
Gly m 8 in its native conformation.   
MS analysis of soybean extract run under native conditions confirmed the identity of nGly m 8 
in band 5 (Figure 34 lane 2 and Table 35 band 5). Moreover, MS analysis identified in band 5 
as well as in band 1-4 N- and C-terminal peptides suggesting the presence of full-length mature 
nGly m 8 without propeptide. Identified peptides of nGly m 8 in bands 1-5 are listed in the 
appendix, in Table A54. 
However, also using native PAGE and IgE immunoblot analysis, no serum IgE binding could be 
detected in soybean-allergic patients in the area where MS analysis identified nGly m 8. Even 
allergic tolerant 
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after a long exposure (10 min), only soybean-tolerant patients 10 and 20 showed a weak IgE 
binding to a soybean protein located in the area of nGly m 8 (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: SDS-PAGE and native PAGE of soybean extract for MS analysis. 
Lane 1, SDS-PAGE of soybean extract under reducing conditions; lane 2, native/non-denaturing PAGE of soybean 
extract; M1, SpectraTM Multicolor Broad Range Protein Ladder used in SDS-PAGE; M2, low-molecular weight marker 
used in native PAGE. 
 
Table 35: Identification of Gly m 8 in soybean extract. 
Band Acc. No. UP Description S P C E 
1 P19594 
Gly m 8 
2S Albumin Glycine max 
4954 3 29.7 0.8 
2 P19594 
Gly m 8 
2S Albumin Glycine max 
12467 5 35.4 1.8 
3 P19594 
Gly m 8 
2S Albumin Glycine max 
42510 7 43.7 2.0 
4 P19594 
Gly m 8 
2S Albumin Glycine max 
15557 10 37.3 2.6 
5 P19594 
Gly m 8 
2S Albumin Glycine max 
1975 7 36.1 5.0 
Acc.No. UP, accession number of Uniprot; S, PLGS protein score; P, number of identified peptides; C, protein 
sequence coverage %; E, precursor RMS mass error [ppm]. 
 
Subsequently, all patients were analyzed for their serum IgE binding to peptides of Gly m 8 and 
Gly m 5.03. Since some studies highlighted the high diagnostic value of sIgE to Gly m 8, all 
soybean patients were individually investigated for their serum IgE binding to peptides of 
Gly m 8, despite no relevant IgE binding to rGly m 8 and nGly m 8 could be identified so far. 
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Full-length Gly m 8 was represented by 32 peptides (see appendix Table A51). Visual evaluation 
of Gly m 8 microarrays revealed no serum IgE binding to peptides of Gly m 8 of all investigated 
soybean-allergic and tolerant children (see appendix Figure A21). Therefore, no Z-score 
calculation was performed. This finding was in accordance with the immunoblot analyses, 
where also no soybean-allergic patient showed a serum IgE binding to rGly m 8 and nGly m 8. 
Hence, in this small study group of soybean-allergic children, Gly m 8 was neither on the protein 
nor on the peptide level an allergen. Similarly, soybean-sensitized but tolerant patients showed 
no and no relevant IgE binding to rGly m 8 and nGly m 8, respectively. Thus, Gly m 8 is not a 
relevant protein with sensitizing properties in this study group of soybean-allergic and 
sensitized but tolerant children.  
Some serum IgE binding was detected to peptides of Gly m 5.03. Thus, the results of this 
multipeptide microarray analysis will be described in more detail. 
Figure 35 shows the spotting layout of the Gly m 5.03 multipeptide microarray, on which both 
isoforms, Gly m 5.0301 and Gly m 5.0302, of the subunit Gly m 5.03 were considered. 
Gly m 5.0302 was the sequence of the recombinant protein investigated in the immunoblot 
analysis. Figure 36 illustrates the sequence alignment of both isoforms and shows the two amino 
acid residue substitutions (Figure 36, red) from phenylalanine to leucine in Gly m 5.0301 
compared to Gly m 5.0302. Similar to the peanut project, peptides shared by both isoforms 
were spotted once (half dark blue, half light blue spots in Figure 35A). Detailed peptide 
sequence information is presented in the appendix, in Table A50. 
After spotting, staining with Coomassie confirmed consistent spotting of all peptide solutions 
on array slides (Figure 35B). As an example, the immunodetection using serum of soybean-
allergic patient 2 is shown (Figure 35C). Images of the IgE immunodetections of all patients are 
shown in the appendix, in Figure A20. 
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Figure 35: Spotting layout, Coomassie-staining and IgE immunodetection of CelluspotTM multipeptide 
microarray displaying Gly m 5.03. 
(A) Spotting layout of Gly m 5.03 multipeptide microarray. For simplification, only the left segment of the 
multipeptide microarray is shown. Light and dark blue spots represent unique peptides either found in Gly m 5.0301 
or Gly m 5.0302, respectively. Half dark blue, half light blue spots represent peptides shared by both isoforms. In 
general, both Gly m 5.03 isoforms are covered by 102 peptides. Biotinylated control peptides, abbreviated by a “C”, 
were spotted in duplicate in different dilutions (top left and bottom right on each array element) and were used as 
position markers. Gray empty spots represent blank spots composed of peptide printing buffer (DMSO). Blue empty 
spots represent internal control peptides not relevant for peptide analysis. (B) Successful spotting was verified by 
staining with Coomassie Brilliant Blue G250. (C) IgE immunodetection using serum of a soybean-allergic child 
(patient 2; 30 sec exposure).  
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Figure 36: Sequence alignment of Gly m 5.0301 and Gly m 5.0302. 
Mature full-length sequences of Gly m 5.0301 (PDB sequence 1IPJ) and Gly m 5.0302 (PDB sequence 1IPK) were 
aligned using BLAST® (NCBI, Bethesda MD, USA). Differences in amino acid sequence are shown in red. 
 
Initial Z-score calculation resulted for some patients in high Z-scores after control subtraction, 
and consequently incomprehensible positive IgE-binding peptides. As an example, the 
immunodetection of patient 7 is shown in Figure 37. Depending on the analyzed Gly m 5.03 
isoform, Z-score calculation resulted for this patient in at least 80 IgE-binding peptides with Z-
score > 2. This result was not in accordance with the image of the immunodetection as visually 
no serum IgE binding to any of the peptides, except for one peptide (peptide no. 6), could be 
identified for this patient. A possible explanation for this might be the use of just one control 
serum (serum N) due to low serum availability in microarray analysis instead of multiple control 
sera as used in the peanut or pea project. Therefore, no detailed Z-score calculation was 
performed. 
 
 
 
 
 
 
 
Figure 37: IgE immunodetection using serum of soybean-tolerant patient 7 after 30 sec exposure. 
 
Gly m 5.0301  1    LKVREDENNPFYLRSSNSFQTLFENQNGRIRLLQRFNKRSPQLENLRDYRIVQFQSKPNT  60
Gly m 5.0302  1    LKVREDENNPFYFRSSNSFQTLFENQNGRIRLLQRFNKRSPQLENLRDYRIVQFQSKPNT  60
Gly m 5.0301  61   ILLPHHADADFLLFVLSGRAILTLVNNDDRDSYNLHPGDAQRIPAGTTYYLVNPHDHQNL  120
Gly m 5.0302  61   ILLPHHADADFLLFVLSGRAILTLVNNDDRDSYNLHPGDAQRIPAGTTYYLVNPHDHQNL  120
Gly m 5.0301  121  KIIKLAIPVNKPGRYDDFFLSSTQAQQSYLQGFSHNILETSFHSEFEEINRVLLGEEEEQ  180
Gly m 5.0302  121  KIIKLAIPVNKPGRYDDFFLSSTQAQQSYLQGFSHNILETSFHSEFEEINRVLFGEEEEQ  180
Gly m 5.0301  181  RQQEGVIVELSKEQIRQLSRRAKSSSRKTISSEDEPFNLRSRNPIYSNNFGKFFEITPEK  240
Gly m 5.0302  181  RQQEGVIVELSKEQIRQLSRRAKSSSRKTISSEDEPFNLRSRNPIYSNNFGKFFEITPEK  240
Gly m 5.0301  241  NPQLRDLDIFLSSVDINEGALLLPHFNSKAIVILVINEGDANIELVGIKEQQQKQKQEEE  300
Gly m 5.0302  241  NPQLRDLDIFLSSVDINEGALLLPHFNSKAIVILVINEGDANIELVGIKEQQQKQKQEEE  300
Gly m 5.0301  301  PLEVQRYRAELSEDDVFVIPAAYPFVVNATSNLNFLAFGINAENNQRNFLAGEKDNVVRQ  360
Gly m 5.0302  301  PLEVQRYRAELSEDDVFVIPAAYPFVVNATSNLNFLAFGINAENNQRNFLAGEKDNVVRQ  360
Gly m 5.0301  361  IERQVQELAFPGSAQDVERLLKKQRESYFVDAQPQQKEEGSKGRKGPFPSILGALY  416
Gly m 5.0302  361  IERQVQELAFPGSAQDVERLLKKQRESYFVDAQPQQKEEGSKGRKGPFPSILGALY  416
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Visually, 2/6 soybean-allergic children (patients 1 and 2) showed a serum IgE binding to 
peptides of Gly m 5.03 (see appendix Figure A20). However, IgE binding was relatively weak 
and no significant differences could be observed with soybean-tolerant children, some of whom 
also showed IgE binding. 
The limited number of soybean-allergic subjects, and in addition the limited serum IgE binding 
to only a few synthetic peptides of Gly m 5.03, did not allow for further analysis with regard to 
the aims of this project, i.e. to identify peptides as candidate markers for soybean allergy. 
These observations highlighted the need to include more soybean-allergic patients in future 
analysis of IgE binding to Gly m 5.03 peptides.  
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5 Discussion 
 
After a detailed analysis of the medical history, the anamnesis, the status quo in allergy 
diagnosis is the in vitro measurement of allergen-specific IgE (sIgE) in the blood, that is bound 
to allergens in total protein extracts or to single allergen components (Boyce et al. 2010; Renz 
et al. 2018; Yu et al. 2016). Nonetheless, with a few exceptions, the determination of the sIgE 
to extracts or extract components just predicts a sensitization rather than the clinical phenotype. 
Currently, the most specific verification is the double-blind, placebo-controlled food challenge 
(DBPCFC), but it is difficult to do on a routine basis, and also potentially risky for the patient. 
Thus, a simple and more specific in vitro test would be desirable.  
Once an allergy is diagnosed, immunotherapy would be the first choice to modulate the immune 
system in a causative way to tolerate the allergen. Several allergen-specific therapeutic 
approaches using, for example, modified allergens or extracts are under investigation but for 
food allergy, no safe causative immunotherapy is currently available for humans (Cook and 
Burks 2018; Nowak-Węgrzyn and Sampson 2011). The detailed molecular knowledge of 
allergens and their interaction with the immune system may allow the design of therapeutic 
allergen variants with optimized characteristics, including reduced side effects.  
In allergy diagnosis as well as in allergen-specific immunotherapy, allergen-derived peptides 
can potentially increase diagnostic accuracy and therapeutic efficacy as reported by several 
studies on humans and mice (Cook and Burks 2018; Lin et al. 2012; Simms et al. 2016). 
In this PhD project, linear peptides/epitopes were investigated for their properties to bind serum 
IgE and whether this specific IgE binding can serve as a starting point towards the development 
of novel approaches for the in vitro allergy diagnosis and the design of novel therapeutic 
reagents, respectively. This PhD study focused on 2S albumin and 7S globulin storage proteins 
from peanut, pea and soybean, all of which are known allergenic legumes. Further, especially 
2S and 7S storage proteins of legumes have been reported as being of high allergenic 
importance, especially in children (Beyer et al. 2015; Holzhauser et al. 2009; Ito et al. 2011; 
van Erp et al. 2017). 
First, the status quo of specific sensitization, meaning the serum IgE binding to individual 
allergen components, was determined for each individual legume-allergic and legume-
sensitized but clinically tolerant child. By doing so, the relevance of the single allergen 
components in each legume study population was determined. For allergen component testing 
and for subsequent IgE immunoblot and microarray inhibition experiments, 2S albumins and 
7S globulins from the three investigated legumes were heterologously expressed, purified and 
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characterized. In addition, recombinant full-length proteins served as comparators for peptide 
analyses. 
 
5.1 Generation of recombinant proteins 
All recombinant 2S and 7S proteins were initially aimed to be expressed in Pichia pastoris, 
because yeast as eukaryote has been described to enable post-translational modifications like 
folding and disulfide bond formation (Cregg et al. 2000; Daly and Hearn 2005). These 
properties are especially advantageous if the recombinant proteins, such as the 2S albumins, 
are stabilized by disulfide bonds. In addition, cloning of the gene of interest into an expression 
vector containing the α-factor signal sequence enables the secretion of the recombinant protein 
and a simple non-denaturing purification. For better comparability of 2S and 7S proteins, 7S 
globulins should also be expressed using Pichia pastoris. 
Despite a successful integration of all genes of interest into the yeast genome, only the 2S 
albumins were successfully expressed as full-length proteins using Pichia pastoris. Apart from 
pea PA2, all 2S albumins showed comparable physicochemical characteristics with a large 
portion of an α-helical-type secondary structure and hydrodynamic radii between 2.4 and 
3.0 nm. In contrast, 7S globulins showed, in spite of their high nucleotide sequence identity 
(~70%), a high level of heterogeneity regarding their expression and/or secretion as full-length 
proteins. In contrast to soybean Gly m 5.03, peanut Ara h 1 and pea Pis s 1 could not be 
expressed as full-length proteins. The lack of expression of Ara h 1 in Pichia pastoris could have 
several causes. Some studies reported an influence of the adenine and thymine (AT) content on 
the transcription termination and recommended an AT content of 30-55% for proper 
transcription (Sreekrishna et al. 1997). However, all cDNA sequences were purchased as codon 
optimized sequences for the expression in Pichia pastoris and the AT content of Ara h 1 (54%) 
was identical to Pis s 1 (55%) and Gly m 5.03 (55%). In addition, no conspicuous AT-rich 
nucleotide stretches, such as ATTATTTTATAAA, could be found in the sequence of Ara h 1, 
excluding the AT content as possible explanation. Moreover, the expression of a full-length pea 
rPis s 1 failed. Instead, two proteolytic N- and C-terminal fragments of approximately 20 and 
27 kDa were obtained. Despite several optimization strategies, the expression of rPis s 1 as full-
length protein failed giving rise to the hypothesis that rPis s 1 is potentially cleaved 
intracellularly in Pichia pastoris into its natural subunits as described in the literature 
(Gatehouse et al. 1982; Sanchez-Monge et al. 2004). Taking into account the potential cleavage 
site of rPis s 1 (K168 and R187), an analysis of the N-terminal fragment revealed that the 20 kDa 
fragment could potentially correspond in molecular weight and amino acid sequence to the α-
subunit (19 kDa) described by Gatehouse et al. (Gatehouse et al. 1982). In addition, the C-
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terminal 27 kDa fragment could potentially correspond to the 32 kDa subunit composed of β + γ subunit described by Sanchez-Monge et al. (Sanchez-Monge et al. 2004). These findings may 
indicate a possible post-translational subunit-specific proteolysis of rPis s 1 in Pichia pastoris. 
Other studies also reported post-translational subunit-specific processing. A study from Lin and 
co-workers reported a post-translational proteolysis of soybean rGly m 8 subunits expressed in 
Pichia pastoris strain GS115. The authors showed that Pichia pastoris enabled proteolytic 
processing of rGly m 8 subunits within the same loop region as nGly m 8 but at different specific 
sites (Lin et al. 2004). However, this finding could not be confirmed and reproduced within this 
PhD project using Pichia pastoris strain X-33, because rGly m 8 was expressed as full-length 
proprotein without subunit processing. 
Nevertheless, to obtain full-length rPis s 1, the expression system was changed to 
Escherichia coli. This resulted in full-length rPis s 1 that showed good accordance in its 
physicochemical characteristics with rGly m 5.03 expressed in Pichia pastoris. Peanut Ara h 1 
used in this PhD project was also an E. coli-expressed recombinant protein that was kindly 
provided by Dr. Jonas Lidholm (Thermo Fisher Scientific).  
Although the expression of 2S albumins and rGly m 5.03 was possible in Pichia pastoris, it must 
be noted that Pichia pastoris as expression system does not guarantee a successful protein 
expression even of homologous proteins. In addition, the expression in Pichia pastoris far took 
more time and resulted in lower protein yields when compared to Escherichia coli (0.07-2.3 mg 
vs. 8.5 mg). 
 
5.2 Knowledge of specific IgE-binding sites of allergens for the development of 
novel therapeutic reagents 
The knowledge of relevant allergens and their IgE-binding sites, i.e. epitopes, opens up new 
strategies for the rational design of novel therapeutic reagents with improved characteristics. 
For example, a reduced IgE-binding capacity by a rational design of therapeutic peptides or 
modified full-length allergens may reduce undesired side effects in immunotherapy, such as 
adverse events. Since the focus of this PhD project was more on allergy diagnosis, the 
therapeutic benefit of this project will be briefly described below.  
Due to the very limited number of soybean-allergic patients included in the soybean project, no 
conclusions can be drawn. However, additional knowledge was gained for peanut and pea 
allergens that should be considered when developing novel therapeutic reagents. 
Common therapeutic approaches comprise the use of hypoallergens generated by site-directed 
mutagenesis or chemical methods like reduction and alkylation (r/a) with the primary focus on 
destroying the folding of the allergen (Kahlert et al. 2008; Zuidmeer-Jongejan et al. 2012). 
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Here, the IgE-binding capacity should be reduced while maintaining the T-cell immunogenicity. 
This approach appears promising, however, based on the results on Ara h 2, the most relevant 
peanut allergen in this study population, merely destroying the protein structure may not be 
enough in order to create a safe immunotherapeutic molecule in this study population. 
Comparable to the results published by Bernard and co-workers, a strong remaining IgE binding 
to r/a nAra h 2 in peanut extract was observed (Bernard et al. 2015). A remarkable number of 
peanut-allergic children (70%) still showed an IgE binding to r/a nAra h 2, albeit partly to a 
lesser extent than to native nAra h 2. However, even for 50% (12/23) of the peanut-allergic 
children a significant IgE binding could be detected highlighting the presence of major linear 
IgE-binding epitopes on r/a nAra h 2. In addition, multi-peptide microarray data of Ara h 2 
showed a strong IgE-binding capacity of peptides containing the linear DPYSPS motif, which 
was strongly increased when the second proline was hydroxylated. The hydroxylated motif is 
found in natural Ara h 2. The importance of proline hydroxylation for the induction of mast cell 
degranulation was further demonstrated by the fact that the 27-mer peptide without POH was 
binding serum IgE but, compared to the 27-mer with POH, could not induce a specific mediator 
release (see Figure 19A and 19B). In addition, Figure 19B shows that the reduction and 
alkylation of peanut extract led to a 10-fold decrease in its allergenic potency. Even though this 
appears to be a strong decrease of allergenicity, a 10-fold increase in dose would already result 
in the same mediator release. Considering the amount of Ara h 1 in peanut extract, Ara h 1 
contributed only in part to the release of r/a peanut extract. In contrast, the 27-mer peptide 
with POH itself had a high allergenic potency, 10-fold higher than r/a peanut extract. 
Considering the amount of Ara h 2 and Ara h 1 in peanut total protein extract, and considering 
the molar ratio of the 27-mer peptide in Ara h 2 (~1:5), the peptide in r/a peanut extract likely 
had an allergenic potency that was even higher than that of Ara h 1. The r/a rAra h 2.02 
contained the biological inactive 27-mer peptide without POH and did not have any relevant 
allergenic potency suggesting the lack of a potent linear IgE epitope when prolines are not 
hydroxylated. Consequently, it appears that the 27-mer peptide with POH had a relevant 
contribution to the allergenicity of r/a peanut extract. In contrast, the contribution of Ara h 3 
seemed to be negligible according to the immunoblot results, where Ara h 3 was localized 
between the molecular masses of Ara h 1 and Ara h 2. 
The data published by Bernard et al. on the relevance and the allergenic potency of linear IgE 
epitopes of Ara h 2 containing hydroxylated proline residues could thus be confirmed with this 
peanut study population (Bernard et al. 2015). 
In conclusion, these data highlight that linear IgE-binding epitopes containing the DPYSPOHS 
motif must be considered in the development of novel therapeutic approaches for peanut allergy 
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as otherwise patients might be at high risk of unintended side effects. Reduction and alkylation 
of peanut extract or nAra h 2 (demonstrated by the 27-mer peptide POH) may not be a safe 
therapeutic approach as both possessed the ability to induce mast cell degranulation to a 
relevant extent. Drawn on the results of this PhD project, one possibility to avoid side effects 
during allergen-specific immunotherapy would be the use of r/a rAra h 2 lacking 
immunodominant conformational and linear IgE-epitopes that are relevant for mast cell 
degranulation. Thus, the allergenic potency and the T-cell immunogenicity of r/a rAra h 2 
should be investigated in further studies with more patients, prior to its development as an 
immunotherapeutic reagent. 
 
A first important aspect in the development of molecular therapeutic approaches is the 
identification of the relevant allergen(s). With the identification of Pis s 1 as the most relevant 
major pea allergen in this pea-allergic study population, this PhD project makes a decisive 
contribution to that. In addition, as this project was focusing on IgE binding to peptides in 
approximation to linear epitopes, immunodominant linear IgE-binding peptides of Pis s 1, which 
were predominantly located at the C-terminal part, were identified. These linear structures were 
recognized by IgE of the majority of pea-allergic children. Peptides 28, 55, 71, 84, 91, 94-96 
and 101 bound serum IgE of more than 60% of pea-allergic children and could be inhibited in 
their serum IgE binding by rPis s 1 verifying their specificity. Of the peptides mentioned, the 
highest median Z-score values (of allergic-patients showing a positive peptide IgE binding) 
ranging from Z-score 9 to 15 could be observed for peptides 84, 95-96 and 101. Once 
immunodominant IgE-binding peptides are identified, critical amino acids dominating the IgE 
binding have to be determined, e.g. via alanine-walk on the microarray or bioinformatic tools 
assigning peptide reactivity to the molecular protein surface (Dall'Antonia et al. 2014; Negi and 
Braun 2009; Stanley et al. 1997; Subbarayal et al. 2013). Finally, the knowledge of functional 
amino acids dominating the IgE binding can in turn be used for the design of hypoallergenic 
substitution variants of Pis s 1, as was shown for example by Ferreira and co-workers on Bet v 1 
(Ferreira et al. 1998). 
 
5.3 Relevance and diagnostic value of individual legume allergen components 
Measuring the sIgE to individual allergen components is, besides measuring the extract-specific 
IgE, currently the status quo in common allergy diagnosis (Renz et al. 2018). Up to now, several 
studies demonstrated the diagnostic benefit of component testing over extract testing leading 
to an increase of component-resolved diagnostics (CRD) in routine allergy care (Canonica et al. 
2013). As standard in vitro method, the allergen component-specific IgE in the blood is 
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measured by means of ImmunoCAPTM analysis. This requires prior knowledge of the relevant 
allergens. However, controversial or incomplete data exist, at least in part, about the relevance 
of 2S and 7S storage proteins from peanut, pea and soybean. 
Therefore, the relevance and the diagnostic value of the investigated legume allergens should 
be determined in each legume study population. 
Several peanut allergens and isoforms were identified and characterized in numerous studies. 
Previous studies demonstrated that sIgE to Ara h 2 showed, compared to peanut extract and 
other peanut allergens, the best accuracy in the prediction of peanut allergy in children and 
infants (Beyer et al. 2015; Dang et al. 2012; Keet et al. 2013; Klemans et al. 2013b; Nicolaou 
et al. 2011; van Erp et al. 2017). If described, AUCs ranging from 0.90 to 0.99 could be 
determined in the aforementioned studies using ROC curve analysis. However, sensitivity and 
specificity varied within these studies. At a cut-off of 0.35 kUA/L Ara h 2 sIgE, sensitivity varied 
from 81% to 100% and specificity from 71% to 96% (Beyer et al. 2015; Dang et al. 2012; Keet 
et al. 2013; Klemans et al. 2013b; Nicolaou et al. 2011).  
All mentioned studies were based on the measurement of the sIgE by means of the ImmunCAPTM 
or ImmunoCAPTMISAC method, which uses the Ara h 2 isoform Ara h 2.01 expressed in E. coli 
(personal communication Dr. Jonas Lidholm, Thermo Fisher Scientific, and 
http://www.phadia.com/en/Products/Allergy-testing-products/ImmunoCAP-Allergen-
Information/Food-of-Plant-Origin/Allergen-Components/rAra-h-1-recombinant-Peanut/). 
Only one study by Codreanu and co-workers used rAra h 2.02 coupled to the ImmunoCAPTM 
and reported in their French study population, that originated from two clinical centers, at a 
cut-off of 0.23 kUA/L a specificity and a sensitivity of 96% and 93%, respectively (Codreanu et 
al. 2011).  
However, no study has so far investigated the diagnostic value of both Ara h 2 isoforms within 
one pediatric study population originating from one clinical center. 
Due to low serum availability, sIgE levels to the recombinant peanut allergens Ara h 1, 
Ara h 2.01 and Ara 2.02 could not be determined using ImmunoCAPTM but were 
densitometrically quantified by immunoblot analysis. Despite the limitations associated with a 
densitometric quantification by means of immunoblot analysis, such as e.g. lower dynamic 
range and sensitivity, a good correlation could be observed between rAra h 2.01 and rAra h 2.02 
sIgE levels, determined by densitometry, and rAra h 2.01 sIgE levels, determined by 
ImmunoCAPTM analysis, in the range of 0.35 to 40 kUA/L. 
Based on the calculated LOD values for IgE binding to recombinant proteins in immunoblot 
analysis, this study showed that rAra h 2.02 was more frequently bound by serum IgE from 
peanut-allergic children in comparison to rAra h 2.01 and rAra h 1. This finding is in line with 
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other published studies showing a higher IgE-binding capacity of Ara h 2.02 in comparison to 
Ara h 2.01 (Bernard et al. 2015; Hales et al. 2004). This trend was further confirmed using 
ROC curve analysis that showed a higher diagnostic value of sIgE to rAra h 2.02 (AUC 0.86) in 
comparison to sIgE to rAra h 2.01 (AUC 0.75) and rAra h 1 (AUC 0.51) determined by 
densitometric immunoblot analysis. In addition, sIgE to peanut extract, determined using 
ImmunoCAPTM, showed an AUC of 0.79. The observed rank order regarding the diagnostic value 
(Ara h 2.02 > peanut extract > Ara h 1) is also in agreement with other studies analyzing the 
diagnostic value of sIgE to peanut extract, rAra h 2.01 and rAra h 1 (Ebisawa et al. 2012; Eller 
and Bindslev-Jensen 2013; Klemans et al. 2013b). This shows that, although a different method 
was used for the determination of the sIgE levels and another strategy was used for ROC curve 
analysis of densitometrically quantified sIgE levels, tendencies similar to published studies using 
ImmunoCAPTM analysis were achieved in this study. 
sIgE to rAra h 2.01 quantified by ImmunoCAPTM analysis showed an AUC of 1.00 and reached 
at a cut-off of 0.35 kUA/L a sensitivity of 96% and a specificity of 92% in this peanut study 
population reflecting a perfect discriminative ability. In addition, this result showed that a 
representative cohort was included in this PhD project, as comparable results with other study 
populations were obtained (Beyer et al. 2015; Nicolaou et al. 2011). 22/23 (96%) peanut-
allergic children showed a sIgE level to rAra h 2.01 of > 0.35 kUA/L, whereas only 15/23 (65%) 
and 18/23 (78%) peanut-allergic children showed a positive serum IgE binding (> LOD) in 
immunoblot analysis to rAra h 2.01 and rAra h 2.02, respectively. However, as already 
mentioned, it has to be taken into account that the ImmunoCAPTM method is much more 
sensitive than the applied immunoblot analysis. In addition, analyzing both Ara h 2 isoforms in 
a comparable manner by means of immunoblot analysis, it could be clearly shown that 
Ara h 2.02 is the isoform with the higher IgE-binding capacity. This finding leads to the 
suggestion that the use of rAra h 2.02 instead of rAra h 2.01 in ImmunoCAPTM analysis might 
lead to an even higher measurement sensitivity. 
Furthermore, using mediator release assay this study demonstrated that rAra h 2.02 is a major 
potent peanut allergen that elicits a mast cell degranulation almost identical to that of peanut 
extract. In addition, rAra h 2.02 showed an approximately 100-fold higher allergenic potency 
in comparison to rAra h 1, which is in line with studies by Blanc et al. and Palmer et al. both 
using for their in vitro mediator release assays purified allergens from whole peanut extract 
(Blanc et al. 2009; Palmer et al. 2005). 
In conclusion, this study on recombinant peanut allergens showed that rAra h 2.02 is, compared 
to the two other self-generated proteins rAra h 2.01 and rAra h 1, the most relevant peanut 
allergen with regard to IgE-binding and mediator release capacity. Of these three recombinant 
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peanut proteins, rAra h 2.02 showed the highest diagnostic value in densitometric immunoblot 
analysis. These properties make it a target molecule for therapeutic and diagnostic approaches. 
 
Although pea has been recognized as an emerging allergenic food (personal communication 
Prof. Dr. K. Beyer) that has already been described as the elicitor of severe allergic reactions 
(Lavine and Ben-Shoshan 2019; Wensing et al. 2003), detailed data on the relevance and the 
diagnostic value of pea allergens are still lacking. Three pea proteins (Pis s 1, Pis s 2 and Pis s 3) 
were registered as allergens in the WHO/IUIS database of allergens, two of which (Pis s 1 and 
Pis s 2) are described as potential major pea allergens (Sanchez-Monge et al. 2004). So far, no 
pea albumin is registered in the WHO/IUIS database as allergen. Only two studies by Vioque 
and co-workers focused on IgE binding to the 2S pea albumins PA1 and PA2. The authors 
reported a positive and negative serum IgE binding of ten chickpea-sensitive patients to PA2 
and PA1, respectively. However, the relevance of these two studies is questionable since no 
conclusive results were available and individual data on IgE binding were mostly undisclosed 
(Vioque et al. 1998; Vioque et al. 1999). 
The comparison of the serum IgE binding to rPis s 1, rPA1 and rPA2 by means of immunoblot 
analysis showed that rPis s 1 was, compared to both recombinant pea albumins, the most 
relevant pea allergen in this pea study population. The great majority (79%) of pea-allergic 
children showed serum IgE binding to rPis s 1, unequivocally confirming it for the first time as 
a major allergen based on individual patient sera testing. In contrast, no serum IgE binding 
could be detected to rPA1 and rPA2, except for rPA1 and one pea-allergic patient (patient no. 1). 
An altered serum IgE binding to rPA1 due to the expression as a proprotein containing two 
propeptides could be excluded, as natural PA1 was also found as proprotein version in whole 
pea extract and no IgE binding was detected in this low molecular weight region in immunoblot 
analysis. 
The relevance of rPis s 1 was further demonstrated by the majority of serum IgE binding to pea 
extract being inhibited by rPis s 1. In addition, the inhibition experiment illustrated no 
additional major pea allergens in this pea study population. This result is in accordance with 
the study published by Sanchez-Monge and co-workers, who observed the strongest IgE binding 
of a serum pool composed of eighteen pea-allergic patients to Pis s 1 in pea extract. Also in line 
with the mentioned study, no relevant serum IgE binding of pea-allergic patients to low 
molecular weight proteins like 2S albumins or lipid-transfer proteins could be detected 
(Sanchez-Monge et al. 2004). This finding is in contrast to the presented data on peanut where 
the strongest serum IgE binding could be detected to the 2S albumin Ara h 2. 
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For the first time the allergenic potency of rPis s 1 was investigated and described. Using in 
vitro mediator release assay it could be shown that rPis s 1 was capable of eliciting mast cell 
degranulation. In addition, the shown data suggest that the majority of the biological activity 
of pea extract is caused by Pis s 1 making it a target molecule for therapeutic approaches. In 
addition, EC50 of rPis s 1 (0.11 ng/well) and pea extract (2.3 ng/well) differed around the factor 
20 showing that Pis s 1 may account for approximately 5% of total pea protein, assuming that 
the great part of allergenic potency of pea total protein extract was related to Pis s 1. This 
estimated content is in agreement with other studies reporting that Pis s 1 comprises between 
1% and 8% of the total protein in pea (Kroghsbo et al. 2011; Tzitzikas et al. 2006). 
Currently, in vitro diagnosis of pea allergy is solely based on the ImmunoCAPTM analysis of 
specific IgE to pea total protein extract. However, using ROC curve analysis, this study showed 
that rPis s 1 (AUC 0.86) had a higher AUC and thus a better diagnostic value than pea total 
protein extract (AUC 0.81). As a consequence, the diagnostic performance of rPis s 1 should be 
further investigated using the ImmunoCAPTM method as it may lead to an even higher diagnostic 
sensitivity.  
In conclusion, the presented data showed that Pis s 1 is the most relevant major allergen with 
a high diagnostic value in this pea study population. This 7S globulin can elicit mast cell 
degranulation and accounts for the majority of the allergenic potency of pea extract. In addition, 
it was shown that pea 2S albumins and other low molecular weight pea proteins appeared to 
be of no or only minor relevance in this pea study population. 
 
Data on the relevance and the diagnostic value of soybean allergens are controversial. 
Depending on the respective study population and the study design, some authors reported an 
association of sIgE to Gly m 5 and/or Gly m 6 with the severity of allergic reactions and that 
sIgE to Gly m 5 and/or Gly m 6 might be a better predictor for soybean allergy compared to 
soybean extract (Holzhauser et al. 2009; Ito et al. 2011). Whereas other studies reported no 
predominant sensitization to Gly m 5 and Gly m 6 or reported that sIgE to Gly m 8 showed, 
compared to Gly m 5 and Gly m 6, the best diagnostic accuracy (Ebisawa et al. 2013; Fukutomi 
et al. 2012; Kattan and Sampson 2015; Vissers et al. 2011). 
However, with regard to the results gained from this soybean study, the limited number of 
available and included soybean-allergic patients needs to be mentioned. The small sample size 
of allergic children hampered drawing general conclusions about the relevance and diagnostic 
value of Gly m 5.03 and Gly m 8. Nevertheless, tendencies were observed. 
In this study, soybean-allergic and sensitized but tolerant children showed specific IgE binding 
to rGly m 5.03 (50% vs. 20%). A similar trend was reported by a study by Ito and co-workers 
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investigating sera from Japanese children. The study used comparable patient inclusion criteria 
and reported that 67% of soybean-allergic and 49% of sensitized but tolerant children showed 
an IgE reactivity to natural Gly m 5 (Ito et al. 2011). In addition, a study by Klemans et al. 
reported that 63% of soybean-allergic adults and 27% of soybean-tolerant adults showed a 
sensitization (≥ 0.35 kUA/L) to Gly m 5. However, tolerant adults were included in the Klemans 
study solely based on a negative food challenge, regardless of a positive sensitization to soybean 
extract (Klemans et al. 2013a). This was in contrast to this PhD study, which included tolerant 
patients based on a positive sensitization (≥ 0.35 kUA/L) to soybean extract. 
No serum IgE binding to rGly m 8 could be observed in this soybean study population. This 
finding is in line with a study by Lin and co-workers, who reported that none of the 16 
investigated sera from European soybean-allergic patients showed an IgE binding to 
recombinant and natural Gly m 8 purified from soybean extract (Lin et al. 2006). However, 
other studies reported a predominant role of sIgE to Gly m 8 in the prediction of soybean allergy. 
Using sera from either soybean-allergic children from Japan, the US or from soybean-allergic 
adults from Europe, the authors reported a sensitization to natural Gly m 8 with an AUC 
between 0.75 and 0.82 as the best diagnostic marker for clinically relevant soybean allergy 
(Ebisawa et al. 2013; Kattan and Sampson 2015; Klemans et al. 2013a). This could not be 
confirmed in this study population. To exclude that rGly m 8 expressed as proprotein showed a 
different IgE reactivity compared to the natural Gly m 8 purified from soybean extract, a native 
PAGE of soybean total protein extract was performed. The MS data suggested the presence of 
nGly m 8 as full-length protein without propeptide. However, it remains difficult to interpret 
why, under reducing conditions, full-length natural Gly m 8 could also be identified, because 
both Gly m 8 chains that are linked by disulfide bonds should be separated under reducing 
conditions (Ebisawa et al. 2013; Lin et al. 2004). Nonetheless, when using native PAGE of 
soybean total protein extract and subsequent IgE immunoblot analysis, no serum IgE binding 
could be detected to nGly m 8 in soybean-allergic patients. In addition, using SDS-PAGE under 
reducing conditions and IgE immunoblot analysis, the highest IgE reactivities could be 
attributed to 7S and 11S globulins. This is in accordance with a study by Ballmer-Weber and 
co-workers who showed strong serum IgE binding to 7S and 11S globulins (Ballmer-Weber et 
al. 2007). 
The discrepancy in the relevance of Gly m 8 between this study, which was in line with the 
study by Lin et al., and the above-mentioned studies may be due to different study populations 
investigated or different Gly m 8 preparations. Interestingly, all studies reporting a high 
diagnostic value of Gly m 8 were probably based on the same non-commercial Gly m 8 
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ImmunoCAPTM material (Ebisawa et al. 2013; Kattan and Sampson 2015; Klemans et al. 
2013a). 
 
In conclusion, the data discussed in this chapter show that legumes, despite their taxonomic 
relation, behave very differently with regard to the relevance of their respective allergens. In 
each investigated legume allergy, a specific relevance of the analyzed 2S and 7S storage proteins 
could be observed. In peanut, Ara h 1 and Ara h 2 could be identified as relevant allergens.  
However, based on immunoblot analysis, the 2S albumin Ara h 2, in particular the isoform 
Ara h 2.02, was the most relevant allergen with the highest diagnostic value in this peanut study 
population. In contrast, such relevance of 2S albumins could not be detected in pea and 
soybean, which excludes 2S albumins as major allergens in both investigated study populations. 
In pea, the 7S globulin Pis s 1 was identified as the most relevant allergen in this study. A similar 
trend seemed to be observed for Gly m 5.03 and soybean, but due to the limited number of 
soybean-allergic patients included in this study, no further conclusions can be drawn. 
 
5.4 Diagnostic potential of IgE-binding peptides of major legume allergens 
Despite the advantages of a component-resolved diagnosis, studies on allergic and tolerant 
patients have also shown that there is often an overlap in the component sIgE level between 
both groups (Lin et al. 2012). Overlaps in the component sIgE levels can lead to 
misclassifications and demonstrate that there are still patients that need to undergo oral food 
challenge to determine their clinical phenotype. 
Compared to extract- and component-resolved diagnosis, several studies suggested an 
additional diagnostic value of IgE-binding epitopes. Using Ara h 1-, Ara h 2- and Ara h 3-derived 
peptides, Beyer et al. and Shreffler et al. reported a correlation between serum IgE binding to 
specific peptides and clinical reactivity as well as between IgE epitope diversity and clinical 
severity (Beyer et al. 2003; Shreffler et al. 2004). In addition, another more recent study from 
Lin and co-workers, who analyzed the same peanut allergens, identified peptide biomarkers 
predicting peanut allergy with high accuracy by means of a machine learning method (Lin et 
al. 2012). 
In addition to the potential to improve allergy diagnosis, peptide-based microarrays have 
further advantages such as, for example, low serum consumption and the potential to 
investigate multiple peptides of different allergens simultaneously. Furthermore, the synthesis 
of peptides and their quality control is straightforward in comparison to the generation of full-
length proteins or the consistency control of protein extracts. 
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To assess whether peptides have the potential to improve allergy diagnosis, peptides 
representing all examined legume proteins were synthesized and analyzed for their serum IgE 
binding. By comparing IgE binding of sera from legume-allergic with sera from legume-
sensitized but tolerant children, candidate diagnostic peptides were identified and investigated 
for their potential to improve the accuracy of the in vitro allergy diagnosis. 
Initially, the quality of the in-house synthesized peptides was verified. This was done by 
comparing in-house synthesized overlapping peptides comprising Ara h 2 for their IgE binding 
with the same peptides purchased from Intavis AG (peptide specialist). Using a PEI-internal 
control serum, identical IgE-binding peptides confirmed the quality of the in-house synthesized 
peptides (data not shown) and justified their use in microarray analyses. 
 
Multiple immunodominant IgE epitopes have been described for Ara h 1 and Ara h 2 (Burks et 
al. 1997; Han et al. 2016; Shreffler et al. 2004; Stanley et al. 1997). 
However, this PhD study is the first study so far that investigated the diagnostic value of 
synthetic peptides of Ara h 1 and Ara h 2 in direct comparison to the respective full-length 
proteins. In addition, this study examined the contribution of proline hydroxylation (Hyp) in 
the DPYSPOHS motif of Ara h 2, as present in natural Ara h 2, on the diagnostic accuracy.  
For simplification, the full-length sequences of Ara h 2, which contain proline or hydroxyproline 
residues in the DPYSPS motif, are abbreviated as “Ara h 2_P” or “Ara h 2_Hyp” in the following, 
respectively. 
In line with the data of the recombinant allergens, a high diagnostic potential of Ara h 2 was 
also found at the peptide level. Compared to Ara h 1, only peanut-allergic children showed a 
serum IgE binding to Ara h 2-derived peptides, whereas Ara h 1-derived peptides were also 
recognized by peanut-tolerant patients. Furthermore, Ara h 1-derived peptides reached a 
maximum IgE-binding frequency of 43%, whereas Ara h 2_Hyp-derived peptides reached a 
maximum IgE-binding frequency of 70%. The finding that no Ara h 1-derived peptide was 
bound by serum IgE of more than 43% of peanut-allergic patients is in contrast to the initial 
study by Burks and co-workers, who reported serum IgE binding to individual peptides of more 
than 80% (Burks et al. 1997). However, for the identification of the immunodominant IgE-
binding epitopes of Ara h 1, Burks and co-workers analyzed only ten patients individually. In 
addition, a further reason for the discrepancy between the study from Burks et al. and this study 
could be the difference in the study population with regard to patients’ age. The mean age in 
the Burks study was 25 years, whereas the mean age of peanut-allergic patients in this study 
was 4 years. In addition, Lin et al. reported IgE-binding frequencies of up to ~70% to individual 
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Ara h 1-derived peptides using sera of peanut-allergic children; however, they used a different 
more sensitive detection system (Lin et al. 2012).  
On the other hand, the finding of this PhD study is in agreement with Shreffler et al., who 
reported a serum IgE binding to individual peptides of Ara h 1 in less than 30% of the analyzed 
patients (age: 1.5-36 years). However, compared to this PhD study, in which peanut allergy 
was confirmed by food challenge in all patients, Shreffler et al. included patients with confirmed 
peanut allergy as well as patients with suspected peanut allergy. Suspicion of allergy was based 
exclusively on elevated peanut sIgE levels, but the history of peanut ingestion was unknown 
(Shreffler et al. 2004). In addition, a study by Beyer et al. also reported a lower IgE-binding 
frequency of peanut-allergic patients to immunodominant linear epitopes of Ara h 1 compared 
to epitopes of Ara h 2 and Ara h 3 (Beyer et al. 2003). 
In this PhD study, three peptides of Ara h 1, peptide 17, 75 and 86, fulfilled the criteria for 
candidate diagnostic peptides, which were defined prior to analysis. A comparison of the three 
candidate diagnostic peptides with previously identified IgE-binding epitopes and 
immunodominant IgE epitopes showed that peptide 17 overlapped with the immunodominant 
epitope 4 and the IgE-binding epitope 5 identified by Burks et al. In addition, an overlap could 
also be detected between peptide 75 and IgE-binding epitope 12 of the same study (Burks et al. 
1997). Due to peptides of different length and offset that were investigated by Burks and co-
workers (10 AA, offset 8 AA) and in this PhD project (15 AA, offset 4 AA), IgE-binding epitopes 
described by Burks et al. overlap only partially with the identified candidate diagnostic peptides 
of this study. In addition, Beyer et al. analyzed sera from peanut-allergic and sensitized but 
tolerant patients for their IgE binding to immunodominant epitopes of Ara h 1, Ara h 2 and 
Ara h 3. The authors identified i.a. epitope 4 of Ara h 1, which overlapped with peptide 17 of 
this study, as useful for the prediction of clinically relevant peanut allergy (Beyer et al. 2003).  
Peptide 86 was not identified as an important IgE-binding epitope in the initial study by Burks 
and co-workers, which was based on pooled sera (Burks et al. 1997). Only individual sera 
testing, as performed by Shreffler and co-workers, identified this sequence of Ara h 1 as 
important for serum IgE binding (Shreffler et al. 2004). However, it should be noted that both 
studies by Burks and Shreffler were done with the primary focus on identifying 
immunodominant IgE epitopes rather than on identifying candidate diagnostic peptides. Both 
studies focused on IgE epitopes that were recognized by the majority of peanut-allergic patients 
and did not include peanut-sensitized but tolerant patients for comparison. Furthermore, in 
contrast to this study, both studies did not perform inhibition experiments. However, since this 
was the case in this study, some of the published immunodominant IgE epitopes were not 
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identified as candidate diagnostic peptides because they did not fulfill the selection criteria 
established in this study. 
In addition, using BLAST it could be identified that peptide 75 and 86 of Ara h 1 are part of 
conserved regions between Ara h 1 and Pis s 1 that may lead to IgE cross-reactivity. However, 
due to largely unknown co-sensitizations or co-allergies in this study population, further studies 
are necessary, to draw conclusions about possible IgE-binding regions which may result in 
serological and/or clinical cross-reactivity.  
In contrast, no significant overlap was identified between these candidate peptides of Ara h 1 
and Gly m 5.03.  
To compare the diagnostic value of the three identified candidate diagnostic peptides of Ara h 1 
with that of the full-length peanut allergens and of peanut extract, an ROC curve analysis was 
performed. This approach was similar to the study by Lin and co-workers, who also compared 
the diagnostic value of different analysis methods, such as multipeptide microarray and 
ImmunoCAPTM, in one ROC curve analysis (Lin et al. 2012). 
Even though different methods, like ImmunoCAPTM, immunoblot and multipeptide microarray, 
were performed in this study, the ROC curve analysis clearly showed that the peptides of Ara h 1 
as well as full-length rAra h 1 did not contribute to an improvement of the in vitro diagnosis of 
peanut allergy.  
In line with the immunoblot analysis, serum IgE of peanut-sensitized but tolerant patients did 
not bind to any peptide of Ara h 2.01_P and Ara h 2.02_P. Even peptides of both Ara h 2 
sequences containing hydroxyproline residues in the DPYSPOHS motif, Ara h 2.01_Hyp and 
Ara h 2.02_Hyp, did not bind serum IgE of tolerant patients. In contrast, the great majority of 
peanut-allergic patients showed serum IgE binding to peptides of Ara h 2. Moreover, in peanut-
allergic patients, peptide 2 and peptides containing the DPYSPS motif could be identified as 
immunodominant IgE-binding epitopes in this study. This finding is in line with previous studies 
on Ara h 2-derived peptides (Han et al. 2016; Hansen et al. 2016; Stanley et al. 1997). Both, 
the initial study by Stanley and co-workers and the more recent study by Han and co-workers 
identified three peptides of Ara h 2.01 containing the immunodominant IgE epitopes. One of 
these three peptides overlapped with the immunodominant peptide 2 identified in this PhD 
study and the two others contained, in accordance with this study, the DPYSPS motif (Han et 
al. 2016; Stanley et al. 1997). In addition, Hansen et al. identified the same important IgE-
binding peptides of the second isoform Ara h 2.02 (Hansen et al. 2016). However, all three 
previous studies reported also a strong IgE binding to peptides comprising the C-terminal part 
of Ara h 2.01 and Ara h 2.02. This is in contrast to this study where only 4-13% of peanut-
allergic children showed an IgE binding to peptides comprising the C-terminal part of Ara h 2. 
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Reasons for this discrepancy may be that the initial study by Stanley et al. was predominantly 
based on pooled sera of adult patients and not on individual testing of serum samples of 
children (Stanley et al. 1997). Furthermore, Han et al. and Hansen et al. predominantly 
included patients with high peanut sIgE levels and adult patients, respectively (Han et al. 2016; 
Hansen et al. 2016). However, the influence of proline hydroxylation on the diagnostic value 
of Ara h 2-derived peptides has never been investigated on the peptide level using microarray 
analysis, although some studies reported a higher IgE-binding capacity and immunogenicity of 
linear IgE-epitopes of Ara h 2 due to hydroxylation (Bernard et al. 2015; Deak et al. 2017). In 
line with these studies, an increase in IgE-binding capacity could be observed in peptides 
containing hydroxylated compared to unhydroxylated proline residues. Proline hydroxylation 
led to an increase in the number of IgE-bound peptides, to higher signal intensities of IgE-bound 
peptides and to higher IgE-binding frequencies of peanut-allergic children. In addition, it could 
be shown that proline hydroxylation resulted in a higher sensitivity while maintaining the 
specificity, which makes this post-translational modification an interesting target for future 
diagnostic approaches. An increase in IgE-reactivity due to post-translational proline 
hydroxylation was also reported for Phl p 1, a major timothy grass pollen allergen (Petersen et 
al. 1998). 
The stronger IgE-binding capacity of peptides containing hydroxyproline instead of proline is 
not surprising, as the hydroxyl (OH) group constitutes a polar functional group enabling the 
formation of an additional hydrogen bond with other functional groups. Hydrogen bonds are 
described by Steiner as important intermolecular interactions (Steiner 2002), which potentially 
explain why peptides containing hydroxyproline residues may favor serum IgE binding.  
Among the legumes, especially peanut is associated with severe allergic reactions (Worm et al. 
2014). As Ara h 2 is the only legume allergen containing hydroxylated proline residues one 
might speculate that the post-translational hydroxylation might be one reason for the high 
allergenicity of Ara h 2 and consequently of peanut. 
Four peptide pairs of the analyzed Ara 2.01 and Ara h 2.02 sequences could be identified 
meeting the predefined selection criteria for candidate diagnostic peptides. Candidate peptides 
were part of the immunodominant IgE-binding epitopes and overlapped with previously 
identified immunodominant IgE-binding peptides (Han et al. 2016; Hansen et al. 2016; Stanley 
et al. 1997). ROC curve analysis showed that the two selected peptide pairs of Ara h 2.01_Hyp 
(peptide 2 and peptide 11) and of Ara h 2.02_Hyp (peptide 11 and peptide 15) had, with an 
AUC of 0.87-0.90, the best diagnostic accuracy of all identified candidate diagnostic peptides 
in this study population. Moreover, the two selected peptide pairs showed a comparable AUC 
with other studies that analyzed sIgE to rAra h 2.01 by means of ImmunoCAPTM (Beyer et al. 
 150  Discussion 
2015; Klemans et al. 2013b). Due to the consideration of hydroxyproline residues in this study, 
a sensitivity of 70% at a specificity of 100% could be achieved with each of these two candidate 
diagnostic peptide pairs of Ara h 2.01_Hyp or Ara h 2.02_Hyp. In contrast, other studies, that 
analyzed sIgE to rAra h 2.01, reported lower sensitivities (23%-43%) at a specificity of 100% 
(Dang et al. 2012; Keet et al. 2013; Klemans et al. 2013b). 
Interestingly, Lin and co-workers used microarray data combined with bioinformatic methods 
and selected two peptides of Ara h 2.01 as key peptide biomarkers that showed an overlap with 
peptide 2 and peptide 11 identified in this study (Lin et al. 2012). Nevertheless, the authors did 
not consider proline hydroxylation in their study. 
In conclusion, candidate diagnostic peptides could be identified of Ara h 1 and Ara h 2. Despite 
the fact that different methods were compared for their diagnostic accuracy in ROC curve 
analysis in this study, it was clearly shown that Ara h 1-derived peptides as well as full-length 
rAra h 1 showed, compared to rAra h 2 (rAra h 2.01 and rAra h 2.02) and derived peptides, the 
lowest diagnostic accuracy in this peanut study population. The two peptide pairs of 
Ara h 2.01_Hyp and Ara h 2.02_Hyp, investigated in microarray analysis, were comparably 
sensitive as the full-length rAra h 2.02, investigated in immunoblot analysis, and had a 
comparable diagnostic value. Furthermore, it was shown that proline hydroxylation had a 
positive impact on the diagnostic sensitivity and accuracy. With regard to proline hydroxylation, 
it should be emphasized that peptides have the advantage over recombinant proteins that such 
post-translational modifications can be considered. This advantage highlights their potential in 
the future diagnosis of peanut allergy.  
As the microarray is less sensitive than the ImmunoCAPTM, it would be interesting to couple the 
identified candidate diagnostic peptides to the ImmunoCAPTM and investigate their diagnostic 
sensitivity and specificity. In this study population, however, such advanced investigation was 
not feasible due to low serum availability. 
 
To date, no study so far focused on the diagnostic value of single pea proteins and derived 
peptides. Pis s 1 could be identified in this pea study population as the most relevant major pea 
allergen having a diagnostic value better than pea extract. In the next step, peptides derived 
from Pis s 1 were investigated for their potential to further improve the in vitro diagnosis of pea 
allergy. Comparable to Ara h 1-derived peptides, pea-allergic as well as pea-sensitized but 
tolerant children showed a serum IgE binging to peptides of Pis s 1. 
Pis s 1 peptides 28, 30, 55, 71, 84, 91, 94-96 and 101 bound IgE by the great majority of pea-
allergic children (> 60%) and, thus, were identified as immunodominant IgE-binding peptides. 
Of these, the C-terminal peptides 84, 95, 96 and 101 showed the highest signal intensities. A 
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comparison using BLAST of these immunodominant IgE-binding peptides of Pis s 1 with the 
four immunodominant IgE-binding peptides of Ara h 1 described by Burks and co-workers 
revealed no overlap between these peptides. However, by using a serum pool composed of 15 
peanut-allergic patients, Burks et al. identified additional IgE-binding epitopes of Ara h 1, which 
show a partial sequence overlap with the major IgE-binding peptides at the C-terminal end of 
Pis s 1. C-terminal peptides 91 and 94-96 share conserved amino acid residues with the 
previously identified epitopes 19-21 of Ara h 1 (Burks et al. 1997). In addition, 
immunodominant peptide 84 of Pis s 1 is part of a conserved region between Pis s 1 and Ara h 1. 
However, this region is not described in previous studies as an IgE-binding epitope of Ara h 1. 
Furthermore, Sun et al. predicted and characterized eleven major immunodominant linear IgE 
epitopes of Gly m 5.01 (77% sequence identity to Gly m 5.03) using five sera from soybean-
allergic adults (Sun et al. 2013). Using BLAST, it could be observed that the immunodominant 
peptide 30 of Pis s 1 and peptide 9 of Gly m 5.01 belong to conserved regions. Furthermore, it 
could be determined that peptide 55 of Pis s 1 and peptides 11 and 12 of Gly m 5.01 also share 
a conserved region. In addition, immunodominant peptides 84, 91 and 94-96 of Pis s 1 are part 
of conserved regions between Pis s 1 and Gly m 5.01. In Gly m 5.01 a partial sequence of these 
regions is described by Sun et al. as being bound by serum IgE of 2/5 soybean-allergic patients 
(Sun et al. 2013). 
If further verified, homologous IgE-binding epitopes on different allergens might explain 
serological or clinical cross-reactivity between the legumes, whereas divergent IgE-binding 
epitopes might explain divergent allergic phenotypes. 
The selection of candidate diagnostic peptides specific for pea allergy resulted in eleven peptides 
distributed over the entire sequence of Pis s 1. In contrast to full-length rPis s 1, which was 
recognized by 79% of pea-allergic children, 93% showed a serum IgE binding to at least one of 
the eleven candidate diagnostic peptides. In addition to sensitivity, specificity could also be 
increased from 80% to 100% using candidate diagnostic peptides. 
Candidate diagnostic peptides of Pis s 1 share no significant sequence identity with IgE epitopes 
of Ara h 1 described by Burks et al. and Shreffler et al. (Burks et al. 1997; Shreffler et al. 2004). 
Nevertheless, candidate diagnostic peptides 64, 93 and 100 are part of conserved regions 
between Pis s 1 and Ara h 1. However, these regions were not described in previous studies as 
IgE-binding epitopes of Ara h 1. In addition, no overlap could be detected between the eleven 
candidate diagnostic peptides of Pis s 1 and the three candidate diagnostic peptides of Ara h 1. 
A comparison using BLAST of the sequence of the candidate diagnostic peptides of Pis s 1 with 
the described IgE-binding epitopes of Gly m 5.01 by Sun and co-workers, revealed that peptide 
3 and peptide 53 of Pis s 1 share conserved regions with peptide 1 and peptide 11 of Gly m 5.01, 
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respectively. Moreover, sequence homology could be observed between peptides 64, 74, 93 and 
100 of Pis s 1 and regions of Gly m 5.01, which were not described as IgE-binding regions by 
Sun et al. (Sun et al. 2013). 
The analysis using BLAST showed that conserved IgE-binding regions between the legumes 
exist that can influence an accurate diagnosis of legume allergy using full-length legume 
proteins and highlight the potential of the more refined epitope-resolved diagnosis compared 
to a component-resolved diagnosis. 
To what extent these conserved IgE-binding regions lead to serological cross-reactivities, which 
may result in additional allergies, remains an open question, because co-sensitizations or co-
allergies are largely unknown in this study population.  
The high diagnostic potential of peptides could be further shown by ROC curve analysis 
comparing pea extract, rPis s 1 and peptides for their diagnostic accuracy. The eleven candidate 
diagnostic peptides showed of all three test variables with an AUC of 0.99 the best accuracy in 
diagnosing pea allergy. The candidate peptides reached, at a specificity of 100%, an excellent 
sensitivity of 93%, highlighting that peptides of Pis s 1 may improve the diagnosis of pea allergy. 
In this study population, the eleven candidate diagnostic peptides could be further narrowed 
while keeping the sensitivity. To what extent the relatively large number of candidate peptides 
can be narrowed in other study populations, has to be investigated in future prospective studies. 
 
In conclusion, eleven peptides could be identified of the major pea allergen Pis s 1 that may, 
compared to pea extract and rPis s 1, improve the accuracy in the diagnosis of pea allergy. A 
limited number of these peptides (peptide 3 and 53) overlapped with described IgE-binding 
epitopes of Gly m 5.01. In addition, a total of four of the eleven peptides (peptides 64, 74, 93 
and 100) belong to conserved regions, which, however were not described as IgE-epitopes of 
Ara h 1 and Gly m 5.01. These findings highlight the potential and the advantage of an epitope-
resolved diagnosis compared to an extract or component-resolved diagnosis. 
 
5.5 Concluding remarks 
Legumes show, despite of their close taxonomic relation, significant differences with regard to 
the relevance of their 2S and 7S storage proteins. In peanut, the 2S albumin Ara h 2, especially 
the isoform Ara h 2.02, is the most relevant allergen showing the best diagnostic value of the 
investigated recombinant peanut allergens in immunoblot analysis. This finding is in contrast 
to pea and soybean, where 2S albumins could not be identified as relevant allergens. In pea, it 
could be shown that the 7S globulin Pis s 1 is the most relevant allergen. A similar tendency 
seems to be observed in soybean with the homologous allergen Gly m 5.03. However, the very 
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limited number of soybean-allergic patients included in this study does not allow to draw 
further conclusions.  
In contrast to soybean, candidate diagnostic peptides could be identified for peanut and pea 
allergy. Two identified peptide pairs of Ara h 2.01_Hyp and Ara h 2.02_Hyp with AUC (0.87-
0.90) showed a comparable diagnostic value as rAra h 2.02 (AUC 0.86) in immunoblot analysis. 
For pea allergy, eleven peptides (AUC 0.99) could be identified of Pis s 1 showing a diagnostic 
value better than that of pea extract (AUC 0.81) or rPis s 1 (AUC 0.86). 
Analyzing the serum IgE binding on the epitope level instead of on the whole protein level 
seems to be a promising diagnostic approach highlighting that peptides may serve as additional 
or alternative reagents in the in vitro diagnosis of legume allergy. However, further prospective 
studies should verify if these peptides can be applied as biomarkers in clinical routine. In 
addition, coupling of the identified peptides to the more sensitive ImmunoCAPTM solid phase 
would be an additional interesting add-on experiment to investigate a potential improvement 
of the sensitivity of the candidate peptides. 
Moreover, based on the gained data, more efficacious and safer therapeutic approaches can be 
deduced. Based on the mast cell degranulation that was triggered by the 27-mer peptide 
containing hydroxylated proline residues, it could be shown for peanut that linear IgE-binding 
epitopes must be considered in the development of safe therapeutic approaches, as otherwise 
patients might be at high risk of unintended side effects. In addition, identified 
immunodominant IgE-binding peptides of Pis s 1 may allow to generate hypoallergenic 
substitution variants in the near future. 
In summary, the data presented in this thesis, may form a basis towards the development of 
novel diagnostic and therapeutic reagents in food allergy. 
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7.1 Supporting material 
7.1.1 Plasmids 
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Figure A1: Vector map and multiple cloning site of pPICZαA. 
(A) Vector map of pPICZαA. (B) Multiple cloning site of pPICZαA. Both images were taken from the user manual 
(Thermo Fisher Scientific, catalog number V195-20, publication number MAN0000035). 
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Figure A2: Vector map and multiple cloning site of pET-11a. 
(A) Vector map of pET-11a. (B) Multiple cloning site of pET-11a. Both images were taken from the user manual 
(Novagen, pET-11a-d Vectors, TB042 12/98). 
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7.1.2 Sequences of investigated recombinant proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3: DNA fragment of rAra h 1 used for cloning into pPICZαA. 
The amino acid sequence of rAra h 1 is underlined. rAra h 1 contained two additional N-terminal amino acids (EF) 
due to cloning into EcoRI restriction site. Linker (VD) and His6-tag are written in italics. N496D is shown in red. 
E  K  R  E  A  E  A E  F  K  S  S P  Y  Q  K  K T  E  N
1 GAGAAAAGAGAGGCTGAAGCTGAATTCAAGTCCTCCCCATACCAGAAGAAAACTGAGAAC
P  C  A  Q  R  C  L  Q  S  C  Q  Q E  P  D  D L  K  Q  K
61 CCATGTGCTCAGAGATGTTTGCAGTCCTGTCAACAAGAACCAGACGACTTGAAGCAAAAG
A  C  E  S  R  C  T  K  L  E  Y  D  P  R  C  V  Y  D  P  R
121 GCTTGTGAGTCCAGATGTACTAAGTTGGAGTACGACCCAAGATGTGTTTACGACCCTAGA
G  H  T  G  T  T N  Q  R  S  P  P G  E  R  T  R  G  R  Q
181 GGTCACACTGGTACTACAAACCAGAGATCTCCACCAGGTGAGAGAACTAGAGGTAGACAA
P  G  D  Y  D  D D R  R Q  P  R  R E  E G  G R  W  G
241 CCAGGTGATTACGACGACGACAGAAGACAGCCTAGAAGAGAAGAGGGTGGTAGATGGGGT
P  A  G  P  R  E  R  E  R  E  E D  W  R  Q  P  R  E  D  W
301 CCAGCTGGTCCAAGAGAAAGAGAGAGAGAAGAGGATTGGAGACAGCCAAGAGAAGATTGG
R  R P  S  H  Q  Q P  R  K  I  R  P  E  G  R  E  G  E  Q
361 AGAAGACCATCTCACCAGCAACCTAGAAAGATCAGACCAGAGGGTAGAGAAGGTGAACAA
E  W  G  T  P  G  S  H  V  R  E  E T  S  R  N  N P  F  Y
421 GAATGGGGTACTCCAGGTTCTCACGTTAGAGAAGAGACTTCCAGAAACAACCCATTCTAC
F  P  S  R  R F  S  T  R  Y  G  N  Q  N  G  R  I  R  V  L
481 TTCCCATCTAGAAGATTCTCCACTAGATACGGTAACCAGAACGGTAGAATCAGAGTTTTG
Q  R  F  D  Q  R  S  R  Q  F  Q  N  L  Q  N  H  R  I  V  Q
541 CAGAGATTCGACCAAAGATCCAGACAGTTCCAGAACTTGCAGAACCACAGAATCGTTCAG
I  E  A  K  P  N  T  L  V  L  P  K  H  A  D  A  D  N  I  L
601 ATCGAGGCTAAGCCAAACACTTTGGTTTTGCCAAAGCACGCTGACGCTGACAACATCTTG
V  I  Q  Q G  Q  A  T  V  T  V  A  N  G  N  N R  K  S  F
661 GTTATTCAACAGGGTCAGGCTACTGTTACTGTTGCTAACGGTAACAACAGAAAGTCCTTC
N  L  D  E  G  H  A  L  R  I  P  S  G  F  I  S  Y  I  L  N
721 AACTTGGACGAGGGTCACGCTTTGAGAATTCCATCCGGTTTCATCTCTTACATCTTGAAC
R  H  D  N  Q  N  L  R  V  A  K  I  S  M  P  V  N  T  P  G
781 AGACACGACAACCAGAATTTGAGAGTTGCTAAGATCTCCATGCCAGTTAACACTCCAGGT
Q  F  E  D  F  F P  A  S  S R  D  Q  S  S Y  L  Q  G  F
841 CAGTTCGAGGATTTCTTCCCAGCTTCTTCCAGAGATCAGTCCTCCTACTTGCAAGGTTTC
S  R  N  T  L  E  A  A F  N  A  E  F  N  E  I  R  R V  L
901 TCCAGAAATACTTTGGAGGCTGCTTTCAACGCTGAGTTCAACGAGATCAGAAGAGTTTTG
L  E  E N  A  G  G E  Q  E  E R  G  Q  R  R W  S  T  R
961 TTGGAAGAGAACGCTGGTGGTGAGCAAGAAGAAAGAGGTCAAAGAAGATGGTCCACAAGA
S  S E  N  N E  G  V  I  V  K  V  S  K  E  H  V  E  E L
1021 TCCTCCGAAAACAACGAGGGTGTTATCGTTAAGGTTTCCAAAGAGCACGTTGAAGAGTTG
T  K  H  A  K  S  V  S  K  K G  S  E  E E G  D  I  T  N
1081 ACTAAGCACGCTAAGTCCGTTTCCAAGAAGGGTTCTGAAGAGGAAGGTGACATCACTAAC
P  I  N  L  R  E  G  E  P  D  L  S  N  N F  G  K  L  F  E
1141 CCAATCAACTTGAGAGAGGGTGAGCCAGACTTGTCCAACAACTTCGGTAAGTTGTTCGAG
V  K  P  D  K  K N  P  Q  L  Q  D  L  D  M  M L  T  C  V
1201 GTTAAGCCTGACAAGAAGAACCCACAGTTGCAGGACTTGGACATGATGTTGACTTGTGTT
E  I  K  E  G  A  L  M  L  P  H  F  N  S  K  A  M  V  I  V
1261 GAGATCAAAGAGGGTGCTTTGATGTTGCCACACTTCAACTCCAAGGCTATGGTTATCGTT
V  V N  K  G  T  G  N  L  E  L  V  A  V  R  K  E  Q  Q Q
1321 GTTGTTAACAAGGGTACTGGTAACTTGGAATTGGTTGCTGTTAGAAAAGAGCAGCAGCAG
R  G  R  R E  E E E D  E  D  E  E E E G  S  N  R  E
1381 AGAGGAAGAAGAGAAGAGGAAGAGGACGAGGACGAAGAAGAGGAAGGTTCTAACAGAGAG
V  R  R Y  T  A  R  L  K  E  G  D  V  F  I  M  P  A  A H
1441 GTTAGAAGATACACTGCTAGATTGAAAGAAGGTGACGTTTTCATCATGCCAGCTGCTCAC
P  V  A  I D A  S  S E  L  H  L  L G  F  G  I  N  A  E
1501 CCAGTTGCTATTGACGCTTCTTCTGAGTTGCACTTGTTGGGTTTCGGTATTAACGCTGAG
N  N H  R  I  F  L  A  G  D  K  D  N  V  I  D  Q  I  E  K
1561 AACAACCATAGAATTTTCTTGGCTGGTGACAAGGACAACGTTATCGACCAGATTGAGAAG
Q  A  K  D  L  A  F  P  G  S  G  E  Q  V  E  K  L  I  K  N
1621 CAGGCTAAGGACTTGGCTTTTCCAGGATCTGGTGAACAGGTTGAGAAGTTGATCAAAAAC
Q  K  E  S  H  F  V  S  A  R  P  Q  S  Q  S  Q  S  P  S  S
1681 CAGAAAGAGTCCCACTTCGTTTCCGCTAGACCACAATCTCAATCCCAATCTCCATCCTCC
P  E  K  E  S  P  E  K  E  D  Q  E  E E N  Q  G  G K  G
1741 CCAGAGAAAGAATCTCCTGAGAAAGAGGACCAAGAGGAAGAAAACCAGGGAGGTAAGGGT
P  L  L S  I  L  K  A  F  N  V  D  H  H H H H H *  E
1801 CCTTTGTTGTCCATCTTGAAGGCTTTTAACGTTGATCACCACCACCATCACCACTAAGAA
F  T  W  P  S  R
1861 TTCACGTGGCCCAGCCGG
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Figure A4: DNA fragment of rAra h 2.01 used for cloning into pPICZαA. 
The amino acid sequence of rAra h 2.01 is underlined. rAra h 2.01 contained two additional N-terminal amino acids 
(EF) due to cloning into EcoRI restriction site. Linker (VD) and His6-tag are written in italics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A5: DNA fragment of rAra h 2.02 used for cloning into pPICZαA. 
The amino acid sequence of rAra h 2.02 is underlined. rAra h 2.02 contained two additional N-terminal amino acids 
(EF) due to cloning into EcoRI restriction site. Linker (VD) and His6-tag are written in italics. 
 
 
 
 
E  K  R  E  A  E  A E  F  R  Q  Q W  E  L  Q  G  D  R  R
1 GAGAAAAGAGAGGCTGAAGCTGAATTCAGACAGCAGTGGGAATTGCAGGGTGACAGAAGA
C  Q  S  Q  L  E  R  A  N  L  R  P  C  E  Q  H  L  M  Q  K
61 TGTCAATCCCAGTTGGAGAGAGCTAACTTGAGACCTTGTGAGCAGCACTTGATGCAAAAG
I  Q  R  D  E  D  S  Y  G  R  D  P  Y  S  P  S  Q  D  P  Y
121 ATCCAGAGAGATGAGGACTCCTACGGTAGAGATCCATACTCTCCATCTCAAGACCCTTAC
S  P  S  Q  D  P  D  R  R D  P  Y  S  P  S  P  Y  D  R  R
181 TCCCCATCCCAAGATCCTGATAGAAGAGATCCTTATTCACCATCCCCATACGACAGAAGA
G  A  G  S  S Q  H  Q  E  R  C  C N  E  L  N  E  F  E  N
241 GGTGCTGGTTCTTCTCAACACCAAGAGAGATGTTGTAACGAGTTGAACGAGTTCGAGAAC
N  Q  R  C  M  C  E  A  L  Q  Q I  M  E  N  Q  S  D  R  L
301 AACCAGAGATGTATGTGTGAGGCTTTGCAGCAGATCATGGAAAACCAGTCCGACAGATTG
Q  G  R  Q  Q E  Q  Q F  K  R  E  L  R  N  L  P  Q  Q C
361 CAAGGTAGACAACAAGAGCAGCAGTTCAAGAGAGAATTGAGAAACTTGCCACAGCAGTGT
G  L  R  A  P  Q  R  C  D  L  E  V  E  S  G  G R  D  R  Y
421 GGTTTGAGAGCTCCACAAAGATGTGACTTGGAAGTTGAGTCTGGTGGTAGAGACAGATAC
V  D  H  H H H H H *  E  F  T  W  P  S  R
481 GTTGATCATCACCATCACCACCACTAAGAATTCACGTGGCCCAGCCGG
E  K  R  E  A  E  A E  F  R  Q  Q W  E  L  Q  G  D  R  R
1 GAGAAAAGAGAGGCTGAAGCTGAATTCAGACAGCAGTGGGAATTGCAGGGTGACAGAAGA
C  Q  S  Q  L  E  R  A  N  L  R  P  C  E  Q  H  L  M  Q  K
61 TGTCAATCCCAGTTGGAGAGAGCTAACTTGAGACCTTGTGAGCAGCACTTGATGCAAAAG
I  Q  R  D  E  D  S  Y  E  R  D  P  Y  S  P  S  Q  D  P  Y
121 ATCCAGAGAGATGAGGACTCCTACGAGAGAGATCCATACTCTCCATCTCAAGACCCTTAC
S  P  S  P  Y  D  R  R G  A  G  S  S Q  H  Q  E  R  C  C
181 TCCCCATCTCCATACGATAGAAGAGGTGCTGGTTCTTCCCAACACCAAGAGAGATGTTGT
N  E  L  N  E  F  E  N  N Q  R  C  M  C  E  A  L  Q  Q I
241 AACGAGTTGAACGAGTTCGAGAACAACCAGAGATGTATGTGTGAGGCTTTGCAGCAGATC
M  E  N  Q  S  D  R  L  Q  G  R  Q  Q E  Q  Q F  K  R  E
301 ATGGAAAACCAGTCCGACAGATTGCAAGGTAGACAACAAGAGCAGCAGTTCAAGAGAGAA
L  R  N  L  P  Q  Q C  G  L  R  A  P  Q  R  C  D  L  D  V
361 TTGAGAAACTTGCCACAGCAGTGTGGTTTGAGAGCTCCACAAAGATGTGACTTGGACGTT
E  S  G  G R  D  R  Y  V  D  H  H H H H H *  E  F  T
421 GAATCTGGTGGTAGAGACAGATACGTTGATCACCATCATCACCACCACTAAGAATTCACG
W  P  S  R
481 TGGCCCAGCCGG
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Figure A6: DNA fragment of rPis s 1 used for cloning into pPICZαA. 
The amino acid sequence of rPis s 1 is underlined. rPis s 1 contained two additional N-terminal amino acids (EF) 
due to cloning into EcoRI restriction site. Linker (VD) and His6-tag are written in italics. N345D is shown in red. 
 
 
 
E  K  R  E  A  E  A E  F  S  R  S  D  Q  E  N  P  F  I  F
1 GAGAAAAGAGAGGCTGAAGCTGAATTCTCCAGATCCGACCAAGAGAACCCATTCATCTTC
K  S  N  R  F  Q  T  L  Y  E  N  E  N  G  H  I  R  L  L Q
61 AAGTCCAACAGATTCCAGACTTTGTACGAGAACGAGAACGGTCACATCAGATTGTTGCAG
K  F  D  K  R  S  K  I  F  E  N  L  Q  N  Y  R  L  L E  Y
121 AAGTTCGACAAGAGATCCAAGATCTTCGAGAACTTGCAGAACTATAGATTGTTGGAGTAC
K  S  K  P  H  T  L  F  L  P  Q  Y  T  D  A  D  F  I  L  V
181 AAGTCCAAGCCACACACTTTGTTCTTGCCACAGTACACTGACGCTGACTTCATCTTGGTT
V  L  S  G  K  A  T  L  T  V  L  K  S  N  D  R  N  S  F  N
241 GTTTTGTCCGGTAAGGCTACTTTGACTGTTTTGAAGTCCAACGACAGAAACTCCTTCAAC
L  E  R  G  D  A  I  K  L  P  A  G  T  I  A  Y  L  A  N  R
301 TTGGAGAGAGGTGACGCTATCAAGTTGCCAGCTGGTACTATTGCTTACTTGGCTAACAGA
D  D N  E  D  L  R  V  L  D  L  A  I  P  V  N  K  P  G  Q
361 GATGACAACGAGGACTTGAGAGTTTTGGACTTGGCTATCCCAGTTAACAAGCCAGGTCAA
L  Q  S  F  L  L S  G  T  Q  N  Q  P  S  L  L S  G  F  S
421 TTGCAGTCCTTCTTGTTGTCCGGAACTCAAAACCAGCCATCCTTGTTGTCTGGTTTCTCC
K  N  I  L  E  A  A F  N  T  N  Y  E  E I  E  K  V  L  L
481 AAGAACATCTTGGAGGCTGCTTTCAACACTAACTACGAAGAGATCGAGAAGGTTTTGTTG
E  Q  Q E  Q  E  P  Q  H  R  R S  L  K  D  R  R Q  E  I
541 GAGCAGCAAGAGCAAGAGCCACAACACAGAAGATCCTTGAAGGACAGAAGACAAGAAATC
N  E  E N  V  I  V  K  V  S  R  E  Q  I  E  E L  S  K  N
601 AACGAAGAGAACGTTATCGTTAAGGTTTCCAGAGAGCAGATCGAAGAGTTGTCCAAGAAC
A  K  S  S S K  K S  V  S  S E  S  G  P  F  N  L  R  S
661 GCTAAGTCATCCTCCAAGAAGTCTGTTTCTTCTGAGTCCGGTCCATTCAACTTGAGATCC
R  N  P  I  Y  S  N  K  F  G  K  F  F E  I  T  P  E  K  N
721 AGAAACCCAATCTACTCTAACAAGTTCGGTAAGTTCTTCGAGATCACTCCAGAGAAGAAC
Q  Q L  Q  D  L  D  I  F  V  N  S  V  D  I  K  E  G  S  L
781 CAGCAGTTGCAGGACTTGGACATCTTCGTTAACTCCGTTGACATCAAAGAGGGTTCTTTG
L  L P  N  Y  N  S  R  A  I  V  I  V  T  V  T  E  G  K  G
841 TTGTTGCCTAACTACAACTCCAGAGCTATCGTTATCGTTACTGTTACTGAGGGTAAGGGT
D  F  E  L  V  G  Q  R  N  E  N  Q  G  K  E  N  D  K  E  E
901 GACTTCGAGTTGGTTGGTCAGAGAAACGAGAACCAGGGTAAAGAGAACGACAAAGAAGAG
E  Q  E  E E T  S  K  Q  V  Q  L  Y  R  A  K  L  S  P  G
961 GAACAAGAGGAAGAGACTTCCAAGCAGGTTCAGTTGTACAGAGCTAAGTTGTCCCCAGGT
D  V  F  V  I  P  A  G  H  P  V  A  I D A  S  S D  L  N
1021 GACGTTTTCGTTATTCCAGCTGGTCACCCAGTTGCTATTGACGCTTCTTCTGACTTGAAC
L  I  G  F  G  I  N  A  E  N  N E  R  N  F  L  A  G  E  E
1081 TTGATCGGTTTCGGTATCAACGCTGAGAACAACGAGAGAAACTTCTTGGCTGGTGAAGAG
D  N  V  I  S  Q  V  E  R  P  V  K  E  L  A  F  P  G  S  S
1141 GACAACGTTATCTCCCAGGTTGAAAGACCAGTTAAGGAATTGGCTTTCCCAGGTTCTTCC
H  E  V  D  R  L  L K  N  Q  K  Q  S  Y  F  A  N  A  Q  P
1201 CACGAGGTTGACAGATTGTTGAAAAACCAGAAGCAGTCCTACTTCGCTAACGCTCAACCA
L  Q  R  E V  D  H  H H H H H *  E  F  T  W  P  S  R
1261 TTGCAAAGAGAGGTTGATCACCATCATCACCACCACTAAGAATTCACGTGGCCCAGCCGG
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Figure A7: DNA fragment of rPis s 1 used for cloning into pET-11a. 
The amino acid sequence of rPis s 1 is underlined. Thrombin cleavage site (LVPRGS), linker (SSG) and His6-tag are 
written in italics. 
 
*  E  G  D  I  H M  S  R  S  D  Q  E  N  P  F  I  F  K  S
1 TAAGAAGGAGATATACATATGAGCCGCAGCGATCAAGAAAACCCGTTTATCTTTAAAAGC
N  R  F  Q  T  L  Y  E  N  E  N  G  H  I  R  L  L Q  K  F
61 AACCGTTTCCAGACCCTGTATGAAAATGAAAATGGTCATATTCGCCTGCTGCAGAAATTT
D  K  R  S  K  I  F  E  N  L  Q  N  Y  R  L  L E  Y  K  S
121 GATAAACGCAGCAAAATCTTTGAAAACCTGCAGAATTATCGGCTGCTGGAATACAAAAGC
K  P  H  T  L  F  L  P  Q  Y  T  D  A  D  F  I  L  V  V L
181 AAACCGCATACCCTGTTTCTGCCGCAGTATACCGATGCAGATTTCATTCTGGTTGTTCTG
S  G  K  A  T  L  T  V  L  K  S  N  D  R  N  S  F  N  L  E
241 AGCGGTAAAGCAACCCTGACCGTTCTGAAAAGCAATGATCGCAATTCCTTTAATCTGGAA
R  G  D  A  I  K  L  P  A  G  T  I  A  Y  L  A  N  R  D  D
301 CGTGGTGATGCAATTAAACTGCCAGCAGGCACCATTGCATATCTGGCAAATCGTGATGAT
N  E  D  L  R  V  L  D  L  A  I  P  V  N  K  P  G  Q  L  Q
361 AATGAAGATCTGCGTGTTCTGGATCTGGCAATTCCGGTTAATAAACCGGGTCAGCTGCAG
S  F  L  L S  G  T  Q  N  Q  P  S  L  L S  G  F  S  K  N
421 AGCTTTCTGCTGAGCGGCACCCAGAATCAGCCGAGCCTGCTGAGTGGTTTTAGCAAAAAC
I  L  E  A  A F  N  T  N  Y  E  E I  E  K  V  L  L E  Q
481 ATTCTGGAAGCAGCCTTCAACACCAACTATGAAGAAATTGAAAAAGTTCTGCTGGAACAG
Q  E  Q  E  P  Q  H  R  R S  L  K  D  R  R Q  E  I  N  E
541 CAAGAACAAGAACCGCAGCATCGTCGTAGCCTGAAAGATCGTCGTCAAGAAATCAATGAA
E  N  V  I  V  K  V  S  R  E  Q  I  E  E L  S  K  N  A  K
601 GAAAACGTGATTGTGAAAGTTAGCCGTGAGCAGATTGAAGAACTGAGCAAAAATGCAAAA
S  S S K  K S  V  S  S E  S  G  P  F  N  L  R  S  R  N
661 AGCAGCAGCAAAAAAAGCGTTAGCAGCGAAAGCGGTCCGTTTAATCTGCGTAGCCGTAAT
P  I  Y  S  N  K  F  G  K  F  F E  I  T  P  E  K  N  Q  Q
721 CCGATTTATAGCAACAAATTCGGCAAATTCTTTGAGATCACCCCTGAAAAAAATCAGCAG
L  Q  D  L  D  I  F  V  N  S  V  D  I  K  E  G  S  L  L L
781 CTGCAGGATCTGGATATTTTTGTTAATAGCGTGGATATCAAAGAAGGTAGCCTGCTGCTG
P  N  Y  N  S  R  A  I  V  I  V  T  V  T  E  G  K  G  D  F
841 CCGAACTATAATTCACGTGCAATTGTTATTGTTACCGTGACCGAAGGTAAAGGCGATTTT
E  L  V  G  Q  R  N  E  N  Q  G  K  E  N  D  K  E  E E Q
901 GAACTGGTTGGTCAGCGTAATGAAAATCAGGGCAAAGAAAACGACAAAGAAGAGGAACAA
E  E E T  S  K  Q  V  Q  L  Y  R  A  K  L  S  P  G  D  V
961 GAAGAAGAAACCAGCAAACAGGTTCAGCTGTATCGTGCAAAACTGAGTCCGGGTGATGTT
F  V  I  P  A  G  H  P  V  A  I  N  A  S  S D  L  N  L  I
1021 TTTGTTATTCCGGCAGGTCATCCGGTTGCAATTAATGCAAGCAGCGATCTGAATCTGATT
G  F  G  I  N  A  E  N  N E  R  N  F  L  A  G  E  E D  N
1081 GGCTTTGGTATTAATGCCGAAAACAACGAACGTAATTTTCTGGCAGGCGAAGAGGATAAT
V  I  S  Q  V  E  R  P  V  K  E  L  A  F  P  G  S  S H  E
1141 GTTATTAGCCAGGTTGAACGTCCGGTTAAAGAACTGGCATTTCCGGGTAGCAGCCATGAA
V  D  R  L  L K  N  Q  K  Q  S  Y  F  A  N  A  Q  P  L  Q
1201 GTTGATCGTCTGCTGAAAAATCAGAAACAGAGCTATTTTGCAAATGCACAGCCTCTGCAG
R  E  L  V  P  R  G  S  S S G  H  H H H H H *  H  M
1261 CGTGAACTGGTGCCGCGCGGCAGCAGCAGCGGCCATCATCATCATCATCATTAGCATATG
A  S  M  T  G
1321 GCTAGCATGACTGGT
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Figure A8: DNA fragment of rPA1 used for cloning into pPICZαA. 
The amino acid sequence of rPA1 is underlined. rPA1 contained two additional N-terminal amino acids (EF) due to 
cloning into EcoRI restriction site. Linker (VD) and His6-tag are written in italics. Propeptides are shown in blue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A9: DNA fragment of rPA2 used for cloning into pPICZαA. 
The amino acid sequence of rPA2 is underlined. rPA2 contained two additional N-terminal amino acids (EF) due to 
cloning into EcoRI restriction site. Linker (VD) and His6-tag are written in italics. N56D is shown in red. 
 
E  K  R  E A  E  A E F  A  S  C N  G  V  C S  P  F  E
1 GAGAAAAGAGAGGCTGAAGCTGAATTCGCTTCCTGTAACGGTGTTTGTTCCCCATTCGAA
M  P  P C G  S  S A C  R  C  I  P  V  G  L V  V G  Y
61 ATGCCACCATGTGGTTCTTCCGCTTGTAGATGTATCCCAGTTGGTTTGGTTGTTGGTTAC
C  R  H  P S  G V  F L  R  T  N D  E  H  P N  L  C  E
121 TGTAGACACCCATCCGGTGTTTTCTTGAGAACTAACGACGAGCACCCAAACTTGTGTGAA
S  D  A  D C  R  K  K G  S  G  N F  C  G  H Y  P  N  P
181 TCTGACGCTGACTGTAGAAAGAAGGGTTCCGGTAACTTCTGTGGTCACTACCCAAACCCA
D  I  E  Y G  W  C  F A  S  K  S E  A  E  D F  F S  K
241 GACATTGAGTACGGTTGGTGTTTCGCTTCTAAGTCTGAGGCTGAGGACTTCTTCTCCAAA
I  T  Q  K  D L  L K S  V  S  T A V  D  H H H H H
301 ATCACTCAAAAGGACTTGTTGAAGTCCGTTTCCACTGCTGTTGATCACCATCATCACCAC
H *  E  F T  W  P  S R
361 CACTAAGAATTCACGTGGCCCAGCCGG
E  K  R  E A  E  A E F  M  T  K T  G  Y  I N  A  A F
1 GAGAAAAGAGAGGCTGAAGCTGAATTCATGACTAAGACTGGTTACATCAACGCTGCTTTC
R  S  S Q N  N E  A Y  L  F  I N  D  K  Y V  L  L D
61 AGATCCTCCCAAAACAACGAGGCTTACTTGTTCATCAACGACAAGTACGTTTTGTTGGAC
Y  A  P  G T  S  N  D K  V  L  Y G  P  T  P V  R  D  G
121 TACGCTCCAGGTACTTCTAACGACAAGGTTTTGTACGGTCCAACTCCAGTTAGAGATGGT
F  K  S  L D Q  T  V F  G  S  Y G  V  D  C S  F  D  T
181 TTCAAGTCCTTGGACCAGACTGTTTTCGGTTCCTACGGTGTTGACTGTTCCTTCGATACT
D  N  D  E A  F  I  F Y  E  K  F C  A  L  I D  Y  A  P
241 GACAACGACGAGGCTTTCATCTTCTACGAGAAGTTCTGTGCTTTGATCGATTACGCTCCA
H  S  N  K D  K  I  I L  G  P  K K I  A  D M  F  P  F
301 CACTCCAACAAGGACAAGATCATCTTGGGTCCAAAGAAAATCGCTGACATGTTCCCATTC
F  E  G  T V  F  E  N G  I  D  A A Y  R  S T  R  G  K
361 TTCGAGGGTACAGTTTTCGAGAACGGTATCGATGCTGCTTATAGATCCACTAGAGGTAAA
E  V  Y  L F  K  G  D Q  Y  A  R I  D  Y  E T  N  S  M
421 GAGGTTTATTTGTTCAAGGGTGACCAGTACGCTAGAATCGACTACGAGACTAACTCCATG
V  N  K  E I  K  S  I R  N  G  F P  C  F  R N  T  I  F
481 GTTAACAAAGAGATCAAGTCCATCAGAAACGGTTTCCCATGTTTCAGAAACACTATCTTC
E  S  G  T D  A  A F A  S  H  K T  N  E  V Y  F  F K
541 GAGTCCGGTACTGATGCTGCTTTCGCTTCTCACAAGACTAACGAAGTTTACTTCTTTAAG
G  D  Y  Y A  R  V  T V  T  P  G A  T  D  D Q  I  M  D
601 GGTGATTACTACGCTAGAGTTACTGTTACTCCAGGTGCTACTGACGACCAGATTATGGAC
G  V  R  K  T  L  D  Y W  P  S  L  R  G  I  I P  L  E  N
661 GGTGTTAGAAAGACTTTGGACTACTGGCCATCCTTGAGAGGTATCATCCCATTGGAAAAC
V  D  H  H H H H H *  E  F  T  W  P  S  R
721 GTTGATCACCACCACCATCACCACTAAGAATTCACGTGGCCCAGCCGG
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Figure A10: DNA fragment of rGly m 5.03 used for cloning into pPICZαA. 
The amino acid sequence of rGly m 5.03 is underlined. rGly m 5.03 contained two additional N-terminal amino acids 
(EF) due to cloning into EcoRI restriction site. Linker (VD) and His6-tag are written in italics. N328D is shown in red. 
 
E  K  R  E A  E  A E F  L  K  V R  E  D  E N  N P  F
1 GAGAAAAGAGAGGCTGAAGCTGAATTCTTGAAGGTTAGAGAGGACGAGAACAACCCATTC
Y  F  R  S S N  S  F Q  T  L  F E  N  Q  N G  R  I  R
61 TACTTCAGATCCTCCAACTCCTTCCAGACTTTGTTCGAGAACCAGAACGGTAGAATCAGA
L  L Q  R F  N  K  R S  P  Q  L E  N  L  R D  Y  R  I
121 TTGTTGCAGAGATTCAACAAGAGATCCCCACAGTTGGAGAACTTGAGAGACTACAGAATC
V  Q  F  Q S  K  P  N T  I  L  L P  H  H A D  A  D  F
181 GTTCAGTTCCAGTCCAAGCCAAACACTATCTTGTTGCCACATCACGCTGACGCTGACTTT
L  L F  V L  S  G  R A  I  L  T  L  V  N  N D  D R  D
241 TTGTTGTTCGTTTTGTCCGGTAGAGCTATCTTGACTTTGGTTAACAACGACGACAGAGAC
S  Y  N  L H  P  G  D A  Q  R  I P  A  G  T T Y  Y L
301 TCCTACAACTTGCATCCAGGTGACGCTCAAAGAATCCCAGCTGGTACTACTTACTACTTG
V  N  P  H D  H  Q  N L  K  I  I K  L  A  I  P  V  N  K
361 GTTAACCCACACGACCACCAGAACTTGAAGATTATCAAGTTGGCTATCCCAGTTAACAAG
P  G  R  Y D  D F  F L  S  S T Q  A  Q  Q S  Y  L  Q
421 CCAGGTAGATACGACGACTTCTTCTTGTCCTCCACTCAAGCTCAACAGTCCTACTTGCAA
G  F  S  H N  I  L  E T  S  F  H S  E  F  E E I  N  R
481 GGTTTCTCCCACAACATCTTGGAGACATCTTTCCACTCCGAGTTCGAAGAGATCAACAGA
V  L  F  G E  E E E Q  R  Q  Q E  G  V  I V  E  L  S
541 GTTTTGTTCGGTGAGGAAGAGGAACAGAGACAGCAAGAGGGTGTTATCGTTGAGTTGTCC
K  E  Q  I R  Q  L  S R  R A  K S  S S R K  T  I  S
601 AAAGAGCAGATCAGACAGTTGTCTAGAAGAGCTAAGTCCTCCTCAAGAAAGACTATCTCT
S  E  D  E P  F  N  L R  S  R  N P  I  Y  S  N  N F  G
661 TCTGAGGACGAGCCATTCAACTTGAGATCTAGAAACCCAATCTACTCCAACAACTTCGGT
K  F  F E  I  T  P  E  K  N  P  Q L  R  D  L  D  I  F  L
721 AAGTTCTTCGAGATCACTCCAGAGAAGAACCCTCAGTTGAGAGATTTGGACATCTTTTTG
S  S V  D I  N  E  G A  L  L L P  H  F  N S  K  A  I
781 TCCTCTGTTGACATCAACGAGGGTGCTTTGTTGTTGCCTCACTTCAACTCCAAGGCTATC
V  I  L  V I  N  E  G D  A  N  I E  L  V  G I  K  E  Q
841 GTTATCTTGGTTATCAATGAGGGTGACGCTAACATCGAGTTGGTTGGTATCAAAGAGCAA
Q  Q K  Q K  Q  E  E E P  L  E V  Q  R  Y R  A  E  L
901 CAGCAAAAGCAGAAGCAAGAGGAAGAACCATTGGAGGTTCAGAGATACAGAGCTGAATTG
S  E  D  D V  F  V  I P  A  A Y P  F  V  V D A  T  S
961 TCCGAGGACGACGTTTTCGTTATTCCAGCTGCTTACCCATTCGTTGTTGACGCTACTTCC
N  L  N  F L  A  F  G I  N  A  E N  N Q  R N  F  L  A
1021 AACTTGAACTTCTTGGCTTTCGGTATCAACGCTGAAAACAACCAGAGAAACTTTTTGGCT
G  E  K  D  N  V  V R Q  I  E  R Q  V  Q  E L  A  F  P
1081 GGTGAGAAGGATAACGTTGTTAGACAGATCGAGAGACAGGTTCAAGAGTTGGCTTTTCCA
G  S  A  Q  D  V  E  R L  L K  K Q  R  E  S Y  F  V  D
1141 GGTTCCGCTCAAGACGTTGAAAGATTGTTGAAGAAGCAGAGAGAATCCTACTTCGTTGAC
A  Q  P  Q Q K  E  E G  S  K  G R  K  G  P F  P  S  I
1201 GCTCAGCCACAGCAAAAAGAAGAAGGTTCCAAGGGTAGAAAGGGTCCATTCCCATCTATC
L  G  A  L Y  V  D  H H H H H H *  E  F T  W  P  S
1261 TTGGGAGCTTTGTATGTTGATCACCACCACCATCACCACTAAGAATTCACGTGGCCCAGC
R
1321 CGG
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Figure A11: DNA fragment of rGly m 8 used for cloning into pPICZαA. 
The amino acid sequence of rGly m 8 is underlined. rGly m 8 contained two additional N-terminal amino acids (EF) 
due to cloning into EcoRI restriction site. Linker (VD) and His6-tag are written in italics. Propeptide is shown in blue 
and N99D is shown in red. 
 
7.1.3 SDS-PAGE of rPis s 1 expressed in Pichia pastoris 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A12: SDS-PAGE of rPis s 1 expressed in Pichia pastoris. 
Coomassie-stained SDS-PAGE of rPis s 1 secreted into cell culture supernatant. rPis s 1 (lane 1; 12 µl cell culture 
supernatant) was analyzed under reducing conditions. Arrows indicate the two truncated proteolytic fragments of 
rPis s 1. M, SpectraTM Multicolor Broad Range Protein Ladder. 
E  K  R  E  A  E  A E F  S  K  W Q  H  Q  Q D  S  C  R
1 GAGAAAAGAGAGGCTGAAGCTGAATTCTCCAAGTGGCAACACCAACAGGACTCTTGTAGA
K  Q  L  Q G  V  N  L  T  P  C  E K  H  I  M E  K  I  Q
61 AAGCAGTTGCAGGGTGTTAACTTGACTCCATGTGAGAAGCACATCATGGAAAAGATCCAG
G  R  G  D D D D D D D D D N  H  I  L R  T  M  R
121 GGTAGAGGTGATGACGACGATGATGACGATGACGACAACCACATCTTGAGAACTATGAGA
G  R  I  N Y  I  R  R N E  G  K D  E  D  E E E E G
181 GGTAGAATCAACTACATCAGAAGAAACGAGGGTAAGGACGAGGACGAAGAGGAAGAGGGT
H  M  Q  K  C  C T  E M  S  E  L  R  S  P  K C  Q  C  K
241 CATATGCAAAAGTGTTGTACTGAGATGTCCGAGTTGAGATCCCCAAAGTGTCAGTGTAAG
A  L  Q  K I  M  E D Q  S  E  E L  E  E K Q  K  K K
301 GCTTTGCAAAAGATCATGGAAGATCAGTCCGAAGAGTTGGAAGAGAAGCAGAAAAAGAAG
M  E  K  E L  I  N  L A  T  M  C R  F  G  P M  I  Q  C
361 ATGGAAAAAGAGTTGATTAACTTGGCTACTATGTGTAGATTCGGTCCAATGATCCAGTGT
D  L  S  S D  D V  D H  H H H H H *  E F  T  W  P
421 GACTTGTCCTCTGATGATGTTGATCACCACCACCATCACCACTAAGAATTCACGTGGCCC
S  R
481 AGCCGG
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7.1.4 IgE immunodetection of multipeptide microarrays 
7.1.4.1 Ara h 1 multipeptide microarray 
A 
 
Patient 1 (2 min)      Patient 2 (2 min) 
 
 
Patient 3 (2 min)      Patient 4 (2 min) 
 
 
Patient 5 (2 min)      Patient 6 (30 sec) 
 
 
Patient 7 (2 min)      Patient 8 (30 sec) 
 
 
Patient 9 (2 min)      Patient 10 (30 sec) 
 
 
Patient 11 (2 min)     Patient 12 (30 sec) 
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Patient 13 (2 min)     Patient 14 (2 min) 
 
 
Patient 15 (2 min)     Patient 16 (2 min) 
 
 
Patient 17 (2 min)     Patient 18 (30 sec) 
 
 
Patient 19 (30 sec)     Patient 20 (2 min) 
 
 
Patient 21 (30 sec)     Patient 22 (2 min) 
 
 
Patient 23 (30 sec)      
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B 
 
Patient 24 (2 min)     Patient 25 (30 sec) 
 
 
Patient 26 (30 sec)     Patient 27 (2 min) 
 
 
Patient 28 (2 min)     Patient 29 (2 min) 
 
 
Patient 30 (2 min)     Patient 31 (2 min) 
 
 
Patient 32 (2 min)     Patient 33 (2 min)  
 
 
Patient 34 (2 min)     Patient 35 (2 min)  
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C 
 
 Non-allergic control serum N_1 (2 min)   Non-allergic control serum N_2 (2 min) 
 
 
Non-allergic control serum N_3 (2 min)    DLab71S1_1 (2 min) 
 
 
DLab71S1_2 (2 min)      DLab71S1_3 (2 min) 
 
Figure A13: IgE immunodetection of Ara h 1 peptides using peanut-allergic, peanut-tolerant and control sera.  
Peptides representing Ara h 1 were spotted in quadruplicate and analyzed for their IgE binding using sera from 
peanut-allergic children (A), peanut-sensitized but tolerant children (B) and control sera (C). The exposure times 
are shown in parentheses and ranged from 30 sec to 2 min. N_1, N_2 and N_3 mean serum from non-allergic control 
N used on different X-ray films. The same applies for DLab71S1_1, DLab71S1_2 and DLab71S1_3. 
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Serum pool 1 + protein buffer (30 sec)   Serum pool 1 + rAra h 1 (30 sec) 
 
 
Serum pool 2 + protein buffer (30 sec)   Serum pool 2 + rAra h 1 (30 sec) 
 
Figure A14: Inhibition of IgE binding to Ara h 1 peptides. 
Verification of the specificity of IgE binding to Ara h 1 peptides using two serum pools preincubated with 20.5 µg 
rAra h 1. Serum pool 1 was composed of sera from patients 10, 12, 18, 21 and serum pool 2 of sera from patients 6, 
15, 17, 23. As a reference, the respective uninhibited serum pool plus protein buffer without rAra h 1 was used. The 
exposure times are shown in parentheses. 
 
7.1.4.2 Ara h 2 multipeptide microarray 
A 
 
  Patient 1 (2 min)      Patient 2 (2 min) 
 
 
  Patient 3 (2 min)      Patient 4 (2 min) 
 
 
  Patient 5 (2 min)      Patient 6 (30 sec) 
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  Patient 7 (2 min)      Patient 8 (30 sec) 
 
 
  Patient 9 (2 min)      Patient 10 (30 sec) 
 
 
  Patient 11 (2 min)     Patient 12 (30 sec) 
 
 
  Patient 13 (2 min)     Patient 14 (2 min) 
 
 
  Patient 15 (30 sec)     Patient 16 (2 min) 
 
 
  Patient 17 (30 sec)     Patient 18 (30 sec) 
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  Patient 19 (30 sec)     Patient 20 (2 min) 
 
 
  Patient 21 (30 sec)     Patient 22 (30 sec) 
 
 
  Patient 23 (30 sec) 
 
B 
 
  Patient 24 (2 min)     Patient 25 (1 min) 
 
 
  Patient 26 (1 min)     Patient 27 (2 min) 
 
 
  Patient 28 (2 min)     Patient 29 (2 min) 
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  Patient 30 (2 min)     Patient 31 (2 min) 
 
 
  Patient 32 (2 min)     Patient 33 (2 min) 
 
 
  Patient 34 (2 min)     Patient 35 (2 min) 
 
C 
 
 Non-allergic control serum N_2 (2 min)   Non-allergic control serum N_3 (2 min) 
 
 
 Non-allergic control serum N_4 (2 min)    DLab71S1_1 (2 min) 
 
 
  DLab71S1_2 (2 min)     DLab71S1_3 (2 min) 
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  DLab71S1_4 (2 min)     DLab72S1_1 (2 min) 
 
 
  DLab72S1_2 (2 min)     DLab72S1_3 (2 min) 
 
 
  DLab72S1_4 (2 min) 
 
Figure A15: IgE immunodetection of Ara h 2 peptides using peanut-allergic, peanut-tolerant and control sera.  
Peptides representing Ara h 2.01_P, Ara h 2.01_Hyp, Ara h 2.02_P and Ara h 2.02_Hyp were spotted in quadruplicate 
and analyzed for their IgE binding using sera from peanut-allergic children (A), peanut-sensitized but tolerant 
children (B) and control sera (C). The exposure times are shown in parentheses and ranged from 30 sec to 2 min. 
Numbers written behind control sera represent the respective developed X-ray film.  
 
 
 Serum pool + protein buffer (30 sec)   Serum pool + rAra h 2.02 (30 sec) 
 
 
 Serum pool + native peanut extract (30 sec)  Serum pool + red./alk. peanut extract (30 sec) 
 
Figure A16: Inhibition of IgE binding to Ara h 2 peptides. 
Verification of the specificity of IgE binding to Ara h 2 peptides using one serum pool preincubated with 13.5 µg 
rAra h 2.02, 9.5 µg native peanut extract or 9.5 µg reduced/alkylated peanut extract. The used serum pool was 
composed of sera from patients 6, 7, 8, 10, 12, 15, 18, 21, 22 and 23. As a reference, uninhibited serum pool plus 
protein buffer without inhibitor was used. The exposure times are shown in parentheses. 
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7.1.4.3 Pis s 1 multipeptide microarray 
A 
 
  Patient 1 (30 sec)      Patient 2 (2 min) 
 
 
  Patient 3 (1 min)      Patient 4 (30 sec) 
 
 
  Patient 5 (2 min)      Patient 6 (2 min) 
 
 
  Patient 7 (2 min)      Patient 8 (30 sec) 
 
 
  Patient 9 (2 min)      Patient 10 (2 min) 
 
 
  Patient 11 (2 min)     Patient 12 (2 sec) 
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  Patient 13 (2 min)     Patient 14 (2 min) 
 
B 
 
  Patient 15 (2 min)     Patient 16 (2 min) 
 
 
  Patient 17 (2 min)     Patient 18 (2 min) 
 
 
  Patient 19 (2 min) 
 
C 
 
  Serum A (2 min)      Serum B (2 min) 
 
 
  Serum C (2 min)      Serum D (2 min) 
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  Serum E (2 min)      Serum F (2 min) 
 
 
  Serum G (2 min)      Serum H (2 min) 
 
 
  Serum I (2 min)      Serum J (2 min) 
 
Figure A17: IgE immunodetection of Pis s 1 peptides using pea-allergic, pea-tolerant and control sera.  
Peptides representing Pis s 1 were spotted in quadruplicate and analyzed for their IgE binding using sera from pea-
allergic children (A), pea-sensitized but tolerant children (B) and control sera (C). The exposure times are shown in 
parentheses and ranged from 2 sec to 2 min. 
 
 
 Serum pool 1 + protein buffer (1 min)   Serum pool 1 + rPis s 1 (1 min) 
 
 
 Serum pool 2 + protein buffer (1 min)   Serum pool 2 + rPis s 1 (1 min) 
 
Figure A18: Inhibition of IgE binding to Pis s 1 peptides. 
Verification of the specificity of IgE binding to Pis s 1 peptides using two serum pools preincubated with 30 µg rPis s 1. 
Serum pool 1 was composed of sera from patients 1, 4, 8 and serum pool 2 of sera from patients 3, 10, 11, 13. As a 
reference, the respective uninhibited serum pool plus protein buffer without inhibitor was used. The exposure times 
are shown in parentheses. 
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7.1.4.4 PA1/PA2 multipeptide microarray 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
  Patient 1 (30 sec)      Patient 16 (30 sec) 
 
 
 Non-allergic control serum N (30 sec)    PEI177 (30 sec) 
 
Figure A19: Spotting layout and IgE immunodetection of PA1 and PA2 peptides using pea-allergic, pea-
tolerant and control sera. 
(A) Spotting layout of PA1 and PA2 multipeptide microarray. For simplification, only the left segment of the 
multipeptide microarray is shown. Peptide spots representing PA1 and PA2 are shown in light blue and dark blue, 
respectively. PA1 and PA2 are represented by 24 and 55 peptides, respectively. Biotinylated control peptides, 
abbreviated by a ”C”, were spotted in duplicate in different dilutions (top left, middle right and bottom right on each 
array element) and were used as position markers. Gray empty spots represent blank spots composed of peptide 
printing buffer (DMSO). Blue empty spots represent internal control peptides not relevant for peptide analysis. (B) 
IgE immunodetection of patient 1 (allergic), patient 16 (tolerant) and two control sera (serum N and PEI177) after 
30 sec exposure. 
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7.1.4.5 Gly m 5.03 multipeptide microarray 
A 
 
  Patient 1 (30 sec)      Patient 2 (30 sec) 
 
 
  Patient 3 (30 sec)      Patient 4 (30 sec) 
 
 
  Patient 5 (30 sec)      Patient 6 (30 sec) 
 
B 
 
  Patient 7 (30 sec)      Patient 8 (30 sec) 
 
 
  Patient 9 (30 sec)      Patient 10 (30 sec) 
 
 
  Patient 11 (15 sec)     Patient 12 (30 sec) 
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  Patient 13 (30 sec)     Patient 14 (30 sec) 
 
 
  Patient 15 (30 sec)     Patient 16 (30 sec) 
 
 
  Patient 17 (30 sec)     Patient 18 (30 sec) 
 
 
  Patient 19 (30 sec)     Patient 20 (30 sec) 
 
 
  Patient 21 (30 sec) 
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C 
 
 Non-allergic control serum N_1 (30 sec)   Non-allergic control serum N_2 (30 sec) 
 
Figure A20: IgE immunodetection of Gly m 5.03 peptides using soybean-allergic, soybean-tolerant and control 
sera. 
Peptides representing Gly m 5.0301 and Gly m 5.0302 were spotted in quadruplicate and analyzed for their IgE 
binding using sera from soybean-allergic children (A), soybean-sensitized but tolerant children (B) and control sera 
(C). The exposure times are shown in parentheses and ranged from 15 sec to 30 sec. Numbers written behind control 
serum represent the respective developed X-ray film. 
 
7.1.4.6 Gly m 8 multipeptide microarray 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
  Patient 1 (30 sec)      Patient 2 (30 sec) 
 
 Appendix  193 
 
  Patient 3 (30 sec)      Patient 4 (30 sec) 
 
 
  Patient 5 (30 sec)      Patient 6 (30 sec) 
 
C 
 
  Patient 7 (30 sec)      Patient 8 (30 sec) 
 
 
  Patient 9 (30 sec)      Patient 10 (30 sec) 
 
 
  Patient 11 (15 sec)     Patient 12 (30 sec) 
 
 
  Patient 13 (30 sec)     Patient 14 (30 sec) 
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  Patient 15 (30 sec)     Patient 16 (30 sec) 
 
 
  Patient 17 (30 sec)     Patient 18 (30 sec) 
 
 
  Patient 19 (30 sec)     Patient 20 (30 sec) 
 
 
  Patient 21 (30 sec) 
 
D 
 
 Non-allergic control serum N_1 (30 sec)   Non-allergic control serum N_2 (30 sec) 
 
Figure A21: Spotting layout and IgE immunodetection of Gly m 8 peptides using soybean-allergic, soybean-
tolerant and control sera.  
(A) Spotting layout of Gly m 8 multipeptide microarray. For simplification, only the left segment of the multipeptide 
microarray is shown. Full-length sequence of Gly m 8 is represented by 32 peptides that were spotted (each 0.04 μl) 
in duplicate on each segment leading to quadruplicate peptide presentation on the whole array. Biotinylated control 
peptides, abbreviated by a “C”, were spotted in duplicate in different dilutions (top left and bottom right on each 
array element) and were used as position markers. Gray empty spots represent blank spots composed of peptide 
printing buffer (DMSO). Blue empty spots represent internal control peptides not relevant for peptide analysis. (B) 
IgE immunodetection of soybean-allergic children, (C) of soybean-tolerant children and (D) of control sera. The 
exposure times are shown in parentheses and ranged from 15 sec to 30 sec. 
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7.1.5 Calculated Z-scores of patients and controls 
7.1.5.1 Calculated Z-scores of Ara h 1 peptides 
 
Table A1: Calculated Z-scores of Ara h 1 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 1 for each peanut-allergic patient (patients 1-7) are listed. Identified 
candidate diagnostic peptides are highlighted in light blue. 
 Patient No. → 1 2 3 4 5 6 7 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score Z-score 
1 K-S-S-P-Y-Q-K-K-T-E-N-P-C-A-Q -0.43249 -1.18966 -3.05334 -0.09238 -0.65726 7.716425 -0.86427 
2 Y-Q-K-K-T-E-N-P-C-A-Q-R-C-L-Q -0.2293 -0.97681 -2.40181 1.058556 -0.65098 8.98971 0.126512 
3 T-E-N-P-C-A-Q-R-C-L-Q-S-C-Q-Q 0.153717 -0.62976 -2.5701 1.477649 -0.69201 2.972944 -0.59167 
4 C-A-Q-R-C-L-Q-S-C-Q-Q-E-P-D-D 0.563348 -1.05131 -2.33272 1.088213 -0.49084 8.195964 -0.71917 
5 C-L-Q-S-C-Q-Q-E-P-D-D-L-K-Q-K 1.443808 -0.28428 -1.65926 2.21333 -0.8318 1.848827 -1.26008 
6 C-Q-Q-E-P-D-D-L-K-Q-K-A-C-E-S -0.66379 2.051137 -3.33817 -0.41734 -1.50153 1.121159 -1.41863 
7 P-D-D-L-K-Q-K-A-C-E-S-R-C-T-K -0.14799 -1.12187 -2.29136 1.653279 -0.87354 4.04668 -0.69242 
8 K-Q-K-A-C-E-S-R-C-T-K-L-E-Y-D 0.48681 -0.99994 -2.88187 5.476836 -0.88659 0.771805 -0.81759 
9 C-E-S-R-C-T-K-L-E-Y-D-P-R-C-V 0.534612 1.138048 -1.91411 3.82531 -0.68819 0.306613 -0.65364 
10 C-T-K-L-E-Y-D-P-R-C-V-Y-D-P-R 0.655743 -0.8854 -2.34763 4.414928 -1.11059 1.005971 -0.74646 
11 E-Y-D-P-R-C-V-Y-D-P-R-G-H-T-G 0.634182 -0.91976 -1.6751 0.439552 -0.53513 -0.24683 -0.91261 
12 R-C-V-Y-D-P-R-G-H-T-G-T-T-N-Q 0.284124 -1.60874 -2.96043 0.435003 -1.51376 6.293259 -1.44391 
13 D-P-R-G-H-T-G-T-T-N-Q-R-S-P-P 2.609384 -0.6158 -1.68992 0.874976 -0.93787 1.920053 -0.29025 
14 H-T-G-T-T-N-Q-R-S-P-P-G-E-R-T 1.816218 -1.21229 -2.31373 1.663906 -1.08872 3.696066 0.102456 
15 T-N-Q-R-S-P-P-G-E-R-T-R-G-R-Q 1.216094 -2.00447 -2.11337 2.492032 -2.00506 6.960738 -0.93245 
16 S-P-P-G-E-R-T-R-G-R-Q-P-G-D-Y 4.178911 -1.64683 -2.83959 1.789947 -1.60216 67.89797 -1.43876 
17 E-R-T-R-G-R-Q-P-G-D-Y-D-D-D-R 10.12458 -1.28711 -2.23356 0.344458 -0.8324 81.6531 -0.84989 
18 G-R-Q-P-G-D-Y-D-D-D-R-R-Q-P-R 0.499342 -1.14904 -2.52441 8.420034 -1.62162 -0.07544 -1.38884 
19 G-D-Y-D-D-D-R-R-Q-P-R-R-E-E-G 0.645933 -0.97055 -3.05236 2.786423 -1.81955 -0.31908 -1.49194 
20 D-D-R-R-Q-P-R-R-E-E-G-G-R-W-G -0.85795 -0.57554 -3.17097 1.561276 -0.9283 3.664378 -0.76688 
21 Q-P-R-R-E-E-G-G-R-W-G-P-A-G-P -1.06165 -1.46187 -3.35184 0.753237 -1.44382 76.18538 -1.50043 
22 E-E-G-G-R-W-G-P-A-G-P-R-E-R-E -0.40662 -0.95559 -2.55054 -0.51915 -0.97002 81.88536 -0.6107 
23 R-W-G-P-A-G-P-R-E-R-E-R-E-E-D 0.429307 -0.68273 -2.33809 0.260981 -0.41173 7.670801 -0.626 
24 A-G-P-R-E-R-E-R-E-E-D-W-R-Q-P -1.40584 -2.09736 -3.83454 2.92855 -1.56015 5.770623 -1.53188 
25 E-R-E-R-E-E-D-W-R-Q-P-R-E-D-W -0.71285 -0.88072 -2.60752 1.588496 -0.71774 59.90033 -0.60705 
26 E-E-D-W-R-Q-P-R-E-D-W-R-R-P-S -0.98825 -1.48975 -3.26446 -0.27369 -1.26383 60.52137 -1.21396 
27 R-Q-P-R-E-D-W-R-R-P-S-H-Q-Q-P -0.75524 -1.13707 -2.65027 0.466622 -0.96579 53.11317 -0.52431 
28 E-D-W-R-R-P-S-H-Q-Q-P-R-K-I-R 4.940022 -0.99485 -0.36389 1.985738 -0.51119 78.19949 2.075901 
29 R-P-S-H-Q-Q-P-R-K-I-R-P-E-G-R 2.265152 -1.04701 -1.68812 4.222064 -1.18299 28.881 0.111065 
30 Q-Q-P-R-K-I-R-P-E-G-R-E-G-E-Q 1.034502 -0.75841 -1.71815 3.888645 -0.75447 38.68586 -0.30765 
31 K-I-R-P-E-G-R-E-G-E-Q-E-W-G-T -0.65872 -1.05522 -2.82396 7.031268 -1.39863 4.558378 -0.05905 
32 E-G-R-E-G-E-Q-E-W-G-T-P-G-S-H -0.06651 -0.80743 -2.30485 1.767797 -0.63977 8.899734 -0.39689 
33 G-E-Q-E-W-G-T-P-G-S-H-V-R-E-E -0.02294 -0.94347 -2.71136 2.738762 -1.23242 7.549486 -0.63765 
34 W-G-T-P-G-S-H-V-R-E-E-T-S-R-N 1.628933 -0.62304 -2.10483 1.045301 -0.80641 5.973505 -0.33938 
35 G-S-H-V-R-E-E-T-S-R-N-N-P-F-Y 0.636331 -0.47137 -1.82097 0.279929 -0.40971 3.96377 -0.06044 
36 R-E-E-T-S-R-N-N-P-F-Y-F-P-S-R 2.021754 -1.21388 -2.28538 1.723476 -1.21498 6.878459 0.359025 
 196  Appendix 
37 S-R-N-N-P-F-Y-F-P-S-R-R-F-S-T -1.61488 -3.90439 1.386388 -0.10317 -4.13888 2.741538 5.037962 
38 P-F-Y-F-P-S-R-R-F-S-T-R-Y-G-N -3.6408 -5.25917 -4.80843 0.253403 -5.55455 -1.36342 2.386002 
39 P-S-R-R-F-S-T-R-Y-G-N-Q-N-G-R 0.64892 -1.69285 -0.25422 7.108303 -2.46291 -1.47748 -0.03432 
40 F-S-T-R-Y-G-N-Q-N-G-R-I-R-V-L -1.00631 -5.05172 -2.73662 14.43878 -5.58905 1.131453 -3.24344 
41 Y-G-N-Q-N-G-R-I-R-V-L-Q-R-F-D -2.5026 -4.52551 -2.23956 7.177587 -4.36578 -1.71137 -2.06414 
42 N-G-R-I-R-V-L-Q-R-F-D-Q-R-S-R -1.54719 -2.4935 0.936244 0.204262 -2.45237 1.437799 6.335763 
43 R-V-L-Q-R-F-D-Q-R-S-R-Q-F-Q-N 0.271093 -0.70221 -2.83464 0.730639 -1.49754 2.598513 -1.27939 
44 R-F-D-Q-R-S-R-Q-F-Q-N-L-Q-N-H -0.34418 -0.84256 -3.47266 1.224827 -1.25758 14.0627 -0.93492 
45 R-S-R-Q-F-Q-N-L-Q-N-H-R-I-V-Q -0.94922 -2.2791 -4.09536 9.261045 -2.78771 0.6901 -0.64 
46 F-Q-N-L-Q-N-H-R-I-V-Q-I-E-A-K -1.66267 -2.39744 -4.48915 5.254972 -3.1985 -0.78143 -0.75585 
47 Q-N-H-R-I-V-Q-I-E-A-K-P-N-T-L 0.321422 -0.22564 -1.83485 0.184521 -0.70741 3.47718 -0.15816 
48 I-V-Q-I-E-A-K-P-N-T-L-V-L-P-K 0.795895 -0.72068 -2.32937 5.107443 -1.13325 4.954379 -0.51515 
49 E-A-K-P-N-T-L-V-L-P-K-H-A-D-A 0.969916 -1.22504 -2.65041 3.547122 -1.23345 30.48927 0.175025 
50 N-T-L-V-L-P-K-H-A-D-A-D-N-I-L 0.203866 -0.99771 -2.49364 2.809642 -0.67304 13.3791 -0.49408 
51 L-P-K-H-A-D-A-D-N-I-L-V-I-Q-Q 0.594593 -1.6771 -2.82755 12.739 -1.78432 16.81422 -0.01487 
52 A-D-A-D-N-I-L-V-I-Q-Q-G-Q-A-T -1.32498 -2.92181 -4.15424 7.809956 -3.21609 10.47864 -1.55307 
53 N-I-L-V-I-Q-Q-G-Q-A-T-V-T-V-A 0.301779 0.108303 -1.96744 3.858029 -1.20503 15.00025 0.098984 
54 I-Q-Q-G-Q-A-T-V-T-V-A-N-G-N-N 1.666052 -0.89511 -2.61061 8.318539 -1.97238 6.707803 -0.39158 
55 Q-A-T-V-T-V-A-N-G-N-N-R-K-S-F -0.40526 -3.13219 -3.45844 22.60138 -3.93254 8.712123 -1.77557 
56 T-V-A-N-G-N-N-R-K-S-F-N-L-D-E 2.110252 -1.19142 -2.95207 9.664301 -1.84787 15.97225 0.406638 
57 G-N-N-R-K-S-F-N-L-D-E-G-H-A-L -0.04463 -3.27968 -4.6761 16.18581 -4.00906 7.527263 -1.70687 
58 K-S-F-N-L-D-E-G-H-A-L-R-I-P-S 0.951784 -0.39681 -2.24812 7.449546 -0.95312 2.657548 0.436556 
59 L-D-E-G-H-A-L-R-I-P-S-G-F-I-S 0.354827 -0.84085 -0.75271 -0.33647 -0.87988 5.476149 0.185419 
60 H-A-L-R-I-P-S-G-F-I-S-Y-I-L-N 1.27983 -0.34013 -1.90229 4.789845 -0.69278 3.275921 -0.19787 
61 I-P-S-G-F-I-S-Y-I-L-N-R-H-D-N -1.44875 -2.2778 -3.48475 5.888362 -2.59275 -1.22461 -0.60346 
62 F-I-S-Y-I-L-N-R-H-D-N-Q-N-L-R -0.56413 -3.99176 -3.09968 4.02033 -4.35063 2.003851 0.121354 
63 I-L-N-R-H-D-N-Q-N-L-R-V-A-K-I -0.29482 -2.41932 -4.8978 7.745597 -3.48009 -1.30032 -1.52099 
64 H-D-N-Q-N-L-R-V-A-K-I-S-M-P-V 0.763553 -2.10075 -3.1747 9.112189 -2.6302 1.556026 -0.03869 
65 N-L-R-V-A-K-I-S-M-P-V-N-T-P-G 1.762748 -0.65806 -1.54009 1.387809 -1.26901 4.943701 -0.14482 
66 A-K-I-S-M-P-V-N-T-P-G-Q-F-E-D 0.097679 -2.00263 -2.70565 2.404973 -2.45659 3.865393 -2.0749 
67 M-P-V-N-T-P-G-Q-F-E-D-F-F-P-A 2.081545 -1.66788 -3.16714 7.203564 -2.6671 -1.41603 -2.08979 
68 T-P-G-Q-F-E-D-F-F-P-A-S-S-R-D 2.276861 -0.7278 -3.8584 7.067924 -2.77275 7.948578 -1.18195 
69 F-E-D-F-F-P-A-S-S-R-D-Q-S-S-Y 1.174604 -3.72272 -6.29759 20.07324 -5.30457 -1.65357 -1.29931 
70 F-P-A-S-S-R-D-Q-S-S-Y-L-Q-G-F 1.6363 -1.74259 -3.67252 7.208388 -2.34978 1.939091 -0.43325 
71 S-R-D-Q-S-S-Y-L-Q-G-F-S-R-N-T 0.003564 -0.53398 -1.91013 2.44172 -0.73358 5.228478 0.554209 
72 S-S-Y-L-Q-G-F-S-R-N-T-L-E-A-A 1.343762 -1.98017 -1.80987 6.121739 -2.19501 46.65005 -0.26445 
73 Q-G-F-S-R-N-T-L-E-A-A-F-N-A-E 1.023823 -0.90585 -1.99593 2.139241 -0.94896 19.84758 -0.1404 
74 R-N-T-L-E-A-A-F-N-A-E-F-N-E-I 0.487275 -0.8667 -2.31442 5.184757 -0.82155 18.61958 0.406454 
75 E-A-A-F-N-A-E-F-N-E-I-R-R-V-L -2.26439 -3.50915 -4.63532 6.326209 -3.96216 84.79687 -0.81812 
76 N-A-E-F-N-E-I-R-R-V-L-L-E-E-N -1.97503 -2.73207 -3.96148 4.349267 -3.12254 17.50704 -1.02198 
77 N-E-I-R-R-V-L-L-E-E-N-A-G-G-E 1.019229 -0.27111 -0.96504 3.539903 -0.76229 4.903384 0.877217 
78 R-V-L-L-E-E-N-A-G-G-E-Q-E-E-R -0.39796 -1.09535 -2.21322 15.47838 -1.34488 2.734498 -0.15986 
79 E-E-N-A-G-G-E-Q-E-E-R-G-Q-R-R -0.27188 -2.13181 -3.10937 7.975181 -2.59953 82.8984 0.016161 
80 G-G-E-Q-E-E-R-G-Q-R-R-W-S-T-R -1.18236 -0.83977 -3.09828 4.938107 -1.36916 71.03789 -0.18467 
81 E-E-R-G-Q-R-R-W-S-T-R-S-S-E-N -0.88357 -1.12268 -2.95214 3.641478 -1.90443 1.887181 -1.37766 
 Appendix  197 
82 Q-R-R-W-S-T-R-S-S-E-N-N-E-G-V 0.010135 -0.57115 -2.16878 6.035965 -1.05423 3.055322 -0.5497 
83 S-T-R-S-S-E-N-N-E-G-V-I-V-K-V 0.349271 -0.71599 -2.16071 0.067494 -0.6455 4.35222 -0.54183 
84 S-E-N-N-E-G-V-I-V-K-V-S-K-E-H 0.619446 -0.64471 -2.0279 0.867102 -0.57462 3.853674 -0.07418 
85 E-G-V-I-V-K-V-S-K-E-H-V-E-E-L 0.176544 -0.95783 -2.69025 2.578179 -1.09293 4.65444 -0.6995 
86 V-K-V-S-K-E-H-V-E-E-L-T-K-H-A 1.029564 -0.73646 -1.99448 5.78152 -0.7728 3.759325 0.359229 
87 K-E-H-V-E-E-L-T-K-H-A-K-S-V-S 1.60631 -0.60872 -1.65484 1.650923 -0.48078 2.590366 -0.13638 
88 E-E-L-T-K-H-A-K-S-V-S-K-K-G-S 4.137314 -1.84453 -1.87632 12.86526 -3.04345 7.045041 0.083039 
89 K-H-A-K-S-V-S-K-K-G-S-E-E-E-G 0.620582 -1.14283 -2.26767 0.840543 -1.05761 1.924737 -0.46654 
90 S-V-S-K-K-G-S-E-E-E-G-D-I-T-N 0.943515 -1.08291 -2.35526 1.550687 -1.44285 1.899378 -0.94539 
91 K-G-S-E-E-E-G-D-I-T-N-P-I-N-L 1.974438 -2.46689 -3.80354 2.726453 -3.45365 41.15605 -3.09655 
92 E-E-G-D-I-T-N-P-I-N-L-R-E-G-E 0.22862 -0.62852 -3.16838 4.254572 -1.46068 79.51409 -0.95017 
93 I-T-N-P-I-N-L-R-E-G-E-P-D-L-S 0.363528 -0.60529 -2.73898 1.296163 -1.11378 15.28644 -0.85971 
94 I-N-L-R-E-G-E-P-D-L-S-N-N-F-G -1.22606 -2.38749 -4.7741 5.363796 -3.81699 3.868038 -2.57686 
95 E-G-E-P-D-L-S-N-N-F-G-K-L-F-E 0.69008 -0.18977 -1.78817 0.455686 -0.32037 23.86536 -0.04119 
96 D-L-S-N-N-F-G-K-L-F-E-V-K-P-D 0.095137 -1.33558 -2.82432 3.57121 -1.46772 71.06849 -0.03759 
97 N-F-G-K-L-F-E-V-K-P-D-K-K-N-P 0.286455 -0.33365 -1.52579 0.120074 -0.1989 87.98348 0.597717 
98 L-F-E-V-K-P-D-K-K-N-P-Q-L-Q-D 0.985374 -0.23446 -1.40196 0.416865 -0.5247 33.65645 -0.05545 
99 K-P-D-K-K-N-P-Q-L-Q-D-L-D-M-M -0.29081 -0.96209 -2.08834 1.909313 -0.52197 34.5097 -0.05699 
100 K-N-P-Q-L-Q-D-L-D-M-M-L-T-C-V -0.23861 -0.8442 -1.73651 0.38165 -0.62912 11.72243 -0.43121 
101 L-Q-D-L-D-M-M-L-T-C-V-E-I-K-E 0.065326 -0.2387 -1.04457 1.169097 -0.49752 1.17193 -0.1127 
102 D-M-M-L-T-C-V-E-I-K-E-G-A-L-M 0.52351 0.005215 -1.46727 0.730989 -0.52578 7.882506 0.078658 
103 T-C-V-E-I-K-E-G-A-L-M-L-P-H-F 0.390627 -0.4551 -1.47642 0.445399 -0.25364 10.56739 -0.10895 
104 I-K-E-G-A-L-M-L-P-H-F-N-S-K-A 0.678282 -0.24142 -1.89884 1.928522 -0.34137 5.38557 0.928582 
105 A-L-M-L-P-H-F-N-S-K-A-M-V-I-V 1.10833 -0.59734 -1.70139 0.535054 -0.63438 14.95519 0.626058 
106 P-H-F-N-S-K-A-M-V-I-V-V-V-N-K 0.224611 -0.55107 -1.52634 0.202799 -0.70191 0.916232 0.094881 
107 S-K-A-M-V-I-V-V-V-N-K-G-T-G-N 0.929518 -0.83905 -1.78553 -0.42105 -0.58485 7.496838 -0.50099 
108 V-I-V-V-V-N-K-G-T-G-N-L-E-L-V 1.103849 0.010972 -1.53444 0.860202 -0.21427 2.499031 0.296273 
109 V-N-K-G-T-G-N-L-E-L-V-A-V-R-K 1.476227 -0.3665 -1.61933 -0.15819 -0.90177 5.014058 -0.41616 
110 T-G-N-L-E-L-V-A-V-R-K-E-Q-Q-Q 0.812081 -1.00644 -2.01111 1.745129 -0.83667 8.070343 -0.01603 
111 E-L-V-A-V-R-K-E-Q-Q-Q-R-G-R-R 0.306754 -1.29848 -0.50695 1.555976 -1.61355 22.57317 0.803256 
112 V-R-K-E-Q-Q-Q-R-G-R-R-E-E-E-E 0.078815 -0.80032 -2.77954 4.94899 -1.70217 3.583848 -1.90107 
113 Q-Q-Q-R-G-R-R-E-E-E-E-D-E-D-E 1.158755 -0.4896 -1.79243 2.329585 -0.96563 0.448798 -0.30257 
114 G-R-R-E-E-E-E-D-E-D-E-E-E-E-G 0.150689 -0.81422 -2.54762 -0.08744 -1.45023 -0.96502 -1.56727 
115 E-E-E-D-E-D-E-E-E-E-G-S-N-R-E 1.672738 -1.59803 -3.12167 3.3619 -2.04558 -1.28224 -1.93551 
116 E-D-E-E-E-E-G-S-N-R-E-V-R-R-Y -1.16297 -2.06335 -4.02093 1.705248 -2.59788 3.063667 -1.50236 
117 E-E-G-S-N-R-E-V-R-R-Y-T-A-R-L -0.75254 -1.55481 -3.60538 0.118237 -2.69302 5.949141 0.456818 
118 N-R-E-V-R-R-Y-T-A-R-L-K-E-G-D -1.92596 -2.85343 -4.8028 -0.62052 -4.11738 10.09974 -1.58336 
119 R-R-Y-T-A-R-L-K-E-G-D-V-F-I-M -1.76455 -2.34967 -3.61761 1.666245 -2.62181 12.91177 -0.40054 
120 A-R-L-K-E-G-D-V-F-I-M-P-A-A-H -0.18742 -0.66667 -1.92492 1.311712 -0.47342 8.499678 -0.16121 
121 E-G-D-V-F-I-M-P-A-A-H-P-V-A-I 0.34946 -0.50288 -1.66923 -0.0182 -0.36326 13.05531 0.204164 
122 F-I-M-P-A-A-H-P-V-A-I-N-A-S-S 1.25892 -0.60374 -1.87249 -0.73392 -0.67999 17.804 -0.61094 
123 A-A-H-P-V-A-I-N-A-S-S-E-L-H-L 1.245033 -0.29496 -1.47561 0.488373 -0.39192 9.969459 -0.27587 
124 V-A-I-N-A-S-S-E-L-H-L-L-G-F-G 0.905583 -0.35988 -2.10398 1.256405 -0.9979 2.617616 -0.51217 
125 A-S-S-E-L-H-L-L-G-F-G-I-N-A-E 0.721812 -0.68413 -0.73892 5.691862 -0.93617 1.93768 0.801827 
126 L-H-L-L-G-F-G-I-N-A-E-N-N-H-R -0.18883 -0.35492 -1.08954 1.70115 -0.94341 1.156267 2.945872 
 198  Appendix 
127 G-F-G-I-N-A-E-N-N-H-R-I-F-L-A 0.859069 -1.03097 -1.37157 4.770907 -1.28904 5.671551 1.244614 
128 N-A-E-N-N-H-R-I-F-L-A-G-D-K-D 1.811148 -0.05654 -1.71842 1.193345 -0.89886 41.52316 0.340664 
129 N-H-R-I-F-L-A-G-D-K-D-N-V-I-D 0.689382 -0.93498 -2.56878 6.038987 -1.64294 34.07875 -0.12066 
130 F-L-A-G-D-K-D-N-V-I-D-Q-I-E-K -0.86229 -1.16338 -3.08074 1.12141 -2.24074 3.813532 -1.53249 
131 D-K-D-N-V-I-D-Q-I-E-K-Q-A-K-D 0.601287 -0.84525 -2.34227 0.4441 -1.01161 3.196559 -0.2558 
132 V-I-D-Q-I-E-K-Q-A-K-D-L-A-F-P 0.426946 0.2044 -1.31044 0.142505 -0.10134 12.89432 -0.04939 
133 I-E-K-Q-A-K-D-L-A-F-P-G-S-G-E 1.395817 -0.13212 -1.37324 0.28643 -0.41136 32.46964 -0.20266 
134 A-K-D-L-A-F-P-G-S-G-E-Q-V-E-K 4.439058 0.345446 -1.45834 0.167279 -0.44265 56.61579 -0.31642 
135 A-F-P-G-S-G-E-Q-V-E-K-L-I-K-N 1.561207 -0.57819 -1.84461 -0.16999 -1.69778 8.622022 -1.04232 
136 S-G-E-Q-V-E-K-L-I-K-N-Q-K-E-S 0.727859 -0.76574 -1.89778 2.558091 -1.46236 10.53836 -0.67414 
137 V-E-K-L-I-K-N-Q-K-E-S-H-F-V-S 1.527385 -1.00239 -2.06928 1.337903 -1.4349 2.36331 -1.27941 
138 I-K-N-Q-K-E-S-H-F-V-S-A-R-P-Q 1.403968 -1.02841 -2.32454 1.391209 -1.3102 6.293002 -0.49962 
139 K-E-S-H-F-V-S-A-R-P-Q-S-Q-S-Q 0.653673 -0.58107 -2.68351 -0.61288 -0.9825 2.940888 -0.73043 
140 F-V-S-A-R-P-Q-S-Q-S-Q-S-P-S-S 1.62329 -0.69575 -2.2226 0.772396 -1.25317 6.354181 -0.86096 
141 R-P-Q-S-Q-S-Q-S-P-S-S-P-E-K-E 1.29013 -3.78136 -5.68413 8.070539 -5.28954 0.126745 -3.70254 
142 Q-S-Q-S-P-S-S-P-E-K-E-S-P-E-K -0.16997 -1.35748 -3.23488 1.399295 -2.44152 5.067135 -0.3413 
143 P-S-S-P-E-K-E-S-P-E-K-E-D-Q-E -0.4096 -0.66911 -2.1105 1.671941 -1.1692 1.26978 0.644171 
144 E-K-E-S-P-E-K-E-D-Q-E-E-E-N-Q -0.14961 -0.4581 -1.50818 1.138381 -0.75974 0.698105 -0.5293 
145 P-E-K-E-D-Q-E-E-E-N-Q-G-G-K-G 0.106742 -0.36948 -1.19924 -0.40625 -0.38914 5.165898 -0.05509 
146 D-Q-E-E-E-N-Q-G-G-K-G-P-L-L-S 0.560885 -0.68346 -1.61258 1.074246 -0.65625 11.72104 -0.29255 
147 E-N-Q-G-G-K-G-P-L-L-S-I-L-K-A -0.90939 -1.30346 -1.1399 0.047233 -1.83448 13.87053 0.385225 
148 Q-G-G-K-G-P-L-L-S-I-L-K-A-F-N 0.456469 -0.45187 -1.2362 1.783823 -0.87363 3.187916 0.243678 
 m (blanks) 12892.3 12559.93 13066.22 11346.16 12750 12111.35 13386.11 
 s (blanks) 431.2739 445.7373 676.0718 511.396 505.1061 521.3369 590.8274 
 
Table A2: Calculated Z-scores of Ara h 1 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 1 for each peanut-allergic patient (patients 8-14) are listed. 
Identified candidate diagnostic peptides are highlighted in light blue. 
 Patient No. → 8 9 10 11 12 13 14 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score Z-score 
1 K-S-S-P-Y-Q-K-K-T-E-N-P-C-A-Q -1.95659 -0.9748 28.32213 -1.02056 3.154055 -1.3093 -0.95876 
2 Y-Q-K-K-T-E-N-P-C-A-Q-R-C-L-Q -1.70399 -0.72228 27.98061 -0.96722 15.07417 -1.29529 -0.54623 
3 T-E-N-P-C-A-Q-R-C-L-Q-S-C-Q-Q -1.90137 -0.92278 30.25642 -1.32067 5.405221 -1.42 -0.41925 
4 C-A-Q-R-C-L-Q-S-C-Q-Q-E-P-D-D -2.22736 -0.88858 24.55488 -0.74194 8.777184 -1.15074 -0.16411 
5 C-L-Q-S-C-Q-Q-E-P-D-D-L-K-Q-K -2.68886 -1.13065 30.47329 -1.04345 54.6107 -1.62027 -0.20494 
6 C-Q-Q-E-P-D-D-L-K-Q-K-A-C-E-S -2.96386 -1.53973 4.569288 -1.99576 36.5301 -2.26513 -1.21718 
7 P-D-D-L-K-Q-K-A-C-E-S-R-C-T-K -3.06115 -1.21949 29.04902 -1.44213 4.512134 -1.74131 -0.30216 
8 K-Q-K-A-C-E-S-R-C-T-K-L-E-Y-D -2.50033 -1.02714 15.88542 -1.16613 3.087929 -1.6131 -0.25352 
9 C-E-S-R-C-T-K-L-E-Y-D-P-R-C-V -2.0122 -0.63176 9.339628 -1.05525 1.836523 -1.48725 0.04713 
10 C-T-K-L-E-Y-D-P-R-C-V-Y-D-P-R -3.13689 -0.90988 24.98933 -1.43512 4.969902 -1.79121 -0.24999 
11 E-Y-D-P-R-C-V-Y-D-P-R-G-H-T-G -1.65627 -0.76646 4.96319 -0.95284 0.437485 -1.46187 0.035702 
12 R-C-V-Y-D-P-R-G-H-T-G-T-T-N-Q -3.76779 -1.40395 20.80713 -1.86595 8.541282 -2.18965 -0.79305 
13 D-P-R-G-H-T-G-T-T-N-Q-R-S-P-P -2.72852 -1.01334 32.48072 -1.19182 20.23727 -1.89416 -0.11027 
14 H-T-G-T-T-N-Q-R-S-P-P-G-E-R-T -3.04365 -1.14844 20.47111 -1.67933 27.20273 -1.8419 -0.14598 
 Appendix  199 
15 T-N-Q-R-S-P-P-G-E-R-T-R-G-R-Q -4.35739 -1.76217 31.43215 -2.22998 67.17763 -2.5868 -1.03452 
16 S-P-P-G-E-R-T-R-G-R-Q-P-G-D-Y -4.60482 -1.61098 43.95711 -2.17648 40.16761 -2.47917 -0.43438 
17 E-R-T-R-G-R-Q-P-G-D-Y-D-D-D-R -4.27141 -0.89645 44.84097 -1.75723 62.55321 -1.8174 0.151566 
18 G-R-Q-P-G-D-Y-D-D-D-R-R-Q-P-R -4.92826 -2.26625 40.27803 -2.31852 2.922465 -3.20201 -1.0525 
19 G-D-Y-D-D-D-R-R-Q-P-R-R-E-E-G -4.30468 -2.01768 33.4155 -1.56813 4.812093 -2.24927 -2.15071 
20 D-D-R-R-Q-P-R-R-E-E-G-G-R-W-G -3.84646 -0.77439 40.84421 -0.79981 4.347127 -1.15198 -1.63586 
21 Q-P-R-R-E-E-G-G-R-W-G-P-A-G-P -4.08243 -1.30404 39.99965 -1.09358 42.02121 -1.68646 -1.57333 
22 E-E-G-G-R-W-G-P-A-G-P-R-E-R-E -3.20261 -0.9118 38.09706 -0.81459 56.07108 -1.31945 -1.10252 
23 R-W-G-P-A-G-P-R-E-R-E-R-E-E-D -2.1785 -0.13587 28.48982 -0.83454 10.54478 -0.82855 -1.06853 
24 A-G-P-R-E-R-E-R-E-E-D-W-R-Q-P -4.01635 -1.67219 27.05348 -1.36109 11.67284 -2.45914 -2.01368 
25 E-R-E-R-E-E-D-W-R-Q-P-R-E-D-W -2.34874 -0.74291 20.3634 -0.81399 13.07171 -1.07726 -0.63446 
26 E-E-D-W-R-Q-P-R-E-D-W-R-R-P-S -2.43097 -1.25448 31.45863 -1.69233 56.73027 -1.71155 -1.18392 
27 R-Q-P-R-E-D-W-R-R-P-S-H-Q-Q-P -2.42284 -0.88603 27.67624 -1.34498 48.56553 -1.37356 -1.07931 
28 E-D-W-R-R-P-S-H-Q-Q-P-R-K-I-R -1.7439 -0.75816 39.15998 -0.84611 51.25444 -0.98538 -0.02562 
29 R-P-S-H-Q-Q-P-R-K-I-R-P-E-G-R -1.55411 -1.34788 41.66455 -1.2656 64.91187 -1.60245 -0.11078 
30 Q-Q-P-R-K-I-R-P-E-G-R-E-G-E-Q -2.41992 -0.74356 40.1034 -1.11412 26.24605 -1.55143 -0.56376 
31 K-I-R-P-E-G-R-E-G-E-Q-E-W-G-T -3.6755 -1.47951 26.54775 -1.52008 6.79105 -1.6782 -0.47748 
32 E-G-R-E-G-E-Q-E-W-G-T-P-G-S-H -3.22131 -0.75038 41.81443 -0.97398 64.54864 -1.03388 -0.18995 
33 G-E-Q-E-W-G-T-P-G-S-H-V-R-E-E -3.49618 -1.16457 34.43459 -1.58677 32.8207 -1.75933 -0.39217 
34 W-G-T-P-G-S-H-V-R-E-E-T-S-R-N -2.78312 -0.70042 31.02987 -1.14687 12.60519 -1.37668 -0.2298 
35 G-S-H-V-R-E-E-T-S-R-N-N-P-F-Y -1.88367 -0.39236 24.06783 -0.7242 7.009681 -0.87195 0.118452 
36 R-E-E-T-S-R-N-N-P-F-Y-F-P-S-R -3.04226 -1.28867 28.31891 -1.42375 38.86193 -1.70589 -0.51971 
37 S-R-N-N-P-F-Y-F-P-S-R-R-F-S-T -5.26766 -4.13936 19.39534 -4.62836 44.0612 -4.31022 -3.28579 
38 P-F-Y-F-P-S-R-R-F-S-T-R-Y-G-N -6.76174 -5.29454 -1.0646 -5.86614 42.61004 -6.57917 -4.86849 
39 P-S-R-R-F-S-T-R-Y-G-N-Q-N-G-R -5.01532 -2.61147 11.58551 -2.51812 66.81428 -3.15281 -0.97199 
40 F-S-T-R-Y-G-N-Q-N-G-R-I-R-V-L -9.74517 -5.95433 23.02381 -6.23201 8.94139 -6.80864 -3.89949 
41 Y-G-N-Q-N-G-R-I-R-V-L-Q-R-F-D -7.63284 -4.66225 8.338671 -5.01255 3.68042 -5.58776 -3.2951 
42 N-G-R-I-R-V-L-Q-R-F-D-Q-R-S-R -4.33543 -2.67799 8.863296 -3.26766 -0.76943 -3.54223 -1.45271 
43 R-V-L-Q-R-F-D-Q-R-S-R-Q-F-Q-N -3.67881 -1.49484 31.49582 -1.6495 4.079253 -1.77369 -2.56039 
44 R-F-D-Q-R-S-R-Q-F-Q-N-L-Q-N-H -3.54523 -1.20429 38.92599 -1.0706 11.6329 -1.93416 -2.38623 
45 R-S-R-Q-F-Q-N-L-Q-N-H-R-I-V-Q -4.28232 -2.5037 21.27771 -2.60691 2.570334 -2.92144 -2.43714 
46 F-Q-N-L-Q-N-H-R-I-V-Q-I-E-A-K -4.67516 -3.37761 10.424 -2.14983 6.189928 -3.43808 -2.45735 
47 Q-N-H-R-I-V-Q-I-E-A-K-P-N-T-L -2.08582 -0.39765 26.67359 -0.78134 29.03791 -0.8685 -1.22068 
48 I-V-Q-I-E-A-K-P-N-T-L-V-L-P-K -2.72193 -1.26749 29.14652 -0.23567 36.90959 -1.22451 -1.32635 
49 E-A-K-P-N-T-L-V-L-P-K-H-A-D-A -2.40047 -1.03821 38.93817 -1.28687 37.0244 -1.53828 -1.55528 
50 N-T-L-V-L-P-K-H-A-D-A-D-N-I-L -2.30965 -0.88346 21.02735 -1.08714 11.17291 -1.50525 -0.8377 
51 L-P-K-H-A-D-A-D-N-I-L-V-I-Q-Q -3.06083 -1.75711 26.34838 -1.69477 11.04157 -1.99793 -1.41468 
52 A-D-A-D-N-I-L-V-I-Q-Q-G-Q-A-T -4.32171 -3.35 31.99103 -2.46565 8.986276 -3.03584 -2.08664 
53 N-I-L-V-I-Q-Q-G-Q-A-T-V-T-V-A -2.71195 -0.88165 31.87971 -1.18715 26.16084 -1.77105 -0.70725 
54 I-Q-Q-G-Q-A-T-V-T-V-A-N-G-N-N -4.36631 -2.03965 36.56951 -1.28325 8.660403 -2.52724 -1.57681 
55 Q-A-T-V-T-V-A-N-G-N-N-R-K-S-F -6.15323 -3.8656 31.65103 -3.26051 8.065576 -4.49434 -3.39188 
56 T-V-A-N-G-N-N-R-K-S-F-N-L-D-E -3.93427 -2.02134 38.35496 -1.80216 32.68206 -2.21638 -0.6439 
57 G-N-N-R-K-S-F-N-L-D-E-G-H-A-L -6.24716 -3.5042 21.3057 -3.82783 7.128677 -4.47682 -1.90784 
58 K-S-F-N-L-D-E-G-H-A-L-R-I-P-S -3.42325 -0.8617 14.97481 -0.98083 12.95737 -1.28267 -0.08034 
59 L-D-E-G-H-A-L-R-I-P-S-G-F-I-S -2.82814 -0.90822 17.84863 -1.13912 16.41646 -1.16782 -0.01704 
 200  Appendix 
60 H-A-L-R-I-P-S-G-F-I-S-Y-I-L-N -3.03754 -0.89264 11.49409 -0.88715 10.95521 -1.27717 -0.18422 
61 I-P-S-G-F-I-S-Y-I-L-N-R-H-D-N -5.26312 -2.50612 4.403284 -2.8269 10.44105 -3.06633 -1.90367 
62 F-I-S-Y-I-L-N-R-H-D-N-Q-N-L-R -6.55293 -4.33353 7.972951 -4.43163 20.7229 -5.02993 -3.62711 
63 I-L-N-R-H-D-N-Q-N-L-R-V-A-K-I -6.56412 -3.93581 23.73727 -3.55423 10.24125 -4.14117 -2.6765 
64 H-D-N-Q-N-L-R-V-A-K-I-S-M-P-V -6.97025 -3.12334 14.49116 -2.98602 9.581601 -3.26115 -1.23369 
65 N-L-R-V-A-K-I-S-M-P-V-N-T-P-G -4.32774 -1.44849 24.12757 -1.63928 10.58732 -1.66871 -0.25848 
66 A-K-I-S-M-P-V-N-T-P-G-Q-F-E-D -5.79621 -2.9769 17.66403 -3.03783 5.944445 -3.59615 -1.07006 
67 M-P-V-N-T-P-G-Q-F-E-D-F-F-P-A -5.57132 -3.06898 4.990334 -2.07883 -1.90449 -3.01951 -4.14832 
68 T-P-G-Q-F-E-D-F-F-P-A-S-S-R-D -4.90563 -2.56269 28.01848 -1.57662 46.17325 -2.92654 -3.37069 
69 F-E-D-F-F-P-A-S-S-R-D-Q-S-S-Y -8.26829 -5.83556 18.40411 -6.03988 20.54574 -6.32858 -6.45383 
70 F-P-A-S-S-R-D-Q-S-S-Y-L-Q-G-F -4.78177 -2.05902 34.02838 -1.52097 35.56388 -2.60334 -1.49791 
71 S-R-D-Q-S-S-Y-L-Q-G-F-S-R-N-T -2.43575 -0.64598 27.28941 -0.92118 69.60847 -1.26575 -1.35977 
72 S-S-Y-L-Q-G-F-S-R-N-T-L-E-A-A -3.76234 -2.12827 39.24736 -2.39171 68.22886 -2.88902 -2.68849 
73 Q-G-F-S-R-N-T-L-E-A-A-F-N-A-E -2.30039 -0.71307 18.39498 -0.95202 61.99179 -1.31067 -1.43398 
74 R-N-T-L-E-A-A-F-N-A-E-F-N-E-I -2.56312 -0.92668 16.1269 -0.97779 29.32206 -1.19154 -0.84236 
75 E-A-A-F-N-A-E-F-N-E-I-R-R-V-L -5.58834 -4.00334 15.92522 -4.17499 60.79135 -4.24091 -3.95547 
76 N-A-E-F-N-E-I-R-R-V-L-L-E-E-N -5.47853 -3.47741 15.02592 -3.13435 26.7283 -3.56129 -2.6173 
77 N-E-I-R-R-V-L-L-E-E-N-A-G-G-E -2.10309 -1.19695 20.36413 -0.62934 7.936962 -1.13886 -0.02144 
78 R-V-L-L-E-E-N-A-G-G-E-Q-E-E-R -3.67445 -1.46928 14.95988 -1.40336 1.582423 -2.09503 -0.47297 
79 E-E-N-A-G-G-E-Q-E-E-R-G-Q-R-R -4.90388 -2.75702 20.55115 -2.39546 8.796237 -3.02114 -2.12181 
80 G-G-E-Q-E-E-R-G-Q-R-R-W-S-T-R -4.41715 -1.09659 18.1262 -1.34526 62.41933 -1.61712 -1.04978 
81 E-E-R-G-Q-R-R-W-S-T-R-S-S-E-N -4.20101 -1.67343 22.86455 -2.03128 57.77568 -1.93389 -0.78342 
82 Q-R-R-W-S-T-R-S-S-E-N-N-E-G-V -3.97633 -0.92561 17.6941 -0.59024 13.55107 -1.24286 -0.13821 
83 S-T-R-S-S-E-N-N-E-G-V-I-V-K-V -2.83874 -0.58951 18.41104 -0.88999 9.166118 -1.09391 0.073327 
84 S-E-N-N-E-G-V-I-V-K-V-S-K-E-H -2.39698 -0.53751 13.92797 -0.81565 9.493182 -1.00714 0.017886 
85 E-G-V-I-V-K-V-S-K-E-H-V-E-E-L -3.83701 -1.16178 7.494784 -1.35485 16.82802 -1.80667 -0.66811 
86 V-K-V-S-K-E-H-V-E-E-L-T-K-H-A -4.26815 -0.98531 15.01437 -0.92839 68.73451 -1.35001 -0.3372 
87 K-E-H-V-E-E-L-T-K-H-A-K-S-V-S -3.39306 -0.75574 14.43885 -0.79939 21.02147 -1.13556 0.243638 
88 E-E-L-T-K-H-A-K-S-V-S-K-K-G-S -5.93593 -2.81133 11.59875 -3.22317 17.22047 -3.54828 -1.6943 
89 K-H-A-K-S-V-S-K-K-G-S-E-E-E-G -4.13459 -1.55797 4.91766 -1.72304 0.923406 -1.83939 0.16838 
90 S-V-S-K-K-G-S-E-E-E-G-D-I-T-N -4.46371 -1.63945 11.7039 -1.36741 5.777961 -1.97402 -0.50117 
91 K-G-S-E-E-E-G-D-I-T-N-P-I-N-L -6.37508 -2.9604 29.18696 -3.41948 7.741442 -3.54009 -4.81018 
92 E-E-G-D-I-T-N-P-I-N-L-R-E-G-E -4.33165 -1.3087 23.90777 -1.21587 51.32941 -1.94206 -2.74132 
93 I-T-N-P-I-N-L-R-E-G-E-P-D-L-S -3.70798 -0.98746 37.48644 -1.3126 14.57472 -1.46316 -1.79034 
94 I-N-L-R-E-G-E-P-D-L-S-N-N-F-G -6.54988 -4.28538 30.71264 -3.89925 9.437336 -4.58642 -4.3245 
95 E-G-E-P-D-L-S-N-N-F-G-K-L-F-E -1.46864 -0.18839 28.65561 -0.62818 36.15118 -0.6046 -1.05615 
96 D-L-S-N-N-F-G-K-L-F-E-V-K-P-D -3.32656 -1.4513 17.49017 -1.81756 68.98493 -1.91991 -2.17652 
97 N-F-G-K-L-F-E-V-K-P-D-K-K-N-P -1.34616 -0.24934 43.79128 -0.40151 71.75407 -0.36747 -1.09402 
98 L-F-E-V-K-P-D-K-K-N-P-Q-L-Q-D -1.88738 -0.31497 25.41027 -0.19021 49.6988 -0.51912 -0.68788 
99 K-P-D-K-K-N-P-Q-L-Q-D-L-D-M-M -3.34328 -0.83561 22.1567 -0.72622 22.46037 -0.97099 -0.99947 
100 K-N-P-Q-L-Q-D-L-D-M-M-L-T-C-V -3.00073 -0.93314 32.93555 -0.69971 14.14359 -0.83271 -0.80638 
101 L-Q-D-L-D-M-M-L-T-C-V-E-I-K-E -2.16061 -0.75852 18.61924 -0.6068 8.41766 -0.90694 0.00928 
102 D-M-M-L-T-C-V-E-I-K-E-G-A-L-M -1.75093 -0.52462 35.61738 -0.57673 12.83006 -1.01601 -0.25256 
103 T-C-V-E-I-K-E-G-A-L-M-L-P-H-F -2.06488 -0.45057 30.74046 -0.55748 9.895376 -0.77067 -0.17947 
104 I-K-E-G-A-L-M-L-P-H-F-N-S-K-A -2.68508 -0.61064 16.36029 -0.43815 11.84385 -0.79197 -0.31379 
 Appendix  201 
105 A-L-M-L-P-H-F-N-S-K-A-M-V-I-V -1.95496 -0.63669 27.3953 -0.99294 33.78562 -1.02833 -0.58665 
106 P-H-F-N-S-K-A-M-V-I-V-V-V-N-K -1.95991 -0.45497 3.332093 -0.60686 4.327043 -0.67126 -0.05001 
107 S-K-A-M-V-I-V-V-V-N-K-G-T-G-N -2.34644 -0.68172 22.68506 -0.88156 21.24308 -1.07402 -0.34188 
108 V-I-V-V-V-N-K-G-T-G-N-L-E-L-V -1.63305 -0.46442 20.19798 -0.57221 12.88336 -0.65924 0.154055 
109 V-N-K-G-T-G-N-L-E-L-V-A-V-R-K -2.61686 -0.78952 12.16114 -0.93539 14.26844 -1.21454 -0.09956 
110 T-G-N-L-E-L-V-A-V-R-K-E-Q-Q-Q -3.4309 -1.03309 22.7292 -1.01179 28.42642 -1.34545 -0.49917 
111 E-L-V-A-V-R-K-E-Q-Q-Q-R-G-R-R -4.28453 -1.46861 9.242728 -1.90113 15.69295 -1.89389 -1.03123 
112 V-R-K-E-Q-Q-Q-R-G-R-R-E-E-E-E -5.42357 -2.23325 3.134943 -2.15699 5.698975 -3.14783 -1.2912 
113 Q-Q-Q-R-G-R-R-E-E-E-E-D-E-D-E -4.28854 -1.31728 11.02947 -1.10987 2.351958 -1.79373 0.007391 
114 G-R-R-E-E-E-E-D-E-D-E-E-E-E-G -4.44486 -1.6407 5.843318 -1.54489 0.559364 -2.0747 0.238667 
115 E-E-E-D-E-D-E-E-E-E-G-S-N-R-E -5.19245 -1.75737 13.16345 -1.48821 0.230413 -1.85686 -3.66614 
116 E-D-E-E-E-E-G-S-N-R-E-V-R-R-Y -5.97016 -2.66847 26.06144 -2.5327 2.02125 -3.18929 -4.57536 
117 E-E-G-S-N-R-E-V-R-R-Y-T-A-R-L -5.46785 -2.66487 36.82831 -2.73539 8.177685 -2.67505 -3.19838 
118 N-R-E-V-R-R-Y-T-A-R-L-K-E-G-D -6.1529 -4.11179 33.40749 -3.81633 28.26598 -4.74945 -4.95809 
119 R-R-Y-T-A-R-L-K-E-G-D-V-F-I-M -4.73953 -2.52389 26.24127 -2.65123 21.76096 -3.10391 -3.59705 
120 A-R-L-K-E-G-D-V-F-I-M-P-A-A-H -2.40236 -0.68516 36.23816 -0.82042 69.34375 -0.66402 -1.4244 
121 E-G-D-V-F-I-M-P-A-A-H-P-V-A-I -1.98684 -0.5432 29.86549 -0.47905 68.33136 -0.68841 -0.91844 
122 F-I-M-P-A-A-H-P-V-A-I-N-A-S-S -2.03051 -0.81399 35.63426 -0.91636 26.31066 -0.92685 -1.04279 
123 A-A-H-P-V-A-I-N-A-S-S-E-L-H-L -1.90041 -0.4741 32.66196 -0.4481 26.87225 -0.80488 -0.41288 
124 V-A-I-N-A-S-S-E-L-H-L-L-G-F-G -2.77697 -0.9404 41.33419 -1.1193 62.21924 -1.39702 -0.58982 
125 A-S-S-E-L-H-L-L-G-F-G-I-N-A-E -2.83207 -1.36229 44.24118 -0.32327 68.95564 -1.03879 -1.0403 
126 L-H-L-L-G-F-G-I-N-A-E-N-N-H-R -1.74127 -1.19878 32.87419 -1.18007 26.69934 -1.1841 -0.98672 
127 G-F-G-I-N-A-E-N-N-H-R-I-F-L-A -2.65212 -1.02887 17.48057 -0.67573 15.64811 -1.17244 -0.71563 
128 N-A-E-N-N-H-R-I-F-L-A-G-D-K-D -2.45861 -0.82349 38.11183 -0.57664 33.53718 -1.11492 -0.77901 
129 N-H-R-I-F-L-A-G-D-K-D-N-V-I-D -3.07595 -1.49049 25.4557 -1.26836 15.31328 -1.87731 -1.27826 
130 F-L-A-G-D-K-D-N-V-I-D-Q-I-E-K -3.75404 -1.73834 14.19805 -1.85314 16.94452 -2.1449 -1.53697 
131 D-K-D-N-V-I-D-Q-I-E-K-Q-A-K-D -3.02897 -1.04999 9.62185 -0.80391 67.30114 -1.37824 -0.7272 
132 V-I-D-Q-I-E-K-Q-A-K-D-L-A-F-P -2.00311 -0.1268 16.79361 -0.21957 10.28472 -0.45562 0.350361 
133 I-E-K-Q-A-K-D-L-A-F-P-G-S-G-E -1.94985 -0.34616 19.72019 -0.39259 17.80648 -0.73441 0.028981 
134 A-K-D-L-A-F-P-G-S-G-E-Q-V-E-K -2.55642 -0.45477 39.2377 -0.48013 70.46387 -0.69394 -0.14828 
135 A-F-P-G-S-G-E-Q-V-E-K-L-I-K-N -3.97308 -1.49994 21.19931 -1.74397 60.38143 -2.01956 -0.51783 
136 S-G-E-Q-V-E-K-L-I-K-N-Q-K-E-S -3.9641 -1.57241 21.44991 -1.46967 13.61802 -1.87466 -0.40943 
137 V-E-K-L-I-K-N-Q-K-E-S-H-F-V-S -4.40277 -1.68464 23.55864 -1.54123 12.12174 -2.20248 -0.22919 
138 I-K-N-Q-K-E-S-H-F-V-S-A-R-P-Q -4.23144 -2.0294 18.97533 -1.44276 2.129672 -2.1406 -0.88678 
139 K-E-S-H-F-V-S-A-R-P-Q-S-Q-S-Q -3.49273 -0.72007 29.49061 -0.90466 3.473776 -0.87857 -2.35523 
140 F-V-S-A-R-P-Q-S-Q-S-Q-S-P-S-S -3.95662 -1.28279 34.0999 -0.10611 9.606716 -1.1403 -2.93057 
141 R-P-Q-S-Q-S-Q-S-P-S-S-P-E-K-E -8.85993 -6.37182 17.50627 -5.97246 -0.31476 -5.48508 -7.30835 
142 Q-S-Q-S-P-S-S-P-E-K-E-S-P-E-K -4.40123 -2.39583 24.36413 -1.48408 4.115392 -2.28942 -2.64742 
143 P-S-S-P-E-K-E-S-P-E-K-E-D-Q-E -2.63767 -0.93368 9.101563 -0.86804 2.84826 -1.25326 -1.30512 
144 E-K-E-S-P-E-K-E-D-Q-E-E-E-N-Q -2.69051 -0.74105 6.020583 -0.53462 5.785766 -0.82766 -1.586 
145 P-E-K-E-D-Q-E-E-E-N-Q-G-G-K-G -2.06127 -0.52956 8.681872 -0.59942 13.28093 -0.58481 -1.36498 
146 D-Q-E-E-E-N-Q-G-G-K-G-P-L-L-S -2.60921 -1.17338 22.88251 -1.05474 17.46192 -1.03748 -1.39874 
147 E-N-Q-G-G-K-G-P-L-L-S-I-L-K-A -4.25013 -1.7635 28.03346 -1.66148 15.51753 -2.11536 -2.26971 
148 Q-G-G-K-G-P-L-L-S-I-L-K-A-F-N -3.64914 -0.99271 22.94198 -0.51518 14.53463 -1.07225 -1.21109 
 m (blanks) 20519.35 13674.02 11670.57 11374.72 11569.74 12656.75 11931.75 
 202  Appendix 
 s (blanks) 805.9902 491.9029 1013.109 509.6116 658.8546 490.372 397.9312 
 
Table A3: Calculated Z-scores of Ara h 1 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 1 for each peanut-allergic patient (patients 15-21) are listed. 
Identified candidate diagnostic peptides are highlighted in light blue. 
 Patient No. → 15 16 17 18 19 20 21 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score Z-score 
1 K-S-S-P-Y-Q-K-K-T-E-N-P-C-A-Q 0.758263 -1.66117 8.686188 14.59167 -1.79666 -1.9845 14.8168 
2 Y-Q-K-K-T-E-N-P-C-A-Q-R-C-L-Q 6.650542 -1.59004 14.27505 50.21214 -1.56814 -1.99411 18.17452 
3 T-E-N-P-C-A-Q-R-C-L-Q-S-C-Q-Q 5.617234 -1.67897 7.590709 79.50092 -1.67817 -1.94595 6.551018 
4 C-A-Q-R-C-L-Q-S-C-Q-Q-E-P-D-D 1.000938 -0.92755 10.06951 31.98972 -1.41009 -1.36392 17.70244 
5 C-L-Q-S-C-Q-Q-E-P-D-D-L-K-Q-K 0.812902 -1.12838 11.98374 19.47551 -1.89848 -1.86399 10.61772 
6 C-Q-Q-E-P-D-D-L-K-Q-K-A-C-E-S -1.58772 -2.00222 7.512719 26.87851 -1.89182 -1.54865 16.95777 
7 P-D-D-L-K-Q-K-A-C-E-S-R-C-T-K -1.59696 -1.29049 4.578547 30.83419 -1.40282 -1.63588 27.68044 
8 K-Q-K-A-C-E-S-R-C-T-K-L-E-Y-D -0.6145 -1.04544 4.210649 7.300528 -1.78057 -1.59691 6.014428 
9 C-E-S-R-C-T-K-L-E-Y-D-P-R-C-V 1.217389 -0.81995 8.846369 2.930048 -1.40647 -1.18977 6.974979 
10 C-T-K-L-E-Y-D-P-R-C-V-Y-D-P-R -0.43066 -1.26932 15.71256 3.578001 -2.0053 -1.45402 1.970958 
11 E-Y-D-P-R-C-V-Y-D-P-R-G-H-T-G -1.67995 -0.90905 5.737663 2.477852 -1.32823 -0.85221 1.602457 
12 R-C-V-Y-D-P-R-G-H-T-G-T-T-N-Q -0.04374 -1.32199 6.651678 14.41312 -2.64247 -1.83133 5.322504 
13 D-P-R-G-H-T-G-T-T-N-Q-R-S-P-P 5.233717 -0.86873 10.14217 31.00757 -1.51666 -1.07005 5.380502 
14 H-T-G-T-T-N-Q-R-S-P-P-G-E-R-T 5.05205 -0.92656 13.80843 50.37398 -1.37656 -0.98748 13.61322 
15 T-N-Q-R-S-P-P-G-E-R-T-R-G-R-Q 5.396772 -0.96323 23.84259 47.59736 -2.26482 -1.91054 15.21628 
16 S-P-P-G-E-R-T-R-G-R-Q-P-G-D-Y 101.6422 -1.54412 138.9754 75.73122 -2.21237 -1.5714 34.37273 
17 E-R-T-R-G-R-Q-P-G-D-Y-D-D-D-R 94.74203 -0.78214 156.2092 79.27746 -1.69849 -0.65665 35.48695 
18 G-R-Q-P-G-D-Y-D-D-D-R-R-Q-P-R 4.39623 -1.13399 128.5906 38.32581 -2.8064 -1.78989 33.40966 
19 G-D-Y-D-D-D-R-R-Q-P-R-R-E-E-G -1.70135 -3.26375 10.27734 12.89541 -4.55987 -4.30123 12.14392 
20 D-D-R-R-Q-P-R-R-E-E-G-G-R-W-G -1.30447 -2.61614 5.510301 23.62639 -3.12526 -2.60206 31.50405 
21 Q-P-R-R-E-E-G-G-R-W-G-P-A-G-P -1.63822 -2.68659 4.044611 33.37429 -3.34322 -3.11166 32.74187 
22 E-E-G-G-R-W-G-P-A-G-P-R-E-R-E -0.71288 -2.13091 10.18315 20.60521 -2.31348 -2.38675 9.042681 
23 R-W-G-P-A-G-P-R-E-R-E-R-E-E-D 0.279429 -1.69453 7.663261 14.33005 -1.79531 -1.67325 3.067443 
24 A-G-P-R-E-R-E-R-E-E-D-W-R-Q-P -1.69042 -1.97168 4.2548 10.70637 -3.57795 -3.28326 5.536934 
25 E-R-E-R-E-E-D-W-R-Q-P-R-E-D-W 5.472416 -1.74171 24.31029 38.3183 -1.67231 -1.68774 34.68093 
26 E-E-D-W-R-Q-P-R-E-D-W-R-R-P-S 104.7279 -2.18768 119.0229 55.6263 -2.29825 -2.45572 12.731 
27 R-Q-P-R-E-D-W-R-R-P-S-H-Q-Q-P 101.061 -1.35483 121.8896 77.30616 -1.71439 -1.68078 20.01693 
28 E-D-W-R-R-P-S-H-Q-Q-P-R-K-I-R 13.94241 -1.01535 32.19087 71.18853 -0.04886 -1.36856 35.38292 
29 R-P-S-H-Q-Q-P-R-K-I-R-P-E-G-R 5.028631 -1.58021 72.42044 77.746 -1.29973 -1.65364 35.61126 
30 Q-Q-P-R-K-I-R-P-E-G-R-E-G-E-Q 3.2592 -0.924 143.969 67.49117 -1.47808 -1.6132 36.21804 
31 K-I-R-P-E-G-R-E-G-E-Q-E-W-G-T -1.39417 -1.12085 11.92243 13.38672 -1.99567 -2.01372 35.45769 
32 E-G-R-E-G-E-Q-E-W-G-T-P-G-S-H 0.423326 -0.79234 12.94582 50.46335 -1.40024 -0.98384 28.57079 
33 G-E-Q-E-W-G-T-P-G-S-H-V-R-E-E 2.268558 -1.39609 19.65561 47.14635 -2.10994 -1.5474 15.32433 
34 W-G-T-P-G-S-H-V-R-E-E-T-S-R-N 1.668563 -1.06294 14.38033 31.02177 -1.47751 -1.16937 14.78174 
35 G-S-H-V-R-E-E-T-S-R-N-N-P-F-Y 1.904169 -0.47352 12.29089 13.00512 -0.78828 -0.31569 6.951695 
36 R-E-E-T-S-R-N-N-P-F-Y-F-P-S-R 0.664725 -1.01146 15.3664 37.84777 -2.14992 -1.574 20.1949 
37 S-R-N-N-P-F-Y-F-P-S-R-R-F-S-T 2.879661 -3.86148 10.53053 25.83632 -3.82639 -4.72186 6.020433 
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38 P-F-Y-F-P-S-R-R-F-S-T-R-Y-G-N -2.91062 -4.77006 12.3355 9.294225 -5.42918 -5.68308 2.134125 
39 P-S-R-R-F-S-T-R-Y-G-N-Q-N-G-R 2.06314 -1.88039 10.47544 22.99433 -2.29209 -2.45767 11.51753 
40 F-S-T-R-Y-G-N-Q-N-G-R-I-R-V-L 6.12271 -4.46206 12.66561 28.57142 -6.01261 -6.00344 11.45757 
41 Y-G-N-Q-N-G-R-I-R-V-L-Q-R-F-D 6.982778 -4.67576 15.49696 27.14248 -4.67084 -4.99741 4.887234 
42 N-G-R-I-R-V-L-Q-R-F-D-Q-R-S-R -1.429 -2.08553 12.62039 13.28132 -1.57377 -2.43191 6.710459 
43 R-V-L-Q-R-F-D-Q-R-S-R-Q-F-Q-N 0.558192 -2.76385 3.506153 7.233424 -3.43636 -3.68997 2.250496 
44 R-F-D-Q-R-S-R-Q-F-Q-N-L-Q-N-H 1.333604 -3.00143 6.608565 24.15817 -3.00646 -3.21478 11.20161 
45 R-S-R-Q-F-Q-N-L-Q-N-H-R-I-V-Q -0.19648 -3.6533 9.781506 5.598545 -3.90371 -4.48453 4.733501 
46 F-Q-N-L-Q-N-H-R-I-V-Q-I-E-A-K -2.75446 -2.65648 3.76666 -2.57496 -4.54842 -4.58893 -2.43703 
47 Q-N-H-R-I-V-Q-I-E-A-K-P-N-T-L -0.00045 -1.76773 3.098764 2.529633 -1.5295 -2.06496 -0.46991 
48 I-V-Q-I-E-A-K-P-N-T-L-V-L-P-K 2.034737 -1.03758 8.143733 8.81598 -2.60707 -2.67854 8.303972 
49 E-A-K-P-N-T-L-V-L-P-K-H-A-D-A 10.7752 -1.93522 44.02096 55.05688 -2.42544 -2.46962 24.95336 
50 N-T-L-V-L-P-K-H-A-D-A-D-N-I-L 12.15944 -1.21048 11.46783 5.907945 -1.5587 -2.06046 7.32343 
51 L-P-K-H-A-D-A-D-N-I-L-V-I-Q-Q 8.132508 -1.47981 14.64615 18.9476 -2.65497 -2.86101 11.98281 
52 A-D-A-D-N-I-L-V-I-Q-Q-G-Q-A-T 0.384171 -1.50346 12.15213 20.1544 -3.68035 -3.92887 13.79111 
53 N-I-L-V-I-Q-Q-G-Q-A-T-V-T-V-A 1.146884 -1.58 19.91124 44.68331 -1.94136 -2.24317 23.43433 
54 I-Q-Q-G-Q-A-T-V-T-V-A-N-G-N-N 0.646232 -0.94669 12.89486 28.10026 -2.63433 -2.48739 25.28107 
55 Q-A-T-V-T-V-A-N-G-N-N-R-K-S-F -0.16656 -0.53616 26.61677 49.27365 -4.83482 -4.99781 24.33136 
56 T-V-A-N-G-N-N-R-K-S-F-N-L-D-E 5.625827 -1.80621 34.79922 58.66269 -2.57394 -2.43726 24.25644 
57 G-N-N-R-K-S-F-N-L-D-E-G-H-A-L -0.93051 -2.00036 20.56977 28.62635 -4.86913 -4.70138 10.34225 
58 K-S-F-N-L-D-E-G-H-A-L-R-I-P-S 0.761425 -0.43665 13.33631 18.27332 -1.38584 -1.30039 10.85536 
59 L-D-E-G-H-A-L-R-I-P-S-G-F-I-S -0.43787 -0.89598 7.611756 12.01 -0.25115 -0.92492 8.041904 
60 H-A-L-R-I-P-S-G-F-I-S-Y-I-L-N 0.80846 -0.73437 7.771843 21.93277 -1.58461 -1.32308 11.7051 
61 I-P-S-G-F-I-S-Y-I-L-N-R-H-D-N -2.01283 -2.6487 4.323331 15.78383 -2.74889 -2.83217 4.163405 
62 F-I-S-Y-I-L-N-R-H-D-N-Q-N-L-R -1.05096 -3.94832 3.66708 44.18075 -3.96186 -4.61132 6.74679 
63 I-L-N-R-H-D-N-Q-N-L-R-V-A-K-I -2.03015 -2.86501 4.514404 48.54251 -4.01368 -3.76003 14.79915 
64 H-D-N-Q-N-L-R-V-A-K-I-S-M-P-V 0.492965 -1.23841 6.410253 33.1103 -2.80141 -3.09216 12.40274 
65 N-L-R-V-A-K-I-S-M-P-V-N-T-P-G 1.927388 -0.2128 6.415708 33.53159 -1.01998 -0.84067 10.85406 
66 A-K-I-S-M-P-V-N-T-P-G-Q-F-E-D -0.56915 -2.21226 3.383392 10.25419 -3.38119 -2.44618 8.161963 
67 M-P-V-N-T-P-G-Q-F-E-D-F-F-P-A -2.73412 -0.83921 3.414023 7.067644 -5.42976 -5.5943 3.51444 
68 T-P-G-Q-F-E-D-F-F-P-A-S-S-R-D 0.003539 -2.97657 7.355956 19.83838 -4.51405 -3.93523 13.97264 
69 F-E-D-F-F-P-A-S-S-R-D-Q-S-S-Y -2.56025 -3.61569 1.103913 -1.23681 -8.14269 -7.09461 -0.55163 
70 F-P-A-S-S-R-D-Q-S-S-Y-L-Q-G-F 0.273181 -1.86596 3.170334 2.11726 -3.59848 -3.87715 6.816776 
71 S-R-D-Q-S-S-Y-L-Q-G-F-S-R-N-T 0.483109 -1.8368 4.734895 1.604163 -1.272 -1.89775 7.356824 
72 S-S-Y-L-Q-G-F-S-R-N-T-L-E-A-A 13.79686 -2.54002 33.5449 53.80098 -3.62127 -3.9157 23.86414 
73 Q-G-F-S-R-N-T-L-E-A-A-F-N-A-E 6.05654 -1.66962 9.89048 32.18801 -1.84125 -2.42823 18.38054 
74 R-N-T-L-E-A-A-F-N-A-E-F-N-E-I 1.693399 -1.26993 7.10495 14.35592 -1.19494 -2.16781 11.12055 
75 E-A-A-F-N-A-E-F-N-E-I-R-R-V-L -0.18233 -3.84404 8.502414 30.03316 -4.18012 -4.99315 16.58696 
76 N-A-E-F-N-E-I-R-R-V-L-L-E-E-N -1.57072 -3.36625 3.041913 6.82938 -3.60753 -3.96153 9.596066 
77 N-E-I-R-R-V-L-L-E-E-N-A-G-G-E 1.18188 -0.72909 7.626726 28.32934 -1.16322 -1.70779 10.59939 
78 R-V-L-L-E-E-N-A-G-G-E-Q-E-E-R 0.525892 -0.19888 9.526839 7.32294 -1.86918 -2.10006 9.251623 
79 E-E-N-A-G-G-E-Q-E-E-R-G-Q-R-R -0.63483 -2.14629 12.10787 18.16466 -2.78963 -3.32912 9.912691 
80 G-G-E-Q-E-E-R-G-Q-R-R-W-S-T-R -0.89763 -1.65671 3.746807 14.21608 -1.81044 -1.79885 7.126158 
81 E-E-R-G-Q-R-R-W-S-T-R-S-S-E-N -1.10001 -0.94261 7.70673 21.05212 -1.95703 -2.14538 10.27823 
82 Q-R-R-W-S-T-R-S-S-E-N-N-E-G-V -0.47445 -0.87996 13.98661 24.92618 -1.0377 -1.30231 9.42649 
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83 S-T-R-S-S-E-N-N-E-G-V-I-V-K-V 2.255613 -0.81844 10.58789 20.18157 -0.09821 -0.75039 9.731262 
84 S-E-N-N-E-G-V-I-V-K-V-S-K-E-H 0.565426 -0.73057 5.916941 46.82522 -0.44573 -0.65583 14.34043 
85 E-G-V-I-V-K-V-S-K-E-H-V-E-E-L 0.884226 -0.91452 3.777985 45.11822 -1.40306 -1.27132 5.23246 
86 V-K-V-S-K-E-H-V-E-E-L-T-K-H-A 3.125025 -1.12302 2.574044 81.98156 -1.29007 -1.05787 8.149425 
87 K-E-H-V-E-E-L-T-K-H-A-K-S-V-S 1.175013 -0.53455 3.898684 55.2159 -0.76822 -0.43064 11.73383 
88 E-E-L-T-K-H-A-K-S-V-S-K-K-G-S 3.28455 -2.1558 6.100641 50.40856 -3.18763 -3.32008 13.61296 
89 K-H-A-K-S-V-S-K-K-G-S-E-E-E-G 2.144801 -0.50534 4.945178 32.94093 -1.44733 -1.26846 9.146233 
90 S-V-S-K-K-G-S-E-E-E-G-D-I-T-N 2.688383 -1.00897 4.365974 7.171135 -2.14077 -1.07131 6.719895 
91 K-G-S-E-E-E-G-D-I-T-N-P-I-N-L 0.491442 -4.80469 7.024659 74.00956 -6.05139 -5.6899 1.529855 
92 E-E-G-D-I-T-N-P-I-N-L-R-E-G-E -0.42248 -3.32133 2.326791 76.37315 -3.29246 -3.37135 1.949524 
93 I-T-N-P-I-N-L-R-E-G-E-P-D-L-S 0.628915 -2.37774 3.768603 26.45127 -2.40402 -2.71449 4.619271 
94 I-N-L-R-E-G-E-P-D-L-S-N-N-F-G -2.65711 -4.29953 2.007046 0.177289 -6.36404 -6.26035 -0.19891 
95 E-G-E-P-D-L-S-N-N-F-G-K-L-F-E 0.56958 -1.66373 3.039817 10.21795 -0.70784 -1.67639 12.80745 
96 D-L-S-N-N-F-G-K-L-F-E-V-K-P-D 0.032812 -2.36724 6.813636 25.79338 -2.5476 -2.90486 27.23237 
97 N-F-G-K-L-F-E-V-K-P-D-K-K-N-P 1.609543 -1.20808 12.22713 77.75274 -0.55716 -1.53234 35.79457 
98 L-F-E-V-K-P-D-K-K-N-P-Q-L-Q-D 0.765632 -0.99479 6.988228 46.77289 -0.61071 -1.45534 25.73757 
99 K-P-D-K-K-N-P-Q-L-Q-D-L-D-M-M -0.15602 -1.24799 3.475558 42.35868 -1.16042 -1.55434 16.10788 
100 K-N-P-Q-L-Q-D-L-D-M-M-L-T-C-V -1.15822 -1.23646 3.834192 39.20188 -0.91974 -1.54106 19.10049 
101 L-Q-D-L-D-M-M-L-T-C-V-E-I-K-E 0.40628 -0.94894 2.228946 17.13975 -0.89563 -1.45728 10.31285 
102 D-M-M-L-T-C-V-E-I-K-E-G-A-L-M 1.584321 -0.97945 9.13937 32.26898 -0.3729 -0.94917 17.72444 
103 T-C-V-E-I-K-E-G-A-L-M-L-P-H-F 0.051058 -0.87718 9.682749 24.31602 -0.27534 -0.7372 21.23833 
104 I-K-E-G-A-L-M-L-P-H-F-N-S-K-A 0.37463 -0.63113 11.92178 25.77038 -1.02924 -0.8116 13.20649 
105 A-L-M-L-P-H-F-N-S-K-A-M-V-I-V 3.693317 -1.08289 21.74644 53.20744 -0.763 -0.74342 19.65838 
106 P-H-F-N-S-K-A-M-V-I-V-V-V-N-K -0.19588 -0.64352 4.091794 15.73264 -0.19166 -0.43107 4.960995 
107 S-K-A-M-V-I-V-V-V-N-K-G-T-G-N 8.948462 -0.74749 11.82183 32.8327 -0.00316 -0.66073 16.42641 
108 V-I-V-V-V-N-K-G-T-G-N-L-E-L-V 2.815637 -0.45061 4.906719 23.7942 -0.33195 -0.28351 8.258819 
109 V-N-K-G-T-G-N-L-E-L-V-A-V-R-K 1.821475 -0.58334 5.060639 49.27519 -0.93315 -0.6153 11.52114 
110 T-G-N-L-E-L-V-A-V-R-K-E-Q-Q-Q 5.755026 -0.88687 3.964197 64.76099 -1.52764 -0.89039 7.946722 
111 E-L-V-A-V-R-K-E-Q-Q-Q-R-G-R-R 2.779256 -1.00459 4.556745 41.7388 -1.20761 -1.70708 13.79276 
112 V-R-K-E-Q-Q-Q-R-G-R-R-E-E-E-E -0.7306 -1.98496 3.032085 10.82474 -2.44588 -2.40121 5.486927 
113 Q-Q-Q-R-G-R-R-E-E-E-E-D-E-D-E 0.555561 -0.48839 4.599313 8.327343 -1.52843 -1.18192 6.675725 
114 G-R-R-E-E-E-E-D-E-D-E-E-E-E-G 1.050436 -1.03798 3.225533 4.970776 -2.36082 -1.48068 6.291722 
115 E-E-E-D-E-D-E-E-E-E-G-S-N-R-E -0.45226 -2.9844 -0.23085 13.62784 -4.68556 -4.2184 -2.52201 
116 E-D-E-E-E-E-G-S-N-R-E-V-R-R-Y -1.27293 -4.5817 1.620135 11.40208 -5.13086 -4.66275 6.718442 
117 E-E-G-S-N-R-E-V-R-R-Y-T-A-R-L 3.225142 -2.48539 6.775563 20.7375 -4.11099 -4.56352 9.505198 
118 N-R-E-V-R-R-Y-T-A-R-L-K-E-G-D 3.510736 -4.35489 9.855619 21.48321 -6.15202 -6.24847 4.563558 
119 R-R-Y-T-A-R-L-K-E-G-D-V-F-I-M 0.324324 -3.75013 3.189184 -0.57566 -4.29187 -4.1765 0.816455 
120 A-R-L-K-E-G-D-V-F-I-M-P-A-A-H -1.43321 -1.59552 2.133976 3.466246 -1.76 -1.77813 3.551298 
121 E-G-D-V-F-I-M-P-A-A-H-P-V-A-I -0.05351 -1.16201 5.430812 22.62657 -1.06 -1.72718 17.24154 
122 F-I-M-P-A-A-H-P-V-A-I-N-A-S-S 5.311083 -1.01477 5.096779 63.83618 -0.65664 -1.05178 21.005 
123 A-A-H-P-V-A-I-N-A-S-S-E-L-H-L 3.994565 -0.93738 3.8405 57.62347 -0.62674 -0.56993 19.36232 
124 V-A-I-N-A-S-S-E-L-H-L-L-G-F-G 0.534335 -1.19033 7.733454 25.0588 -1.40539 -0.9957 14.76579 
125 A-S-S-E-L-H-L-L-G-F-G-I-N-A-E 0.233382 -1.36833 4.427056 18.77328 -1.74252 -2.08845 17.93215 
126 L-H-L-L-G-F-G-I-N-A-E-N-N-H-R -0.22166 -1.31261 3.604658 7.857842 -0.48333 -1.49514 13.12782 
127 G-F-G-I-N-A-E-N-N-H-R-I-F-L-A 4.420579 -0.97226 5.452588 15.31423 -1.13986 -1.38603 13.30913 
 Appendix  205 
128 N-A-E-N-N-H-R-I-F-L-A-G-D-K-D 4.385259 -1.13582 23.78885 64.98063 -0.85484 -1.23699 26.38865 
129 N-H-R-I-F-L-A-G-D-K-D-N-V-I-D 2.498449 -1.54271 19.18897 32.11885 -1.83682 -1.90744 11.06618 
130 F-L-A-G-D-K-D-N-V-I-D-Q-I-E-K 0.385411 -1.60956 8.70718 29.24332 -2.4132 -2.14689 11.66448 
131 D-K-D-N-V-I-D-Q-I-E-K-Q-A-K-D 2.048915 -1.15672 5.30862 20.75059 -1.45906 -1.1998 8.205495 
132 V-I-D-Q-I-E-K-Q-A-K-D-L-A-F-P 0.116513 -0.21955 2.449824 17.38991 -0.25684 -0.31871 12.18103 
133 I-E-K-Q-A-K-D-L-A-F-P-G-S-G-E 1.688853 -0.52652 6.992434 39.47771 -0.62198 -0.36719 24.75003 
134 A-K-D-L-A-F-P-G-S-G-E-Q-V-E-K 4.887313 -0.17504 4.629524 63.67664 -0.65469 -0.32236 35.01905 
135 A-F-P-G-S-G-E-Q-V-E-K-L-I-K-N 3.416727 0.543476 4.537165 36.67111 -1.80814 -1.28883 15.65822 
136 S-G-E-Q-V-E-K-L-I-K-N-Q-K-E-S 1.690728 -0.80209 4.977953 46.95641 -1.18723 -1.1018 13.63121 
137 V-E-K-L-I-K-N-Q-K-E-S-H-F-V-S 0.292926 -1.20195 3.360106 20.01658 -1.63476 -1.39449 9.531064 
138 I-K-N-Q-K-E-S-H-F-V-S-A-R-P-Q 0.627639 -0.99542 5.973301 33.24773 -2.36784 -1.30785 10.80822 
139 K-E-S-H-F-V-S-A-R-P-Q-S-Q-S-Q -1.19089 -2.22065 0.752184 14.13455 -3.3484 -3.08824 9.134007 
140 F-V-S-A-R-P-Q-S-Q-S-Q-S-P-S-S 0.743476 -2.27155 3.920178 12.2823 -3.59278 -3.11468 5.145278 
141 R-P-Q-S-Q-S-Q-S-P-S-S-P-E-K-E -1.61278 -5.61425 5.185441 -3.20812 -9.15315 -8.08324 -1.83727 
142 Q-S-Q-S-P-S-S-P-E-K-E-S-P-E-K -1.10026 -2.35776 1.590671 16.48993 -3.90891 -3.96924 3.160473 
143 P-S-S-P-E-K-E-S-P-E-K-E-D-Q-E -0.98098 -1.81189 0.530596 2.398958 -2.78423 -2.37454 -0.11548 
144 E-K-E-S-P-E-K-E-D-Q-E-E-E-N-Q -1.9921 -0.63426 -0.31813 1.260656 -1.92195 -1.93519 0.402007 
145 P-E-K-E-D-Q-E-E-E-N-Q-G-G-K-G -0.62386 -1.30003 1.226884 8.736883 -1.25358 -1.54171 12.43007 
146 D-Q-E-E-E-N-Q-G-G-K-G-P-L-L-S -0.30523 -1.6141 5.276036 22.68592 -1.86188 -2.1375 16.86427 
147 E-N-Q-G-G-K-G-P-L-L-S-I-L-K-A 1.091935 -2.28209 6.756705 46.14077 -2.84575 -2.61573 16.91618 
148 Q-G-G-K-G-P-L-L-S-I-L-K-A-F-N 0.050847 -1.14198 2.290236 39.98288 -2.13063 -1.81654 15.93818 
 m (blanks) 13064.72 11944.52 11980.02 11826.06 30213.72 12411.71 13647.98 
 s (blanks) 405.2419 496.9434 279.4139 579.7481 12783.8 440.7967 1229.712 
 
Table A4: Calculated Z-scores of Ara h 1 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 1 for each peanut-allergic patient (patients 22-23) and tolerant 
patient (24-28) are listed. Identified candidate diagnostic peptides are highlighted in light blue. 
 Patient No. → 22 23 24 25 26 27 28 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score Z-score 
1 K-S-S-P-Y-Q-K-K-T-E-N-P-C-A-Q -0.96593 -1.88741 -1.9334 -5.48229 -1.16104 -1.24353 -1.89544 
2 Y-Q-K-K-T-E-N-P-C-A-Q-R-C-L-Q -0.22367 -1.29926 -1.76534 -5.1789 -0.75234 -1.18467 -1.54099 
3 T-E-N-P-C-A-Q-R-C-L-Q-S-C-Q-Q -1.1109 -0.63789 -1.86761 -5.43652 -1.19922 -1.23916 -1.7233 
4 C-A-Q-R-C-L-Q-S-C-Q-Q-E-P-D-D -0.9305 4.028964 -1.65366 -4.28096 -0.55941 -0.5893 -1.30832 
5 C-L-Q-S-C-Q-Q-E-P-D-D-L-K-Q-K -0.94482 73.39521 -1.95855 -4.67359 -1.09063 -0.73853 -1.78404 
6 C-Q-Q-E-P-D-D-L-K-Q-K-A-C-E-S -2.01721 105.5123 -2.3351 -4.37118 -1.06265 -1.3399 -1.67991 
7 P-D-D-L-K-Q-K-A-C-E-S-R-C-T-K -1.76552 3.469808 -1.70308 -3.8795 -0.76011 -0.67009 -1.2161 
8 K-Q-K-A-C-E-S-R-C-T-K-L-E-Y-D -1.36655 -0.96888 -1.96856 -4.84412 -1.24488 -0.12082 -1.13246 
9 C-E-S-R-C-T-K-L-E-Y-D-P-R-C-V -0.6769 -1.90235 -1.41533 -4.81263 -0.86405 -0.41627 -0.73189 
10 C-T-K-L-E-Y-D-P-R-C-V-Y-D-P-R -1.36556 -2.6392 -1.99698 -5.17975 -1.18146 -0.47228 -1.16717 
11 E-Y-D-P-R-C-V-Y-D-P-R-G-H-T-G -1.31096 -1.63034 -1.3407 -3.39335 -0.2387 0.039489 -0.43825 
12 R-C-V-Y-D-P-R-G-H-T-G-T-T-N-Q -1.25763 -1.1982 -2.04591 -6.10252 -1.8111 -0.42561 -1.28305 
13 D-P-R-G-H-T-G-T-T-N-Q-R-S-P-P -0.47983 0.156837 -1.57647 -4.30831 -0.67615 0.417156 -0.50098 
14 H-T-G-T-T-N-Q-R-S-P-P-G-E-R-T -0.66363 2.51993 -1.65629 -3.93559 -1.1396 0.609136 -0.25981 
15 T-N-Q-R-S-P-P-G-E-R-T-R-G-R-Q -1.10583 0.800835 -2.08916 -5.66977 -2.26942 0.244989 -1.03663 
 206  Appendix 
16 S-P-P-G-E-R-T-R-G-R-Q-P-G-D-Y -0.71889 68.87155 -1.84813 -6.58955 -2.13665 -0.05873 -0.53409 
17 E-R-T-R-G-R-Q-P-G-D-Y-D-D-D-R 2.213756 76.82545 -1.31895 -6.90829 -1.20418 0.849557 0.241959 
18 G-R-Q-P-G-D-Y-D-D-D-R-R-Q-P-R -1.1273 8.727532 -2.01196 -7.3864 -2.28928 0.138119 -0.66491 
19 G-D-Y-D-D-D-R-R-Q-P-R-R-E-E-G -2.74601 -4.90397 -3.46436 -7.90928 -4.20499 -3.72737 -4.28444 
20 D-D-R-R-Q-P-R-R-E-E-G-G-R-W-G -2.43837 -3.4936 -2.25873 -8.00302 -2.64256 -2.30754 -2.70192 
21 Q-P-R-R-E-E-G-G-R-W-G-P-A-G-P -2.96305 -3.62384 -2.88056 -8.06445 -2.69409 -2.91109 -2.73536 
22 E-E-G-G-R-W-G-P-A-G-P-R-E-R-E -1.61768 -2.82585 -2.3444 -6.5753 -1.92236 -2.05578 -2.42958 
23 R-W-G-P-A-G-P-R-E-R-E-R-E-E-D -0.88741 -0.67394 -1.99686 -5.67864 -1.07129 -1.52214 -1.70827 
24 A-G-P-R-E-R-E-R-E-E-D-W-R-Q-P -1.96477 -2.47122 -3.2808 -7.34573 -2.73166 -2.02215 -2.87608 
25 E-R-E-R-E-E-D-W-R-Q-P-R-E-D-W 1.587921 4.444458 -1.63233 -5.29603 -1.37911 -1.44882 -1.60814 
26 E-E-D-W-R-Q-P-R-E-D-W-R-R-P-S -1.82889 -0.42065 -2.10399 -5.62975 -1.57063 -1.78652 -1.89796 
27 R-Q-P-R-E-D-W-R-R-P-S-H-Q-Q-P -0.57374 1.736924 -1.88224 -4.98528 -0.92097 -1.21297 -1.54323 
28 E-D-W-R-R-P-S-H-Q-Q-P-R-K-I-R -0.66931 99.26503 -1.44464 -2.9662 -0.31777 -0.31715 -1.20496 
29 R-P-S-H-Q-Q-P-R-K-I-R-P-E-G-R -0.10115 103.67 -1.74402 -4.11382 -0.62705 -0.6785 -1.44666 
30 Q-Q-P-R-K-I-R-P-E-G-R-E-G-E-Q -0.64085 61.2642 -1.56681 -3.61118 -0.75149 -0.63052 -1.40217 
31 K-I-R-P-E-G-R-E-G-E-Q-E-W-G-T -0.94825 -0.36632 -2.31787 -5.20441 -1.64788 -1.16359 -1.69845 
32 E-G-R-E-G-E-Q-E-W-G-T-P-G-S-H -1.00753 1.050155 -1.26259 -5.39806 -0.7756 -0.23816 -0.60607 
33 G-E-Q-E-W-G-T-P-G-S-H-V-R-E-E -1.00291 2.974034 -1.58262 -5.89941 -1.15947 -0.37596 -1.20982 
34 W-G-T-P-G-S-H-V-R-E-E-T-S-R-N -0.42901 0.343593 -1.55681 -4.93593 -0.73769 -0.19858 -0.67666 
35 G-S-H-V-R-E-E-T-S-R-N-N-P-F-Y -0.51856 -0.56572 -0.71089 -4.22168 0.179986 0.6312 0.010161 
36 R-E-E-T-S-R-N-N-P-F-Y-F-P-S-R 0.130909 0.802006 -1.74933 -5.85427 -1.22835 -0.25625 -1.0514 
37 S-R-N-N-P-F-Y-F-P-S-R-R-F-S-T -1.37067 0.952129 -4.91258 -5.3611 -4.21586 -1.87428 -4.11434 
38 P-F-Y-F-P-S-R-R-F-S-T-R-Y-G-N -2.84609 -3.60192 -6.14402 -7.83549 -5.97018 -2.69523 -4.94688 
39 P-S-R-R-F-S-T-R-Y-G-N-Q-N-G-R -1.48485 -2.36242 -3.10558 -5.86693 -2.89298 -0.75458 -1.35295 
40 F-S-T-R-Y-G-N-Q-N-G-R-I-R-V-L -3.17611 -3.98037 -6.35998 -10.7655 -7.11584 -2.46929 -4.90415 
41 Y-G-N-Q-N-G-R-I-R-V-L-Q-R-F-D -3.62562 -3.40967 -5.22683 -10.0711 -5.43696 -2.39852 -3.83078 
42 N-G-R-I-R-V-L-Q-R-F-D-Q-R-S-R -2.20673 -1.4678 -2.84051 -7.3006 -2.8337 -0.72208 -0.81155 
43 R-V-L-Q-R-F-D-Q-R-S-R-Q-F-Q-N -3.25074 -3.78535 -3.17762 -8.48035 -3.83661 -3.06263 -3.49398 
44 R-F-D-Q-R-S-R-Q-F-Q-N-L-Q-N-H -2.77069 -3.70588 -2.73329 -6.78921 -3.27117 -2.97671 -3.14436 
45 R-S-R-Q-F-Q-N-L-Q-N-H-R-I-V-Q -2.95689 -5.37591 -4.27938 -7.89753 -3.90011 -3.88248 -4.46512 
46 F-Q-N-L-Q-N-H-R-I-V-Q-I-E-A-K -2.88042 -6.06893 -4.93681 -7.77337 -4.53564 -4.27985 -4.66242 
47 Q-N-H-R-I-V-Q-I-E-A-K-P-N-T-L -1.77684 -1.81969 -2.07833 -4.39299 -1.64245 -1.60165 -1.95572 
48 I-V-Q-I-E-A-K-P-N-T-L-V-L-P-K -0.2137 0.157028 -2.91585 -6.1498 -2.86155 -2.09678 -2.52997 
49 E-A-K-P-N-T-L-V-L-P-K-H-A-D-A 0.80656 8.397982 -2.4134 -5.41115 -2.39937 -1.51247 -2.43391 
50 N-T-L-V-L-P-K-H-A-D-A-D-N-I-L -1.01459 0.016104 -1.83741 -4.96782 -1.80415 -1.44871 -1.81019 
51 L-P-K-H-A-D-A-D-N-I-L-V-I-Q-Q 1.32399 2.546529 -2.74966 -5.65179 -2.92503 -0.97919 -2.86152 
52 A-D-A-D-N-I-L-V-I-Q-Q-G-Q-A-T -1.60849 6.666821 -3.9495 -6.02428 -3.63972 -2.53526 -3.88086 
53 N-I-L-V-I-Q-Q-G-Q-A-T-V-T-V-A -0.63796 8.94339 -2.17572 -4.63878 -1.83868 -0.94452 -2.03524 
54 I-Q-Q-G-Q-A-T-V-T-V-A-N-G-N-N -0.21328 2.742649 -2.63951 -4.8146 -2.77781 -0.72892 -2.38194 
55 Q-A-T-V-T-V-A-N-G-N-N-R-K-S-F -2.02488 -2.74472 -5.07179 -7.42406 -5.23848 -2.90401 -4.51457 
56 T-V-A-N-G-N-N-R-K-S-F-N-L-D-E -0.39295 1.547072 -2.2155 -6.3912 -2.79791 -0.61471 -1.84534 
57 G-N-N-R-K-S-F-N-L-D-E-G-H-A-L -2.05016 -3.50132 -4.7703 -8.22817 -5.14956 -2.39285 -4.38543 
58 K-S-F-N-L-D-E-G-H-A-L-R-I-P-S -0.25904 -1.79172 -1.7461 -5.27804 -1.38826 -0.26538 -0.91124 
59 L-D-E-G-H-A-L-R-I-P-S-G-F-I-S -0.87128 -0.76361 -1.28544 -3.05431 -0.46119 0.026135 -0.37126 
60 H-A-L-R-I-P-S-G-F-I-S-Y-I-L-N 0.045053 -0.72693 -1.17563 -6.00307 -1.81202 0.050173 -0.68295 
 Appendix  207 
61 I-P-S-G-F-I-S-Y-I-L-N-R-H-D-N -2.15687 -3.28503 -2.81353 -6.62933 -3.01534 -1.04473 -1.8101 
62 F-I-S-Y-I-L-N-R-H-D-N-Q-N-L-R -2.90558 -3.84163 -4.74124 -7.4773 -4.96383 -2.56415 -3.71703 
63 I-L-N-R-H-D-N-Q-N-L-R-V-A-K-I -1.03532 -3.44675 -4.38729 -8.68597 -4.51924 -1.98556 -2.84062 
64 H-D-N-Q-N-L-R-V-A-K-I-S-M-P-V -0.88733 -1.90299 -2.87013 -8.60814 -3.8618 -0.8994 -1.98835 
65 N-L-R-V-A-K-I-S-M-P-V-N-T-P-G -0.64355 -1.32081 -1.40693 -7.39942 -1.74408 0.555563 -0.16868 
66 A-K-I-S-M-P-V-N-T-P-G-Q-F-E-D -2.35598 -3.34461 -3.46685 -9.69208 -3.98484 0.008007 -1.66147 
67 M-P-V-N-T-P-G-Q-F-E-D-F-F-P-A -2.79829 -6.1347 -5.02035 -8.69216 -6.38315 -3.08785 -5.28328 
68 T-P-G-Q-F-E-D-F-F-P-A-S-S-R-D -3.57138 -4.77384 -4.48884 -8.66395 -5.05552 -3.31468 -4.62915 
69 F-E-D-F-F-P-A-S-S-R-D-Q-S-S-Y -3.94157 -8.96239 -8.01268 -12.0841 -8.64472 -5.90745 -8.16398 
70 F-P-A-S-S-R-D-Q-S-S-Y-L-Q-G-F -2.01852 -3.86933 -3.94799 -7.31701 -4.12451 -2.9561 -4.0892 
71 S-R-D-Q-S-S-Y-L-Q-G-F-S-R-N-T -1.06273 0.333018 -2.12839 -4.14836 -2.20852 -1.52996 -2.15398 
72 S-S-Y-L-Q-G-F-S-R-N-T-L-E-A-A 3.597006 39.95089 -4.20983 -6.26647 -4.17238 -2.59155 -4.02274 
73 Q-G-F-S-R-N-T-L-E-A-A-F-N-A-E -0.52198 47.08792 -2.10013 -4.85823 -2.11863 -1.54834 -2.14014 
74 R-N-T-L-E-A-A-F-N-A-E-F-N-E-I 0.069256 16.20381 -1.80885 -6.77821 -2.079 -1.01855 -1.73 
75 E-A-A-F-N-A-E-F-N-E-I-R-R-V-L -1.78469 9.029146 -4.88754 -6.46461 -5.26286 -3.79904 -4.76696 
76 N-A-E-F-N-E-I-R-R-V-L-L-E-E-N -2.31255 0.660755 -4.40296 -6.54036 -4.19647 -2.85777 -3.84284 
77 N-E-I-R-R-V-L-L-E-E-N-A-G-G-E 0.069005 3.842076 -1.81044 -3.23003 -1.40076 -0.5564 -1.43547 
78 R-V-L-L-E-E-N-A-G-G-E-Q-E-E-R -0.07618 -0.13095 -2.25377 -4.15397 -2.71525 -1.07257 -2.15288 
79 E-E-N-A-G-G-E-Q-E-E-R-G-Q-R-R -1.4575 -2.31006 -3.52853 -5.12545 -3.34151 -2.09516 -2.89655 
80 G-G-E-Q-E-E-R-G-Q-R-R-W-S-T-R -1.01058 -1.70582 -1.76681 -5.56822 -2.20975 -0.73135 -1.30343 
81 E-E-R-G-Q-R-R-W-S-T-R-S-S-E-N -0.87961 -1.95928 -2.17875 -4.59396 -2.49261 -0.92536 -1.8309 
82 Q-R-R-W-S-T-R-S-S-E-N-N-E-G-V -0.12028 -1.67085 -1.74452 -4.28946 -1.70393 -0.15521 -0.91505 
83 S-T-R-S-S-E-N-N-E-G-V-I-V-K-V -0.68781 0.031608 -0.93823 -2.55198 -0.20397 0.471262 -0.0969 
84 S-E-N-N-E-G-V-I-V-K-V-S-K-E-H 0.097479 0.417683 -0.82879 -3.60745 -0.6192 0.595277 -0.01427 
85 E-G-V-I-V-K-V-S-K-E-H-V-E-E-L -0.51303 -1.63809 -1.44765 -5.02007 -1.48957 0.166225 -0.52785 
86 V-K-V-S-K-E-H-V-E-E-L-T-K-H-A -0.59467 -0.99365 -1.44338 -5.13499 -1.37344 0.226367 -0.17213 
87 K-E-H-V-E-E-L-T-K-H-A-K-S-V-S 0.16758 0.865034 -0.90147 -5.30604 -0.91029 0.852171 0.330606 
88 E-E-L-T-K-H-A-K-S-V-S-K-K-G-S -1.82794 -2.95619 -3.90883 -8.48398 -4.10911 1.347697 -2.4566 
89 K-H-A-K-S-V-S-K-K-G-S-E-E-E-G -1.2882 -1.55618 -1.63232 -8.18078 -1.98714 -0.01677 -0.32277 
90 S-V-S-K-K-G-S-E-E-E-G-D-I-T-N -1.44028 -0.01346 -1.49709 -8.54417 -2.47469 0.757111 -0.04766 
91 K-G-S-E-E-E-G-D-I-T-N-P-I-N-L -1.76289 -6.15943 -5.39685 -9.94773 -6.62282 -4.36613 -5.42499 
92 E-E-G-D-I-T-N-P-I-N-L-R-E-G-E -1.91574 -3.88243 -3.19721 -7.22899 -3.94755 -2.82767 -3.34837 
93 I-T-N-P-I-N-L-R-E-G-E-P-D-L-S -1.68446 -2.13366 -2.70067 -6.33934 -2.95605 -2.55337 -2.79313 
94 I-N-L-R-E-G-E-P-D-L-S-N-N-F-G -4.10653 -5.1647 -6.17546 -9.29722 -6.79894 -3.85684 -6.22619 
95 E-G-E-P-D-L-S-N-N-F-G-K-L-F-E -0.43904 10.14929 -1.68286 -3.17693 -1.535 -1.31479 -1.702 
96 D-L-S-N-N-F-G-K-L-F-E-V-K-P-D -1.09976 98.7807 -2.96299 -4.76067 -3.15548 -2.3293 -2.97098 
97 N-F-G-K-L-F-E-V-K-P-D-K-K-N-P -0.43547 109.2173 -1.23506 -2.86099 -1.12575 -0.84298 -1.16425 
98 L-F-E-V-K-P-D-K-K-N-P-Q-L-Q-D 0.552438 93.36322 -1.18874 -3.94505 -1.44728 -0.81265 -1.19686 
99 K-P-D-K-K-N-P-Q-L-Q-D-L-D-M-M -0.60961 42.15726 -1.63249 -4.16139 -1.7959 -0.80002 -1.19815 
100 K-N-P-Q-L-Q-D-L-D-M-M-L-T-C-V -0.89098 11.42406 -1.44017 -3.32093 -2.01379 -0.59575 -1.26307 
101 L-Q-D-L-D-M-M-L-T-C-V-E-I-K-E -0.07294 3.784291 -1.26922 -3.28153 -1.54154 -0.53136 -0.74456 
102 D-M-M-L-T-C-V-E-I-K-E-G-A-L-M -0.51002 1.546282 -0.94538 -3.30079 -0.93388 -0.34005 -0.5694 
103 T-C-V-E-I-K-E-G-A-L-M-L-P-H-F -0.16756 -0.43497 -1.04727 -4.17986 -0.89873 -0.24061 -0.45506 
104 I-K-E-G-A-L-M-L-P-H-F-N-S-K-A -0.00764 -0.71608 -1.20391 -4.82348 -1.48337 0.513301 -0.42273 
105 A-L-M-L-P-H-F-N-S-K-A-M-V-I-V 0.064219 1.607191 -1.19854 -3.07983 -1.08471 0.023127 -0.29375 
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106 P-H-F-N-S-K-A-M-V-I-V-V-V-N-K -0.45085 -1.40921 -0.95869 -2.31421 -0.83743 0.247611 -0.37433 
107 S-K-A-M-V-I-V-V-V-N-K-G-T-G-N -0.19941 -0.46304 -0.97818 -3.04711 -0.65044 0.629788 -0.22597 
108 V-I-V-V-V-N-K-G-T-G-N-L-E-L-V -0.10304 0.046326 -0.73713 -3.02069 -0.54341 0.792302 0.171513 
109 V-N-K-G-T-G-N-L-E-L-V-A-V-R-K 0.023356 -0.23746 -0.97552 -3.25464 -1.05292 0.443865 -0.09766 
110 T-G-N-L-E-L-V-A-V-R-K-E-Q-Q-Q -0.22143 0.846341 -1.22364 -5.16306 -1.38398 0.31351 0.070047 
111 E-L-V-A-V-R-K-E-Q-Q-Q-R-G-R-R -0.01233 1.70455 -2.00781 -6.60302 -2.22503 0.533122 -0.80269 
112 V-R-K-E-Q-Q-Q-R-G-R-R-E-E-E-E -1.43443 -2.02255 -2.5771 -8.28375 -3.2421 -0.75711 -1.44138 
113 Q-Q-Q-R-G-R-R-E-E-E-E-D-E-D-E -0.2868 -2.06331 -1.58545 -8.34046 -2.37237 0.265208 -0.33481 
114 G-R-R-E-E-E-E-D-E-D-E-E-E-E-G -1.36932 -1.50447 -1.66291 -8.83286 -2.81345 0.725189 -0.42721 
115 E-E-E-D-E-D-E-E-E-E-G-S-N-R-E -3.89408 -5.2525 -3.71621 -7.61443 -4.98856 -3.81668 -4.52105 
116 E-D-E-E-E-E-G-S-N-R-E-V-R-R-Y -1.19888 -5.26656 -4.57091 -7.95208 -5.55482 -4.16882 -4.61318 
117 E-E-G-S-N-R-E-V-R-R-Y-T-A-R-L -1.82031 -3.969 -4.57504 -7.61459 -5.21431 -3.56644 -4.36858 
118 N-R-E-V-R-R-Y-T-A-R-L-K-E-G-D -1.64969 -5.83612 -5.99515 -8.94103 -6.81823 -4.62704 -6.15757 
119 R-R-Y-T-A-R-L-K-E-G-D-V-F-I-M -3.30176 -2.94949 -4.24546 -4.74492 -4.61798 -3.73769 -4.34381 
120 A-R-L-K-E-G-D-V-F-I-M-P-A-A-H -1.24071 4.240484 -1.91398 5.975579 -2.07006 -1.4699 -1.83221 
121 E-G-D-V-F-I-M-P-A-A-H-P-V-A-I -0.46455 22.44662 -1.33396 -3.00896 -1.58091 -1.07645 -1.45141 
122 F-I-M-P-A-A-H-P-V-A-I-N-A-S-S -0.20312 1.916798 -1.11275 -3.8424 -0.99729 -0.1043 -0.43932 
123 A-A-H-P-V-A-I-N-A-S-S-E-L-H-L 0.29908 0.881559 -0.71629 -3.56839 -0.60245 0.180781 -0.242 
124 V-A-I-N-A-S-S-E-L-H-L-L-G-F-G -0.78204 -0.80642 -1.46373 -4.05807 -1.47796 -0.2122 -0.61168 
125 A-S-S-E-L-H-L-L-G-F-G-I-N-A-E -0.28197 -0.68726 -2.1274 -1.78915 -2.28071 -1.14109 -1.65696 
126 L-H-L-L-G-F-G-I-N-A-E-N-N-H-R -0.72338 -0.71928 -1.78729 -1.7079 -1.4751 -0.85817 -1.33199 
127 G-F-G-I-N-A-E-N-N-H-R-I-F-L-A 0.021241 -1.85202 -1.60154 -3.65235 -1.71196 -0.37891 -1.26089 
128 N-A-E-N-N-H-R-I-F-L-A-G-D-K-D 0.597911 0.698823 -1.05483 -3.95982 -1.4164 0.041232 -0.55475 
129 N-H-R-I-F-L-A-G-D-K-D-N-V-I-D 0.353081 -1.0316 -1.8242 -4.32249 -2.14159 -0.77481 -1.15323 
130 F-L-A-G-D-K-D-N-V-I-D-Q-I-E-K -0.68109 -1.89161 -2.71347 -4.91345 -2.4049 -1.38392 -1.78431 
131 D-K-D-N-V-I-D-Q-I-E-K-Q-A-K-D 0.026234 -1.50698 -1.6048 -3.24169 -1.51328 -0.34256 -0.73462 
132 V-I-D-Q-I-E-K-Q-A-K-D-L-A-F-P -0.09504 0.0538 -0.53057 -1.50892 -0.47197 1.114052 0.341803 
133 I-E-K-Q-A-K-D-L-A-F-P-G-S-G-E -0.06977 1.582521 -0.51844 9.373499 -0.60908 0.575843 0.228411 
134 A-K-D-L-A-F-P-G-S-G-E-Q-V-E-K 0.537195 28.85953 -0.62821 -0.59609 -1.00759 0.851699 0.456705 
135 A-F-P-G-S-G-E-Q-V-E-K-L-I-K-N -0.2464 4.745072 -1.89834 -6.72622 -2.48935 0.429462 -0.53325 
136 S-G-E-Q-V-E-K-L-I-K-N-Q-K-E-S -0.4134 -0.67259 -1.6125 -6.84798 -2.04693 0.298238 -0.53982 
137 V-E-K-L-I-K-N-Q-K-E-S-H-F-V-S -0.13159 -1.34983 -1.69171 -8.03865 -2.37266 0.39802 -0.38793 
138 I-K-N-Q-K-E-S-H-F-V-S-A-R-P-Q -0.31254 -0.83526 -1.51017 -8.75554 -2.51362 0.273687 0.008129 
139 K-E-S-H-F-V-S-A-R-P-Q-S-Q-S-Q -2.62867 -2.59702 -2.4771 -6.96425 -3.47161 -2.53391 -2.7745 
140 F-V-S-A-R-P-Q-S-Q-S-Q-S-P-S-S -2.36492 -3.30074 -2.8715 -7.24818 -3.83652 -2.69975 -3.11195 
141 R-P-Q-S-Q-S-Q-S-P-S-S-P-E-K-E -4.98134 -9.04071 -7.28264 -11.4012 -9.40041 -5.87239 -8.62151 
142 Q-S-Q-S-P-S-S-P-E-K-E-S-P-E-K -3.11686 -4.01253 -3.84125 -7.43564 -4.39026 -2.6927 -3.83887 
143 P-S-S-P-E-K-E-S-P-E-K-E-D-Q-E -2.45398 -2.09637 -2.58219 -5.40626 -3.05632 -2.3048 -2.59593 
144 E-K-E-S-P-E-K-E-D-Q-E-E-E-N-Q -1.68344 -0.7066 -2.10358 -3.94709 -2.29124 -1.49827 -2.04934 
145 P-E-K-E-D-Q-E-E-E-N-Q-G-G-K-G -1.50593 1.313218 -1.63151 -3.75374 -1.95518 -1.37046 -1.51578 
146 D-Q-E-E-E-N-Q-G-G-K-G-P-L-L-S -1.13567 3.263379 -1.74451 -4.74822 -2.42087 -1.43382 -1.89263 
147 E-N-Q-G-G-K-G-P-L-L-S-I-L-K-A -0.87581 0.331808 -3.01931 -5.80164 -3.8935 -2.14828 -2.74216 
148 Q-G-G-K-G-P-L-L-S-I-L-K-A-F-N -0.33289 -0.13049 -1.8276 -4.37701 -2.81068 -1.17849 -1.48254 
 m (blanks) 13089.69 12093.18 13360.35 33476.14 26609.57 13484.05 12349.44 
 s (blanks) 476.6536 439.4543 499.9719 2886.569 9751.287 375.3086 414.1513 
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Table A5: Calculated Z-scores of Ara h 1 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 1 for each peanut-tolerant patient (patients 29-35) are listed. 
Identified candidate diagnostic peptides are highlighted in light blue. 
 Patient No. → 29 30 31 32 33 34 35 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score Z-score 
1 K-S-S-P-Y-Q-K-K-T-E-N-P-C-A-Q -1.96098 -2.40195 -0.81397 -1.78074 -1.69102 -2.00107 -2.50144 
2 Y-Q-K-K-T-E-N-P-C-A-Q-R-C-L-Q -1.71713 -1.85872 -0.68889 -1.71758 -1.36501 -1.0472 -2.40786 
3 T-E-N-P-C-A-Q-R-C-L-Q-S-C-Q-Q -1.83232 -2.32718 -1.07615 -2.05178 -1.80273 -1.57224 -2.71814 
4 C-A-Q-R-C-L-Q-S-C-Q-Q-E-P-D-D -1.16849 -1.94313 -0.09479 -1.48779 -1.36059 -0.43869 -2.00044 
5 C-L-Q-S-C-Q-Q-E-P-D-D-L-K-Q-K -2.00628 -2.11968 -0.69619 -1.96348 -2.07297 -0.52157 -2.71761 
6 C-Q-Q-E-P-D-D-L-K-Q-K-A-C-E-S -1.95992 -2.29368 -0.88767 -2.12455 -2.12152 -1.2312 -2.75647 
7 P-D-D-L-K-Q-K-A-C-E-S-R-C-T-K -1.19909 -1.74503 -0.37792 -1.64453 -1.44126 0.390454 -1.99683 
8 K-Q-K-A-C-E-S-R-C-T-K-L-E-Y-D -1.36374 -1.55097 -0.39419 -1.65111 -1.78716 0.278091 -2.146 
9 C-E-S-R-C-T-K-L-E-Y-D-P-R-C-V -0.80363 -1.10953 0.455956 -1.24625 -1.1528 1.490519 -1.55207 
10 C-T-K-L-E-Y-D-P-R-C-V-Y-D-P-R -1.19466 -1.59953 -0.52083 -1.64188 -1.47003 0.782012 -2.23772 
11 E-Y-D-P-R-C-V-Y-D-P-R-G-H-T-G -0.43086 -0.77084 -0.04499 -0.82984 -0.98366 1.848603 -1.40551 
12 R-C-V-Y-D-P-R-G-H-T-G-T-T-N-Q -1.08522 -1.5556 -0.81931 -1.84505 -1.80461 0.613636 -2.50472 
13 D-P-R-G-H-T-G-T-T-N-Q-R-S-P-P -0.40748 -0.81841 0.43405 -1.10117 -0.52077 2.272838 -1.45777 
14 H-T-G-T-T-N-Q-R-S-P-P-G-E-R-T -0.16359 -0.53245 0.468962 -1.00479 -0.58585 2.471696 -1.28467 
15 T-N-Q-R-S-P-P-G-E-R-T-R-G-R-Q -1.09609 -1.34363 -0.25253 -1.78121 -1.51069 1.513614 -2.27749 
16 S-P-P-G-E-R-T-R-G-R-Q-P-G-D-Y -0.67311 -1.11558 0.125521 -1.37477 -1.25372 1.064519 -1.91362 
17 E-R-T-R-G-R-Q-P-G-D-Y-D-D-D-R 0.192743 -0.0466 1.006891 -0.79795 -0.3607 1.836339 -0.99402 
18 G-R-Q-P-G-D-Y-D-D-D-R-R-Q-P-R -0.667 -0.9999 -0.00244 -1.67302 -1.39058 2.22806 -2.14727 
19 G-D-Y-D-D-D-R-R-Q-P-R-R-E-E-G -4.48229 -4.55056 -3.27029 -4.23338 -4.2206 -3.31441 -4.76474 
20 D-D-R-R-Q-P-R-R-E-E-G-G-R-W-G -2.82402 -3.155 -1.84359 -2.61513 -2.90935 -2.53401 -3.14969 
21 Q-P-R-R-E-E-G-G-R-W-G-P-A-G-P -3.12714 -3.46375 -2.10791 -2.90911 -3.09689 -3.1318 -3.20343 
22 E-E-G-G-R-W-G-P-A-G-P-R-E-R-E -2.58628 -2.88043 -1.57822 -2.34018 -2.46505 -2.17455 -2.85083 
23 R-W-G-P-A-G-P-R-E-R-E-R-E-E-D -1.83231 -2.25652 -0.96241 -1.66278 -1.6223 -2.45344 -2.425 
24 A-G-P-R-E-R-E-R-E-E-D-W-R-Q-P -3.27316 -3.81312 -2.15165 -3.2158 -3.14433 -3.64954 -3.78977 
25 E-R-E-R-E-E-D-W-R-Q-P-R-E-D-W -1.98915 -2.31693 -0.83361 -1.5388 -1.64667 -1.73639 -2.48978 
26 E-E-D-W-R-Q-P-R-E-D-W-R-R-P-S -1.98414 -2.69081 -1.26301 -1.94332 -2.05191 -1.6568 -2.61789 
27 R-Q-P-R-E-D-W-R-R-P-S-H-Q-Q-P -1.61314 -2.37918 -0.88226 -1.72193 -1.66359 -1.00035 -2.45924 
28 E-D-W-R-R-P-S-H-Q-Q-P-R-K-I-R -1.26404 -1.62897 -0.50543 -1.65135 -1.47052 2.772519 -1.93226 
29 R-P-S-H-Q-Q-P-R-K-I-R-P-E-G-R -1.24047 -1.84867 -0.76907 -1.60093 -1.80348 0.679832 -2.20327 
30 Q-Q-P-R-K-I-R-P-E-G-R-E-G-E-Q -1.49654 -1.85575 -0.43065 -1.56617 -1.59888 1.073113 -2.19143 
31 K-I-R-P-E-G-R-E-G-E-Q-E-W-G-T -1.78499 -2.21226 -0.92722 -2.06017 -2.19764 -0.78581 -2.77595 
32 E-G-R-E-G-E-Q-E-W-G-T-P-G-S-H -0.80859 -0.92786 0.083089 -1.02481 -0.89604 -0.74084 -1.51788 
33 G-E-Q-E-W-G-T-P-G-S-H-V-R-E-E -1.12135 -1.32287 -0.59095 -1.59858 -1.42527 -0.84743 -2.07836 
34 W-G-T-P-G-S-H-V-R-E-E-T-S-R-N -0.53332 -1.14455 -0.05914 -1.20476 -1.06486 0.978097 -1.55899 
35 G-S-H-V-R-E-E-T-S-R-N-N-P-F-Y -0.01043 -0.09614 0.440311 -0.50006 -0.32543 1.134864 -1.18208 
36 R-E-E-T-S-R-N-N-P-F-Y-F-P-S-R -0.82036 -1.40932 -0.1763 -1.5243 -1.43969 2.120055 -1.95952 
37 S-R-N-N-P-F-Y-F-P-S-R-R-F-S-T -3.44752 -3.95816 -3.20639 -4.74483 -4.20258 6.11492 -5.01601 
38 P-F-Y-F-P-S-R-R-F-S-T-R-Y-G-N -5.06892 -5.32476 -3.69021 -5.54657 -5.54197 1.857467 -5.87802 
39 P-S-R-R-F-S-T-R-Y-G-N-Q-N-G-R -1.46638 -1.85275 -0.93971 -2.6365 -2.08728 5.462969 -2.87961 
40 F-S-T-R-Y-G-N-Q-N-G-R-I-R-V-L -5.51754 -4.9093 -3.59513 -6.07071 -5.54662 1.951398 -6.1746 
 210  Appendix 
41 Y-G-N-Q-N-G-R-I-R-V-L-Q-R-F-D -3.80173 -4.28143 -3.51195 -4.77467 -4.53855 1.637606 -4.99667 
42 N-G-R-I-R-V-L-Q-R-F-D-Q-R-S-R -1.05402 -1.4463 -0.37499 -2.09876 -1.85343 8.269298 -2.47961 
43 R-V-L-Q-R-F-D-Q-R-S-R-Q-F-Q-N -3.77368 -4.26005 -2.81649 -3.46217 -3.76985 -3.08607 -3.81267 
44 R-F-D-Q-R-S-R-Q-F-Q-N-L-Q-N-H -3.51472 -3.76369 -2.65536 -3.32275 -3.37184 -1.93313 -3.75799 
45 R-S-R-Q-F-Q-N-L-Q-N-H-R-I-V-Q -4.65688 -5.20262 -3.67376 -4.37583 -4.3852 -2.9254 -4.83482 
46 F-Q-N-L-Q-N-H-R-I-V-Q-I-E-A-K -4.96953 -5.19897 -4.1249 -4.81221 -5.01963 -3.5504 -5.15906 
47 Q-N-H-R-I-V-Q-I-E-A-K-P-N-T-L -1.84435 -2.61608 -1.24135 -1.99534 -1.85301 -0.89474 -2.3293 
48 I-V-Q-I-E-A-K-P-N-T-L-V-L-P-K -2.79282 -3.19444 -2.12935 -2.79919 -2.76277 -1.42306 -3.56109 
49 E-A-K-P-N-T-L-V-L-P-K-H-A-D-A -2.58609 -2.53274 -1.5097 -2.47911 -2.36149 -0.87698 -2.99702 
50 N-T-L-V-L-P-K-H-A-D-A-D-N-I-L -2.03782 -2.43916 -1.10017 -1.73145 -1.60425 0.241955 -2.379 
51 L-P-K-H-A-D-A-D-N-I-L-V-I-Q-Q -2.81641 -3.7833 -2.41846 -3.1225 -3.30017 1.703604 -3.77154 
52 A-D-A-D-N-I-L-V-I-Q-Q-G-Q-A-T -4.19235 -4.3313 -3.26534 -4.09327 -4.33864 -1.00651 -4.652 
53 N-I-L-V-I-Q-Q-G-Q-A-T-V-T-V-A -2.16774 -2.13731 -1.27606 -2.39048 -2.42897 0.209174 -2.64583 
54 I-Q-Q-G-Q-A-T-V-T-V-A-N-G-N-N -2.68989 -2.60579 -1.90558 -2.87914 -2.90811 0.692469 -3.47579 
55 Q-A-T-V-T-V-A-N-G-N-N-R-K-S-F -4.75025 -4.47719 -3.99292 -4.88241 -4.93557 -0.46567 -5.21174 
56 T-V-A-N-G-N-N-R-K-S-F-N-L-D-E -1.86184 -2.27533 -1.75553 -2.35259 -2.23456 -0.76586 -2.87459 
57 G-N-N-R-K-S-F-N-L-D-E-G-H-A-L -4.56008 -4.34359 -3.16136 -4.98688 -4.90878 -1.51123 -5.22503 
58 K-S-F-N-L-D-E-G-H-A-L-R-I-P-S -0.91191 -1.43548 -0.23171 -1.45091 -1.47296 1.616476 -1.88548 
59 L-D-E-G-H-A-L-R-I-P-S-G-F-I-S -0.43649 -0.7397 0.05526 -0.8411 -0.93607 4.109905 -1.36711 
60 H-A-L-R-I-P-S-G-F-I-S-Y-I-L-N -0.78396 -1.15791 -0.0508 -1.23558 -1.25632 2.256282 -1.51057 
61 I-P-S-G-F-I-S-Y-I-L-N-R-H-D-N -1.84747 -2.13996 -1.55845 -2.59927 -2.38757 0.955149 -2.88912 
62 F-I-S-Y-I-L-N-R-H-D-N-Q-N-L-R -3.59099 -3.73401 -3.22023 -4.57768 -4.23679 1.134951 -4.7398 
63 I-L-N-R-H-D-N-Q-N-L-R-V-A-K-I -2.88255 -3.44661 -2.73926 -3.77429 -3.67302 0.770051 -4.28396 
64 H-D-N-Q-N-L-R-V-A-K-I-S-M-P-V -1.97813 -2.0283 -0.98189 -2.95385 -2.59865 0.826378 -2.94594 
65 N-L-R-V-A-K-I-S-M-P-V-N-T-P-G -0.06683 -0.34011 0.182529 -0.76292 -0.63256 1.861246 -1.14492 
66 A-K-I-S-M-P-V-N-T-P-G-Q-F-E-D -1.38379 -1.52475 -1.38817 -2.40464 -2.37183 0.172457 -2.86822 
67 M-P-V-N-T-P-G-Q-F-E-D-F-F-P-A -5.85822 -5.20927 -4.92427 -5.43 -5.6348 -3.79248 -6.03225 
68 T-P-G-Q-F-E-D-F-F-P-A-S-S-R-D -5.12523 -4.7924 -3.86626 -4.76564 -5.0775 -2.74772 -5.17944 
69 F-E-D-F-F-P-A-S-S-R-D-Q-S-S-Y -8.47565 -8.33525 -7.09172 -8.10856 -8.22756 -5.29794 -8.77113 
70 F-P-A-S-S-R-D-Q-S-S-Y-L-Q-G-F -4.33994 -4.31495 -3.36856 -4.21691 -4.08812 -2.66787 -4.6224 
71 S-R-D-Q-S-S-Y-L-Q-G-F-S-R-N-T -2.16972 -2.79448 -1.40468 -2.20131 -2.2241 0.762336 -2.67811 
72 S-S-Y-L-Q-G-F-S-R-N-T-L-E-A-A -3.93724 -4.48038 -2.8885 -3.82911 -4.04678 -1.6196 -4.547 
73 Q-G-F-S-R-N-T-L-E-A-A-F-N-A-E -2.27504 -2.51554 -1.50664 -2.20462 -2.19394 -1.11055 -2.65728 
74 R-N-T-L-E-A-A-F-N-A-E-F-N-E-I -1.71356 -2.41752 -1.04764 -1.94978 -1.85634 0.944732 -2.3838 
75 E-A-A-F-N-A-E-F-N-E-I-R-R-V-L -5.03462 -5.35444 -4.39359 -5.18735 -5.4194 -0.20395 -5.56858 
76 N-A-E-F-N-E-I-R-R-V-L-L-E-E-N -4.20345 -4.0091 -3.27078 -4.39007 -4.33249 -1.61252 -4.49492 
77 N-E-I-R-R-V-L-L-E-E-N-A-G-G-E -1.80583 -1.47294 -0.82549 -1.65952 -1.92247 2.170454 -2.27343 
78 R-V-L-L-E-E-N-A-G-G-E-Q-E-E-R -2.48007 -2.28278 -1.70954 -2.53663 -2.44476 -0.22067 -3.09094 
79 E-E-N-A-G-G-E-Q-E-E-R-G-Q-R-R -3.02944 -3.03866 -2.4653 -3.39789 -3.43389 0.593273 -3.55882 
80 G-G-E-Q-E-E-R-G-Q-R-R-W-S-T-R -1.35112 -1.57238 -1.23478 -1.84748 -1.83559 -1.55267 -2.0053 
81 E-E-R-G-Q-R-R-W-S-T-R-S-S-E-N -1.49783 -1.70226 -0.9506 -2.01922 -2.27405 0.053035 -2.4349 
82 Q-R-R-W-S-T-R-S-S-E-N-N-E-G-V -0.57615 -1.05202 -0.32236 -1.23418 -1.45929 -0.29071 -1.84418 
83 S-T-R-S-S-E-N-N-E-G-V-I-V-K-V -0.05901 -0.11086 0.316488 -0.66801 -0.63321 1.758435 -1.00417 
84 S-E-N-N-E-G-V-I-V-K-V-S-K-E-H 0.28641 -0.1019 0.471391 -0.3614 -0.40723 1.853793 -0.85168 
85 E-G-V-I-V-K-V-S-K-E-H-V-E-E-L -0.16239 -0.48878 0.110208 -1.08097 -0.87345 2.711468 -1.40266 
 Appendix  211 
86 V-K-V-S-K-E-H-V-E-E-L-T-K-H-A -0.1189 -0.44542 0.040216 -0.89944 -0.81816 1.27644 -1.14074 
87 K-E-H-V-E-E-L-T-K-H-A-K-S-V-S 0.543002 0.035546 0.846052 -0.09278 -0.12561 2.9907 -0.68633 
88 E-E-L-T-K-H-A-K-S-V-S-K-K-G-S -2.39508 -1.71374 -1.48004 -2.88311 -2.68003 1.902759 -3.7943 
89 K-H-A-K-S-V-S-K-K-G-S-E-E-E-G -0.23525 -0.47456 0.065399 -1.13809 -0.94217 0.072079 -1.13614 
90 S-V-S-K-K-G-S-E-E-E-G-D-I-T-N 0.087879 -0.37212 -0.06961 -1.00511 -0.35301 1.492912 -1.13601 
91 K-G-S-E-E-E-G-D-I-T-N-P-I-N-L -6.08251 -5.91936 -5.24423 -5.58883 -5.75125 -3.95706 -6.28482 
92 E-E-G-D-I-T-N-P-I-N-L-R-E-G-E -3.58016 -3.68533 -3.07699 -3.39914 -3.65236 -1.84062 -3.90622 
93 I-T-N-P-I-N-L-R-E-G-E-P-D-L-S -2.79064 -3.34776 -2.19172 -2.78314 -2.87749 -0.89131 -3.29161 
94 I-N-L-R-E-G-E-P-D-L-S-N-N-F-G -6.46538 -6.59322 -5.76331 -6.44506 -6.59334 -5.55489 -6.89539 
95 E-G-E-P-D-L-S-N-N-F-G-K-L-F-E -1.73921 -2.02205 -0.84639 -1.65204 -1.75084 0.267964 -1.89913 
96 D-L-S-N-N-F-G-K-L-F-E-V-K-P-D -3.22114 -3.63672 -2.60546 -3.10983 -3.162 -0.06525 -3.5238 
97 N-F-G-K-L-F-E-V-K-P-D-K-K-N-P -1.31596 -1.62981 -0.25386 -1.27443 -1.1992 1.523191 -1.63908 
98 L-F-E-V-K-P-D-K-K-N-P-Q-L-Q-D -1.17964 -1.62633 -0.52397 -1.20924 -1.17964 1.809375 -1.65344 
99 K-P-D-K-K-N-P-Q-L-Q-D-L-D-M-M -1.48463 -1.8325 -0.78873 -1.67927 -1.74847 0.81194 -1.93796 
100 K-N-P-Q-L-Q-D-L-D-M-M-L-T-C-V -1.1888 -1.33911 -0.83262 -1.49981 -1.53864 0.551244 -1.77933 
101 L-Q-D-L-D-M-M-L-T-C-V-E-I-K-E -1.07302 -1.24302 -0.4837 -1.36357 -1.35759 0.565644 -1.5592 
102 D-M-M-L-T-C-V-E-I-K-E-G-A-L-M -0.75028 -0.82139 -0.13536 -1.16192 -0.99911 -0.0593 -1.44571 
103 T-C-V-E-I-K-E-G-A-L-M-L-P-H-F -0.36114 -0.85343 0.038987 -0.9403 -0.89087 0.028327 -1.12037 
104 I-K-E-G-A-L-M-L-P-H-F-N-S-K-A -0.55012 -0.78821 -0.50482 -0.8001 -1.06928 0.873289 -1.20742 
105 A-L-M-L-P-H-F-N-S-K-A-M-V-I-V -0.42655 -0.58278 -0.23174 -1.01486 -0.9662 0.99738 -1.06592 
106 P-H-F-N-S-K-A-M-V-I-V-V-V-N-K -0.0925 -0.36752 0.200043 -0.77501 -0.59099 2.871109 -0.95162 
107 S-K-A-M-V-I-V-V-V-N-K-G-T-G-N 0.173235 -0.35064 0.432994 -0.73092 -0.69294 1.195947 -1.14421 
108 V-I-V-V-V-N-K-G-T-G-N-L-E-L-V 0.537866 0.248393 0.824026 -0.26237 -0.21496 4.333803 -0.61314 
109 V-N-K-G-T-G-N-L-E-L-V-A-V-R-K 0.413391 -0.1447 0.535107 -0.62545 -0.40154 2.190412 -0.8985 
110 T-G-N-L-E-L-V-A-V-R-K-E-Q-Q-Q 0.18656 -0.31804 0.49589 -0.76449 -0.32634 1.811087 -0.96414 
111 E-L-V-A-V-R-K-E-Q-Q-Q-R-G-R-R -0.68506 -0.6671 -0.12759 -1.34106 -1.52936 1.899978 -1.8767 
112 V-R-K-E-Q-Q-Q-R-G-R-R-E-E-E-E -1.68546 -1.39896 -1.15009 -2.14635 -2.04733 -0.85528 -2.21273 
113 Q-Q-Q-R-G-R-R-E-E-E-E-D-E-D-E 0.148499 -0.35106 0.042775 -0.94841 -0.77974 0.284108 -1.25717 
114 G-R-R-E-E-E-E-D-E-D-E-E-E-E-G -0.12566 -0.38224 -0.02598 -1.18015 -0.95077 0.555771 -1.46751 
115 E-E-E-D-E-D-E-E-E-E-G-S-N-R-E -4.43209 -4.32553 -3.83032 -4.17066 -4.47604 -2.46544 -4.92847 
116 E-D-E-E-E-E-G-S-N-R-E-V-R-R-Y -5.17861 -4.79219 -4.63093 -4.8571 -5.13206 -3.78025 -5.18906 
117 E-E-G-S-N-R-E-V-R-R-Y-T-A-R-L -4.67646 -4.65452 -3.95036 -4.76744 -4.70542 -1.22555 -4.86127 
118 N-R-E-V-R-R-Y-T-A-R-L-K-E-G-D -6.32906 -6.18001 -5.61922 -6.39417 -6.36808 -3.57857 -6.41153 
119 R-R-Y-T-A-R-L-K-E-G-D-V-F-I-M -4.64388 -4.75712 -3.79146 -4.41361 -4.24739 -1.12305 -4.74242 
120 A-R-L-K-E-G-D-V-F-I-M-P-A-A-H -1.77888 -2.24825 -1.32342 -1.89917 -2.05783 -0.4094 -2.10347 
121 E-G-D-V-F-I-M-P-A-A-H-P-V-A-I -1.63326 -1.51474 -0.89538 -1.24835 -1.39583 1.632756 -1.66071 
122 F-I-M-P-A-A-H-P-V-A-I-N-A-S-S -0.24594 -0.73 -0.51764 -0.94672 -0.92693 -0.6024 -1.11852 
123 A-A-H-P-V-A-I-N-A-S-S-E-L-H-L -0.0888 -0.42306 0.010493 -0.77237 -0.70429 0.041462 -0.63688 
124 V-A-I-N-A-S-S-E-L-H-L-L-G-F-G -0.69734 -0.543 -0.31077 -1.19915 -1.37762 -0.18655 -1.59389 
125 A-S-S-E-L-H-L-L-G-F-G-I-N-A-E -1.77673 -1.84522 -1.55784 -2.20931 -2.2245 -0.80088 -2.3461 
126 L-H-L-L-G-F-G-I-N-A-E-N-N-H-R -1.75273 -1.57223 -0.84303 -1.66117 -1.55857 2.041928 -2.294 
127 G-F-G-I-N-A-E-N-N-H-R-I-F-L-A -1.26419 -1.58705 -1.01378 -1.83206 -1.6283 1.645773 -2.05492 
128 N-A-E-N-N-H-R-I-F-L-A-G-D-K-D -0.79452 -0.83485 -0.7815 -1.2169 -1.10286 1.319537 -1.42178 
129 N-H-R-I-F-L-A-G-D-K-D-N-V-I-D -1.44956 -1.44486 -1.18522 -1.84764 -2.06453 0.939484 -2.30841 
130 F-L-A-G-D-K-D-N-V-I-D-Q-I-E-K -1.969 -1.85691 -1.66995 -2.41359 -2.23676 1.542752 -2.67637 
 212  Appendix 
131 D-K-D-N-V-I-D-Q-I-E-K-Q-A-K-D -0.38422 -0.96466 -0.75624 -1.27404 -1.36663 1.253026 -1.39168 
132 V-I-D-Q-I-E-K-Q-A-K-D-L-A-F-P 0.700561 0.343285 0.708647 -0.20513 -0.14982 1.513708 -0.46916 
133 I-E-K-Q-A-K-D-L-A-F-P-G-S-G-E 0.745155 0.610842 1.853715 -0.15906 -0.04367 0.885985 -0.4803 
134 A-K-D-L-A-F-P-G-S-G-E-Q-V-E-K 0.689793 0.549704 4.461783 -0.02356 -0.01489 3.67867 -0.17478 
135 A-F-P-G-S-G-E-Q-V-E-K-L-I-K-N -0.53511 -0.76289 -0.17308 -1.17784 -1.33922 1.009453 -1.58414 
136 S-G-E-Q-V-E-K-L-I-K-N-Q-K-E-S -0.21969 -0.51256 0.012519 -1.04923 -0.62634 -0.57752 -1.02176 
137 V-E-K-L-I-K-N-Q-K-E-S-H-F-V-S -0.35575 -0.21945 -0.27371 -1.24861 -0.956 -1.15982 -1.51356 
138 I-K-N-Q-K-E-S-H-F-V-S-A-R-P-Q 0.072311 -0.1279 0.000766 -1.05071 -0.89162 -0.30476 -1.09003 
139 K-E-S-H-F-V-S-A-R-P-Q-S-Q-S-Q -2.97073 -2.73124 -2.51785 -2.53422 -3.16457 -1.61284 -2.98804 
140 F-V-S-A-R-P-Q-S-Q-S-Q-S-P-S-S -3.31237 -3.36941 -2.91323 -2.95238 -3.36365 -2.42809 -3.44926 
141 R-P-Q-S-Q-S-Q-S-P-S-S-P-E-K-E -8.82035 -8.58667 -7.81938 -8.4913 -8.71475 -6.16303 -8.08372 
142 Q-S-Q-S-P-S-S-P-E-K-E-S-P-E-K -3.73943 -3.92663 -3.46774 -3.93155 -3.96514 -1.72332 -4.17279 
143 P-S-S-P-E-K-E-S-P-E-K-E-D-Q-E -2.68931 -2.76318 -2.45208 -2.71261 -2.65349 -0.36627 -2.90363 
144 E-K-E-S-P-E-K-E-D-Q-E-E-E-N-Q -2.02813 -2.48894 -1.48227 -2.12817 -2.16613 -0.01414 -2.26965 
145 P-E-K-E-D-Q-E-E-E-N-Q-G-G-K-G -1.37895 -1.29748 -1.15837 -1.43399 -1.57587 -0.34633 -1.7935 
146 D-Q-E-E-E-N-Q-G-G-K-G-P-L-L-S -1.94893 -1.87866 -1.67339 -1.94198 -1.84066 -0.21488 -2.1844 
147 E-N-Q-G-G-K-G-P-L-L-S-I-L-K-A -2.61285 -2.91023 -2.471 -3.03415 -3.09521 -0.77711 -3.30461 
148 Q-G-G-K-G-P-L-L-S-I-L-K-A-F-N -1.60418 -1.7631 -1.47978 -2.18875 -1.87553 -0.31158 -2.13019 
 m (blanks) 12537.95 10771.03 12268.53 14071.12 13118.96 11883.05 11332.93 
 s (blanks) 353.6775 354.0388 363.7228 459.9209 431.5639 526.1645 436.8518 
 
Table A6: Calculated Z-scores of Ara h 1 peptides of controls and derived maximum Z-score. 
The calculated Z-scores of every peptide of Ara h 1 for each control and the maximum Z-score (Max.) of the controls 
are listed. Numbers written behind control sera represent the respective developed X-ray film. 
 Control No. → N_1 N_2 N_3 DLab71S1_
1 
DLab71S1_
2 
DLab71S1_
3 
Max. 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score Z-score 
1 K-S-S-P-Y-Q-K-K-T-E-N-P-C-A-Q 1.070546 0.580083 2.082704 0.059552 -0.05839 1.68182 2.082704 
2 Y-Q-K-K-T-E-N-P-C-A-Q-R-C-L-Q 1.334444 0.563629 1.858645 0.212815 0.017896 1.723178 1.858645 
3 T-E-N-P-C-A-Q-R-C-L-Q-S-C-Q-Q 1.981947 0.584197 1.996702 0.901739 -0.01071 2.168927 2.168927 
4 C-A-Q-R-C-L-Q-S-C-Q-Q-E-P-D-D 1.190252 0.376458 1.654955 -0.26518 -0.15185 1.461243 1.654955 
5 C-L-Q-S-C-Q-Q-E-P-D-D-L-K-Q-K 1.462312 0.701436 2.195865 0.516306 -0.01834 1.913885 2.195865 
6 C-Q-Q-E-P-D-D-L-K-Q-K-A-C-E-S 0.287013 0.503981 2.200392 -0.27732 -0.06793 0.838574 2.200392 
7 P-D-D-L-K-Q-K-A-C-E-S-R-C-T-K 0.586279 0.765197 1.770379 -0.13316 -0.17473 1.116592 1.770379 
8 K-Q-K-A-C-E-S-R-C-T-K-L-E-Y-D 1.350768 0.650015 1.937858 0.540585 0.206712 1.801299 1.937858 
9 C-E-S-R-C-T-K-L-E-Y-D-P-R-C-V 1.290914 0.222197 1.428632 0.481404 -0.1137 1.309597 1.428632 
10 C-T-K-L-E-Y-D-P-R-C-V-Y-D-P-R 1.323562 0.273617 1.924278 0.508718 -0.04886 1.54396 1.924278 
11 E-Y-D-P-R-C-V-Y-D-P-R-G-H-T-G 0.371351 0.263333 1.233995 0.422224 -0.20716 1.072936 1.233995 
12 R-C-V-Y-D-P-R-G-H-T-G-T-T-N-Q 2.349228 0.275674 1.75001 0.38884 -0.22051 0.742071 2.349228 
13 D-P-R-G-H-T-G-T-T-N-Q-R-S-P-P 1.535768 0.724061 1.512371 1.102043 -0.09082 1.465839 1.535768 
14 H-T-G-T-T-N-Q-R-S-P-P-G-E-R-T 1.122237 0.563629 1.591584 0.683226 0.021711 0.944267 1.591584 
15 T-N-Q-R-S-P-P-G-E-R-T-R-G-R-Q 2.648494 0.861868 2.075914 1.457128 0.086556 1.872527 2.648494 
16 S-P-P-G-E-R-T-R-G-R-Q-P-G-D-Y 2.259448 0.724061 1.295102 0.672604 0.212433 0.900611 2.259448 
17 E-R-T-R-G-R-Q-P-G-D-Y-D-D-D-R 1.628269 0.818674 1.000883 0.985199 0.485167 1.155653 1.628269 
18 G-R-Q-P-G-D-Y-D-D-D-R-R-Q-P-R 2.667538 1.244436 2.827305 2.099011 0.925735 2.649141 2.827305 
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19 G-D-Y-D-D-D-R-R-Q-P-R-R-E-E-G 2.683862 1.546789 4.73973 1.939678 1.043983 4.069105 4.73973 
20 D-D-R-R-Q-P-R-R-E-E-G-G-R-W-G 0.986207 1.371959 2.852201 -0.13772 0.797951 3.104081 3.104081 
21 Q-P-R-R-E-E-G-G-R-W-G-P-A-G-P 0.869221 1.2033 3.189421 0.38277 0.456558 3.395886 3.395886 
22 E-E-G-G-R-W-G-P-A-G-P-R-E-R-E 1.990109 0.728174 2.734513 0.951815 0.410785 2.761728 2.761728 
23 R-W-G-P-A-G-P-R-E-R-E-R-E-E-D 1.195693 0.62122 2.112126 0.469265 0.391712 2.132165 2.132165 
24 A-G-P-R-E-R-E-R-E-E-D-W-R-Q-P 1.709887 0.528663 3.522115 1.275033 0.136144 2.922565 3.522115 
25 E-R-E-R-E-E-D-W-R-Q-P-R-E-D-W 0.825692 0.431992 1.901646 0.012511 -0.02406 1.603699 1.901646 
26 E-E-D-W-R-Q-P-R-E-D-W-R-R-P-S 0.967163 0.345606 1.575742 -0.23332 0.006453 2.2953 2.2953 
27 R-Q-P-R-E-D-W-R-R-P-S-H-Q-Q-P 0.569955 0.512208 1.969543 0.276548 -0.0069 1.904695 1.969543 
28 E-D-W-R-R-P-S-H-Q-Q-P-R-K-I-R 0.915472 0.497811 1.611953 0.064104 -0.12705 1.580723 1.611953 
29 R-P-S-H-Q-Q-P-R-K-I-R-P-E-G-R 1.538489 0.345606 1.933331 0.190053 -0.05076 1.25675 1.933331 
30 Q-Q-P-R-K-I-R-P-E-G-R-E-G-E-Q 0.959001 0.549231 1.768116 1.007961 0.046505 1.504899 1.768116 
31 K-I-R-P-E-G-R-E-G-E-Q-E-W-G-T 1.775181 0.85364 2.213971 1.337249 -0.12133 2.325169 2.325169 
32 E-G-R-E-G-E-Q-E-W-G-T-P-G-S-H 0.414881 0.549231 1.215889 -0.04667 -0.1404 1.08902 1.215889 
33 G-E-Q-E-W-G-T-P-G-S-H-V-R-E-E 1.323562 0.736402 1.747747 -0.02846 -0.05839 1.867932 1.867932 
34 W-G-T-P-G-S-H-V-R-E-E-T-S-R-N 0.303336 0.092617 1.424106 0.736337 -0.43602 1.254453 1.424106 
35 G-S-H-V-R-E-E-T-S-R-N-N-P-F-Y 0.689662 0.201628 0.754191 0.498096 -0.22814 0.691522 0.754191 
36 R-E-E-T-S-R-N-N-P-F-Y-F-P-S-R 1.992829 0.450504 2.03065 1.478372 0.174289 1.236071 2.03065 
37 S-R-N-N-P-F-Y-F-P-S-R-R-F-S-T 5.409904 1.773039 4.502092 3.373673 0.710219 2.196499 5.409904 
38 P-F-Y-F-P-S-R-R-F-S-T-R-Y-G-N 6.457335 1.038754 3.092103 1.894154 0.344032 1.71169 6.457335 
39 P-S-R-R-F-S-T-R-Y-G-N-Q-N-G-R 2.784524 0.839243 3.442902 1.542105 0.54429 2.134462 3.442902 
40 F-S-T-R-Y-G-N-Q-N-G-R-I-R-V-L 7.129323 1.51388 4.196556 3.109635 0.830374 3.25343 7.129323 
41 Y-G-N-Q-N-G-R-I-R-V-L-Q-R-F-D 5.894171 1.275289 2.78883 2.126325 0.710219 2.607783 5.894171 
42 N-G-R-I-R-V-L-Q-R-F-D-Q-R-S-R 3.287835 1.828573 2.739039 1.883532 0.464187 1.849551 3.287835 
43 R-V-L-Q-R-F-D-Q-R-S-R-Q-F-Q-N 0.450249 1.287629 3.182632 0.381252 1.22517 4.098974 4.098974 
44 R-F-D-Q-R-S-R-Q-F-Q-N-L-Q-N-H 1.818711 1.102516 3.698647 0.778825 0.813209 3.326956 3.698647 
45 R-S-R-Q-F-Q-N-L-Q-N-H-R-I-V-Q 2.542391 1.232095 3.612644 2.479892 0.981045 5.038724 5.038724 
46 F-Q-N-L-Q-N-H-R-I-V-Q-I-E-A-K 5.388139 0.617106 3.157736 2.79097 0.490888 3.726751 5.388139 
47 Q-N-H-R-I-V-Q-I-E-A-K-P-N-T-L 0.929075 0.39497 1.96728 0.135425 0.227691 2.251644 2.251644 
48 I-V-Q-I-E-A-K-P-N-T-L-V-L-P-K 3.089231 0.425822 3.101155 1.794002 0.326867 2.823765 3.101155 
49 E-A-K-P-N-T-L-V-L-P-K-H-A-D-A 1.36165 0.538947 2.562508 0.757581 0.191454 2.676714 2.676714 
50 N-T-L-V-L-P-K-H-A-D-A-D-N-I-L 1.144002 0.586254 1.697956 0.300827 0.126608 2.074723 2.074723 
51 L-P-K-H-A-D-A-D-N-I-L-V-I-Q-Q 3.480998 0.62122 2.809199 2.795522 0.347846 3.232751 3.480998 
52 A-D-A-D-N-I-L-V-I-Q-Q-G-Q-A-T 4.514826 0.499867 2.404082 2.109633 0.349754 2.633058 4.514826 
53 N-I-L-V-I-Q-Q-G-Q-A-T-V-T-V-A 2.575038 0.518379 2.118916 0.678673 0.557641 2.336658 2.575038 
54 I-Q-Q-G-Q-A-T-V-T-V-A-N-G-N-N 3.102834 0.62739 2.485558 1.435883 0.094185 2.139058 3.102834 
55 Q-A-T-V-T-V-A-N-G-N-N-R-K-S-F 5.170491 0.806334 4.404773 2.71358 0.361197 5.443114 5.443114 
56 T-V-A-N-G-N-N-R-K-S-F-N-L-D-E 2.732833 0.508095 2.218498 2.162744 0.263928 2.099997 2.732833 
57 G-N-N-R-K-S-F-N-L-D-E-G-H-A-L 3.908132 0.573913 2.17097 1.862288 0.471816 5.323635 5.323635 
58 K-S-F-N-L-D-E-G-H-A-L-R-I-P-S 0.572676 0.119356 1.297365 0.520858 -0.09654 1.709392 1.709392 
59 L-D-E-G-H-A-L-R-I-P-S-G-F-I-S 0.746794 0.347663 1.18873 0.02465 -0.20716 0.542173 1.18873 
60 H-A-L-R-I-P-S-G-F-I-S-Y-I-L-N 0.746794 0.619163 1.654955 1.149084 0.014082 1.491113 1.654955 
61 I-P-S-G-F-I-S-Y-I-L-N-R-H-D-N 3.170849 0.512208 1.89712 1.058037 0.187639 0.969541 3.170849 
62 F-I-S-Y-I-L-N-R-H-D-N-Q-N-L-R 5.140564 0.880379 2.684722 2.501136 0.20099 1.647355 5.140564 
63 I-L-N-R-H-D-N-Q-N-L-R-V-A-K-I 4.604606 0.652072 2.152864 1.936643 0.246763 3.478602 4.604606 
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64 H-D-N-Q-N-L-R-V-A-K-I-S-M-P-V 3.875485 0.979106 2.487821 2.668056 0.540476 3.005281 3.875485 
65 N-L-R-V-A-K-I-S-M-P-V-N-T-P-G 1.930256 0.645902 1.89033 1.305382 0.481352 1.693309 1.930256 
66 A-K-I-S-M-P-V-N-T-P-G-Q-F-E-D 3.674161 1.388414 3.144157 2.006446 0.832281 2.764025 3.674161 
67 M-P-V-N-T-P-G-Q-F-E-D-F-F-P-A 5.311962 1.489198 5.405119 3.699925 1.593264 6.327719 6.327719 
68 T-P-G-Q-F-E-D-F-F-P-A-S-S-R-D 5.023578 1.256777 5.178796 2.786418 1.175582 5.374184 5.374184 
69 F-E-D-F-F-P-A-S-S-R-D-Q-S-S-Y 7.006896 2.019857 5.280641 2.828906 2.594557 9.078036 9.078036 
70 F-P-A-S-S-R-D-Q-S-S-Y-L-Q-G-F 4.427767 0.89889 3.368216 3.871398 0.50996 4.549319 4.549319 
71 S-R-D-Q-S-S-Y-L-Q-G-F-S-R-N-T 2.322022 0.752856 2.24113 0.754546 0.18001 2.483709 2.483709 
72 S-S-Y-L-Q-G-F-S-R-N-T-L-E-A-A 4.53115 0.884493 3.311635 2.54059 0.714034 4.234537 4.53115 
73 Q-G-F-S-R-N-T-L-E-A-A-F-N-A-E 2.22136 0.378515 2.467452 0.78186 0.159031 2.143653 2.467452 
74 R-N-T-L-E-A-A-F-N-A-E-F-N-E-I 1.884005 0.489583 1.89033 0.44195 0.138052 2.132165 2.132165 
75 E-A-A-F-N-A-E-F-N-E-I-R-R-V-L 5.458875 1.049038 3.064944 2.097493 0.50996 2.20569 5.458875 
76 N-A-E-F-N-E-I-R-R-V-L-L-E-E-N 4.520267 0.545117 2.759408 0.957885 0.216248 2.950137 4.520267 
77 N-E-I-R-R-V-L-L-E-E-N-A-G-G-E 1.737093 0.707606 1.747747 1.989754 0.141866 1.863337 1.989754 
78 R-V-L-L-E-E-N-A-G-G-E-Q-E-E-R 1.514004 0.631504 2.31129 1.561832 0.33831 2.695095 2.695095 
79 E-E-N-A-G-G-E-Q-E-E-R-G-Q-R-R 2.433567 0.489583 2.118916 1.479889 0.267743 3.54983 3.54983 
80 G-G-E-Q-E-E-R-G-Q-R-R-W-S-T-R 2.058124 0.384685 1.451264 0.156669 0.035061 2.019579 2.058124 
81 E-E-R-G-Q-R-R-W-S-T-R-S-S-E-N 1.843196 0.364117 1.360735 0.534515 -0.10989 2.332062 2.332062 
82 Q-R-R-W-S-T-R-S-S-E-N-N-E-G-V 0.221718 0.154322 1.623269 0.375182 -0.1404 1.68182 1.68182 
83 S-T-R-S-S-E-N-N-E-G-V-I-V-K-V -0.5727 0.345606 0.56408 0.839524 -0.28345 0.356062 0.839524 
84 S-E-N-N-E-G-V-I-V-K-V-S-K-E-H 0.197233 0.043253 0.822088 0.193088 -0.22432 0.333085 0.822088 
85 E-G-V-I-V-K-V-S-K-E-H-V-E-E-L 0.175468 0.285958 1.482949 0.127837 0.094185 0.581234 1.482949 
86 V-K-V-S-K-E-H-V-E-E-L-T-K-H-A 0.763118 0.590367 1.566689 0.575486 0.046505 1.236071 1.566689 
87 K-E-H-V-E-E-L-T-K-H-A-K-S-V-S -0.06939 0.545117 1.068779 0.715092 -0.01643 0.788025 1.068779 
88 E-E-L-T-K-H-A-K-S-V-S-K-K-G-S 4.346149 0.85364 2.772988 2.913884 0.864704 3.513067 4.346149 
89 K-H-A-K-S-V-S-K-K-G-S-E-E-E-G 2.033638 0.715833 1.702482 1.05045 0.454651 1.169439 2.033638 
90 S-V-S-K-K-G-S-E-E-E-G-D-I-T-N 1.835035 1.026413 1.503319 1.64074 0.382176 2.072425 2.072425 
91 K-G-S-E-E-E-G-D-I-T-N-P-I-N-L 2.964084 1.415152 4.698992 1.930573 1.351047 6.532212 6.532212 
92 E-E-G-D-I-T-N-P-I-N-L-R-E-G-E 3.429307 1.184788 3.594539 1.187021 1.167953 4.018556 4.018556 
93 I-T-N-P-I-N-L-R-E-G-E-P-D-L-S 0.303336 0.913288 3.246002 0.21585 0.828467 2.931756 3.246002 
94 I-N-L-R-E-G-E-P-D-L-S-N-N-F-G 6.968808 1.084004 3.77786 3.032245 0.89522 4.85491 6.968808 
95 E-G-E-P-D-L-S-N-N-F-G-K-L-F-E 1.337165 0.551288 1.906173 0.133907 0.260114 1.851848 1.906173 
96 D-L-S-N-N-F-G-K-L-F-E-V-K-P-D 1.571136 0.48547 2.560245 0.794 0.502332 3.368314 3.368314 
97 N-F-G-K-L-F-E-V-K-P-D-K-K-N-P 0.784883 0.224253 1.426369 0.373665 0.036969 1.270536 1.426369 
98 L-F-E-V-K-P-D-K-K-N-P-Q-L-Q-D 0.265248 0.349719 1.372051 0.176396 0.103721 1.323383 1.372051 
99 K-P-D-K-K-N-P-Q-L-Q-D-L-D-M-M 0.452969 0.318867 1.713798 0.083831 0.164753 1.44516 1.713798 
100 K-N-P-Q-L-Q-D-L-D-M-M-L-T-C-V 0.216277 0.304469 1.573478 -0.15593 -0.01643 1.036174 1.573478 
101 L-Q-D-L-D-M-M-L-T-C-V-E-I-K-E 0.205395 0.31681 1.317734 0.177913 -0.07937 1.378527 1.378527 
102 D-M-M-L-T-C-V-E-I-K-E-G-A-L-M -0.20814 0.658242 0.939775 -0.08764 0.092278 1.024685 1.024685 
103 T-C-V-E-I-K-E-G-A-L-M-L-P-H-F -0.30336 0.335322 0.946565 -0.12406 0.006453 0.719094 0.946565 
104 I-K-E-G-A-L-M-L-P-H-F-N-S-K-A 1.051502 0.306526 1.141202 0.30538 0.069391 0.95116 1.141202 
105 A-L-M-L-P-H-F-N-S-K-A-M-V-I-V 0.403999 0.279788 0.616134 0.103558 0.025525 1.079829 1.079829 
106 P-H-F-N-S-K-A-M-V-I-V-V-V-N-K -0.66248 0.133753 0.889985 0.003406 -0.15375 0.838574 0.889985 
107 S-K-A-M-V-I-V-V-V-N-K-G-T-G-N 0.915472 0.121412 0.751928 0.674121 -0.26437 0.443373 0.915472 
108 V-I-V-V-V-N-K-G-T-G-N-L-E-L-V 0.518264 0.047367 0.55729 0.297792 -0.05458 0.590425 0.590425 
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109 V-N-K-G-T-G-N-L-E-L-V-A-V-R-K -0.05306 0.183117 0.55729 0.252269 -0.04123 0.994815 0.994815 
110 T-G-N-L-E-L-V-A-V-R-K-E-Q-Q-Q 0.959001 0.370288 1.396947 0.577004 0.193361 0.689225 1.396947 
111 E-L-V-A-V-R-K-E-Q-Q-Q-R-G-R-R 2.243125 0.594481 1.550846 2.130877 0.14568 1.417588 2.243125 
112 V-R-K-E-Q-Q-Q-R-G-R-R-E-E-E-E 3.048422 0.736402 1.858645 1.982167 0.40697 2.612379 3.048422 
113 Q-Q-Q-R-G-R-R-E-E-E-E-D-E-D-E 1.772461 0.637674 2.014807 1.71206 0.607229 2.028769 2.028769 
114 G-R-R-E-E-E-E-D-E-D-E-E-E-E-G 2.232242 0.773424 1.247574 1.017066 0.7579 2.102295 2.232242 
115 E-E-E-D-E-D-E-E-E-E-G-S-N-R-E 3.821073 1.334936 4.843839 2.780348 1.705791 4.983579 4.983579 
116 E-D-E-E-E-E-G-S-N-R-E-V-R-R-Y 3.660558 1.262948 3.859336 1.448023 1.232799 5.498259 5.498259 
117 E-E-G-S-N-R-E-V-R-R-Y-T-A-R-L 3.774823 0.80839 5.106373 2.432851 0.838003 3.924351 5.106373 
118 N-R-E-V-R-R-Y-T-A-R-L-K-E-G-D 6.737557 0.826902 5.16069 3.516313 0.956251 6.750491 6.750491 
119 R-R-Y-T-A-R-L-K-E-G-D-V-F-I-M 4.680783 0.524549 2.417661 1.780345 0.529033 2.566425 4.680783 
120 A-R-L-K-E-G-D-V-F-I-M-P-A-A-H 0.374072 0.514265 2.053282 0.095971 0.273465 1.895504 2.053282 
121 E-G-D-V-F-I-M-P-A-A-H-P-V-A-I 0.684221 0.127583 1.537267 0.338764 0.134237 1.491113 1.537267 
122 F-I-M-P-A-A-H-P-V-A-I-N-A-S-S -0.14012 0.300356 0.43055 0.161221 -0.17664 1.066043 1.066043 
123 A-A-H-P-V-A-I-N-A-S-S-E-L-H-L -0.33873 0.125526 0.659136 0.004924 -0.03932 0.815597 0.815597 
124 V-A-I-N-A-S-S-E-L-H-L-L-G-F-G 0.202674 0.032969 0.91488 0.6984 -0.35211 1.47503 1.47503 
125 A-S-S-E-L-H-L-L-G-F-G-I-N-A-E 1.260988 0.503981 2.254709 1.572454 0.170474 2.244751 2.254709 
126 L-H-L-L-G-F-G-I-N-A-E-N-N-H-R 1.258267 0.510151 1.806591 1.28262 0.057948 1.511792 1.806591 
127 G-F-G-I-N-A-E-N-N-H-R-I-F-L-A 1.494959 0.448447 1.894856 0.731784 0.128515 1.688713 1.894856 
128 N-A-E-N-N-H-R-I-F-L-A-G-D-K-D 0.199954 0.102901 1.26568 0.696883 -0.00499 1.360146 1.360146 
129 N-H-R-I-F-L-A-G-D-K-D-N-V-I-D 1.010693 0.179003 1.535004 0.854698 0.023618 2.173523 2.173523 
130 F-L-A-G-D-K-D-N-V-I-D-Q-I-E-K 1.002531 0.037083 1.541793 0.957885 -0.15757 2.63076 2.63076 
131 D-K-D-N-V-I-D-Q-I-E-K-Q-A-K-D 1.552092 -0.06987 0.980514 1.227992 -0.17283 1.213095 1.552092 
132 V-I-D-Q-I-E-K-Q-A-K-D-L-A-F-P 0.31966 -0.03696 0.441866 0.13239 -0.3254 0.195224 0.441866 
133 I-E-K-Q-A-K-D-L-A-F-P-G-S-G-E 0.360469 -0.09044 0.195174 0.139977 -0.07556 0.569746 0.569746 
134 A-K-D-L-A-F-P-G-S-G-E-Q-V-E-K 0.749515 0.207799 0.525605 0.53148 0.027432 0.746667 0.749515 
135 A-F-P-G-S-G-E-Q-V-E-K-L-I-K-N 2.101653 0.335322 0.923933 1.21737 0.206712 1.635867 2.101653 
136 S-G-E-Q-V-E-K-L-I-K-N-Q-K-E-S 1.756137 0.477242 0.946565 1.907811 0.241042 1.082127 1.907811 
137 V-E-K-L-I-K-N-Q-K-E-S-H-F-V-S 2.205036 0.769311 1.315471 2.03983 0.464187 1.605997 2.205036 
138 I-K-N-Q-K-E-S-H-F-V-S-A-R-P-Q 2.161507 0.796049 1.152519 1.722682 0.889498 1.11889 2.161507 
139 K-E-S-H-F-V-S-A-R-P-Q-S-Q-S-Q 1.862241 0.9318 2.582877 -0.04515 1.106922 3.338444 3.338444 
140 F-V-S-A-R-P-Q-S-Q-S-Q-S-P-S-S 1.18209 0.855697 2.671143 0.270478 0.979138 3.634844 3.634844 
141 R-P-Q-S-Q-S-Q-S-P-S-S-P-E-K-E 9.352054 2.063051 4.855155 3.540593 1.494089 9.156157 9.352054 
142 Q-S-Q-S-P-S-S-P-E-K-E-S-P-E-K 2.379155 0.516322 2.415398 1.581559 0.54429 4.296575 4.296575 
143 P-S-S-P-E-K-E-S-P-E-K-E-D-Q-E 2.90151 0.49164 2.322606 0.502649 0.361197 2.706583 2.90151 
144 E-K-E-S-P-E-K-E-D-Q-E-E-E-N-Q 1.222899 0.36206 1.765853 0.71054 0.244856 2.214881 2.214881 
145 P-E-K-E-D-Q-E-E-E-N-Q-G-G-K-G 0.472014 0.133753 1.541793 0.323589 0.014082 1.596806 1.596806 
146 D-Q-E-E-E-N-Q-G-G-K-G-P-L-L-S 0.349587 0.382629 1.661744 0.393392 0.29063 2.06783 2.06783 
147 E-N-Q-G-G-K-G-P-L-L-S-I-L-K-A 3.192614 0.493697 1.786222 1.80159 0.237227 2.66063 3.192614 
148 Q-G-G-K-G-P-L-L-S-I-L-K-A-F-N 1.209296 0.343549 2.118916 0.828901 0.172382 1.932267 2.118916 
 m (blanks) 13069.5 12623.97 12097.76 12973.76 11876.62 12228.03 
 s (blanks) 367.5659 486.1874 441.8473 658.9983 524.322 435.2225 
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Table A7: Calculated Z-scores of Ara h 1 IgE inhibition experiments. 
The calculated Z-scores of serum pool 1 (peanut patients 10, 12, 18 and 21) and serum pool 2 (peanut patients 6, 
15, 17, 23) inhibited (+) and uninhibited (-) are listed. For inhibition 20.5 µg rAra h 1 was preincubated with both 
serum pools. As references, uninhibited serum pools preincubated with protein buffer without rAra h 1 were used. 
Identified candidate diagnostic peptides are highlighted in light blue. 
 IgE inhibition experiment → Pool 1 - Pool 1 + Pool 2- Pool 2 + 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score 
1 K-S-S-P-Y-Q-K-K-T-E-N-P-C-A-Q 3.201425 16.39898 1.118071 3.6101 
2 Y-Q-K-K-T-E-N-P-C-A-Q-R-C-L-Q 3.004696 19.31349 0.345692 4.680069 
3 T-E-N-P-C-A-Q-R-C-L-Q-S-C-Q-Q 12.18876 27.99487 0.491081 6.82209 
4 C-A-Q-R-C-L-Q-S-C-Q-Q-E-P-D-D 3.406185 23.16972 1.530006 7.033583 
5 C-L-Q-S-C-Q-Q-E-P-D-D-L-K-Q-K 2.775847 32.46468 1.414906 5.005123 
6 C-Q-Q-E-P-D-D-L-K-Q-K-A-C-E-S 0.912937 9.100103 0.385068 1.082599 
7 P-D-D-L-K-Q-K-A-C-E-S-R-C-T-K 2.950495 14.35437 0.860611 4.540462 
8 K-Q-K-A-C-E-S-R-C-T-K-L-E-Y-D 2.029077 23.77553 1.193794 7.9952 
9 C-E-S-R-C-T-K-L-E-Y-D-P-R-C-V 1.806251 22.37168 0.669788 4.580052 
10 C-T-K-L-E-Y-D-P-R-C-V-Y-D-P-R 2.017032 23.0804 0.357808 1.781673 
11 E-Y-D-P-R-C-V-Y-D-P-R-G-H-T-G 1.583424 13.22041 0.600122 1.968162 
12 R-C-V-Y-D-P-R-G-H-T-G-T-T-N-Q 1.980898 15.19707 0.845466 2.563052 
13 D-P-R-G-H-T-G-T-T-N-Q-R-S-P-P 0.939034 14.91164 0.575891 2.592224 
14 H-T-G-T-T-N-Q-R-S-P-P-G-E-R-T 1.573387 11.88645 0.981769 1.791049 
15 T-N-Q-R-S-P-P-G-E-R-T-R-G-R-Q 7.278548 18.35817 1.629961 3.709075 
16 S-P-P-G-E-R-T-R-G-R-Q-P-G-D-Y 69.67598 20.86103 11.47703 4.894688 
17 E-R-T-R-G-R-Q-P-G-D-Y-D-D-D-R 90.99506 26.06869 12.11311 4.538379 
18 G-R-Q-P-G-D-Y-D-D-D-R-R-Q-P-R 61.25073 12.83401 2.011607 5.382268 
19 G-D-Y-D-D-D-R-R-Q-P-R-R-E-E-G 5.760919 33.8763 1.224083 3.753874 
20 D-D-R-R-Q-P-R-R-E-E-G-G-R-W-G 9.615215 33.33456 0.966624 3.652816 
21 Q-P-R-R-E-E-G-G-R-W-G-P-A-G-P 15.21398 40.74995 2.387195 5.582301 
22 E-E-G-G-R-W-G-P-A-G-P-R-E-R-E 11.97396 28.45117 1.77535 3.637188 
23 R-W-G-P-A-G-P-R-E-R-E-R-E-E-D 3.990352 26.67645 0.80609 3.573636 
24 A-G-P-R-E-R-E-R-E-E-D-W-R-Q-P 4.797345 42.96252 2.072186 6.035501 
25 E-R-E-R-E-E-D-W-R-Q-P-R-E-D-W 3.633026 29.95599 2.753696 5.488536 
26 E-E-D-W-R-Q-P-R-E-D-W-R-R-P-S 7.629851 28.00263 3.874403 6.090719 
27 R-Q-P-R-E-D-W-R-R-P-S-H-Q-Q-P 11.23924 34.16756 4.374177 9.142265 
28 E-D-W-R-R-P-S-H-Q-Q-P-R-K-I-R 22.73187 33.66271 3.695696 6.788751 
29 R-P-S-H-Q-Q-P-R-K-I-R-P-E-G-R 39.80118 32.43167 4.240904 5.548963 
30 Q-Q-P-R-K-I-R-P-E-G-R-E-G-E-Q 13.61605 36.15101 3.041445 4.726952 
31 K-I-R-P-E-G-R-E-G-E-Q-E-W-G-T 8.03937 34.48017 1.218026 5.280168 
32 E-G-R-E-G-E-Q-E-W-G-T-P-G-S-H 4.843516 25.42016 0.83638 3.067302 
33 G-E-Q-E-W-G-T-P-G-S-H-V-R-E-E 3.450349 26.70169 1.420964 4.702989 
34 W-G-T-P-G-S-H-V-R-E-E-T-S-R-N 2.723653 26.77159 0.569833 3.004792 
35 G-S-H-V-R-E-E-T-S-R-N-N-P-F-Y 0.896878 18.64748 0.369923 4.644646 
36 R-E-E-T-S-R-N-N-P-F-Y-F-P-S-R 3.741428 30.16958 2.308443 7.80246 
37 S-R-N-N-P-F-Y-F-P-S-R-R-F-S-T 3.719346 30.28705 2.605278 7.304461 
38 P-F-Y-F-P-S-R-R-F-S-T-R-Y-G-N 2.155546 37.53157 1.854102 8.224405 
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39 P-S-R-R-F-S-T-R-Y-G-N-Q-N-G-R 3.01674 27.7871 2.305414 7.839966 
40 F-S-T-R-Y-G-N-Q-N-G-R-I-R-V-L 5.353407 34.82482 2.617394 11.68227 
41 Y-G-N-Q-N-G-R-I-R-V-L-Q-R-F-D 4.644779 31.5744 2.047954 8.143142 
42 N-G-R-I-R-V-L-Q-R-F-D-Q-R-S-R 2.998673 16.42034 1.929826 4.236245 
43 R-V-L-Q-R-F-D-Q-R-S-R-Q-F-Q-N 5.301214 44.58288 1.296778 6.030292 
44 R-F-D-Q-R-S-R-Q-F-Q-N-L-Q-N-H 11.44801 50.66528 1.230141 7.441984 
45 R-S-R-Q-F-Q-N-L-Q-N-H-R-I-V-Q 4.080687 59.62141 1.678424 12.90226 
46 F-Q-N-L-Q-N-H-R-I-V-Q-I-E-A-K 3.241574 61.86894 1.554238 4.495663 
47 Q-N-H-R-I-V-Q-I-E-A-K-P-N-T-L 3.064919 39.12668 1.009029 8.996408 
48 I-V-Q-I-E-A-K-P-N-T-L-V-L-P-K 7.368883 53.94483 2.414455 8.162937 
49 E-A-K-P-N-T-L-V-L-P-K-H-A-D-A 10.11908 36.75391 2.393253 7.493034 
50 N-T-L-V-L-P-K-H-A-D-A-D-N-I-L 4.729092 39.96161 2.102475 11.7927 
51 L-P-K-H-A-D-A-D-N-I-L-V-I-Q-Q 5.110506 47.58573 2.166083 9.502741 
52 A-D-A-D-N-I-L-V-I-Q-Q-G-Q-A-T 4.185074 48.48668 2.920288 15.91734 
53 N-I-L-V-I-Q-Q-G-Q-A-T-V-T-V-A 3.594885 50.24199 2.069157 10.09138 
54 I-Q-Q-G-Q-A-T-V-T-V-A-N-G-N-N 3.141202 60.37965 1.772321 17.75411 
55 Q-A-T-V-T-V-A-N-G-N-N-R-K-S-F 3.484475 68.75909 2.705233 18.54486 
56 T-V-A-N-G-N-N-R-K-S-F-N-L-D-E 5.285154 47.24011 2.920288 9.930937 
57 G-N-N-R-K-S-F-N-L-D-E-G-H-A-L 4.072657 66.40768 2.590134 17.93955 
58 K-S-F-N-L-D-E-G-H-A-L-R-I-P-S 3.20544 38.01602 1.848044 10.13722 
59 L-D-E-G-H-A-L-R-I-P-S-G-F-I-S 0.740297 21.51344 0.615267 8.335882 
60 H-A-L-R-I-P-S-G-F-I-S-Y-I-L-N 2.761795 30.74821 2.108533 14.3077 
61 I-P-S-G-F-I-S-Y-I-L-N-R-H-D-N 2.085286 29.80454 2.668886 9.028705 
62 F-I-S-Y-I-L-N-R-H-D-N-Q-N-L-R 2.087293 38.44611 1.91771 12.9033 
63 I-L-N-R-H-D-N-Q-N-L-R-V-A-K-I 3.859868 34.21707 3.032359 16.25282 
64 H-D-N-Q-N-L-R-V-A-K-I-S-M-P-V 2.797929 40.30433 1.969202 14.16705 
65 N-L-R-V-A-K-I-S-M-P-V-N-T-P-G 1.950787 26.37354 1.996462 5.267666 
66 A-K-I-S-M-P-V-N-T-P-G-Q-F-E-D 2.326179 32.81321 2.450803 3.161068 
67 M-P-V-N-T-P-G-Q-F-E-D-F-F-P-A 4.446042 60.45537 2.553787 17.99008 
68 T-P-G-Q-F-E-D-F-F-P-A-S-S-R-D 10.91604 70.16294 2.478063 20.72387 
69 F-E-D-F-F-P-A-S-S-R-D-Q-S-S-Y 6.475569 82.78211 2.917259 25.04594 
70 F-P-A-S-S-R-D-Q-S-S-Y-L-Q-G-F 7.714163 55.39819 3.156545 8.778663 
71 S-R-D-Q-S-S-Y-L-Q-G-F-S-R-N-T 14.46922 48.81095 2.138822 11.41347 
72 S-S-Y-L-Q-G-F-S-R-N-T-L-E-A-A 40.57806 53.58367 2.272095 8.23274 
73 Q-G-F-S-R-N-T-L-E-A-A-F-N-A-E 9.761758 37.38691 3.032359 8.032707 
74 R-N-T-L-E-A-A-F-N-A-E-F-N-E-I 5.809097 43.06058 2.97178 11.48953 
75 E-A-A-F-N-A-E-F-N-E-I-R-R-V-L 22.75997 52.10117 52.19503 13.47111 
76 N-A-E-F-N-E-I-R-R-V-L-L-E-E-N 3.436297 45.73917 3.459439 8.626555 
77 N-E-I-R-R-V-L-L-E-E-N-A-G-G-E 2.438596 44.9586 1.420964 12.88663 
78 R-V-L-L-E-E-N-A-G-G-E-Q-E-E-R 2.834063 45.45179 1.947999 11.85417 
79 E-E-N-A-G-G-E-Q-E-E-R-G-Q-R-R 6.19252 54.52248 9.126579 14.15455 
80 G-G-E-Q-E-E-R-G-Q-R-R-W-S-T-R 4.96597 46.0945 2.705233 11.57183 
81 E-E-R-G-Q-R-R-W-S-T-R-S-S-E-N 3.544699 58.4127 1.881363 9.089131 
82 Q-R-R-W-S-T-R-S-S-E-N-N-E-G-V 2.906331 44.60521 1.445196 7.662854 
83 S-T-R-S-S-E-N-N-E-G-V-I-V-K-V 0.991228 13.22429 0.006451 1.822305 
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84 S-E-N-N-E-G-V-I-V-K-V-S-K-E-H 0.585724 16.3252 0.981769 3.416318 
85 E-G-V-I-V-K-V-S-K-E-H-V-E-E-L 2.498819 28.42398 2.081272 6.987742 
86 V-K-V-S-K-E-H-V-E-E-L-T-K-H-A 60.2972 23.90174 1.557266 9.595465 
87 K-E-H-V-E-E-L-T-K-H-A-K-S-V-S 2.534953 28.83951 1.708713 8.038958 
88 E-E-L-T-K-H-A-K-S-V-S-K-K-G-S 3.847823 43.12757 3.311021 13.67114 
89 K-H-A-K-S-V-S-K-K-G-S-E-E-E-G 2.013017 31.41907 1.754147 8.847425 
90 S-V-S-K-K-G-S-E-E-E-G-D-I-T-N 2.442611 23.27263 1.884392 8.42548 
91 K-G-S-E-E-E-G-D-I-T-N-P-I-N-L 15.26417 53.5293 3.1414 7.682649 
92 E-E-G-D-I-T-N-P-I-N-L-R-E-G-E 20.33297 52.64388 5.264685 11.5187 
93 I-T-N-P-I-N-L-R-E-G-E-P-D-L-S 5.907462 43.25863 2.038867 8.325463 
94 I-N-L-R-E-G-E-P-D-L-S-N-N-F-G 4.014441 67.38824 2.750667 12.95019 
95 E-G-E-P-D-L-S-N-N-F-G-K-L-F-E 3.77957 30.50938 1.184707 5.800046 
96 D-L-S-N-N-F-G-K-L-F-E-V-K-P-D 9.223763 42.11885 5.061746 8.6974 
97 N-F-G-K-L-F-E-V-K-P-D-K-K-N-P 62.96108 36.97527 49.20547 8.225447 
98 L-F-E-V-K-P-D-K-K-N-P-Q-L-Q-D 5.829172 40.54218 2.438687 9.619427 
99 K-P-D-K-K-N-P-Q-L-Q-D-L-D-M-M 3.293768 44.71492 2.175169 8.276497 
100 K-N-P-Q-L-Q-D-L-D-M-M-L-T-C-V 6.612076 41.71498 2.414455 8.607802 
101 L-Q-D-L-D-M-M-L-T-C-V-E-I-K-E 3.645071 42.80136 1.851073 8.528622 
102 D-M-M-L-T-C-V-E-I-K-E-G-A-L-M 4.468124 31.77537 1.896507 6.232409 
103 T-C-V-E-I-K-E-G-A-L-M-L-P-H-F 1.764094 23.70952 0.727338 4.457115 
104 I-K-E-G-A-L-M-L-P-H-F-N-S-K-A 3.528639 40.1752 1.857131 8.824504 
105 A-L-M-L-P-H-F-N-S-K-A-M-V-I-V 3.482468 24.14834 1.260431 4.309174 
106 P-H-F-N-S-K-A-M-V-I-V-V-V-N-K 2.587147 25.85122 1.039318 3.880978 
107 S-K-A-M-V-I-V-V-V-N-K-G-T-G-N 1.689819 11.05152 0.024625 1.803551 
108 V-I-V-V-V-N-K-G-T-G-N-L-E-L-V 2.424544 21.60665 1.505775 5.404147 
109 V-N-K-G-T-G-N-L-E-L-V-A-V-R-K 2.119412 24.70561 1.611787 7.822255 
110 T-G-N-L-E-L-V-A-V-R-K-E-Q-Q-Q 4.652809 31.23558 2.123678 7.431566 
111 E-L-V-A-V-R-K-E-Q-Q-Q-R-G-R-R 3.974292 34.31707 2.468976 13.53987 
112 V-R-K-E-Q-Q-Q-R-G-R-R-E-E-E-E 3.396148 29.36377 2.68706 7.476365 
113 Q-Q-Q-R-G-R-R-E-E-E-E-D-E-D-E 2.488782 25.05124 2.484121 9.695482 
114 G-R-R-E-E-E-E-D-E-D-E-E-E-E-G 1.679781 22.40663 2.335703 5.356222 
115 E-E-E-D-E-D-E-E-E-E-G-S-N-R-E 4.670876 58.0962 2.45989 4.14248 
116 E-D-E-E-E-E-G-S-N-R-E-V-R-R-Y 7.172153 60.87575 3.117169 8.570296 
117 E-E-G-S-N-R-E-V-R-R-Y-T-A-R-L 8.173869 67.4795 3.365542 13.25961 
118 N-R-E-V-R-R-Y-T-A-R-L-K-E-G-D 6.52977 61.5903 2.132764 12.25736 
119 R-R-Y-T-A-R-L-K-E-G-D-V-F-I-M 4.273401 45.4916 1.678424 11.29054 
120 A-R-L-K-E-G-D-V-F-I-M-P-A-A-H 19.09839 41.4276 1.417935 8.031665 
121 E-G-D-V-F-I-M-P-A-A-H-P-V-A-I 15.73391 34.54813 2.820333 6.184484 
122 F-I-M-P-A-A-H-P-V-A-I-N-A-S-S 8.13372 13.26895 1.287691 1.745208 
123 A-A-H-P-V-A-I-N-A-S-S-E-L-H-L 10.34994 18.10575 1.381588 2.301551 
124 V-A-I-N-A-S-S-E-L-H-L-L-G-F-G 48.96416 38.79465 2.362964 5.432277 
125 A-S-S-E-L-H-L-L-G-F-G-I-N-A-E 44.57589 69.1785 2.290269 12.55846 
126 L-H-L-L-G-F-G-I-N-A-E-N-N-H-R 4.146932 38.46844 2.063099 9.510034 
127 G-F-G-I-N-A-E-N-N-H-R-I-F-L-A 2.629303 48.80707 1.920739 7.930606 
128 N-A-E-N-N-H-R-I-F-L-A-G-D-K-D 13.19851 35.38112 3.080822 5.777125 
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129 N-H-R-I-F-L-A-G-D-K-D-N-V-I-D 5.06835 38.2432 3.556365 6.866889 
130 F-L-A-G-D-K-D-N-V-I-D-Q-I-E-K 3.837786 43.46543 1.729916 12.16777 
131 D-K-D-N-V-I-D-Q-I-E-K-Q-A-K-D 8.948743 31.83362 1.036289 7.908728 
132 V-I-D-Q-I-E-K-Q-A-K-D-L-A-F-P 2.536961 21.63383 1.37553 5.570841 
133 I-E-K-Q-A-K-D-L-A-F-P-G-S-G-E 3.400162 18.97563 1.554238 6.372015 
134 A-K-D-L-A-F-P-G-S-G-E-Q-V-E-K 41.56371 22.05324 2.40234 7.693067 
135 A-F-P-G-S-G-E-Q-V-E-K-L-I-K-N 4.849538 32.88506 2.620423 11.74582 
136 S-G-E-Q-V-E-K-L-I-K-N-Q-K-E-S 2.56908 24.6726 2.590134 8.122305 
137 V-E-K-L-I-K-N-Q-K-E-S-H-F-V-S 2.205732 24.22795 2.641626 6.721031 
138 I-K-N-Q-K-E-S-H-F-V-S-A-R-P-Q 2.205732 23.72699 2.74461 7.035667 
139 K-E-S-H-F-V-S-A-R-P-Q-S-Q-S-Q 5.682628 35.31705 1.390675 5.685443 
140 F-V-S-A-R-P-Q-S-Q-S-Q-S-P-S-S 8.246137 43.15864 2.06007 7.543042 
141 R-P-Q-S-Q-S-Q-S-P-S-S-P-E-K-E 5.69668 84.11218 3.347368 10.34246 
142 Q-S-Q-S-P-S-S-P-E-K-E-S-P-E-K 6.754604 51.32352 1.293749 10.29246 
143 P-S-S-P-E-K-E-S-P-E-K-E-D-Q-E 3.853845 41.56741 1.790495 10.62793 
144 E-K-E-S-P-E-K-E-D-Q-E-E-E-N-Q 2.713616 37.02187 1.314952 7.271122 
145 P-E-K-E-D-Q-E-E-E-N-Q-G-G-K-G 1.886548 29.07446 1.069608 4.984286 
146 D-Q-E-E-E-N-Q-G-G-K-G-P-L-L-S 4.438012 30.88607 1.551209 8.704693 
147 E-N-Q-G-G-K-G-P-L-L-S-I-L-K-A 7.499367 47.12458 2.114591 14.44939 
148 Q-G-G-K-G-P-L-L-S-I-L-K-A-F-N 4.815412 41.814 2.041896 9.341256 
 m (blanks) 10717.22 8541.352 19300.87 11504.88 
 s (blanks) 498.1455 515.0104 330.1489 959.8412 
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7.1.5.2 Calculated Z-scores of Ara h 2 peptides 
 
Table A8: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-allergic patient 
(patients 1-3) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 1 1 2 2 3 3 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -15.6093 -15.6093 -15.837 -15.837 -16.689 -16.689 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 24.88522 24.88522 -5.86766 -5.86766 59.0829 59.0829 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -4.87386 -4.87386 -6.21678 -6.21678 -6.30131 -6.30131 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.00265 -7.00265 -7.65226 -7.65226 -7.58173 -7.58173 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -5.60232 -5.60232 -6.02318 -6.02318 -6.28988 -6.28988 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -5.24843 -5.24843 -5.48072 -5.48072 -6.5791 -6.5791 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.85529 -7.85529 -8.39668 -8.39668 -8.74548 -8.74548 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P -4.56223 -4.56223 -5.23503 -5.23503 -5.95913 -5.95913 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S -6.50438 50.45201 -7.37746 -8.63089 -6.59976 101.0125 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y -2.6656 67.35533 -4.75173 -7.3996 -4.14034 104.0379 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P 10.52902 78.46497 -5.61295 -6.20157 -5.15643 105.189 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R 24.89748 57.4557 -3.92433 -5.90315 -1.09104 66.18312 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 2.063132 69.57115 -5.03383 -5.31909 -3.06448 2.182899 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -6.5968 -2.46917 -8.52696 -5.31568 -7.2064 -4.87626 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.9879 -3.9879 -3.46818 -3.46818 -3.88176 -3.88176 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.72463 -6.72463 -6.81773 -6.81773 -6.73745 -6.73745 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.71527 -6.71527 -6.03765 -6.03765 -6.17534 -6.17534 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -3.90081 -3.90081 -3.53767 -3.53767 -3.70113 -3.70113 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -5.75533 -5.75533 -5.71415 -5.71415 -5.36392 -5.36392 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -3.08554 -3.08554 -2.63815 -2.63815 -3.23009 -3.23009 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.62827 -3.62827 -3.14614 -3.14614 -3.75113 -3.75113 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -2.80749 -2.80749 -2.71651 -2.71651 -3.13417 -3.13417 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -2.50519 -2.50519 -2.38013 -2.38013 -2.5867 -2.5867 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -1.95556 -1.95556 -2.7433 -2.7433 -3.26308 -3.26308 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -8.4171 -8.4171 -9.06065 -9.06065 -10.0842 -10.0842 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -6.36362 -6.36362 -7.90793 -7.90793 -8.20809 -8.20809 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -6.04957 -6.04957 -6.81515 -6.81515 -7.38515 -7.38515 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.0542 -10.0542 -10.4244 -10.4244 -10.7791 -10.7791 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.33437 -8.33437 -8.7882 -8.7882 -8.99561 -8.99561 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -6.11608 -6.11608 -6.06069 -6.06069 -6.95578 -6.95578 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -7.77094 -7.77094 -7.88059 -7.88059 -8.11028 -8.11028 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y -5.04439 -5.04439 -5.53251 -5.53251 -5.79355 -5.79355 
 m (blanks) 9592.208333 10493.32271 8641.234136 
 s (blanks) 379.4304356 413.3282315 469.0740411 
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Table A9: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-allergic patient 
(patients 4-6) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 4 4 5 5 6 6 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -16.034 -16.034 -17.0706 -17.0706 -15.8523 -15.8523 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -7.44156 -7.44156 -5.58058 -5.58058 51.91572 51.91572 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -6.27436 -6.27436 -7.41301 -7.41301 -2.94865 -2.94865 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -6.96289 -6.96289 -7.92274 -7.92274 -7.97566 -7.97566 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -4.33781 -4.33781 -6.42141 -6.42141 -6.42816 -6.42816 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -4.02306 -4.02306 -6.18127 -6.18127 -6.15366 -6.15366 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -3.79996 -3.79996 -8.71047 -8.71047 -9.03132 -9.03132 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P -4.96707 -4.96707 -5.90369 -5.90369 -2.56747 -2.56747 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S -7.48847 -8.52555 -7.89264 -8.75144 55.90624 56.00539 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y -4.51986 -7.28309 -5.17681 -7.46052 59.01025 57.94627 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P -2.17419 -6.52974 -5.93918 -6.36355 58.36761 58.81588 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R -1.96642 -6.20248 -4.48643 -6.33512 58.98501 57.80829 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 0.831244 -5.17911 -5.25413 -5.21392 -1.06828 44.31241 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -4.77099 -5.16686 -8.96274 -5.1901 -7.61904 -3.80097 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.16531 -3.16531 -3.94346 -3.94346 -3.75623 -3.75623 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -4.1665 -4.1665 -7.01191 -7.01191 -6.75581 -6.75581 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -5.94676 -5.94676 -6.29549 -6.29549 -6.8409 -6.8409 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -3.12277 -3.12277 -3.8991 -3.8991 -4.19802 -4.19802 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -1.87359 -1.87359 -6.02505 -6.02505 -6.34557 -6.34557 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -2.47114 -2.47114 -3.03512 -3.03512 -3.817 -3.817 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.10827 -3.10827 -3.31852 -3.31852 -4.3667 -4.3667 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -2.73123 -2.73123 -3.07695 -3.07695 -4.17304 -4.17304 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -1.51882 -1.51882 -2.84764 -2.84764 -4.03821 -4.03821 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -2.82996 -2.82996 -3.02953 -3.02953 -4.09812 -4.09812 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -8.7023 -8.7023 -10.1329 -10.1329 -9.64301 -9.64301 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -7.77342 -7.77342 -8.39344 -8.39344 -7.14176 -7.14176 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -6.62425 -6.62425 -7.29984 -7.29984 -6.34687 -6.34687 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -9.94065 -9.94065 -11.2671 -11.2671 -10.8884 -10.8884 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -5.14938 -5.14938 -9.31585 -9.31585 -9.07486 -9.07486 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -3.84026 -3.84026 -7.39172 -7.39172 -7.49798 -7.49798 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -7.75516 -7.75516 -8.04786 -8.04786 -8.22812 -8.22812 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y -5.35739 -5.35739 -5.80933 -5.80933 -5.94022 -5.94022 
 m (blanks) 9287.655706 10237.31141 10105.10092 
 s (blanks) 467.2674622 444.6433874 799.5560648 
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Table A10: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-allergic patient 
(patients 7-9) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 7 7 8 8 9 9 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -14.4476 -14.4476 -15.9077 -15.9077 -17.2683 -17.2683 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 95.69471 95.69471 61.10624 61.10624 -8.33003 -8.33003 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 9.238021 9.238021 -3.8278 -3.8278 -7.47646 -7.47646 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.50257 -7.50257 -7.69436 -7.69436 -7.83942 -7.83942 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -6.38187 -6.38187 -6.09855 -6.09855 -6.13145 -6.13145 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -6.31751 -6.31751 -6.3266 -6.3266 -6.1345 -6.1345 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.90387 -7.90387 -9.27057 -9.27057 -8.72767 -8.72767 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P -6.2985 -6.2985 -6.10366 -6.10366 -5.60088 -5.60088 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S -7.13438 102.8193 -1.61687 67.89819 -7.64128 -4.41413 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y 40.34229 105.6412 21.63283 70.01325 -5.03924 0.681385 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P 51.96222 106.1379 13.10152 71.14677 -5.91251 4.091164 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R 0.3607 100.4569 44.46546 70.47244 -1.89835 -0.52399 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -1.90809 47.56017 -1.74783 64.89771 -4.53255 0.801029 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -6.98664 -3.24033 -7.31896 -0.98894 -8.33918 -4.18569 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -2.82447 -2.82447 -4.04253 -4.04253 -3.92705 -3.92705 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.38536 -6.38536 -7.01856 -7.01856 -6.97447 -6.97447 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.44016 -6.44016 -6.72121 -6.72121 -6.48997 -6.48997 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -4.29073 -4.29073 -4.44403 -4.44403 -3.90429 -3.90429 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -6.24939 -6.24939 -6.53757 -6.53757 -5.92693 -5.92693 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -3.41191 -3.41191 -3.88966 -3.88966 -3.19863 -3.19863 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.92372 -3.92372 -4.32659 -4.32659 -3.79856 -3.79856 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -3.34883 -3.34883 -3.83497 -3.83497 -3.25885 -3.25885 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -2.84324 -2.84324 -3.80769 -3.80769 -2.73745 -2.73745 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -3.67502 -3.67502 -4.16047 -4.16047 -2.92809 -2.92809 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -8.2292 -8.2292 -9.46967 -9.46967 -9.78381 -9.78381 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -2.63336 -2.63336 -7.51587 -7.51587 -8.26953 -8.26953 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -6.89182 -6.89182 -7.12252 -7.12252 -7.24864 -7.24864 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.0466 -10.0466 -10.7588 -10.7588 -10.724 -10.724 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.5297 -8.5297 -8.68611 -8.68611 -8.56673 -8.56673 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -7.00544 -7.00544 -7.43377 -7.43377 -6.96476 -6.96476 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -8.06217 -8.06217 -8.1199 -8.1199 -8.00979 -8.00979 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y -6.12965 -6.12965 -5.96241 -5.96241 -5.49849 -5.49849 
 m (blanks) 6735.093596 10444.14595 8851.646586 
 s (blanks) 479.5367787 668.9231327 450.4718604 
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Table A11: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-allergic patient 
(patients 10-12) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 10 10 11 11 12 12 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q 34.90244 34.90244 -15.9818 -15.9818 -17.8098 -17.8098 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 77.86174 77.86174 -7.26357 -7.26357 13.83561 13.83561 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 53.44922 53.44922 -5.3545 -5.3545 -3.56168 -3.56168 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H 7.806267 7.806267 -6.64606 -6.64606 -8.54491 -8.54491 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K 3.38525 3.38525 -5.42017 -5.42017 -5.86026 -5.86026 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D 26.37885 26.37885 -4.61825 -4.61825 -6.34004 -6.34004 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y 2.068571 2.068571 -7.73704 -7.73704 -8.12188 -8.12188 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P 4.426784 4.426784 -4.51894 -4.51894 -4.22012 -4.22012 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S 76.40374 79.28816 -7.039 -8.72365 67.74573 69.60111 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y 80.25448 81.43362 -4.2905 -7.06556 71.11914 71.83692 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P 77.71787 82.48198 -5.50871 -5.85081 68.56887 72.73969 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R 81.59492 82.49334 -3.34859 -6.21098 66.0015 71.05328 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 60.24778 82.81043 -2.91201 -4.98538 -2.40095 62.6302 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q 29.58067 48.48469 -7.70878 -4.59509 -7.59642 -4.47731 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C 3.14076 3.14076 -2.73329 -2.73329 -4.04453 -4.04453 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -2.61696 -2.61696 -5.30176 -5.30176 -7.15365 -7.15365 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -1.25619 -1.25619 -5.6368 -5.6368 -6.99015 -6.99015 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C 1.889151 1.889151 -2.5663 -2.5663 -3.97514 -3.97514 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -1.04855 -1.04855 -4.3117 -4.3117 -6.11518 -6.11518 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I 7.531052 7.531052 -1.80271 -1.80271 -3.2052 -3.2052 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q 2.154222 2.154222 -2.02491 -2.02491 -3.8255 -3.8255 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 5.984522 5.984522 -1.65396 -1.65396 -3.44586 -3.44586 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 15.79713 15.79713 -1.43365 -1.43365 -3.0482 -3.0482 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 65.87531 65.87531 -1.72775 -1.72775 -2.8405 -2.8405 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E 77.20752 77.20752 -9.6337 -9.6337 -9.67242 -9.67242 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L 78.60053 78.60053 -7.29348 -7.29348 -8.90514 -8.90514 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C 22.67847 22.67847 -6.33612 -6.33612 -8.29259 -8.29259 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A 5.618181 5.618181 -10.2303 -10.2303 -11.5797 -11.5797 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C 8.58615 8.58615 -6.90792 -6.90792 -9.54587 -9.54587 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -4.46196 -4.46196 -6.06212 -6.06212 -7.93377 -7.93377 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -2.61169 -2.61169 -7.20712 -7.20712 -8.57672 -8.57672 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y 1.861737 1.861737 -4.97037 -4.97037 -6.03808 -6.03808 
 m (blanks) 9362.16 8731.827506 10648.40678 
 s (blanks) 586.3116638 301.7226214 649.1258417 
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Table A12: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-allergic patient 
(patients 13-15) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 13 13 14 14 15 15 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -14.7109 -14.7109 -14.3288 -14.3288 -17.7549 -17.7549 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -6.53269 -6.53269 -5.55297 -5.55297 -1.04593 -1.04593 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -5.32674 -5.32674 -5.67415 -5.67415 -6.20294 -6.20294 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -6.27821 -6.27821 -5.90228 -5.90228 -6.9653 -6.9653 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -4.49461 -4.49461 -4.52588 -4.52588 -6.44673 -6.44673 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -4.40416 -4.40416 -4.17412 -4.17412 -5.35961 -5.35961 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.26123 -7.26123 -6.38768 -6.38768 -9.64886 -9.64886 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P -3.85701 -3.85701 -4.08935 -4.08935 -6.02544 -6.02544 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S -6.49767 -5.12675 -5.89138 -7.45829 46.71625 74.55703 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y -3.82701 -3.84307 -3.73324 -5.6671 64.10364 76.55486 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P -4.46734 -1.04848 -3.78522 -4.36366 57.78697 77.71325 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R -1.35417 -3.26083 -2.0679 -4.56282 50.54214 77.39425 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -2.42721 -3.5721 -2.66344 -3.22683 20.554 77.17393 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -5.97438 -4.0885 -7.10543 -3.92467 6.379057 9.471324 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -1.68813 -1.68813 -1.66895 -1.66895 -1.05645 -1.05645 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -4.68084 -4.68084 -5.00329 -5.00329 -6.15518 -6.15518 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -4.54011 -4.54011 -4.65663 -4.65663 -6.01381 -6.01381 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -1.35293 -1.35293 -1.74551 -1.74551 -2.57572 -2.57572 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -3.17075 -3.17075 -2.8896 -2.8896 -5.67057 -5.67057 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -0.02071 -0.02071 0.275816 0.275816 -3.3901 -3.3901 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -0.47059 -0.47059 -0.77225 -0.77225 -3.96937 -3.96937 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 0.138865 0.138865 -0.45385 -0.45385 -3.6236 -3.6236 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 0.667789 0.667789 0.84444 0.84444 -3.10565 -3.10565 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 0.539898 0.539898 0.61623 0.61623 -3.08725 -3.08725 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -7.87056 -7.87056 -7.8961 -7.8961 10.38215 10.38215 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -6.19471 -6.19471 -6.42128 -6.42128 70.46785 70.46785 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -5.96223 -5.96223 -5.55134 -5.55134 2.545822 2.545822 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -9.09529 -9.09529 -9.14142 -9.14142 -9.87605 -9.87605 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -6.4216 -6.4216 -6.27616 -6.27616 -8.034 -8.034 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -5.87594 -5.87594 -5.3597 -5.3597 -6.47082 -6.47082 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -6.79957 -6.79957 -6.00209 -6.00209 -8.56262 -8.56262 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y -4.0438 -4.0438 -3.44199 -3.44199 -6.09044 -6.09044 
 m (blanks) 9020.593472 9055.216301 8750.54717 
 s (blanks) 199.1464024 198.9558915 626.7018591 
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Table A13: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-allergic patient 
(patients 16-18) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 16 16 17 17 18 18 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -16.5582 -16.5582 -16.3451 -16.3451 -16.0744 -16.0744 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -7.88047 -7.88047 73.6812 73.6812 93.44976 93.44976 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -6.79672 -6.79672 69.92526 69.92526 19.02107 19.02107 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.78089 -7.78089 -5.34555 -5.34555 -1.88096 -1.88096 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -5.58071 -5.58071 -6.04793 -6.04793 -1.47517 -1.47517 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -5.87647 -5.87647 -4.98714 -4.98714 3.853184 3.853184 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.18918 -7.18918 -9.06053 -9.06053 -6.0447 -6.0447 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P -5.19417 -5.19417 -5.8386 -5.8386 -1.42439 -1.42439 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S -7.19171 5.729859 -7.20573 61.51052 93.08172 102.2842 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y -4.88902 8.039574 -4.21562 72.17792 96.82627 104.4802 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P -5.371 16.41597 -5.83812 69.51945 87.17452 105.6427 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R -2.98534 11.99356 -1.66842 52.48091 105.5101 105.4889 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -3.86616 2.28513 -4.43115 26.62258 88.44766 105.5339 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -7.82748 -4.6469 -8.35633 -3.27074 45.5348 66.87927 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -2.92936 -2.92936 -4.08974 -4.08974 5.658221 5.658221 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.17857 -6.17857 -7.13607 -7.13607 -5.22368 -5.22368 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -5.99052 -5.99052 -6.96013 -6.96013 -5.49551 -5.49551 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -2.88884 -2.88884 -3.81331 -3.81331 -1.56216 -1.56216 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -4.64394 -4.64394 -6.1348 -6.1348 -3.53141 -3.53141 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -2.09137 -2.09137 -3.44831 -3.44831 -2.26763 -2.26763 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -2.36326 -2.36326 -3.75596 -3.75596 -2.51895 -2.51895 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -1.99669 -1.99669 -3.23375 -3.23375 -2.46322 -2.46322 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -1.855 -1.855 -2.89908 -2.89908 -0.94734 -0.94734 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -1.90765 -1.90765 -2.81963 -2.81963 3.373468 3.373468 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -9.75742 -9.75742 -9.94956 -9.94956 48.1538 48.1538 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -7.98079 -7.98079 -7.40712 -7.40712 92.42276 92.42276 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -7.03544 -7.03544 -7.38833 -7.38833 2.326035 2.326035 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.9152 -10.9152 -11.1958 -11.1958 -6.0797 -6.0797 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.06822 -8.06822 -8.76832 -8.76832 -6.26779 -6.26779 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -6.60362 -6.60362 -7.46755 -7.46755 -5.6742 -5.6742 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -7.70452 -7.70452 -8.47639 -8.47639 -5.47405 -5.47405 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y -5.48437 -5.48437 -6.01524 -6.01524 -4.64974 -4.64974 
 m (blanks) 9243.229314 11596.62551 10027.6129 
 s (blanks) 319.4069177 597.7429055 465.2042138 
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Table A14: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-allergic patient 
(patients 19-21) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 19 19 20 20 21 21 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -18.8479 -18.8479 -17.3958 -17.3958 -10.692 -10.692 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -9.49114 -9.49114 -6.4329 -6.4329 19.0295 19.0295 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -8.42145 -8.42145 -6.93501 -6.93501 13.57041 13.57041 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -8.77158 -8.77158 -8.27701 -8.27701 -5.72108 -5.72108 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -6.98684 -6.98684 -6.24875 -6.24875 -1.95257 -1.95257 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -6.83238 -6.83238 -6.1527 -6.1527 -0.91571 -0.91571 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -9.69779 -9.69779 -9.08661 -9.08661 -4.9797 -4.9797 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P -5.97311 -5.97311 -5.89388 -5.89388 10.54227 10.54227 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S -7.88123 -9.80357 -7.62729 55.79632 21.25456 20.12038 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y -4.43948 -5.63887 -5.24122 43.24526 24.02745 21.73475 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P -5.43235 -4.32516 -6.04807 55.90512 23.16422 22.81892 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R -4.82232 -6.77996 -4.02221 8.32792 24.7854 23.02096 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -5.60346 -5.98881 -4.82291 -1.36421 22.88784 23.93745 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -9.11512 -5.9428 -8.38959 -4.50856 9.59778 14.18211 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.8364 -3.8364 -3.68774 -3.68774 3.213946 3.213946 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -7.07964 -7.07964 -6.42866 -6.42866 -1.99622 -1.99622 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.79922 -6.79922 -6.31247 -6.31247 -2.80329 -2.80329 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -4.0151 -4.0151 -3.59415 -3.59415 -0.28184 -0.28184 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -6.06909 -6.06909 -5.35637 -5.35637 -3.97071 -3.97071 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -3.32256 -3.32256 -2.67321 -2.67321 -2.68056 -2.68056 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.91461 -3.91461 -3.04905 -3.04905 -1.86458 -1.86458 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -4.33977 -4.33977 -2.56758 -2.56758 -3.84413 -3.84413 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -4.13791 -4.13791 -2.10077 -2.10077 1.544414 1.544414 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -4.25733 -4.25733 -2.56136 -2.56136 -3.28397 -3.28397 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -11.4855 -11.4855 -9.94244 -9.94244 -2.78567 -2.78567 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -9.66175 -9.66175 -8.53565 -8.53565 -4.83594 -4.83594 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -8.42903 -8.42903 -7.12196 -7.12196 -5.8296 -5.8296 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -11.7138 -11.7138 -10.6796 -10.6796 -8.4868 -8.4868 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -9.51595 -9.51595 -8.86204 -8.86204 -6.96985 -6.96985 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -7.56632 -7.56632 -7.25394 -7.25394 -6.08432 -6.08432 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -8.16934 -8.16934 -8.08462 -8.08462 -6.15732 -6.15732 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y -5.90544 -5.90544 -5.76256 -5.76256 0.386153 0.386153 
 m (blanks) 26168.36654 8583.473684 10659.28796 
 s (blanks) 9679.687758 342.5203501 1674.184356 
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Table A15: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-allergic patient 
(patients 22-23) and peanut-tolerant patient 24 are listed. Identified candidate diagnostic peptides are highlighted 
in light blue. Prolines undergoing post-translational hydroxylation are written in bold and blue. 
 Patient No. → 22 22 23 23 24 24 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -16.6399 -16.6399 -15.6171 -15.6171 -15.6128 -15.6128 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -1.27362 -1.27362 62.1056 62.1056 -6.93763 -6.93763 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -6.23693 -6.23693 -3.79314 -3.79314 -6.10302 -6.10302 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.25223 -7.25223 -7.62967 -7.62967 -5.98791 -5.98791 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -5.94598 -5.94598 -6.10374 -6.10374 -5.26139 -5.26139 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -5.22242 -5.22242 -5.85019 -5.85019 -4.81836 -4.81836 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -9.05493 -9.05493 -9.1365 -9.1365 -7.30082 -7.30082 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P -4.88343 -4.88343 -4.88203 -4.88203 -4.74749 -4.74749 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S 53.57238 78.92373 64.9842 72.68565 -7.09529 -7.82299 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y 48.01901 80.7125 75.17871 74.79566 -4.4566 -6.68099 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P 21.04359 81.6537 73.82538 75.40046 -4.62491 -5.76982 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R 80.54702 81.00486 65.27153 72.35843 -3.28592 -5.28894 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 8.764985 78.6878 2.406967 60.40548 -4.51761 -4.82614 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -5.12402 1.574228 -7.26903 -2.91505 -8.00328 -4.56013 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.75026 -3.75026 -3.80419 -3.80419 -3.26279 -3.26279 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.92884 -6.92884 -6.88913 -6.88913 -5.90084 -5.90084 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.56524 -6.56524 -6.76973 -6.76973 -5.42116 -5.42116 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -3.98639 -3.98639 -4.3532 -4.3532 -3.27003 -3.27003 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -6.14108 -6.14108 -6.44635 -6.44635 -5.6705 -5.6705 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -3.57284 -3.57284 -3.9137 -3.9137 -2.30145 -2.30145 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.97929 -3.97929 -4.41712 -4.41712 -3.03544 -3.03544 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -3.83171 -3.83171 -4.11809 -4.11809 -2.44722 -2.44722 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -3.38208 -3.38208 -2.7914 -2.7914 -2.48563 -2.48563 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -3.52935 -3.52935 54.65392 54.65392 -2.59404 -2.59404 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -8.25758 -8.25758 0.726862 0.726862 -7.54432 -7.54432 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -7.0386 -7.0386 -6.25742 -6.25742 -6.91186 -6.91186 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -6.46838 -6.46838 -6.71567 -6.71567 -6.0481 -6.0481 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.2871 -10.2871 -10.5324 -10.5324 -9.99401 -9.99401 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.18412 -8.18412 -8.81047 -8.81047 -7.39489 -7.39489 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -6.40301 -6.40301 -7.21732 -7.21732 -5.3693 -5.3693 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -8.10192 -8.10192 -8.25982 -8.25982 -6.83499 -6.83499 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y -5.91261 -5.91261 -5.79713 -5.79713 -5.30066 -5.30066 
 m (blanks) 9950.296073 9928.151057 11096.52677 
 s (blanks) 595.2847421 639.6703802 403.5663398 
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Table A16: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-tolerant patient 
(patients 25-27) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 25 25 26 26 27 27 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -14.403 -14.403 -20.1323 -20.1323 -15.8076 -15.8076 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -6.01015 -6.01015 -11.0327 -11.0327 -7.75596 -7.75596 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -4.21737 -4.21737 -9.42864 -9.42864 -6.5184 -6.5184 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -5.8365 -5.8365 -10.5685 -10.5685 -6.50266 -6.50266 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -2.75056 -2.75056 -8.66636 -8.66636 -5.51326 -5.51326 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -3.41084 -3.41084 -8.21585 -8.21585 -4.89704 -4.89704 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -4.66993 -4.66993 -10.4581 -10.4581 -5.48119 -5.48119 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P -3.46197 -3.46197 -7.34271 -7.34271 -4.69147 -4.69147 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S -5.61074 -6.56676 -8.78813 -10.3758 -6.91386 -7.7332 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y -1.91178 -4.82824 -5.29738 -9.04915 -4.54837 -6.64946 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P -3.85716 -3.93796 -6.49369 -8.25358 -5.06727 -5.56856 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R -2.03711 -3.41736 -4.76431 -8.06179 -2.95667 -5.4287 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -0.99995 -2.55159 -4.747 -6.69918 -2.31304 -4.70111 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -5.90191 -2.28449 -8.72375 -6.42734 -5.73057 -4.61289 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -2.67444 -2.67444 -4.25869 -4.25869 -2.96116 -2.96116 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -4.9155 -4.9155 -6.65536 -6.65536 -4.50414 -4.50414 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.44484 -6.44484 -6.1806 -6.1806 -5.24058 -5.24058 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -3.0167 -3.0167 -3.12349 -3.12349 -3.09262 -3.09262 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -6.04653 -6.04653 -4.62019 -4.62019 -4.84881 -4.84881 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -3.10656 -3.10656 -1.16117 -1.16117 -2.69461 -2.69461 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -4.14433 -4.14433 -1.99643 -1.99643 -3.23534 -3.23534 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -4.03421 -4.03421 -0.39939 -0.39939 -2.35837 -2.35837 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -3.44764 -3.44764 -0.85233 -0.85233 -2.38317 -2.38317 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -4.00782 -4.00782 -0.56959 -0.56959 -2.73132 -2.73132 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -5.2364 -5.2364 -12.9257 -12.9257 -8.22009 -8.22009 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -4.88895 -4.88895 -11.0496 -11.0496 -6.83468 -6.83468 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -5.22516 -5.22516 -9.88632 -9.88632 -5.72654 -5.72654 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -8.234 -8.234 -13.1876 -13.1876 -9.69944 -9.69944 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -5.45557 -5.45557 -10.8999 -10.8999 -6.14743 -6.14743 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -3.57322 -3.57322 -8.93191 -8.93191 -5.6722 -5.6722 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -5.11988 -5.11988 -9.02178 -9.02178 -7.42233 -7.42233 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y -3.00069 -3.00069 -7.18025 -7.18025 -4.93121 -4.93121 
  m (blanks) 12197.20253 14751.29909 11851.53209 
  s (blanks) 1714.718816 1597.646395 461.1748893 
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Table A17: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-tolerant patient 
(patients 28-30) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 28 28 29 29 30 30 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -16.1315 -16.1315 -16.1435 -16.1435 -15.9711 -15.9711 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -7.62222 -7.62222 -7.85828 -7.85828 -7.33023 -7.33023 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -6.51832 -6.51832 -6.36353 -6.36353 -6.01509 -6.01509 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.1998 -7.1998 -6.85042 -6.85042 -7.36758 -7.36758 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -5.88483 -5.88483 -5.49648 -5.49648 -5.17322 -5.17322 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -5.37518 -5.37518 -5.67097 -5.67097 -5.48496 -5.48496 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.81996 -7.81996 -8.11885 -8.11885 -7.48527 -7.48527 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P -4.99419 -4.99419 -5.22646 -5.22646 -4.74622 -4.74622 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S -7.32541 -7.93583 -7.24292 -7.51373 -6.93503 -5.36634 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y -4.80348 -6.93444 -3.98552 -6.21494 -4.56318 -5.18641 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P -5.49605 -5.82621 -5.12551 -5.77264 -5.52327 -4.35204 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R -3.54339 -5.87909 -4.12231 -5.25581 -3.85339 -4.54282 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -4.27148 -5.02536 -4.76046 -4.34831 -4.51062 -3.90443 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -8.21094 -4.92154 -8.42008 -4.79801 -8.56386 -3.83761 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.66215 -3.66215 -3.48713 -3.48713 -3.19686 -3.19686 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.32261 -6.32261 -6.81214 -6.81214 -6.37968 -6.37968 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -5.95125 -5.95125 -6.45309 -6.45309 -6.22553 -6.22553 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -3.14778 -3.14778 -3.77435 -3.77435 -3.46751 -3.46751 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -4.51958 -4.51958 -5.66493 -5.66493 -5.56529 -5.56529 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -2.33378 -2.33378 -2.62856 -2.62856 -2.58738 -2.58738 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.03036 -3.03036 -3.31512 -3.31512 -3.03907 -3.03907 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -2.53202 -2.53202 -2.97149 -2.97149 -3.11186 -3.11186 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -2.26669 -2.26669 -2.66838 -2.66838 -2.34768 -2.34768 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -2.94247 -2.94247 -3.2777 -3.2777 -2.67929 -2.67929 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -8.78904 -8.78904 -8.71254 -8.71254 -8.29625 -8.29625 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -7.47421 -7.47421 -7.13505 -7.13505 -6.33661 -6.33661 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -6.09591 -6.09591 -6.60001 -6.60001 -5.74918 -5.74918 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.1136 -10.1136 -9.76832 -9.76832 -9.37562 -9.37562 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.27336 -8.27336 -8.33809 -8.33809 -6.6277 -6.6277 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -6.45465 -6.45465 -6.74533 -6.74533 -5.55567 -5.55567 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -7.18427 -7.18427 -7.59955 -7.59955 -7.0514 -7.0514 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y -5.35702 -5.35702 -5.25459 -5.25459 -4.9214 -4.9214 
 m (blanks) 12315.06472 14543.81696 10913.91392 
 s (blanks) 500.0454477 384.1710475 327.9266085 
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Table A18: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-tolerant patient 
(patients 31-33) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 31 31 32 32 33 33 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -16.7887 -16.7887 -17.6274 -17.6274 -17.2259 -17.2259 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -8.26537 -8.26537 -9.33768 -9.33768 -8.87163 -8.87163 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -7.21115 -7.21115 -7.48401 -7.48401 -7.74605 -7.74605 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.50519 -7.50519 -8.15567 -8.15567 -8.1327 -8.1327 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -5.76727 -5.76727 -6.25402 -6.25402 -6.31786 -6.31786 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -5.36563 -5.36563 -6.01389 -6.01389 -6.26277 -6.26277 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.98976 -7.98976 -8.45314 -8.45314 -8.70007 -8.70007 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P -5.4683 -5.4683 -5.53614 -5.53614 -5.51828 -5.51828 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S -7.18293 -8.48354 -7.61505 -8.71449 -7.42921 -8.39349 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y -4.61552 -7.16751 -4.96669 -7.48204 -4.78481 -7.39734 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P -5.63514 -6.45595 -5.74031 -6.5245 -5.69911 -6.55528 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R -3.35667 -6.27173 -4.04467 -6.34089 -4.051 -6.00386 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -4.28348 -5.14944 -4.7494 -5.12299 -4.74462 -4.93864 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -7.46789 -5.10172 -8.23087 -5.31731 -8.20714 -5.23644 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.30554 -3.30554 -3.56242 -3.56242 -3.44765 -3.44765 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.22196 -6.22196 -6.68035 -6.68035 -6.32937 -6.32937 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.01436 -6.01436 -6.0449 -6.0449 -6.11147 -6.11147 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -2.99621 -2.99621 -3.52031 -3.52031 -3.64677 -3.64677 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -4.84845 -4.84845 -5.27068 -5.27068 -5.33036 -5.33036 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -2.33978 -2.33978 -2.60911 -2.60911 -2.71434 -2.71434 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -2.46843 -2.46843 -3.07917 -3.07917 -2.84428 -2.84428 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -2.30882 -2.30882 -2.66893 -2.66893 -2.48194 -2.48194 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -1.56976 -1.56976 -2.20574 -2.20574 -2.23401 -2.23401 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -1.58082 -1.58082 -2.62377 -2.62377 -2.60475 -2.60475 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -9.70918 -9.70918 -10.1905 -10.1905 -10.0671 -10.0671 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -8.15775 -8.15775 -8.71408 -8.71408 -8.68301 -8.68301 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -7.50076 -7.50076 -7.40233 -7.40233 -7.62749 -7.62749 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.8529 -10.8529 -10.8681 -10.8681 -10.9929 -10.9929 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.66204 -8.66204 -8.77289 -8.77289 -8.81125 -8.81125 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -6.55204 -6.55204 -6.91173 -6.91173 -7.35723 -7.35723 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -7.56077 -7.56077 -7.97043 -7.97043 -7.98609 -7.98609 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y -5.66254 -5.66254 -5.3136 -5.3136 -5.56505 -5.56505 
  m (blanks) 12100.85777 11909.87841 10981.51739 
  s (blanks) 429.7547642 444.6552176 408.3888554 
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Table A19: Calculated Z-scores of Ara h 2.01 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each peanut-tolerant patient 
(patients 34-35) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 34 34 35 35 
 Ara h 2.01_P/Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -17.8392 -17.8392 -17.6687 -17.6687 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -9.23519 -9.23519 -9.06935 -9.06935 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -7.68299 -7.68299 -7.94408 -7.94408 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -8.78861 -8.78861 -8.12819 -8.12819 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -6.77961 -6.77961 -6.44503 -6.44503 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -7.07231 -7.07231 -6.37625 -6.37625 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -9.6506 -9.6506 -9.02647 -9.02647 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P -6.279 -6.279 -5.90881 -5.90881 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S -8.02753 -9.26037 -7.73411 -8.53431 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y -5.26101 -7.79732 -5.36161 -7.0576 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P -5.98613 -6.70337 -6.05308 -6.43796 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R -4.12088 -6.36759 -4.58381 -5.65342 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -3.89956 -4.71507 -5.56081 -4.73287 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -7.72748 -5.63145 -8.82928 -4.91599 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.83128 -3.83128 -4.13538 -4.13538 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.68164 -6.68164 -6.94447 -6.94447 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.77929 -6.77929 -6.5081 -6.5081 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -4.40655 -4.40655 -4.12249 -4.12249 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -6.03547 -6.03547 -5.79592 -5.79592 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -2.6388 -2.6388 -3.05105 -3.05105 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.72641 -3.72641 -3.42906 -3.42906 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -3.69882 -3.69882 -2.84092 -2.84092 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -3.35388 -3.35388 -2.8154 -2.8154 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -3.81816 -3.81816 -3.23611 -3.23611 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -10.5205 -10.5205 -10.2296 -10.2296 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -8.51213 -8.51213 -8.55121 -8.55121 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -7.67201 -7.67201 -7.68731 -7.68731 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -11.328 -11.328 -10.7786 -10.7786 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -9.15491 -9.15491 -9.04834 -9.04834 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V -7.74015 -7.74015 -7.61202 -7.61202 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G -8.74966 -8.74966 -8.06676 -8.06676 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y -6.20049 -6.20049 -5.77861 -5.77861 
  m (blanks) 12530.63095 10368.17722 
  s (blanks) 506.3960279 455.1615403 
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Table A20: Calculated Z-scores of Ara h 2.01 peptides of controls.  
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each control are listed. Numbers 
written behind control sera represent the respective developed X-ray film. Prolines undergoing post-translational 
hydroxylation are written in bold and blue. 
 Control No. → N_2 N_2 N_3 N_3 N_4 N_4 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q 2.618215 2.618215 2.289753 2.289753 3.022174 3.022174 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 2.46384 2.46384 1.745793 1.745793 2.937296 2.937296 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 2.178675 2.178675 1.569007 1.569007 2.746965 2.746965 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H 2.208692 2.208692 1.617963 1.617963 2.394596 2.394596 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K 2.324473 2.324473 1.66148 1.66148 2.152824 2.152824 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D 2.315897 2.315897 0.899936 0.899936 1.671852 1.671852 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y 2.789743 2.789743 1.481973 1.481973 1.952205 1.952205 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P 1.342476 1.342476 1.264389 1.264389 1.406932 1.406932 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S 1.160228 0.673518 0.774826 1.074003 1.507242 2.309719 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y 1.245992 0.493413 0.758507 0.872738 1.352919 2.085951 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P 1.16666 0.221113 0.695952 0.44573 0.959397 2.178544 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R 1.676956 0.077458 0.709551 0.598039 1.383784 1.846751 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 2.255862 0.257563 2.390385 0.200948 1.455801 1.468661 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q 2.045741 0.017424 2.512776 -0.07647 1.257754 1.059707 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C 1.170949 1.170949 1.174636 1.174636 0.671329 0.671329 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N 1.597624 1.597624 1.131119 1.131119 0.535011 0.535011 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N 1.040159 1.040159 0.826502 0.826502 0.411553 0.411553 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C 1.014429 1.014429 0.98969 0.98969 0.645608 0.645608 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A 0.920089 0.920089 0.85098 0.85098 0.691905 0.691905 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I 0.514854 0.514854 1.579886 1.579886 0.625032 0.625032 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q 0.825749 0.825749 0.823782 0.823782 0.694477 0.694477 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 0.881495 0.881495 1.234472 1.234472 0.828223 0.828223 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 1.32318 1.32318 2.053131 2.053131 0.398692 0.398692 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 0.892216 0.892216 1.688678 1.688678 0.645608 0.645608 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E 1.434673 1.434673 2.009614 2.009614 2.422888 2.422888 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L 1.546166 1.546166 1.949778 1.949778 2.574639 2.574639 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C 1.514004 1.514004 2.080329 2.080329 2.129676 2.129676 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A 1.218119 1.218119 1.626122 1.626122 2.157968 2.157968 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C 2.009291 2.009291 1.751233 1.751233 1.988213 1.988213 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V 1.177381 1.177381 1.990575 1.990575 1.710433 1.710433 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G 0.838613 0.838613 1.25079 1.25079 1.085427 1.085427 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y 0.757138 0.757138 0.627957 0.627957 1.093143 1.093143 
  m (blanks) 9170.873662 8143.116379 11455.98985 
  s (blanks) 466.3965312 367.6744314 388.7963548 
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Table A21: Calculated Z-scores of Ara h 2.01 peptides of controls. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each control are listed. Numbers 
written behind control sera represent the respective developed X-ray film. Prolines undergoing post-translational 
hydroxylation are written in bold and blue. 
 Control No. → DLab71S1_1 DLab71S1_1 DLab71S1_2 DLab71S1_2 DLab71S1_3 DLab71S1_3 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q 2.490168 2.490168 2.887099 2.887099 2.550297 2.550297 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 1.48453 1.48453 2.551398 2.551398 2.118537 2.118537 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 1.005075 1.005075 2.418741 2.418741 2.128406 2.128406 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H 0.633293 0.633293 2.080332 2.080332 0.976222 0.976222 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K 1.04977 1.04977 1.768996 1.768996 1.193336 1.193336 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D 1.02539 1.02539 1.590316 1.590316 0.976222 0.976222 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y 1.482499 1.482499 1.936847 1.936847 1.000894 1.000894 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P 0.651577 0.651577 1.48744 1.48744 0.865198 0.865198 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S 0.519524 0.296049 1.092178 1.944969 0.433437 1.662104 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y 0.466703 0.151806 1.046154 1.552414 1.220475 1.213073 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P 1.021327 -0.14074 1.855629 1.254614 0.971287 0.773911 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R 0.720652 -0.26467 1.509098 1.503683 1.220475 0.875066 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 1.48453 -0.09808 1.9937 1.495562 1.588088 0.512388 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q 1.370761 0.076637 1.766289 0.518236 1.889087 0.396429 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C 0.446387 0.446387 1.113836 1.113836 1.15386 1.15386 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N 0.657672 0.657672 0.918913 0.918913 0.618477 0.618477 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N 0.99898 0.99898 0.680673 0.680673 0.376691 0.376691 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C 1.027422 1.027422 0.518236 0.518236 0.603674 0.603674 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A 1.204171 1.204171 1.113836 1.113836 1.158795 1.158795 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I 1.393109 1.393109 0.761891 0.761891 0.640682 0.640682 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q 0.812073 0.812073 0.242095 0.242095 0.455642 0.455642 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 1.722227 1.722227 1.062398 1.062398 0.645616 0.645616 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 1.447962 1.447962 1.084056 1.084056 1.225409 1.225409 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 1.571889 1.571889 1.154445 1.154445 0.949082 0.949082 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E 1.244802 1.244802 3.017048 3.017048 2.261635 2.261635 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L 1.261055 1.261055 2.602836 2.602836 2.345519 2.345519 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C 0.8974 0.8974 2.17238 2.17238 1.935964 1.935964 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A 0.517492 0.517492 1.741923 1.741923 1.437589 1.437589 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C 1.324034 1.324034 2.296914 2.296914 2.505888 2.505888 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V 1.12697 1.12697 1.750045 1.750045 1.42772 1.42772 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G 0.25948 0.25948 0.983887 0.983887 0.608608 0.608608 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y 0.547966 0.547966 1.13008 1.13008 0.791181 0.791181 
 m (blanks) 11243.27745 11721.57619 9079.320513 
 s (blanks) 492.2247585 369.3755052 405.3172388 
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Table A22: Calculated Z-scores of Ara h 2.01 peptides of controls. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each control are listed. Numbers 
written behind control sera represent the respective developed X-ray film. Prolines undergoing post-translational 
hydroxylation are written in bold and blue. 
 Control No. → DLab71S1_4 DLab71S1_4 DLab72S1_1 DLab72S1_1 DLab72S1_2 DLab72S1_2 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q 1.554046 1.554046 1.91215 1.91215 2.307903 2.307903 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 1.661996 1.661996 0.798671 0.798671 1.742894 1.742894 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 2.303697 2.303697 1.347073 1.347073 1.591359 1.591359 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H 1.627512 1.627512 0.704182 0.704182 1.420341 1.420341 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K 1.137241 1.137241 0.66157 0.66157 0.82719 0.82719 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D 0.828385 0.828385 0.291028 0.291028 1.032844 1.032844 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y 2.723501 2.723501 1.085841 1.085841 1.097788 1.097788 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P 1.795434 1.795434 0.278059 0.278059 0.604217 0.604217 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S 0.675457 1.269179 0.226183 0.48371 0.675655 1.708257 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y 1.212206 1.104256 0.580051 0.376253 0.51979 1.42467 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P 0.985812 0.829884 0.59302 0.100199 0.61937 0.944088 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R 0.564508 0.886858 0.685655 -0.0369 1.242828 0.853167 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 1.042785 0.834382 1.185887 -0.04431 0.92677 0.699467 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q 0.141706 0.669459 0.596725 -0.14065 0.935429 0.47 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C 0.41158 0.41158 0.291028 0.291028 0.6237 0.6237 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N 0.254153 0.254153 0.498531 0.498531 0.686479 0.686479 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N 3.705542 3.705542 0.433687 0.433687 0.335783 0.335783 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -0.00523 -0.00523 0.828314 0.828314 0.513296 0.513296 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A 0.551015 0.551015 0.909833 0.909833 0.539273 0.539273 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I 0.318623 0.318623 1.002469 1.002469 0.396397 0.396397 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q 0.048749 0.048749 0.568934 0.568934 0.580404 0.580404 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 0.416078 0.416078 1.076577 1.076577 0.467835 0.467835 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 0.387591 0.387591 1.178476 1.178476 0.359596 0.359596 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 0.210673 0.210673 1.302608 1.302608 0.664831 0.664831 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E 3.834482 3.834482 1.636096 1.636096 1.745059 1.745059 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L 1.576536 1.576536 1.967731 1.967731 1.548063 1.548063 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C 2.140273 2.140273 0.991352 0.991352 1.257982 1.257982 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A 0.912346 0.912346 0.454066 0.454066 1.766706 1.766706 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C 1.52556 1.52556 1.247026 1.247026 1.322925 1.322925 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V 2.257218 2.257218 0.657865 0.657865 0.863991 0.863991 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G 0.726433 0.726433 0.331787 0.331787 0.894298 0.894298 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y 0.756419 0.756419 0.194687 0.194687 0.565251 0.565251 
 m (blanks) 11903.48548 11209.91781 11229.88839 
 s (blanks) 666.977806 539.7497324 461.9395702 
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Table A23: Calculated Z-scores of Ara h 2.01 peptides of controls and derived maximum Z-score. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp for each control and the maximum Z-
score (Max.) of the controls are listed. Numbers written behind control sera represent the respective developed X-
ray film. Prolines undergoing post-translational hydroxylation are written in bold and blue. 
 Control No. → DLab72S1_3 DLab72S1_3 DLab72S1_4 DLab72S1_4 Max. Max. 
 Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q 2.898064 2.898064 18.05717 18.05717 18.05717 18.05717 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 2.144974 2.144974 9.391927 9.391927 9.391927 9.391927 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 2.429927 2.429927 7.970057 7.970057 7.970057 7.970057 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H 1.663268 1.663268 8.459553 8.459553 8.459553 8.459553 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K 1.699452 1.699452 6.600633 6.600633 6.600633 6.600633 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D 0.926009 0.926009 6.45495 6.45495 6.45495 6.45495 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y 1.84419 1.84419 9.467682 9.467682 9.467682 9.467682 
8 M-Q-K-I-Q-R-D-E-D-S-Y-E-R-D-P 0.833286 0.833286 5.947972 5.947972 5.947972 5.947972 
9 Q-R-D-E-D-S-Y-E-R-D-P-Y-S-P-S 0.394549 1.082055 7.795237 9.065596 7.795237 9.065596 
10 D-S-Y-E-R-D-P-Y-S-P-S-Q-D-P-Y 0.650102 0.876255 5.29531 7.626244 5.29531 7.626244 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-P 0.711164 0.846855 6.221856 6.554015 6.221856 6.554015 
12 S-P-S-Q-D-P-Y-S-P-S-P-Y-D-R-R 0.885302 0.324442 4.625166 6.320921 4.625166 6.320921 
13 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 1.789914 0.575472 5.703224 5.231209 5.703224 5.231209 
14 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q 1.165731 0.168396 9.094733 5.225382 9.094733 5.225382 
15 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C 0.663672 0.663672 3.989987 3.989987 3.989987 3.989987 
16 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N 0.797102 0.797102 7.148403 7.148403 7.148403 7.148403 
17 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N 1.127285 1.127285 6.857036 6.857036 6.857036 6.857036 
18 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C 1.631607 1.631607 4.07157 4.07157 4.07157 4.07157 
19 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A 0.559641 0.559641 6.10531 6.10531 6.10531 6.10531 
20 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I 0.299565 0.299565 3.26157 3.26157 3.26157 3.26157 
21 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q 0.091504 0.091504 3.646174 3.646174 3.646174 3.646174 
22 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 0.607133 0.607133 3.5238 3.5238 3.5238 3.5238 
23 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 0.844594 0.844594 3.366462 3.366462 3.366462 3.366462 
24 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 0.659148 0.659148 3.710275 3.710275 3.710275 3.710275 
25 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E 2.016067 2.016067 10.71473 10.71473 10.71473 10.71473 
26 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L 2.158543 2.158543 9.053941 9.053941 9.053941 9.053941 
27 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C 1.457469 1.457469 7.917611 7.917611 7.917611 7.917611 
28 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A 2.429927 2.429927 11.43732 11.43732 11.43732 11.43732 
29 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C 2.090697 2.090697 9.351136 9.351136 9.351136 9.351136 
30 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-D-V 0.978024 0.978024 7.620417 7.620417 7.620417 7.620417 
31 L-R-A-P-Q-R-C-D-L-D-V-E-S-G-G 0.756394 0.756394 8.308043 8.308043 8.308043 8.308043 
32 Q-R-C-D-L-D-V-E-S-G-G-R-D-R-Y 0.704379 0.704379 5.918835 5.918835 5.918835 5.918835 
  m (blanks) 8431.538776 10277.29825 
  s (blanks) 442.1784235 171.6050136 
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Table A24: Calculated Z-scores of Ara h 2.01 IgE inhibition experiments. 
The calculated Z-scores of every peptide of Ara h 2.01_P and Ara h 2.01_Hyp are listed for the uninhibited serum 
pool (peanut patients 6, 7, 8, 10, 12, 15, 18, 21, 22 and 23) plus protein buffer without inhibitor (Pool -), for the 
serum pool preincubated with 13.5 µg rAra h 2.02 (Pool + rAra h 2.02), with 9.5 µg native peanut extract (Pool + 
n. extract) or preincubated with 9.5 µg reduced/alkylated peanut extract (Pool + r/a extract). Identified candidate 
diagnostic peptides are highlighted in light blue. 
IgE inhibition experiment → Pool - Pool - Pool + 
rAra h 2.02 
Pool + 
rAra h 2.02 
Pool + 
n. extract 
Pool + 
n. extract 
Pool + 
r/a extract 
Pool + 
r/a extract 
Ara h 2.01_P/Hyp P Hyp P Hyp P Hyp P Hyp 
Peptide No. ↓ Z-score Z-score Z-score Z-score Z-score Z-score Z-score Z-score 
1 4.122965 4.122965 0.557347 0.557347 2.998953 2.998953 2.882607 2.882607 
2 95.36572 95.36572 1.192915 1.192915 3.017292 3.017292 14.3761 14.3761 
3 8.055646 8.055646 0.284365 0.284365 2.082018 2.082018 2.142944 2.142944 
4 2.653214 2.653214 -0.1449 -0.1449 1.673982 1.673982 1.769522 1.769522 
5 1.633348 1.633348 0.092653 0.092653 2.19205 2.19205 2.010092 2.010092 
6 1.448438 1.448438 0.169754 0.169754 1.536442 1.536442 1.690529 1.690529 
7 1.059554 1.059554 0.125994 0.125994 2.320421 2.320421 3.453511 3.453511 
8 1.091961 1.091961 -0.13448 -0.13448 1.568535 1.568535 1.428416 1.428416 
9 66.54831 101.3172 0.044724 105.87 1.165083 5.923975 1.112443 5.826895 
10 72.34725 101.7327 0.103072 104.4426 1.678567 9.92181 1.780294 10.47672 
11 33.7353 101.8395 0.751143 101.5189 2.274574 7.400239 1.424825 9.622154 
12 78.24531 99.80738 3.826877 57.0177 2.4763 1.811522 1.916736 1.733616 
13 9.100294 92.41288 1.107478 18.06778 4.278077 1.513519 2.340427 0.843148 
14 4.050526 4.967453 0.605275 0.253108 2.008663 1.027543 1.668985 0.642075 
15 1.189182 1.189182 -0.21367 -0.21367 1.463087 1.463087 1.299154 1.299154 
16 2.186173 2.186173 0.113491 0.113491 1.829861 1.829861 1.676167 1.676167 
17 1.183463 1.183463 0.138497 0.138497 2.705534 2.705534 1.611536 1.611536 
18 2.193798 2.193798 -0.01362 -0.01362 2.567994 2.567994 1.902374 1.902374 
19 1.330248 1.330248 0.028054 0.028054 2.865997 2.865997 2.455326 2.455326 
20 1.086242 1.086242 0.155167 0.155167 2.114111 2.114111 1.353013 1.353013 
21 0.451447 0.451447 0.530257 0.530257 1.994909 1.994909 1.205799 1.205799 
22 1.454157 1.454157 0.986616 0.986616 3.031046 3.031046 2.193212 2.193212 
23 1.991731 1.991731 1.003287 1.003287 2.916429 2.916429 2.699486 2.699486 
24 3.402387 3.402387 1.040796 1.040796 2.742211 2.742211 2.124991 2.124991 
25 81.56226 81.56226 0.96161 0.96161 3.411573 3.411573 20.54475 20.54475 
26 60.93046 60.93046 0.371886 0.371886 3.154832 3.154832 4.534281 4.534281 
27 2.67609 2.67609 0.369802 0.369802 1.742752 1.742752 2.282977 2.282977 
28 2.077514 2.077514 0.078066 0.078066 2.214974 2.214974 2.372742 2.372742 
29 0.708797 0.708797 0.05306 0.05306 2.389191 2.389191 3.123177 3.123177 
30 0.765985 0.765985 -0.01571 -0.01571 3.086062 3.086062 2.42301 2.42301 
31 0.291319 0.291319 -0.07614 -0.07614 1.797768 1.797768 1.618717 1.618717 
32 0.878457 0.878457 -0.08656 -0.08656 0.945019 0.945019 1.432006 1.432006 
m(blanks) 6887.180488 9474.537374 19293.87429 14432.17866 
s(blanks) 524.5786309 479.8854558 218.1180411 278.5053352 
 
 
 Appendix  237 
Table A25: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-allergic patient 
(patients 1-3) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 1 1 2 2 3 3 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -15.6093 -15.6093 -15.837 -15.837 -16.689 -16.689 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 24.88522 24.88522 -5.86766 -5.86766 59.0829 59.0829 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -4.87386 -4.87386 -6.21678 -6.21678 -6.30131 -6.30131 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.00265 -7.00265 -7.65226 -7.65226 -7.58173 -7.58173 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -5.60232 -5.60232 -6.02318 -6.02318 -6.28988 -6.28988 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -5.24843 -5.24843 -5.48072 -5.48072 -6.5791 -6.5791 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.85529 -7.85529 -8.39668 -8.39668 -8.74548 -8.74548 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P -2.99305 -2.99305 -3.57739 -3.57739 -4.16075 -4.16075 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S -2.5275 53.079 -3.41774 -3.92737 -3.45695 105.7587 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y -1.7339 46.26586 -3.61779 -3.58699 -3.15993 108.3396 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q 3.805916 82.91889 -3.85671 -3.21147 -2.90594 108.5642 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R -3.9494 26.18066 -6.06158 -3.42052 -6.23019 74.33564 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y -5.03707 1.970248 -5.9539 -4.27563 -5.52637 7.493399 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P -0.63999 44.22516 -3.5051 -4.35461 -1.96051 103.5128 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R 16.62031 55.46646 -2.87767 -3.21141 -1.23041 74.49012 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 2.063132 69.57115 -5.03383 -5.31909 -3.06448 2.182899 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -6.5968 -2.46917 -8.52696 -5.31568 -7.2064 -4.87626 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.9879 -3.9879 -3.46818 -3.46818 -3.88176 -3.88176 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.72463 -6.72463 -6.81773 -6.81773 -6.73745 -6.73745 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.71527 -6.71527 -6.03765 -6.03765 -6.17534 -6.17534 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -3.90081 -3.90081 -3.53767 -3.53767 -3.70113 -3.70113 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -5.75533 -5.75533 -5.71415 -5.71415 -5.36392 -5.36392 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -3.08554 -3.08554 -2.63815 -2.63815 -3.23009 -3.23009 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.62827 -3.62827 -3.14614 -3.14614 -3.75113 -3.75113 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -2.80749 -2.80749 -2.71651 -2.71651 -3.13417 -3.13417 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -2.50519 -2.50519 -2.38013 -2.38013 -2.5867 -2.5867 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -1.95556 -1.95556 -2.7433 -2.7433 -3.26308 -3.26308 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -8.4171 -8.4171 -9.06065 -9.06065 -10.0842 -10.0842 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -6.36362 -6.36362 -7.90793 -7.90793 -8.20809 -8.20809 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -6.04957 -6.04957 -6.81515 -6.81515 -7.38515 -7.38515 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.0542 -10.0542 -10.4244 -10.4244 -10.7791 -10.7791 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.33437 -8.33437 -8.7882 -8.7882 -8.99561 -8.99561 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -3.80065 -3.80065 -4.321 -4.321 -3.92286 -3.92286 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -2.3958 -2.3958 -2.4209 -2.4209 -3.25623 -3.25623 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -2.78834 -2.78834 -2.73773 -2.73773 -2.96914 -2.96914 
 m (blanks) 9592.208333 10493.32271 8641.234136 
 s (blanks) 379.4304356 413.3282315 469.0740411 
 
 238  Appendix 
Table A26: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-allergic patient 
(patients 4-6) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 4 4 5 5 6 6 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -16.034 -16.034 -17.0706 -17.0706 -15.8523 -15.8523 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -7.44156 -7.44156 -5.58058 -5.58058 51.91572 51.91572 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -6.27436 -6.27436 -7.41301 -7.41301 -2.94865 -2.94865 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -6.96289 -6.96289 -7.92274 -7.92274 -7.97566 -7.97566 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -4.33781 -4.33781 -6.42141 -6.42141 -6.42816 -6.42816 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -4.02306 -4.02306 -6.18127 -6.18127 -6.15366 -6.15366 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -3.79996 -3.79996 -8.71047 -8.71047 -9.03132 -9.03132 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P -3.77511 -3.77511 -3.76773 -3.76773 -0.67626 -0.67626 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S -2.43561 -4.0963 -3.95888 -3.91921 56.1284 61.27734 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y -2.80977 -3.46961 -4.18443 -3.46427 55.12316 62.22379 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q -3.54256 -3.53794 -4.01635 -3.07345 57.86879 62.61336 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R -5.60294 -3.28695 -6.41272 -3.3469 54.88822 61.44064 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y -5.9148 -4.48906 -5.8809 -4.58721 1.197256 51.76891 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P -3.13846 -4.29 -3.35818 -4.20569 59.97855 60.91007 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R -2.22716 -3.3706 -3.07111 -3.37258 59.54316 60.71855 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 0.831244 -5.17911 -5.25413 -5.21392 -1.06828 44.31241 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -4.77099 -5.16686 -8.96274 -5.1901 -7.61904 -3.80097 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.16531 -3.16531 -3.94346 -3.94346 -3.75623 -3.75623 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -4.1665 -4.1665 -7.01191 -7.01191 -6.75581 -6.75581 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -5.94676 -5.94676 -6.29549 -6.29549 -6.8409 -6.8409 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -3.12277 -3.12277 -3.8991 -3.8991 -4.19802 -4.19802 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -1.87359 -1.87359 -6.02505 -6.02505 -6.34557 -6.34557 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -2.47114 -2.47114 -3.03512 -3.03512 -3.817 -3.817 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.10827 -3.10827 -3.31852 -3.31852 -4.3667 -4.3667 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -2.73123 -2.73123 -3.07695 -3.07695 -4.17304 -4.17304 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -1.51882 -1.51882 -2.84764 -2.84764 -4.03821 -4.03821 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -2.82996 -2.82996 -3.02953 -3.02953 -4.09812 -4.09812 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -8.7023 -8.7023 -10.1329 -10.1329 -9.64301 -9.64301 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -7.77342 -7.77342 -8.39344 -8.39344 -7.14176 -7.14176 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -6.62425 -6.62425 -7.29984 -7.29984 -6.34687 -6.34687 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -9.94065 -9.94065 -11.2671 -11.2671 -10.8884 -10.8884 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -5.14938 -5.14938 -9.31585 -9.31585 -9.07486 -9.07486 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -2.96668 -2.96668 -4.58773 -4.58773 -3.42426 -3.42426 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -2.51767 -2.51767 -2.82329 -2.82329 -3.42388 -3.42388 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -2.79029 -2.79029 -2.74692 -2.74692 -3.6799 -3.6799 
 m (blanks) 9287.655706 10237.31141 10105.10092 
 s (blanks) 467.2674622 444.6433874 799.5560648 
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Table A27: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-allergic patient 
(patients 7-9) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 7 7 8 8 9 9 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -14.4476 -14.4476 -15.9077 -15.9077 -17.2683 -17.2683 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 95.69471 95.69471 61.10624 61.10624 -8.33003 -8.33003 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 9.238021 9.238021 -3.8278 -3.8278 -7.47646 -7.47646 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.50257 -7.50257 -7.69436 -7.69436 -7.83942 -7.83942 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -6.38187 -6.38187 -6.09855 -6.09855 -6.13145 -6.13145 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -6.31751 -6.31751 -6.3266 -6.3266 -6.1345 -6.1345 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.90387 -7.90387 -9.27057 -9.27057 -8.72767 -8.72767 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P -3.94731 -3.94731 -3.67584 -3.67584 -3.88625 -3.88625 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S -3.26232 107.5682 -1.20208 72.88889 -3.56048 1.690126 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y 11.40277 109.4753 3.825641 74.10853 -4.26198 1.192878 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q 43.14967 109.815 2.911781 74.63243 -3.81688 3.656131 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R -5.7335 107.5882 -4.76436 73.87764 -6.58126 4.318492 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y -5.85832 57.57434 -5.08781 58.64393 -5.9236 -2.06095 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P -2.30512 107.226 9.883701 73.08679 -3.28466 3.988816 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R -1.90838 104.9979 51.1047 73.52093 -2.21743 3.255435 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -1.90809 47.56017 -1.74783 64.89771 -4.53255 0.801029 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -6.98664 -3.24033 -7.31896 -0.98894 -8.33918 -4.18569 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -2.82447 -2.82447 -4.04253 -4.04253 -3.92705 -3.92705 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.38536 -6.38536 -7.01856 -7.01856 -6.97447 -6.97447 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.44016 -6.44016 -6.72121 -6.72121 -6.48997 -6.48997 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -4.29073 -4.29073 -4.44403 -4.44403 -3.90429 -3.90429 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -6.24939 -6.24939 -6.53757 -6.53757 -5.92693 -5.92693 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -3.41191 -3.41191 -3.88966 -3.88966 -3.19863 -3.19863 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.92372 -3.92372 -4.32659 -4.32659 -3.79856 -3.79856 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -3.34883 -3.34883 -3.83497 -3.83497 -3.25885 -3.25885 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -2.84324 -2.84324 -3.80769 -3.80769 -2.73745 -2.73745 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -3.67502 -3.67502 -4.16047 -4.16047 -2.92809 -2.92809 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -8.2292 -8.2292 -9.46967 -9.46967 -9.78381 -9.78381 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -2.63336 -2.63336 -7.51587 -7.51587 -8.26953 -8.26953 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -6.89182 -6.89182 -7.12252 -7.12252 -7.24864 -7.24864 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.0466 -10.0466 -10.7588 -10.7588 -10.724 -10.724 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.5297 -8.5297 -8.68611 -8.68611 -8.56673 -8.56673 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -4.54409 -4.54409 -3.64547 -3.64547 -4.45983 -4.45983 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -3.36073 -3.36073 -3.31664 -3.31664 -2.93723 -2.93723 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -3.05424 -3.05424 -3.39364 -3.39364 -3.1212 -3.1212 
 m (blanks) 6735.093596 10444.14595 8851.646586 
 s (blanks) 479.5367787 668.9231327 450.4718604 
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Table A28: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-allergic patient 
(patients 10-12) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 10 10 11 11 12 12 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q 34.90244 34.90244 -15.9818 -15.9818 -17.8098 -17.8098 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 77.86174 77.86174 -7.26357 -7.26357 13.83561 13.83561 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 53.44922 53.44922 -5.3545 -5.3545 -3.56168 -3.56168 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H 7.806267 7.806267 -6.64606 -6.64606 -8.54491 -8.54491 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K 3.38525 3.38525 -5.42017 -5.42017 -5.86026 -5.86026 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D 26.37885 26.37885 -4.61825 -4.61825 -6.34004 -6.34004 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y 2.068571 2.068571 -7.73704 -7.73704 -8.12188 -8.12188 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P 7.138491 7.138491 -3.41502 -3.41502 -3.57547 -3.57547 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S 50.31376 84.22832 -2.93219 -3.4073 6.592385 74.77807 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y 72.32368 85.30851 -3.11666 -2.90797 33.6432 76.06382 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q 66.51903 85.92153 -3.00255 -3.00092 42.40838 76.22799 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R 50.78709 86.02486 -5.03779 -2.83771 -0.34555 75.0606 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y 27.7416 84.33265 -5.21949 -3.75333 -5.07626 59.61445 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P 83.10036 84.66779 -2.60149 -3.23415 36.83785 74.738 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R 84.06202 85.20973 -2.23356 -2.14703 45.48413 74.67908 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 60.24778 82.81043 -2.91201 -4.98538 -2.40095 62.6302 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q 29.58067 48.48469 -7.70878 -4.59509 -7.59642 -4.47731 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C 3.14076 3.14076 -2.73329 -2.73329 -4.04453 -4.04453 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -2.61696 -2.61696 -5.30176 -5.30176 -7.15365 -7.15365 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -1.25619 -1.25619 -5.6368 -5.6368 -6.99015 -6.99015 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C 1.889151 1.889151 -2.5663 -2.5663 -3.97514 -3.97514 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -1.04855 -1.04855 -4.3117 -4.3117 -6.11518 -6.11518 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I 7.531052 7.531052 -1.80271 -1.80271 -3.2052 -3.2052 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q 2.154222 2.154222 -2.02491 -2.02491 -3.8255 -3.8255 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 5.984522 5.984522 -1.65396 -1.65396 -3.44586 -3.44586 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 15.79713 15.79713 -1.43365 -1.43365 -3.0482 -3.0482 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 65.87531 65.87531 -1.72775 -1.72775 -2.8405 -2.8405 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E 77.20752 77.20752 -9.6337 -9.6337 -9.67242 -9.67242 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L 78.60053 78.60053 -7.29348 -7.29348 -8.90514 -8.90514 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C 22.67847 22.67847 -6.33612 -6.33612 -8.29259 -8.29259 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A 5.618181 5.618181 -10.2303 -10.2303 -11.5797 -11.5797 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C 8.58615 8.58615 -6.90792 -6.90792 -9.54587 -9.54587 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V 26.91765 26.91765 -3.5382 -3.5382 -4.03282 -4.03282 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G 6.356191 6.356191 -2.08482 -2.08482 -3.06192 -3.06192 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y 11.51741 11.51741 -1.55191 -1.55191 -3.01738 -3.01738 
 m (blanks) 9362.16 8731.827506 10648.40678 
 s (blanks) 586.3116638 301.7226214 649.1258417 
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Table A29: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-allergic patient 
(patients 13-15) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 13 13 14 14 15 15 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -14.7109 -14.7109 -14.3288 -14.3288 -17.7549 -17.7549 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -6.53269 -6.53269 -5.55297 -5.55297 -1.04593 -1.04593 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -5.32674 -5.32674 -5.67415 -5.67415 -6.20294 -6.20294 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -6.27821 -6.27821 -5.90228 -5.90228 -6.9653 -6.9653 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -4.49461 -4.49461 -4.52588 -4.52588 -6.44673 -6.44673 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -4.40416 -4.40416 -4.17412 -4.17412 -5.35961 -5.35961 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.26123 -7.26123 -6.38768 -6.38768 -9.64886 -9.64886 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P -2.72192 -2.72192 -2.5178 -2.5178 -2.71822 -2.71822 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S -2.00622 -1.35399 -1.77138 -2.531 1.068816 79.90971 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y -2.3318 0.3073 -1.92091 -2.18041 29.87652 81.07799 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q -2.49577 0.066333 -2.37182 -1.83871 38.76177 81.38324 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R -4.8039 0.32162 -4.48874 -1.64348 22.02419 81.31837 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y -4.34112 -2.46701 -4.29739 -2.98603 2.572304 79.24477 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P -1.33105 0.982156 -1.36214 -2.48407 61.6226 80.16823 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R -0.60319 1.642752 -1.0109 -1.25573 37.38926 80.4774 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -2.42721 -3.5721 -2.66344 -3.22683 20.554 77.17393 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -5.97438 -4.0885 -7.10543 -3.92467 6.379057 9.471324 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -1.68813 -1.68813 -1.66895 -1.66895 -1.05645 -1.05645 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -4.68084 -4.68084 -5.00329 -5.00329 -6.15518 -6.15518 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -4.54011 -4.54011 -4.65663 -4.65663 -6.01381 -6.01381 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -1.35293 -1.35293 -1.74551 -1.74551 -2.57572 -2.57572 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -3.17075 -3.17075 -2.8896 -2.8896 -5.67057 -5.67057 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -0.02071 -0.02071 0.275816 0.275816 -3.3901 -3.3901 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -0.47059 -0.47059 -0.77225 -0.77225 -3.96937 -3.96937 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 0.138865 0.138865 -0.45385 -0.45385 -3.6236 -3.6236 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 0.667789 0.667789 0.84444 0.84444 -3.10565 -3.10565 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 0.539898 0.539898 0.61623 0.61623 -3.08725 -3.08725 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -7.87056 -7.87056 -7.8961 -7.8961 10.38215 10.38215 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -6.19471 -6.19471 -6.42128 -6.42128 70.46785 70.46785 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -5.96223 -5.96223 -5.55134 -5.55134 2.545822 2.545822 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -9.09529 -9.09529 -9.14142 -9.14142 -9.87605 -9.87605 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -6.4216 -6.4216 -6.27616 -6.27616 -8.034 -8.034 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -2.23392 -2.23392 -1.61153 -1.61153 -2.77147 -2.77147 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -0.64646 -0.64646 -0.17488 -0.17488 -3.13321 -3.13321 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -0.38634 -0.38634 -0.16585 -0.16585 -2.6509 -2.6509 
 m (blanks) 9020.593472 9055.216301 8750.54717 
 s (blanks) 199.1464024 198.9558915 626.7018591 
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Table A30: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-allergic patient 
(patients 16-18) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 16 16 17 17 18 18 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -16.5582 -16.5582 -16.3451 -16.3451 -16.0744 -16.0744 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -7.88047 -7.88047 73.6812 73.6812 93.44976 93.44976 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -6.79672 -6.79672 69.92526 69.92526 19.02107 19.02107 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.78089 -7.78089 -5.34555 -5.34555 -1.88096 -1.88096 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -5.58071 -5.58071 -6.04793 -6.04793 -1.47517 -1.47517 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -5.87647 -5.87647 -4.98714 -4.98714 3.853184 3.853184 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.18918 -7.18918 -9.06053 -9.06053 -6.0447 -6.0447 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P -3.88417 -3.88417 -4.33335 -4.33335 2.11779 2.11779 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S -3.25817 12.33794 -3.93747 62.30287 78.82741 107.5541 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y -3.51459 8.145488 -4.04732 77.20336 78.66647 108.9296 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q -3.45577 6.274935 -3.79449 76.275 84.739 109.3633 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R -6.02554 7.737454 -6.46408 76.65061 93.56194 109.1726 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y -5.21583 -1.69664 -5.62321 59.35653 20.20769 106.7326 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P -3.04125 14.80113 -0.07724 62.07124 103.6341 108.0219 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R -2.61734 21.69133 -2.19527 48.79285 106.82 108.4642 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -3.86616 2.28513 -4.43115 26.62258 88.44766 105.5339 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -7.82748 -4.6469 -8.35633 -3.27074 45.5348 66.87927 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -2.92936 -2.92936 -4.08974 -4.08974 5.658221 5.658221 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.17857 -6.17857 -7.13607 -7.13607 -5.22368 -5.22368 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -5.99052 -5.99052 -6.96013 -6.96013 -5.49551 -5.49551 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -2.88884 -2.88884 -3.81331 -3.81331 -1.56216 -1.56216 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -4.64394 -4.64394 -6.1348 -6.1348 -3.53141 -3.53141 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -2.09137 -2.09137 -3.44831 -3.44831 -2.26763 -2.26763 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -2.36326 -2.36326 -3.75596 -3.75596 -2.51895 -2.51895 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -1.99669 -1.99669 -3.23375 -3.23375 -2.46322 -2.46322 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -1.855 -1.855 -2.89908 -2.89908 -0.94734 -0.94734 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -1.90765 -1.90765 -2.81963 -2.81963 3.373468 3.373468 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -9.75742 -9.75742 -9.94956 -9.94956 48.1538 48.1538 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -7.98079 -7.98079 -7.40712 -7.40712 92.42276 92.42276 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -7.03544 -7.03544 -7.38833 -7.38833 2.326035 2.326035 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.9152 -10.9152 -11.1958 -11.1958 -6.0797 -6.0797 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.06822 -8.06822 -8.76832 -8.76832 -6.26779 -6.26779 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -2.79967 -2.79967 -4.58202 -4.58202 17.70899 17.70899 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -2.13639 -2.13639 -2.95943 -2.95943 -0.56794 -0.56794 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -2.01333 -2.01333 -2.15571 -2.15571 4.860977 4.860977 
 m (blanks) 9243.229314 11596.62551 10027.6129 
 s (blanks) 319.4069177 597.7429055 465.2042138 
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Table A31: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-allergic patient 
(patients 19-21) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 19 19 20 20 21 21 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -18.8479 -18.8479 -17.3958 -17.3958 -10.692 -10.692 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -9.49114 -9.49114 -6.4329 -6.4329 19.0295 19.0295 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -8.42145 -8.42145 -6.93501 -6.93501 13.57041 13.57041 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -8.77158 -8.77158 -8.27701 -8.27701 -5.72108 -5.72108 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -6.98684 -6.98684 -6.24875 -6.24875 -1.95257 -1.95257 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -6.83238 -6.83238 -6.1527 -6.1527 -0.91571 -0.91571 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -9.69779 -9.69779 -9.08661 -9.08661 -4.9797 -4.9797 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P -3.68507 -3.68507 -4.02065 -4.02065 17.86603 17.86603 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S -3.48435 -3.61603 -3.62969 64.50912 25.56568 25.72075 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y -3.60383 -1.79459 -3.76597 43.26565 25.20641 26.34223 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q -2.15981 -1.60427 -3.61184 23.75118 25.50286 26.50584 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R -6.25716 -3.11351 -5.98617 15.24659 22.91885 26.49105 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y -6.10546 -4.81832 -5.62803 -1.11197 22.27196 25.12514 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P -3.63024 -4.40949 -3.29726 48.99579 25.71304 25.2796 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R -3.27886 -3.74271 -2.65569 21.30513 25.9943 26.03679 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -5.60346 -5.98881 -4.82291 -1.36421 22.88784 23.93745 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -9.11512 -5.9428 -8.38959 -4.50856 9.59778 14.18211 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.8364 -3.8364 -3.68774 -3.68774 3.213946 3.213946 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -7.07964 -7.07964 -6.42866 -6.42866 -1.99622 -1.99622 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.79922 -6.79922 -6.31247 -6.31247 -2.80329 -2.80329 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -4.0151 -4.0151 -3.59415 -3.59415 -0.28184 -0.28184 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -6.06909 -6.06909 -5.35637 -5.35637 -3.97071 -3.97071 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -3.32256 -3.32256 -2.67321 -2.67321 -2.68056 -2.68056 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.91461 -3.91461 -3.04905 -3.04905 -1.86458 -1.86458 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -4.33977 -4.33977 -2.56758 -2.56758 -3.84413 -3.84413 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -4.13791 -4.13791 -2.10077 -2.10077 1.544414 1.544414 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -4.25733 -4.25733 -2.56136 -2.56136 -3.28397 -3.28397 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -11.4855 -11.4855 -9.94244 -9.94244 -2.78567 -2.78567 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -9.66175 -9.66175 -8.53565 -8.53565 -4.83594 -4.83594 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -8.42903 -8.42903 -7.12196 -7.12196 -5.8296 -5.8296 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -11.7138 -11.7138 -10.6796 -10.6796 -8.4868 -8.4868 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -9.51595 -9.51595 -8.86204 -8.86204 -6.96985 -6.96985 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -4.76539 -4.76539 -3.82666 -3.82666 17.7496 17.7496 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -2.91999 -2.91999 -2.45186 -2.45186 1.036338 1.036338 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -3.39666 -3.39666 -2.33222 -2.33222 2.99955 2.99955 
 m (blanks) 26168.36654 8583.473684 10659.28796 
 s (blanks) 9679.687758 342.5203501 1674.184356 
 
 244  Appendix 
Table A32: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-allergic patient 
(patients 22-23) and peanut tolerant patient 24 are listed. Identified candidate diagnostic peptides are highlighted 
in light blue. Prolines undergoing post-translational hydroxylation are written in bold and blue. 
 Patient No. → 22 22 23 23 24 24 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -16.6399 -16.6399 -15.6171 -15.6171 -15.6128 -15.6128 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -1.27362 -1.27362 62.1056 62.1056 -6.93763 -6.93763 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -6.23693 -6.23693 -3.79314 -3.79314 -6.10302 -6.10302 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.25223 -7.25223 -7.62967 -7.62967 -5.98791 -5.98791 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -5.94598 -5.94598 -6.10374 -6.10374 -5.26139 -5.26139 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -5.22242 -5.22242 -5.85019 -5.85019 -4.81836 -4.81836 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -9.05493 -9.05493 -9.1365 -9.1365 -7.30082 -7.30082 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P -2.67299 -2.67299 -1.72329 -1.72329 -3.81174 -3.81174 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S 18.78786 83.51056 43.00367 77.58335 -3.65628 -3.57369 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y 8.467562 84.87044 74.53287 78.84682 -3.21307 -2.64413 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q 13.36838 85.17403 75.01098 79.14414 -3.37094 -2.67438 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R 0.279667 84.53657 66.3178 76.41504 -5.1492 -2.928 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y -3.85541 78.73708 2.315558 54.56675 -5.17933 -4.35594 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P 59.94622 83.5708 73.13518 76.60482 -3.37142 -4.01812 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R 81.92574 83.26128 30.96051 75.19209 -2.48481 -2.88866 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 8.764985 78.6878 2.406967 60.40548 -4.51761 -4.82614 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -5.12402 1.574228 -7.26903 -2.91505 -8.00328 -4.56013 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.75026 -3.75026 -3.80419 -3.80419 -3.26279 -3.26279 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.92884 -6.92884 -6.88913 -6.88913 -5.90084 -5.90084 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.56524 -6.56524 -6.76973 -6.76973 -5.42116 -5.42116 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -3.98639 -3.98639 -4.3532 -4.3532 -3.27003 -3.27003 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -6.14108 -6.14108 -6.44635 -6.44635 -5.6705 -5.6705 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -3.57284 -3.57284 -3.9137 -3.9137 -2.30145 -2.30145 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.97929 -3.97929 -4.41712 -4.41712 -3.03544 -3.03544 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -3.83171 -3.83171 -4.11809 -4.11809 -2.44722 -2.44722 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -3.38208 -3.38208 -2.7914 -2.7914 -2.48563 -2.48563 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -3.52935 -3.52935 54.65392 54.65392 -2.59404 -2.59404 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -8.25758 -8.25758 0.726862 0.726862 -7.54432 -7.54432 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -7.0386 -7.0386 -6.25742 -6.25742 -6.91186 -6.91186 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -6.46838 -6.46838 -6.71567 -6.71567 -6.0481 -6.0481 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.2871 -10.2871 -10.5324 -10.5324 -9.99401 -9.99401 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.18412 -8.18412 -8.81047 -8.81047 -7.39489 -7.39489 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -1.04865 -1.04865 -4.0538 -4.0538 -3.69785 -3.69785 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -3.00073 -3.00073 -3.54872 -3.54872 -2.4918 -2.4918 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -2.95311 -2.95311 -3.41797 -3.41797 -2.08355 -2.08355 
 m (blanks) 9950.296073 9928.151057 11096.52677 
 s (blanks) 595.2847421 639.6703802 403.5663398 
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Table A33: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-tolerant patient 
(patients 25-27) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 25 25 26 26 27 27 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -14.403 -14.403 -20.1323 -20.1323 -15.8076 -15.8076 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -6.01015 -6.01015 -11.0327 -11.0327 -7.75596 -7.75596 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -4.21737 -4.21737 -9.42864 -9.42864 -6.5184 -6.5184 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -5.8365 -5.8365 -10.5685 -10.5685 -6.50266 -6.50266 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -2.75056 -2.75056 -8.66636 -8.66636 -5.51326 -5.51326 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -3.41084 -3.41084 -8.21585 -8.21585 -4.89704 -4.89704 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -4.66993 -4.66993 -10.4581 -10.4581 -5.48119 -5.48119 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P -1.79677 -1.79677 -4.92707 -4.92707 -3.66846 -3.66846 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S -1.18686 -1.14554 -4.79511 -5.12586 -3.57062 -3.39634 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y -1.27223 -1.56579 -5.57113 -4.56328 -3.53157 -2.98436 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q -2.128 -1.11102 -5.04653 -4.37128 -3.61886 -2.9536 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R -5.09737 -1.42652 -7.67512 -4.51794 -5.50608 -3.10037 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y -4.76824 -2.90976 -6.95129 -5.41135 -5.27544 -3.98097 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P -2.80302 -3.23118 -3.72821 -4.76003 -3.36815 -4.23602 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R -1.94835 -2.00659 -3.12656 -4.50188 -2.8941 -3.01485 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -0.99995 -2.55159 -4.747 -6.69918 -2.31304 -4.70111 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -5.90191 -2.28449 -8.72375 -6.42734 -5.73057 -4.61289 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -2.67444 -2.67444 -4.25869 -4.25869 -2.96116 -2.96116 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -4.9155 -4.9155 -6.65536 -6.65536 -4.50414 -4.50414 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.44484 -6.44484 -6.1806 -6.1806 -5.24058 -5.24058 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -3.0167 -3.0167 -3.12349 -3.12349 -3.09262 -3.09262 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -6.04653 -6.04653 -4.62019 -4.62019 -4.84881 -4.84881 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -3.10656 -3.10656 -1.16117 -1.16117 -2.69461 -2.69461 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -4.14433 -4.14433 -1.99643 -1.99643 -3.23534 -3.23534 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -4.03421 -4.03421 -0.39939 -0.39939 -2.35837 -2.35837 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -3.44764 -3.44764 -0.85233 -0.85233 -2.38317 -2.38317 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -4.00782 -4.00782 -0.56959 -0.56959 -2.73132 -2.73132 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -5.2364 -5.2364 -12.9257 -12.9257 -8.22009 -8.22009 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -4.88895 -4.88895 -11.0496 -11.0496 -6.83468 -6.83468 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -5.22516 -5.22516 -9.88632 -9.88632 -5.72654 -5.72654 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -8.234 -8.234 -13.1876 -13.1876 -9.69944 -9.69944 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -5.45557 -5.45557 -10.8999 -10.8999 -6.14743 -6.14743 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -3.20642 -3.20642 -3.71805 -3.71805 -4.00955 -4.00955 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -2.7347 -2.7347 -2.00099 -2.00099 -2.88625 -2.88625 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -3.44037 -3.44037 -2.57086 -2.57086 -2.46464 -2.46464 
  m (blanks) 12197.20253 14751.29909 11851.53209 
 s (blanks) 1714.718816 1597.646395 461.1748893 
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Table A34: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-tolerant patient 
(patients 28-30) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 28 28 29 29 30 30 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -16.1315 -16.1315 -16.1435 -16.1435 -15.9711 -15.9711 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -7.62222 -7.62222 -7.85828 -7.85828 -7.33023 -7.33023 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -6.51832 -6.51832 -6.36353 -6.36353 -6.01509 -6.01509 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.1998 -7.1998 -6.85042 -6.85042 -7.36758 -7.36758 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -5.88483 -5.88483 -5.49648 -5.49648 -5.17322 -5.17322 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -5.37518 -5.37518 -5.67097 -5.67097 -5.48496 -5.48496 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.81996 -7.81996 -8.11885 -8.11885 -7.48527 -7.48527 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P -3.69535 -3.69535 -3.59731 -3.59731 -3.20791 -3.20791 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S -3.49115 -3.62824 -3.27909 -3.27572 -3.03397 -2.58144 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y -3.70136 -3.24205 -3.77391 -3.16094 -2.61581 -2.45374 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q -3.65632 -2.95437 -3.64009 -2.67947 -3.03246 -2.44833 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R -5.30146 -3.35017 -6.09627 -2.80763 -5.13155 -2.57004 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y -5.52756 -4.46523 -5.8605 -4.17182 -5.35814 -3.59143 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P -3.23503 -4.38033 -3.24756 -4.06172 -3.12249 -3.59327 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R -2.53177 -3.53275 -3.06847 -3.05561 -2.38001 -2.52177 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -4.27148 -5.02536 -4.76046 -4.34831 -4.51062 -3.90443 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -8.21094 -4.92154 -8.42008 -4.79801 -8.56386 -3.83761 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.66215 -3.66215 -3.48713 -3.48713 -3.19686 -3.19686 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.32261 -6.32261 -6.81214 -6.81214 -6.37968 -6.37968 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -5.95125 -5.95125 -6.45309 -6.45309 -6.22553 -6.22553 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -3.14778 -3.14778 -3.77435 -3.77435 -3.46751 -3.46751 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -4.51958 -4.51958 -5.66493 -5.66493 -5.56529 -5.56529 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -2.33378 -2.33378 -2.62856 -2.62856 -2.58738 -2.58738 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.03036 -3.03036 -3.31512 -3.31512 -3.03907 -3.03907 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -2.53202 -2.53202 -2.97149 -2.97149 -3.11186 -3.11186 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -2.26669 -2.26669 -2.66838 -2.66838 -2.34768 -2.34768 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -2.94247 -2.94247 -3.2777 -3.2777 -2.67929 -2.67929 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -8.78904 -8.78904 -8.71254 -8.71254 -8.29625 -8.29625 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -7.47421 -7.47421 -7.13505 -7.13505 -6.33661 -6.33661 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -6.09591 -6.09591 -6.60001 -6.60001 -5.74918 -5.74918 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.1136 -10.1136 -9.76832 -9.76832 -9.37562 -9.37562 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.27336 -8.27336 -8.33809 -8.33809 -6.6277 -6.6277 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -4.03221 -4.03221 -4.21291 -4.21291 -3.91574 -3.91574 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -2.59168 -2.59168 -2.56094 -2.56094 -2.35896 -2.35896 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -2.51655 -2.51655 -2.64113 -2.64113 -2.72016 -2.72016 
  m (blanks) 12315.06472 14543.81696 10913.91392 
 s (blanks) 500.0454477 384.1710475 327.9266085 
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Table A35: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-tolerant patient 
(patients 31-33) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 31 31 32 32 33 33 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -16.7887 -16.7887 -17.6274 -17.6274 -17.2259 -17.2259 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -8.26537 -8.26537 -9.33768 -9.33768 -8.87163 -8.87163 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -7.21115 -7.21115 -7.48401 -7.48401 -7.74605 -7.74605 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -7.50519 -7.50519 -8.15567 -8.15567 -8.1327 -8.1327 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -5.76727 -5.76727 -6.25402 -6.25402 -6.31786 -6.31786 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -5.36563 -5.36563 -6.01389 -6.01389 -6.26277 -6.26277 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -7.98976 -7.98976 -8.45314 -8.45314 -8.70007 -8.70007 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P -3.74177 -3.74177 -3.60259 -3.60259 -3.32361 -3.32361 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S -3.11096 -3.82048 -3.53286 -3.63712 -3.46966 -3.23009 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y -3.87964 -3.42876 -3.69769 -3.29237 -4.08521 -2.98918 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q -3.23456 -3.11786 -3.48462 -2.95103 -3.52998 -2.85084 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R -5.73338 -3.24004 -5.86751 -2.93437 -5.89253 -2.81504 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y -5.38817 -4.34514 -5.22774 -4.24214 -5.47836 -3.8711 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P -2.8756 -4.13089 -3.38196 -4.05179 -3.07563 -3.79069 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R -2.53524 -3.4115 -2.46068 -2.98029 -2.71924 -3.01664 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -4.28348 -5.14944 -4.7494 -5.12299 -4.74462 -4.93864 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -7.46789 -5.10172 -8.23087 -5.31731 -8.20714 -5.23644 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.30554 -3.30554 -3.56242 -3.56242 -3.44765 -3.44765 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.22196 -6.22196 -6.68035 -6.68035 -6.32937 -6.32937 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.01436 -6.01436 -6.0449 -6.0449 -6.11147 -6.11147 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -2.99621 -2.99621 -3.52031 -3.52031 -3.64677 -3.64677 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -4.84845 -4.84845 -5.27068 -5.27068 -5.33036 -5.33036 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -2.33978 -2.33978 -2.60911 -2.60911 -2.71434 -2.71434 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -2.46843 -2.46843 -3.07917 -3.07917 -2.84428 -2.84428 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -2.30882 -2.30882 -2.66893 -2.66893 -2.48194 -2.48194 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -1.56976 -1.56976 -2.20574 -2.20574 -2.23401 -2.23401 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -1.58082 -1.58082 -2.62377 -2.62377 -2.60475 -2.60475 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -9.70918 -9.70918 -10.1905 -10.1905 -10.0671 -10.0671 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -8.15775 -8.15775 -8.71408 -8.71408 -8.68301 -8.68301 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -7.50076 -7.50076 -7.40233 -7.40233 -7.62749 -7.62749 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -10.8529 -10.8529 -10.8681 -10.8681 -10.9929 -10.9929 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -8.66204 -8.66204 -8.77289 -8.77289 -8.81125 -8.81125 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -4.02328 -4.02328 -4.092 -4.092 -3.81373 -3.81373 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -2.43007 -2.43007 -2.73686 -2.73686 -2.48301 -2.48301 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -2.58709 -2.58709 -2.32541 -2.32541 -2.34124 -2.34124 
  m (blanks) 12100.85777 11909.87841 10981.51739 
 s (blanks) 429.7547642 444.6552176 408.3888554 
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Table A36: Calculated Z-scores of Ara h 2.02 peptides after control subtraction. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each peanut-tolerant patient 
(patients 34-35) are listed. Identified candidate diagnostic peptides are highlighted in light blue. Prolines undergoing 
post-translational hydroxylation are written in bold and blue. 
 Patient No. → 34 34 35 35 
 Ara h 2.02_P/Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q -17.8392 -17.8392 -17.6687 -17.6687 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A -9.23519 -9.23519 -9.06935 -9.06935 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P -7.68299 -7.68299 -7.94408 -7.94408 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H -8.78861 -8.78861 -8.12819 -8.12819 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K -6.77961 -6.77961 -6.44503 -6.44503 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D -7.07231 -7.07231 -6.37625 -6.37625 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y -9.6506 -9.6506 -9.02647 -9.02647 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P -4.04325 -4.04325 -3.78481 -3.78481 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S -3.59317 -3.50408 -3.75328 -3.59785 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y -4.24893 -2.97865 -4.3359 -3.12068 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q -4.17696 -2.72633 -4.08341 -2.81681 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R -6.19456 -2.85261 -6.57513 -2.87537 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y -5.88062 -3.6198 -5.7963 -3.95325 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P -3.54907 -4.02637 -3.48704 -3.82419 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R -2.28729 -2.80698 -2.96976 -3.21163 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S -3.89956 -4.71507 -5.56081 -4.73287 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q -7.72748 -5.63145 -8.82928 -4.91599 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C -3.83128 -3.83128 -4.13538 -4.13538 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N -6.68164 -6.68164 -6.94447 -6.94447 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N -6.77929 -6.77929 -6.5081 -6.5081 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -4.40655 -4.40655 -4.12249 -4.12249 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A -6.03547 -6.03547 -5.79592 -5.79592 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I -2.6388 -2.6388 -3.05105 -3.05105 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q -3.72641 -3.72641 -3.42906 -3.42906 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L -3.69882 -3.69882 -2.84092 -2.84092 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q -3.35388 -3.35388 -2.8154 -2.8154 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q -3.81816 -3.81816 -3.23611 -3.23611 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E -10.5205 -10.5205 -10.2296 -10.2296 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L -8.51213 -8.51213 -8.55121 -8.55121 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C -7.67201 -7.67201 -7.68731 -7.68731 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A -11.328 -11.328 -10.7786 -10.7786 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C -9.15491 -9.15491 -9.04834 -9.04834 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -3.78171 -3.78171 -3.91315 -3.91315 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -2.61758 -2.61758 -2.66655 -2.66655 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -3.25986 -3.25986 -2.5693 -2.5693 
  m (blanks) 12530.63095 10368.17722 
 s (blanks) 506.3960279 455.1615403 
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Table A37: Calculated Z-scores of Ara h 2.02 peptides of controls. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each control are listed. Numbers 
written behind control sera represent the respective developed X-ray film. Prolines undergoing post-translational 
hydroxylation are written in bold and blue. 
 Control No. → N_2 N_2 N_3 N_3 N_4 N_4 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q 2.618215 2.618215 2.289753 2.289753 3.022174 3.022174 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 2.46384 2.46384 1.745793 1.745793 2.937296 2.937296 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 2.178675 2.178675 1.569007 1.569007 2.746965 2.746965 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H 2.208692 2.208692 1.617963 1.617963 2.394596 2.394596 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K 2.324473 2.324473 1.66148 1.66148 2.152824 2.152824 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D 2.315897 2.315897 0.899936 0.899936 1.671852 1.671852 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y 2.789743 2.789743 1.481973 1.481973 1.952205 1.952205 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P 0.553448 0.553448 0.296141 0.296141 0.6096 0.6096 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S 0.482693 -0.17126 0.608918 -0.06287 0.666185 0.50929 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y 0.950106 0.056017 0.546363 -0.21246 0.751062 0.529866 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q 0.956539 0.028144 0.551802 -0.23966 0.542727 0.419269 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R 1.168804 0.051729 0.598039 -0.04111 0.902812 0.607028 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y 0.289724 0.049585 0.328779 0.054079 0.421841 0.465565 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P 0.279004 -0.23129 0.508286 -0.11183 0.48357 0.311243 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R 0.435523 -0.28489 0.875458 0.116635 0.3704 0.329247 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 2.255862 0.257563 2.390385 0.200948 1.455801 1.468661 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q 2.045741 0.017424 2.512776 -0.07647 1.257754 1.059707 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C 1.170949 1.170949 1.174636 1.174636 0.671329 0.671329 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N 1.597624 1.597624 1.131119 1.131119 0.535011 0.535011 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N 1.040159 1.040159 0.826502 0.826502 0.411553 0.411553 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C 1.014429 1.014429 0.98969 0.98969 0.645608 0.645608 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A 0.920089 0.920089 0.85098 0.85098 0.691905 0.691905 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I 0.514854 0.514854 1.579886 1.579886 0.625032 0.625032 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q 0.825749 0.825749 0.823782 0.823782 0.694477 0.694477 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 0.881495 0.881495 1.234472 1.234472 0.828223 0.828223 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 1.32318 1.32318 2.053131 2.053131 0.398692 0.398692 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 0.892216 0.892216 1.688678 1.688678 0.645608 0.645608 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E 1.434673 1.434673 2.009614 2.009614 2.422888 2.422888 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L 1.546166 1.546166 1.949778 1.949778 2.574639 2.574639 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C 1.514004 1.514004 2.080329 2.080329 2.129676 2.129676 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A 1.218119 1.218119 1.626122 1.626122 2.157968 2.157968 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C 2.009291 2.009291 1.751233 1.751233 1.988213 1.988213 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V -0.00831 -0.00831 1.182795 1.182795 0.542727 0.542727 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -0.04047 -0.04047 0.793864 0.793864 0.535011 0.535011 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y 0.049585 0.049585 0.668754 0.668754 0.437273 0.437273 
  m (blanks) 9170.873662 8143.116379 11455.98985 
 s (blanks) 466.3965312 367.6744314 388.7963548 
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Table A38: Calculated Z-scores of Ara h 2.02 peptides of controls. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each control are listed. Numbers 
written behind control sera represent the respective developed X-ray film. Prolines undergoing post-translational 
hydroxylation are written in bold and blue. 
 Control No. → DLab71S1_1 DLab71S1_1 DLab71S1_2 DLab71S1_2 DLab71S1_3 DLab71S1_3 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q 2.490168 2.490168 2.887099 2.887099 2.550297 2.550297 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 1.48453 1.48453 2.551398 2.551398 2.118537 2.118537 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 1.005075 1.005075 2.418741 2.418741 2.128406 2.128406 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H 0.633293 0.633293 2.080332 2.080332 0.976222 0.976222 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K 1.04977 1.04977 1.768996 1.768996 1.193336 1.193336 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D 1.02539 1.02539 1.590316 1.590316 0.976222 0.976222 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y 1.482499 1.482499 1.936847 1.936847 1.000894 1.000894 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P 0.023815 0.023815 0.688794 0.688794 0.240995 0.240995 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S 0.564219 -0.3886 1.373734 0.518236 0.724567 0.194118 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y 0.643451 -0.64255 0.864767 0.361215 0.601207 0.206454 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q 0.048195 -0.39469 0.501993 0.279996 0.285405 0.502519 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R 0.306207 -0.5369 0.515529 0.515529 0.238528 0.221258 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y 0.127427 -0.23623 0.718574 0.558845 0.134905 0.680157 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P 0.296049 -0.21998 0.407238 0.225851 0.28047 -0.10441 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R 0.29808 0.332617 0.501993 0.331435 0.440839 0.566666 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 1.48453 -0.09808 1.9937 1.495562 1.588088 0.512388 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q 1.370761 0.076637 1.766289 0.518236 1.889087 0.396429 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C 0.446387 0.446387 1.113836 1.113836 1.15386 1.15386 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N 0.657672 0.657672 0.918913 0.918913 0.618477 0.618477 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N 0.99898 0.99898 0.680673 0.680673 0.376691 0.376691 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C 1.027422 1.027422 0.518236 0.518236 0.603674 0.603674 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A 1.204171 1.204171 1.113836 1.113836 1.158795 1.158795 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I 1.393109 1.393109 0.761891 0.761891 0.640682 0.640682 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q 0.812073 0.812073 0.242095 0.242095 0.455642 0.455642 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 1.722227 1.722227 1.062398 1.062398 0.645616 0.645616 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 1.447962 1.447962 1.084056 1.084056 1.225409 1.225409 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 1.571889 1.571889 1.154445 1.154445 0.949082 0.949082 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E 1.244802 1.244802 3.017048 3.017048 2.261635 2.261635 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L 1.261055 1.261055 2.602836 2.602836 2.345519 2.345519 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C 0.8974 0.8974 2.17238 2.17238 1.935964 1.935964 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A 0.517492 0.517492 1.741923 1.741923 1.437589 1.437589 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C 1.324034 1.324034 2.296914 2.296914 2.505888 2.505888 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V 0.560156 0.560156 0.612991 0.612991 0.576535 0.576535 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G 0.470766 0.470766 0.109438 0.109438 0.260733 0.260733 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y 0.239164 0.239164 0.144633 0.144633 0.32488 0.32488 
  m (blanks) 11243.27745 11721.57619 9079.320513 
 s (blanks) 492.2247585 369.3755052 405.3172388 
 
 Appendix  251 
Table A39: Calculated Z-scores of Ara h 2.02 peptides of controls. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each control are listed. Numbers 
written behind control sera represent the respective developed X-ray film. Prolines undergoing post-translational 
hydroxylation are written in bold and blue. 
 Control No. → DLab71S1_4 DLab71S1_4 DLab72S1_1 DLab72S1_1 DLab72S1_2 DLab72S1_2 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q 1.554046 1.554046 1.91215 1.91215 2.307903 2.307903 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 1.661996 1.661996 0.798671 0.798671 1.742894 1.742894 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 2.303697 2.303697 1.347073 1.347073 1.591359 1.591359 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H 1.627512 1.627512 0.704182 0.704182 1.420341 1.420341 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K 1.137241 1.137241 0.66157 0.66157 0.82719 0.82719 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D 0.828385 0.828385 0.291028 0.291028 1.032844 1.032844 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y 2.723501 2.723501 1.085841 1.085841 1.097788 1.097788 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P 0.444564 0.444564 -0.1036 -0.1036 0.305476 0.305476 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S 1.670992 0.165694 0.207656 -0.30925 0.396397 0.205896 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y 0.735429 0.056246 0.077966 -0.42968 0.563086 0.244862 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q 0.598992 0.008268 0.002005 -0.5112 0.591228 0.229709 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R 1.723467 -0.08619 0.437392 -0.11472 0.515461 0.002406 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y 0.029258 0.038254 0.103904 -0.26108 0.350937 0.231874 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P 0.171692 0.273644 0.263237 -0.18697 0.251357 0.255686 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R 0.416078 -0.11018 0.294733 0.378105 0.17126 0.457011 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 1.042785 0.834382 1.185887 -0.04431 0.92677 0.699467 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q 0.141706 0.669459 0.596725 -0.14065 0.935429 0.47 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C 0.41158 0.41158 0.291028 0.291028 0.6237 0.6237 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N 0.254153 0.254153 0.498531 0.498531 0.686479 0.686479 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N 3.705542 3.705542 0.433687 0.433687 0.335783 0.335783 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C -0.00523 -0.00523 0.828314 0.828314 0.513296 0.513296 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A 0.551015 0.551015 0.909833 0.909833 0.539273 0.539273 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I 0.318623 0.318623 1.002469 1.002469 0.396397 0.396397 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q 0.048749 0.048749 0.568934 0.568934 0.580404 0.580404 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 0.416078 0.416078 1.076577 1.076577 0.467835 0.467835 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 0.387591 0.387591 1.178476 1.178476 0.359596 0.359596 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 0.210673 0.210673 1.302608 1.302608 0.664831 0.664831 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E 3.834482 3.834482 1.636096 1.636096 1.745059 1.745059 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L 1.576536 1.576536 1.967731 1.967731 1.548063 1.548063 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C 2.140273 2.140273 0.991352 0.991352 1.257982 1.257982 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A 0.912346 0.912346 0.454066 0.454066 1.766706 1.766706 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C 1.52556 1.52556 1.247026 1.247026 1.322925 1.322925 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V 0.02476 0.02476 0.961709 0.961709 0.22105 0.22105 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G -0.16715 -0.16715 0.66157 0.66157 0.16693 0.16693 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y -0.12067 -0.12067 0.289175 0.289175 0.374749 0.374749 
  m (blanks) 11903.48548 11209.91781 11229.88839 
 s (blanks) 666.977806 539.7497324 461.9395702 
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Table A40: Calculated Z-scores of Ara h 2.02 peptides of controls and derived maximum Z-score. 
The calculated Z-scores of every peptide of Ara h 2.02_P and Ara h 2.02_Hyp for each control and the maximum Z-
score (Max.) of the controls are listed. Numbers written behind control sera represent the respective developed X-
ray film. Prolines undergoing post-translational hydroxylation are written in bold and blue. 
 Control No. → DLab72S1_3 DLab72S1_3 DLab72S1_4 DLab72S1_4 Max. Max. 
 Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 R-Q-Q-W-E-L-Q-G-D-R-R-C-Q-S-Q 2.898064 2.898064 18.05717 18.05717 18.05717 18.05717 
2 E-L-Q-G-D-R-R-C-Q-S-Q-L-E-R-A 2.144974 2.144974 9.391927 9.391927 9.391927 9.391927 
3 D-R-R-C-Q-S-Q-L-E-R-A-N-L-R-P 2.429927 2.429927 7.970057 7.970057 7.970057 7.970057 
4 Q-S-Q-L-E-R-A-N-L-R-P-C-E-Q-H 1.663268 1.663268 8.459553 8.459553 8.459553 8.459553 
5 E-R-A-N-L-R-P-C-E-Q-H-L-M-Q-K 1.699452 1.699452 6.600633 6.600633 6.600633 6.600633 
6 L-R-P-C-E-Q-H-L-M-Q-K-I-Q-R-D 0.926009 0.926009 6.45495 6.45495 6.45495 6.45495 
7 E-Q-H-L-M-Q-K-I-Q-R-D-E-D-S-Y 1.84419 1.84419 9.467682 9.467682 9.467682 9.467682 
8 M-Q-K-I-Q-R-D-E-D-S-Y-G-R-D-P 0.328965 0.328965 3.949196 3.949196 3.949196 3.949196 
9 Q-R-D-E-D-S-Y-G-R-D-P-Y-S-P-S 1.014209 -0.13239 3.820994 3.716102 3.820994 3.716102 
10 D-S-Y-G-R-D-P-Y-S-P-S-Q-D-P-Y 0.812933 -0.08263 4.287181 3.249915 4.287181 3.249915 
11 R-D-P-Y-S-P-S-Q-D-P-Y-S-P-S-Q 0.249811 -0.02836 3.98416 3.104232 3.98416 3.104232 
12 S-P-S-Q-D-P-Y-S-P-S-Q-D-P-D-R 0.860425 -0.04871 6.513223 3.110059 6.513223 3.110059 
13 D-P-Y-S-P-S-Q-D-P-D-R-R-D-P-Y 0.326703 0.021397 6.035382 4.357109 6.035382 4.357109 
14 P-S-Q-D-P-D-R-R-D-P-Y-S-P-S-P 0.116381 -0.06454 3.622865 4.252217 3.622865 4.252217 
15 P-D-R-R-D-P-Y-S-P-S-P-Y-D-R-R 0.55738 0.213627 3.26157 3.360635 3.26157 3.360635 
16 D-P-Y-S-P-S-P-Y-D-R-R-G-A-G-S 1.789914 0.575472 5.703224 5.231209 5.703224 5.231209 
17 P-S-P-Y-D-R-R-G-A-G-S-S-Q-H-Q 1.165731 0.168396 9.094733 5.225382 9.094733 5.225382 
18 D-R-R-G-A-G-S-S-Q-H-Q-E-R-C-C 0.663672 0.663672 3.989987 3.989987 3.989987 3.989987 
19 A-G-S-S-Q-H-Q-E-R-C-C-N-E-L-N 0.797102 0.797102 7.148403 7.148403 7.148403 7.148403 
20 Q-H-Q-E-R-C-C-N-E-L-N-E-F-E-N 1.127285 1.127285 6.857036 6.857036 6.857036 6.857036 
21 R-C-C-N-E-L-N-E-F-E-N-N-Q-R-C 1.631607 1.631607 4.07157 4.07157 4.07157 4.07157 
22 E-L-N-E-F-E-N-N-Q-R-C-M-C-E-A 0.559641 0.559641 6.10531 6.10531 6.10531 6.10531 
23 F-E-N-N-Q-R-C-M-C-E-A-L-Q-Q-I 0.299565 0.299565 3.26157 3.26157 3.26157 3.26157 
24 Q-R-C-M-C-E-A-L-Q-Q-I-M-E-N-Q 0.091504 0.091504 3.646174 3.646174 3.646174 3.646174 
25 C-E-A-L-Q-Q-I-M-E-N-Q-S-D-R-L 0.607133 0.607133 3.5238 3.5238 3.5238 3.5238 
26 Q-Q-I-M-E-N-Q-S-D-R-L-Q-G-R-Q 0.844594 0.844594 3.366462 3.366462 3.366462 3.366462 
27 E-N-Q-S-D-R-L-Q-G-R-Q-Q-E-Q-Q 0.659148 0.659148 3.710275 3.710275 3.710275 3.710275 
28 D-R-L-Q-G-R-Q-Q-E-Q-Q-F-K-R-E 2.016067 2.016067 10.71473 10.71473 10.71473 10.71473 
29 G-R-Q-Q-E-Q-Q-F-K-R-E-L-R-N-L 2.158543 2.158543 9.053941 9.053941 9.053941 9.053941 
30 E-Q-Q-F-K-R-E-L-R-N-L-P-Q-Q-C 1.457469 1.457469 7.917611 7.917611 7.917611 7.917611 
31 K-R-E-L-R-N-L-P-Q-Q-C-G-L-R-A 2.429927 2.429927 11.43732 11.43732 11.43732 11.43732 
32 R-N-L-P-Q-Q-C-G-L-R-A-P-Q-R-C 2.090697 2.090697 9.351136 9.351136 9.351136 9.351136 
33 Q-Q-C-G-L-R-A-P-Q-R-C-D-L-E-V 0.419426 0.419426 4.59603 4.59603 4.59603 4.59603 
34 L-R-A-P-Q-R-C-D-L-E-V-E-S-G-G 0.344796 0.344796 2.993513 2.993513 2.993513 2.993513 
35 Q-R-C-D-L-E-V-E-S-G-G-R-D-R-Y 0.148043 0.148043 2.964376 2.964376 2.964376 2.964376 
  m (blanks) 8431.538776 10277.29825 
 s (blanks) 442.1784235 171.6050136 
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Table A41: Calculated Z-scores of Ara h 2.02 IgE inhibition experiments. 
The calculated Z-scores of every peptide of Ara h 2.02_P/Hyp are listed for the uninhibited peanut serum pool plus protein 
buffer without inhibitor (Pool -), for the peanut serum pool preincubated with rAra h 2.02 (Pool + rAra h 2.02), with native 
peanut extract (Pool + n. extract) or with reduced/alkylated peanut extract (Pool + r/a extract). Candidate diagnostic 
peptides are highlighted in light blue. 
IgE inhibition  
experiment → Pool - Pool - 
Pool + 
rAra h 2.02 
Pool + 
rAra h 2.02 
Pool + 
n. extract 
Pool + 
n. extract 
Pool + 
r/a extract 
Pool + 
r/a extract 
Ara h 2.02_P/Hyp P Hyp P Hyp P Hyp P Hyp 
Peptide No. ↓ Z-score Z-score Z-score Z-score Z-score Z-score Z-score Z-score 
1 4.12296534 4.12296534 0.55734681 0.55734681 2.99895282 2.99895282 2.88260668 2.88260668 
2 95.3657213 95.3657213 1.19291514 1.19291514 3.01729151 3.01729151 14.3761028 14.3761028 
3 8.05564555 8.05564555 0.284365 0.284365 2.08201812 2.08201812 2.14294401 2.14294401 
4 2.65321428 2.65321428 -0.14490411 -0.14490411 1.67398218 1.67398218 1.76952208 1.76952208 
5 1.6333481 1.6333481 0.09265258 0.09265258 2.19205029 2.19205029 2.01009198 2.01009198 
6 1.44843779 1.44843779 0.16975431 0.16975431 1.53644198 1.53644198 1.69052898 1.69052898 
7 1.05955424 1.05955424 0.12599387 0.12599387 2.32042114 2.32042114 3.45351136 3.45351136 
8 1.43128116 1.43128116 0.29686798 0.29686798 0.90834171 0.90834171 0.72465879 0.72465879 
9 3.13550613 100.747183 0.11765855 100.672904 1.03671257 3.7279159 0.93291333 3.37092767 
10 6.95762141 101.412479 0.25935903 101.81276 1.59145806 6.20822426 1.80542803 4.83589063 
11 8.78956793 101.62789 0.18017347 102.019059 1.59604273 6.74004638 1.42841551 10.1679249 
12 3.18316343 100.737652 0.29478415 76.32126 1.56395002 1.33930102 1.45354968 1.1160337 
13 2.2223923 89.4714667 0.42189782 13.1249292 1.41265579 1.25677689 1.84133399 0.30455912 
14 14.7257609 101.784206 0.39897568 100.816689 2.14161888 8.97736705 1.29197288 8.34749301 
15 40.4025598 99.8416947 0.86575374 80.6452085 2.35709853 2.99436815 1.48945563 1.91673649 
16 9.10029351 92.4128751 1.10747809 18.0677754 4.27807672 1.51351861 2.34042676 0.84314844 
17 4.05052625 4.96745265 0.60527491 0.25310754 2.00866335 1.02754322 1.66898541 0.6420751 
18 1.18918209 1.18918209 -0.21367052 -0.21367052 1.4630872 1.4630872 1.29915407 1.29915407 
19 2.18617276 2.18617276 0.11349089 0.11349089 1.82986108 1.82986108 1.6761666 1.6761666 
20 1.18346321 1.18346321 0.13849685 0.13849685 2.70553372 2.70553372 1.61153588 1.61153588 
21 2.19379793 2.19379793 -0.01362278 -0.01362278 2.56799351 2.56799351 1.90237411 1.90237411 
22 1.33024769 1.33024769 0.02805383 0.02805383 2.86599729 2.86599729 2.45532582 2.45532582 
23 1.08624233 1.08624233 0.1551675 0.1551675 2.11411084 2.11411084 1.353013 1.353013 
24 0.45144712 0.45144712 0.53025701 0.53025701 1.99490933 1.99490933 1.20579859 1.20579859 
25 1.45415666 1.45415666 0.98661591 0.98661591 3.03104553 3.03104553 2.19321235 2.19321235 
26 1.99173098 1.99173098 1.00328656 1.00328656 2.9164287 2.9164287 2.69948631 2.69948631 
27 3.402387 3.402387 1.04079551 1.04079551 2.7422111 2.7422111 2.12499103 2.12499103 
28 81.5622616 81.5622616 0.96160994 0.96160994 3.41157343 3.41157343 20.5447459 20.5447459 
29 60.9304642 60.9304642 0.37188588 0.37188588 3.15483172 3.15483172 4.53428061 4.53428061 
30 2.67608978 2.67608978 0.36980205 0.36980205 1.74275228 1.74275228 2.28297723 2.28297723 
31 2.07751412 2.07751412 0.07806577 0.07806577 2.21497365 2.21497365 2.37274212 2.37274212 
32 0.70879653 0.70879653 0.0530598 0.0530598 2.38919125 2.38919125 3.12317658 3.12317658 
33 1.22349534 1.22349534 0.1551675 0.1551675 2.66427165 2.66427165 1.4320061 1.4320061 
34 0.48576037 0.48576037 0.06973044 0.06973044 1.85278445 1.85278445 0.82160487 0.82160487 
35 1.06146053 1.06146053 0.45732294 0.45732294 1.74733696 1.74733696 1.36737539 1.36737539 
m(blanks) 6887.180488 9474.537374 19293.87429 14432.17866 
s(blanks) 524.5786309 479.8854558 218.1180411 278.5053352 
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7.1.5.3 Calculated Z-scores of Pis s 1 peptides 
 
Table A42: Calculated Z-scores of Pis s 1 peptides after control subtraction. 
The calculated Z-scores of every peptide of Pis s 1 for each pea-allergic patient (patients 1-7) are listed. Identified 
candidate diagnostic peptides are highlighted in light blue. 
 Patient No. → 1 2 3 4 5 6 7 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score Z-score 
1 S-R-S-D-Q-E-N-P-F-I-F-K-S-N-R -10.5309 -9.46465 -10.6778 -3.96957 -10.5275 -4.72091 -8.02724 
2 Q-E-N-P-F-I-F-K-S-N-R-F-Q-T-L -12.2751 -11.603 -13.3058 -5.03865 -11.0193 -4.0631 -3.89503 
3 F-I-F-K-S-N-R-F-Q-T-L-Y-E-N-E 2.090892 -0.06186 0.411962 12.82627 1.535048 7.696264 2.78552 
4 S-N-R-F-Q-T-L-Y-E-N-E-N-G-H-I 2.612442 1.410022 3.63417 14.99363 1.626418 4.782956 2.551252 
5 Q-T-L-Y-E-N-E-N-G-H-I-R-L-L-Q 3.218103 2.369175 0.768995 8.559985 0.889885 3.289293 1.558609 
6 E-N-E-N-G-H-I-R-L-L-Q-K-F-D-K -4.45952 -4.53468 -5.94043 -5.48877 -7.48853 -2.22716 -3.45339 
7 G-H-I-R-L-L-Q-K-F-D-K-R-S-K-I -30.1759 -24.3011 -26.6026 -23.0893 -23.5681 -2.10184 -4.64472 
8 L-L-Q-K-F-D-K-R-S-K-I-F-E-N-L -1.26056 -2.89415 -1.82134 8.728744 -2.76111 1.457342 -0.29759 
9 F-D-K-R-S-K-I-F-E-N-L-Q-N-Y-R -13.7991 -14.1687 -12.8785 -6.1962 -12.1531 -8.53486 -7.34012 
10 S-K-I-F-E-N-L-Q-N-Y-R-L-L-E-Y -0.74305 -1.95426 -0.02966 2.408014 -2.28009 2.064805 -0.99076 
11 E-N-L-Q-N-Y-R-L-L-E-Y-K-S-K-P -6.08846 -5.61855 -3.95807 -3.09112 -5.59648 -0.35238 0.230783 
12 N-Y-R-L-L-E-Y-K-S-K-P-H-T-L-F -8.80944 -7.74146 -5.17451 -2.67718 -7.25844 -3.78246 -2.11138 
13 L-E-Y-K-S-K-P-H-T-L-F-L-P-Q-Y -8.34012 -8.12264 -5.17606 3.634752 -9.21854 3.465189 -1.01692 
14 S-K-P-H-T-L-F-L-P-Q-Y-T-D-A-D 2.511129 -1.94265 1.425025 21.60567 -2.22342 8.543576 2.066228 
15 T-L-F-L-P-Q-Y-T-D-A-D-F-I-L-V 1.6304 -2.14891 -0.29177 24.7479 -3.15707 11.12796 3.16967 
16 P-Q-Y-T-D-A-D-F-I-L-V-V-L-S-G -1.9238 -5.39107 -1.8642 13.27394 -4.84575 8.481657 0.790868 
17 D-A-D-F-I-L-V-V-L-S-G-K-A-T-L -15.9675 -15.5858 -12.3471 0.736501 -15.6619 13.68749 7.331134 
18 I-L-V-V-L-S-G-K-A-T-L-T-V-L-K -9.53085 -10.1468 -8.39849 4.16522 -12.6191 6.84126 4.686985 
19 L-S-G-K-A-T-L-T-V-L-K-S-N-D-R -1.82265 -4.66876 -1.16883 12.07631 -6.54259 2.503649 4.507498 
20 A-T-L-T-V-L-K-S-N-D-R-N-S-F-N 0.538323 -3.72059 -1.29529 11.76476 -3.61255 13.19017 6.946854 
21 V-L-K-S-N-D-R-N-S-F-N-L-E-R-G -1.62549 -2.47007 -2.28448 12.7868 -2.40583 5.450079 3.410066 
22 N-D-R-N-S-F-N-L-E-R-G-D-A-I-K -3.06508 -5.0999 -0.56215 10.92419 -4.46687 3.565495 3.049704 
23 S-F-N-L-E-R-G-D-A-I-K-L-P-A-G -0.40525 -3.97911 -2.37106 13.7626 -2.59786 3.114325 0.451875 
24 E-R-G-D-A-I-K-L-P-A-G-T-I-A-Y 0.232908 -2.77959 -1.46504 10.90085 -1.27212 5.389901 19.44002 
25 A-I-K-L-P-A-G-T-I-A-Y-L-A-N-R -6.38797 -6.99169 -8.2296 3.126432 -7.30122 -5.33415 -7.43907 
26 P-A-G-T-I-A-Y-L-A-N-R-D-D-N-E -0.01261 -0.28158 -3.72475 7.981769 -1.1882 4.027554 -2.38786 
27 I-A-Y-L-A-N-R-D-D-N-E-D-L-R-V -2.9128 -3.08892 -5.73733 9.482944 -3.14504 9.754615 0.774336 
28 A-N-R-D-D-N-E-D-L-R-V-L-D-L-A 5.777238 0.722055 2.264753 9.964865 3.022396 9.532204 2.756042 
29 D-N-E-D-L-R-V-L-D-L-A-I-P-V-N 5.999491 0.412868 0.259976 13.56267 3.979282 8.395579 3.44504 
30 L-R-V-L-D-L-A-I-P-V-N-K-P-G-Q 6.693737 1.136713 1.915241 11.56879 8.145987 5.719216 6.273872 
31 D-L-A-I-P-V-N-K-P-G-Q-L-Q-S-F 4.193609 -1.39301 -0.34959 8.864606 -3.81689 3.205944 -0.83328 
32 P-V-N-K-P-G-Q-L-Q-S-F-L-L-S-G 4.984036 -0.34499 2.356422 7.068273 -0.52217 2.509449 0.013138 
33 P-G-Q-L-Q-S-F-L-L-S-G-T-Q-N-Q -1.2832 -0.21224 -4.34667 8.960293 -0.95953 3.518867 -0.63075 
34 Q-S-F-L-L-S-G-T-Q-N-Q-P-S-L-L 3.833144 0.260894 0.799559 13.25493 2.054154 5.86136 3.72952 
35 L-S-G-T-Q-N-Q-P-S-L-L-S-G-F-S -1.37214 -3.24364 -2.85876 9.368696 -2.76493 1.334022 -1.7238 
36 Q-N-Q-P-S-L-L-S-G-F-S-K-N-I-L -1.63033 1.204264 -0.06499 5.776599 -2.77938 0.495834 2.673118 
37 S-L-L-S-G-F-S-K-N-I-L-E-A-A-F 1.793282 -1.45992 3.869664 14.72835 -1.02973 1.752846 3.100017 
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38 G-F-S-K-N-I-L-E-A-A-F-N-T-N-Y 1.383962 -2.71259 0.82768 18.08994 -2.83587 3.577405 2.871174 
39 N-I-L-E-A-A-F-N-T-N-Y-E-E-I-E 0.192607 -2.9097 -0.26251 15.39546 -2.65176 3.129273 -0.97128 
40 A-A-F-N-T-N-Y-E-E-I-E-K-V-L-L -0.05999 -2.45204 0.365505 21.33392 -2.94183 5.979964 1.290693 
41 T-N-Y-E-E-I-E-K-V-L-L-E-Q-Q-E -1.73178 -1.43261 -0.72888 11.03196 -3.76814 2.067562 -0.19162 
42 E-I-E-K-V-L-L-E-Q-Q-E-Q-E-P-Q -0.55314 -2.12327 1.571556 8.507774 -2.79875 2.613184 1.279057 
43 V-L-L-E-Q-Q-E-Q-E-P-Q-H-R-R-S 0.731218 -1.95218 3.41436 6.017752 -2.13356 2.689308 3.15173 
44 Q-Q-E-Q-E-P-Q-H-R-R-S-L-K-D-R 0.52806 -1.85856 4.557498 10.78453 -2.81785 2.838024 5.190264 
45 E-P-Q-H-R-R-S-L-K-D-R-R-Q-E-I -17.095 -12.7173 -11.5967 -7.40311 -8.76291 9.615661 8.774303 
46 R-R-S-L-K-D-R-R-Q-E-I-N-E-E-N 0.117823 -2.17983 -1.11531 9.596477 -1.9904 5.08288 6.417096 
47 K-D-R-R-Q-E-I-N-E-E-N-V-I-V-K -1.33484 -4.92204 -3.19539 7.217198 -3.46168 4.426172 -0.06936 
48 Q-E-I-N-E-E-N-V-I-V-K-V-S-R-E 2.134784 -1.57343 -0.43696 18.88174 -0.32714 12.44053 3.241052 
49 E-E-N-V-I-V-K-V-S-R-E-Q-I-E-E 1.566656 -0.00766 -2.82063 7.302274 -0.49477 1.891113 -3.07897 
50 I-V-K-V-S-R-E-Q-I-E-E-L-S-K-N 2.076582 1.78776 -2.79039 9.790269 0.726109 2.70424 -1.67731 
51 S-R-E-Q-I-E-E-L-S-K-N-A-K-S-S 2.48216 -0.23984 -0.91134 5.671486 2.944714 2.328423 -0.93638 
52 I-E-E-L-S-K-N-A-K-S-S-S-K-K-S -13.3178 -10.8975 -9.99684 -8.41396 -9.15579 -1.8459 -1.78169 
53 S-K-N-A-K-S-S-S-K-K-S-V-S-S-E 2.741248 -1.93334 0.320026 12.49301 5.107093 3.377901 3.276868 
54 K-S-S-S-K-K-S-V-S-S-E-S-G-P-F 6.064404 -1.36414 0.637707 17.33392 1.800313 5.567717 2.010493 
55 K-K-S-V-S-S-E-S-G-P-F-N-L-R-S 8.633018 0.22755 2.252867 22.5075 3.135521 3.994672 4.040989 
56 S-S-E-S-G-P-F-N-L-R-S-R-N-P-I 2.288639 -2.29369 -0.65917 15.19035 -1.29167 0.728345 0.519631 
57 G-P-F-N-L-R-S-R-N-P-I-Y-S-N-K -37.9551 -33.3032 -34.6763 -12.4847 -26.0553 0.193242 -11.278 
58 L-R-S-R-N-P-I-Y-S-N-K-F-G-K-F -40.6655 -36.2857 -39.2972 -16.3835 -19.9754 14.85147 -12.9861 
59 N-P-I-Y-S-N-K-F-G-K-F-F-E-I-T 3.059435 -1.07734 -3.17006 25.6919 -2.50029 3.304393 -0.16243 
60 S-N-K-F-G-K-F-F-E-I-T-P-E-K-N 4.625283 0.383156 -0.38702 25.10105 -0.62787 1.023545 0.732993 
61 G-K-F-F-E-I-T-P-E-K-N-Q-Q-L-Q 2.296988 -1.05604 1.48857 28.40486 -0.24523 3.74048 -0.02319 
62 E-I-T-P-E-K-N-Q-Q-L-Q-D-L-D-I 4.227438 -1.33692 3.698734 30.95001 -1.3195 3.865156 1.072578 
63 E-K-N-Q-Q-L-Q-D-L-D-I-F-V-N-S 7.560559 -1.18087 2.020102 34.20865 -1.14768 5.885953 2.27638 
64 Q-L-Q-D-L-D-I-F-V-N-S-V-D-I-K 5.914372 -0.53136 6.961027 33.82082 -1.73688 8.502636 2.31189 
65 L-D-I-F-V-N-S-V-D-I-K-E-G-S-L 3.320574 -0.45831 2.979496 25.30886 -0.73421 5.281205 1.377918 
66 V-N-S-V-D-I-K-E-G-S-L-L-L-P-N 3.021156 -2.65594 1.303705 22.4685 -0.53752 7.863785 4.808514 
67 D-I-K-E-G-S-L-L-L-P-N-Y-N-S-R -1.98571 -3.97336 -0.56915 16.75311 -2.88654 1.041249 2.252869 
68 G-S-L-L-L-P-N-Y-N-S-R-A-I-V-I -1.34385 -4.02649 -1.68399 11.27882 -4.11514 4.175076 3.510956 
69 L-P-N-Y-N-S-R-A-I-V-I-V-T-V-T -4.01863 -3.78902 -2.151 13.15501 -2.28686 12.8682 7.42568 
70 N-S-R-A-I-V-I-V-T-V-T-E-G-K-G -3.33638 -5.78534 -2.32991 22.20884 -4.53755 13.45803 7.663475 
71 I-V-I-V-T-V-T-E-G-K-G-D-F-E-L 6.889609 -0.55084 5.806017 33.60079 0.205413 7.160616 5.219416 
72 T-V-T-E-G-K-G-D-F-E-L-V-G-Q-R 5.071344 -0.93334 1.903718 32.05923 -1.99385 8.846595 5.354521 
73 G-K-G-D-F-E-L-V-G-Q-R-N-E-N-Q 5.296378 -1.83315 -2.68609 4.781424 -1.54813 -0.12328 -4.45089 
74 F-E-L-V-G-Q-R-N-E-N-Q-G-K-E-N 6.422961 4.390234 -0.39038 12.36706 1.63479 4.479886 0.045552 
75 G-Q-R-N-E-N-Q-G-K-E-N-D-K-E-E 2.609272 0.753812 1.70486 3.816325 -1.4771 0.415805 -2.32193 
76 E-N-Q-G-K-E-N-D-K-E-E-E-Q-E-E 0.970757 -0.51274 7.668478 2.268469 -1.41979 -0.40678 -1.10332 
77 K-E-N-D-K-E-E-E-Q-E-E-E-T-S-K 4.931304 0.966154 7.760659 7.389933 -0.49591 1.12645 0.501257 
78 K-E-E-E-Q-E-E-E-T-S-K-Q-V-Q-L 8.456177 -0.30665 3.032057 11.15886 1.473152 5.23006 0.211462 
79 Q-E-E-E-T-S-K-Q-V-Q-L-Y-R-A-K 8.10252 0.932493 0.491612 13.86043 -0.14372 1.731035 0.436978 
80 T-S-K-Q-V-Q-L-Y-R-A-K-L-S-P-G 0.813897 -3.45831 -3.43447 21.9388 -3.57547 5.890986 3.192777 
81 V-Q-L-Y-R-A-K-L-S-P-G-D-V-F-V -0.29545 -3.90783 -3.40332 28.22442 0.46693 3.585538 0.360856 
82 R-A-K-L-S-P-G-D-V-F-V-I-P-A-G 8.508339 0.855691 2.415826 34.96222 4.900988 6.389808 -0.45357 
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83 S-P-G-D-V-F-V-I-P-A-G-H-P-V-A 10.84649 1.232026 7.501944 37.34794 2.456817 3.783556 0.272683 
84 V-F-V-I-P-A-G-H-P-V-A-I-N-A-S 9.406568 0.531597 3.753001 35.6474 5.576492 9.005023 1.194817 
85 P-A-G-H-P-V-A-I-N-A-S-S-D-L-N 5.596367 -1.51501 0.276765 29.25137 0.045064 7.567014 -0.061 
86 P-V-A-I-N-A-S-S-D-L-N-L-I-G-F 6.021637 -1.53364 -3.42973 32.75131 0.764875 7.08186 -1.00746 
87 N-A-S-S-D-L-N-L-I-G-F-G-I-N-A 6.788298 -4.68605 -0.48836 33.05649 0.422313 2.871794 -3.28233 
88 D-L-N-L-I-G-F-G-I-N-A-E-N-N-E 8.90907 -2.06978 1.42784 35.78641 -1.31983 5.843576 0.291208 
89 I-G-F-G-I-N-A-E-N-N-E-R-N-F-L 5.253261 -1.18743 0.173815 32.75868 -0.45967 10.28601 0.558966 
90 I-N-A-E-N-N-E-R-N-F-L-A-G-E-E -2.83805 -13.9276 -10.7819 21.99911 21.79074 -2.9373 -10.3445 
91 N-N-E-R-N-F-L-A-G-E-E-D-N-V-I 7.1123 -3.47123 -0.87748 33.9903 6.032384 2.825362 2.211427 
92 N-F-L-A-G-E-E-D-N-V-I-S-Q-V-E 0.856132 -2.47024 1.788573 18.12826 -0.66382 4.155449 0.089739 
93 G-E-E-D-N-V-I-S-Q-V-E-R-P-V-K -0.41212 -2.16006 -1.31281 15.93288 -0.90224 5.68074 2.892422 
94 N-V-I-S-Q-V-E-R-P-V-K-E-L-A-F 4.120173 -0.98495 3.757626 32.63297 1.570174 8.318921 3.999988 
95 Q-V-E-R-P-V-K-E-L-A-F-P-G-S-S 5.588146 13.77671 11.52922 32.186 7.391694 3.001639 2.205856 
96 P-V-K-E-L-A-F-P-G-S-S-H-E-V-D 8.202078 14.98353 13.98078 34.63 34.81028 8.781856 60.48037 
97 L-A-F-P-G-S-S-H-E-V-D-R-L-L-K 8.159771 0.120814 12.59132 6.97535 3.450639 0.860178 -0.3118 
98 G-S-S-H-E-V-D-R-L-L-K-N-Q-K-Q 5.883925 -0.92573 0.011273 1.876871 -1.71492 -1.09575 -2.85998 
99 E-V-D-R-L-L-K-N-Q-K-Q-S-Y-F-A 1.126948 -1.19532 -3.44025 25.66664 -2.46879 -0.57718 -6.55732 
100 L-L-K-N-Q-K-Q-S-Y-F-A-N-A-Q-P 7.300018 0.949288 13.7509 32.67821 -0.43074 -0.77202 6.237889 
101 Q-K-Q-S-Y-F-A-N-A-Q-P-L-Q-R-E 7.730445 0.627144 13.301 32.55821 12.73965 3.627507 6.965832 
 m (blanks) 20535.63 14861.14 14342.39 11846.79 9434.028 9808.343 10057.57 
 s (blanks) 3476.642 2354.966 2687.228 1345.152 1206.837 518.3151 657.7803 
 
Table A43: Calculated Z-scores of Pis s 1 peptides after control subtraction. 
The calculated Z-scores of every peptide of Pis s 1 for each pea-allergic patient (patients 8-14) are listed. Identified 
candidate diagnostic peptides are highlighted in light blue. 
 Patient No. → 8 9 10 11 12 13 14 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score Z-score 
1 S-R-S-D-Q-E-N-P-F-I-F-K-S-N-R -10.2048 -10.2714 -9.94922 -8.09417 -11.5047 -8.92543 -9.85826 
2 Q-E-N-P-F-I-F-K-S-N-R-F-Q-T-L -6.63055 -11.1714 -10.64 -5.0821 -15.4895 -10.3766 -9.32076 
3 F-I-F-K-S-N-R-F-Q-T-L-Y-E-N-E 8.983865 -0.8895 2.478525 7.866443 -2.10504 2.140051 -0.40102 
4 S-N-R-F-Q-T-L-Y-E-N-E-N-G-H-I 4.108445 0.027464 2.580308 4.79595 0.135541 1.168597 0.798883 
5 Q-T-L-Y-E-N-E-N-G-H-I-R-L-L-Q 3.888052 -0.70903 1.187946 2.109534 -0.13531 0.463244 -0.10134 
6 E-N-E-N-G-H-I-R-L-L-Q-K-F-D-K -4.05861 -7.89764 -6.51231 -6.49825 -7.73976 -5.38584 -5.11145 
7 G-H-I-R-L-L-Q-K-F-D-K-R-S-K-I -25.4841 -22.152 -29.9044 -25.844 -33.6198 -27.5886 -26.9745 
8 L-L-Q-K-F-D-K-R-S-K-I-F-E-N-L 8.398056 -4.8384 -1.2943 -3.20085 -6.14205 -2.5384 -5.04725 
9 F-D-K-R-S-K-I-F-E-N-L-Q-N-Y-R -9.22516 -13.2744 -14.6752 -12.951 -16.7983 -13.1335 -14.4459 
10 S-K-I-F-E-N-L-Q-N-Y-R-L-L-E-Y 1.460095 -2.04811 -1.79529 -1.11854 -2.07226 -1.46783 -2.3407 
11 E-N-L-Q-N-Y-R-L-L-E-Y-K-S-K-P -3.89541 -4.81998 -5.08657 -6.57906 -6.38108 -4.20365 -4.47754 
12 N-Y-R-L-L-E-Y-K-S-K-P-H-T-L-F 0.031794 -7.6524 -6.16626 -7.07201 -10.0257 -5.99142 -6.66043 
13 L-E-Y-K-S-K-P-H-T-L-F-L-P-Q-Y 1.974939 -7.26183 -7.2484 -6.99326 -10.2088 -5.58832 -6.97463 
14 S-K-P-H-T-L-F-L-P-Q-Y-T-D-A-D 17.17633 -2.21045 0.593432 3.014678 -2.4796 0.528871 -3.27262 
15 T-L-F-L-P-Q-Y-T-D-A-D-F-I-L-V 17.45499 -2.72388 -0.68258 2.881373 -4.63346 -0.51519 -4.95449 
16 P-Q-Y-T-D-A-D-F-I-L-V-V-L-S-G 8.61695 -3.97002 -4.1381 -0.29107 -6.13263 -2.19202 -5.74932 
17 D-A-D-F-I-L-V-V-L-S-G-K-A-T-L 3.528927 -17.0695 -16.641 -8.81724 -19.8498 -15.3455 -16.4854 
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18 I-L-V-V-L-S-G-K-A-T-L-T-V-L-K 8.386515 -8.65533 -10.0874 -0.54583 -13.6171 -6.6154 -9.89171 
19 L-S-G-K-A-T-L-T-V-L-K-S-N-D-R 13.02 -4.70983 -2.95544 2.800711 1.404287 0.269636 -3.14796 
20 A-T-L-T-V-L-K-S-N-D-R-N-S-F-N 14.24501 -2.15239 -0.55992 3.305823 2.513176 0.87497 0.602229 
21 V-L-K-S-N-D-R-N-S-F-N-L-E-R-G 7.90013 -2.75799 -1.94478 4.626593 3.501281 3.559365 -0.01419 
22 N-D-R-N-S-F-N-L-E-R-G-D-A-I-K 19.59179 -5.19495 -1.41857 3.450057 -5.40825 -0.63176 -3.4624 
23 S-F-N-L-E-R-G-D-A-I-K-L-P-A-G 9.633813 -4.26439 0.21289 0.836571 -4.55191 -2.05431 -4.16214 
24 E-R-G-D-A-I-K-L-P-A-G-T-I-A-Y 7.062155 -2.60887 1.431596 -0.33469 -3.0962 -2.0213 -3.63413 
25 A-I-K-L-P-A-G-T-I-A-Y-L-A-N-R -2.4057 -7.14246 -5.72097 -4.04999 -8.83641 -7.07549 -6.7774 
26 P-A-G-T-I-A-Y-L-A-N-R-D-D-N-E 3.772197 -2.25676 0.615739 4.712762 -4.27999 -1.70977 -2.50015 
27 I-A-Y-L-A-N-R-D-D-N-E-D-L-R-V 0.621597 -3.31672 -1.32753 5.434854 -7.39504 -3.76042 -5.09878 
28 A-N-R-D-D-N-E-D-L-R-V-L-D-L-A 6.021402 0.095972 2.921814 6.650664 -0.97558 0.290552 -0.21075 
29 D-N-E-D-L-R-V-L-D-L-A-I-P-V-N 15.78444 -0.54929 3.851405 10.92319 -1.54138 1.269412 -0.7978 
30 L-R-V-L-D-L-A-I-P-V-N-K-P-G-Q 19.31143 0.354649 5.490765 11.33449 0.026469 2.788748 -0.39833 
31 D-L-A-I-P-V-N-K-P-G-Q-L-Q-S-F -2.02424 -2.63852 0.27718 -1.22192 -2.7221 1.509109 -3.62289 
32 P-V-N-K-P-G-Q-L-Q-S-F-L-L-S-G 12.88187 -1.32515 1.260762 4.093779 -1.26598 2.194086 -1.97283 
33 P-G-Q-L-Q-S-F-L-L-S-G-T-Q-N-Q 8.842039 -4.89652 -0.33243 0.240076 -4.9309 -2.88297 -4.71059 
34 Q-S-F-L-L-S-G-T-Q-N-Q-P-S-L-L 18.40619 0.262881 2.34371 5.120569 -2.00076 1.648636 -2.11005 
35 L-S-G-T-Q-N-Q-P-S-L-L-S-G-F-S 11.14791 -3.78764 -2.7025 0.922758 -4.57934 -3.16056 -4.70801 
36 Q-N-Q-P-S-L-L-S-G-F-S-K-N-I-L 7.946933 -2.35556 1.473322 -2.18899 -2.74653 -0.74923 -2.13444 
37 S-L-L-S-G-F-S-K-N-I-L-E-A-A-F 15.78799 -1.14448 0.606908 3.826505 -1.68147 0.568944 -1.91552 
38 G-F-S-K-N-I-L-E-A-A-F-N-T-N-Y 15.29004 -2.46356 0.505527 2.702483 -3.31008 0.577059 -3.3423 
39 N-I-L-E-A-A-F-N-T-N-Y-E-E-I-E 8.252952 -2.53346 -1.37604 0.89492 -2.48333 -0.95087 -3.75072 
40 A-A-F-N-T-N-Y-E-E-I-E-K-V-L-L 16.64576 -2.11701 -1.58657 4.250589 -3.15764 -0.50757 -4.44183 
41 T-N-Y-E-E-I-E-K-V-L-L-E-Q-Q-E 10.6009 -1.74394 -2.48714 2.08073 -3.3836 -0.6547 -3.50978 
42 E-I-E-K-V-L-L-E-Q-Q-E-Q-E-P-Q 13.17028 -2.17601 -0.27544 5.060719 -2.55652 0.368662 -1.82639 
43 V-L-L-E-Q-Q-E-Q-E-P-Q-H-R-R-S 17.31133 -1.90373 2.067706 7.633024 -1.90579 0.881792 0.163845 
44 Q-Q-E-Q-E-P-Q-H-R-R-S-L-K-D-R 12.5985 -2.17513 0.079773 7.106346 -2.3981 2.794986 1.672636 
45 E-P-Q-H-R-R-S-L-K-D-R-R-Q-E-I 2.73805 -9.62477 -12.6639 -9.06075 -18.1558 -9.32395 -9.76644 
46 R-R-S-L-K-D-R-R-Q-E-I-N-E-E-N 15.2471 -2.90992 0.521375 4.098121 -2.58212 0.511729 -1.8243 
47 K-D-R-R-Q-E-I-N-E-E-N-V-I-V-K 12.93871 -4.7385 -0.59554 1.533438 -4.94487 -3.35532 -5.2501 
48 Q-E-I-N-E-E-N-V-I-V-K-V-S-R-E 20.09891 -1.64398 4.269022 4.56753 -2.73756 0.02588 -2.89223 
49 E-E-N-V-I-V-K-V-S-R-E-Q-I-E-E 1.694651 -0.72585 1.06947 3.68999 -3.0576 -1.71992 -2.80153 
50 I-V-K-V-S-R-E-Q-I-E-E-L-S-K-N 7.013111 -1.49431 2.63883 7.854344 -3.17143 -1.87566 -2.66663 
51 S-R-E-Q-I-E-E-L-S-K-N-A-K-S-S 9.638157 -1.57953 2.617368 8.954074 -3.74712 -0.85498 -2.21744 
52 I-E-E-L-S-K-N-A-K-S-S-S-K-K-S -10.8657 -10.7079 -14.967 -4.81964 -18.7811 -12.3053 -13.1299 
53 S-K-N-A-K-S-S-S-K-K-S-V-S-S-E 9.058007 -3.4792 -0.98639 11.97582 -5.59819 -1.77073 -3.54114 
54 K-S-S-S-K-K-S-V-S-S-E-S-G-P-F 6.699502 -1.5265 1.944281 9.563492 -2.42419 -0.42862 -2.71156 
55 K-K-S-V-S-S-E-S-G-P-F-N-L-R-S 12.10288 -0.14942 3.881052 7.71819 -1.10517 1.551206 -1.79729 
56 S-S-E-S-G-P-F-N-L-R-S-R-N-P-I 17.98396 -2.91603 -0.79933 0.424173 -4.70548 -0.49276 -4.82885 
57 G-P-F-N-L-R-S-R-N-P-I-Y-S-N-K -9.28238 -11.5012 -35.305 -28.1298 -42.665 -35.7518 -36.6245 
58 L-R-S-R-N-P-I-Y-S-N-K-F-G-K-F -16.65 -20.08 -40.3601 -29.8161 -48.1048 -40.1486 -40.8516 
59 N-P-I-Y-S-N-K-F-G-K-F-F-E-I-T 27.1435 -2.96516 -3.57233 4.332919 -4.49684 -2.07623 -4.69066 
60 S-N-K-F-G-K-F-F-E-I-T-P-E-K-N 24.63675 -0.77676 -1.03938 4.498331 -1.86813 0.169367 -1.92672 
61 G-K-F-F-E-I-T-P-E-K-N-Q-Q-L-Q 20.15338 -0.92707 0.591618 2.891999 -1.87374 -0.3005 -2.21619 
62 E-I-T-P-E-K-N-Q-Q-L-Q-D-L-D-I 28.44564 -1.62879 2.781417 6.869579 -2.53588 1.749469 -2.79209 
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63 E-K-N-Q-Q-L-Q-D-L-D-I-F-V-N-S 29.28988 -0.98768 1.333496 8.843022 -2.33452 1.787476 -2.82543 
64 Q-L-Q-D-L-D-I-F-V-N-S-V-D-I-K 32.0517 -0.49256 2.7884 15.84811 -2.33056 1.877137 -2.79892 
65 L-D-I-F-V-N-S-V-D-I-K-E-G-S-L 24.69747 0.02791 0.811937 7.150099 -1.34354 2.092048 -1.56679 
66 V-N-S-V-D-I-K-E-G-S-L-L-L-P-N 29.8012 -1.26868 2.467722 12.34733 -2.87538 2.375586 -2.21317 
67 D-I-K-E-G-S-L-L-L-P-N-Y-N-S-R 31.18535 -3.08199 0.448639 6.670182 -4.17719 0.493556 -1.61979 
68 G-S-L-L-L-P-N-Y-N-S-R-A-I-V-I 25.27933 -2.71278 -3.16121 7.848274 -6.43439 -1.48581 -3.59476 
69 L-P-N-Y-N-S-R-A-I-V-I-V-T-V-T 21.12295 -2.43589 -0.89521 6.134128 -7.21908 -0.06419 -3.74802 
70 N-S-R-A-I-V-I-V-T-V-T-E-G-K-G 20.72911 -6.12752 -0.45205 3.547835 -9.30162 -3.94506 -7.1857 
71 I-V-I-V-T-V-T-E-G-K-G-D-F-E-L 37.83927 -0.53358 6.512703 16.23704 -2.28169 2.185225 -1.95453 
72 T-V-T-E-G-K-G-D-F-E-L-V-G-Q-R 29.70321 -0.90949 6.682954 16.53343 -3.02598 0.744416 -2.81495 
73 G-K-G-D-F-E-L-V-G-Q-R-N-E-N-Q 10.6583 -1.89841 2.553099 4.978139 -4.99448 -2.99661 -4.55669 
74 F-E-L-V-G-Q-R-N-E-N-Q-G-K-E-N 12.95894 -0.55264 5.292882 8.747864 -1.84911 -0.30131 -1.06078 
75 G-Q-R-N-E-N-Q-G-K-E-N-D-K-E-E 8.396359 -1.33827 3.525614 5.505535 -3.25194 -2.01695 -2.24295 
76 E-N-Q-G-K-E-N-D-K-E-E-E-Q-E-E 7.312862 -1.04291 0.495388 4.720078 -2.11764 -1.35775 -2.37024 
77 K-E-N-D-K-E-E-E-Q-E-E-E-T-S-K 20.805 1.357316 2.984326 14.53277 -1.71907 0.227568 -1.72269 
78 K-E-E-E-Q-E-E-E-T-S-K-Q-V-Q-L 18.32081 0.605867 1.542492 7.730916 -1.54122 0.586685 -1.50817 
79 Q-E-E-E-T-S-K-Q-V-Q-L-Y-R-A-K 17.98378 -0.89925 2.023704 5.99386 -2.63621 0.279925 -1.46997 
80 T-S-K-Q-V-Q-L-Y-R-A-K-L-S-P-G 34.2292 -5.28146 -3.25664 -2.66791 -8.81643 -2.89614 -6.68902 
81 V-Q-L-Y-R-A-K-L-S-P-G-D-V-F-V 35.77427 -5.17561 1.003032 0.577256 -8.31492 -4.88142 -7.93632 
82 R-A-K-L-S-P-G-D-V-F-V-I-P-A-G 42.36209 -0.59944 3.197434 12.19635 -2.4858 0.839336 -3.4817 
83 S-P-G-D-V-F-V-I-P-A-G-H-P-V-A 44.62468 0.802652 3.401417 32.10015 -0.21237 1.450046 -1.25612 
84 V-F-V-I-P-A-G-H-P-V-A-I-N-A-S 38.6 0.054293 6.646819 18.18606 -2.00559 3.041365 -1.84458 
85 P-A-G-H-P-V-A-I-N-A-S-S-D-L-N 22.94567 1.503215 3.683072 8.510971 -3.58964 1.717051 -3.20502 
86 P-V-A-I-N-A-S-S-D-L-N-L-I-G-F 34.42912 2.346335 4.638937 10.59915 -4.10466 5.438116 -3.10712 
87 N-A-S-S-D-L-N-L-I-G-F-G-I-N-A 36.27955 1.081879 -1.46738 18.36248 -5.15992 4.75053 -4.31898 
88 D-L-N-L-I-G-F-G-I-N-A-E-N-N-E 41.70165 -0.98203 2.765379 26.95381 -2.48445 1.792561 -2.23743 
89 I-G-F-G-I-N-A-E-N-N-E-R-N-F-L 32.7789 -1.20562 1.791902 9.935915 -2.94537 3.63183 -2.80602 
90 I-N-A-E-N-N-E-R-N-F-L-A-G-E-E 26.43588 -11.4802 -5.37013 3.339923 -13.5591 -5.46546 -13.2407 
91 N-N-E-R-N-F-L-A-G-E-E-D-N-V-I 41.71823 -2.64899 5.524388 29.45299 -3.04758 2.708808 -2.81142 
92 N-F-L-A-G-E-E-D-N-V-I-S-Q-V-E 40.26949 -1.21274 0.408713 30.32234 -2.62698 0.240538 -2.22343 
93 G-E-E-D-N-V-I-S-Q-V-E-R-P-V-K 25.52586 -2.37157 2.158329 11.21335 -3.60109 1.041618 -2.84263 
94 N-V-I-S-Q-V-E-R-P-V-K-E-L-A-F 34.66043 0.274454 6.174538 11.31815 -2.74769 2.158549 -2.77759 
95 Q-V-E-R-P-V-K-E-L-A-F-P-G-S-S 39.62622 33.04637 5.577837 27.17795 -5.19328 5.552355 9.540851 
96 P-V-K-E-L-A-F-P-G-S-S-H-E-V-D 41.86569 23.22202 8.202726 29.73849 -3.3988 7.757944 9.21691 
97 L-A-F-P-G-S-S-H-E-V-D-R-L-L-K 36.28509 -0.73579 7.223069 9.98607 -3.30081 -1.78469 -2.29882 
98 G-S-S-H-E-V-D-R-L-L-K-N-Q-K-Q 31.0689 -2.42739 3.136829 -0.347 -4.16397 -1.69396 -1.14624 
99 E-V-D-R-L-L-K-N-Q-K-Q-S-Y-F-A 22.86062 -1.81624 3.346059 1.752694 -6.87008 -6.0694 -4.10947 
100 L-L-K-N-Q-K-Q-S-Y-F-A-N-A-Q-P 31.87528 2.058952 5.604967 28.93225 -3.26374 -1.92711 -2.18347 
101 Q-K-Q-S-Y-F-A-N-A-Q-P-L-Q-R-E 40.19413 18.53059 7.956363 28.23146 -2.83293 1.982335 -1.45702 
 m (blanks) 11374.69 10344.18 19821.69 10941.98 15028.41 16420.91 17118.34 
 s (blanks) 1145.706 633.1946 3696.333 1513.151 2871.091 3507.765 2684.082 
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Table A44: Calculated Z-scores of Pis s 1 peptides after control subtraction. 
The calculated Z-scores of every peptide of Pis s 1 for each pea-tolerant patient (patients 15-19) are listed. Identified 
candidate diagnostic peptides are highlighted in light blue. 
 Patient No. → 15 16 17 18 19 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score 
1 S-R-S-D-Q-E-N-P-F-I-F-K-S-N-R -13.4603 -10.422 -7.52854 -8.78572 -12.6583 
2 Q-E-N-P-F-I-F-K-S-N-R-F-Q-T-L -16.9484 -8.90916 -1.64303 -7.68206 -15.4212 
3 F-I-F-K-S-N-R-F-Q-T-L-Y-E-N-E -4.20707 1.259707 -0.52012 -1.51547 -3.2172 
4 S-N-R-F-Q-T-L-Y-E-N-E-N-G-H-I -2.19337 0.085916 0.140929 -1.96043 -1.71911 
5 Q-T-L-Y-E-N-E-N-G-H-I-R-L-L-Q -2.0429 -1.08791 -0.2209 -2.47398 -1.68366 
6 E-N-E-N-G-H-I-R-L-L-Q-K-F-D-K -9.03846 -6.12228 0.165448 -5.56419 -7.96272 
7 G-H-I-R-L-L-Q-K-F-D-K-R-S-K-I -34.0497 -13.7884 1.634479 -17.6893 -27.9433 
8 L-L-Q-K-F-D-K-R-S-K-I-F-E-N-L -8.16534 -1.98529 -2.46481 -5.54022 -6.46899 
9 F-D-K-R-S-K-I-F-E-N-L-Q-N-Y-R -17.7182 -8.83819 -5.28659 -11.1148 -16.9958 
10 S-K-I-F-E-N-L-Q-N-Y-R-L-L-E-Y -2.97589 -1.83706 -1.12713 -3.19246 -3.24367 
11 E-N-L-Q-N-Y-R-L-L-E-Y-K-S-K-P -6.62683 -3.72966 -0.39366 -3.07698 -4.52322 
12 N-Y-R-L-L-E-Y-K-S-K-P-H-T-L-F -10.8086 -3.08973 -0.37147 -0.76911 -8.49749 
13 L-E-Y-K-S-K-P-H-T-L-F-L-P-Q-Y -10.1416 2.571167 0.237506 -1.92509 -9.67602 
14 S-K-P-H-T-L-F-L-P-Q-Y-T-D-A-D -3.57086 -0.66793 0.593583 -2.0426 -2.87127 
15 T-L-F-L-P-Q-Y-T-D-A-D-F-I-L-V -4.48562 0.050592 -2.26893 -3.20423 -4.78392 
16 P-Q-Y-T-D-A-D-F-I-L-V-V-L-S-G -5.06597 -0.47533 1.631879 -4.30273 -5.82983 
17 D-A-D-F-I-L-V-V-L-S-G-K-A-T-L -18.219 -12.4306 -10.6441 -14.7891 -17.5906 
18 I-L-V-V-L-S-G-K-A-T-L-T-V-L-K -13.7903 -4.1188 -4.10497 -6.41761 -12.3622 
19 L-S-G-K-A-T-L-T-V-L-K-S-N-D-R -7.71387 -3.57051 -1.72013 -1.47568 -4.98055 
20 A-T-L-T-V-L-K-S-N-D-R-N-S-F-N -5.39905 -0.56084 -2.27481 -0.85004 -0.88524 
21 V-L-K-S-N-D-R-N-S-F-N-L-E-R-G -4.13897 -0.48813 -1.56806 -2.04585 -1.42867 
22 N-D-R-N-S-F-N-L-E-R-G-D-A-I-K -6.43281 -1.80049 -4.07451 -5.24309 -4.49879 
23 S-F-N-L-E-R-G-D-A-I-K-L-P-A-G -5.64984 -1.76849 -2.18166 -4.475 -3.55776 
24 E-R-G-D-A-I-K-L-P-A-G-T-I-A-Y -4.66715 -0.80011 -0.89253 -3.17447 -2.29159 
25 A-I-K-L-P-A-G-T-I-A-Y-L-A-N-R -10.2625 -5.81982 -6.3322 -7.1863 -9.84547 
26 P-A-G-T-I-A-Y-L-A-N-R-D-D-N-E -5.35885 -1.26187 -2.34948 -3.55645 -5.58816 
27 I-A-Y-L-A-N-R-D-D-N-E-D-L-R-V -7.97583 -1.99836 -2.72029 -5.15946 -8.62149 
28 A-N-R-D-D-N-E-D-L-R-V-L-D-L-A -2.21238 0.472777 -0.44397 -1.7264 -2.95764 
29 D-N-E-D-L-R-V-L-D-L-A-I-P-V-N -3.01174 1.935923 0.513233 -2.61532 -3.04264 
30 L-R-V-L-D-L-A-I-P-V-N-K-P-G-Q -1.57763 3.600266 0.125761 -0.8336 -1.53395 
31 D-L-A-I-P-V-N-K-P-G-Q-L-Q-S-F -5.05828 -1.58129 -2.97782 -5.45859 -4.36359 
32 P-V-N-K-P-G-Q-L-Q-S-F-L-L-S-G -3.33606 1.974875 -0.04909 -2.78614 -2.70182 
33 P-G-Q-L-Q-S-F-L-L-S-G-T-Q-N-Q -6.36312 0.878546 -3.95481 -5.80052 -5.88136 
34 Q-S-F-L-L-S-G-T-Q-N-Q-P-S-L-L -2.84126 3.166369 -1.11093 -1.4832 -2.62268 
35 L-S-G-T-Q-N-Q-P-S-L-L-S-G-F-S -4.91525 -2.32246 -3.66383 -5.34223 -5.11906 
36 Q-N-Q-P-S-L-L-S-G-F-S-K-N-I-L -3.07291 6.333727 -1.32427 -2.35792 -3.2983 
37 S-L-L-S-G-F-S-K-N-I-L-E-A-A-F -1.83071 5.118468 -1.1236 -1.96441 -2.19508 
38 G-F-S-K-N-I-L-E-A-A-F-N-T-N-Y -3.34711 -0.27968 -1.87905 -2.4637 -3.45209 
39 N-I-L-E-A-A-F-N-T-N-Y-E-E-I-E -2.91487 -2.66201 -2.64225 -2.88285 -2.60401 
40 A-A-F-N-T-N-Y-E-E-I-E-K-V-L-L -3.1865 -2.04753 -3.19696 -2.64777 -2.81491 
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41 T-N-Y-E-E-I-E-K-V-L-L-E-Q-Q-E -3.36837 -3.10694 -3.52619 -2.58193 -2.60948 
42 E-I-E-K-V-L-L-E-Q-Q-E-Q-E-P-Q -3.30013 -1.69357 -2.303 -2.52566 -2.14668 
43 V-L-L-E-Q-Q-E-Q-E-P-Q-H-R-R-S -3.15423 -2.36111 -1.46756 -1.62396 -1.08916 
44 Q-Q-E-Q-E-P-Q-H-R-R-S-L-K-D-R -3.38302 -0.83284 -1.52812 -1.78652 -1.75911 
45 E-P-Q-H-R-R-S-L-K-D-R-R-Q-E-I -15.4728 -5.12003 -7.37737 -6.03377 -9.77115 
46 R-R-S-L-K-D-R-R-Q-E-I-N-E-E-N -3.46304 0.856794 -1.73739 -2.2206 -2.51251 
47 K-D-R-R-Q-E-I-N-E-E-N-V-I-V-K -6.46214 -3.06195 -4.1582 -4.58095 -4.67381 
48 Q-E-I-N-E-E-N-V-I-V-K-V-S-R-E -4.35652 3.650018 -0.28099 -1.5872 -2.33384 
49 E-E-N-V-I-V-K-V-S-R-E-Q-I-E-E -3.74768 1.076509 -2.17483 -2.48467 -4.08036 
50 I-V-K-V-S-R-E-Q-I-E-E-L-S-K-N -3.83605 0.397113 -2.71479 -3.30659 -3.1948 
51 S-R-E-Q-I-E-E-L-S-K-N-A-K-S-S -4.02411 -0.6716 -2.56331 -3.85023 -4.39627 
52 I-E-E-L-S-K-N-A-K-S-S-S-K-K-S -17.3006 -9.29332 -0.54867 -13.1742 -15.2045 
53 S-K-N-A-K-S-S-S-K-K-S-V-S-S-E -6.13419 -0.45986 -2.15514 -5.85461 -6.0273 
54 K-S-S-S-K-K-S-V-S-S-E-S-G-P-F -3.79553 0.704617 -1.97862 -3.77091 -2.65291 
55 K-K-S-V-S-S-E-S-G-P-F-N-L-R-S -2.42465 3.158841 -1.36425 -1.93768 -1.74967 
56 S-S-E-S-G-P-F-N-L-R-S-R-N-P-I -5.95837 -2.84435 -4.0608 -4.3827 -4.66199 
57 G-P-F-N-L-R-S-R-N-P-I-Y-S-N-K -38.3891 -19.8819 -0.01358 -12.6886 -21.9217 
58 L-R-S-R-N-P-I-Y-S-N-K-F-G-K-F -42.4633 -11.6145 -7.83901 -23.2642 -30.9289 
59 N-P-I-Y-S-N-K-F-G-K-F-F-E-I-T -3.6033 0.747322 -1.97963 -2.36429 -3.64132 
60 S-N-K-F-G-K-F-F-E-I-T-P-E-K-N -1.33034 0.434152 -0.68787 -1.70076 -1.90578 
61 G-K-F-F-E-I-T-P-E-K-N-Q-Q-L-Q -1.37353 -0.48238 -1.49369 -1.69566 -1.88514 
62 E-I-T-P-E-K-N-Q-Q-L-Q-D-L-D-I -1.85371 0.567526 -2.56902 -2.72708 -2.67114 
63 E-K-N-Q-Q-L-Q-D-L-D-I-F-V-N-S -1.34824 -0.44501 -2.46839 -1.66056 -1.59287 
64 Q-L-Q-D-L-D-I-F-V-N-S-V-D-I-K -1.20803 0.402305 -0.80799 -1.07828 -0.11545 
65 L-D-I-F-V-N-S-V-D-I-K-E-G-S-L -1.09874 -1.066 -1.46389 -1.39026 -0.81339 
66 V-N-S-V-D-I-K-E-G-S-L-L-L-P-N -3.08318 0.17098 -2.2453 -1.32905 -1.45367 
67 D-I-K-E-G-S-L-L-L-P-N-Y-N-S-R -4.26151 -1.8026 -1.8897 0.00886 -3.23673 
68 G-S-L-L-L-P-N-Y-N-S-R-A-I-V-I -5.37453 -0.49335 -1.69539 -2.12186 -5.20999 
69 L-P-N-Y-N-S-R-A-I-V-I-V-T-V-T -5.58824 10.90429 -0.73141 -0.45558 -4.81024 
70 N-S-R-A-I-V-I-V-T-V-T-E-G-K-G -8.37323 1.487374 -3.16822 -4.20666 -6.51673 
71 I-V-I-V-T-V-T-E-G-K-G-D-F-E-L -3.08293 2.872502 -1.75592 -1.69986 -1.73316 
72 T-V-T-E-G-K-G-D-F-E-L-V-G-Q-R -4.59664 2.592549 -1.96595 -2.74241 -2.96915 
73 G-K-G-D-F-E-L-V-G-Q-R-N-E-N-Q -5.15821 -1.70502 -4.29219 -3.4089 -5.35218 
74 F-E-L-V-G-Q-R-N-E-N-Q-G-K-E-N -2.12256 -0.15217 -1.2786 -1.25687 -2.58318 
75 G-Q-R-N-E-N-Q-G-K-E-N-D-K-E-E -3.72655 -2.52896 -3.24724 -3.39677 -4.12105 
76 E-N-Q-G-K-E-N-D-K-E-E-E-Q-E-E -2.8132 -2.48367 -1.63009 -3.03207 -2.99558 
77 K-E-N-D-K-E-E-E-Q-E-E-E-T-S-K -1.74724 -0.88303 -0.8686 -2.73222 -2.92119 
78 K-E-E-E-Q-E-E-E-T-S-K-Q-V-Q-L -2.26655 0.164954 -1.16767 -2.4701 -2.47922 
79 Q-E-E-E-T-S-K-Q-V-Q-L-Y-R-A-K -2.76508 1.664128 -1.39374 -0.85452 -3.39084 
80 T-S-K-Q-V-Q-L-Y-R-A-K-L-S-P-G -7.65786 1.434236 6.686576 9.847755 -7.44623 
81 V-Q-L-Y-R-A-K-L-S-P-G-D-V-F-V -6.56392 8.931629 0.69736 1.456627 -4.44008 
82 R-A-K-L-S-P-G-D-V-F-V-I-P-A-G -1.55695 49.89676 -1.41812 -1.33788 8.920229 
83 S-P-G-D-V-F-V-I-P-A-G-H-P-V-A 0.260205 15.19058 -0.16898 -1.00629 -0.08154 
84 V-F-V-I-P-A-G-H-P-V-A-I-N-A-S -0.34396 11.61097 -1.49301 -1.48172 -0.70142 
85 P-A-G-H-P-V-A-I-N-A-S-S-D-L-N -1.60097 5.151142 -2.40592 -2.5114 -1.71168 
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86 P-V-A-I-N-A-S-S-D-L-N-L-I-G-F -1.2487 29.55598 -2.00901 -2.31034 -2.36744 
87 N-A-S-S-D-L-N-L-I-G-F-G-I-N-A -2.8855 5.178131 -3.62042 -1.66584 0.74321 
88 D-L-N-L-I-G-F-G-I-N-A-E-N-N-E -0.95704 11.27963 -2.00867 -1.54164 11.95395 
89 I-G-F-G-I-N-A-E-N-N-E-R-N-F-L -1.95184 8.479497 -2.54269 -2.03195 -1.28217 
90 I-N-A-E-N-N-E-R-N-F-L-A-G-E-E -11.4088 -3.44133 -13.3101 -13.5696 -12.8608 
91 N-N-E-R-N-F-L-A-G-E-E-D-N-V-I -1.40201 32.40804 -3.27134 -3.43653 -2.3998 
92 N-F-L-A-G-E-E-D-N-V-I-S-Q-V-E -2.01481 5.250574 -2.1614 -2.02444 -1.41137 
93 G-E-E-D-N-V-I-S-Q-V-E-R-P-V-K -2.17424 1.992644 -1.65407 -2.02686 -1.77432 
94 N-V-I-S-Q-V-E-R-P-V-K-E-L-A-F -2.85441 2.784612 -2.09036 -2.08895 -0.28559 
95 Q-V-E-R-P-V-K-E-L-A-F-P-G-S-S -6.15842 28.97455 -5.02417 -4.01177 -3.46389 
96 P-V-K-E-L-A-F-P-G-S-S-H-E-V-D -4.39766 37.95628 -2.58731 -2.60492 -1.87354 
97 L-A-F-P-G-S-S-H-E-V-D-R-L-L-K -3.22764 0.250596 -2.35524 -0.90021 -3.54301 
98 G-S-S-H-E-V-D-R-L-L-K-N-Q-K-Q -4.03293 -2.79565 -3.46959 -2.64969 -4.51543 
99 E-V-D-R-L-L-K-N-Q-K-Q-S-Y-F-A -6.82711 -5.52933 -3.11373 -3.62955 -6.78223 
100 L-L-K-N-Q-K-Q-S-Y-F-A-N-A-Q-P -3.17756 -0.98784 -2.02133 -2.08102 -3.63068 
101 Q-K-Q-S-Y-F-A-N-A-Q-P-L-Q-R-E -1.89472 8.403089 -0.82905 -1.02467 -3.24907 
 m (blanks) 17725.34 10699.67 10097.17 10987.35 10346.84 
 s (blanks) 2939.751 954.8014 570.9965 1183.068 1124.607 
 
Table A45: Calculated Z-scores of Pis s 1 peptides of atopic controls. 
The calculated Z-scores of every peptide of Pis s 1 for each atopic control serum (A-E) are listed.  
 Control No. → Serum A Serum B Serum C Serum D Serum E 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score 
1 S-R-S-D-Q-E-N-P-F-I-F-K-S-N-R 1.966491 2.267412 2.080794 1.632326 4.039627 
2 Q-E-N-P-F-I-F-K-S-N-R-F-Q-T-L 7.428312 6.18019 5.673549 4.106311 17.77417 
3 F-I-F-K-S-N-R-F-Q-T-L-Y-E-N-E 1.241756 1.721836 1.584658 1.55256 3.990945 
4 S-N-R-F-Q-T-L-Y-E-N-E-N-G-H-I 0.52381 0.470853 0.784075 0.444564 2.026911 
5 Q-T-L-Y-E-N-E-N-G-H-I-R-L-L-Q 0.688445 0.29415 0.579701 0.31993 2.227726 
6 E-N-E-N-G-H-I-R-L-L-Q-K-F-D-K 1.635523 3.045937 3.1675 2.137093 6.317055 
7 G-H-I-R-L-L-Q-K-F-D-K-R-S-K-I 11.14534 10.03297 14.59413 14.19419 26.27383 
8 L-L-Q-K-F-D-K-R-S-K-I-F-E-N-L 1.391116 2.018997 2.200599 2.552125 4.521888 
9 F-D-K-R-S-K-I-F-E-N-L-Q-N-Y-R 8.831956 4.665793 4.646041 4.632266 9.635071 
10 S-K-I-F-E-N-L-Q-N-Y-R-L-L-E-Y 0.209814 -0.07144 0.841864 0.379754 0.453858 
11 E-N-L-Q-N-Y-R-L-L-E-Y-K-S-K-P 1.396207 1.18329 0.581111 2.604471 0.969588 
12 N-Y-R-L-L-E-Y-K-S-K-P-H-T-L-F 2.674253 2.213042 0.992678 2.815102 5.389045 
13 L-E-Y-K-S-K-P-H-T-L-F-L-P-Q-Y 7.243309 3.307008 1.397198 6.149062 3.513248 
14 S-K-P-H-T-L-F-L-P-Q-Y-T-D-A-D 0.724088 0.844414 0.101889 0.213991 2.218598 
15 T-L-F-L-P-Q-Y-T-D-A-D-F-I-L-V 1.937637 1.412488 0.396469 0.877044 2.676518 
16 P-Q-Y-T-D-A-D-F-I-L-V-V-L-S-G 3.203802 2.419274 1.308401 1.628587 4.658808 
17 D-A-D-F-I-L-V-V-L-S-G-K-A-T-L 9.327559 3.699785 2.998363 4.378013 6.266851 
18 I-L-V-V-L-S-G-K-A-T-L-T-V-L-K 4.709282 3.599013 3.721424 4.451547 4.855059 
19 L-S-G-K-A-T-L-T-V-L-K-S-N-D-R 2.143007 3.165458 1.677684 1.647282 3.108575 
20 A-T-L-T-V-L-K-S-N-D-R-N-S-F-N 1.428456 2.573948 1.354913 1.440389 2.331176 
21 V-L-K-S-N-D-R-N-S-F-N-L-E-R-G 1.372446 2.063056 0.605072 0.685107 2.481788 
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22 N-D-R-N-S-F-N-L-E-R-G-D-A-I-K 1.382629 1.969314 1.653722 0.651456 1.562906 
23 S-F-N-L-E-R-G-D-A-I-K-L-P-A-G 0.483075 0.797543 0.358414 0.140457 0.78855 
24 E-R-G-D-A-I-K-L-P-A-G-T-I-A-Y -0.16528 -0.11831 0.358414 0.200281 0.237829 
25 A-I-K-L-P-A-G-T-I-A-Y-L-A-N-R 1.139919 2.285692 1.36337 2.05982 4.605561 
26 P-A-G-T-I-A-Y-L-A-N-R-D-D-N-E 2.585995 2.073367 1.340819 1.637311 3.499556 
27 I-A-Y-L-A-N-R-D-D-N-E-D-L-R-V 4.55483 3.089058 2.09066 2.931012 4.289125 
28 A-N-R-D-D-N-E-D-L-R-V-L-D-L-A 1.105974 0.673804 1.073018 1.066487 2.664347 
29 D-N-E-D-L-R-V-L-D-L-A-I-P-V-N 0.724088 1.319684 1.614257 0.944346 2.411807 
30 L-R-V-L-D-L-A-I-P-V-N-K-P-G-Q 0.50514 0.948936 1.625533 1.451606 2.273366 
31 D-L-A-I-P-V-N-K-P-G-Q-L-Q-S-F 0.937944 0.46851 3.250659 0.645224 1.185617 
32 P-V-N-K-P-G-Q-L-Q-S-F-L-L-S-G 0.578122 -0.11784 1.228061 1.379319 2.153181 
33 P-G-Q-L-Q-S-F-L-L-S-G-T-Q-N-Q 0.605279 0.191972 1.332362 1.462823 1.903683 
34 Q-S-F-L-L-S-G-T-Q-N-Q-P-S-L-L 0.391422 0.325085 1.347866 1.582472 1.806318 
35 L-S-G-T-Q-N-Q-P-S-L-L-S-G-F-S 0.124951 -0.0991 0.705145 0.802263 1.337749 
36 Q-N-Q-P-S-L-L-S-G-F-S-K-N-I-L 0.111373 0.363519 0.519094 0.76238 1.065432 
37 S-L-L-S-G-F-S-K-N-I-L-E-A-A-F 0.252246 -0.02785 0.310491 0.362305 0.637939 
38 G-F-S-K-N-I-L-E-A-A-F-N-T-N-Y 0.4678 0.089793 0.09766 0.218976 0.936119 
39 N-I-L-E-A-A-F-N-T-N-Y-E-E-I-E 0.454222 0.120259 0.0441 -0.2484 0.205882 
40 A-A-F-N-T-N-Y-E-E-I-E-K-V-L-L 0.678261 0.447886 0.309082 0.086864 1.328621 
41 T-N-Y-E-E-I-E-K-V-L-L-E-Q-Q-E 1.428456 0.655055 0.361233 0.185325 1.26929 
42 E-I-E-K-V-L-L-E-Q-Q-E-Q-E-P-Q 0.260733 0.476946 0.39506 0.007098 1.363612 
43 V-L-L-E-Q-Q-E-Q-E-P-Q-H-R-R-S 0.610371 0.657868 0.330224 0.186571 0.567958 
44 Q-Q-E-Q-E-P-Q-H-R-R-S-L-K-D-R 2.871137 2.09399 1.061742 1.995011 1.864129 
45 E-P-Q-H-R-R-S-L-K-D-R-R-Q-E-I 15.80944 6.366736 9.498868 12.49418 6.342918 
46 R-R-S-L-K-D-R-R-Q-E-I-N-E-E-N 0.937944 1.449985 1.178729 0.18034 1.273854 
47 K-D-R-R-Q-E-I-N-E-E-N-V-I-V-K 0.265824 0.506006 0.213238 0.280047 0.619683 
48 Q-E-I-N-E-E-N-V-I-V-K-V-S-R-E 1.000743 0.537878 0.481038 0.787307 0.698792 
49 E-E-N-V-I-V-K-V-S-R-E-Q-I-E-E 1.027899 1.853074 1.184367 1.224772 3.421968 
50 I-V-K-V-S-R-E-Q-I-E-E-L-S-K-N 0.520415 1.323902 0.82636 1.206077 4.419959 
51 S-R-E-Q-I-E-E-L-S-K-N-A-K-S-S 0.922669 1.373585 1.130807 1.228511 3.035551 
52 I-E-E-L-S-K-N-A-K-S-S-S-K-K-S 9.054298 6.876691 8.297994 11.1095 18.1682 
53 S-K-N-A-K-S-S-S-K-K-S-V-S-S-E 1.160287 1.381085 1.784804 1.768177 4.973723 
54 K-S-S-S-K-K-S-V-S-S-E-S-G-P-F 0.863264 0.207908 1.563516 2.095964 2.738892 
55 K-K-S-V-S-S-E-S-G-P-F-N-L-R-S 0.501745 0.259934 1.285849 1.075212 2.471139 
56 S-S-E-S-G-P-F-N-L-R-S-R-N-P-I 2.285578 0.743173 5.156271 3.212685 6.423548 
57 G-P-F-N-L-R-S-R-N-P-I-Y-S-N-K 18.30952 8.158374 22.91708 38.74958 42.80686 
58 L-R-S-R-N-P-I-Y-S-N-K-F-G-K-F 22.3049 12.63524 29.76855 44.96009 49.68707 
59 N-P-I-Y-S-N-K-F-G-K-F-F-E-I-T 1.146708 1.336558 1.71292 2.537169 4.921998 
60 S-N-K-F-G-K-F-F-E-I-T-P-E-K-N 0.57982 0.891285 0.499361 0.708788 2.058859 
61 G-K-F-F-E-I-T-P-E-K-N-Q-Q-L-Q 0.369358 0.055109 0.2076 0.004606 0.913299 
62 E-I-T-P-E-K-N-Q-Q-L-Q-D-L-D-I 0.72239 -0.01192 0.734744 0.192803 1.412294 
63 E-K-N-Q-Q-L-Q-D-L-D-I-F-V-N-S 1.009229 -0.2158 0.654404 0.065676 1.287546 
64 Q-L-Q-D-L-D-I-F-V-N-S-V-D-I-K 1.229875 0.389298 0.603662 0.549256 1.801754 
65 L-D-I-F-V-N-S-V-D-I-K-E-G-S-L 0.810649 -0.02551 0.221694 0.160398 1.582683 
66 V-N-S-V-D-I-K-E-G-S-L-L-L-P-N 0.732574 0.396328 0.600844 0.427115 2.159266 
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67 D-I-K-E-G-S-L-L-L-P-N-Y-N-S-R 2.331404 1.438267 0.641718 1.035329 3.466087 
68 G-S-L-L-L-P-N-Y-N-S-R-A-I-V-I 3.962483 2.643317 1.33659 2.729105 3.449352 
69 L-P-N-Y-N-S-R-A-I-V-I-V-T-V-T 6.936103 3.66182 3.610076 4.513864 6.913416 
70 N-S-R-A-I-V-I-V-T-V-T-E-G-K-G 5.982236 4.549554 4.416296 3.525516 5.986927 
71 I-V-I-V-T-V-T-E-G-K-G-D-F-E-L 0.751244 0.545846 0.170953 0.273815 0.534488 
72 T-V-T-E-G-K-G-D-F-E-L-V-G-Q-R 0.814043 0.691615 0.209009 0.746178 -1.06138 
73 G-K-G-D-F-E-L-V-G-Q-R-N-E-N-Q 1.145011 1.736366 1.050467 1.384304 2.279451 
74 F-E-L-V-G-Q-R-N-E-N-Q-G-K-E-N 1.402997 1.091892 1.002544 0.956809 2.623271 
75 G-Q-R-N-E-N-Q-G-K-E-N-D-K-E-E 1.090699 0.786763 0.624805 0.777336 1.889991 
76 E-N-Q-G-K-E-N-D-K-E-E-E-Q-E-E 0.50514 0.29415 0.788304 0.402188 1.144541 
77 K-E-N-D-K-E-E-E-Q-E-E-E-T-S-K 0.267522 0.328366 0.974355 0.298742 1.471626 
78 K-E-E-E-Q-E-E-E-T-S-K-Q-V-Q-L 0.342202 -0.13519 0.63608 0.298742 1.576598 
79 Q-E-E-E-T-S-K-Q-V-Q-L-Y-R-A-K 1.627036 0.398203 1.562106 1.619862 3.610613 
80 T-S-K-Q-V-Q-L-Y-R-A-K-L-S-P-G 6.275864 3.460275 5.315542 7.984921 8.964165 
81 V-Q-L-Y-R-A-K-L-S-P-G-D-V-F-V 4.59896 3.780872 3.253478 7.28697 9.254739 
82 R-A-K-L-S-P-G-D-V-F-V-I-P-A-G 0.912485 0.318523 1.126578 0.833422 3.148129 
83 S-P-G-D-V-F-V-I-P-A-G-H-P-V-A 0.186053 -1.07823 0.352776 0.134225 -0.22618 
84 V-F-V-I-P-A-G-H-P-V-A-I-N-A-S 1.995344 -0.34048 1.789032 0.798524 1.389475 
85 P-A-G-H-P-V-A-I-N-A-S-S-D-L-N 1.924059 0.107604 0.435935 0.665166 1.217565 
86 P-V-A-I-N-A-S-S-D-L-N-L-I-G-F 2.221082 0.387892 0.396469 0.569198 2.250546 
87 N-A-S-S-D-L-N-L-I-G-F-G-I-N-A 3.891197 0.373362 0.328815 0.506881 1.839788 
88 D-L-N-L-I-G-F-G-I-N-A-E-N-N-E 1.672863 0.023237 0.059605 0.160398 1.622238 
89 I-G-F-G-I-N-A-E-N-N-E-R-N-F-L 1.233269 0.41742 0.524732 0.80351 2.87429 
90 I-N-A-E-N-N-E-R-N-F-L-A-G-E-E 0.724088 0.56647 0.311901 0.677629 1.062389 
91 N-N-E-R-N-F-L-A-G-E-E-D-N-V-I 0.763125 0.664898 0.661451 0.400942 2.03756 
92 N-F-L-A-G-E-E-D-N-V-I-S-Q-V-E 1.03978 0.622715 1.075837 1.118834 1.768285 
93 G-E-E-D-N-V-I-S-Q-V-E-R-P-V-K 2.005528 1.072206 2.014548 1.221033 2.080157 
94 N-V-I-S-Q-V-E-R-P-V-K-E-L-A-F 2.025895 1.132201 2.368327 1.272133 3.078148 
95 Q-V-E-R-P-V-K-E-L-A-F-P-G-S-S 0.934549 0.612872 2.664317 1.390536 1.564427 
96 P-V-K-E-L-A-F-P-G-S-S-H-E-V-D 0.564544 -0.13519 1.057514 0.686354 -0.51979 
97 L-A-F-P-G-S-S-H-E-V-D-R-L-L-K 1.689835 0.711769 1.1745 0.806002 1.445764 
98 G-S-S-H-E-V-D-R-L-L-K-N-Q-K-Q 1.442034 1.986656 1.867963 0.946839 3.009689 
99 E-V-D-R-L-L-K-N-Q-K-Q-S-Y-F-A 2.830402 2.117426 3.62558 3.086804 6.046259 
100 L-L-K-N-Q-K-Q-S-Y-F-A-N-A-Q-P 1.184048 0.540691 1.151949 1.966345 1.620716 
101 Q-K-Q-S-Y-F-A-N-A-Q-P-L-Q-R-E 2.789668 0.087918 0.69105 0.523083 2.273366 
 m (blanks) 9352.381 12190.42 9346.712 9851.305 10695.67 
 s (blanks) 589.1808 2133.523 709.4833 802.3493 657.3206 
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Table A46: Calculated Z-scores of Pis s 1 peptides of non-atopic controls and derived maximum Z-score of all 
controls (A-J). 
The calculated Z-scores of every peptide of Pis s 1 for each non-atopic control serum (F-J) and the derived maximum 
Z-score of atopic and non-atopic controls are listed.  
 Control No. → Serum F Serum G Serum H Serum I Serum J Max. (A-J) 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score Z-score Z-score 
1 S-R-S-D-Q-E-N-P-F-I-F-K-S-N-R 1.475394 13.13598 0.644663 2.121503 3.121124 13.13598 
2 Q-E-N-P-F-I-F-K-S-N-R-F-Q-T-L 4.501443 15.07625 3.140877 3.693318 14.78129 17.77417 
3 F-I-F-K-S-N-R-F-Q-T-L-Y-E-N-E 0.790414 3.964828 0.68646 1.165285 2.410617 3.990945 
4 S-N-R-F-Q-T-L-Y-E-N-E-N-G-H-I 0.504284 1.225024 -0.0566 0.454314 1.518057 2.026911 
5 Q-T-L-Y-E-N-E-N-G-H-I-R-L-L-Q 0.568446 0.895512 0.287066 0.332929 2.376482 2.376482 
6 E-N-E-N-G-H-I-R-L-L-Q-K-F-D-K 1.504874 10.38948 1.624572 1.233409 7.611736 10.38948 
7 G-H-I-R-L-L-Q-K-F-D-K-R-S-K-I 10.3888 37.02395 18.14603 13.26169 25.91806 37.02395 
8 L-L-Q-K-F-D-K-R-S-K-I-F-E-N-L 1.660945 8.12304 1.640827 1.227216 6.266575 8.12304 
9 F-D-K-R-S-K-I-F-E-N-L-Q-N-Y-R 3.04998 18.24258 3.702816 3.485229 12.10614 18.24258 
10 S-K-I-F-E-N-L-Q-N-Y-R-L-L-E-Y 0.190407 2.865896 0.472831 0.183056 1.549663 2.865896 
11 E-N-L-Q-N-Y-R-L-L-E-Y-K-S-K-P 0.356883 7.029126 2.648601 2.091776 3.318347 7.029126 
12 N-Y-R-L-L-E-Y-K-S-K-P-H-T-L-F 1.811814 10.77754 3.377728 1.198728 7.387964 10.77754 
13 L-E-Y-K-S-K-P-H-T-L-F-L-P-Q-Y 2.002568 11.36297 4.919575 6.164374 8.642099 11.36297 
14 S-K-P-H-T-L-F-L-P-Q-Y-T-D-A-D 0.407173 3.369364 0.881513 0.528632 2.824026 3.369364 
15 T-L-F-L-P-Q-Y-T-D-A-D-F-I-L-V 1.272501 5.324694 2.985299 0.706994 3.544648 5.324694 
16 P-Q-Y-T-D-A-D-F-I-L-V-V-L-S-G 2.092742 6.938803 4.601453 3.945997 6.552295 6.938803 
17 D-A-D-F-I-L-V-V-L-S-G-K-A-T-L 2.685813 20.62109 4.866168 5.350598 10.16678 20.62109 
18 I-L-V-V-L-S-G-K-A-T-L-T-V-L-K 2.382341 14.76849 4.761675 3.368798 9.276751 14.76849 
19 L-S-G-K-A-T-L-T-V-L-K-S-N-D-R 1.520481 7.46067 2.527854 1.053809 3.281684 7.46067 
20 A-T-L-T-V-L-K-S-N-D-R-N-S-F-N 1.912393 3.180354 4.130075 0.321782 4.645808 4.645808 
21 V-L-K-S-N-D-R-N-S-F-N-L-E-R-G 2.174246 2.544747 3.424169 0.576938 2.282928 3.424169 
22 N-D-R-N-S-F-N-L-E-R-G-D-A-I-K 2.219334 6.107495 3.7748 0.454314 4.338596 6.107495 
23 S-F-N-L-E-R-G-D-A-I-K-L-P-A-G 2.399683 1.37389 4.766319 0.786266 2.133746 4.766319 
24 E-R-G-D-A-I-K-L-P-A-G-T-I-A-Y 2.332052 0.726574 3.027097 0.064148 2.065477 3.027097 
25 A-I-K-L-P-A-G-T-I-A-Y-L-A-N-R 0.733188 10.38446 0.284744 1.91713 3.719114 10.38446 
26 P-A-G-T-I-A-Y-L-A-N-R-D-D-N-E 0.781744 5.585627 -0.26791 1.334977 4.398016 5.585627 
27 I-A-Y-L-A-N-R-D-D-N-E-D-L-R-V 1.726842 8.872388 1.269297 3.578126 5.418264 8.872388 
28 A-N-R-D-D-N-E-D-L-R-V-L-D-L-A 0.911803 1.526102 -0.00551 0.838288 2.363839 2.664347 
29 D-N-E-D-L-R-V-L-D-L-A-I-P-V-N 0.663823 0.999216 0.136132 0.71938 3.486492 3.486492 
30 L-R-V-L-D-L-A-I-P-V-N-K-P-G-Q 0.653418 1.962664 0.303321 0.923753 2.576233 2.576233 
31 D-L-A-I-P-V-N-K-P-G-Q-L-Q-S-F 0.434919 2.670195 1.285552 0.750346 5.166679 5.166679 
32 P-V-N-K-P-G-Q-L-Q-S-F-L-L-S-G 0.721049 2.347374 0.391559 0.576938 3.167902 3.167902 
33 P-G-Q-L-Q-S-F-L-L-S-G-T-Q-N-Q 0.533764 6.30654 1.494537 1.135558 3.539591 6.30654 
34 Q-S-F-L-L-S-G-T-Q-N-Q-P-S-L-L 0.701974 2.800662 1.76854 0.580654 1.438409 2.800662 
35 L-S-G-T-Q-N-Q-P-S-L-L-S-G-F-S 0.584053 0.537565 0.58429 0.132272 5.213456 5.213456 
36 Q-N-Q-P-S-L-L-S-G-F-S-K-N-I-L 0.707176 3.366019 0.84436 0.127318 1.396689 3.366019 
37 S-L-L-S-G-F-S-K-N-I-L-E-A-A-F 0.563244 0.763372 1.501503 0.191726 2.188109 2.188109 
38 G-F-S-K-N-I-L-E-A-A-F-N-T-N-Y 0.486942 1.39229 0.909378 0.424587 3.745663 3.745663 
39 N-I-L-E-A-A-F-N-T-N-Y-E-E-I-E 0.556307 0.624542 1.071922 -0.07334 2.901145 2.901145 
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40 A-A-F-N-T-N-Y-E-E-I-E-K-V-L-L 0.851109 1.863977 0.656274 1.036468 3.666016 3.666016 
41 T-N-Y-E-E-I-E-K-V-L-L-E-Q-Q-E 1.152847 3.839379 1.559555 0.526155 2.995964 3.839379 
42 E-I-E-K-V-L-L-E-Q-Q-E-Q-E-P-Q 1.322791 -0.01107 0.588934 -0.29505 3.068026 3.068026 
43 V-L-L-E-Q-Q-E-Q-E-P-Q-H-R-R-S 1.501406 0.201362 1.05799 -0.14023 2.563591 2.563591 
44 Q-Q-E-Q-E-P-Q-H-R-R-S-L-K-D-R 2.233207 3.454669 3.468288 1.244557 2.989643 3.468288 
45 E-P-Q-H-R-R-S-L-K-D-R-R-Q-E-I 13.03334 19.99887 13.39974 18.69182 17.6347 19.99887 
46 R-R-S-L-K-D-R-R-Q-E-I-N-E-E-N 2.430897 1.688349 2.776314 0.545973 3.336047 3.336047 
47 K-D-R-R-Q-E-I-N-E-E-N-V-I-V-K 2.481187 0.835297 3.071216 0.222692 5.403093 5.403093 
48 Q-E-I-N-E-E-N-V-I-V-K-V-S-R-E 2.918186 1.303639 2.799535 0.524916 2.277871 2.918186 
49 E-E-N-V-I-V-K-V-S-R-E-Q-I-E-E 0.603129 4.160528 0.078081 1.711519 3.394202 4.160528 
50 I-V-K-V-S-R-E-Q-I-E-E-L-S-K-N 0.59099 1.830524 -0.12394 1.554213 4.422036 4.422036 
51 S-R-E-Q-I-E-E-L-S-K-N-A-K-S-S 0.825097 1.29193 0.222048 1.271807 4.815218 4.815218 
52 I-E-E-L-S-K-N-A-K-S-S-S-K-K-S 6.324008 20.19122 4.164906 7.109445 15.29331 20.19122 
53 S-K-N-A-K-S-S-S-K-K-S-V-S-S-E 1.090418 3.197081 0.331185 1.585179 6.920192 6.920192 
54 K-S-S-S-K-K-S-V-S-S-E-S-G-P-F 0.544169 0.616179 0.303321 1.076104 3.887259 3.887259 
55 K-K-S-V-S-S-E-S-G-P-F-N-L-R-S 0.714113 -0.0211 0.379949 0.31435 2.518078 2.518078 
56 S-S-E-S-G-P-F-N-L-R-S-R-N-P-I 3.186976 2.466132 1.882321 1.574031 6.442306 6.442306 
57 G-P-F-N-L-R-S-R-N-P-I-Y-S-N-K 14.77093 33.217 44.98904 22.7285 30.68491 44.98904 
58 L-R-S-R-N-P-I-Y-S-N-K-F-G-K-F 14.69983 49.96944 42.55087 33.55222 33.94288 49.96944 
59 N-P-I-Y-S-N-K-F-G-K-F-F-E-I-T 1.463255 4.739266 1.550267 0.884117 5.243798 5.243798 
60 S-N-K-F-G-K-F-F-E-I-T-P-E-K-N 0.521625 -0.3088 0.349762 0.035659 1.346119 2.058859 
61 G-K-F-F-E-I-T-P-E-K-N-Q-Q-L-Q 0.70891 0.221433 0.983684 0.408485 2.027549 2.027549 
62 E-I-T-P-E-K-N-Q-Q-L-Q-D-L-D-I 0.618736 0.586071 0.616799 -0.01512 2.836668 2.836668 
63 E-K-N-Q-Q-L-Q-D-L-D-I-F-V-N-S 0.604863 1.884049 1.740675 0.383713 2.475093 2.475093 
64 Q-L-Q-D-L-D-I-F-V-N-S-V-D-I-K 1.222212 2.725393 1.582775 0.5757 2.013643 2.725393 
65 L-D-I-F-V-N-S-V-D-I-K-E-G-S-L 1.567302 -0.12481 1.013871 -0.19968 1.241187 1.582683 
66 V-N-S-V-D-I-K-E-G-S-L-L-L-P-N 2.541881 0.226451 1.132296 -0.01265 3.267777 3.267777 
67 D-I-K-E-G-S-L-L-L-P-N-Y-N-S-R 2.441302 2.885967 2.147036 0.702039 4.686264 4.686264 
68 G-S-L-L-L-P-N-Y-N-S-R-A-I-V-I 2.774254 7.502486 4.489994 2.691271 4.586389 7.502486 
69 L-P-N-Y-N-S-R-A-I-V-I-V-T-V-T 3.929181 8.002609 6.185098 5.844809 7.312109 8.002609 
70 N-S-R-A-I-V-I-V-T-V-T-E-G-K-G 4.185832 9.998082 6.879394 4.547969 5.427114 9.998082 
71 I-V-I-V-T-V-T-E-G-K-G-D-F-E-L 2.564425 0.221433 2.258495 0.279668 2.624275 2.624275 
72 T-V-T-E-G-K-G-D-F-E-L-V-G-Q-R 3.075992 -2.30594 1.00226 1.019127 3.004814 3.075992 
73 G-K-G-D-F-E-L-V-G-Q-R-N-E-N-Q 0.686367 1.870668 0.438 3.061619 5.582617 5.582617 
74 F-E-L-V-G-Q-R-N-E-N-Q-G-K-E-N 0.922208 1.977718 0.20115 1.234648 2.794948 2.794948 
75 G-Q-R-N-E-N-Q-G-K-E-N-D-K-E-E 0.722783 0.084276 0.275456 0.95348 3.926451 3.926451 
76 E-N-Q-G-K-E-N-D-K-E-E-E-Q-E-E 0.998509 0.311757 0.159353 0.517484 2.887238 2.887238 
77 K-E-N-D-K-E-E-E-Q-E-E-E-T-S-K 0.760934 -0.46603 -0.02641 0.475371 2.372689 2.372689 
78 K-E-E-E-Q-E-E-E-T-S-K-Q-V-Q-L 0.70024 -0.43926 -0.33525 0.827141 2.40556 2.40556 
79 Q-E-E-E-T-S-K-Q-V-Q-L-Y-R-A-K 1.801409 2.206871 0.749156 1.033991 2.9947 3.610613 
80 T-S-K-Q-V-Q-L-Y-R-A-K-L-S-P-G 3.287555 10.26069 4.81276 5.805173 9.267902 10.26069 
81 V-Q-L-Y-R-A-K-L-S-P-G-D-V-F-V 3.282352 8.397355 5.372377 4.929465 9.764752 9.764752 
82 R-A-K-L-S-P-G-D-V-F-V-I-P-A-G 0.67076 2.047969 1.2275 0.682221 2.716565 3.148129 
83 S-P-G-D-V-F-V-I-P-A-G-H-P-V-A 0.792148 -0.03448 0.312609 0.106261 0.002223 0.792148 
84 V-F-V-I-P-A-G-H-P-V-A-I-N-A-S 0.382895 1.576281 1.612962 1.032752 1.682409 1.995344 
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85 P-A-G-H-P-V-A-I-N-A-S-S-D-L-N 0.840704 2.310575 3.398626 0.570745 2.963093 3.398626 
86 P-V-A-I-N-A-S-S-D-L-N-L-I-G-F 0.969029 2.190144 3.700494 0.415917 3.228586 3.700494 
87 N-A-S-S-D-L-N-L-I-G-F-G-I-N-A 1.295045 1.547846 4.705946 0.650017 2.558534 4.705946 
88 D-L-N-L-I-G-F-G-I-N-A-E-N-N-E 1.634933 1.1531 2.409429 -0.05476 1.212109 2.409429 
89 I-G-F-G-I-N-A-E-N-N-E-R-N-F-L 1.952278 1.245096 1.673336 -0.03742 2.950451 2.950451 
90 I-N-A-E-N-N-E-R-N-F-L-A-G-E-E 2.295635 -0.35229 1.489893 0.216499 13.70036 13.70036 
91 N-N-E-R-N-F-L-A-G-E-E-D-N-V-I 2.188119 -0.05288 2.695042 0.075295 3.76842 3.76842 
92 N-F-L-A-G-E-E-D-N-V-I-S-Q-V-E 2.793329 0.273286 1.7012 0.140942 1.562306 2.793329 
93 G-E-E-D-N-V-I-S-Q-V-E-R-P-V-K 3.797388 1.420725 2.237596 0.843243 3.61671 3.797388 
94 N-V-I-S-Q-V-E-R-P-V-K-E-L-A-F 3.620507 0.766718 2.21902 0.63887 3.997249 3.997249 
95 Q-V-E-R-P-V-K-E-L-A-F-P-G-S-S 2.997956 -0.68514 2.160968 1.333738 5.95557 5.95557 
96 P-V-K-E-L-A-F-P-G-S-S-H-E-V-D 3.289289 -2.15875 1.262331 0.562075 2.810119 3.289289 
97 L-A-F-P-G-S-S-H-E-V-D-R-L-L-K 0.856311 3.489795 0.523916 1.744961 3.376503 3.489795 
98 G-S-S-H-E-V-D-R-L-L-K-N-Q-K-Q 0.917005 2.962909 0.231337 1.25075 4.467549 4.467549 
99 E-V-D-R-L-L-K-N-Q-K-Q-S-Y-F-A 2.472516 3.079995 2.172579 1.386999 7.477726 7.477726 
100 L-L-K-N-Q-K-Q-S-Y-F-A-N-A-Q-P 1.019319 1.646533 0.198828 1.15166 3.66728 3.66728 
101 Q-K-Q-S-Y-F-A-N-A-Q-P-L-Q-R-E 0.814692 -0.40247 -0.11929 1.062479 3.298119 3.298119 
 m (blanks) 9544.2 12428.62 9019.374 10125.21 10837.24 
 s (blanks) 576.6596 597.8531 430.6522 807.3471 790.9836 
 
Table A47: Calculated Z-scores of Pis s 1 IgE inhibition experiments. 
The calculated Z-scores of serum pool 1 (pea patients 1, 4, 8) and serum pool 2 (pea patients 3, 10, 11, 13) inhibited 
(+) and uninhibited (-) are listed. For inhibition 30 µg rPis s 1 was preincubated with both serum pools. As 
references, uninhibited serum pools preincubated with protein buffer without rPis s 1 were used. Identified candidate 
diagnostic peptides are highlighted in light blue. 
 IgE inhibition experiment → Pool 1 - Pool 1 + Pool 2- Pool 2 + 
Peptide No. Peptide sequence ↓ Z-score Z-score Z-score Z-score 
1 S-R-S-D-Q-E-N-P-F-I-F-K-S-N-R 4.836787 3.552239 6.88609 2.935156 
2 Q-E-N-P-F-I-F-K-S-N-R-F-Q-T-L 4.353223 13.07424 13.78663 8.044058 
3 F-I-F-K-S-N-R-F-Q-T-L-Y-E-N-E 4.360865 2.799871 9.379283 4.011408 
4 S-N-R-F-Q-T-L-Y-E-N-E-N-G-H-I 4.822196 0.959604 5.301167 2.312833 
5 Q-T-L-Y-E-N-E-N-G-H-I-R-L-L-Q 5.216134 2.751331 24.67098 10.08528 
6 E-N-E-N-G-H-I-R-L-L-Q-K-F-D-K 3.957895 4.129863 7.496566 7.749736 
7 G-H-I-R-L-L-Q-K-F-D-K-R-S-K-I 3.33885 2.632409 10.73755 4.870945 
8 L-L-Q-K-F-D-K-R-S-K-I-F-E-N-L 3.404854 0.896503 5.595652 6.802342 
9 F-D-K-R-S-K-I-F-E-N-L-Q-N-Y-R 1.916644 0.949897 5.314402 6.234198 
10 S-K-I-F-E-N-L-Q-N-Y-R-L-L-E-Y 2.38006 5.322123 9.63737 7.967915 
11 E-N-L-Q-N-Y-R-L-L-E-Y-K-S-K-P 3.626487 2.06874 6.755392 2.169333 
12 N-Y-R-L-L-E-Y-K-S-K-P-H-T-L-F 1.44767 1.145876 2.759996 1.946761 
13 L-E-Y-K-S-K-P-H-T-L-F-L-P-Q-Y 1.38653 1.540262 8.075609 1.129688 
14 S-K-P-H-T-L-F-L-P-Q-Y-T-D-A-D 1.304547 0.380767 7.48664 2.652548 
15 T-L-F-L-P-Q-Y-T-D-A-D-F-I-L-V 2.045178 1.941323 32.81232 21.48476 
16 P-Q-Y-T-D-A-D-F-I-L-V-V-L-S-G 1.382362 6.946387 14.6039 10.0106 
17 D-A-D-F-I-L-V-V-L-S-G-K-A-T-L 1.632481 8.978993 27.75314 19.0189 
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18 I-L-V-V-L-S-G-K-A-T-L-T-V-L-K 3.27632 3.805253 36.39825 21.2988 
19 L-S-G-K-A-T-L-T-V-L-K-S-N-D-R 1.004403 2.276854 12.46475 5.398089 
20 A-T-L-T-V-L-K-S-N-D-R-N-S-F-N 0.101195 0.513038 7.003553 2.022904 
21 V-L-K-S-N-D-R-N-S-F-N-L-E-R-G 0.156082 -0.22537 6.73223 4.425801 
22 N-D-R-N-S-F-N-L-E-R-G-D-A-I-K 0.322828 -0.49598 13.65262 1.167759 
23 S-F-N-L-E-R-G-D-A-I-K-L-P-A-G 0.338114 0.072539 11.14784 0.77533 
24 E-R-G-D-A-I-K-L-P-A-G-T-I-A-Y 0.579895 -0.94801 5.676718 -1.04478 
25 A-I-K-L-P-A-G-T-I-A-Y-L-A-N-R 5.141099 11.70481 8.998769 5.310232 
26 P-A-G-T-I-A-Y-L-A-N-R-D-D-N-E 5.249484 5.613362 10.6631 10.23756 
27 I-A-Y-L-A-N-R-D-D-N-E-D-L-R-V 7.885463 7.084726 18.61253 10.6256 
28 A-N-R-D-D-N-E-D-L-R-V-L-D-L-A 5.912994 8.293064 26.8945 12.14407 
29 D-N-E-D-L-R-V-L-D-L-A-I-P-V-N 6.506333 13.22289 38.30578 48.60778 
30 L-R-V-L-D-L-A-I-P-V-N-K-P-G-Q 7.010045 6.331751 11.13626 8.244666 
31 D-L-A-I-P-V-N-K-P-G-Q-L-Q-S-F 7.774993 7.332886 29.10313 13.79725 
32 P-V-N-K-P-G-Q-L-Q-S-F-L-L-S-G 4.041963 2.150044 9.164209 4.286694 
33 P-G-Q-L-Q-S-F-L-L-S-G-T-Q-N-Q 4.747855 4.496339 8.527262 31.48439 
34 Q-S-F-L-L-S-G-T-Q-N-Q-P-S-L-L 5.086906 3.653566 14.32431 6.619306 
35 L-S-G-T-Q-N-Q-P-S-L-L-S-G-F-S 6.309017 2.397597 6.108518 4.589802 
36 Q-N-Q-P-S-L-L-S-G-F-S-K-N-I-L 2.591966 0.080427 2.348049 2.033154 
37 S-L-L-S-G-F-S-K-N-I-L-E-A-A-F 2.091033 0.223619 7.643809 2.33919 
38 G-F-S-K-N-I-L-E-A-A-F-N-T-N-Y 3.239497 1.226574 12.8188 6.036519 
39 N-I-L-E-A-A-F-N-T-N-Y-E-E-I-E 2.059073 1.006324 18.61253 11.91417 
40 A-A-F-N-T-N-Y-E-E-I-E-K-V-L-L 2.00627 0.585848 13.75188 7.083485 
41 T-N-Y-E-E-I-E-K-V-L-L-E-Q-Q-E 0.745252 4.003659 13.66254 6.260555 
42 E-I-E-K-V-L-L-E-Q-Q-E-Q-E-P-Q 1.40251 6.180671 48.53829 20.04683 
43 V-L-L-E-Q-Q-E-Q-E-P-Q-H-R-R-S 0.348535 -0.21749 8.219543 2.132726 
44 Q-Q-E-Q-E-P-Q-H-R-R-S-L-K-D-R 0.345756 -0.53239 9.710164 2.525155 
45 E-P-Q-H-R-R-S-L-K-D-R-R-Q-E-I 0.953685 0.965065 12.59049 4.065586 
46 R-R-S-L-K-D-R-R-Q-E-I-N-E-E-N -0.0322 0.695669 11.49858 3.438871 
47 K-D-R-R-Q-E-I-N-E-E-N-V-I-V-K 0.7522 -0.65617 5.552637 2.601298 
48 Q-E-I-N-E-E-N-V-I-V-K-V-S-R-E 1.661661 -0.97714 5.496387 0.650866 
49 E-E-N-V-I-V-K-V-S-R-E-Q-I-E-E 9.235412 8.060376 8.257594 3.78005 
50 I-V-K-V-S-R-E-Q-I-E-E-L-S-K-N 9.177746 9.08487 19.15849 6.090698 
51 S-R-E-Q-I-E-E-L-S-K-N-A-K-S-S 7.700652 8.1344 14.0596 10.51138 
52 I-E-E-L-S-K-N-A-K-S-S-S-K-K-S 7.413015 10.70974 29.87409 23.97259 
53 S-K-N-A-K-S-S-S-K-K-S-V-S-S-E 7.622838 10.47554 51.27055 34.37856 
54 K-S-S-S-K-K-S-V-S-S-E-S-G-P-F 6.11309 4.186897 14.27302 7.915201 
55 K-K-S-V-S-S-E-S-G-P-F-N-L-R-S 8.828274 2.251978 19.27264 7.516915 
56 S-S-E-S-G-P-F-N-L-R-S-R-N-P-I 10.49782 3.23855 15.29214 10.72956 
57 G-P-F-N-L-R-S-R-N-P-I-Y-S-N-K 11.29403 6.016242 25.00351 12.47646 
58 L-R-S-R-N-P-I-Y-S-N-K-F-G-K-F 15.6079 3.832556 19.29249 17.88261 
59 N-P-I-Y-S-N-K-F-G-K-F-F-E-I-T 9.659225 5.431944 10.55557 5.468375 
60 S-N-K-F-G-K-F-F-E-I-T-P-E-K-N 9.091594 0.958998 9.9302 2.468048 
61 G-K-F-F-E-I-T-P-E-K-N-Q-Q-L-Q 5.753196 -0.0482 7.013479 1.391796 
62 E-I-T-P-E-K-N-Q-Q-L-Q-D-L-D-I 6.263856 -0.6859 8.509064 0.338972 
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63 E-K-N-Q-Q-L-Q-D-L-D-I-F-V-N-S 8.295381 3.605633 18.19728 4.737695 
64 Q-L-Q-D-L-D-I-F-V-N-S-V-D-I-K 7.484577 3.176055 13.42596 5.253124 
65 L-D-I-F-V-N-S-V-D-I-K-E-G-S-L 2.977567 1.065179 15.51548 3.41105 
66 V-N-S-V-D-I-K-E-G-S-L-L-L-P-N 4.471335 1.176214 10.27432 5.332196 
67 D-I-K-E-G-S-L-L-L-P-N-Y-N-S-R 3.349272 -0.13194 13.14306 2.678905 
68 G-S-L-L-L-P-N-Y-N-S-R-A-I-V-I 4.806217 2.89331 13.0438 5.575268 
69 L-P-N-Y-N-S-R-A-I-V-I-V-T-V-T 1.187824 4.971422 15.95225 7.389521 
70 N-S-R-A-I-V-I-V-T-V-T-E-G-K-G 4.323347 9.239895 13.44085 10.76617 
71 I-V-I-V-T-V-T-E-G-K-G-D-F-E-L 3.052603 -1.14824 6.781862 0.70358 
72 T-V-T-E-G-K-G-D-F-E-L-V-G-Q-R 8.538552 -1.23622 7.986271 -0.24967 
73 G-K-G-D-F-E-L-V-G-Q-R-N-E-N-Q 20.77842 4.721442 7.683514 4.827017 
74 F-E-L-V-G-Q-R-N-E-N-Q-G-K-E-N 14.06966 7.043467 9.189026 7.882987 
75 G-Q-R-N-E-N-Q-G-K-E-N-D-K-E-E 9.798181 4.054019 27.83007 13.64789 
76 E-N-Q-G-K-E-N-D-K-E-E-E-Q-E-E 7.146221 4.13411 38.88151 11.76774 
77 K-E-N-D-K-E-E-E-Q-E-E-E-T-S-K 9.278488 3.732443 40.90154 8.695667 
78 K-E-E-E-Q-E-E-E-T-S-K-Q-V-Q-L 11.52956 8.86189 36.86313 12.30367 
79 Q-E-E-E-T-S-K-Q-V-Q-L-Y-R-A-K 34.76773 1.519026 15.68589 4.324766 
80 T-S-K-Q-V-Q-L-Y-R-A-K-L-S-P-G 29.13101 13.58815 19.75407 10.07796 
81 V-Q-L-Y-R-A-K-L-S-P-G-D-V-F-V 35.29715 24.24963 13.56163 7.415879 
82 R-A-K-L-S-P-G-D-V-F-V-I-P-A-G 35.33258 7.96451 34.07298 6.286912 
83 S-P-G-D-V-F-V-I-P-A-G-H-P-V-A 35.27561 4.53153 44.13674 4.37748 
84 V-F-V-I-P-A-G-H-P-V-A-I-N-A-S 34.35781 10.50011 6.565135 1.61876 
85 P-A-G-H-P-V-A-I-N-A-S-S-D-L-N 10.89454 0.148382 2.925437 1.110652 
86 P-V-A-I-N-A-S-S-D-L-N-L-I-G-F 26.15807 4.587351 42.05136 5.518161 
87 N-A-S-S-D-L-N-L-I-G-F-G-I-N-A 34.31682 10.38786 25.66197 6.172698 
88 D-L-N-L-I-G-F-G-I-N-A-E-N-N-E 34.5718 20.56242 19.84176 5.125731 
89 I-G-F-G-I-N-A-E-N-N-E-R-N-F-L 18.42208 1.157404 9.245275 5.250196 
90 I-N-A-E-N-N-E-R-N-F-L-A-G-E-E 24.48227 0.85039 20.98165 5.800768 
91 N-N-E-R-N-F-L-A-G-E-E-D-N-V-I 33.78809 7.281919 71.46756 5.513768 
92 N-F-L-A-G-E-E-D-N-V-I-S-Q-V-E 18.61662 -0.66163 25.073 3.668764 
93 G-E-E-D-N-V-I-S-Q-V-E-R-P-V-K 2.072274 -0.81574 9.516598 2.595441 
94 N-V-I-S-Q-V-E-R-P-V-K-E-L-A-F 9.355608 -0.965 12.83369 3.993836 
95 Q-V-E-R-P-V-K-E-L-A-F-P-G-S-S 34.12784 0.499689 83.10797 2.183976 
96 P-V-K-E-L-A-F-P-G-S-S-H-E-V-D 34.31473 -1.10091 80.55026 0.671366 
97 L-A-F-P-G-S-S-H-E-V-D-R-L-L-K 34.99214 2.031121 26.60663 1.497224 
98 G-S-S-H-E-V-D-R-L-L-K-N-Q-K-Q 13.88485 2.604498 7.673588 2.091726 
99 E-V-D-R-L-L-K-N-Q-K-Q-S-Y-F-A 14.77034 2.313866 22.15628 1.56751 
100 L-L-K-N-Q-K-Q-S-Y-F-A-N-A-Q-P 30.17387 5.913095 81.90687 1.26001 
101 Q-K-Q-S-Y-F-A-N-A-Q-P-L-Q-R-E 33.43723 2.741623 71.95726 1.028652 
 m (blanks) 11292.35 13142.45 12164.73 10943.51 
 s (blanks) 1439.313 1648.131 604.4458 682.9255 
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7.1.6 Peptide sequences of PA1, PA2, Gly m 5.03 and Gly m 8 
 
Table A48: Peptide sequences of PA1. 
Peptide No. Peptide sequence 
1 A-S-C-N-G-V-C-S-P-F-E-M-P-P-C 
2 G-V-C-S-P-F-E-M-P-P-C-G-S-S-A 
3 P-F-E-M-P-P-C-G-S-S-A-C-R-C-I 
4 P-P-C-G-S-S-A-C-R-C-I-P-V-G-L 
5 S-S-A-C-R-C-I-P-V-G-L-V-V-G-Y 
6 R-C-I-P-V-G-L-V-V-G-Y-C-R-H-P 
7 V-G-L-V-V-G-Y-C-R-H-P-S-G-V-F 
8 V-G-Y-C-R-H-P-S-G-V-F-L-R-T-N 
9 R-H-P-S-G-V-F-L-R-T-N-D-E-H-P 
10 G-V-F-L-R-T-N-D-E-H-P-N-L-C-E 
11 R-T-N-D-E-H-P-N-L-C-E-S-D-A-D 
12 E-H-P-N-L-C-E-S-D-A-D-C-R-K-K 
13 L-C-E-S-D-A-D-C-R-K-K-G-S-G-N 
14 D-A-D-C-R-K-K-G-S-G-N-F-C-G-H 
15 R-K-K-G-S-G-N-F-C-G-H-Y-P-N-P 
16 S-G-N-F-C-G-H-Y-P-N-P-D-I-E-Y 
17 C-G-H-Y-P-N-P-D-I-E-Y-G-W-C-F 
18 P-N-P-D-I-E-Y-G-W-C-F-A-S-K-S 
19 I-E-Y-G-W-C-F-A-S-K-S-E-A-E-D 
20 W-C-F-A-S-K-S-E-A-E-D-F-F-S-K 
21 S-K-S-E-A-E-D-F-F-S-K-I-T-Q-K 
22 A-E-D-F-F-S-K-I-T-Q-K-D-L-L-K 
23 F-S-K-I-T-Q-K-D-L-L-K-S-V-S-T 
24 S-K-I-T-Q-K-D-L-L-K-S-V-S-T-A 
 
Table A49: Peptide sequences of PA2. 
Peptide No. Peptide sequence 
1 M-T-K-T-G-Y-I-N-A-A-F-R-S-S-Q 
2 G-Y-I-N-A-A-F-R-S-S-Q-N-N-E-A 
3 A-A-F-R-S-S-Q-N-N-E-A-Y-L-F-I 
4 S-S-Q-N-N-E-A-Y-L-F-I-N-D-K-Y 
5 N-E-A-Y-L-F-I-N-D-K-Y-V-L-L-D 
6 L-F-I-N-D-K-Y-V-L-L-D-Y-A-P-G 
7 D-K-Y-V-L-L-D-Y-A-P-G-T-S-N-D 
8 L-L-D-Y-A-P-G-T-S-N-D-K-V-L-Y 
9 A-P-G-T-S-N-D-K-V-L-Y-G-P-T-P 
10 S-N-D-K-V-L-Y-G-P-T-P-V-R-D-G 
11 V-L-Y-G-P-T-P-V-R-D-G-F-K-S-L 
12 P-T-P-V-R-D-G-F-K-S-L-N-Q-T-V 
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13 R-D-G-F-K-S-L-N-Q-T-V-F-G-S-Y 
14 K-S-L-N-Q-T-V-F-G-S-Y-G-V-D-C 
15 Q-T-V-F-G-S-Y-G-V-D-C-S-F-D-T 
16 G-S-Y-G-V-D-C-S-F-D-T-D-N-D-E 
17 V-D-C-S-F-D-T-D-N-D-E-A-F-I-F 
18 F-D-T-D-N-D-E-A-F-I-F-Y-E-K-F 
19 N-D-E-A-F-I-F-Y-E-K-F-C-A-L-I 
20 F-I-F-Y-E-K-F-C-A-L-I-D-Y-A-P 
21 E-K-F-C-A-L-I-D-Y-A-P-H-S-N-K 
22 A-L-I-D-Y-A-P-H-S-N-K-D-K-I-I 
23 Y-A-P-H-S-N-K-D-K-I-I-L-G-P-K 
24 S-N-K-D-K-I-I-L-G-P-K-K-I-A-D 
25 K-I-I-L-G-P-K-K-I-A-D-M-F-P-F 
26 G-P-K-K-I-A-D-M-F-P-F-F-E-G-T 
27 I-A-D-M-F-P-F-F-E-G-T-V-F-E-N 
28 F-P-F-F-E-G-T-V-F-E-N-G-I-D-A 
29 E-G-T-V-F-E-N-G-I-D-A-A-Y-R-S 
30 F-E-N-G-I-D-A-A-Y-R-S-T-R-G-K 
31 I-D-A-A-Y-R-S-T-R-G-K-E-V-Y-L 
32 Y-R-S-T-R-G-K-E-V-Y-L-F-K-G-D 
33 R-G-K-E-V-Y-L-F-K-G-D-Q-Y-A-R 
34 V-Y-L-F-K-G-D-Q-Y-A-R-I-D-Y-E 
35 K-G-D-Q-Y-A-R-I-D-Y-E-T-N-S-M 
36 Y-A-R-I-D-Y-E-T-N-S-M-V-N-K-E 
37 D-Y-E-T-N-S-M-V-N-K-E-I-K-S-I 
38 N-S-M-V-N-K-E-I-K-S-I-R-N-G-F 
39 N-K-E-I-K-S-I-R-N-G-F-P-C-F-R 
40 K-S-I-R-N-G-F-P-C-F-R-N-T-I-F 
41 N-G-F-P-C-F-R-N-T-I-F-E-S-G-T 
42 C-F-R-N-T-I-F-E-S-G-T-D-A-A-F 
43 T-I-F-E-S-G-T-D-A-A-F-A-S-H-K 
44 S-G-T-D-A-A-F-A-S-H-K-T-N-E-V 
45 A-A-F-A-S-H-K-T-N-E-V-Y-F-F-K 
46 S-H-K-T-N-E-V-Y-F-F-K-G-D-Y-Y 
47 N-E-V-Y-F-F-K-G-D-Y-Y-A-R-V-T 
48 F-F-K-G-D-Y-Y-A-R-V-T-V-T-P-G 
49 D-Y-Y-A-R-V-T-V-T-P-G-A-T-D-D 
50 R-V-T-V-T-P-G-A-T-D-D-Q-I-M-D 
51 T-P-G-A-T-D-D-Q-I-M-D-G-V-R-K 
52 T-D-D-Q-I-M-D-G-V-R-K-T-L-D-Y 
53 I-M-D-G-V-R-K-T-L-D-Y-W-P-S-L 
54 V-R-K-T-L-D-Y-W-P-S-L-R-G-I-I 
55 L-D-Y-W-P-S-L-R-G-I-I-P-L-E-N 
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Table A50: Peptide sequences of Gly m 5.0301 and Gly m 5.0302. 
Gly m 5.0301 contains a leucine (L) in peptides 1-4 and in peptides 41-44. In contrast Gly m 5.0302 contains in the 
respective peptides a phenylalanine (F). Amino acid differences between both isoforms are shown in red. 
Peptide No. Peptide sequence 
1 L-K-V-R-E-D-E-N-N-P-F-Y-F/L-R-S 
2 E-D-E-N-N-P-F-Y-F/L-R-S-S-N-S-F 
3 N-P-F-Y-F/L-R-S-S-N-S-F-Q-T-L-F 
4 F/L-R-S-S-N-S-F-Q-T-L-F-E-N-Q-N 
5 N-S-F-Q-T-L-F-E-N-Q-N-G-R-I-R 
6 T-L-F-E-N-Q-N-G-R-I-R-L-L-Q-R 
7 N-Q-N-G-R-I-R-L-L-Q-R-F-N-K-R 
8 R-I-R-L-L-Q-R-F-N-K-R-S-P-Q-L 
9 L-Q-R-F-N-K-R-S-P-Q-L-E-N-L-R 
10 N-K-R-S-P-Q-L-E-N-L-R-D-Y-R-I 
11 P-Q-L-E-N-L-R-D-Y-R-I-V-Q-F-Q 
12 N-L-R-D-Y-R-I-V-Q-F-Q-S-K-P-N 
13 Y-R-I-V-Q-F-Q-S-K-P-N-T-I-L-L 
14 Q-F-Q-S-K-P-N-T-I-L-L-P-H-H-A 
15 K-P-N-T-I-L-L-P-H-H-A-D-A-D-F 
16 I-L-L-P-H-H-A-D-A-D-F-L-L-F-V 
17 H-H-A-D-A-D-F-L-L-F-V-L-S-G-R 
18 A-D-F-L-L-F-V-L-S-G-R-A-I-L-T 
19 L-F-V-L-S-G-R-A-I-L-T-L-V-N-N 
20 S-G-R-A-I-L-T-L-V-N-N-D-D-R-D 
21 I-L-T-L-V-N-N-D-D-R-D-S-Y-N-L 
22 V-N-N-D-D-R-D-S-Y-N-L-H-P-G-D 
23 D-R-D-S-Y-N-L-H-P-G-D-A-Q-R-I 
24 Y-N-L-H-P-G-D-A-Q-R-I-P-A-G-T 
25 P-G-D-A-Q-R-I-P-A-G-T-T-Y-Y-L 
26 Q-R-I-P-A-G-T-T-Y-Y-L-V-N-P-H 
27 A-G-T-T-Y-Y-L-V-N-P-H-D-H-Q-N 
28 Y-Y-L-V-N-P-H-D-H-Q-N-L-K-I-I 
29 N-P-H-D-H-Q-N-L-K-I-I-K-L-A-I 
30 H-Q-N-L-K-I-I-K-L-A-I-P-V-N-K 
31 K-I-I-K-L-A-I-P-V-N-K-P-G-R-Y 
32 L-A-I-P-V-N-K-P-G-R-Y-D-D-F-F 
33 V-N-K-P-G-R-Y-D-D-F-F-L-S-S-T 
34 G-R-Y-D-D-F-F-L-S-S-T-Q-A-Q-Q 
35 D-F-F-L-S-S-T-Q-A-Q-Q-S-Y-L-Q 
36 S-S-T-Q-A-Q-Q-S-Y-L-Q-G-F-S-H 
37 A-Q-Q-S-Y-L-Q-G-F-S-H-N-I-L-E 
38 Y-L-Q-G-F-S-H-N-I-L-E-T-S-F-H 
39 F-S-H-N-I-L-E-T-S-F-H-S-E-F-E 
40 I-L-E-T-S-F-H-S-E-F-E-E-I-N-R 
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41 S-F-H-S-E-F-E-E-I-N-R-V-L-F/L-G 
42 E-F-E-E-I-N-R-V-L-F/L-G-E-E-E-E 
43 I-N-R-V-L-F/L-G-E-E-E-E-Q-R-Q-Q 
44 L-F/L-G-E-E-E-E-Q-R-Q-Q-E-G-V-I 
45 E-E-E-Q-R-Q-Q-E-G-V-I-V-E-L-S 
46 R-Q-Q-E-G-V-I-V-E-L-S-K-E-Q-I 
47 G-V-I-V-E-L-S-K-E-Q-I-R-Q-L-S 
48 E-L-S-K-E-Q-I-R-Q-L-S-R-R-A-K 
49 E-Q-I-R-Q-L-S-R-R-A-K-S-S-S-R 
50 Q-L-S-R-R-A-K-S-S-S-R-K-T-I-S 
51 R-A-K-S-S-S-R-K-T-I-S-S-E-D-E 
52 S-S-R-K-T-I-S-S-E-D-E-P-F-N-L 
53 T-I-S-S-E-D-E-P-F-N-L-R-S-R-N 
54 E-D-E-P-F-N-L-R-S-R-N-P-I-Y-S 
55 F-N-L-R-S-R-N-P-I-Y-S-N-N-F-G 
56 S-R-N-P-I-Y-S-N-N-F-G-K-F-F-E 
57 I-Y-S-N-N-F-G-K-F-F-E-I-T-P-E 
58 N-F-G-K-F-F-E-I-T-P-E-K-N-P-Q 
59 F-F-E-I-T-P-E-K-N-P-Q-L-R-D-L 
60 T-P-E-K-N-P-Q-L-R-D-L-D-I-F-L 
61 N-P-Q-L-R-D-L-D-I-F-L-S-S-V-D 
62 R-D-L-D-I-F-L-S-S-V-D-I-N-E-G 
63 I-F-L-S-S-V-D-I-N-E-G-A-L-L-L 
64 S-V-D-I-N-E-G-A-L-L-L-P-H-F-N 
65 N-E-G-A-L-L-L-P-H-F-N-S-K-A-I 
66 L-L-L-P-H-F-N-S-K-A-I-V-I-L-V 
67 H-F-N-S-K-A-I-V-I-L-V-I-N-E-G 
68 K-A-I-V-I-L-V-I-N-E-G-D-A-N-I 
69 I-L-V-I-N-E-G-D-A-N-I-E-L-V-G 
70 N-E-G-D-A-N-I-E-L-V-G-I-K-E-Q 
71 A-N-I-E-L-V-G-I-K-E-Q-Q-Q-K-Q 
72 L-V-G-I-K-E-Q-Q-Q-K-Q-K-Q-E-E 
73 K-E-Q-Q-Q-K-Q-K-Q-E-E-E-P-L-E 
74 Q-K-Q-K-Q-E-E-E-P-L-E-V-Q-R-Y 
75 Q-E-E-E-P-L-E-V-Q-R-Y-R-A-E-L 
76 P-L-E-V-Q-R-Y-R-A-E-L-S-E-D-D 
77 Q-R-Y-R-A-E-L-S-E-D-D-V-F-V-I 
78 A-E-L-S-E-D-D-V-F-V-I-P-A-A-Y 
79 E-D-D-V-F-V-I-P-A-A-Y-P-F-V-V 
80 F-V-I-P-A-A-Y-P-F-V-V-N-A-T-S 
81 A-A-Y-P-F-V-V-N-A-T-S-N-L-N-F 
82 F-V-V-N-A-T-S-N-L-N-F-L-A-F-G 
83 A-T-S-N-L-N-F-L-A-F-G-I-N-A-E 
84 L-N-F-L-A-F-G-I-N-A-E-N-N-Q-R 
85 A-F-G-I-N-A-E-N-N-Q-R-N-F-L-A 
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86 N-A-E-N-N-Q-R-N-F-L-A-G-E-K-D 
87 N-Q-R-N-F-L-A-G-E-K-D-N-V-V-R 
88 F-L-A-G-E-K-D-N-V-V-R-Q-I-E-R 
89 E-K-D-N-V-V-R-Q-I-E-R-Q-V-Q-E 
90 V-V-R-Q-I-E-R-Q-V-Q-E-L-A-F-P 
91 I-E-R-Q-V-Q-E-L-A-F-P-G-S-A-Q 
92 V-Q-E-L-A-F-P-G-S-A-Q-D-V-E-R 
93 A-F-P-G-S-A-Q-D-V-E-R-L-L-K-K 
94 S-A-Q-D-V-E-R-L-L-K-K-Q-R-E-S 
95 V-E-R-L-L-K-K-Q-R-E-S-Y-F-V-D 
96 L-K-K-Q-R-E-S-Y-F-V-D-A-Q-P-Q 
97 R-E-S-Y-F-V-D-A-Q-P-Q-Q-K-E-E 
98 F-V-D-A-Q-P-Q-Q-K-E-E-G-S-K-G 
99 Q-P-Q-Q-K-E-E-G-S-K-G-R-K-G-P 
100 K-E-E-G-S-K-G-R-K-G-P-F-P-S-I 
101 S-K-G-R-K-G-P-F-P-S-I-L-G-A-L 
102 K-G-R-K-G-P-F-P-S-I-L-G-A-L-Y 
 
Table A51: Peptide sequence of Gly m 8. 
Peptide No. Peptide sequence 
1 S-K-W-Q-H-Q-Q-D-S-C-R-K-Q-L-Q 
2 H-Q-Q-D-S-C-R-K-Q-L-Q-G-V-N-L 
3 S-C-R-K-Q-L-Q-G-V-N-L-T-P-C-E 
4 Q-L-Q-G-V-N-L-T-P-C-E-K-H-I-M 
5 V-N-L-T-P-C-E-K-H-I-M-E-K-I-Q 
6 P-C-E-K-H-I-M-E-K-I-Q-G-R-G-D 
7 H-I-M-E-K-I-Q-G-R-G-D-D-D-D-D 
8 K-I-Q-G-R-G-D-D-D-D-D-D-D-D-D 
9 R-G-D-D-D-D-D-D-D-D-D-N-H-I-L 
10 D-D-D-D-D-D-D-N-H-I-L-R-T-M-R 
11 D-D-D-N-H-I-L-R-T-M-R-G-R-I-N 
12 H-I-L-R-T-M-R-G-R-I-N-Y-I-R-R 
13 T-M-R-G-R-I-N-Y-I-R-R-N-E-G-K 
14 R-I-N-Y-I-R-R-N-E-G-K-D-E-D-E 
15 I-R-R-N-E-G-K-D-E-D-E-E-E-E-G 
16 E-G-K-D-E-D-E-E-E-E-G-H-M-Q-K 
17 E-D-E-E-E-E-G-H-M-Q-K-C-C-T-E 
18 E-E-G-H-M-Q-K-C-C-T-E-M-S-E-L 
19 M-Q-K-C-C-T-E-M-S-E-L-R-S-P-K 
20 C-T-E-M-S-E-L-R-S-P-K-C-Q-C-K 
21 S-E-L-R-S-P-K-C-Q-C-K-A-L-Q-K 
22 S-P-K-C-Q-C-K-A-L-Q-K-I-M-E-N 
23 Q-C-K-A-L-Q-K-I-M-E-N-Q-S-E-E 
24 L-Q-K-I-M-E-N-Q-S-E-E-L-E-E-K 
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25 M-E-N-Q-S-E-E-L-E-E-K-Q-K-K-K 
26 S-E-E-L-E-E-K-Q-K-K-K-M-E-K-E 
27 E-E-K-Q-K-K-K-M-E-K-E-L-I-N-L 
28 K-K-K-M-E-K-E-L-I-N-L-A-T-M-C 
29 E-K-E-L-I-N-L-A-T-M-C-R-F-G-P 
30 I-N-L-A-T-M-C-R-F-G-P-M-I-Q-C 
31 T-M-C-R-F-G-P-M-I-Q-C-D-L-S-S 
32 C-R-F-G-P-M-I-Q-C-D-L-S-S-D-D 
 
7.1.7 Mass spectrometry analysis 
7.1.7.1 Peanut extract 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A22: Alignment of variants of nAra h 2.01 and nAra h 2.02 (Hales et al. 2004). 
 
Table A52: Ara h 2.0101- and Ara h 2.0201-specific peptides identified with MSE. 
Band PM E S Start End Peptide sequence Description 
1 1121.5 0.5 8.0 160 169 CDLEVESGGR Ara h 2.0201 
1 1196.5 2.2 6.7 82 91 DPYSPSPYDR Ara h 2.0201 
2 1107.5 0.9 8.6 129 138 CDLDVESGGR Ara h 2.0101 
2 2865.2 6.3 7.1 56 79 DEDSYERDPYSPSQDPYSPSPYDR Ara h 2.0101 
2 1236.5 1.7 6.8 160 170 CDLEVESGGRD Ara h 2.0201 
3 1121.5 0.8 6.8 160 169 CDLEVESGGR Ara h 2.0201 
4 1121.5 5.0 7.2 160 169 CDLEVESGGR Ara h 2.0201 
5 1107.5 1.3 7.8 129 138 CDLDVESGGR Ara h 2.0101 
PM, precursor mass; E, precursor mass error [ppm]; S, PLGS peptide score; start and end position refers to the 
accession number outlined in Table 23. 
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7.1.7.2 Pea extract 
 
Figure A23: Alignment of PA1 isoforms. 
Multiple sequence alignment of PA1 isoforms PA1 A-F. Numbers written in parentheses represent the respective 
UniProt accession number. Differences in the amino acid sequences are shown in red. Amino acid residues framed 
in a blue box belong to the propeptide. 
 
Table A53: PA1 isoform-specific peptides identified with MSE. 
Band PM E S Start End Peptide sequence Description 
3 1059.5 0.7 6.0 109 117 SEAEDFFSK 
PA1 
peptide shared by 
isoform A, B, D and F 
3 1902.7 0.4 6.0 68 83 ANDEHPNLCESDADCR PA1 D 
4 1059.5 -0.5 8.4 109 117 SEAEDFFSK 
PA1 
peptide shared by 
isoform A, B, D and F 
4 2663.1 -1.1 7.2 86 108 GSGNFCGHYPNPDIEYGWCFASK 
PA1 
peptide shared by 
isoform A, B, D and E 
4 1902.7 -0.1 7.9 68 83 ANDEHPNLCESDADCR PA1 D 
4 1011.5 -0.1 8.2 109 117 SEAEDVFSK 
PA1 
peptide shared by 
isoform E and C 
PM, precursor mass; E, precursor mass error [ppm]; S, PLGS peptide score; start and end position refers to the 
accession number outlined in Table 27; amino acid residues written in blue belong to the propeptide. 
 
 
 
 
 
 
 
 
PA1 C (P62928)  1    ISCNGVCSPFDIPPCGSPLCRCIPAGLVIGNCRNPYGVFLRTNDEHPNLCESDADCRKKG  60
PA1 E (P62930)  1    ASCNGVCSPFEMPPCGSSACRCIPVGLLIGYCRNPSGVFLKGNDEHPNLCESDADCKKKG  60
PA1 F (P62931)  1    ASCNGVCSPFEMPPCGTSACRCIPVGLVIGYCRNPSGVFLRTNDEHPNLCESDADCRKKG  60
PA1 D (P62929)  1    ASCNGVCSPFEMPPCGTSACRCIPVGLFIGYCRNPSGVFLKANDEHPNLCESDADCRKKG  60
PA1 A (P62926)  1    ASCNGVCSPFEMPPCGTSACRCIPVGLVVGYCRNPSGVFLRTNDEHPNLCESDADCRKKG  60
PA1 B (P62927)  1    ASCNGVCSPFEMPPCGSSACRCIPVGLVVGYCRHPSGVFLRTNDEHPNLCESDADCRKKG  60
PA1 C (P62928)  61   SGTFCGHYPNPDIEYGWCFASKSEAEDVFSKITPKDLLKSVSTA  104
PA1 E (P62930)  61   SGNFCGHYPNPDIEYGWCFASKSEAEDVFSKITPKDLLKSVSTA  104
PA1 F (P62931)  61   SGKFCGHYPNPGIEYGWCFASKSEAEDFFSKITQKDLLKSVSTA  104
PA1 D (P62929)  61   SGNFCGHYPNPDIEYGWCFASKSEAEDFFSKITPKDLLKSVSTA  104
PA1 A (P62926)  61   SGNFCGHYPNPDIEYGWCFASKSEAEDFFSKITPKDLLKSVSTA  104
PA1 B (P62927)  61   SGNFCGHYPNPDIEYGWCFASKSEAEDFFSKITQKDLLKSVSTA  104
 276  Appendix 
7.1.7.3 Soybean extract 
 
Table A54: Gly m 8-specific peptides identified with MSE. 
Band PM E S Start End Peptide sequence Description 
1 1478.7 -1.3 8.4 117 128 IMENQSEELEEK Gly m 8  
1 1220.6 -0.4 7.6 136 145 ELINLATMCR Gly m 8  
1 1386.7 -0.2 7.5 34 45 QLQGVNLTPCEK Gly m 8  
2 1478.7 0.0 9.2 117 128 IMENQSEELEEK Gly m 8  
2 1220.6 0.6 8.5 136 145 ELINLATMCR Gly m 8  
2 1484.6 0.8 8.1 146 158 FGPMIQCDLSSDD Gly m 8  
2 1386.7 0.2 8.0 34 45 QLQGVNLTPCEK Gly m 8  
2 1185.5 1.0 7.9 97 105 CCTEMSELR Gly m 8  
3 1478.7 -0.1 10.0 117 128 IMENQSEELEEK Gly m 8  
3 1220.6 0.3 9.7 136 145 ELINLATMCR Gly m 8  
3 1185.5 0.4 9.7 97 105 CCTEMSELR Gly m 8  
3 1386.7 0.4 9.5 34 45 QLQGVNLTPCEK Gly m 8  
3 1484.6 0.5 9.4 146 158 FGPMIQCDLSSDD Gly m 8  
3 1514.8 -0.4 8.4 33 45 KQLQGVNLTPCEK Gly m 8  
3 1475.6 -1.3 8.4 85 96 DEDEEEEGHMQK Gly m 8  
4 1478.7 0.8 8.9 117 128 IMENQSEELEEK Gly m 8  
4 1386.7 0.2 8.9 34 45 QLQGVNLTPCEK Gly m 8  
4 1484.6 1.5 8.8 146 158 FGPMIQCDLSSDD Gly m 8  
4 1220.6 0.6 8.7 136 145 ELINLATMCR Gly m 8  
4 1185.5 0.4 8.7 97 105 CCTEMSELR Gly m 8  
4 1514.8 -0.2 8.4 33 45 KQLQGVNLTPCEK Gly m 8  
4 1387.7 -0.2 7.8 34 45 QLQGVNLTPCEK Gly m 8  
4 1221.6 0.3 7.6 136 145 ELINLATMCR Gly m 8  
4 1734.8 0.8 7.5 117 130 IMENQSEELEEKQK Gly m 8  
4 1387.7 0.5 7.5 34 45 QLQGVNLTPCEK Gly m 8  
5 1494.7 2.6 7.9 117 128 IMENQSEELEEK Gly m 8  
5 1386.7 -6.4 7.7 34 45 QLQGVNLTPCEK Gly m 8  
5 1201.5 4.4 7.4 97 105 CCTEMSELR Gly m 8  
5 1236.6 -1.1 7.3 136 145 ELINLATMCR Gly m 8  
5 1514.8 2.5 7.2 33 45 KQLQGVNLTPCEK Gly m 8  
5 1500.6 -1.8 7.1 146 158 FGPMIQCDLSSDD Gly m 8  
5 1185.5 -0.7 6.6 97 105 CCTEMSELR Gly m 8  
PM, precursor mass; E, precursor mass error [ppm]; S, PLGS peptide score; start and end position refers to the 
accession number outlined in Table 35. 
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7.1.8 Circular dichroism spectroscopy 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A24: Circular dichroism spectra of r/a rAra h 1, r/a rAra h 2.02 and 27-mer peptides. 
Far-UV CD-spectra (190-255nm) of r/a rAra h 1 (black solid line), r/a rAra h 2.02 (black dashed line), 27-mer 
peptide P (pink) and 27-mer peptide POH (cyan). Samples were measured at 3 µM (exception r/a rAra h 1 at 2 µM). 
 
7.1.9 IgE immunoblot inhibition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A25: IgE immunoblot inhibition using rPis s 1, rPA1 and nPru p 3. 
IgE immunoblot inhibition of pea total protein using sera of pea-allergic patient 1, pea-tolerant patient 16 and an 
LPT-sensitized donor (PEI131). Serum samples were preincubated with inhibitor protein (+) or untreated (-). As 
inhibitors rPis s 1, rPA1 and nPru p 3 were used. Pea extract was analyzed under reducing conditions. The detection 
after 2 min of exposure is shown. M, low-molecular weight marker; P, total protein stained with Ponceau S. 
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